Sentence,Tags
22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .,"(('22', 'O'), ('-', 'O'), ('oxacalcitriol', 'O'), ('suppresses', 'O'), ('secondary', 'B'), ('hyperparathyroidism', 'I'), ('without', 'O'), ('inducing', 'O'), ('low', 'B'), ('bone', 'I'), ('turnover', 'I'), ('in', 'O'), ('dogs', 'O'), ('with', 'O'), ('renal', 'B'), ('failure', 'I'), ('.', 'O'))"
"BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .","(('BACKGROUND', 'O'), (':', 'O'), ('Calcitriol', 'O'), ('therapy', 'O'), ('suppresses', 'O'), ('serum', 'O'), ('levels', 'O'), ('of', 'O'), ('parathyroid', 'O'), ('hormone', 'O'), ('(', 'O'), ('PTH', 'O'), (')', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('renal', 'B'), ('failure', 'I'), ('but', 'O'), ('has', 'O'), ('several', 'O'), ('drawbacks', 'O'), (',', 'O'), ('including', 'O'), ('hypercalcemia', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('marked', 'O'), ('suppression', 'B'), ('of', 'I'), ('bone', 'I'), ('turnover', 'I'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('lead', 'O'), ('to', 'O'), ('adynamic', 'B'), ('bone', 'I'), ('disease', 'I'), ('.', 'O'))"
This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('OCT', 'O'), ('on', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('and', 'O'), ('bone', 'O'), ('turnover', 'O'), ('in', 'O'), ('states', 'O'), ('of', 'O'), ('normal', 'O'), ('or', 'O'), ('impaired', 'B'), ('renal', 'I'), ('function', 'I'), ('.', 'O'))"
"RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .","(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('Nx', 'O'), ('dogs', 'O'), (',', 'O'), ('OCT', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('soon', 'O'), ('after', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('renal', 'B'), ('insufficiency', 'I'), ('.', 'O'))"
"In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .","(('In', 'O'), ('long', 'O'), ('-', 'O'), ('standing', 'O'), ('secondary', 'B'), ('hyperparathyroidism', 'I'), (',', 'O'), ('OCT', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('stabilized', 'O'), ('serum', 'O'), ('PTH', 'O'), ('levels', 'O'), ('during', 'O'), ('the', 'O'), ('first', 'O'), ('months', 'O'), ('.', 'O'))"
These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .,"(('These', 'O'), ('effects', 'O'), ('were', 'O'), ('accompanied', 'O'), ('by', 'O'), ('episodes', 'O'), ('of', 'O'), ('hypercalcemia', 'B'), ('and', 'O'), ('hyperphosphatemia', 'B'), ('.', 'O'))"
"In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .","(('In', 'O'), ('Nx', 'O'), ('dogs', 'O'), (',', 'O'), ('OCT', 'O'), ('reversed', 'O'), ('abnormal', 'O'), ('bone', 'O'), ('formation', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('woven', 'B'), ('osteoid', 'I'), ('and', 'O'), ('fibrosis', 'B'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('significantly', 'O'), ('alter', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('bone', 'O'), ('turnover', 'O'), ('.', 'O'))"
"CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .","(('CONCLUSIONS', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('even', 'O'), ('though', 'O'), ('OCT', 'O'), ('does', 'O'), ('not', 'O'), ('completely', 'O'), ('prevent', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('hypercalcemia', 'B'), ('in', 'O'), ('experimental', 'O'), ('dogs', 'O'), ('with', 'O'), ('renal', 'B'), ('insufficiency', 'I'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('use', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('secondary', 'B'), ('hyperparathyroidism', 'I'), ('because', 'O'), ('it', 'O'), ('does', 'O'), ('not', 'O'), ('induce', 'O'), ('low', 'B'), ('bone', 'I'), ('turnover', 'I'), ('and', 'O'), (',', 'O'), ('therefore', 'O'), (',', 'O'), ('does', 'O'), ('not', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('adynamic', 'B'), ('bone', 'I'), ('disease', 'I'), ('.', 'O'))"
"Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .","(('Hypotension', 'B'), (',', 'O'), ('bradycardia', 'B'), (',', 'O'), ('and', 'O'), ('asystole', 'B'), ('after', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('intravenous', 'O'), ('methylprednisolone', 'O'), ('in', 'O'), ('a', 'O'), ('monitored', 'O'), ('patient', 'O'), ('.', 'O'))"
"We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .","(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('hypotension', 'B'), (',', 'O'), ('bradycardia', 'B'), (',', 'O'), ('and', 'O'), ('asystole', 'B'), ('after', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('in', 'O'), ('a', 'O'), ('73', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), ('who', 'O'), ('underwent', 'O'), ('electrocardiographic', 'O'), ('(', 'O'), ('ECG', 'O'), (')', 'O'), ('monitoring', 'O'), ('throughout', 'O'), ('the', 'O'), ('episode', 'O'), ('.', 'O'))"
There was a history of ischemic cardiac disease 9 years earlier .,"(('There', 'O'), ('was', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('ischemic', 'B'), ('cardiac', 'B'), ('disease', 'I'), ('9', 'O'), ('years', 'O'), ('earlier', 'O'), ('.', 'O'))"
"The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .","(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('admitted', 'O'), ('with', 'O'), ('a', 'O'), ('pulmonary', 'B'), ('-', 'I'), ('renal', 'I'), ('syndrome', 'I'), ('with', 'O'), ('hemoptysis', 'B'), (',', 'O'), ('rapidly', 'O'), ('progressive', 'O'), ('renal', 'B'), ('failure', 'I'), (',', 'O'), ('and', 'O'), ('hypoxemia', 'B'), ('that', 'O'), ('required', 'O'), ('mechanical', 'O'), ('ventilation', 'O'), ('in', 'O'), ('the', 'O'), ('intensive', 'O'), ('care', 'O'), ('unit', 'O'), ('.', 'O'))"
The ECG showed a junctional rhythm without ventricular arrhythmia .,"(('The', 'O'), ('ECG', 'O'), ('showed', 'O'), ('a', 'O'), ('junctional', 'O'), ('rhythm', 'O'), ('without', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('.', 'O'))"
This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .,"(('This', 'O'), ('study', 'O'), ('reviews', 'O'), ('the', 'O'), ('current', 'O'), ('proposed', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('sudden', 'B'), ('death', 'I'), ('after', 'O'), ('a', 'O'), ('high', 'O'), ('dose', 'O'), ('of', 'O'), ('intravenous', 'O'), ('methylprednisolone', 'O'), ('(', 'O'), ('IVMP', 'O'), (')', 'O'), ('.', 'O'))"
"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .","(('Rapid', 'O'), ('infusion', 'O'), ('and', 'O'), ('underlying', 'O'), ('cardiac', 'B'), ('disease', 'I'), ('were', 'O'), ('important', 'O'), ('risk', 'O'), ('factors', 'O'), ('in', 'O'), ('the', 'O'), ('case', 'O'), ('reported', 'O'), ('here', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('authors', 'O'), ('discount', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('as', 'O'), ('the', 'O'), ('main', 'O'), ('mechanism', 'O'), ('.', 'O'))"
Worsening of levodopa - induced dyskinesias by motor and mental tasks .,"(('Worsening', 'O'), ('of', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('by', 'O'), ('motor', 'O'), ('and', 'O'), ('mental', 'O'), ('tasks', 'O'), ('.', 'O'))"
"Ten patients who had Parkinson ' s disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .","(('Ten', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('with', 'O'), ('disabling', 'O'), ('dyskinesia', 'B'), ('were', 'O'), ('included', 'O'), ('in', 'O'), ('this', 'O'), ('study', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('mental', 'O'), ('(', 'O'), ('mental', 'O'), ('calculation', 'O'), (')', 'O'), ('and', 'O'), ('motor', 'O'), ('(', 'O'), ('flexion', 'O'), ('/', 'O'), ('extension', 'O'), ('of', 'O'), ('right', 'O'), ('fingers', 'O'), (',', 'O'), ('flexion', 'O'), ('/', 'O'), ('extension', 'O'), ('of', 'O'), ('left', 'O'), ('fingers', 'O'), (',', 'O'), ('flexion', 'O'), ('/', 'O'), ('extension', 'O'), ('of', 'O'), ('the', 'O'), ('neck', 'O'), (',', 'O'), ('speaking', 'O'), ('aloud', 'O'), (')', 'O'), ('tasks', 'O'), ('on', 'O'), ('the', 'O'), ('worsening', 'O'), ('of', 'O'), ('peak', 'O'), ('-', 'O'), ('dose', 'O'), ('dyskinesia', 'B'), ('following', 'O'), ('administration', 'O'), ('of', 'O'), ('an', 'O'), ('effective', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('apomorphine', 'O'), ('.', 'O'))"
"Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 +","(('Compared', 'O'), ('with', 'O'), ('the', 'O'), ('score', 'O'), ('at', 'O'), ('rest', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('significant', 'O'), ('aggravation', 'O'), ('of', 'O'), ('the', 'O'), ('dyskinesia', 'B'), ('score', 'O'), ('was', 'O'), ('observed', 'O'), ('during', 'O'), ('speaking', 'O'), ('aloud', 'O'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('2', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), (',', 'O'), ('movements', 'O'), ('of', 'O'), ('right', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('left', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('fingers', 'O'), (',', 'O'), ('movements', 'O'), ('of', 'O'), ('the', 'O'), ('neck', 'O'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('mental', 'O'), ('calculation', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'))"
"These results suggest that activation tasks such as "" speaking aloud "" could be used for objective assessment of dyskinesia severity .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('activation', 'O'), ('tasks', 'O'), ('such', 'O'), ('as', 'O'), ('""', 'O'), ('speaking', 'O'), ('aloud', 'O'), ('""', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('for', 'O'), ('objective', 'O'), ('assessment', 'O'), ('of', 'O'), ('dyskinesia', 'B'), ('severity', 'O'), ('.', 'O'))"
"BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .","(('BACKGROUND', 'O'), (':', 'O'), ('Although', 'O'), ('an', 'O'), ('indicator', 'O'), ('of', 'O'), ('renal', 'B'), ('tubular', 'I'), ('dysfunction', 'I'), (',', 'O'), ('an', 'O'), ('increased', 'O'), ('urinary', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), ('(', 'O'), ('NAG', 'O'), (')', 'O'), ('activity', 'O'), ('might', 'O'), ('reflect', 'O'), ('increased', 'O'), ('lysosomal', 'O'), ('activity', 'O'), ('in', 'O'), ('renal', 'O'), ('tubular', 'O'), ('cells', 'O'), ('.', 'O'))"
METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .,"(('METHODS', 'O'), (':', 'O'), ('Puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('PAN', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('Sprague', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('to', 'O'), ('induce', 'O'), ('proteinuria', 'B'), ('.', 'O'))"
Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .,"(('Peak', 'O'), ('urine', 'O'), ('NAG', 'O'), ('activity', 'O'), ('and', 'O'), ('a', 'O'), ('change', 'O'), ('in', 'O'), ('NAG', 'O'), ('isoenzyme', 'O'), ('pattern', 'O'), ('coincided', 'O'), ('with', 'O'), ('both', 'O'), ('the', 'O'), ('peak', 'O'), ('proteinuria', 'B'), ('and', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('intracellular', 'O'), ('protein', 'O'), ('and', 'O'), ('NAG', 'O'), ('droplets', 'O'), ('(', 'O'), ('day', 'O'), ('six', 'O'), ('onwards', 'O'), (')', 'O'), ('.', 'O'))"
Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .,"(('Cauda', 'B'), ('equina', 'I'), ('syndrome', 'I'), ('after', 'O'), ('spinal', 'O'), ('anaesthesia', 'O'), ('with', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), (':', 'O'), ('a', 'O'), ('review', 'O'), ('of', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('cauda', 'B'), ('equina', 'I'), ('syndrome', 'I'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('Swedish', 'O'), ('Pharmaceutical', 'O'), ('Insurance', 'O'), ('1993', 'O'), ('-', 'O'), ('1997', 'O'), ('.', 'O'))"
Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .,"(('Six', 'O'), ('cases', 'O'), ('of', 'O'), ('cauda', 'B'), ('equina', 'I'), ('syndrome', 'I'), ('with', 'O'), ('varying', 'O'), ('severity', 'O'), ('were', 'O'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('Swedish', 'O'), ('Pharmaceutical', 'O'), ('Insurance', 'O'), ('during', 'O'), ('the', 'O'), ('period', 'O'), ('1993', 'O'), ('-', 'O'), ('1997', 'O'), ('.', 'O'))"
Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .,"(('Three', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('were', 'O'), ('most', 'O'), ('likely', 'O'), ('caused', 'O'), ('by', 'O'), ('direct', 'O'), ('neurotoxicity', 'B'), ('of', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), ('.', 'O'))"
"In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .","(('In', 'O'), ('the', 'O'), ('other', 'O'), ('3', 'O'), ('cases', 'O'), (',', 'O'), ('direct', 'O'), ('neurotoxicity', 'B'), ('was', 'O'), ('also', 'O'), ('probable', 'O'), (',', 'O'), ('but', 'O'), ('unfortunately', 'O'), ('radiological', 'O'), ('investigations', 'O'), ('were', 'O'), ('not', 'O'), ('done', 'O'), ('to', 'O'), ('definitely', 'O'), ('exclude', 'O'), ('a', 'O'), ('compressive', 'O'), ('aetiology', 'O'), ('.', 'O'))"
All cases sustained permanent neurological deficits .,"(('All', 'O'), ('cases', 'O'), ('sustained', 'O'), ('permanent', 'O'), ('neurological', 'B'), ('deficits', 'I'), ('.', 'O'))"
Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .,"(('Systemic', 'O'), ('toxicity', 'B'), ('following', 'O'), ('administration', 'O'), ('of', 'O'), ('sirolimus', 'O'), ('(', 'O'), ('formerly', 'O'), ('rapamycin', 'O'), (')', 'O'), ('for', 'O'), ('psoriasis', 'B'), (':', 'O'), ('association', 'O'), ('of', 'O'), ('capillary', 'B'), ('leak', 'I'), ('syndrome', 'I'), ('with', 'O'), ('apoptosis', 'O'), ('of', 'O'), ('lesional', 'O'), ('lymphocytes', 'O'), ('.', 'O'))"
After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .,"(('After', 'O'), ('2', 'O'), ('individuals', 'O'), ('with', 'O'), ('psoriasis', 'B'), ('developed', 'O'), ('a', 'O'), ('capillary', 'B'), ('leak', 'I'), ('syndrome', 'I'), ('following', 'O'), ('treatment', 'O'), ('with', 'O'), ('oral', 'O'), ('sirolimus', 'O'), ('lesional', 'O'), ('skin', 'O'), ('cells', 'O'), ('and', 'O'), ('activated', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('cells', 'O'), ('were', 'O'), ('analyzed', 'O'), ('for', 'O'), ('induction', 'O'), ('of', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .,"(('OBSERVATIONS', 'O'), (':', 'O'), ('A', 'O'), ('keratome', 'O'), ('skin', 'O'), ('specimen', 'O'), ('from', 'O'), ('1', 'O'), ('patient', 'O'), ('with', 'O'), ('sirolimus', 'O'), ('-', 'O'), ('induced', 'O'), ('capillary', 'B'), ('leak', 'I'), ('syndrome', 'I'), ('had', 'O'), ('a', 'O'), ('2', 'O'), ('.', 'O'), ('3', 'O'), ('-', 'O'), ('fold', 'O'), ('increase', 'O'), ('in', 'O'), ('percentage', 'O'), ('of', 'O'), ('apoptotic', 'O'), ('cells', 'O'), ('(', 'O'), ('to', 'O'), ('48', 'O'), ('%', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('an', 'O'), ('unaffected', 'O'), ('sirolimus', 'O'), ('-', 'O'), ('treated', 'O'), ('patient', 'O'), ('with', 'O'), ('psoriasis', 'B'), ('(', 'O'), ('21', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .","(('Activated', 'O'), ('peripheral', 'O'), ('blood', 'O'), ('T', 'O'), ('cells', 'O'), ('from', 'O'), ('patients', 'O'), ('with', 'O'), ('psoriasis', 'B'), ('tended', 'O'), ('to', 'O'), ('exhibit', 'O'), ('greater', 'O'), ('spontaneous', 'O'), ('or', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('than', 'O'), ('did', 'O'), ('normal', 'O'), ('T', 'O'), ('cells', 'O'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('sirolimus', 'O'), ('.', 'O'))"
"CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Severe', 'O'), ('adverse', 'O'), ('effects', 'O'), ('of', 'O'), ('sirolimus', 'O'), ('include', 'O'), ('fever', 'B'), (',', 'O'), ('anemia', 'B'), (',', 'O'), ('and', 'O'), ('capillary', 'B'), ('leak', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .","(('Because', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('psoriasis', 'B'), ('may', 'O'), ('develop', 'O'), ('capillary', 'B'), ('leak', 'I'), ('from', 'O'), ('various', 'O'), ('systemic', 'O'), ('therapies', 'O'), (',', 'O'), ('clinical', 'O'), ('monitoring', 'O'), ('is', 'O'), ('advisable', 'O'), ('for', 'O'), ('patients', 'O'), ('with', 'O'), ('inflammatory', 'B'), ('diseases', 'I'), ('who', 'O'), ('are', 'O'), ('treated', 'O'), ('with', 'O'), ('immune', 'O'), ('modulators', 'O'), ('.', 'O'))"
"These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .","(('These', 'O'), ('were', 'O'), ('evaluated', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('lithium', 'O'), ('therapy', 'O'), (',', 'O'), ('age', 'O'), (',', 'O'), ('sex', 'O'), (',', 'O'), ('and', 'O'), ('family', 'O'), ('history', 'O'), ('(', 'O'), ('whether', 'O'), ('or', 'O'), ('not', 'O'), ('the', 'O'), ('patient', 'O'), ('had', 'O'), ('a', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relative', 'O'), ('with', 'O'), ('thyroid', 'B'), ('disease', 'I'), (')', 'O'), ('.', 'O'))"
PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .,"(('PATIENTS', 'O'), (':', 'O'), ('One', 'O'), ('hundred', 'O'), ('and', 'O'), ('one', 'O'), ('patients', 'O'), ('(', 'O'), ('28', 'O'), ('men', 'O'), ('and', 'O'), ('73', 'O'), ('women', 'O'), (')', 'O'), ('with', 'O'), ('bipolar', 'B'), ('disorder', 'I'), ('receiving', 'O'), ('lithium', 'O'), ('maintenance', 'O'), ('therapy', 'O'), ('ranging', 'O'), ('from', 'O'), ('1', 'O'), ('year', 'O'), (""'"", 'O'), ('s', 'O'), ('to', 'O'), ('32', 'O'), ('years', 'O'), (""'"", 'O'), ('duration', 'O'), ('.', 'O'))"
The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital ' s out - patient clinics .,"(('The', 'O'), ('control', 'O'), ('group', 'O'), ('consisted', 'O'), ('of', 'O'), ('82', 'O'), ('patients', 'O'), ('with', 'O'), ('no', 'O'), ('psychiatric', 'B'), ('or', 'O'), ('endocrinological', 'O'), ('diagnoses', 'O'), ('from', 'O'), ('the', 'O'), ('hospital', 'O'), (""'"", 'O'), ('s', 'O'), ('out', 'O'), ('-', 'O'), ('patient', 'O'), ('clinics', 'O'), ('.', 'O'))"
"RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .","(('RESULTS', 'O'), (':', 'O'), ('Hypothyroidism', 'B'), ('developed', 'O'), ('in', 'O'), ('40', 'O'), ('patients', 'O'), (',', 'O'), ('excluding', 'O'), ('8', 'O'), ('patients', 'O'), ('who', 'O'), ('were', 'O'), ('hypothyroid', 'B'), ('at', 'O'), ('baseline', 'O'), ('.', 'O'))"
All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .,"(('All', 'O'), ('patients', 'O'), ('having', 'O'), ('first', 'O'), ('-', 'O'), ('degree', 'O'), ('relatives', 'O'), ('affected', 'O'), ('by', 'O'), ('thyroid', 'B'), ('illness', 'I'), ('had', 'O'), ('accelerated', 'O'), ('onset', 'O'), ('of', 'O'), ('hypothyroidism', 'B'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('7', 'O'), ('years', 'O'), ('after', 'O'), ('onset', 'O'), ('of', 'O'), ('lithium', 'O'), ('therapy', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('patients', 'O'), ('without', 'O'), ('a', 'O'), ('family', 'O'), ('history', 'O'), ('(', 'O'), ('8', 'O'), ('.', 'O'), ('6', 'O'), ('years', 'O'), ('after', 'O'), ('onset', 'O'), ('of', 'O'), ('lithium', 'O'), ('therapy', 'O'), (')', 'O'), ('.', 'O'))"
Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .,"(('Women', 'O'), ('over', 'O'), ('60', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('were', 'O'), ('more', 'O'), ('often', 'O'), ('affected', 'O'), ('by', 'O'), ('hypothyroidism', 'B'), ('than', 'O'), ('women', 'O'), ('under', 'O'), ('60', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('(', 'O'), ('34', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('versus', 'O'), ('31', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Familial', 'O'), ('thyroid', 'B'), ('illness', 'I'), ('is', 'O'), ('a', 'O'), ('risk', 'O'), ('factor', 'O'), ('for', 'O'), ('hypothyroidism', 'B'), ('and', 'O'), ('hypercalcemia', 'B'), ('during', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('.', 'O'))"
Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .,"(('Severe', 'O'), ('immune', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('associated', 'O'), ('with', 'O'), ('prophylactic', 'O'), ('use', 'O'), ('of', 'O'), ('cefotetan', 'O'), ('in', 'O'), ('obstetric', 'O'), ('and', 'O'), ('gynecologic', 'O'), ('procedures', 'O'), ('.', 'O'))"
"Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .","(('Second', 'O'), ('-', 'O'), ('and', 'O'), ('third', 'O'), ('-', 'O'), ('generation', 'O'), ('cephalosporins', 'O'), (',', 'O'), ('especially', 'O'), ('cefotetan', 'O'), (',', 'O'), ('are', 'O'), ('increasingly', 'O'), ('associated', 'O'), ('with', 'O'), ('severe', 'O'), (',', 'O'), ('sometimes', 'O'), ('fatal', 'O'), ('immune', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('.', 'O'))"
We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .,"(('We', 'O'), ('noticed', 'O'), ('that', 'O'), ('10', 'O'), ('of', 'O'), ('our', 'O'), ('35', 'O'), ('cases', 'O'), ('of', 'O'), ('cefotetan', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemias', 'I'), ('were', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('received', 'O'), ('cefotetan', 'O'), ('prophylactically', 'O'), ('for', 'O'), ('obstetric', 'O'), ('and', 'O'), ('gynecologic', 'O'), ('procedures', 'O'), ('.', 'O'))"
Eight of these cases of severe immune hemolytic anemia are described .,"(('Eight', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), ('of', 'O'), ('severe', 'O'), ('immune', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .,"(('Effects', 'O'), ('of', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drugs', 'O'), ('on', 'O'), ('hemostasis', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('aneurysmal', 'B'), ('subarachnoid', 'I'), ('hemorrhage', 'I'), ('.', 'O'))"
"Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .","(('Patients', 'O'), ('with', 'O'), ('aneurysmal', 'B'), ('subarachnoid', 'I'), ('hemorrhage', 'I'), ('(', 'O'), ('SAH', 'B'), (')', 'O'), ('were', 'O'), ('randomized', 'O'), ('to', 'O'), ('receive', 'O'), ('either', 'O'), ('ketoprofen', 'O'), (',', 'O'), ('100', 'O'), ('mg', 'O'), (',', 'O'), ('three', 'O'), ('times', 'O'), ('a', 'O'), ('day', 'O'), ('(', 'O'), ('ketoprofen', 'O'), ('group', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('9', 'O'), (')', 'O'), ('or', 'O'), ('a', 'O'), ('weak', 'O'), ('NSAID', 'O'), (',', 'O'), ('acetaminophen', 'O'), (',', 'O'), ('1', 'O'), ('g', 'O'), (',', 'O'), ('three', 'O'), ('times', 'O'), ('a', 'O'), ('day', 'O'), ('(', 'O'), ('acetaminophen', 'O'), ('group', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('9', 'O'), (')', 'O'), ('starting', 'O'), ('immediately', 'O'), ('after', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('aneurysmal', 'B'), ('SAH', 'B'), ('.', 'O'))"
Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .,"(('Maximal', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('induced', 'O'), ('by', 'O'), ('6', 'O'), ('microM', 'O'), ('of', 'O'), ('adenosine', 'O'), ('diphosphate', 'O'), ('decreased', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('ketoprofen', 'O'), ('.', 'O'))"
"In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('maximal', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('acetaminophen', 'O'), ('group', 'O'), ('on', 'O'), ('the', 'O'), ('third', 'O'), ('postoperative', 'O'), ('day', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('pretreatment', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('results', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
One patient in the ketoprofen group developed a postoperative intracranial hematoma .,"(('One', 'O'), ('patient', 'O'), ('in', 'O'), ('the', 'O'), ('ketoprofen', 'O'), ('group', 'O'), ('developed', 'O'), ('a', 'O'), ('postoperative', 'O'), ('intracranial', 'O'), ('hematoma', 'B'), ('.', 'O'))"
"If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .","(('If', 'O'), ('ketoprofen', 'O'), ('is', 'O'), ('used', 'O'), ('before', 'O'), ('surgery', 'O'), ('on', 'O'), ('cerebral', 'O'), ('artery', 'B'), ('aneurysms', 'I'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('pose', 'O'), ('an', 'O'), ('additional', 'O'), ('risk', 'O'), ('factor', 'O'), ('for', 'O'), ('hemorrhage', 'B'), ('.', 'O'))"
Nitric oxide synthase expression in the course of lead - induced hypertension .,"(('Nitric', 'O'), ('oxide', 'O'), ('synthase', 'O'), ('expression', 'O'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('lead', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('.', 'O'))"
"We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .","(('We', 'O'), ('recently', 'O'), ('showed', 'O'), ('elevated', 'O'), ('reactive', 'O'), ('oxygen', 'O'), ('species', 'O'), ('(', 'O'), ('ROS', 'O'), (')', 'O'), (',', 'O'), ('reduced', 'O'), ('urinary', 'O'), ('excretion', 'O'), ('of', 'O'), ('NO', 'O'), ('metabolites', 'O'), ('(', 'O'), ('NOx', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('NO', 'O'), ('sequestration', 'O'), ('as', 'O'), ('nitrotyrosine', 'O'), ('in', 'O'), ('various', 'O'), ('tissues', 'O'), ('in', 'O'), ('rats', 'O'), ('with', 'O'), ('lead', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('.', 'O'))"
"This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .","(('This', 'O'), ('study', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('discern', 'O'), ('whether', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('urinary', 'O'), ('NOx', 'O'), ('in', 'O'), ('lead', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('is', 'O'), (',', 'O'), ('in', 'O'), ('part', 'O'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('depressed', 'O'), ('NO', 'O'), ('synthase', 'O'), ('(', 'O'), ('NOS', 'O'), (')', 'O'), ('expression', 'O'), ('.', 'O'))"
"Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .","(('Vitamin', 'O'), ('E', 'O'), ('supplementation', 'O'), ('ameliorated', 'O'), ('hypertension', 'B'), (',', 'O'), ('lowered', 'O'), ('plasma', 'O'), ('MDA', 'O'), ('concentration', 'O'), (',', 'O'), ('and', 'O'), ('raised', 'O'), ('urinary', 'O'), ('NOx', 'O'), ('excretion', 'O'), ('while', 'O'), ('significantly', 'O'), ('lowering', 'O'), ('vascular', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('renal', 'O'), (',', 'O'), ('tissue', 'O'), ('eNOS', 'O'), ('and', 'O'), ('iNOS', 'O'), ('expression', 'O'), ('.', 'O'))"
"In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('lead', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('in', 'O'), ('this', 'O'), ('model', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('compensatory', 'O'), ('upregulation', 'O'), ('of', 'O'), ('renal', 'O'), ('and', 'O'), ('vascular', 'O'), ('eNOS', 'O'), ('and', 'O'), ('iNOS', 'O'), ('expression', 'O'), ('.', 'O'))"
"This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .","(('This', 'O'), ('is', 'O'), (',', 'O'), ('in', 'O'), ('part', 'O'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('ROS', 'O'), ('-', 'O'), ('mediated', 'O'), ('NO', 'O'), ('inactivation', 'O'), (',', 'O'), ('lead', 'O'), ('-', 'O'), ('associated', 'O'), ('inhibition', 'O'), ('of', 'O'), ('NOS', 'O'), ('activity', 'O'), (',', 'O'), ('and', 'O'), ('perhaps', 'O'), ('stimulatory', 'O'), ('actions', 'O'), ('of', 'O'), ('increased', 'O'), ('shear', 'O'), ('stress', 'O'), ('associated', 'O'), ('with', 'O'), ('hypertension', 'B'), ('.', 'O'))"
Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .,"(('Glyceryl', 'O'), ('trinitrate', 'O'), ('induces', 'O'), ('attacks', 'O'), ('of', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('in', 'O'), ('sufferers', 'O'), ('of', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('.', 'O'))"
"Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .","(('Migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('and', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('have', 'O'), ('the', 'O'), ('same', 'O'), ('pain', 'B'), ('phase', 'O'), (',', 'O'), ('thus', 'O'), ('indicating', 'O'), ('that', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('and', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('share', 'O'), ('a', 'O'), ('common', 'O'), ('pathway', 'O'), ('of', 'O'), ('nociception', 'O'), ('.', 'O'))"
"In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .","(('In', 'O'), ('recent', 'O'), ('years', 'O'), (',', 'O'), ('increasing', 'O'), ('evidence', 'O'), ('has', 'O'), ('suggested', 'O'), ('that', 'O'), ('the', 'O'), ('messenger', 'O'), ('molecule', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('NO', 'O'), (')', 'O'), ('is', 'O'), ('involved', 'O'), ('in', 'O'), ('pain', 'B'), ('mechanisms', 'O'), ('of', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('.', 'O'))"
"In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('clarify', 'O'), ('whether', 'O'), ('the', 'O'), ('same', 'O'), ('is', 'O'), ('true', 'O'), ('for', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('we', 'O'), ('examined', 'O'), ('the', 'O'), ('headache', 'B'), ('response', 'O'), ('to', 'O'), ('intravenous', 'O'), ('infusion', 'O'), ('of', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('(', 'O'), ('GTN', 'O'), (')', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('min', 'O'), ('for', 'O'), ('20', 'O'), ('min', 'O'), (')', 'O'), ('in', 'O'), ('12', 'O'), ('sufferers', 'O'), ('of', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('.', 'O'))"
The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .,"(('The', 'O'), ('specific', 'O'), ('aim', 'O'), ('was', 'O'), ('to', 'O'), ('elucidate', 'O'), ('whether', 'O'), ('an', 'O'), ('aura', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('an', 'O'), ('attack', 'O'), ('of', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('could', 'O'), ('be', 'O'), ('induced', 'O'), ('.', 'O'))"
Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .,"(('Headache', 'B'), ('was', 'O'), ('more', 'O'), ('severe', 'O'), ('in', 'O'), ('migraineurs', 'B'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('controls', 'O'), ('during', 'O'), ('and', 'O'), ('immediately', 'O'), ('after', 'O'), ('GTN', 'O'), ('infusion', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('037', 'O'), (')', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('during', 'O'), ('the', 'O'), ('following', 'O'), ('11', 'O'), ('h', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('008', 'O'), (')', 'O'), ('.', 'O'))"
"In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .","(('In', 'O'), ('the', 'O'), ('controls', 'O'), (',', 'O'), ('the', 'O'), ('GTN', 'O'), ('-', 'O'), ('induced', 'O'), ('headache', 'B'), ('gradually', 'O'), ('disappeared', 'O'), (',', 'O'), ('whereas', 'O'), ('in', 'O'), ('migraineurs', 'B'), ('peak', 'O'), ('headache', 'B'), ('intensity', 'O'), ('occurred', 'O'), ('at', 'O'), ('a', 'O'), ('mean', 'O'), ('time', 'O'), ('of', 'O'), ('240', 'O'), ('min', 'O'), ('post', 'O'), ('-', 'O'), ('infusion', 'O'), ('.', 'O'))"
At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .,"(('At', 'O'), ('this', 'O'), ('time', 'O'), ('the', 'O'), ('induced', 'O'), ('headache', 'B'), ('in', 'O'), ('6', 'O'), ('of', 'O'), ('12', 'O'), ('migraineurs', 'B'), ('fulfilled', 'O'), ('the', 'O'), ('diagnostic', 'O'), ('criteria', 'O'), ('for', 'O'), ('migraine', 'B'), ('without', 'I'), ('aura', 'I'), ('of', 'O'), ('the', 'O'), ('International', 'O'), ('Headache', 'B'), ('Society', 'O'), ('.', 'O'))"
The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .,"(('The', 'O'), ('results', 'O'), ('therefore', 'O'), ('suggest', 'O'), ('that', 'O'), ('NO', 'O'), ('is', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('pain', 'B'), ('mechanisms', 'O'), ('of', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('.', 'O'))"
"Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .","(('Since', 'O'), ('cortical', 'O'), ('spreading', 'O'), ('depression', 'B'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('liberate', 'O'), ('NO', 'O'), ('in', 'O'), ('animals', 'O'), (',', 'O'), ('this', 'O'), ('finding', 'O'), ('may', 'O'), ('help', 'O'), ('our', 'O'), ('understanding', 'O'), ('of', 'O'), ('the', 'O'), ('coupling', 'O'), ('between', 'O'), ('cortical', 'O'), ('spreading', 'O'), ('depression', 'B'), ('and', 'O'), ('headache', 'B'), ('in', 'O'), ('migraine', 'B'), ('with', 'I'), ('aura', 'I'), ('.', 'O'))"
Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .,"(('Rapid', 'O'), ('reversal', 'O'), ('of', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('diltiazem', 'O'), ('-', 'O'), ('induced', 'O'), ('tetany', 'B'), ('with', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('.', 'O'))"
We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('tetany', 'B'), ('with', 'O'), ('sudden', 'O'), ('respiratory', 'B'), ('arrest', 'I'), ('after', 'O'), ('the', 'O'), ('infusion', 'O'), ('of', 'O'), ('intravenous', 'O'), ('diltiazem', 'O'), ('.', 'O'))"
"The administration of calcium chloride rapidly resolved the patient ' s tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .","(('The', 'O'), ('administration', 'O'), ('of', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('rapidly', 'O'), ('resolved', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('tetany', 'B'), ('with', 'O'), ('prompt', 'O'), ('recovery', 'O'), ('of', 'O'), ('respiratory', 'O'), ('function', 'O'), (',', 'O'), ('averting', 'O'), ('the', 'O'), ('need', 'O'), ('for', 'O'), ('more', 'O'), ('aggressive', 'O'), ('airway', 'O'), ('management', 'O'), ('and', 'O'), ('ventilatory', 'O'), ('support', 'O'), ('.', 'O'))"
The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .,"(('The', 'O'), ('emergency', 'O'), ('physician', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('that', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('tetany', 'B'), ('may', 'O'), ('accompany', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('intravenous', 'O'), ('diltiazem', 'O'), ('and', 'O'), ('that', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('rapid', 'O'), ('and', 'O'), ('effective', 'O'), ('remedy', 'O'), ('.', 'O'))"
Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD ),"(('Predictors', 'O'), ('of', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('heart', 'B'), ('failure', 'I'), ('during', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('inhibitor', 'O'), ('therapy', 'O'), (':', 'O'), ('results', 'O'), ('from', 'O'), ('the', 'O'), ('studies', 'O'), ('of', 'O'), ('left', 'B'), ('ventricular', 'I'), ('dysfunction', 'I'), ('(', 'O'), ('SOLVD', 'O'), (')', 'O'))"
"BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .","(('BACKGROUND', 'O'), (':', 'O'), ('Although', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('inhibitor', 'O'), ('therapy', 'O'), ('reduces', 'O'), ('mortality', 'O'), ('rates', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('(', 'O'), ('CHF', 'B'), (')', 'O'), (',', 'O'), ('it', 'O'), ('may', 'O'), ('also', 'O'), ('cause', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('.', 'O'))"
OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('quantify', 'O'), ('specific', 'O'), ('clinical', 'O'), ('predictors', 'O'), ('of', 'O'), ('reduction', 'B'), ('in', 'I'), ('renal', 'I'), ('function', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'B'), ('who', 'O'), ('are', 'O'), ('prescribed', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('inhibitor', 'O'), ('therapy', 'O'), ('.', 'O'))"
"METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .","(('METHOD', 'O'), (':', 'O'), ('We', 'O'), ('analyzed', 'O'), ('data', 'O'), ('from', 'O'), ('the', 'O'), ('Studies', 'O'), ('of', 'O'), ('Left', 'B'), ('Ventricular', 'I'), ('Dysfunction', 'I'), ('(', 'O'), ('SOLVD', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('of', 'O'), ('enalapril', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('CHF', 'B'), ('.', 'O'))"
Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .,"(('Decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('was', 'O'), ('defined', 'O'), ('as', 'O'), ('a', 'O'), ('rise', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('>', 'O'), ('/', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), ('(', 'O'), ('44', 'O'), ('micromol', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), ('from', 'O'), ('baseline', 'O'), ('.', 'O'))"
"We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .","(('We', 'O'), ('used', 'O'), ('time', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('event', 'O'), ('analysis', 'O'), ('to', 'O'), ('identify', 'O'), ('potential', 'O'), ('predictors', 'O'), ('of', 'O'), ('decrease', 'O'), ('in', 'O'), ('renal', 'O'), ('function', 'O'), ('including', 'O'), ('age', 'O'), (',', 'O'), ('baseline', 'O'), ('ejection', 'O'), ('fraction', 'O'), (',', 'O'), ('baseline', 'O'), ('creatinine', 'O'), (',', 'O'), ('low', 'O'), ('systolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('(', 'O'), ('<', 'O'), ('100', 'O'), ('mm', 'O'), ('Hg', 'O'), (')', 'O'), (',', 'O'), ('history', 'O'), ('of', 'O'), ('hypertension', 'B'), (',', 'O'), ('diabetes', 'B'), (',', 'O'), ('and', 'O'), ('use', 'O'), ('of', 'O'), ('antiplatelet', 'O'), (',', 'O'), ('diuretic', 'O'), (',', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('.', 'O'))"
RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .,"(('RESULTS', 'O'), (':', 'O'), ('Patients', 'O'), ('randomly', 'O'), ('assigned', 'O'), ('to', 'O'), ('enalapril', 'O'), ('had', 'O'), ('a', 'O'), ('33', 'O'), ('%', 'O'), ('greater', 'O'), ('likelihood', 'O'), ('of', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('than', 'O'), ('controls', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('003', 'O'), (')', 'O'), ('.', 'O'))"
"By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .","(('By', 'O'), ('multivariate', 'O'), ('analysis', 'O'), (',', 'O'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('placebo', 'O'), ('and', 'O'), ('enalapril', 'O'), ('groups', 'O'), ('older', 'O'), ('age', 'O'), (',', 'O'), ('diuretic', 'O'), ('therapy', 'O'), (',', 'O'), ('and', 'O'), ('diabetes', 'B'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), (',', 'O'), ('whereas', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('and', 'O'), ('higher', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('were', 'O'), ('renoprotective', 'O'), ('.', 'O'))"
"Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .","(('Older', 'O'), ('age', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('greater', 'O'), ('risk', 'O'), ('of', 'O'), ('developing', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), (',', 'O'), ('but', 'O'), ('significantly', 'O'), ('more', 'O'), ('so', 'O'), ('in', 'O'), ('the', 'O'), ('enalapril', 'O'), ('group', 'O'), ('(', 'O'), ('enalapril', 'O'), (':', 'O'), ('risk', 'O'), ('ratio', 'O'), ('[', 'O'), ('RR', 'O'), (']', 'O'), ('1', 'O'), ('.', 'O'), ('42', 'O'), ('per', 'O'), ('10', 'O'), ('years', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('[', 'O'), ('CI', 'O'), (']', 'O'), ('1', 'O'), ('.', 'O'), ('32', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('52', 'O'), ('with', 'O'), ('enalapril', 'O'), (';', 'O'), ('placebo', 'O'), (':', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('18', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('12', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('25', 'O'), (')', 'O'), ('.', 'O'))"
"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .","(('Diuretic', 'O'), ('therapy', 'O'), ('was', 'O'), ('likewise', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('greater', 'O'), ('risk', 'O'), ('of', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('in', 'O'), ('the', 'O'), ('enalapril', 'O'), ('group', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('89', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('70', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('08', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('35', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('09', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('66', 'O'), (')', 'O'), ('.', 'O'))"
"Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .","(('Conversely', 'O'), (',', 'O'), ('enalapril', 'O'), ('had', 'O'), ('a', 'O'), ('relative', 'O'), ('renoprotective', 'O'), ('effect', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('33', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('13', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('53', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('RR', 'O'), ('1', 'O'), ('.', 'O'), ('96', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('57', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('44', 'O'), (')', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('diabetes', 'B'), ('.', 'O'))"
"A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .","(('A', 'O'), ('lower', 'O'), ('risk', 'O'), ('of', 'O'), ('renal', 'B'), ('impairment', 'I'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('with', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('(', 'O'), ('RR', 'O'), ('0', 'O'), ('.', 'O'), ('70', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('57', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('85', 'O'), (')', 'O'), ('and', 'O'), ('higher', 'O'), ('baseline', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('(', 'O'), ('RR', 'O'), ('0', 'O'), ('.', 'O'), ('93', 'O'), ('per', 'O'), ('5', 'O'), ('%', 'O'), ('increment', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('91', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('96', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Enalapril', 'O'), ('use', 'O'), ('caused', 'O'), ('a', 'O'), ('33', 'O'), ('%', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('decreased', 'B'), ('renal', 'I'), ('function', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'B'), ('.', 'O'))"
"Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .","(('Diabetes', 'B'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('renal', 'B'), ('impairment', 'I'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('with', 'O'), ('CHF', 'B'), (',', 'O'), ('but', 'O'), ('this', 'O'), ('risk', 'O'), ('was', 'O'), ('reduced', 'O'), ('in', 'O'), ('the', 'O'), ('enalapril', 'O'), ('group', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O'))"
We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('female', 'O'), ('patient', 'O'), ('with', 'O'), ('a', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('a', 'O'), ('not', 'O'), ('otherwise', 'O'), ('specified', 'O'), ('psychotic', 'B'), ('disorder', 'I'), ('(', 'O'), ('DSM', 'O'), ('-', 'O'), ('IV', 'O'), (')', 'O'), ('who', 'O'), ('developed', 'O'), ('hypomania', 'B'), ('shortly', 'O'), ('after', 'O'), ('the', 'O'), ('introduction', 'O'), ('of', 'O'), ('olanzapine', 'O'), ('treatment', 'O'), ('.', 'O'))"
Acetazolamide - induced Gerstmann syndrome .,"(('Acetazolamide', 'O'), ('-', 'O'), ('induced', 'O'), ('Gerstmann', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .,"(('Acute', 'O'), ('confusion', 'B'), ('induced', 'O'), ('by', 'O'), ('acetazolamide', 'O'), ('is', 'O'), ('a', 'O'), ('well', 'O'), ('known', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reaction', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('renal', 'B'), ('impairment', 'I'), ('.', 'O'))"
"We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .","(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('acetazolamide', 'O'), ('-', 'O'), ('induced', 'O'), ('Gerstmann', 'B'), ('syndrome', 'I'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('normal', 'O'), ('renal', 'O'), ('function', 'O'), (',', 'O'), ('to', 'O'), ('highlight', 'O'), ('predisposing', 'O'), ('factors', 'O'), ('that', 'O'), ('are', 'O'), ('frequently', 'O'), ('overlooked', 'O'), ('.', 'O'))"
Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .,"(('Vasopressin', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('milrinone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('severe', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('phosphodiesterase', 'O'), ('inhibitors', 'O'), ('such', 'O'), ('as', 'O'), ('milrinone', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('heart', 'B'), ('failure', 'I'), ('is', 'O'), ('frequently', 'O'), ('restricted', 'O'), ('because', 'O'), ('they', 'O'), ('cause', 'O'), ('vasodilation', 'O'), ('and', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .","(('In', 'O'), ('patients', 'O'), ('with', 'O'), ('decompensated', 'O'), ('heart', 'B'), ('failure', 'I'), ('with', 'O'), ('hypotension', 'B'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('milrinone', 'O'), (',', 'O'), ('low', 'O'), ('doses', 'O'), ('of', 'O'), ('vasopressin', 'O'), ('restored', 'O'), ('blood', 'O'), ('pressure', 'O'), ('without', 'O'), ('inhibiting', 'O'), ('the', 'O'), ('inotropic', 'O'), ('effect', 'O'), ('of', 'O'), ('milrinone', 'O'), ('.', 'O'))"
"Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease (","(('Indications', 'O'), ('for', 'O'), ('early', 'O'), ('conversion', 'O'), ('were', 'O'), ('neurotoxicity', 'B'), ('(', 'O'), ('20', 'O'), (')', 'O'), (',', 'O'), ('(', 'B'), ('insulin', 'I'), ('-', 'I'), ('dependent', 'I'), (')', 'I'), ('diabetes', 'I'), ('mellitus', 'I'), ('(', 'O'), ('IDDM', 'B'), (')', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), (',', 'O'), ('nephrotoxicity', 'B'), ('(', 'O'), ('3', 'O'), (')', 'O'), (',', 'O'), ('gastrointestinal', 'B'), ('(', 'I'), ('GI', 'I'), (')', 'I'), ('toxicity', 'I'), ('(', 'O'), ('6', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('cardiomyopathy', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('for', 'O'), ('late', 'O'), ('conversion', 'O'), ('were', 'O'), ('neurotoxicity', 'B'), ('(', 'O'), ('15', 'O'), (')', 'O'), (',', 'O'), ('IDDM', 'B'), ('(', 'O'), ('12', 'O'), (')', 'O'), (',', 'O'), ('nephrotoxicity', 'B'), ('(', 'O'), ('3', 'O'), (')', 'O'), (',', 'O'), ('GI', 'B'), ('toxicity', 'I'), ('(', 'O'), ('5', 'O'), (')', 'O'), (',', 'O'), ('hepatotoxicity', 'B'), ('(', 'O'), ('6', 'O'), (')', 'O'), (',', 'O'), ('post', 'B'), ('-', 'I'), ('transplant', 'I'), ('lmphoproliferate', 'I'), ('disease', 'I'), ('(', 'O'))"
"PTLD ) ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .","(('PTLD', 'B'), (')', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('cardiomyopathy', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('(', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('pruritus', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
Ocular manifestations of juvenile rheumatoid arthritis .,"(('Ocular', 'O'), ('manifestations', 'O'), ('of', 'O'), ('juvenile', 'B'), ('rheumatoid', 'I'), ('arthritis', 'I'), ('.', 'O'))"
We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .,"(('We', 'O'), ('followed', 'O'), ('210', 'O'), ('cases', 'O'), ('of', 'O'), ('juvenile', 'B'), ('rheumatoid', 'I'), ('arthritis', 'I'), ('closely', 'O'), ('for', 'O'), ('eleven', 'O'), ('years', 'O'), ('.', 'O'))"
Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .,"(('Iridocyclitis', 'B'), ('was', 'O'), ('seen', 'O'), ('most', 'O'), ('frequently', 'O'), ('in', 'O'), ('young', 'O'), ('female', 'O'), ('patients', 'O'), ('(', 'O'), ('0', 'O'), ('to', 'O'), ('4', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('the', 'O'), ('monoarticular', 'O'), ('or', 'O'), ('pauciatricular', 'O'), ('form', 'O'), ('of', 'O'), ('the', 'O'), ('arthritis', 'B'), ('.', 'O'))"
"Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .","(('Forty', 'O'), ('-', 'O'), ('four', 'O'), ('percent', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('uveitis', 'B'), ('had', 'O'), ('one', 'O'), ('or', 'O'), ('more', 'O'), ('identifiable', 'O'), ('signs', 'O'), ('or', 'O'), ('symptoms', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('red', 'O'), ('eye', 'O'), (',', 'O'), ('ocular', 'B'), ('pain', 'I'), (',', 'O'), ('decreased', 'B'), ('visual', 'I'), ('acuity', 'I'), (',', 'O'), ('or', 'O'), ('photophobia', 'B'), (',', 'O'), ('in', 'O'), ('order', 'O'), ('of', 'O'), ('decreasing', 'O'), ('frequency', 'O'), ('.', 'O'))"
Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .,"(('Systemically', 'O'), ('administered', 'O'), ('corticosteroids', 'O'), ('were', 'O'), ('used', 'O'), ('in', 'O'), ('75', 'O'), ('of', 'O'), ('210', 'O'), ('cases', 'O'), (';', 'O'), ('a', 'O'), ('significant', 'O'), ('number', 'O'), ('of', 'O'), ('posterior', 'O'), ('subcapsular', 'O'), ('cataracts', 'B'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
"Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .","(('Surgical', 'O'), ('treatment', 'O'), ('of', 'O'), ('cataracts', 'B'), (',', 'O'), ('band', 'B'), ('keratopathy', 'I'), (',', 'O'), ('and', 'O'), ('glaucoma', 'B'), ('achieved', 'O'), ('uniformly', 'O'), ('discouraging', 'O'), ('results', 'O'), ('.', 'O'))"
Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .,"(('Cyclophosphamide', 'O'), ('-', 'O'), ('induced', 'O'), ('cystitis', 'B'), ('in', 'O'), ('freely', 'O'), ('-', 'O'), ('moving', 'O'), ('conscious', 'O'), ('rats', 'O'), (':', 'O'), ('behavioral', 'O'), ('approach', 'O'), ('to', 'O'), ('a', 'O'), ('new', 'O'), ('model', 'O'), ('of', 'O'), ('visceral', 'B'), ('pain', 'I'), ('.', 'O'))"
PURPOSE : To develop a model of visceral pain in rats using a behavioral approach .,"(('PURPOSE', 'O'), (':', 'O'), ('To', 'O'), ('develop', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('visceral', 'B'), ('pain', 'I'), ('in', 'O'), ('rats', 'O'), ('using', 'O'), ('a', 'O'), ('behavioral', 'O'), ('approach', 'O'), ('.', 'O'))"
"Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .","(('Cyclophosphamide', 'O'), ('(', 'O'), ('CP', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('antitumoral', 'O'), ('agent', 'O'), ('known', 'O'), ('to', 'O'), ('produce', 'O'), ('toxic', 'O'), ('effects', 'O'), ('on', 'O'), ('the', 'O'), ('bladder', 'O'), ('wall', 'O'), ('through', 'O'), ('its', 'O'), ('main', 'O'), ('toxic', 'O'), ('metabolite', 'O'), ('acrolein', 'O'), (',', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('induce', 'O'), ('cystitis', 'B'), ('.', 'O'))"
Morphine dose - dependently reversed these behavioral disorders .,"(('Morphine', 'O'), ('dose', 'O'), ('-', 'O'), ('dependently', 'O'), ('reversed', 'O'), ('these', 'O'), ('behavioral', 'B'), ('disorders', 'I'), ('.', 'O'))"
"At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .","(('At', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('administration', 'O'), ('of', 'O'), ('morphine', 'O'), (',', 'O'), ('histological', 'O'), ('modifications', 'O'), ('of', 'O'), ('the', 'O'), ('bladder', 'O'), ('wall', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('chorionic', 'O'), ('and', 'O'), ('muscle', 'O'), ('layer', 'O'), ('edema', 'B'), (',', 'O'), ('were', 'O'), ('observed', 'O'), ('.', 'O'))"
"CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Overall', 'O'), (',', 'O'), ('these', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('this', 'O'), ('experimental', 'O'), ('model', 'O'), ('of', 'O'), ('CP', 'O'), ('-', 'O'), ('induced', 'O'), ('cystitis', 'B'), ('may', 'O'), ('be', 'O'), ('an', 'O'), ('interesting', 'O'), ('new', 'O'), ('behavioral', 'O'), ('model', 'O'), ('of', 'O'), ('inflammatory', 'O'), ('visceral', 'B'), ('pain', 'I'), (',', 'O'), ('allowing', 'O'), ('a', 'O'), ('better', 'O'), ('understanding', 'O'), ('of', 'O'), ('these', 'O'), ('painful', 'B'), ('syndromes', 'I'), ('and', 'O'), ('thus', 'O'), ('a', 'O'), ('better', 'O'), ('therapeutic', 'O'), ('approach', 'O'), ('to', 'O'), ('them', 'O'), ('.', 'O'))"
Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .,"(('Prednisolone', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('dysfunction', 'I'), ('is', 'O'), ('caused', 'O'), ('more', 'O'), ('by', 'O'), ('atrophy', 'B'), ('than', 'O'), ('by', 'O'), ('altered', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('expression', 'O'), ('.', 'O'))"
"On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .","(('On', 'O'), ('Day', 'O'), ('8', 'O'), (',', 'O'), ('the', 'O'), ('nerve', 'O'), ('-', 'O'), ('evoked', 'O'), ('peak', 'O'), ('twitch', 'O'), ('tensions', 'O'), (',', 'O'), ('tetanic', 'B'), ('tensions', 'O'), (',', 'O'), ('and', 'O'), ('fatigability', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('curves', 'O'), ('of', 'O'), ('d', 'O'), ('-', 'O'), ('tubocurarine', 'O'), ('in', 'O'), ('the', 'O'), ('tibialis', 'O'), ('cranialis', 'O'), ('muscle', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('vivo', 'O'), ('and', 'O'), ('related', 'O'), ('to', 'O'), ('muscle', 'O'), ('mass', 'O'), ('or', 'O'), ('expression', 'O'), ('of', 'O'), ('AChRs', 'O'), ('.', 'O'))"
"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .","(('The', 'O'), ('evoked', 'O'), ('peak', 'O'), ('twitch', 'O'), ('and', 'O'), ('tetanic', 'B'), ('tensions', 'O'), ('were', 'O'), ('less', 'O'), ('in', 'O'), ('the', 'O'), ('P100', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('P10', 'O'), ('or', 'O'), ('S', 'O'), ('groups', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('tension', 'O'), ('per', 'O'), ('milligram', 'O'), ('of', 'O'), ('muscle', 'O'), ('mass', 'O'), ('was', 'O'), ('greater', 'O'), ('in', 'O'), ('the', 'O'), ('P100', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('S', 'O'), ('group', 'O'), ('.', 'O'))"
"Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('neuromuscular', 'B'), ('dysfunction', 'I'), ('after', 'O'), ('prednisolone', 'O'), ('is', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), (',', 'O'), ('and', 'O'), ('derives', 'O'), ('primarily', 'O'), ('from', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('and', 'O'), ('derives', 'O'), ('less', 'O'), ('so', 'O'), ('from', 'O'), ('changes', 'O'), ('in', 'O'), ('AChR', 'O'), ('expression', 'O'), ('.', 'O'))"
We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .,"(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('observed', 'O'), ('effects', 'O'), ('are', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('and', 'O'), ('derive', 'O'), ('primarily', 'O'), ('from', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('and', 'O'), ('derive', 'O'), ('less', 'O'), ('from', 'O'), ('changes', 'O'), ('in', 'O'), ('acetylcholine', 'O'), ('receptor', 'O'), ('expression', 'O'), ('.', 'O'))"
Apomorphine : an underutilized therapy for Parkinson ' s disease .,"(('Apomorphine', 'O'), (':', 'O'), ('an', 'O'), ('underutilized', 'O'), ('therapy', 'O'), ('for', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson ' s disease .,"(('Apomorphine', 'O'), ('was', 'O'), ('the', 'O'), ('first', 'O'), ('dopaminergic', 'O'), ('drug', 'O'), ('ever', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('symptoms', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson ' s disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .","(('While', 'O'), ('powerful', 'O'), ('antiparkinsonian', 'O'), ('effects', 'O'), ('had', 'O'), ('been', 'O'), ('observed', 'O'), ('as', 'O'), ('early', 'O'), ('as', 'O'), ('1951', 'O'), (',', 'O'), ('the', 'O'), ('potential', 'O'), ('of', 'O'), ('treating', 'O'), ('fluctuating', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('by', 'O'), ('subcutaneous', 'O'), ('administration', 'O'), ('of', 'O'), ('apomorphine', 'O'), ('has', 'O'), ('only', 'O'), ('recently', 'O'), ('become', 'O'), ('the', 'O'), ('subject', 'O'), ('of', 'O'), ('systematic', 'O'), ('study', 'O'), ('.', 'O'))"
"In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('convincing', 'O'), ('clinical', 'O'), ('evidence', 'O'), ('that', 'O'), ('monotherapy', 'O'), ('with', 'O'), ('continuous', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('infusions', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('marked', 'O'), ('reductions', 'O'), ('of', 'O'), ('preexisting', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('.', 'O'))"
"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .","(('The', 'O'), ('main', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('treatment', 'O'), ('are', 'O'), ('related', 'O'), ('to', 'O'), ('cutaneous', 'O'), ('tolerability', 'O'), ('problems', 'O'), (',', 'O'), ('whereas', 'O'), ('sedation', 'O'), ('and', 'O'), ('psychiatric', 'B'), ('complications', 'O'), ('play', 'O'), ('a', 'O'), ('lesser', 'O'), ('role', 'O'), ('.', 'O'))"
"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson ' s disease , this approach seems to deserve more widespread clinical use .","(('Given', 'O'), ('the', 'O'), ('marked', 'O'), ('degree', 'O'), ('of', 'O'), ('efficacy', 'O'), ('of', 'O'), ('subcutaneous', 'O'), ('apomorphine', 'O'), ('treatment', 'O'), ('in', 'O'), ('fluctuating', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('this', 'O'), ('approach', 'O'), ('seems', 'O'), ('to', 'O'), ('deserve', 'O'), ('more', 'O'), ('widespread', 'O'), ('clinical', 'O'), ('use', 'O'), ('.', 'O'))"
"OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer ' s disease , yet correlations between central and peripheral responses have not been properly studied .","(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('pharmacological', 'O'), ('response', 'O'), ('to', 'O'), ('drugs', 'O'), ('that', 'O'), ('act', 'O'), ('on', 'O'), ('the', 'O'), ('cholinergic', 'O'), ('system', 'O'), ('of', 'O'), ('the', 'O'), ('iris', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('predict', 'O'), ('deficits', 'O'), ('in', 'O'), ('central', 'O'), ('cholinergic', 'O'), ('functioning', 'O'), ('due', 'O'), ('to', 'O'), ('diseases', 'O'), ('such', 'O'), ('as', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('yet', 'O'), ('correlations', 'O'), ('between', 'O'), ('central', 'O'), ('and', 'O'), ('peripheral', 'O'), ('responses', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('properly', 'O'), ('studied', 'O'), ('.', 'O'))"
OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .,"(('OUTCOME', 'O'), ('MEASURES', 'O'), (':', 'O'), ('Pupil', 'O'), ('size', 'O'), ('at', 'O'), ('time', 'O'), ('points', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('tropicamide', 'O'), ('and', 'O'), ('pilocarpine', 'O'), (';', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('impairment', 'B'), ('in', 'I'), ('word', 'I'), ('recall', 'I'), ('.', 'O'))"
"Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .","(('Compared', 'O'), ('with', 'O'), ('the', 'O'), ('young', 'O'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('elderly', 'O'), ('group', 'O'), ('had', 'O'), ('greater', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('impairment', 'B'), ('in', 'I'), ('word', 'I'), ('recall', 'I'), ('60', 'O'), (',', 'O'), ('90', 'O'), ('and', 'O'), ('120', 'O'), ('minutes', 'O'), ('after', 'O'), ('administration', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Pain responses in methadone - maintained opioid abusers .,"(('Pain', 'B'), ('responses', 'O'), ('in', 'O'), ('methadone', 'O'), ('-', 'O'), ('maintained', 'O'), ('opioid', 'O'), ('abusers', 'O'), ('.', 'O'))"
"Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .","(('Providing', 'O'), ('pain', 'B'), ('management', 'O'), ('for', 'O'), ('known', 'O'), ('opioid', 'O'), ('abusers', 'O'), ('is', 'O'), ('a', 'O'), ('challenging', 'O'), ('clinical', 'O'), ('task', 'O'), (',', 'O'), ('in', 'O'), ('part', 'O'), ('because', 'O'), ('little', 'O'), ('is', 'O'), ('known', 'O'), ('about', 'O'), ('their', 'O'), ('pain', 'B'), ('experience', 'O'), ('and', 'O'), ('analgesic', 'O'), ('requirements', 'O'), ('.', 'O'))"
This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('describe', 'O'), ('pain', 'B'), ('tolerance', 'O'), ('and', 'O'), ('analgesic', 'O'), ('response', 'O'), ('in', 'O'), ('a', 'O'), ('sample', 'O'), ('of', 'O'), ('opioid', 'B'), ('addicts', 'I'), ('stabilized', 'O'), ('in', 'O'), ('methadone', 'O'), ('-', 'O'), ('maintenance', 'O'), ('(', 'O'), ('MM', 'O'), (')', 'O'), ('treatment', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('60', 'O'), (')', 'O'), ('in', 'O'), ('comparison', 'O'), ('to', 'O'), ('matched', 'O'), ('nondependent', 'O'), ('control', 'O'), ('subjects', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('60', 'O'), (')', 'O'), ('.', 'O'))"
"By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .","(('By', 'O'), ('using', 'O'), ('a', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('two', 'O'), ('-', 'O'), ('way', 'O'), ('factorial', 'O'), ('design', 'O'), (',', 'O'), ('tolerance', 'O'), ('to', 'O'), ('cold', 'O'), ('-', 'O'), ('pressor', 'O'), ('(', 'O'), ('CP', 'O'), (')', 'O'), ('pain', 'B'), ('was', 'O'), ('examined', 'O'), (',', 'O'), ('both', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('therapeutic', 'O'), ('doses', 'O'), ('of', 'O'), ('common', 'O'), ('opioid', 'O'), ('(', 'O'), ('hydromorphone', 'O'), ('2', 'O'), ('mg', 'O'), (')', 'O'), ('and', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('(', 'O'), ('ketorolac', 'O'), ('10', 'O'), ('mg', 'O'), (')', 'O'), ('analgesic', 'O'), ('agents', 'O'), ('.', 'O'))"
"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .","(('Results', 'O'), ('showed', 'O'), ('that', 'O'), ('MM', 'O'), ('individuals', 'O'), ('were', 'O'), ('significantly', 'O'), ('less', 'O'), ('tolerant', 'O'), ('of', 'O'), ('CP', 'O'), ('pain', 'B'), ('than', 'O'), ('control', 'O'), ('subjects', 'O'), (',', 'O'), ('replicating', 'O'), ('previous', 'O'), ('work', 'O'), ('.', 'O'))"
These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .,"(('These', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('MM', 'O'), ('opioid', 'O'), ('abusers', 'O'), ('represent', 'O'), ('a', 'O'), ('pain', 'B'), ('-', 'I'), ('intolerant', 'I'), ('subset', 'O'), ('of', 'O'), ('clinical', 'O'), ('patients', 'O'), ('.', 'O'))"
Their complaints of pain should be evaluated seriously and managed aggressively .,"(('Their', 'O'), ('complaints', 'O'), ('of', 'O'), ('pain', 'B'), ('should', 'O'), ('be', 'O'), ('evaluated', 'O'), ('seriously', 'O'), ('and', 'O'), ('managed', 'O'), ('aggressively', 'O'), ('.', 'O'))"
High - dose methylprednisolone may do more harm for spinal cord injury .,"(('High', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('may', 'O'), ('do', 'O'), ('more', 'O'), ('harm', 'O'), ('for', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('.', 'O'))"
"Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .","(('Because', 'O'), ('of', 'O'), ('the', 'O'), ('National', 'O'), ('Acute', 'O'), ('Spinal', 'B'), ('Cord', 'I'), ('Injury', 'I'), ('Studies', 'O'), ('(', 'O'), ('NASCIS', 'O'), (')', 'O'), (',', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('became', 'O'), ('the', 'O'), ('standard', 'O'), ('of', 'O'), ('care', 'O'), ('for', 'O'), ('the', 'O'), ('acute', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('.', 'O'))"
"In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .","(('In', 'O'), ('the', 'O'), ('NASCIS', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('mention', 'O'), ('regarding', 'O'), ('the', 'O'), ('possibility', 'O'), ('of', 'O'), ('acute', 'O'), ('corticosteroid', 'O'), ('myopathy', 'B'), ('that', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('methylprednisolone', 'O'), ('may', 'O'), ('cause', 'O'), ('.', 'O'))"
We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .,"(('We', 'O'), ('hypothesize', 'O'), ('that', 'O'), ('it', 'O'), ('may', 'O'), ('cause', 'O'), ('some', 'O'), ('damage', 'B'), ('to', 'I'), ('the', 'I'), ('muscle', 'I'), ('of', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('patients', 'O'), ('.', 'O'))"
"Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .","(('Further', 'O'), (',', 'O'), ('steroid', 'O'), ('myopathy', 'B'), ('recovers', 'O'), ('naturally', 'O'), ('and', 'O'), ('the', 'O'), ('neurological', 'O'), ('improvement', 'O'), ('shown', 'O'), ('in', 'O'), ('the', 'O'), ('NASCIS', 'O'), ('may', 'O'), ('be', 'O'), ('just', 'O'), ('a', 'O'), ('recording', 'O'), ('of', 'O'), ('this', 'O'), ('natural', 'O'), ('motor', 'O'), ('recovery', 'O'), ('from', 'O'), ('the', 'O'), ('steroid', 'O'), ('myopathy', 'B'), (',', 'O'), ('instead', 'O'), ('of', 'O'), ('any', 'O'), ('protection', 'O'), ('that', 'O'), ('methylprednisolone', 'O'), ('offers', 'O'), ('to', 'O'), ('the', 'O'), ('spinal', 'B'), ('cord', 'I'), ('injury', 'I'), ('.', 'O'))"
"To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .","(('To', 'O'), ('our', 'O'), ('knowledge', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('discussion', 'O'), ('considering', 'O'), ('the', 'O'), ('possibility', 'O'), ('that', 'O'), ('the', 'O'), ('methylprednisolone', 'O'), ('recommended', 'O'), ('by', 'O'), ('NASCIS', 'O'), ('may', 'O'), ('cause', 'O'), ('acute', 'O'), ('corticosteroid', 'O'), ('myopathy', 'B'), ('.', 'O'))"
BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('is', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('RAPA', 'O'), ('conversion', 'O'), ('in', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('cyclosporine', 'O'), ('(', 'O'), ('CsA', 'O'), (')', 'O'), ('or', 'O'), ('tacrolimus', 'O'), ('(', 'O'), ('Tac', 'O'), (')', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .","(('The', 'O'), ('indications', 'O'), ('for', 'O'), ('switch', 'O'), ('were', 'O'), ('chronic', 'O'), ('CsA', 'O'), ('or', 'O'), ('Tac', 'O'), ('nephrotoxicity', 'B'), ('(', 'O'), ('12', 'O'), (')', 'O'), (',', 'O'), ('acute', 'O'), ('CsA', 'O'), ('or', 'O'), ('Tac', 'O'), ('toxicity', 'B'), ('(', 'O'), ('3', 'O'), (')', 'O'), (',', 'O'), ('severe', 'O'), ('facial', 'B'), ('dysmorphism', 'I'), ('(', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('posttransplant', 'B'), ('lymphoproliferative', 'I'), ('disorder', 'I'), ('(', 'O'), ('PTLD', 'B'), (')', 'O'), ('in', 'O'), ('remission', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('hepatotoxicity', 'B'), ('in', 'O'), ('1', 'O'), ('.', 'O'))"
RESULTS : In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .,"(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('the', 'O'), ('12', 'O'), ('patients', 'O'), ('switched', 'O'), ('because', 'O'), ('of', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('[', 'O'), ('233', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('34', 'O'), ('to', 'O'), ('210', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('56', 'O'), ('micromol', 'O'), ('/', 'O'), ('liter', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('at', 'O'), ('6', 'O'), ('months', 'O'), (']', 'O'), ('.', 'O'))"
"Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .","(('Five', 'O'), ('patients', 'O'), ('developed', 'O'), ('pneumonia', 'B'), ('(', 'O'), ('two', 'O'), ('Pneumocystis', 'B'), ('carinii', 'I'), ('pneumonia', 'I'), (',', 'O'), ('one', 'O'), ('infectious', 'B'), ('mononucleosis', 'I'), ('with', 'O'), ('polyclonal', 'O'), ('PTLD', 'B'), ('lung', 'O'), ('infiltrate', 'O'), (')', 'O'), ('and', 'O'), ('two', 'O'), ('had', 'O'), ('bronchiolitis', 'B'), ('obliterans', 'I'), ('.', 'O'))"
"RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .","(('RAPA', 'O'), ('was', 'O'), ('discontinued', 'O'), ('in', 'O'), ('four', 'O'), ('patients', 'O'), (',', 'O'), ('because', 'O'), ('of', 'O'), ('pneumonia', 'B'), ('in', 'O'), ('two', 'O'), (',', 'O'), ('PTLD', 'B'), ('in', 'O'), ('one', 'O'), (',', 'O'), ('and', 'O'), ('oral', 'O'), ('aphtous', 'B'), ('ulcers', 'I'), ('in', 'O'), ('one', 'O'), ('.', 'O'))"
"However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .","(('However', 'O'), (',', 'O'), ('when', 'O'), ('converting', 'O'), ('patients', 'O'), ('to', 'O'), ('RAPA', 'O'), ('drug', 'O'), ('levels', 'O'), ('should', 'O'), ('be', 'O'), ('monitored', 'O'), ('to', 'O'), ('avoid', 'O'), ('over', 'O'), ('-', 'O'), ('immunosuppression', 'O'), ('and', 'O'), ('adequate', 'O'), ('antiviral', 'O'), ('and', 'O'), ('Pneumocystis', 'B'), ('carinii', 'I'), ('pneumonia', 'I'), ('prophylaxis', 'O'), ('should', 'O'), ('be', 'O'), ('given', 'O'), ('.', 'O'))"
"Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .","(('Electro', 'O'), ('-', 'O'), ('oculography', 'O'), (',', 'O'), ('electroretinography', 'O'), (',', 'O'), ('visual', 'O'), ('evoked', 'O'), ('potentials', 'O'), (',', 'O'), ('and', 'O'), ('multifocal', 'O'), ('electroretinography', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('vigabatrin', 'O'), ('-', 'O'), ('attributed', 'O'), ('visual', 'B'), ('field', 'I'), ('constriction', 'I'), ('.', 'O'))"
PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .,"(('PURPOSE', 'O'), (':', 'O'), ('Symptomatic', 'O'), ('visual', 'B'), ('field', 'I'), ('constriction', 'I'), ('thought', 'O'), ('to', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('vigabatrin', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .","(('The', 'O'), ('current', 'O'), ('study', 'O'), ('investigated', 'O'), ('the', 'O'), ('visual', 'O'), ('fields', 'O'), ('and', 'O'), ('visual', 'O'), ('electrophysiology', 'O'), ('of', 'O'), ('eight', 'O'), ('patients', 'O'), ('with', 'O'), ('known', 'O'), ('vigabatrin', 'O'), ('-', 'O'), ('attributed', 'O'), ('visual', 'B'), ('field', 'I'), ('loss', 'I'), (',', 'O'), ('three', 'O'), ('of', 'O'), ('whom', 'O'), ('were', 'O'), ('reported', 'O'), ('previously', 'O'), ('.', 'O'))"
RESULTS : Seven patients showed marked visual field constriction with some sparing of the temporal visual field .,"(('RESULTS', 'O'), (':', 'O'), ('Seven', 'O'), ('patients', 'O'), ('showed', 'O'), ('marked', 'O'), ('visual', 'B'), ('field', 'I'), ('constriction', 'I'), ('with', 'O'), ('some', 'O'), ('sparing', 'O'), ('of', 'O'), ('the', 'O'), ('temporal', 'O'), ('visual', 'O'), ('field', 'O'), ('.', 'O'))"
CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .,"(('CONCLUSION', 'O'), (':', 'O'), ('Marked', 'O'), ('visual', 'B'), ('field', 'I'), ('constriction', 'I'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('vigabatrin', 'O'), ('therapy', 'O'), ('.', 'O'))"
Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .,"(('Myocardial', 'B'), ('ischemia', 'I'), ('due', 'O'), ('to', 'O'), ('coronary', 'B'), ('artery', 'I'), ('spasm', 'I'), ('during', 'O'), ('dobutamine', 'O'), ('stress', 'O'), ('echocardiography', 'O'), ('.', 'O'))"
Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .,"(('Dobutamine', 'O'), ('stress', 'O'), ('echocardiography', 'O'), ('(', 'O'), ('DSE', 'O'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('useful', 'O'), ('and', 'O'), ('safe', 'O'), ('provocation', 'O'), ('test', 'O'), ('for', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('.', 'O'))"
"Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .","(('Until', 'O'), ('now', 'O'), (',', 'O'), ('the', 'O'), ('test', 'O'), ('has', 'O'), ('been', 'O'), ('focused', 'O'), ('only', 'O'), ('on', 'O'), ('the', 'O'), ('organic', 'O'), ('lesion', 'O'), ('in', 'O'), ('the', 'O'), ('coronary', 'O'), ('artery', 'O'), (',', 'O'), ('and', 'O'), ('positive', 'O'), ('DSE', 'O'), ('has', 'O'), ('indicated', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('significant', 'O'), ('fixed', 'O'), ('coronary', 'B'), ('artery', 'I'), ('stenosis', 'I'), ('.', 'O'))"
The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('is', 'O'), ('to', 'O'), ('examine', 'O'), ('whether', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('due', 'O'), ('to', 'O'), ('coronary', 'B'), ('spasm', 'I'), ('is', 'O'), ('induced', 'O'), ('by', 'O'), ('dobutamine', 'O'), ('.', 'O'))"
We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .,"(('We', 'O'), ('performed', 'O'), ('DSE', 'O'), ('on', 'O'), ('51', 'O'), ('patients', 'O'), ('with', 'O'), ('coronary', 'B'), ('spastic', 'I'), ('angina', 'I'), ('but', 'O'), ('without', 'O'), ('significant', 'O'), ('fixed', 'O'), ('coronary', 'B'), ('artery', 'I'), ('stenosis', 'I'), ('.', 'O'))"
All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .,"(('All', 'O'), ('patients', 'O'), ('had', 'O'), ('anginal', 'B'), ('attacks', 'O'), ('at', 'O'), ('rest', 'O'), ('with', 'O'), ('ST', 'O'), ('elevation', 'O'), ('on', 'O'), ('the', 'O'), ('electrocardiogram', 'O'), ('(', 'O'), ('variant', 'B'), ('angina', 'I'), (')', 'O'), ('.', 'O'))"
"Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .","(('Coronary', 'O'), ('spasm', 'O'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('intracoronary', 'O'), ('injection', 'O'), ('of', 'O'), ('acetylcholine', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('fixed', 'O'), ('coronary', 'B'), ('artery', 'I'), ('stenosis', 'I'), ('was', 'O'), ('documented', 'O'), ('on', 'O'), ('angiograms', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('.', 'O'))"
"All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .","(('All', 'O'), ('7', 'O'), ('patients', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('chest', 'B'), ('pain', 'I'), ('during', 'O'), ('asynergy', 'O'), (',', 'O'), ('and', 'O'), ('both', 'O'), ('chest', 'B'), ('pain', 'I'), ('and', 'O'), ('electrocardiographic', 'O'), ('changes', 'O'), ('were', 'O'), ('preceded', 'O'), ('by', 'O'), ('asynergy', 'O'), ('.', 'O'))"
These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .,"(('These', 'O'), ('findings', 'O'), ('indicate', 'O'), ('that', 'O'), ('dobutamine', 'O'), ('can', 'O'), ('provoke', 'O'), ('coronary', 'B'), ('spasm', 'I'), ('in', 'O'), ('some', 'O'), ('patients', 'O'), ('with', 'O'), ('coronary', 'B'), ('spastic', 'I'), ('angina', 'I'), ('.', 'O'))"
"When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .","(('When', 'O'), ('DSE', 'O'), ('is', 'O'), ('performed', 'O'), ('to', 'O'), ('evaluate', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), (',', 'O'), ('not', 'O'), ('only', 'O'), ('fixed', 'O'), ('coronary', 'B'), ('stenosis', 'I'), (',', 'O'), ('but', 'O'), ('also', 'O'), ('coronary', 'B'), ('spasm', 'I'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('as', 'O'), ('a', 'O'), ('genesis', 'O'), ('of', 'O'), ('asynergy', 'O'), ('.', 'O'))"
Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .,"(('Effect', 'O'), ('of', 'O'), ('intravenous', 'O'), ('metoprolol', 'O'), ('or', 'O'), ('intravenous', 'O'), ('metoprolol', 'O'), ('plus', 'O'), ('glucagon', 'O'), ('on', 'O'), ('dobutamine', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('.', 'O'))"
"CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .","(('CONCLUSION', 'O'), (':', 'O'), ('During', 'O'), ('dobutamine', 'O'), ('stress', 'O'), ('testing', 'O'), (',', 'O'), ('metoprolol', 'O'), ('attenuates', 'O'), ('or', 'O'), ('eliminates', 'O'), ('evidence', 'O'), ('of', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('.', 'O'))"
The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .,"(('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('explore', 'O'), ('the', 'O'), ('functional', 'O'), ('anatomy', 'O'), ('of', 'O'), ('the', 'O'), ('globus', 'O'), ('pallidus', 'O'), ('internus', 'O'), ('(', 'O'), ('GPi', 'O'), (')', 'O'), ('by', 'O'), ('studying', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('unilateral', 'O'), ('pallidotomy', 'O'), ('on', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('and', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('(', 'O'), ('LID', 'B'), (')', 'O'), ('.', 'O'))"
"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .","(('We', 'O'), ('found', 'O'), ('significant', 'O'), ('positive', 'O'), ('correlations', 'O'), ('between', 'O'), ('the', 'O'), ('preoperative', 'O'), ('levodopa', 'O'), ('responsiveness', 'O'), ('of', 'O'), ('motor', 'O'), ('signs', 'O'), ('and', 'O'), ('the', 'O'), ('levodopa', 'O'), ('responsiveness', 'O'), ('of', 'O'), ('scores', 'O'), ('in', 'O'), ('timed', 'O'), ('tests', 'O'), ('(', 'O'), ('Core', 'O'), ('Assessment', 'O'), ('Program', 'O'), ('for', 'O'), ('Intracerebral', 'O'), ('Transplantations', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('contralateral', 'O'), ('limbs', 'O'), ('and', 'O'), ('the', 'O'), ('improvement', 'O'), ('in', 'O'), ('these', 'O'), ('scores', 'O'), ('after', 'O'), ('surgery', 'O'), (',', 'O'), ('whereas', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('correlation', 'O'), ('with', 'O'), ('the', 'O'), ('improvement', 'O'), ('in', 'O'), ('LID', 'B'), ('.', 'O'))"
"We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .","(('We', 'O'), ('also', 'O'), ('found', 'O'), ('a', 'O'), ('highly', 'O'), ('significant', 'O'), ('correlation', 'O'), ('(', 'O'), ('P', 'O'), (':', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (',', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), (')', 'O'), ('between', 'O'), ('the', 'O'), ('volume', 'O'), ('of', 'O'), ('the', 'O'), ('ventral', 'O'), ('lesion', 'O'), ('in', 'O'), ('the', 'O'), ('GPi', 'O'), ('and', 'O'), ('the', 'O'), ('improvement', 'O'), ('in', 'O'), ('LID', 'B'), ('in', 'O'), ('the', 'O'), ('contralateral', 'O'), ('limbs', 'O'), (',', 'O'), ('whereas', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('correlation', 'O'), ('between', 'O'), ('the', 'O'), ('ventral', 'O'), ('volume', 'O'), ('and', 'O'), ('the', 'O'), ('improvement', 'O'), ('in', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('.', 'O'))"
The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .,"(('The', 'O'), ('volumes', 'O'), ('of', 'O'), ('the', 'O'), ('total', 'O'), ('lesion', 'O'), ('cylinder', 'O'), ('and', 'O'), ('the', 'O'), ('dorsal', 'O'), ('lesion', 'O'), ('did', 'O'), ('not', 'O'), ('correlate', 'O'), ('with', 'O'), ('the', 'O'), ('outcome', 'O'), ('of', 'O'), ('either', 'O'), ('dyskinesias', 'B'), ('or', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('.', 'O'))"
The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .,"(('The', 'O'), ('differential', 'O'), ('predictive', 'O'), ('value', 'O'), ('of', 'O'), ('levodopa', 'O'), ('responsiveness', 'O'), ('for', 'O'), ('the', 'O'), ('outcome', 'O'), ('of', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('and', 'O'), ('LID', 'B'), ('and', 'O'), ('the', 'O'), ('different', 'O'), ('correlations', 'O'), ('of', 'O'), ('ventral', 'O'), ('lesion', 'O'), ('volume', 'O'), ('with', 'O'), ('dyskinesias', 'B'), ('and', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('indicate', 'O'), ('that', 'O'), ('different', 'O'), ('anatomical', 'O'), ('or', 'O'), ('pathophysiological', 'O'), ('substrates', 'O'), ('may', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('generation', 'O'), ('of', 'O'), ('parkinsonian', 'B'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('signs', 'O'), ('and', 'O'), ('dyskinesias', 'B'), ('.', 'O'))"
"Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .","(('Whereas', 'O'), ('cells', 'O'), ('in', 'O'), ('a', 'O'), ('wider', 'O'), ('area', 'O'), ('of', 'O'), ('the', 'O'), ('GPi', 'O'), ('may', 'O'), ('be', 'O'), ('implicated', 'O'), ('in', 'O'), ('parkinsonism', 'B'), (',', 'O'), ('the', 'O'), ('ventral', 'O'), ('GPi', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('crucial', 'O'), ('for', 'O'), ('the', 'O'), ('manifestation', 'O'), ('of', 'O'), ('LID', 'B'), ('.', 'O'))"
"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .","(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('our', 'O'), ('observations', 'O'), ('are', 'O'), ('additional', 'O'), ('proof', 'O'), ('of', 'O'), ('the', 'O'), ('functional', 'O'), ('somatotopy', 'O'), ('of', 'O'), ('the', 'O'), ('systems', 'O'), ('within', 'O'), ('the', 'O'), ('GPi', 'O'), ('that', 'O'), ('mediate', 'O'), ('parkinsonism', 'B'), ('and', 'O'), ('dyskinesias', 'B'), (',', 'O'), ('especially', 'O'), ('along', 'O'), ('the', 'O'), ('dorsoventral', 'O'), ('trajectory', 'O'), ('used', 'O'), ('in', 'O'), ('pallidotomy', 'O'), ('.', 'O'))"
Screening for stimulant use in adult emergency department seizure patients .,"(('Screening', 'O'), ('for', 'O'), ('stimulant', 'O'), ('use', 'O'), ('in', 'O'), ('adult', 'O'), ('emergency', 'O'), ('department', 'O'), ('seizure', 'B'), ('patients', 'O'), ('.', 'O'))"
OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('positive', 'O'), ('plasma', 'O'), ('drug', 'O'), ('screening', 'O'), ('for', 'O'), ('cocaine', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('in', 'O'), ('adult', 'O'), ('emergency', 'O'), ('department', 'O'), ('seizure', 'B'), ('patients', 'O'), ('.', 'O'))"
METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .,"(('METHODS', 'O'), (':', 'O'), ('This', 'O'), ('prospective', 'O'), ('study', 'O'), ('evaluated', 'O'), ('consecutive', 'O'), ('eligible', 'O'), ('seizure', 'B'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('a', 'O'), ('plasma', 'O'), ('sample', 'O'), ('collected', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('their', 'O'), ('clinical', 'O'), ('evaluation', 'O'), ('.', 'O'))"
"Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .","(('Patient', 'O'), ('demographics', 'O'), (',', 'O'), ('history', 'O'), ('of', 'O'), ('underlying', 'O'), ('drug', 'O'), ('or', 'O'), ('alcohol', 'O'), ('-', 'O'), ('related', 'O'), ('seizure', 'B'), ('disorder', 'O'), (',', 'O'), ('estimated', 'O'), ('time', 'O'), ('from', 'O'), ('seizure', 'B'), ('to', 'O'), ('sample', 'O'), ('collection', 'O'), (',', 'O'), ('history', 'O'), ('or', 'O'), ('suspicion', 'O'), ('of', 'O'), ('cocaine', 'B'), ('or', 'I'), ('amphetamine', 'I'), ('abuse', 'I'), (',', 'O'), ('results', 'O'), ('of', 'O'), ('clinical', 'O'), ('urine', 'O'), ('testing', 'O'), ('for', 'O'), ('drugs', 'O'), ('of', 'O'), ('abuse', 'O'), (',', 'O'), ('and', 'O'), ('assay', 'O'), ('results', 'O'), ('were', 'O'), ('recorded', 'O'), ('without', 'O'), ('patient', 'O'), ('identifiers', 'O'), ('.', 'O'))"
Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .,"(('Positive', 'O'), ('test', 'O'), ('results', 'O'), ('were', 'O'), ('more', 'O'), ('common', 'O'), ('in', 'O'), ('patient', 'O'), ('visits', 'O'), ('where', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('history', 'O'), ('or', 'O'), ('suspicion', 'O'), ('of', 'O'), ('cocaine', 'B'), ('or', 'I'), ('amphetamine', 'I'), ('abuse', 'I'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('0005', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .","(('CONCLUSIONS', 'O'), (':', 'O'), ('During', 'O'), ('this', 'O'), ('study', 'O'), ('period', 'O'), (',', 'O'), ('routine', 'O'), ('plasma', 'O'), ('screening', 'O'), ('for', 'O'), ('cocaine', 'O'), ('and', 'O'), ('amphetamines', 'O'), ('in', 'O'), ('adult', 'O'), ('seizure', 'B'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('low', 'O'), ('yield', 'O'), ('.', 'O'))"
"As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .","(('As', 'O'), ('a', 'O'), ('result', 'O'), (',', 'O'), ('routine', 'O'), ('plasma', 'O'), ('screening', 'O'), ('would', 'O'), ('yield', 'O'), ('few', 'O'), ('cases', 'O'), ('of', 'O'), ('stimulant', 'O'), ('drug', 'O'), ('in', 'O'), ('which', 'O'), ('there', 'O'), ('was', 'O'), ('neither', 'O'), ('a', 'O'), ('history', 'O'), ('nor', 'O'), ('suspicion', 'O'), ('of', 'O'), ('drug', 'B'), ('abuse', 'I'), ('in', 'O'), ('this', 'O'), ('population', 'O'), ('.', 'O'))"
Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .,"(('Contribution', 'O'), ('of', 'O'), ('sodium', 'O'), ('valproate', 'O'), ('to', 'O'), ('the', 'O'), ('syndrome', 'B'), ('of', 'I'), ('inappropriate', 'I'), ('secretion', 'I'), ('of', 'I'), ('antidiuretic', 'I'), ('hormone', 'I'), ('.', 'O'))"
We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('62', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('who', 'O'), ('was', 'O'), ('administered', 'O'), ('sodium', 'O'), ('valproate', 'O'), ('(', 'O'), ('VPA', 'O'), (')', 'O'), ('and', 'O'), ('who', 'O'), ('subsequently', 'O'), ('developed', 'O'), ('the', 'O'), ('syndrome', 'B'), ('of', 'I'), ('inappropriate', 'I'), ('secretion', 'I'), ('of', 'I'), ('antidiuretic', 'I'), ('hormone', 'I'), ('(', 'O'), ('SIADH', 'B'), (')', 'O'), ('.', 'O'))"
He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .,"(('He', 'O'), ('had', 'O'), ('been', 'O'), ('taking', 'O'), ('VPA', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('idiopathic', 'O'), ('generalized', 'O'), ('tonic', 'B'), ('-', 'I'), ('clonic', 'I'), ('convulsions', 'I'), ('since', 'O'), ('he', 'O'), ('was', 'O'), ('56', 'O'), ('years', 'O'), ('old', 'O'), ('.', 'O'))"
We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .,"(('We', 'O'), ('consider', 'O'), ('this', 'O'), ('episode', 'O'), ('of', 'O'), ('SIADH', 'B'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('result', 'O'), ('of', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('factors', 'O'), ('including', 'O'), ('a', 'O'), ('weakness', 'B'), ('of', 'I'), ('the', 'I'), ('central', 'I'), ('nervous', 'I'), ('system', 'I'), ('and', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), ('of', 'O'), ('VPA', 'O'), ('.', 'O'))"
Association of nitric oxide production and apoptosis in a model of experimental nephropathy .,"(('Association', 'O'), ('of', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('production', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('experimental', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .,"(('We', 'O'), ('have', 'O'), ('studied', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('NO', 'O'), ('and', 'O'), ('its', 'O'), ('association', 'O'), ('with', 'O'), ('apoptosis', 'O'), ('in', 'O'), ('an', 'O'), ('experimental', 'O'), ('model', 'O'), ('of', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('induced', 'O'), ('by', 'O'), ('a', 'O'), ('single', 'O'), ('injection', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('(', 'O'), ('ADR', 'O'), (')', 'O'), ('.', 'O'))"
Rats were stratified into control groups and ADR - induced nephropathy groups .,"(('Rats', 'O'), ('were', 'O'), ('stratified', 'O'), ('into', 'O'), ('control', 'O'), ('groups', 'O'), ('and', 'O'), ('ADR', 'O'), ('-', 'O'), ('induced', 'O'), ('nephropathy', 'B'), ('groups', 'O'), ('.', 'O'))"
They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .,"(('They', 'O'), ('also', 'O'), ('had', 'O'), ('significantly', 'O'), ('higher', 'O'), ('levels', 'O'), ('of', 'O'), ('proteinuria', 'B'), ('compared', 'O'), ('with', 'O'), ('control', 'O'), ('and', 'O'), ('treatment', 'O'), ('groups', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .,"(('Urine', 'O'), ('nitrite', 'O'), ('levels', 'O'), ('were', 'O'), ('significantly', 'O'), ('increased', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'O'), ('-', 'O'), ('nephropathy', 'B'), ('group', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .,"(('In', 'O'), ('the', 'O'), ('IPRK', 'O'), ('phenylephrine', 'O'), ('and', 'O'), ('acetylcholine', 'O'), ('related', 'O'), ('responses', 'O'), ('were', 'O'), ('significantly', 'O'), ('impaired', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'O'), ('-', 'O'), ('nephropathy', 'B'), ('group', 'O'), ('.', 'O'))"
"However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .","(('However', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('ADR', 'O'), ('-', 'O'), ('nephropathy', 'B'), ('group', 'O'), (',', 'O'), ('numerous', 'O'), ('apoptotic', 'O'), ('cells', 'O'), ('were', 'O'), ('identified', 'O'), ('in', 'O'), ('the', 'O'), ('tubulointerstitial', 'O'), ('areas', 'O'), ('.', 'O'))"
CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .,"(('CONCLUSION', 'O'), (':', 'O'), ('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('interactions', 'O'), ('between', 'O'), ('NO', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('are', 'O'), ('important', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('the', 'O'), ('ADR', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrosis', 'B'), ('.', 'O'))"
"Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .","(('Reduced', 'O'), ('cardiotoxicity', 'B'), ('and', 'O'), ('preserved', 'O'), ('antitumor', 'O'), ('efficacy', 'O'), ('of', 'O'), ('liposome', 'O'), ('-', 'O'), ('encapsulated', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('cyclophosphamide', 'O'), ('compared', 'O'), ('with', 'O'), ('conventional', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('cyclophosphamide', 'O'), ('in', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('multicenter', 'O'), ('trial', 'O'), ('of', 'O'), ('metastatic', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .","(('PURPOSE', 'O'), (':', 'O'), ('To', 'O'), ('determine', 'O'), ('whether', 'O'), ('Myocet', 'O'), ('(', 'O'), ('liposome', 'O'), ('-', 'O'), ('encapsulated', 'O'), ('doxorubicin', 'O'), (';', 'O'), ('The', 'O'), ('Liposome', 'O'), ('Company', 'O'), (',', 'O'), ('Elan', 'O'), ('Corporation', 'O'), (',', 'O'), ('Princeton', 'O'), (',', 'O'), ('NJ', 'O'), (')', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('cyclophosphamide', 'O'), ('significantly', 'O'), ('reduces', 'O'), ('doxorubicin', 'O'), ('cardiotoxicity', 'B'), ('while', 'O'), ('providing', 'O'), ('comparable', 'O'), ('antitumor', 'O'), ('efficacy', 'O'), ('in', 'O'), ('first', 'O'), ('-', 'O'), ('line', 'O'), ('treatment', 'O'), ('of', 'O'), ('metastatic', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('MBC', 'B'), (')', 'O'), ('.', 'O'))"
"PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .","(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('Two', 'O'), ('hundred', 'O'), ('ninety', 'O'), ('-', 'O'), ('seven', 'O'), ('patients', 'O'), ('with', 'O'), ('MBC', 'B'), ('and', 'O'), ('no', 'O'), ('prior', 'O'), ('chemotherapy', 'O'), ('for', 'O'), ('metastatic', 'O'), ('disease', 'O'), ('were', 'O'), ('randomized', 'O'), ('to', 'O'), ('receive', 'O'), ('either', 'O'), ('60', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('of', 'O'), ('Myocet', 'O'), ('(', 'O'), ('M', 'O'), (')', 'O'), ('or', 'O'), ('conventional', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), (',', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('600', 'O'), ('mg', 'O'), ('/', 'O'), ('m', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('(', 'O'), ('C', 'O'), (')', 'O'), (',', 'O'), ('every', 'O'), ('3', 'O'), ('weeks', 'O'), ('until', 'O'), ('disease', 'O'), ('progression', 'O'), ('or', 'O'), ('unacceptable', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .","(('Cardiotoxicity', 'B'), ('was', 'O'), ('defined', 'O'), ('by', 'O'), ('reductions', 'O'), ('in', 'O'), ('left', 'O'), ('-', 'O'), ('ventricular', 'O'), ('ejection', 'O'), ('fraction', 'O'), (',', 'O'), ('assessed', 'O'), ('by', 'O'), ('serial', 'O'), ('multigated', 'O'), ('radionuclide', 'O'), ('angiography', 'O'), ('scans', 'O'), (',', 'O'), ('or', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('(', 'O'), ('CHF', 'B'), (')', 'O'), ('.', 'O'))"
"Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .","(('Antitumor', 'O'), ('efficacy', 'O'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('objective', 'O'), ('tumor', 'B'), ('response', 'O'), ('rates', 'O'), ('(', 'O'), ('World', 'O'), ('Health', 'O'), ('Organization', 'O'), ('criteria', 'O'), (')', 'O'), (',', 'O'), ('time', 'O'), ('to', 'O'), ('progression', 'O'), (',', 'O'), ('and', 'O'), ('survival', 'O'), ('.', 'O'))"
RESULTS : Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .,"(('RESULTS', 'O'), (':', 'O'), ('Six', 'O'), ('percent', 'O'), ('of', 'O'), ('MC', 'O'), ('patients', 'O'), ('versus', 'O'), ('21', 'O'), ('%', 'O'), ('(', 'O'), ('including', 'O'), ('five', 'O'), ('cases', 'O'), ('of', 'O'), ('CHF', 'B'), (')', 'O'), ('of', 'O'), ('AC', 'O'), ('patients', 'O'), ('developed', 'O'), ('cardiotoxicity', 'B'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('0002', 'O'), (')', 'O'), ('.', 'O'))"
MC patients also experienced less grade 4 neutropenia .,"(('MC', 'O'), ('patients', 'O'), ('also', 'O'), ('experienced', 'O'), ('less', 'O'), ('grade', 'O'), ('4', 'O'), ('neutropenia', 'B'), ('.', 'O'))"
"CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .","(('CONCLUSION', 'O'), (':', 'O'), ('Myocet', 'O'), ('improves', 'O'), ('the', 'O'), ('therapeutic', 'O'), ('index', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('by', 'O'), ('significantly', 'O'), ('reducing', 'O'), ('cardiotoxicity', 'B'), ('and', 'O'), ('grade', 'O'), ('4', 'O'), ('neutropenia', 'B'), ('and', 'O'), ('provides', 'O'), ('comparable', 'O'), ('antitumor', 'O'), ('efficacy', 'O'), (',', 'O'), ('when', 'O'), ('used', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('cyclophosphamide', 'O'), ('as', 'O'), ('first', 'O'), ('-', 'O'), ('line', 'O'), ('therapy', 'O'), ('for', 'O'), ('MBC', 'B'), ('.', 'O'))"
The role of nitrergic system in lidocaine - induced convulsion in the mouse .,"(('The', 'O'), ('role', 'O'), ('of', 'O'), ('nitrergic', 'O'), ('system', 'O'), ('in', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsion', 'B'), ('in', 'O'), ('the', 'O'), ('mouse', 'O'), ('.', 'O'))"
"The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('N', 'O'), ('-', 'O'), ('nitro', 'O'), ('-', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), ('-', 'O'), ('methyl', 'O'), ('ester', 'O'), ('(', 'O'), ('L', 'O'), ('-', 'O'), ('NAME', 'O'), (')', 'O'), ('a', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('NO', 'O'), (')', 'O'), ('synthase', 'O'), ('inhibitor', 'O'), ('and', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), (',', 'O'), ('a', 'O'), ('NO', 'O'), ('precursor', 'O'), (',', 'O'), ('were', 'O'), ('investigated', 'O'), ('on', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
"L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .","(('L', 'O'), ('-', 'O'), ('NAME', 'O'), ('(', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('and', 'O'), ('diazepam', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
"In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('L', 'O'), ('-', 'O'), ('arginine', 'O'), ('treatment', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('(', 'O'), ('80', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('significantly', 'O'), ('.', 'O'))"
These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .,"(('These', 'O'), ('results', 'O'), ('may', 'O'), ('suggest', 'O'), ('that', 'O'), ('NO', 'O'), ('is', 'O'), ('a', 'O'), ('proconvulsant', 'O'), ('mediator', 'O'), ('in', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .,"(('Erythropoietin', 'O'), ('restores', 'O'), ('the', 'O'), ('anemia', 'B'), ('-', 'O'), ('induced', 'O'), ('reduction', 'O'), ('in', 'O'), ('cyclophosphamide', 'O'), ('cytotoxicity', 'B'), ('in', 'O'), ('rat', 'O'), ('tumors', 'B'), ('.', 'O'))"
The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('impact', 'O'), ('of', 'O'), ('anemia', 'B'), ('prevention', 'O'), ('by', 'O'), ('recombinant', 'O'), ('human', 'O'), ('erythropoietin', 'O'), ('(', 'O'), ('rHuEPO', 'O'), (')', 'O'), ('treatment', 'O'), ('on', 'O'), ('the', 'O'), ('cytotoxicity', 'B'), ('of', 'O'), ('cyclophosphamide', 'O'), ('in', 'O'), ('solid', 'O'), ('experimental', 'O'), ('tumors', 'B'), ('.', 'O'))"
"In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .","(('In', 'O'), ('a', 'O'), ('second', 'O'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('anemia', 'B'), ('was', 'O'), ('prevented', 'O'), ('by', 'O'), ('rHuEPO', 'O'), ('(', 'O'), ('1000', 'O'), ('IU', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('administered', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('three', 'O'), ('times', 'O'), ('/', 'O'), ('week', 'O'), ('starting', 'O'), ('7', 'O'), ('days', 'O'), ('before', 'O'), ('carboplatin', 'O'), ('application', 'O'), ('.', 'O'))"
"Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c . onto the hind food dorsum .","(('Four', 'O'), ('days', 'O'), ('after', 'O'), ('carboplatin', 'O'), ('treatment', 'O'), (',', 'O'), ('tumors', 'B'), ('(', 'O'), ('DS', 'O'), ('-', 'O'), ('sarcoma', 'B'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), (')', 'O'), ('were', 'O'), ('implanted', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), ('onto', 'O'), ('the', 'O'), ('hind', 'O'), ('food', 'O'), ('dorsum', 'O'), ('.', 'O'))"
Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .,"(('Neither', 'O'), ('carboplatin', 'O'), ('nor', 'O'), ('rHuEPO', 'O'), ('treatment', 'O'), ('influenced', 'O'), ('tumor', 'B'), ('growth', 'O'), ('rate', 'O'), ('per', 'O'), ('se', 'O'), ('.', 'O'))"
"When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .","(('When', 'O'), ('tumors', 'B'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('(', 'O'), ('60', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('5', 'O'), ('days', 'O'), ('after', 'O'), ('implantation', 'O'), (',', 'O'), ('a', 'O'), ('growth', 'O'), ('delay', 'O'), ('with', 'O'), ('a', 'O'), ('subsequent', 'O'), ('regrowth', 'O'), ('of', 'O'), ('the', 'O'), ('tumors', 'B'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .","(('In', 'O'), ('the', 'O'), ('anemia', 'B'), ('group', 'O'), (',', 'O'), ('the', 'O'), ('growth', 'O'), ('delay', 'O'), ('was', 'O'), ('significantly', 'O'), ('shorter', 'O'), ('compared', 'O'), ('with', 'O'), ('nonanemic', 'O'), ('controls', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('3', 'O'), ('days', 'O'), ('versus', 'O'), ('8', 'O'), ('.', 'O'), ('6', 'O'), ('days', 'O'), (')', 'O'), ('.', 'O'))"
"In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .","(('In', 'O'), ('the', 'O'), ('group', 'O'), ('where', 'O'), ('anemia', 'B'), ('was', 'O'), ('prevented', 'O'), ('by', 'O'), ('rHuEPO', 'O'), ('treatment', 'O'), (',', 'O'), ('growth', 'O'), ('delay', 'O'), ('was', 'O'), ('comparable', 'O'), ('with', 'O'), ('that', 'O'), ('of', 'O'), ('nonanemic', 'O'), ('controls', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('3', 'O'), ('days', 'O'), (')', 'O'), ('.', 'O'))"
"These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('chemotherapy', 'O'), ('-', 'O'), ('induced', 'O'), ('anemia', 'B'), ('reduces', 'O'), ('cytotoxicity', 'B'), ('of', 'O'), ('cyclophosphamide', 'O'), ('in', 'O'), ('tumors', 'B'), (',', 'O'), ('whereas', 'O'), ('correction', 'O'), ('of', 'O'), ('anemia', 'B'), ('by', 'O'), ('rHuEPO', 'O'), ('treatment', 'O'), ('(', 'O'), ('epoetin', 'O'), ('alpha', 'O'), (')', 'O'), ('increases', 'O'), ('the', 'O'), ('sensitivity', 'O'), (',', 'O'), ('probably', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('an', 'O'), ('improved', 'O'), ('oxygen', 'O'), ('supply', 'O'), ('to', 'O'), ('tumor', 'B'), ('tissue', 'O'), ('.', 'O'))"
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .,"(('Fatal', 'O'), ('haemorrhagic', 'B'), ('myocarditis', 'I'), ('secondary', 'O'), ('to', 'O'), ('cyclophosphamide', 'O'), ('therapy', 'O'), ('.', 'O'))"
Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .,"(('Haemorrhagic', 'B'), ('myocarditis', 'I'), ('is', 'O'), ('a', 'O'), ('rare', 'O'), ('but', 'O'), ('important', 'O'), ('complication', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('therapy', 'O'), ('.', 'O'))"
Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .,"(('Effects', 'O'), ('of', 'O'), ('verapamil', 'O'), ('on', 'O'), ('atrial', 'B'), ('fibrillation', 'I'), ('and', 'O'), ('its', 'O'), ('electrophysiological', 'O'), ('determinants', 'O'), ('in', 'O'), ('dogs', 'O'), ('.', 'O'))"
BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .,"(('BACKGROUND', 'O'), (':', 'O'), ('Atrial', 'B'), ('tachycardia', 'I'), ('-', 'O'), ('induced', 'O'), ('remodeling', 'O'), ('promotes', 'O'), ('the', 'O'), ('occurrence', 'O'), ('and', 'O'), ('maintenance', 'O'), ('of', 'O'), ('atrial', 'B'), ('fibrillation', 'I'), ('(', 'O'), ('AF', 'B'), (')', 'O'), ('and', 'O'), ('decreases', 'O'), ('L', 'O'), ('-', 'O'), ('type', 'O'), ('Ca', 'O'), ('(', 'O'), ('2', 'O'), ('+', 'O'), (')', 'O'), ('current', 'O'), ('.', 'O'))"
Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .,"(('Calcitonin', 'O'), ('gene', 'O'), ('-', 'O'), ('related', 'O'), ('peptide', 'O'), ('levels', 'O'), ('during', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('-', 'O'), ('induced', 'O'), ('headache', 'B'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('tension', 'B'), ('-', 'I'), ('type', 'I'), ('headache', 'I'), ('.', 'O'))"
It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .,"(('It', 'O'), ('has', 'O'), ('been', 'O'), ('proposed', 'O'), ('that', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('NO', 'O'), (')', 'O'), ('induced', 'O'), ('headache', 'B'), ('in', 'O'), ('primary', 'B'), ('headaches', 'I'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('release', 'O'), ('of', 'O'), ('calcitonin', 'O'), ('gene', 'O'), ('-', 'O'), ('related', 'O'), ('peptide', 'O'), ('(', 'O'), ('CGRP', 'O'), (')', 'O'), ('.', 'O'))"
In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .,"(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('we', 'O'), ('aimed', 'O'), ('to', 'O'), ('investigate', 'O'), ('plasma', 'O'), ('levels', 'O'), ('of', 'O'), ('CGRP', 'O'), ('during', 'O'), ('headache', 'B'), ('induced', 'O'), ('by', 'O'), ('the', 'O'), ('NO', 'O'), ('donor', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('(', 'O'), ('GTN', 'O'), (')', 'O'), ('in', 'O'), ('16', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('tension', 'B'), ('-', 'I'), ('type', 'I'), ('headache', 'I'), ('and', 'O'), ('16', 'O'), ('healthy', 'O'), ('controls', 'O'), ('.', 'O'))"
The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .,"(('The', 'O'), ('subjects', 'O'), ('were', 'O'), ('randomly', 'O'), ('allocated', 'O'), ('to', 'O'), ('receive', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('min', 'O'), ('GTN', 'O'), ('or', 'O'), ('placebo', 'O'), ('over', 'O'), ('20', 'O'), ('min', 'O'), ('on', 'O'), ('two', 'O'), ('headache', 'B'), ('-', 'O'), ('free', 'O'), ('days', 'O'), ('.', 'O'))"
Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .,"(('Both', 'O'), ('patients', 'O'), ('and', 'O'), ('controls', 'O'), ('developed', 'O'), ('significantly', 'O'), ('stronger', 'O'), ('immediate', 'O'), ('headache', 'B'), ('on', 'O'), ('the', 'O'), ('GTN', 'O'), ('day', 'O'), ('than', 'O'), ('on', 'O'), ('the', 'O'), ('placebo', 'O'), ('day', 'O'), ('and', 'O'), ('the', 'O'), ('headache', 'B'), ('was', 'O'), ('significantly', 'O'), ('more', 'O'), ('pronounced', 'O'), ('in', 'O'), ('patients', 'O'), ('than', 'O'), ('in', 'O'), ('controls', 'O'), ('.', 'O'))"
The present study indicates that NO - induced immediate headache is not associated with release of CGRP .,"(('The', 'O'), ('present', 'O'), ('study', 'O'), ('indicates', 'O'), ('that', 'O'), ('NO', 'O'), ('-', 'O'), ('induced', 'O'), ('immediate', 'O'), ('headache', 'B'), ('is', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('release', 'O'), ('of', 'O'), ('CGRP', 'O'), ('.', 'O'))"
Fluconazole - induced torsade de pointes .,"(('Fluconazole', 'O'), ('-', 'O'), ('induced', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('.', 'O'))"
OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole ' s role in causing TDP .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('fluconazole', 'O'), ('-', 'O'), ('associated', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('(', 'O'), ('TDP', 'B'), (')', 'O'), ('and', 'O'), ('discuss', 'O'), ('fluconazole', 'O'), (""'"", 'O'), ('s', 'O'), ('role', 'O'), ('in', 'O'), ('causing', 'O'), ('TDP', 'B'), ('.', 'O'))"
"CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .","(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('68', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('white', 'O'), ('woman', 'O'), ('with', 'O'), ('Candida', 'O'), ('glabrata', 'O'), ('isolated', 'O'), ('from', 'O'), ('a', 'O'), ('presacral', 'O'), ('abscess', 'O'), ('developed', 'O'), ('TDP', 'B'), ('eight', 'O'), ('days', 'O'), ('after', 'O'), ('commencing', 'O'), ('oral', 'O'), ('fluconazole', 'O'), ('The', 'O'), ('patient', 'O'), ('had', 'O'), ('no', 'O'), ('other', 'O'), ('risk', 'O'), ('factors', 'O'), ('for', 'O'), ('TDP', 'B'), (',', 'O'), ('including', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), (',', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), (',', 'O'), ('and', 'O'), ('electrolyte', 'O'), ('abnormalities', 'O'), ('There', 'O'), ('was', 'O'), ('a', 'O'), ('temporal', 'O'), ('association', 'O'), ('between', 'O'), ('the', 'O'), ('initiation', 'O'), ('of', 'O'), ('fluconazole', 'O'), ('and', 'O'), ('TDP', 'B'), ('.', 'O'))"
"The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .","(('The', 'O'), ('TDP', 'B'), ('resolved', 'O'), ('when', 'O'), ('fluconazole', 'O'), ('was', 'O'), ('discontinued', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('continued', 'O'), ('to', 'O'), ('have', 'O'), ('premature', 'B'), ('ventricular', 'I'), ('contractions', 'I'), ('and', 'O'), ('nonsustained', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('(', 'O'), ('NSVT', 'B'), (')', 'O'), ('until', 'O'), ('six', 'O'), ('days', 'O'), ('after', 'O'), ('drug', 'O'), ('cessation', 'O'), ('DISCUSSION', 'O'), (':', 'O'), ('Use', 'O'), ('of', 'O'), ('the', 'O'), ('Naranjo', 'O'), ('probability', 'O'), ('scale', 'O'), ('indicates', 'O'), ('a', 'O'), ('probable', 'O'), ('relationship', 'O'), ('between', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('fluconazole', 'O'), ('and', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('TDP', 'B'), ('.', 'O'))"
The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .,"(('The', 'O'), ('possible', 'O'), ('mechanism', 'O'), ('is', 'O'), ('depression', 'B'), ('of', 'O'), ('rapidly', 'O'), ('activating', 'O'), ('delayed', 'O'), ('rectifier', 'O'), ('potassium', 'O'), ('currents', 'O'), ('.', 'O'))"
"In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .","(('In', 'O'), ('our', 'O'), ('patient', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('other', 'O'), ('etiology', 'O'), ('identified', 'O'), ('that', 'O'), ('could', 'O'), ('explain', 'O'), ('QT', 'B'), ('prolongation', 'I'), ('or', 'O'), ('TDP', 'B'), ('The', 'O'), ('complete', 'O'), ('disappearance', 'O'), ('of', 'O'), ('NSVT', 'B'), ('and', 'O'), ('premature', 'B'), ('ventricular', 'I'), ('contractions', 'I'), ('followed', 'O'), ('by', 'O'), ('normalization', 'O'), ('of', 'O'), ('QT', 'O'), ('interval', 'O'), ('after', 'O'), ('the', 'O'), ('drug', 'O'), ('was', 'O'), ('stopped', 'O'), ('strongly', 'O'), ('suggests', 'O'), ('fluconazole', 'O'), ('as', 'O'), ('the', 'O'), ('etiology', 'O'), ('.', 'O'))"
"CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Clinicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('that', 'O'), ('fluconazole', 'O'), (',', 'O'), ('even', 'O'), ('at', 'O'), ('low', 'O'), ('doses', 'O'), (',', 'O'), ('may', 'O'), ('cause', 'O'), ('prolongation', 'B'), ('of', 'I'), ('the', 'I'), ('QT', 'I'), ('interval', 'I'), (',', 'O'), ('leading', 'O'), ('to', 'O'), ('TDP', 'B'), ('.', 'O'))"
Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .,"(('Serial', 'O'), ('electrocardiographic', 'O'), ('monitoring', 'O'), ('may', 'O'), ('be', 'O'), ('considered', 'O'), ('when', 'O'), ('fluconazole', 'O'), ('is', 'O'), ('administered', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('are', 'O'), ('at', 'O'), ('risk', 'O'), ('for', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
Cutaneous leucocytoclastic vasculitis associated with oxacillin .,"(('Cutaneous', 'B'), ('leucocytoclastic', 'I'), ('vasculitis', 'I'), ('associated', 'O'), ('with', 'O'), ('oxacillin', 'O'), ('.', 'O'))"
"A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .","(('A', 'O'), ('67', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('who', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('oxacillin', 'O'), ('for', 'O'), ('one', 'O'), ('week', 'O'), ('because', 'O'), ('of', 'O'), ('Staphylococcus', 'B'), ('aureus', 'I'), ('bacteremia', 'I'), (',', 'O'), ('developed', 'O'), ('renal', 'B'), ('failure', 'I'), ('and', 'O'), ('diffuse', 'O'), (',', 'O'), ('symmetric', 'O'), (',', 'O'), ('palpable', 'O'), ('purpuric', 'B'), ('lesions', 'I'), ('on', 'O'), ('his', 'O'), ('feet', 'O'), ('.', 'O'))"
Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .,"(('Skin', 'O'), ('biopsies', 'O'), ('showed', 'O'), ('findings', 'O'), ('diagnostic', 'O'), ('of', 'O'), ('leucocytoclastic', 'B'), ('vasculitis', 'I'), ('.', 'O'))"
The rash disappeared after three weeks and renal function returned to normal .,"(('The', 'O'), ('rash', 'B'), ('disappeared', 'O'), ('after', 'O'), ('three', 'O'), ('weeks', 'O'), ('and', 'O'), ('renal', 'O'), ('function', 'O'), ('returned', 'O'), ('to', 'O'), ('normal', 'O'), ('.', 'O'))"
"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .","(('Leucocytoclastic', 'B'), ('vasculitis', 'I'), ('presents', 'O'), ('as', 'O'), ('palpable', 'O'), ('purpura', 'B'), ('of', 'O'), ('the', 'O'), ('lower', 'O'), ('extremities', 'O'), ('often', 'O'), ('accompanied', 'O'), ('by', 'O'), ('abdominal', 'B'), ('pain', 'I'), (',', 'O'), ('arthralgia', 'B'), (',', 'O'), ('and', 'O'), ('renal', 'B'), ('involvement', 'I'), ('.', 'O'))"
"Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .","(('Etiologic', 'O'), ('factors', 'O'), ('or', 'O'), ('associated', 'O'), ('disorders', 'O'), ('include', 'O'), ('infections', 'B'), (',', 'O'), ('medications', 'O'), (',', 'O'), ('collagen', 'B'), ('vascular', 'I'), ('disease', 'I'), ('and', 'O'), ('neoplasia', 'B'), ('.', 'O'))"
Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .,"(('Oxacillin', 'O'), ('should', 'O'), ('be', 'O'), ('included', 'O'), ('among', 'O'), ('the', 'O'), ('drugs', 'O'), ('that', 'O'), ('can', 'O'), ('cause', 'O'), ('leucocytoclastic', 'B'), ('vasculitis', 'I'), ('.', 'O'))"
The renal pathology in a case of lithium - induced diabetes insipidus .,"(('The', 'O'), ('renal', 'O'), ('pathology', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('insipidus', 'I'), ('.', 'O'))"
A case of lithium - induced diabetes insipidus is reported .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('insipidus', 'I'), ('is', 'O'), ('reported', 'O'), ('.', 'O'))"
Cholestatic jaundice associated with the use of metformin .,"(('Cholestatic', 'B'), ('jaundice', 'I'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('metformin', 'O'), ('.', 'O'))"
We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('cholestatic', 'B'), ('jaundice', 'I'), ('shortly', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('metformin', 'O'), ('hydrochloride', 'O'), ('.', 'O'))"
"A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .","(('A', 'O'), ('percutaneous', 'O'), ('liver', 'O'), ('biopsy', 'O'), ('was', 'O'), ('obtained', 'O'), ('showing', 'O'), ('marked', 'O'), ('cholestasis', 'B'), (',', 'O'), ('with', 'O'), ('portal', 'O'), ('edema', 'B'), (',', 'O'), ('ductular', 'O'), ('proliferation', 'O'), (',', 'O'), ('and', 'O'), ('acute', 'O'), ('inflammation', 'B'), ('.', 'O'))"
"Metformin hydrochloride was discontinued , and the patient ' s jaundice resolved slowly over a period of several months .","(('Metformin', 'O'), ('hydrochloride', 'O'), ('was', 'O'), ('discontinued', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('jaundice', 'B'), ('resolved', 'O'), ('slowly', 'O'), ('over', 'O'), ('a', 'O'), ('period', 'O'), ('of', 'O'), ('several', 'O'), ('months', 'O'), ('.', 'O'))"
"Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .","(('Given', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('his', 'O'), ('jaundice', 'B'), ('2', 'O'), ('wk', 'O'), ('after', 'O'), ('the', 'O'), ('initiation', 'O'), ('of', 'O'), ('metformin', 'O'), (',', 'O'), ('we', 'O'), ('believe', 'O'), ('that', 'O'), ('this', 'O'), ('case', 'O'), ('represents', 'O'), ('an', 'O'), ('example', 'O'), ('of', 'O'), ('metformin', 'O'), ('-', 'O'), ('associated', 'O'), ('hepatotoxicity', 'B'), (',', 'O'), ('the', 'O'), ('first', 'O'), ('such', 'O'), ('case', 'O'), ('reported', 'O'), ('.', 'O'))"
"Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .","(('Systemic', 'O'), ('toxicity', 'B'), ('and', 'O'), ('resuscitation', 'O'), ('in', 'O'), ('bupivacaine', 'O'), ('-', 'O'), (',', 'O'), ('levobupivacaine', 'O'), ('-', 'O'), (',', 'O'), ('or', 'O'), ('ropivacaine', 'O'), ('-', 'O'), ('infused', 'O'), ('rats', 'O'), ('.', 'O'))"
"We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .","(('We', 'O'), ('compared', 'O'), ('the', 'O'), ('systemic', 'O'), ('toxicity', 'B'), ('of', 'O'), ('bupivacaine', 'O'), (',', 'O'), ('levobupivacaine', 'O'), (',', 'O'), ('and', 'O'), ('ropivacaine', 'O'), ('in', 'O'), ('anesthetized', 'O'), ('rats', 'O'), ('.', 'O'))"
"When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .","(('When', 'O'), ('asystole', 'B'), ('was', 'O'), ('recorded', 'O'), (',', 'O'), ('drug', 'O'), ('infusion', 'O'), ('was', 'O'), ('stopped', 'O'), ('and', 'O'), ('a', 'O'), ('resuscitation', 'O'), ('sequence', 'O'), ('was', 'O'), ('begun', 'O'), ('.', 'O'))"
The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .,"(('The', 'O'), ('cumulative', 'O'), ('doses', 'O'), ('of', 'O'), ('levobupivacaine', 'O'), ('and', 'O'), ('ropivacaine', 'O'), ('that', 'O'), ('produced', 'O'), ('seizures', 'B'), ('were', 'O'), ('similar', 'O'), ('and', 'O'), ('were', 'O'), ('larger', 'O'), ('than', 'O'), ('those', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('.', 'O'))"
"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .","(('The', 'O'), ('cumulative', 'O'), ('doses', 'O'), ('of', 'O'), ('levobupivacaine', 'O'), ('that', 'O'), ('produced', 'O'), ('dysrhythmias', 'B'), ('and', 'O'), ('asystole', 'B'), ('were', 'O'), ('smaller', 'O'), ('than', 'O'), ('the', 'O'), ('corresponding', 'O'), ('doses', 'O'), ('of', 'O'), ('ropivacaine', 'O'), (',', 'O'), ('but', 'O'), ('they', 'O'), ('were', 'O'), ('larger', 'O'), ('than', 'O'), ('those', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('.', 'O'))"
We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('systemic', 'O'), ('toxicity', 'B'), ('of', 'O'), ('levobupivacaine', 'O'), ('is', 'O'), ('intermediate', 'O'), ('between', 'O'), ('that', 'O'), ('of', 'O'), ('ropivacaine', 'O'), ('and', 'O'), ('bupivacaine', 'O'), ('when', 'O'), ('administered', 'O'), ('at', 'O'), ('the', 'O'), ('same', 'O'), ('rate', 'O'), ('and', 'O'), ('that', 'O'), ('ropivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('more', 'O'), ('susceptible', 'O'), ('to', 'O'), ('treatment', 'O'), ('than', 'O'), ('that', 'O'), ('induced', 'O'), ('by', 'O'), ('bupivacaine', 'O'), ('or', 'O'), ('levobupivacaine', 'O'), ('.', 'O'))"
Amphotericin B - induced seizures in a patient with AIDS .,"(('Amphotericin', 'O'), ('B', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('AIDS', 'B'), ('.', 'O'))"
OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('multiple', 'O'), ('episodes', 'O'), ('of', 'O'), ('seizure', 'B'), ('activity', 'O'), ('in', 'O'), ('an', 'O'), ('AIDS', 'B'), ('patent', 'O'), ('following', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('infusion', 'O'), ('.', 'O'))"
"CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .","(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('46', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('African', 'O'), ('-', 'O'), ('American', 'O'), ('man', 'O'), ('experienced', 'O'), ('recurrent', 'O'), ('grand', 'B'), ('mal', 'I'), ('seizures', 'I'), ('during', 'O'), ('intravenous', 'O'), ('infusion', 'O'), ('of', 'O'), ('amphotericin', 'O'), ('B', 'O'), (',', 'O'), ('then', 'O'), ('petit', 'O'), ('mal', 'O'), ('seizures', 'B'), ('as', 'O'), ('the', 'O'), ('infusion', 'O'), ('was', 'O'), ('stopped', 'O'), ('and', 'O'), ('the', 'O'), ('drug', 'O'), ('concentrations', 'O'), ('decreased', 'O'), ('with', 'O'), ('time', 'O'), ('.', 'O'))"
"Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .","(('Despite', 'O'), ('administration', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('and', 'O'), ('lorazepam', 'O'), (',', 'O'), ('the', 'O'), ('seizures', 'B'), ('persisted', 'O'), ('and', 'O'), ('occurred', 'O'), ('only', 'O'), ('during', 'O'), ('amphotercin', 'O'), ('B', 'O'), ('administration', 'O'), ('.', 'O'))"
"DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .","(('DISCUSSION', 'O'), (':', 'O'), ('AIDS', 'B'), ('and', 'O'), ('cryptococcal', 'B'), ('meningitis', 'I'), (',', 'O'), ('both', 'O'), ('of', 'O'), ('which', 'O'), ('the', 'O'), ('patient', 'O'), ('had', 'O'), (',', 'O'), ('can', 'O'), ('potentially', 'O'), ('cause', 'O'), ('seizures', 'B'), ('.', 'O'))"
The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .,"(('The', 'O'), ('patient', 'O'), ('had', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('alcohol', 'B'), ('abuse', 'I'), (';', 'O'), ('alcohol', 'O'), ('intake', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('withdrawal', 'O'), ('can', 'O'), ('also', 'O'), ('cause', 'O'), ('seizures', 'B'), ('.', 'O'))"
Didanosine also has a potential for inducing seizures .,"(('Didanosine', 'O'), ('also', 'O'), ('has', 'O'), ('a', 'O'), ('potential', 'O'), ('for', 'O'), ('inducing', 'O'), ('seizures', 'B'), ('.', 'O'))"
"However , these other potential causes of seizure were ruled out .","(('However', 'O'), (',', 'O'), ('these', 'O'), ('other', 'O'), ('potential', 'O'), ('causes', 'O'), ('of', 'O'), ('seizure', 'B'), ('were', 'O'), ('ruled', 'O'), ('out', 'O'), ('.', 'O'))"
The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .,"(('The', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('events', 'O'), ('suggested', 'O'), ('that', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('was', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('seizures', 'B'), ('in', 'O'), ('this', 'O'), ('AIDS', 'B'), ('patient', 'O'), ('.', 'O'))"
CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Amphotericin', 'O'), ('B', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('probable', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('seizures', 'B'), ('.', 'O'))"
"To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .","(('To', 'O'), ('date', 'O'), (',', 'O'), ('only', 'O'), ('three', 'O'), ('cases', 'O'), ('of', 'O'), ('seizures', 'B'), ('associated', 'O'), ('with', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('but', 'O'), ('healthcare', 'O'), ('providers', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('the', 'O'), ('potential', 'O'), ('for', 'O'), ('this', 'O'), ('rare', 'O'), ('adverse', 'O'), ('effect', 'O'), ('.', 'O'))"
"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .","(('Although', 'O'), ('these', 'O'), ('drugs', 'O'), ('are', 'O'), ('highly', 'O'), ('effective', 'O'), ('and', 'O'), ('represent', 'O'), ('the', 'O'), ('mainstay', 'O'), ('of', 'O'), ('transplant', 'O'), ('immunosuppression', 'O'), (',', 'O'), ('they', 'O'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('acute', 'O'), ('and', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
"Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .","(('Acute', 'O'), ('nephrotoxicity', 'B'), (',', 'O'), ('which', 'O'), ('occurs', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('period', 'O'), ('after', 'O'), ('transplantation', 'O'), (',', 'O'), ('leads', 'O'), ('to', 'O'), ('a', 'O'), ('higher', 'O'), ('rate', 'O'), ('of', 'O'), ('dialysis', 'O'), (',', 'O'), ('and', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('may', 'O'), ('eventually', 'O'), ('result', 'O'), ('in', 'O'), ('graft', 'O'), ('loss', 'O'), ('.', 'O'))"
Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .,"(('Acute', 'O'), ('and', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('is', 'O'), ('becoming', 'O'), ('more', 'O'), ('common', 'O'), ('as', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('marginal', 'O'), ('kidneys', 'O'), ('for', 'O'), ('transplantation', 'O'), ('increases', 'O'), ('.', 'O'))"
"Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .","(('Two', 'O'), ('recently', 'O'), ('available', 'O'), ('immunosuppressive', 'O'), ('agents', 'O'), (',', 'O'), ('mycophenolate', 'O'), ('mofetil', 'O'), ('and', 'O'), ('sirolimus', 'O'), ('(', 'O'), ('rapamycin', 'O'), (')', 'O'), (',', 'O'), ('have', 'O'), ('no', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .,"(('Tolerability', 'O'), ('of', 'O'), ('nimesulide', 'O'), ('and', 'O'), ('paracetamol', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('NSAID', 'O'), ('-', 'O'), ('induced', 'O'), ('urticaria', 'B'), ('/', 'O'), ('angioedema', 'B'), ('.', 'O'))"
In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .,"(('In', 'O'), ('this', 'O'), ('study', 'O'), ('we', 'O'), ('investigated', 'O'), ('tolerability', 'O'), ('and', 'O'), ('reliability', 'O'), ('of', 'O'), ('nimesulide', 'O'), ('and', 'O'), ('paracetamol', 'O'), ('in', 'O'), ('a', 'O'), ('very', 'O'), ('large', 'O'), ('number', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('an', 'O'), ('exclusive', 'O'), ('well', 'O'), ('-', 'O'), ('documented', 'O'), ('history', 'O'), ('of', 'O'), ('NSAID', 'O'), ('-', 'O'), ('induced', 'O'), ('urticaria', 'B'), ('/', 'O'), ('angioedema', 'B'), ('.', 'O'))"
A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .,"(('A', 'O'), ('single', 'O'), ('-', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('oral', 'O'), ('challenge', 'O'), ('procedure', 'O'), ('with', 'O'), ('nimesulide', 'O'), ('or', 'O'), ('paracetamol', 'O'), ('was', 'O'), ('applied', 'O'), ('to', 'O'), ('829', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('NSAID', 'O'), ('-', 'O'), ('induced', 'O'), ('urticaria', 'B'), ('/', 'O'), ('angioedema', 'B'), ('.', 'O'))"
"Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .","(('Furthermore', 'O'), (',', 'O'), ('18', 'O'), ('.', 'O'), ('28', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('chronic', 'O'), ('urticaria', 'B'), ('and', 'O'), ('11', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), ('with', 'O'), ('an', 'O'), ('history', 'O'), ('of', 'O'), ('NSAID', 'O'), ('-', 'O'), ('induced', 'O'), ('urticaria', 'B'), ('/', 'O'), ('angioedema', 'B'), ('or', 'O'), ('angioedema', 'B'), ('alone', 'O'), ('(', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('chronic', 'O'), ('urticaria', 'B'), (')', 'O'), ('resulted', 'O'), ('to', 'O'), ('be', 'O'), ('intolerant', 'O'), ('to', 'O'), ('alternative', 'O'), ('drugs', 'O'), ('.', 'O'))"
"Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .","(('Taken', 'O'), ('together', 'O'), (',', 'O'), ('our', 'O'), ('results', 'O'), ('confirm', 'O'), ('the', 'O'), ('good', 'O'), ('tolerability', 'O'), ('of', 'O'), ('nimesulide', 'O'), ('and', 'O'), ('paracetamol', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('experienced', 'O'), ('urticaria', 'B'), ('/', 'O'), ('angioedema', 'B'), ('caused', 'O'), ('by', 'O'), ('NSAIDs', 'O'), ('.', 'O'))"
"However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('reaction', 'O'), ('to', 'O'), ('these', 'O'), ('alternative', 'O'), ('study', 'O'), ('drugs', 'O'), ('is', 'O'), ('statistically', 'O'), ('increased', 'O'), ('by', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('chronic', 'O'), ('urticaria', 'B'), ('and', 'O'), (',', 'O'), ('above', 'O'), ('all', 'O'), (',', 'O'), ('by', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('NSAID', 'O'), ('-', 'O'), ('induced', 'O'), ('angioedema', 'B'), ('.', 'O'))"
Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .,"(('Comparison', 'O'), ('of', 'O'), ('aqueous', 'O'), ('and', 'O'), ('gellan', 'O'), ('ophthalmic', 'O'), ('timolol', 'O'), ('with', 'O'), ('placebo', 'O'), ('on', 'O'), ('the', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('response', 'O'), ('in', 'O'), ('patients', 'O'), ('on', 'O'), ('treatment', 'O'), ('for', 'O'), ('glaucoma', 'B'), ('.', 'O'))"
PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .,"(('PURPOSE', 'O'), (':', 'O'), ('Topical', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('treatment', 'O'), ('is', 'O'), ('routine', 'O'), ('therapy', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('glaucoma', 'B'), ('.', 'O'))"
"DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .","(('DESIGN', 'O'), (':', 'O'), ('This', 'O'), ('trial', 'O'), ('evaluated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('placebo', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('aqueous', 'O'), ('timolol', 'O'), ('(', 'O'), ('timolol', 'O'), ('solution', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('timolol', 'O'), ('suspension', 'O'), ('that', 'O'), ('forms', 'O'), ('a', 'O'), ('gel', 'O'), ('on', 'O'), ('application', 'O'), ('to', 'O'), ('the', 'O'), ('conjunctiva', 'O'), ('(', 'O'), ('timolol', 'O'), ('gellan', 'O'), (')', 'O'), ('on', 'O'), ('the', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('heart', 'O'), ('rate', 'O'), ('in', 'O'), ('patients', 'O'), ('currently', 'O'), ('being', 'O'), ('treated', 'O'), ('for', 'O'), ('glaucoma', 'B'), ('to', 'O'), ('quantify', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('mean', 'O'), ('heart', 'O'), ('rate', 'O'), ('.', 'O'))"
"METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .","(('METHODS', 'O'), (':', 'O'), ('Forty', 'O'), ('-', 'O'), ('three', 'O'), ('Caucasian', 'O'), ('patients', 'O'), ('with', 'O'), ('primary', 'O'), ('open', 'B'), ('-', 'I'), ('angle', 'I'), ('glaucoma', 'I'), ('or', 'O'), ('ocular', 'B'), ('hypertension', 'I'), ('with', 'O'), ('a', 'O'), ('mean', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SD', 'O'), (')', 'O'), ('age', 'O'), ('of', 'O'), ('63', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), (')', 'O'), ('years', 'O'), ('were', 'O'), ('randomized', 'O'), ('and', 'O'), ('crossed', 'O'), ('over', 'O'), ('in', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('masked', 'O'), ('manner', 'O'), ('to', 'O'), ('14', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('morning', 'O'), ('and', 'O'), ('evening', 'O'), ('in', 'O'), ('both', 'O'), ('eyes', 'O'), (')', 'O'), (',', 'O'), ('timolol', 'O'), ('solution', 'O'), ('(', 'O'), ('morning', 'O'), ('and', 'O'), ('evening', 'O'), ('in', 'O'), ('both', 'O'), ('eyes', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('timolol', 'O'), ('gellan', 'O'), ('(', 'O'), ('morning', 'O'), ('in', 'O'), ('both', 'O'), ('eyes', 'O'), ('with', 'O'), ('placebo', 'O'), ('in', 'O'), ('the', 'O'), ('evening', 'O'), (')', 'O'), ('.', 'O'))"
These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .,"(('These', 'O'), ('data', 'O'), ('quantify', 'O'), ('the', 'O'), ('modest', 'O'), ('bradycardia', 'B'), ('associated', 'O'), ('with', 'O'), ('ophthalmic', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('therapy', 'O'), ('in', 'O'), ('a', 'O'), ('typical', 'O'), ('patient', 'O'), ('population', 'O'), ('on', 'O'), ('therapy', 'O'), ('for', 'O'), ('glaucoma', 'B'), ('.', 'O'))"
Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .,"(('Management', 'O'), ('strategies', 'O'), ('for', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('C', 'I'), (':', 'O'), ('clinical', 'O'), ('and', 'O'), ('economic', 'O'), ('implications', 'O'), ('.', 'O'))"
OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .,"(('OBJECTIVES', 'O'), (':', 'O'), ('Recently', 'O'), ('published', 'O'), ('studies', 'O'), ('have', 'O'), ('demonstrated', 'O'), ('increased', 'O'), ('efficacy', 'O'), ('and', 'O'), ('cost', 'O'), ('-', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('combination', 'O'), ('therapy', 'O'), ('with', 'O'), ('interferon', 'O'), ('and', 'O'), ('alpha', 'O'), ('-', 'O'), ('2b', 'O'), ('/', 'O'), ('ribavirin', 'O'), ('compared', 'O'), ('with', 'O'), ('interferon', 'O'), ('-', 'O'), ('alpha', 'O'), ('monotherapy', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('(', 'O'), ('CHC', 'B'), (')', 'O'), ('.', 'O'))"
Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .,"(('Combination', 'O'), ('therapy', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('clinically', 'O'), ('important', 'O'), ('adverse', 'O'), ('effect', 'O'), (':', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('(', 'O'), ('RIHA', 'B'), (')', 'O'), ('.', 'O'))"
The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .,"(('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('direct', 'O'), ('health', 'O'), ('-', 'O'), ('care', 'O'), ('costs', 'O'), ('and', 'O'), ('management', 'O'), ('of', 'O'), ('RIHA', 'B'), ('during', 'O'), ('treatment', 'O'), ('of', 'O'), ('CHC', 'B'), ('in', 'O'), ('a', 'O'), ('clinical', 'O'), ('trial', 'O'), ('setting', 'O'), ('.', 'O'))"
"BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .","(('BACKGROUND', 'O'), (':', 'O'), ('Preclinical', 'O'), ('studies', 'O'), ('of', 'O'), ('intrathecal', 'O'), ('adenosine', 'O'), ('suggest', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('effective', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('acute', 'B'), ('and', 'I'), ('chronic', 'I'), ('pain', 'I'), ('in', 'O'), ('humans', 'O'), (',', 'O'), ('and', 'O'), ('preliminary', 'O'), ('studies', 'O'), ('in', 'O'), ('volunteers', 'O'), ('and', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('Swedish', 'O'), ('formulation', 'O'), ('of', 'O'), ('adenosine', 'O'), ('suggests', 'O'), ('it', 'O'), ('may', 'O'), ('be', 'O'), ('effective', 'O'), ('in', 'O'), ('hypersensitivity', 'B'), ('states', 'O'), ('but', 'O'), ('not', 'O'), ('with', 'O'), ('acute', 'O'), ('noxious', 'O'), ('stimulation', 'O'), ('.', 'O'))"
"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .","(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('screen', 'O'), ('for', 'O'), ('efficacy', 'O'), ('of', 'O'), ('a', 'O'), ('different', 'O'), ('formulation', 'O'), ('of', 'O'), ('adenosine', 'O'), ('marketed', 'O'), ('in', 'O'), ('the', 'O'), ('US', 'O'), (',', 'O'), ('using', 'O'), ('both', 'O'), ('acute', 'O'), ('noxious', 'O'), ('stimulation', 'O'), ('and', 'O'), ('capsaicin', 'O'), ('-', 'O'), ('evoked', 'O'), ('mechanical', 'O'), ('hypersensitivity', 'B'), ('.', 'O'))"
"Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .","(('Cerebrospinal', 'O'), ('fluid', 'O'), ('was', 'O'), ('obtained', 'O'), ('for', 'O'), ('pharmacokinetic', 'O'), ('analysis', 'O'), (',', 'O'), ('and', 'O'), ('pain', 'B'), ('ratings', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('acute', 'O'), ('heat', 'O'), ('stimuli', 'O'), ('and', 'O'), ('areas', 'O'), ('of', 'O'), ('mechanical', 'B'), ('hyperalgesia', 'I'), ('and', 'O'), ('allodynia', 'B'), ('after', 'O'), ('intradermal', 'O'), ('capsaicin', 'O'), ('injection', 'O'), ('were', 'O'), ('determined', 'O'), ('.', 'O'))"
RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .,"(('RESULTS', 'O'), (':', 'O'), ('Adenosine', 'O'), ('produced', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('pain', 'B'), ('report', 'O'), ('to', 'O'), ('acute', 'O'), ('noxious', 'O'), ('thermal', 'O'), ('or', 'O'), ('chemical', 'O'), ('stimulation', 'O'), ('but', 'O'), ('reduced', 'O'), ('mechanical', 'B'), ('hyperalgesia', 'I'), ('and', 'O'), ('allodynia', 'B'), ('from', 'O'), ('intradermal', 'O'), ('capsaicin', 'O'), ('injection', 'O'), ('for', 'O'), ('at', 'O'), ('least', 'O'), ('24', 'O'), ('h', 'O'), ('.', 'O'))"
"CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .","(('CONCLUSIONS', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('show', 'O'), ('selective', 'O'), ('inhibition', 'O'), ('by', 'O'), ('intrathecal', 'O'), ('adenosine', 'O'), ('of', 'O'), ('hypersensitivity', 'B'), (',', 'O'), ('presumed', 'O'), ('to', 'O'), ('reflect', 'O'), ('central', 'O'), ('sensitization', 'O'), ('in', 'O'), ('humans', 'O'), ('after', 'O'), ('peripheral', 'O'), ('capsaicin', 'O'), ('injection', 'O'), ('.', 'O'))"
The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .,"(('The', 'O'), ('long', 'O'), ('-', 'O'), ('lasting', 'O'), ('effect', 'O'), ('is', 'O'), ('consistent', 'O'), ('with', 'O'), ('that', 'O'), ('observed', 'O'), ('in', 'O'), ('preliminary', 'O'), ('reports', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('neuropathic', 'B'), ('pain', 'I'), ('and', 'O'), ('is', 'O'), ('not', 'O'), ('due', 'O'), ('to', 'O'), ('prolonged', 'O'), ('residence', 'O'), ('of', 'O'), ('adenosine', 'O'), ('in', 'O'), ('cerebrospinal', 'O'), ('fluid', 'O'), ('.', 'O'))"
Delayed - onset heparin - induced thrombocytopenia .,"(('Delayed', 'O'), ('-', 'O'), ('onset', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('.', 'O'))"
"BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .","(('BACKGROUND', 'O'), (':', 'O'), ('Heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('presents', 'O'), ('5', 'O'), ('to', 'O'), ('12', 'O'), ('days', 'O'), ('after', 'O'), ('heparin', 'O'), ('exposure', 'O'), (',', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('arterial', 'B'), ('or', 'I'), ('venous', 'I'), ('thromboemboli', 'I'), ('.', 'O'))"
Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .,"(('Delayed', 'O'), ('recognition', 'O'), ('and', 'O'), ('treatment', 'O'), ('of', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('contribute', 'O'), ('to', 'O'), ('poor', 'O'), ('patient', 'O'), ('outcomes', 'O'), ('.', 'O'))"
OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('describe', 'O'), ('and', 'O'), ('increase', 'O'), ('awareness', 'O'), ('of', 'O'), ('a', 'O'), ('clinical', 'O'), ('scenario', 'O'), ('in', 'O'), ('which', 'O'), ('the', 'O'), ('onset', 'O'), ('or', 'O'), ('manifestations', 'O'), ('of', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('are', 'O'), ('delayed', 'O'), ('.', 'O'))"
PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .,"(('PATIENTS', 'O'), (':', 'O'), ('14', 'O'), ('patients', 'O'), ('seen', 'O'), ('over', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('year', 'O'), ('period', 'O'), ('in', 'O'), ('whom', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('became', 'O'), ('apparent', 'O'), ('on', 'O'), ('delayed', 'O'), ('presentation', 'O'), ('with', 'O'), ('thromboembolic', 'B'), ('complications', 'O'), ('.', 'O'))"
"RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .","(('RESULTS', 'O'), (':', 'O'), ('Patients', 'O'), ('went', 'O'), ('home', 'O'), ('after', 'O'), ('hospitalizations', 'O'), ('that', 'O'), ('had', 'O'), ('included', 'O'), ('heparin', 'O'), ('exposure', 'O'), ('-', 'O'), ('-', 'O'), ('in', 'O'), ('most', 'O'), ('cases', 'O'), (',', 'O'), ('with', 'O'), ('no', 'O'), ('thrombocytopenia', 'B'), ('recognized', 'O'), ('-', 'O'), ('-', 'O'), ('only', 'O'), ('to', 'O'), ('return', 'O'), ('to', 'O'), ('the', 'O'), ('hospital', 'O'), ('(', 'O'), ('median', 'O'), (',', 'O'), ('day', 'O'), ('14', 'O'), (')', 'O'), ('with', 'O'), ('thromboembolic', 'B'), ('complications', 'O'), ('.', 'O'))"
"Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .","(('Thromboemboli', 'B'), ('were', 'O'), ('venous', 'O'), ('(', 'O'), ('12', 'O'), ('patients', 'O'), (',', 'O'), ('7', 'O'), ('with', 'O'), ('pulmonary', 'B'), ('emboli', 'I'), (')', 'O'), ('or', 'O'), ('arterial', 'O'), ('(', 'O'), ('4', 'O'), ('patients', 'O'), (')', 'O'), ('or', 'O'), ('both', 'O'), ('.', 'O'))"
CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Delayed', 'O'), ('-', 'O'), ('onset', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('is', 'O'), ('increasingly', 'O'), ('being', 'O'), ('recognized', 'O'), ('.', 'O'))"
"To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .","(('To', 'O'), ('avoid', 'O'), ('disastrous', 'O'), ('outcomes', 'O'), (',', 'O'), ('physicians', 'O'), ('must', 'O'), ('consider', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('whenever', 'O'), ('a', 'O'), ('recently', 'O'), ('hospitalized', 'O'), ('patient', 'O'), ('returns', 'O'), ('with', 'O'), ('thromboembolism', 'B'), (';', 'O'), ('therapy', 'O'), ('with', 'O'), ('alternative', 'O'), ('anticoagulants', 'O'), (',', 'O'), ('not', 'O'), ('heparin', 'O'), (',', 'O'), ('should', 'O'), ('be', 'O'), ('initiated', 'O'), ('.', 'O'))"
Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .,"(('Treatment', 'O'), ('of', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('with', 'O'), ('a', 'O'), ('dopamine', 'O'), ('agonist', 'O'), ('in', 'O'), ('children', 'O'), ('.', 'O'))"
"BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .","(('BACKGROUND', 'O'), (':', 'O'), ('Risperidone', 'O'), (',', 'O'), ('a', 'O'), ('potent', 'O'), ('antagonist', 'O'), ('of', 'O'), ('both', 'O'), ('serotonergic', 'O'), ('(', 'O'), ('5HT2A', 'O'), (')', 'O'), ('and', 'O'), ('dopaminergic', 'O'), ('D2', 'O'), ('receptors', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('hyperprolactinemia', 'B'), ('in', 'O'), ('adults', 'O'), ('and', 'O'), ('children', 'O'), ('.', 'O'))"
Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .,"(('Chronically', 'O'), ('elevated', 'O'), ('prolactin', 'O'), ('levels', 'O'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('prolactinomas', 'B'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('arrested', 'O'), ('growth', 'O'), ('and', 'O'), ('development', 'O'), ('resulting', 'O'), ('in', 'O'), ('either', 'O'), ('delayed', 'B'), ('puberty', 'I'), ('or', 'O'), ('short', 'O'), ('stature', 'O'), ('.', 'O'))"
These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .,"(('These', 'O'), ('possibilities', 'O'), ('stress', 'O'), ('the', 'O'), ('importance', 'O'), ('of', 'O'), ('developing', 'O'), ('a', 'O'), ('safe', 'O'), ('and', 'O'), ('effective', 'O'), ('approach', 'O'), ('to', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('in', 'O'), ('youth', 'O'), ('.', 'O'))"
We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('successful', 'O'), ('treatment', 'O'), ('of', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('with', 'O'), ('cabergoline', 'O'), ('in', 'O'), ('youth', 'O'), ('.', 'O'))"
METHODS : We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .,"(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('undertook', 'O'), ('a', 'O'), ('retrospective', 'O'), ('case', 'O'), ('review', 'O'), ('of', 'O'), ('four', 'O'), ('children', 'O'), ('with', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('treated', 'O'), ('with', 'O'), ('cabergoline', 'O'), ('.', 'O'))"
"RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .","(('RESULTS', 'O'), (':', 'O'), ('Four', 'O'), ('males', 'O'), ('(', 'O'), ('age', 'O'), ('6', 'O'), ('-', 'O'), ('11', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('Diagnostic', 'O'), ('and', 'O'), ('Statistical', 'O'), ('Manual', 'O'), ('of', 'O'), ('Mental', 'B'), ('Disorders', 'I'), ('(', 'O'), ('fourth', 'O'), ('edition', 'O'), (')', 'O'), ('bipolar', 'B'), ('disorder', 'I'), ('or', 'O'), ('psychoses', 'B'), (',', 'O'), ('with', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('elevations', 'O'), ('in', 'O'), ('serum', 'O'), ('prolactin', 'O'), ('levels', 'O'), ('(', 'O'), ('57', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('129', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), (',', 'O'), ('normal', 'O'), ('5', 'O'), ('-', 'O'), ('15', 'O'), ('ng', 'O'), ('/', 'O'), ('mL', 'O'), (')', 'O'), (',', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('cabergoline', 'O'), ('(', 'O'), ('mean', 'O'), ('dose', 'O'), ('2', 'O'), ('.', 'O'), ('13', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('09', 'O'), ('mg', 'O'), ('/', 'O'), ('week', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Cabergoline', 'O'), ('may', 'O'), ('be', 'O'), ('useful', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('in', 'O'), ('youth', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('further', 'O'), ('research', 'O'), ('is', 'O'), ('needed', 'O'), ('.', 'O'))"
Acute cholestatic hepatitis after exposure to isoflurane .,"(('Acute', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('after', 'O'), ('exposure', 'O'), ('to', 'O'), ('isoflurane', 'O'), ('.', 'O'))"
OBJECTIVE : To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('acute', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('following', 'O'), ('exposure', 'O'), ('to', 'O'), ('the', 'O'), ('inhalational', 'O'), ('anesthetic', 'O'), ('isoflurane', 'O'), ('.', 'O'))"
CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .,"(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('70', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('healthy', 'O'), ('woman', 'O'), ('from', 'O'), ('Iraq', 'O'), ('developed', 'O'), ('acute', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('3', 'O'), ('weeks', 'O'), ('following', 'O'), ('repair', 'O'), ('of', 'O'), ('the', 'O'), ('right', 'O'), ('rotator', 'O'), ('cuff', 'O'), ('under', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
"There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .","(('There', 'O'), ('was', 'O'), ('no', 'O'), ('evidence', 'O'), ('for', 'O'), ('viral', 'O'), (',', 'O'), ('autoimmune', 'O'), (',', 'O'), ('or', 'O'), ('metabolic', 'O'), ('causes', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
"DISCUSSION : The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .","(('DISCUSSION', 'O'), (':', 'O'), ('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('histologic', 'O'), ('picture', 'O'), ('of', 'O'), ('this', 'O'), ('case', 'O'), ('resembles', 'O'), ('halothane', 'B'), ('hepatitis', 'I'), (',', 'O'), ('which', 'O'), ('has', 'O'), ('a', 'O'), ('significant', 'O'), ('mortality', 'O'), ('rate', 'O'), ('.', 'O'))"
"CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Isoflurane', 'O'), (',', 'O'), ('a', 'O'), ('common', 'O'), ('anesthetic', 'O'), ('agent', 'O'), (',', 'O'), ('can', 'O'), ('cause', 'O'), ('severe', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('.', 'O'))"
Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .,"(('Torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('induced', 'O'), ('by', 'O'), ('metoclopramide', 'O'), ('in', 'O'), ('an', 'O'), ('elderly', 'O'), ('woman', 'O'), ('with', 'O'), ('preexisting', 'O'), ('complete', 'O'), ('left', 'B'), ('bundle', 'I'), ('branch', 'I'), ('block', 'I'), ('.', 'O'))"
There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .,"(('There', 'O'), ('is', 'O'), ('a', 'O'), ('growing', 'O'), ('list', 'O'), ('of', 'O'), ('drugs', 'O'), ('implicated', 'O'), ('in', 'O'), ('acquired', 'O'), ('long', 'B'), ('QT', 'I'), ('syndrome', 'I'), ('and', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('.', 'O'))"
We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .,"(('We', 'O'), ('report', 'O'), ('on', 'O'), ('a', 'O'), ('92', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('preexisting', 'O'), ('complete', 'O'), ('left', 'B'), ('bundle', 'I'), ('branch', 'I'), ('block', 'I'), ('who', 'O'), ('developed', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('after', 'O'), ('intravenous', 'O'), ('and', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('metoclopramide', 'O'), ('.', 'O'))"
This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .,"(('This', 'O'), ('patient', 'O'), ('also', 'O'), ('developed', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('when', 'O'), ('cisapride', 'O'), ('and', 'O'), ('erythromycin', 'O'), ('were', 'O'), ('given', 'O'), ('simultaneously', 'O'), ('.', 'O'))"
This is the first documentation that metoclopramide provokes torsade de pointes clinically .,"(('This', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('documentation', 'O'), ('that', 'O'), ('metoclopramide', 'O'), ('provokes', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('clinically', 'O'), ('.', 'O'))"
Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .,"(('Metoclopramide', 'O'), ('should', 'O'), ('be', 'O'), ('used', 'O'), ('cautiously', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('risk', 'O'), ('of', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('.', 'O'))"
"Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .","(('Dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), (',', 'O'), ('through', 'O'), ('D1', 'O'), ('/', 'O'), ('D2', 'O'), ('receptor', 'O'), ('-', 'O'), ('mediated', 'O'), ('signaling', 'O'), (',', 'O'), ('plays', 'O'), ('a', 'O'), ('major', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('of', 'O'), ('epileptic', 'B'), ('seizures', 'I'), ('arising', 'O'), ('in', 'O'), ('the', 'O'), ('limbic', 'O'), ('system', 'O'), ('.', 'O'))"
Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .,"(('Excitotoxicity', 'B'), ('leading', 'O'), ('to', 'O'), ('neuronal', 'O'), ('cell', 'O'), ('death', 'O'), ('in', 'O'), ('the', 'O'), ('affected', 'O'), ('areas', 'O'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('consequence', 'O'), ('of', 'O'), ('seizures', 'B'), ('at', 'O'), ('the', 'O'), ('cellular', 'O'), ('level', 'O'), ('.', 'O'))"
"In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .","(('In', 'O'), ('this', 'O'), ('respect', 'O'), (',', 'O'), ('little', 'O'), ('is', 'O'), ('known', 'O'), ('about', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('DA', 'O'), ('receptors', 'O'), ('in', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('induced', 'O'), ('neuronal', 'O'), ('cell', 'O'), ('death', 'O'), ('.', 'O'))"
Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .,"(('Here', 'O'), ('we', 'O'), ('analyze', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('seizures', 'B'), ('and', 'O'), ('neurotoxicity', 'B'), ('in', 'O'), ('D2R', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('cholinergic', 'O'), ('agonist', 'O'), ('pilocarpine', 'O'), ('.', 'O'))"
"Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .","(('Importantly', 'O'), (',', 'O'), ('D2R', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('develop', 'O'), ('seizures', 'B'), ('at', 'O'), ('doses', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('that', 'O'), ('are', 'O'), ('not', 'O'), ('epileptogenic', 'O'), ('for', 'O'), ('WT', 'O'), ('littermates', 'O'), ('and', 'O'), ('show', 'O'), ('greater', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
"However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .","(('However', 'O'), (',', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('result', 'O'), ('in', 'O'), ('a', 'O'), ('more', 'O'), ('widespread', 'O'), ('neuronal', 'O'), ('death', 'O'), ('in', 'O'), ('both', 'O'), ('WT', 'O'), ('and', 'O'), ('D2R', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('brains', 'O'), ('in', 'O'), ('comparison', 'O'), ('to', 'O'), ('KA', 'O'), ('.', 'O'))"
"Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('D2R', 'O'), ('lowers', 'O'), ('the', 'O'), ('threshold', 'O'), ('for', 'O'), ('seizures', 'B'), ('induced', 'O'), ('by', 'O'), ('both', 'O'), ('glutamate', 'O'), ('and', 'O'), ('acetylcholine', 'O'), ('.', 'O'))"
"Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .","(('Moreover', 'O'), (',', 'O'), ('the', 'O'), ('dopaminergic', 'O'), ('control', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('induced', 'O'), ('neurodegeneration', 'B'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('mediated', 'O'), ('by', 'O'), ('distinct', 'O'), ('interactions', 'O'), ('of', 'O'), ('D2R', 'O'), ('signaling', 'O'), ('with', 'O'), ('these', 'O'), ('two', 'O'), ('neurotransmitters', 'O'), ('.', 'O'))"
Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .,"(('Steroid', 'O'), ('structure', 'O'), ('and', 'O'), ('pharmacological', 'O'), ('properties', 'O'), ('determine', 'O'), ('the', 'O'), ('anti', 'O'), ('-', 'O'), ('amnesic', 'B'), ('effects', 'O'), ('of', 'O'), ('pregnenolone', 'O'), ('sulphate', 'O'), ('in', 'O'), ('the', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .","(('Moreover', 'O'), (',', 'O'), ('PREGS', 'O'), ('is', 'O'), ('able', 'O'), ('to', 'O'), ('reverse', 'O'), ('the', 'O'), ('amnesic', 'B'), ('-', 'O'), ('like', 'O'), ('effects', 'O'), ('of', 'O'), ('NMDAR', 'O'), ('and', 'O'), ('GABA', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('R', 'O'), ('ligands', 'O'), ('.', 'O'))"
The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .,"(('The', 'O'), ('memory', 'O'), ('-', 'O'), ('enhancing', 'O'), ('effects', 'O'), ('of', 'O'), ('PREGS', 'O'), ('and', 'O'), ('its', 'O'), ('analogs', 'O'), ('were', 'O'), ('tested', 'O'), ('in', 'O'), ('the', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('using', 'O'), ('the', 'O'), ('model', 'O'), ('of', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
"Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .","(('Moreover', 'O'), (',', 'O'), ('enantioselectivity', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('by', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('natural', 'O'), ('PREGS', 'O'), ('to', 'O'), ('be', 'O'), ('an', 'O'), ('order', 'O'), ('of', 'O'), ('magnitude', 'O'), ('more', 'O'), ('effective', 'O'), ('than', 'O'), ('its', 'O'), ('synthetic', 'O'), ('enantiomer', 'O'), ('in', 'O'), ('reversing', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .,"(('Activation', 'O'), ('of', 'O'), ('poly', 'O'), ('(', 'O'), ('ADP', 'O'), ('-', 'O'), ('ribose', 'O'), (')', 'O'), ('polymerase', 'O'), ('contributes', 'O'), ('to', 'O'), ('development', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .","(('Increased', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('factor', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('cardiotoxicity', 'B'), ('of', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('DOX', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('widely', 'O'), ('used', 'O'), ('antitumor', 'O'), ('anthracycline', 'O'), ('antibiotic', 'O'), ('.', 'O'))"
"Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .","(('Thus', 'O'), (',', 'O'), ('we', 'O'), ('hypothesized', 'O'), ('that', 'O'), ('the', 'O'), ('activation', 'O'), ('of', 'O'), ('PARP', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('the', 'O'), ('DOX', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .","(('Using', 'O'), ('a', 'O'), ('dual', 'O'), ('approach', 'O'), ('of', 'O'), ('PARP', 'O'), ('-', 'O'), ('1', 'O'), ('suppression', 'O'), (',', 'O'), ('by', 'O'), ('genetic', 'O'), ('deletion', 'O'), ('or', 'O'), ('pharmacological', 'O'), ('inhibition', 'O'), ('with', 'O'), ('the', 'O'), ('phenanthridinone', 'O'), ('PARP', 'O'), ('inhibitor', 'O'), ('PJ34', 'O'), (',', 'O'), ('we', 'O'), ('now', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('PARP', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('induced', 'O'), ('by', 'O'), ('DOX', 'O'), ('.', 'O'))"
Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .,"(('Treatment', 'O'), ('with', 'O'), ('a', 'O'), ('PJ34', 'O'), ('significantly', 'O'), ('improved', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('increased', 'O'), ('the', 'O'), ('survival', 'O'), ('of', 'O'), ('the', 'O'), ('animals', 'O'), ('.', 'O'))"
"Thus , PARP activation contributes to the cardiotoxicity of DOX .","(('Thus', 'O'), (',', 'O'), ('PARP', 'O'), ('activation', 'O'), ('contributes', 'O'), ('to', 'O'), ('the', 'O'), ('cardiotoxicity', 'B'), ('of', 'O'), ('DOX', 'O'), ('.', 'O'))"
PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .,"(('PARP', 'O'), ('inhibitors', 'O'), ('may', 'O'), ('exert', 'O'), ('protective', 'O'), ('effects', 'O'), ('against', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('severe', 'O'), ('cardiac', 'B'), ('complications', 'I'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('DOX', 'O'), ('treatment', 'O'), ('.', 'O'))"
Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?,"(('Spironolactone', 'O'), (':', 'O'), ('is', 'O'), ('it', 'O'), ('a', 'O'), ('novel', 'O'), ('drug', 'O'), ('for', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('-', 'O'), ('related', 'O'), ('hypokalemia', 'B'), ('in', 'O'), ('cancer', 'B'), ('patients', 'O'), ('?', 'O'))"
"OBJECTIVE : Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .","(('OBJECTIVE', 'O'), (':', 'O'), ('Nephrotoxicity', 'B'), ('is', 'O'), ('the', 'O'), ('major', 'O'), ('adverse', 'O'), ('effect', 'O'), ('of', 'O'), ('amphotericin', 'O'), ('B', 'O'), ('(', 'O'), ('AmB', 'O'), (')', 'O'), (',', 'O'), ('often', 'O'), ('limiting', 'O'), ('administration', 'O'), ('of', 'O'), ('full', 'O'), ('dosage', 'O'), ('.', 'O'))"
Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .,"(('Selective', 'O'), ('distal', 'O'), ('tubular', 'O'), ('epithelial', 'O'), ('toxicity', 'B'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('the', 'O'), ('profound', 'O'), ('potassium', 'O'), ('wasting', 'O'), ('that', 'O'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('clinical', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('AmB', 'O'), ('.', 'O'))"
Potassium depletion also potentiates the tubular toxicity of AmB .,"(('Potassium', 'O'), ('depletion', 'O'), ('also', 'O'), ('potentiates', 'O'), ('the', 'O'), ('tubular', 'O'), ('toxicity', 'B'), ('of', 'O'), ('AmB', 'O'), ('.', 'O'))"
METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .,"(('METHODS', 'O'), (':', 'O'), ('In', 'O'), ('this', 'O'), ('study', 'O'), ('26', 'O'), ('patients', 'O'), ('with', 'O'), ('various', 'O'), ('hematological', 'B'), ('disorders', 'I'), ('were', 'O'), ('randomized', 'O'), ('to', 'O'), ('receive', 'O'), ('either', 'O'), ('intravenous', 'O'), ('AmB', 'O'), ('alone', 'O'), ('or', 'O'), ('AmB', 'O'), ('and', 'O'), ('oral', 'O'), ('spironolactone', 'O'), ('100', 'O'), ('mg', 'O'), ('twice', 'O'), ('daily', 'O'), ('when', 'O'), ('developing', 'O'), ('a', 'O'), ('proven', 'O'), ('or', 'O'), ('suspected', 'O'), ('fungal', 'B'), ('infection', 'I'), ('.', 'O'))"
Erectile dysfunction occurs following substantia nigra lesions in the rat .,"(('Erectile', 'B'), ('dysfunction', 'I'), ('occurs', 'O'), ('following', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('lesions', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson ' s disease .,"(('Lesions', 'O'), ('of', 'O'), ('the', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('are', 'O'), ('therefore', 'O'), ('associated', 'O'), ('with', 'O'), ('erectile', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('may', 'O'), ('serve', 'O'), ('as', 'O'), ('a', 'O'), ('model', 'O'), ('to', 'O'), ('study', 'O'), ('erectile', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
Nicotine potentiation of morphine - induced catalepsy in mice .,"(('Nicotine', 'O'), ('potentiation', 'O'), ('of', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('effects', 'O'), ('of', 'O'), ('nicotine', 'O'), ('on', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('morphine', 'O'), ('in', 'O'), ('mice', 'O'), ('have', 'O'), ('been', 'O'), ('investigated', 'O'), ('.', 'O'))"
Morphine but not nicotine induced a dose - dependent catalepsy .,"(('Morphine', 'O'), ('but', 'O'), ('not', 'O'), ('nicotine', 'O'), ('induced', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
"Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .","(('Intraperitoneal', 'O'), ('administration', 'O'), ('of', 'O'), ('atropine', 'O'), (',', 'O'), ('naloxone', 'O'), (',', 'O'), ('mecamylamine', 'O'), (',', 'O'), ('and', 'O'), ('hexamethonium', 'O'), ('to', 'O'), ('mice', 'O'), ('reduced', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('morphine', 'O'), ('with', 'O'), ('nicotine', 'O'), ('.', 'O'))"
"Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .","(('Intracerebroventricular', 'O'), ('injection', 'O'), ('of', 'O'), ('atropine', 'O'), (',', 'O'), ('hexamethonium', 'O'), (',', 'O'), ('and', 'O'), ('naloxone', 'O'), ('also', 'O'), ('decreased', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('morphine', 'O'), ('plus', 'O'), ('nicotine', 'O'), ('.', 'O'))"
"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .","(('It', 'O'), ('was', 'O'), ('concluded', 'O'), ('that', 'O'), ('morphine', 'O'), ('catalepsy', 'B'), ('can', 'O'), ('be', 'O'), ('elicited', 'O'), ('by', 'O'), ('opioid', 'O'), ('and', 'O'), ('cholinergic', 'O'), ('receptors', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('potentiation', 'O'), ('of', 'O'), ('morphine', 'O'), ('induced', 'O'), ('by', 'O'), ('nicotine', 'O'), ('may', 'O'), ('also', 'O'), ('be', 'O'), ('mediated', 'O'), ('through', 'O'), ('cholinergic', 'O'), ('receptor', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
Force overflow and levodopa - induced dyskinesias in Parkinson ' s disease .,"(('Force', 'O'), ('overflow', 'O'), ('and', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .","(('We', 'O'), ('assessed', 'O'), ('force', 'O'), ('coordination', 'O'), ('of', 'O'), ('the', 'O'), ('hand', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('and', 'O'), ('its', 'O'), ('relationship', 'O'), ('to', 'O'), ('motor', 'O'), ('complications', 'O'), ('of', 'O'), ('levodopa', 'O'), ('therapy', 'O'), (',', 'O'), ('particularly', 'O'), ('to', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('(', 'O'), ('LID', 'B'), (')', 'O'), ('.', 'O'))"
"We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .","(('We', 'O'), ('studied', 'O'), ('two', 'O'), ('groups', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('patients', 'O'), ('with', 'O'), ('(', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('+', 'O'), ('LID', 'B'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('23', 'O'), (')', 'O'), ('and', 'O'), ('without', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('(', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('-', 'O'), ('LID', 'B'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('10', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('age', 'O'), ('-', 'O'), ('matched', 'O'), ('healthy', 'O'), ('controls', 'O'), ('.', 'O'))"
"The motor score of the Unified Parkinson ' s Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .","(('The', 'O'), ('motor', 'O'), ('score', 'O'), ('of', 'O'), ('the', 'O'), ('Unified', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('Disease', 'I'), ('Rating', 'O'), ('Scale', 'O'), (',', 'O'), ('a', 'O'), ('dyskinesia', 'B'), ('score', 'O'), ('and', 'O'), ('force', 'O'), ('in', 'O'), ('a', 'O'), ('grip', 'O'), ('-', 'O'), ('lift', 'O'), ('paradigm', 'O'), ('were', 'O'), ('assessed', 'O'), ('ON', 'O'), ('and', 'O'), ('OFF', 'O'), ('levodopa', 'O'), ('.', 'O'))"
A pathological increase of forces was seen in ON - state in Parkinson ' s disease + LID only .,"(('A', 'O'), ('pathological', 'O'), ('increase', 'O'), ('of', 'O'), ('forces', 'O'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('ON', 'O'), ('-', 'O'), ('state', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('+', 'O'), ('LID', 'B'), ('only', 'O'), ('.', 'O'))"
"In Parkinson ' s disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .","(('In', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('+', 'O'), ('LID', 'B'), (',', 'O'), ('the', 'O'), ('force', 'O'), ('involved', 'O'), ('in', 'O'), ('pressing', 'O'), ('down', 'O'), ('the', 'O'), ('object', 'O'), ('before', 'O'), ('lifting', 'O'), ('was', 'O'), ('significantly', 'O'), ('increased', 'O'), ('by', 'O'), ('levodopa', 'O'), ('(', 'O'), ('by', 'O'), ('61', 'O'), ('%', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"In contrast , no excessive force was found in Parkinson ' s disease - LID .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('no', 'O'), ('excessive', 'O'), ('force', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('-', 'O'), ('LID', 'B'), ('.', 'O'))"
"Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson ' s disease + LID than in Parkinson ' s disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .","(('Peak', 'O'), ('grip', 'O'), ('force', 'O'), ('in', 'O'), ('ON', 'O'), ('-', 'O'), ('state', 'O'), ('was', 'O'), ('140', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('higher', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('+', 'O'), ('LID', 'B'), ('than', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('-', 'O'), ('LID', 'B'), (',', 'O'), ('while', 'O'), ('static', 'O'), ('grip', 'O'), ('force', 'O'), ('was', 'O'), ('increased', 'O'), ('by', 'O'), ('138', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('between', 'O'), ('groups', 'O'), ('.', 'O'))"
"Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .","(('Severity', 'O'), ('of', 'O'), ('peak', 'O'), ('-', 'O'), ('dose', 'O'), ('dyskinesias', 'B'), ('was', 'O'), ('strongly', 'O'), ('correlated', 'O'), ('with', 'O'), ('grip', 'O'), ('force', 'O'), ('in', 'O'), ('ON', 'O'), ('-', 'O'), ('state', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('79', 'O'), ('with', 'O'), ('peak', 'O'), ('force', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Force excess was only observed in patients with LID and motor fluctuations .,"(('Force', 'O'), ('excess', 'O'), ('was', 'O'), ('only', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('LID', 'B'), ('and', 'O'), ('motor', 'O'), ('fluctuations', 'O'), ('.', 'O'))"
A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .,"(('A', 'O'), ('close', 'O'), ('relationship', 'O'), ('was', 'O'), ('seen', 'O'), ('between', 'O'), ('the', 'O'), ('overshooting', 'O'), ('of', 'O'), ('forces', 'O'), ('and', 'O'), ('dyskinesias', 'B'), ('in', 'O'), ('the', 'O'), ('ON', 'O'), ('-', 'O'), ('drug', 'O'), ('condition', 'O'), ('.', 'O'))"
We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .,"(('We', 'O'), ('postulate', 'O'), ('that', 'O'), ('both', 'O'), ('LID', 'B'), ('and', 'O'), ('grip', 'O'), ('force', 'O'), ('excess', 'O'), ('share', 'O'), ('common', 'O'), ('pathophysiological', 'O'), ('mechanisms', 'O'), ('related', 'O'), ('to', 'O'), ('motor', 'O'), ('fluctuations', 'O'), ('.', 'O'))"
"This study focuses on behavioral syndromes that may used as models for Parkinson ' s disease , or tardive dyskinesia , and its response after glutamatergic blockage .","(('This', 'O'), ('study', 'O'), ('focuses', 'O'), ('on', 'O'), ('behavioral', 'O'), ('syndromes', 'O'), ('that', 'O'), ('may', 'O'), ('used', 'O'), ('as', 'O'), ('models', 'O'), ('for', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('or', 'O'), ('tardive', 'B'), ('dyskinesia', 'I'), (',', 'O'), ('and', 'O'), ('its', 'O'), ('response', 'O'), ('after', 'O'), ('glutamatergic', 'O'), ('blockage', 'O'), ('.', 'O'))"
"Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .","(('Reserpine', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('administered', 'O'), ('once', 'O'), ('every', 'O'), ('other', 'O'), ('day', 'O'), ('for', 'O'), ('4', 'O'), ('days', 'O'), (',', 'O'), ('produced', 'O'), ('increases', 'O'), ('in', 'O'), ('orofacial', 'B'), ('dyskinesia', 'I'), (',', 'O'), ('tongue', 'O'), ('protrusion', 'O'), ('and', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('in', 'O'), ('mice', 'O'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('signs', 'O'), ('indicative', 'O'), ('of', 'O'), ('tardive', 'B'), ('dyskinesia', 'I'), ('.', 'O'))"
"Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson ' s disease .","(('Reserpine', 'O'), ('also', 'O'), ('produced', 'O'), ('tremor', 'B'), ('and', 'O'), ('catalepsy', 'B'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('signs', 'O'), ('suggestive', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .","(('MK', 'O'), ('-', 'O'), ('801', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('administered', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('the', 'O'), ('observation', 'O'), ('test', 'O'), (',', 'O'), ('prevented', 'O'), ('the', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('movements', 'O'), (',', 'O'), ('tongue', 'O'), ('protrusions', 'O'), ('and', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('reserpine', 'O'), ('.', 'O'))"
"However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .","(('However', 'O'), (',', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), ('injection', 'O'), ('produced', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('of', 'O'), ('tremor', 'B'), ('in', 'O'), ('reserpine', 'O'), ('-', 'O'), ('treated', 'O'), ('mice', 'O'), ('.', 'O'))"
"Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .","(('Reserpine', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('administered', 'O'), ('90', 'O'), ('min', 'O'), ('before', 'O'), ('the', 'O'), ('test', 'O'), ('and', 'O'), ('followed', 'O'), ('by', 'O'), ('apomophine', 'O'), ('injection', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('5', 'O'), ('min', 'O'), ('before', 'O'), ('the', 'O'), ('test', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('oral', 'B'), ('dyskinesia', 'I'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('reserpine', 'O'), ('induced', 'O'), ('increases', 'O'), ('in', 'O'), ('tremor', 'B'), ('and', 'O'), ('catalepsy', 'B'), ('compared', 'O'), ('to', 'O'), ('control', 'O'), ('mice', 'O'), ('.', 'O'))"
MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .,"(('MK', 'O'), ('-', 'O'), ('801', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('administration', 'O'), ('attenuated', 'O'), ('the', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('tremor', 'B'), ('induced', 'O'), ('by', 'O'), ('reserpine', 'O'), ('.', 'O'))"
"Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .","(('Pretreatment', 'O'), ('with', 'O'), ('reserpine', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('24', 'O'), ('h', 'O'), ('before', 'O'), ('the', 'O'), ('observation', 'O'), ('test', 'O'), ('produced', 'O'), ('increases', 'O'), ('in', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('movements', 'O'), ('and', 'O'), ('tongue', 'O'), ('protrusion', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('increases', 'O'), ('in', 'O'), ('tremor', 'B'), ('and', 'O'), ('catalepsy', 'B'), (',', 'O'), ('whereas', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('injection', 'O'), ('90', 'O'), ('min', 'O'), ('before', 'O'), ('the', 'O'), ('test', 'O'), ('reversed', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('reserpine', 'O'), ('.', 'O'))"
"These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .","(('These', 'O'), ('results', 'O'), ('show', 'O'), ('that', 'O'), ('reserpine', 'O'), ('produces', 'O'), ('different', 'O'), ('and', 'O'), ('abnormal', 'B'), ('movements', 'I'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('related', 'O'), ('to', 'O'), ('dose', 'O'), ('and', 'O'), ('schedule', 'O'), ('employed', 'O'), ('and', 'O'), ('can', 'O'), ('be', 'O'), ('considered', 'O'), ('as', 'O'), ('parkinsonian', 'B'), ('-', 'O'), ('like', 'O'), ('and', 'O'), ('tardive', 'B'), ('dsykinesia', 'I'), ('signs', 'O'), ('.', 'O'))"
"The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .","(('The', 'O'), ('glutamatergic', 'O'), ('blockage', 'O'), ('produced', 'O'), ('by', 'O'), ('NMDA', 'O'), ('can', 'O'), ('restore', 'O'), ('these', 'O'), ('signs', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('vacuous', 'O'), ('chewing', 'O'), ('movements', 'O'), (',', 'O'), ('tongue', 'O'), ('protrusions', 'O'), (',', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('tremor', 'B'), ('according', 'O'), ('to', 'O'), ('the', 'O'), ('employed', 'O'), ('model', 'O'), ('.', 'O'))"
"Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .","(('Risperidone', 'O'), ('-', 'O'), ('associated', 'O'), (',', 'O'), ('benign', 'O'), ('transient', 'O'), ('visual', 'B'), ('disturbances', 'I'), ('in', 'O'), ('schizophrenic', 'B'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('past', 'O'), ('history', 'O'), ('of', 'O'), ('LSD', 'O'), ('abuse', 'O'), ('.', 'O'))"
"Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .","(('Two', 'O'), ('schizophrenic', 'B'), ('patients', 'O'), (',', 'O'), ('who', 'O'), ('had', 'O'), ('a', 'O'), ('prior', 'O'), ('history', 'O'), ('of', 'O'), ('LSD', 'O'), ('abuse', 'O'), ('and', 'O'), ('who', 'O'), ('had', 'O'), ('previously', 'O'), ('developed', 'O'), ('EPS', 'B'), ('with', 'O'), ('classic', 'O'), ('antipsychotics', 'O'), (',', 'O'), ('were', 'O'), ('successfully', 'O'), ('treated', 'O'), ('with', 'O'), ('risperidone', 'O'), ('.', 'O'))"
"They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .","(('They', 'O'), ('both', 'O'), ('reported', 'O'), ('short', 'O'), ('episodes', 'O'), ('of', 'O'), ('transient', 'O'), ('visual', 'B'), ('disturbances', 'I'), (',', 'O'), ('which', 'O'), ('appeared', 'O'), ('immediately', 'O'), ('after', 'O'), ('starting', 'O'), ('treatment', 'O'), ('with', 'O'), ('risperidone', 'O'), ('.', 'O'))"
"This imagery resembled visual disturbances previously experienced as "" flashbacks "" related to prior LSD consumption .","(('This', 'O'), ('imagery', 'O'), ('resembled', 'O'), ('visual', 'B'), ('disturbances', 'I'), ('previously', 'O'), ('experienced', 'O'), ('as', 'O'), ('""', 'O'), ('flashbacks', 'O'), ('""', 'O'), ('related', 'O'), ('to', 'O'), ('prior', 'O'), ('LSD', 'O'), ('consumption', 'O'), ('.', 'O'))"
Risperidone administration was continued and the visual disturbances gradually wore off .,"(('Risperidone', 'O'), ('administration', 'O'), ('was', 'O'), ('continued', 'O'), ('and', 'O'), ('the', 'O'), ('visual', 'B'), ('disturbances', 'I'), ('gradually', 'O'), ('wore', 'O'), ('off', 'O'), ('.', 'O'))"
"During a six - month follow - up period , there was no recurrence of visual disturbances .","(('During', 'O'), ('a', 'O'), ('six', 'O'), ('-', 'O'), ('month', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('period', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('recurrence', 'O'), ('of', 'O'), ('visual', 'B'), ('disturbances', 'I'), ('.', 'O'))"
Topiramate - induced nephrolithiasis .,"(('Topiramate', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrolithiasis', 'B'), ('.', 'O'))"
Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .,"(('Topiramate', 'O'), ('is', 'O'), ('a', 'O'), ('recently', 'O'), ('developed', 'O'), ('antiepileptic', 'O'), ('medication', 'O'), ('that', 'O'), ('is', 'O'), ('becoming', 'O'), ('more', 'O'), ('widely', 'O'), ('prescribed', 'O'), ('because', 'O'), ('of', 'O'), ('its', 'O'), ('efficacy', 'O'), ('in', 'O'), ('treating', 'O'), ('refractory', 'B'), ('seizures', 'I'), ('.', 'O'))"
Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .,"(('Urologists', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('that', 'O'), ('this', 'O'), ('medication', 'O'), ('can', 'O'), ('cause', 'O'), ('metabolic', 'B'), ('acidosis', 'I'), ('in', 'O'), ('patients', 'O'), ('secondary', 'O'), ('to', 'O'), ('inhibition', 'O'), ('of', 'O'), ('carbonic', 'O'), ('anhydrase', 'O'), ('.', 'O'))"
These factors can lead to the development of calcium phosphate nephrolithiasis .,"(('These', 'O'), ('factors', 'O'), ('can', 'O'), ('lead', 'O'), ('to', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('calcium', 'O'), ('phosphate', 'O'), ('nephrolithiasis', 'B'), ('.', 'O'))"
We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('first', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('topiramate', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrolithiasis', 'B'), ('in', 'O'), ('the', 'O'), ('urologic', 'O'), ('literature', 'O'), ('.', 'O'))"
"Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .","(('Diazepam', 'O'), (',', 'O'), ('unless', 'O'), ('contraindicated', 'O'), ('or', 'O'), ('risky', 'O'), (',', 'O'), ('remains', 'O'), ('the', 'O'), ('only', 'O'), ('necessary', 'O'), ('complementary', 'O'), ('drug', 'O'), ('to', 'O'), ('ketamine', 'O'), ('as', 'O'), ('it', 'O'), ('buffers', 'O'), ('its', 'O'), ('cardiovascular', 'O'), ('response', 'O'), ('and', 'O'), ('decreases', 'O'), ('the', 'O'), ('duration', 'O'), ('and', 'O'), ('intensity', 'O'), ('of', 'O'), ('operative', 'O'), ('and', 'O'), ('postoperative', 'O'), ('hallucinations', 'B'), ('.', 'O'))"
Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .,"(('Intravenous', 'O'), ('ribavirin', 'O'), ('treatment', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('immunocompromised', 'O'), ('children', 'O'), ('.', 'O'))"
"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('pediatrics', 'O'), ('is', 'O'), ('increasing', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('growing', 'O'), ('numbers', 'O'), ('of', 'O'), ('immunocompromised', 'O'), ('children', 'O'), (',', 'O'), ('where', 'O'), ('case', 'O'), ('fatality', 'O'), ('rates', 'O'), ('as', 'O'), ('high', 'O'), ('as', 'O'), ('50', 'O'), ('%', 'O'), ('to', 'O'), ('80', 'O'), ('%', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .","(('There', 'O'), ('are', 'O'), ('no', 'O'), ('approved', 'O'), ('antiviral', 'O'), ('agents', 'O'), ('with', 'O'), ('proven', 'O'), ('efficacy', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), (',', 'O'), ('nor', 'O'), ('are', 'O'), ('there', 'O'), ('any', 'O'), ('prospective', 'O'), ('randomized', 'O'), (',', 'O'), ('controlled', 'O'), ('trials', 'O'), ('of', 'O'), ('potentially', 'O'), ('useful', 'O'), ('anti', 'O'), ('-', 'O'), ('adenovirus', 'O'), ('therapies', 'O'), ('.', 'O'))"
Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .,"(('Apparent', 'O'), ('clinical', 'O'), ('success', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('is', 'O'), ('limited', 'O'), ('to', 'O'), ('a', 'O'), ('few', 'O'), ('case', 'O'), ('reports', 'O'), ('and', 'O'), ('small', 'O'), ('series', 'O'), ('.', 'O'))"
"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C .","(('Ribavirin', 'O'), ('is', 'O'), ('licensed', 'O'), ('in', 'O'), ('aerosol', 'O'), ('form', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('respiratory', 'B'), ('syncytial', 'I'), ('virus', 'I'), ('infection', 'I'), (',', 'O'), ('and', 'O'), ('orally', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('interferon', 'O'), ('to', 'O'), ('treat', 'O'), ('hepatitis', 'B'), ('C', 'I'), ('.', 'O'))"
Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .,"(('Intravenous', 'O'), ('ribavirin', 'O'), ('is', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('choice', 'O'), ('for', 'O'), ('infection', 'B'), ('with', 'I'), ('hemorrhagic', 'I'), ('fever', 'I'), ('viruses', 'I'), ('.', 'O'))"
The most common adverse effect of intravenous ribavirin is reversible mild anemia .,"(('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('effect', 'O'), ('of', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('is', 'O'), ('reversible', 'O'), ('mild', 'O'), ('anemia', 'B'), ('.', 'O'))"
"The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .","(('The', 'O'), ('use', 'O'), ('of', 'O'), ('cidofovir', 'O'), ('in', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('infection', 'I'), ('has', 'O'), ('been', 'O'), ('limited', 'O'), ('by', 'O'), ('adverse', 'O'), ('effects', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('significant', 'O'), ('of', 'O'), ('which', 'O'), ('is', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .,"(('OBJECTIVE', 'O'), (':', 'O'), ('We', 'O'), ('report', 'O'), ('our', 'O'), ('experience', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('therapy', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('a', 'O'), ('series', 'O'), ('of', 'O'), ('immunocompromised', 'O'), ('children', 'O'), ('and', 'O'), ('review', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .,"(('DESIGN', 'O'), ('/', 'O'), ('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('retrospectively', 'O'), ('reviewed', 'O'), ('the', 'O'), ('medical', 'O'), ('records', 'O'), ('of', 'O'), ('5', 'O'), ('children', 'O'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('for', 'O'), ('documented', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('.', 'O'))"
"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .","(('Two', 'O'), ('patients', 'O'), ('developed', 'O'), ('adenovirus', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('after', 'O'), ('cardiac', 'O'), ('and', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplants', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .","(('An', 'O'), ('additional', 'O'), ('3', 'O'), ('children', 'O'), ('developed', 'O'), ('adenovirus', 'B'), ('pneumonia', 'I'), (';', 'O'), ('2', 'O'), ('were', 'O'), ('neonates', 'O'), (',', 'O'), ('1', 'O'), ('of', 'O'), ('whom', 'O'), ('had', 'O'), ('partial', 'O'), ('DiGeorge', 'B'), ('syndrome', 'I'), ('.', 'O'))"
RESULTS : Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .,"(('RESULTS', 'O'), (':', 'O'), ('Complete', 'O'), ('clinical', 'O'), ('recovery', 'O'), ('followed', 'O'), ('later', 'O'), ('by', 'O'), ('viral', 'O'), ('clearance', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('2', 'O'), ('children', 'O'), (':', 'O'), ('the', 'O'), ('cardiac', 'O'), ('transplant', 'O'), ('recipient', 'O'), ('with', 'O'), ('adenovirus', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('and', 'O'), ('the', 'O'), ('immunocompetent', 'O'), ('neonate', 'O'), ('with', 'O'), ('adenovirus', 'B'), ('pneumonia', 'I'), ('.', 'O'))"
The remaining 3 children died of adenovirus disease .,"(('The', 'O'), ('remaining', 'O'), ('3', 'O'), ('children', 'O'), ('died', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('.', 'O'))"
Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .,"(('Use', 'O'), ('of', 'O'), ('cidofovir', 'O'), ('in', 'O'), ('1', 'O'), ('child', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('progressive', 'B'), ('renal', 'I'), ('failure', 'I'), ('and', 'O'), ('neutropenia', 'B'), ('.', 'O'))"
"DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .","(('DISCUSSION', 'O'), (':', 'O'), ('Our', 'O'), ('series', 'O'), ('of', 'O'), ('patients', 'O'), ('is', 'O'), ('representative', 'O'), ('of', 'O'), ('the', 'O'), ('spectrum', 'O'), ('of', 'O'), ('immunocompromised', 'O'), ('children', 'O'), ('at', 'O'), ('greatest', 'O'), ('risk', 'O'), ('for', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), (',', 'O'), ('namely', 'O'), ('solid', 'O'), ('-', 'O'), ('organ', 'O'), ('and', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplant', 'O'), ('recipients', 'O'), (',', 'O'), ('neonates', 'O'), (',', 'O'), ('and', 'O'), ('children', 'O'), ('with', 'O'), ('immunodeficiency', 'B'), ('.', 'O'))"
"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .","(('Although', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('was', 'O'), ('not', 'O'), ('effective', 'O'), ('for', 'O'), ('all', 'O'), ('children', 'O'), ('with', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('this', 'O'), ('series', 'O'), ('or', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('therapy', 'O'), ('is', 'O'), ('unlikely', 'O'), ('to', 'O'), ('be', 'O'), ('of', 'O'), ('benefit', 'O'), ('if', 'O'), ('begun', 'O'), ('late', 'O'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('the', 'O'), ('infection', 'B'), ('.', 'O'))"
"Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .","(('Early', 'O'), ('identification', 'O'), (',', 'O'), ('eg', 'O'), ('by', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), ('of', 'O'), ('those', 'O'), ('patients', 'O'), ('at', 'O'), ('risk', 'O'), ('of', 'O'), ('disseminated', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('may', 'O'), ('permit', 'O'), ('earlier', 'O'), ('antiviral', 'O'), ('treatment', 'O'), ('and', 'O'), ('better', 'O'), ('evaluation', 'O'), ('of', 'O'), ('therapeutic', 'O'), ('response', 'O'), ('.', 'O'))"
CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Two', 'O'), ('of', 'O'), ('5', 'O'), ('children', 'O'), ('with', 'O'), ('severe', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('treated', 'O'), ('with', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), ('recovered', 'O'), ('.', 'O'))"
"The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .","(('The', 'O'), ('availability', 'O'), ('of', 'O'), ('newer', 'O'), ('rapid', 'O'), ('diagnostic', 'O'), ('techniques', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('polymerase', 'O'), ('chain', 'O'), ('reaction', 'O'), (',', 'O'), ('may', 'O'), ('make', 'O'), ('earlier', 'O'), (',', 'O'), ('more', 'O'), ('effective', 'O'), ('treatment', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('infection', 'I'), ('possible', 'O'), ('.', 'O'))"
"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .","(('Given', 'O'), ('the', 'O'), ('seriousness', 'O'), ('and', 'O'), ('increasing', 'O'), ('prevalence', 'O'), ('of', 'O'), ('adenovirus', 'B'), ('disease', 'I'), ('in', 'O'), ('certain', 'O'), ('hosts', 'O'), (',', 'O'), ('especially', 'O'), ('children', 'O'), (',', 'O'), ('a', 'O'), ('large', 'O'), (',', 'O'), ('multicenter', 'O'), ('clinical', 'O'), ('trial', 'O'), ('of', 'O'), ('potentially', 'O'), ('useful', 'O'), ('anti', 'O'), ('-', 'O'), ('adenoviral', 'O'), ('therapies', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('intravenous', 'O'), ('ribavirin', 'O'), (',', 'O'), ('is', 'O'), ('clearly', 'O'), ('required', 'O'), ('to', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('most', 'O'), ('effective', 'O'), ('and', 'O'), ('least', 'O'), ('toxic', 'O'), ('therapy', 'O'), ('.', 'O'))"
Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .,"(('Delayed', 'O'), ('asystolic', 'B'), ('cardiac', 'B'), ('arrest', 'I'), ('after', 'O'), ('diltiazem', 'O'), ('overdose', 'B'), (';', 'O'), ('resuscitation', 'O'), ('with', 'O'), ('high', 'O'), ('dose', 'O'), ('intravenous', 'O'), ('calcium', 'O'), ('.', 'O'))"
"A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .","(('A', 'O'), ('51', 'O'), ('year', 'O'), ('old', 'O'), ('man', 'O'), ('took', 'O'), ('a', 'O'), ('mixed', 'O'), ('overdose', 'B'), ('including', 'O'), ('1', 'O'), ('.', 'O'), ('8', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('g', 'O'), ('of', 'O'), ('diltiazem', 'O'), (',', 'O'), ('paracetamol', 'O'), (',', 'O'), ('aspirin', 'O'), (',', 'O'), ('isosorbide', 'O'), ('nitrate', 'O'), (',', 'O'), ('and', 'O'), ('alcohol', 'O'), ('.', 'O'))"
He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .,"(('He', 'O'), ('initially', 'O'), ('presented', 'O'), ('to', 'O'), ('hospital', 'O'), ('after', 'O'), ('six', 'O'), ('hours', 'O'), ('with', 'O'), ('mild', 'O'), ('hypotension', 'B'), ('and', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('activated', 'O'), ('charcoal', 'O'), ('and', 'O'), ('intravenous', 'O'), ('fluids', 'O'), ('.', 'O'))"
Eighteen hours after the overdose he had two generalised tonic - clonic seizures .,"(('Eighteen', 'O'), ('hours', 'O'), ('after', 'O'), ('the', 'O'), ('overdose', 'B'), ('he', 'O'), ('had', 'O'), ('two', 'O'), ('generalised', 'O'), ('tonic', 'B'), ('-', 'I'), ('clonic', 'I'), ('seizures', 'I'), ('.', 'O'))"
"The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .","(('The', 'O'), ('patient', 'O'), ('remained', 'O'), ('unresponsive', 'O'), ('with', 'O'), ('junctional', 'O'), ('bradycardia', 'B'), (',', 'O'), ('unrecordable', 'O'), ('blood', 'O'), ('pressure', 'O'), (',', 'O'), ('and', 'O'), ('then', 'O'), ('became', 'O'), ('asystolic', 'B'), ('.', 'O'))"
"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .","(('This', 'O'), ('case', 'O'), ('suggests', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('aggressive', 'O'), ('high', 'O'), ('dose', 'O'), ('intravenous', 'O'), ('calcium', 'O'), ('therapy', 'O'), ('in', 'O'), ('severe', 'O'), ('diltiazem', 'O'), ('overdose', 'B'), (',', 'O'), ('particularly', 'O'), ('with', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('asystole', 'B'), ('.', 'O'))"
It should be considered early in cases of cardiac arrest after diltiazem overdose .,"(('It', 'O'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('early', 'O'), ('in', 'O'), ('cases', 'O'), ('of', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('after', 'O'), ('diltiazem', 'O'), ('overdose', 'B'), ('.', 'O'))"
The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .,"(('The', 'O'), ('case', 'O'), ('also', 'O'), ('highlights', 'O'), ('the', 'O'), ('problems', 'O'), ('with', 'O'), ('delayed', 'O'), ('toxicity', 'B'), ('when', 'O'), ('whole', 'O'), ('bowel', 'O'), ('irrigation', 'O'), ('is', 'O'), ('not', 'O'), ('administered', 'O'), ('.', 'O'))"
Data to establish the thromboembolic risk were incomplete .,"(('Data', 'O'), ('to', 'O'), ('establish', 'O'), ('the', 'O'), ('thromboembolic', 'B'), ('risk', 'O'), ('were', 'O'), ('incomplete', 'O'), ('.', 'O'))"
"The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .","(('The', 'O'), ('incidence', 'O'), ('rate', 'O'), ('of', 'O'), ('thromboembolism', 'B'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('for', 'O'), ('all', 'O'), ('the', 'O'), ('studies', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), (',', 'O'), ('0', 'O'), (',', 'O'), ('20', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), ('%', 'O'), ('in', 'O'), ('groups', 'O'), ('a', 'O'), (',', 'O'), ('b', 'O'), (',', 'O'), ('c', 'O'), (',', 'O'), ('and', 'O'), ('d', 'O'), (',', 'O'), ('respectively', 'O'), (';', 'O'), ('for', 'O'), ('hemorrhage', 'B'), (',', 'O'), ('the', 'O'), ('overall', 'O'), ('rate', 'O'), ('was', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('6', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('and', 'O'), ('0', 'O'), ('%', 'O'), ('for', 'O'), ('the', 'O'), ('respective', 'O'), ('groups', 'O'), (')', 'O'), ('.', 'O'))"
Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .,"(('Cardiac', 'B'), ('arrest', 'I'), ('after', 'O'), ('intravenous', 'O'), ('metoclopramide', 'O'), ('-', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('five', 'O'), ('repeated', 'O'), ('injections', 'O'), ('of', 'O'), ('metoclopramide', 'O'), ('causing', 'O'), ('five', 'O'), ('episodes', 'O'), ('of', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('.', 'O'))"
We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('patient', 'O'), ('where', 'O'), ('intravenous', 'O'), ('injection', 'O'), ('of', 'O'), ('metoclopramide', 'O'), ('was', 'O'), ('immediately', 'O'), ('followed', 'O'), ('by', 'O'), ('asystole', 'B'), ('repeatedly', 'O'), ('.', 'O'))"
"After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .","(('After', 'O'), ('interviewing', 'O'), ('the', 'O'), ('attending', 'O'), ('nurses', 'O'), ('and', 'O'), ('reviewing', 'O'), ('the', 'O'), ('written', 'O'), ('documentation', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('clear', 'O'), ('that', 'O'), ('every', 'O'), ('administration', 'O'), ('of', 'O'), ('metoclopramide', 'O'), ('was', 'O'), ('immediately', 'O'), ('(', 'O'), ('within', 'O'), ('s', 'O'), (')', 'O'), ('followed', 'O'), ('by', 'O'), ('asystole', 'B'), ('.', 'O'))"
"The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .","(('The', 'O'), ('asystole', 'B'), ('lasted', 'O'), ('15', 'O'), ('-', 'O'), ('30', 'O'), ('s', 'O'), ('on', 'O'), ('four', 'O'), ('occasions', 'O'), (',', 'O'), ('on', 'O'), ('one', 'O'), ('occasion', 'O'), ('it', 'O'), ('lasted', 'O'), ('2', 'O'), ('min', 'O'), ('.', 'O'))"
We interpret this as episodes of cardiac arrest caused by metoclopramide .,"(('We', 'O'), ('interpret', 'O'), ('this', 'O'), ('as', 'O'), ('episodes', 'O'), ('of', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('caused', 'O'), ('by', 'O'), ('metoclopramide', 'O'), ('.', 'O'))"
"Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .","(('Immunohistochemical', 'O'), ('study', 'O'), ('on', 'O'), ('inducible', 'O'), ('type', 'O'), ('of', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('(', 'O'), ('iNOS', 'O'), (')', 'O'), (',', 'O'), ('basic', 'O'), ('fibroblast', 'O'), ('growth', 'O'), ('factor', 'O'), ('(', 'O'), ('bFGF', 'O'), (')', 'O'), ('and', 'O'), ('tumor', 'B'), ('growth', 'O'), ('factor', 'O'), ('-', 'O'), ('beta1', 'O'), ('(', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), (')', 'O'), ('in', 'O'), ('arteritis', 'B'), ('induced', 'O'), ('in', 'O'), ('rats', 'O'), ('by', 'O'), ('fenoldopam', 'O'), ('and', 'O'), ('theophylline', 'O'), (',', 'O'), ('vasodilators', 'O'), ('.', 'O'))"
"Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .","(('Arteritis', 'B'), ('induced', 'O'), ('in', 'O'), ('rats', 'O'), ('by', 'O'), ('vasodilators', 'O'), (',', 'O'), ('fenoldopam', 'O'), ('and', 'O'), ('theophylline', 'O'), (',', 'O'), ('was', 'O'), ('examined', 'O'), ('immunohistochemically', 'O'), ('for', 'O'), ('expressions', 'O'), ('of', 'O'), ('inducible', 'O'), ('type', 'O'), ('of', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('synthase', 'O'), ('(', 'O'), ('iNOS', 'O'), (')', 'O'), (',', 'O'), ('basic', 'O'), ('fibroblast', 'O'), ('growth', 'O'), ('factor', 'O'), ('(', 'O'), ('bFGF', 'O'), (')', 'O'), ('and', 'O'), ('tumor', 'B'), ('growth', 'O'), ('factor', 'O'), ('-', 'O'), ('beta1', 'O'), ('(', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), (')', 'O'), ('.', 'O'))"
"Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .","(('Haloperidol', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('ip', 'O'), (')', 'O'), ('induced', 'O'), ('parkinsonian', 'B'), ('-', 'O'), ('like', 'O'), ('muscle', 'B'), ('rigidity', 'I'), (',', 'O'), ('measured', 'O'), ('as', 'O'), ('an', 'O'), ('increased', 'O'), ('resistance', 'O'), ('of', 'O'), ('a', 'O'), ('rat', 'O'), (""'"", 'O'), ('s', 'O'), ('hind', 'O'), ('foot', 'O'), ('to', 'O'), ('passive', 'O'), ('flexion', 'O'), ('and', 'O'), ('extension', 'O'), ('at', 'O'), ('the', 'O'), ('ankle', 'O'), ('joint', 'O'), ('.', 'O'))"
AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .,"(('AIDA', 'O'), ('in', 'O'), ('doses', 'O'), ('of', 'O'), ('7', 'O'), ('.', 'O'), ('5', 'O'), ('-', 'O'), ('15', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('diminished', 'O'), ('the', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('.', 'O'))"
"The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .","(('The', 'O'), ('present', 'O'), ('results', 'O'), ('may', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('blockade', 'O'), ('of', 'O'), ('striatal', 'O'), ('mGluR1', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('the', 'O'), ('stimulation', 'O'), ('of', 'O'), ('group', 'O'), ('II', 'O'), ('mGluRs', 'O'), (',', 'O'), ('may', 'O'), ('ameliorate', 'O'), ('parkinsonian', 'B'), ('muscle', 'B'), ('rigidity', 'I'), ('.', 'O'))"
A phase II study of thalidomide in advanced metastatic renal cell carcinoma .,"(('A', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('advanced', 'O'), ('metastatic', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
"OBJECTIVES : To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('toxicity', 'B'), ('and', 'O'), ('activity', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('advanced', 'O'), ('metastatic', 'O'), ('renal', 'B'), ('cell', 'I'), ('cancer', 'I'), ('and', 'O'), ('to', 'O'), ('measure', 'O'), ('changes', 'O'), ('of', 'O'), ('one', 'O'), ('angiogenic', 'O'), ('factor', 'O'), (',', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('(', 'O'), ('VEGF', 'O'), (')', 'O'), ('165', 'O'), (',', 'O'), ('with', 'O'), ('therapy', 'O'), ('.', 'O'))"
Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .,"(('Somnolence', 'B'), ('and', 'O'), ('constipation', 'B'), ('were', 'O'), ('prominent', 'O'), ('toxicities', 'B'), ('and', 'O'), ('most', 'O'), ('patients', 'O'), ('could', 'O'), ('not', 'O'), ('tolerate', 'O'), ('the', 'O'), ('1200', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('dose', 'O'), ('level', 'O'), ('.', 'O'))"
CONCLUSION : These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .,"(('CONCLUSION', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('a', 'O'), ('low', 'O'), ('level', 'O'), ('of', 'O'), ('activity', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('in', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
"The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .","(('The', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('relationship', 'O'), (',', 'O'), ('if', 'O'), ('any', 'O'), (',', 'O'), ('of', 'O'), ('thalidomide', 'O'), ('for', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('is', 'O'), ('unclear', 'O'), ('.', 'O'))"
Can lidocaine reduce succinylcholine induced postoperative myalgia ?,"(('Can', 'O'), ('lidocaine', 'O'), ('reduce', 'O'), ('succinylcholine', 'O'), ('induced', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('?', 'O'))"
This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('pretreatment', 'O'), ('on', 'O'), ('reduction', 'O'), ('of', 'O'), ('succinylcholine', 'O'), ('-', 'O'), ('induced', 'O'), ('myalgia', 'B'), ('in', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('gynecological', 'O'), ('surgery', 'O'), ('.', 'O'))"
"Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .","(('Following', 'O'), ('administration', 'O'), ('of', 'O'), ('these', 'O'), ('agents', 'O'), (',', 'O'), ('the', 'O'), ('presence', 'O'), (',', 'O'), ('and', 'O'), ('degree', 'O'), ('of', 'O'), ('fasciculation', 'B'), ('were', 'O'), ('assessed', 'O'), ('visually', 'O'), ('on', 'O'), ('a', 'O'), ('four', 'O'), ('point', 'O'), ('scale', 'O'), ('by', 'O'), ('one', 'O'), ('investigator', 'O'), ('who', 'O'), ('was', 'O'), ('blinded', 'O'), ('to', 'O'), ('the', 'O'), ('drug', 'O'), ('administered', 'O'), ('.', 'O'))"
"Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .","(('Twenty', 'O'), ('-', 'O'), ('four', 'O'), ('hours', 'O'), ('later', 'O'), (',', 'O'), ('any', 'O'), ('myalgia', 'B'), ('experienced', 'O'), ('was', 'O'), ('assessed', 'O'), ('according', 'O'), ('to', 'O'), ('a', 'O'), ('structured', 'O'), ('questionaire', 'O'), ('and', 'O'), ('graded', 'O'), ('by', 'O'), ('a', 'O'), ('four', 'O'), ('point', 'O'), ('scale', 'O'), ('by', 'O'), ('one', 'O'), ('investigator', 'O'), ('blinded', 'O'), ('to', 'O'), ('the', 'O'), ('intraoperative', 'O'), ('management', 'O'), ('.', 'O'))"
The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .,"(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('muscle', 'B'), ('fasciculation', 'I'), ('was', 'O'), ('not', 'O'), ('found', 'O'), ('in', 'O'), ('Group', 'O'), ('PR', 'O'), ('while', 'O'), ('the', 'O'), ('patients', 'O'), ('in', 'O'), ('Group', 'O'), ('LS', 'O'), ('had', 'O'), ('a', 'O'), ('lower', 'O'), ('incidence', 'O'), ('of', 'O'), ('muscle', 'B'), ('fasciculation', 'I'), ('than', 'O'), ('those', 'O'), ('in', 'O'), ('Group', 'O'), ('PS', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .","(('At', 'O'), ('24', 'O'), ('h', 'O'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('myalgia', 'B'), ('was', 'O'), ('higher', 'O'), ('in', 'O'), ('Group', 'O'), ('PS', 'O'), ('than', 'O'), ('in', 'O'), ('Group', 'O'), ('LS', 'O'), ('and', 'O'), ('PR', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .,"(('A', 'O'), ('correlation', 'O'), ('was', 'O'), ('not', 'O'), ('found', 'O'), ('between', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('myalgia', 'B'), ('and', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('muscle', 'B'), ('fasciculation', 'I'), ('.', 'O'))"
"In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('where', 'O'), ('succinylcholine', 'O'), ('is', 'O'), ('used', 'O'), (',', 'O'), ('lidocaine', 'O'), ('is', 'O'), ('proven', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('useful', 'O'), ('pretreatment', 'O'), ('agent', 'O'), ('for', 'O'), ('the', 'O'), ('reduction', 'O'), ('of', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('.', 'O'))"
"Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .","(('Reduced', 'O'), ('sodium', 'O'), ('channel', 'O'), ('density', 'O'), (',', 'O'), ('altered', 'O'), ('voltage', 'O'), ('dependence', 'O'), ('of', 'O'), ('inactivation', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('seizures', 'B'), ('in', 'O'), ('mice', 'O'), ('lacking', 'O'), ('sodium', 'O'), ('channel', 'O'), ('beta', 'O'), ('2', 'O'), ('-', 'O'), ('subunits', 'O'), ('.', 'O'))"
"beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .","(('beta2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('displayed', 'O'), ('increased', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('seizures', 'B'), (',', 'O'), ('as', 'O'), ('indicated', 'O'), ('by', 'O'), ('reduced', 'O'), ('latency', 'O'), ('and', 'O'), ('threshold', 'O'), ('for', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), (',', 'O'), ('but', 'O'), ('seemed', 'O'), ('normal', 'O'), ('in', 'O'), ('other', 'O'), ('neurological', 'O'), ('tests', 'O'), ('.', 'O'))"
Acute liver failure with concurrent bupropion and carbimazole therapy .,"(('Acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('with', 'O'), ('concurrent', 'O'), ('bupropion', 'O'), ('and', 'O'), ('carbimazole', 'O'), ('therapy', 'O'), ('.', 'O'))"
OBJECTIVE : To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('fatal', 'O'), ('liver', 'B'), ('failure', 'I'), ('possibly', 'O'), ('associated', 'O'), ('with', 'O'), ('concurrent', 'O'), ('use', 'O'), ('of', 'O'), ('bupropion', 'O'), ('and', 'O'), ('carbimazole', 'O'), ('.', 'O'))"
CASE SUMMARY : A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .,"(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('41', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('Chinese', 'O'), ('man', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('hyperthyroidism', 'B'), ('had', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('carbimazole', 'O'), ('and', 'O'), ('propranolol', 'O'), ('for', 'O'), ('the', 'O'), ('past', 'O'), ('5', 'O'), ('years', 'O'), ('.', 'O'))"
He developed acute liver failure with rapid deterioration of renal function .,"(('He', 'O'), ('developed', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('with', 'O'), ('rapid', 'O'), ('deterioration', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .,"(('Liver', 'O'), ('biopsy', 'O'), ('showed', 'O'), ('evidence', 'O'), ('of', 'O'), ('nonspecific', 'O'), ('drug', 'B'), ('-', 'I'), ('induced', 'I'), ('acute', 'I'), ('liver', 'I'), ('injury', 'I'), ('.', 'O'))"
His condition was further complicated by sepsis and coagulopathy .,"(('His', 'O'), ('condition', 'O'), ('was', 'O'), ('further', 'O'), ('complicated', 'O'), ('by', 'O'), ('sepsis', 'B'), ('and', 'O'), ('coagulopathy', 'B'), ('.', 'O'))"
"The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .","(('The', 'O'), ('likelihood', 'O'), ('that', 'O'), ('bupropion', 'O'), ('induced', 'O'), ('hepatotoxicity', 'B'), ('in', 'O'), ('our', 'O'), ('patient', 'O'), ('was', 'O'), ('possible', 'O'), (',', 'O'), ('based', 'O'), ('on', 'O'), ('the', 'O'), ('Naranjo', 'O'), ('probability', 'O'), ('scale', 'O'), ('.', 'O'))"
"DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .","(('DISCUSSION', 'O'), (':', 'O'), ('Although', 'O'), ('there', 'O'), ('is', 'O'), ('increasing', 'O'), ('evidence', 'O'), ('of', 'O'), ('hepatotoxicity', 'B'), ('induced', 'O'), ('by', 'O'), ('bupropion', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('case', 'O'), ('of', 'O'), ('fatality', 'O'), ('that', 'O'), ('could', 'O'), ('have', 'O'), ('resulted', 'O'), ('from', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('receiving', 'O'), ('bupropion', 'O'), ('while', 'O'), ('on', 'O'), ('concomitant', 'O'), ('treatment', 'O'), ('with', 'O'), ('carbimazole', 'O'), ('.', 'O'))"
CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Clinicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('the', 'O'), ('possibility', 'O'), ('of', 'O'), ('acute', 'B'), ('liver', 'I'), ('insult', 'I'), ('induced', 'O'), ('by', 'O'), ('bupropion', 'O'), ('given', 'O'), ('concurrently', 'O'), ('with', 'O'), ('other', 'O'), ('hepatotoxic', 'B'), ('drugs', 'O'), ('.', 'O'))"
The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .,"(('The', 'O'), ('etiology', 'O'), ('of', 'O'), ('pyeloureteritis', 'B'), ('cystica', 'I'), ('has', 'O'), ('long', 'O'), ('been', 'O'), ('attributed', 'O'), ('to', 'O'), ('chronic', 'O'), ('infection', 'B'), ('and', 'O'), ('inflammation', 'B'), ('.', 'O'))"
There is no evidence of antecedent or concurrent infection in this patient .,"(('There', 'O'), ('is', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('antecedent', 'O'), ('or', 'O'), ('concurrent', 'O'), ('infection', 'B'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .,"(('The', 'O'), ('rate', 'O'), ('of', 'O'), ('resolution', 'O'), ('of', 'O'), ('the', 'O'), ('radiographic', 'O'), ('findings', 'O'), ('may', 'O'), ('be', 'O'), ('helpful', 'O'), ('in', 'O'), ('distinguishing', 'O'), ('between', 'O'), ('true', 'O'), ('pyeloureteritis', 'B'), ('cystica', 'I'), ('and', 'O'), ('submucosal', 'B'), ('hemorrhage', 'I'), ('.', 'O'))"
BACKGROUND : The use of iodinated contrast medium can result in nephropathy .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('use', 'O'), ('of', 'O'), ('iodinated', 'O'), ('contrast', 'O'), ('medium', 'O'), ('can', 'O'), ('result', 'O'), ('in', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .,"(('Whether', 'O'), ('iso', 'O'), ('-', 'O'), ('osmolar', 'O'), ('contrast', 'O'), ('medium', 'O'), ('is', 'O'), ('less', 'O'), ('nephrotoxic', 'B'), ('than', 'O'), ('low', 'O'), ('-', 'O'), ('osmolar', 'O'), ('contrast', 'O'), ('medium', 'O'), ('in', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('patients', 'O'), ('is', 'O'), ('uncertain', 'O'), ('.', 'O'))"
"METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .","(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('conducted', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('prospective', 'O'), (',', 'O'), ('multicenter', 'O'), ('study', 'O'), ('comparing', 'O'), ('the', 'O'), ('nephrotoxic', 'B'), ('effects', 'O'), ('of', 'O'), ('an', 'O'), ('iso', 'O'), ('-', 'O'), ('osmolar', 'O'), (',', 'O'), ('dimeric', 'O'), (',', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('medium', 'O'), (',', 'O'), ('iodixanol', 'O'), (',', 'O'), ('with', 'O'), ('those', 'O'), ('of', 'O'), ('a', 'O'), ('low', 'O'), ('-', 'O'), ('osmolar', 'O'), (',', 'O'), ('nonionic', 'O'), (',', 'O'), ('monomeric', 'O'), ('contrast', 'O'), ('medium', 'O'), (',', 'O'), ('iohexol', 'O'), ('.', 'O'))"
The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .,"(('The', 'O'), ('study', 'O'), ('involved', 'O'), ('129', 'O'), ('patients', 'O'), ('with', 'O'), ('diabetes', 'B'), ('with', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('concentrations', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('to', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('per', 'O'), ('deciliter', 'O'), ('who', 'O'), ('underwent', 'O'), ('coronary', 'O'), ('or', 'O'), ('aortofemoral', 'O'), ('angiography', 'O'), ('.', 'O'))"
"Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .","(('Edaravone', 'O'), (',', 'O'), ('a', 'O'), ('free', 'O'), ('radical', 'O'), ('scavenger', 'O'), (',', 'O'), ('has', 'O'), ('potent', 'O'), ('free', 'O'), ('radical', 'O'), ('quenching', 'O'), ('action', 'O'), ('and', 'O'), ('is', 'O'), ('used', 'O'), ('in', 'O'), ('clinical', 'O'), ('practice', 'O'), ('to', 'O'), ('treat', 'O'), ('cerebral', 'B'), ('infarction', 'I'), ('.', 'O'))"
Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .,"(('Levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('oromandibular', 'O'), ('dystonia', 'B'), ('in', 'O'), ('progressive', 'B'), ('supranuclear', 'I'), ('palsy', 'I'), ('.', 'O'))"
Levodopa - induced dyskinesias have been reported in Parkinson ' s disease and multiple system atrophy .,"(('Levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('and', 'O'), ('multiple', 'B'), ('system', 'I'), ('atrophy', 'I'), ('.', 'O'))"
Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .,"(('Cranial', 'O'), ('dystonias', 'B'), ('are', 'O'), ('rare', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('progressive', 'B'), ('supranuclear', 'I'), ('palsy', 'I'), ('(', 'O'), ('PSP', 'B'), (')', 'O'), ('.', 'O'))"
"In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .","(('In', 'O'), ('this', 'O'), ('report', 'O'), ('we', 'O'), ('describe', 'O'), ('an', 'O'), ('unusual', 'O'), ('case', 'O'), ('of', 'O'), ('reversible', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('Oromandibular', 'B'), ('dystonia', 'I'), ('(', 'O'), ('OMD', 'B'), (')', 'O'), ('in', 'O'), ('a', 'O'), ('PSP', 'B'), ('patient', 'O'), ('to', 'O'), ('highlight', 'O'), ('the', 'O'), ('importance', 'O'), ('of', 'O'), ('recognizing', 'O'), ('this', 'O'), ('drug', 'O'), ('related', 'O'), ('complication', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('PSP', 'B'), (',', 'O'), ('and', 'O'), ('discuss', 'O'), ('the', 'O'), ('possible', 'O'), ('underlying', 'O'), ('pathophysiology', 'O'), ('.', 'O'))"
Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .,"(('Case', 'O'), ('report', 'O'), (':', 'O'), ('Dexatrim', 'O'), ('(', 'O'), ('Phenylpropanolamine', 'O'), (')', 'O'), ('as', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('.', 'O'))"
Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .,"(('Its', 'O'), ('use', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('hypertensive', 'B'), ('episodes', 'O'), ('and', 'O'), ('hemorrhagic', 'B'), ('strokes', 'I'), ('in', 'O'), ('younger', 'O'), ('women', 'O'), ('.', 'O'))"
"Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .","(('Several', 'O'), ('reports', 'O'), ('have', 'O'), ('linked', 'O'), ('the', 'O'), ('abuse', 'O'), ('of', 'O'), ('PPA', 'O'), ('with', 'O'), ('myocardial', 'B'), ('injury', 'I'), (',', 'O'), ('especially', 'O'), ('when', 'O'), ('overdose', 'B'), ('is', 'O'), ('involved', 'O'), ('.', 'O'))"
We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .,"(('We', 'O'), ('report', 'O'), ('here', 'O'), ('the', 'O'), ('first', 'O'), ('case', 'O'), ('of', 'O'), ('Dexatrim', 'O'), ('(', 'O'), ('PPA', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('injury', 'I'), ('in', 'O'), ('a', 'O'), ('young', 'O'), ('woman', 'O'), ('who', 'O'), ('was', 'O'), ('using', 'O'), ('it', 'O'), ('at', 'O'), ('recommended', 'O'), ('doses', 'O'), ('for', 'O'), ('weight', 'O'), ('control', 'O'), ('.', 'O'))"
"In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('we', 'O'), ('review', 'O'), ('the', 'O'), ('7', 'O'), ('other', 'O'), ('cases', 'O'), ('of', 'O'), ('PPA', 'O'), ('related', 'O'), ('myocardial', 'B'), ('injury', 'I'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('so', 'O'), ('far', 'O'), ('.', 'O'))"
Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .,"(('Differential', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('high', 'O'), ('serum', 'O'), ('creatine', 'O'), ('kinase', 'O'), ('levels', 'O'), ('in', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematosus', 'I'), ('.', 'O'))"
We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('clinical', 'O'), ('and', 'O'), ('bioptic', 'O'), ('findings', 'O'), ('for', 'O'), ('a', 'O'), ('57', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('severe', 'O'), ('chloroquine', 'O'), ('-', 'O'), ('induced', 'O'), ('myopathy', 'B'), ('.', 'O'))"
"Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .","(('Since', 'O'), ('1989', 'O'), (',', 'O'), ('she', 'O'), ('had', 'O'), ('been', 'O'), ('suffering', 'O'), ('from', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematosus', 'I'), ('(', 'O'), ('SLE', 'B'), (')', 'O'), ('with', 'O'), ('renal', 'B'), ('involvement', 'I'), ('and', 'O'), ('undergone', 'O'), ('periods', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('azathioprine', 'O'), ('and', 'O'), ('cyclophosphamide', 'O'), ('.', 'O'))"
"The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .","(('The', 'O'), ('CK', 'O'), ('increase', 'O'), ('persisted', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('and', 'O'), ('she', 'O'), ('developed', 'O'), ('progressive', 'O'), ('muscular', 'B'), ('weakness', 'I'), ('and', 'O'), ('muscular', 'B'), ('atrophy', 'I'), ('.', 'O'))"
"Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .","(('Thus', 'O'), (',', 'O'), ('muscle', 'O'), ('biopsy', 'O'), ('of', 'O'), ('the', 'O'), ('deltoid', 'O'), ('muscle', 'O'), ('was', 'O'), ('performed', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('exclude', 'O'), ('polymyositis', 'B'), ('or', 'O'), ('toxic', 'O'), ('myopathy', 'B'), ('.', 'O'))"
"As it revealed chloroquine - induced myopathy , medication was stopped .","(('As', 'O'), ('it', 'O'), ('revealed', 'O'), ('chloroquine', 'O'), ('-', 'O'), ('induced', 'O'), ('myopathy', 'B'), (',', 'O'), ('medication', 'O'), ('was', 'O'), ('stopped', 'O'), ('.', 'O'))"
Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .,"(('Discriminating', 'O'), ('between', 'O'), ('primary', 'O'), ('SLE', 'B'), ('-', 'O'), ('induced', 'O'), ('affection', 'B'), ('of', 'I'), ('the', 'I'), ('musculoskeletal', 'I'), ('system', 'I'), ('and', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('side', 'O'), ('effects', 'O'), ('is', 'O'), ('important', 'O'), ('for', 'O'), ('appropriate', 'O'), ('treatment', 'O'), ('of', 'O'), ('SLE', 'B'), ('patients', 'O'), ('.', 'O'))"
Seizure associated with sleep deprivation and sustained - release bupropion .,"(('Seizure', 'B'), ('associated', 'O'), ('with', 'O'), ('sleep', 'B'), ('deprivation', 'I'), ('and', 'O'), ('sustained', 'O'), ('-', 'O'), ('release', 'O'), ('bupropion', 'O'), ('.', 'O'))"
This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .,"(('This', 'O'), ('case', 'O'), ('report', 'O'), ('describes', 'O'), ('a', 'O'), ('generalized', 'O'), ('seizure', 'B'), ('associated', 'O'), ('with', 'O'), ('sustained', 'O'), ('-', 'O'), ('release', 'O'), ('bupropion', 'O'), ('use', 'O'), ('and', 'O'), ('sleep', 'B'), ('deprivation', 'I'), ('.', 'O'))"
"After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .","(('After', 'O'), ('5', 'O'), ('weeks', 'O'), ('of', 'O'), ('bupropion', 'O'), ('use', 'O'), (',', 'O'), ('the', 'O'), ('subject', 'O'), ('experienced', 'O'), ('a', 'O'), ('generalized', 'O'), ('tonic', 'O'), ('clonic', 'O'), ('seizure', 'B'), ('after', 'O'), ('staying', 'O'), ('up', 'O'), ('nearly', 'O'), ('all', 'O'), ('night', 'O'), ('packing', 'O'), ('and', 'O'), ('moving', 'O'), ('to', 'O'), ('a', 'O'), ('new', 'O'), ('residence', 'O'), ('.', 'O'))"
The patient had no other risk factors for seizures .,"(('The', 'O'), ('patient', 'O'), ('had', 'O'), ('no', 'O'), ('other', 'O'), ('risk', 'O'), ('factors', 'O'), ('for', 'O'), ('seizures', 'B'), ('.', 'O'))"
We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .,"(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('sleep', 'B'), ('deprivation', 'I'), ('may', 'O'), ('add', 'O'), ('to', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('bupropion', 'O'), ('-', 'O'), ('associated', 'O'), ('seizures', 'B'), ('.', 'O'))"
A common side effect associated with succinylcholine is postoperative myalgia .,"(('A', 'O'), ('common', 'O'), ('side', 'O'), ('effect', 'O'), ('associated', 'O'), ('with', 'O'), ('succinylcholine', 'O'), ('is', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('.', 'O'))"
The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .,"(('The', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('this', 'O'), ('myalgia', 'B'), ('is', 'O'), ('still', 'O'), ('unclear', 'O'), (';', 'O'), ('inflammation', 'B'), ('has', 'O'), ('been', 'O'), ('suggested', 'O'), ('but', 'O'), ('without', 'O'), ('convincing', 'O'), ('evidence', 'O'), ('.', 'O'))"
We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .,"(('We', 'O'), ('designed', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('to', 'O'), ('investigate', 'O'), ('whether', 'O'), ('an', 'O'), ('inflammatory', 'O'), ('reaction', 'O'), ('contributes', 'O'), ('to', 'O'), ('this', 'O'), ('myalgia', 'B'), ('.', 'O'))"
The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .,"(('The', 'O'), ('incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('succinylcholine', 'O'), ('-', 'O'), ('associated', 'O'), ('myalgia', 'B'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('64', 'O'), ('patients', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('or', 'O'), ('dexamethasone', 'O'), ('before', 'O'), ('succinylcholine', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('32', 'O'), ('for', 'O'), ('each', 'O'), (')', 'O'), ('.', 'O'))"
"Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .","(('Incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('myalgia', 'B'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), (':', 'O'), ('15', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('dexamethasone', 'O'), ('group', 'O'), ('complained', 'O'), ('of', 'O'), ('myalgia', 'B'), ('compared', 'O'), ('with', 'O'), ('18', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('saline', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('severe', 'O'), ('myalgia', 'B'), ('was', 'O'), ('reported', 'O'), ('by', 'O'), ('five', 'O'), ('patients', 'O'), ('and', 'O'), ('three', 'O'), ('patients', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('not', 'O'), ('significant', 'O'), (')', 'O'), ('.', 'O'))"
"At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .","(('At', 'O'), ('48', 'O'), ('h', 'O'), ('after', 'O'), ('surgery', 'O'), (',', 'O'), ('12', 'O'), ('patients', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('still', 'O'), ('suffered', 'O'), ('from', 'O'), ('myalgia', 'B'), ('(', 'O'), ('not', 'O'), ('significant', 'O'), (')', 'O'), ('.', 'O'))"
"In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('interleukin', 'O'), ('-', 'O'), ('6', 'O'), ('(', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), (')', 'O'), ('as', 'O'), ('an', 'O'), ('early', 'O'), ('marker', 'O'), ('of', 'O'), ('inflammation', 'B'), ('was', 'O'), ('assessed', 'O'), ('in', 'O'), ('a', 'O'), ('subgroup', 'O'), ('of', 'O'), ('10', 'O'), ('patients', 'O'), ('pretreated', 'O'), ('with', 'O'), ('saline', 'O'), ('.', 'O'))"
"We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .","(('We', 'O'), ('found', 'O'), ('an', 'O'), ('increase', 'O'), ('of', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), ('for', 'O'), ('only', 'O'), ('three', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('only', 'O'), ('one', 'O'), ('patient', 'O'), ('reported', 'O'), ('myalgia', 'B'), (';', 'O'), ('no', 'O'), ('relationship', 'O'), ('between', 'O'), ('myalgia', 'B'), ('and', 'O'), ('the', 'O'), ('increase', 'O'), ('of', 'O'), ('IL', 'O'), ('-', 'O'), ('6', 'O'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
"In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('there', 'O'), ('is', 'O'), ('no', 'O'), ('evidence', 'O'), ('for', 'O'), ('an', 'O'), ('inflammatory', 'O'), ('origin', 'O'), ('of', 'O'), ('succinylcholine', 'O'), ('-', 'O'), ('associated', 'O'), ('myalgia', 'B'), ('.', 'O'))"
IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .,"(('IMPLICATIONS', 'O'), (':', 'O'), ('Administration', 'O'), ('of', 'O'), ('dexamethasone', 'O'), ('before', 'O'), ('succinylcholine', 'O'), ('was', 'O'), ('not', 'O'), ('effective', 'O'), ('in', 'O'), ('decreasing', 'O'), ('the', 'O'), ('incidence', 'O'), ('or', 'O'), ('the', 'O'), ('severity', 'O'), ('of', 'O'), ('succinylcholine', 'O'), ('-', 'O'), ('induced', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('.', 'O'))"
"Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .","(('Furthermore', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('significant', 'O'), ('relationship', 'O'), ('between', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('and', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('interleukin', 'O'), ('-', 'O'), ('6', 'O'), ('concentrations', 'O'), (',', 'O'), ('a', 'O'), ('marker', 'O'), ('of', 'O'), ('inflammation', 'B'), ('.', 'O'))"
Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .,"(('Pretreatment', 'O'), ('with', 'O'), ('dexamethasone', 'O'), ('is', 'O'), ('not', 'O'), ('justified', 'O'), ('to', 'O'), ('prevent', 'O'), ('postoperative', 'B'), ('myalgia', 'I'), ('after', 'O'), ('succinylcholine', 'O'), ('.', 'O'))"
Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .,"(('Effect', 'O'), ('of', 'O'), ('lindane', 'O'), ('on', 'O'), ('hepatic', 'O'), ('and', 'O'), ('brain', 'O'), ('cytochrome', 'O'), ('P450s', 'O'), ('and', 'O'), ('influence', 'O'), ('of', 'O'), ('P450', 'O'), ('modulation', 'O'), ('in', 'O'), ('lindane', 'O'), ('induced', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
"Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .","(('Induction', 'O'), ('studies', 'O'), ('have', 'O'), ('further', 'O'), ('shown', 'O'), ('that', 'O'), ('while', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('3', 'O'), ('-', 'O'), ('methylcholanthrene', 'O'), ('(', 'O'), ('MC', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P4501A1', 'O'), ('/', 'O'), ('1A2', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('any', 'O'), ('significant', 'O'), ('effect', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lindane', 'O'), ('induced', 'O'), ('convulsions', 'B'), (',', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('phenobarbital', 'O'), ('(', 'O'), ('PB', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P450', 'O'), ('2B1', 'O'), ('/', 'O'), ('2B2', 'O'), ('or', 'O'), ('ethanol', 'O'), (',', 'O'), ('an', 'O'), ('inducer', 'O'), ('of', 'O'), ('P450', 'O'), ('2E1', 'O'), ('catalysed', 'O'), ('reactions', 'O'), (',', 'O'), ('significantly', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('lindane', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
"Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .","(('Similarly', 'O'), (',', 'O'), ('when', 'O'), ('the', 'O'), ('P450', 'O'), ('-', 'O'), ('mediated', 'O'), ('metabolism', 'O'), ('of', 'O'), ('lindane', 'O'), ('was', 'O'), ('blocked', 'O'), ('by', 'O'), ('cobalt', 'O'), ('chloride', 'O'), ('incidence', 'O'), ('of', 'O'), ('convulsions', 'B'), ('was', 'O'), ('increased', 'O'), ('in', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('lindane', 'O'), ('indicating', 'O'), ('that', 'O'), ('lindane', 'O'), ('per', 'O'), ('se', 'O'), ('or', 'O'), ('its', 'O'), ('metabolites', 'O'), ('formed', 'O'), ('by', 'O'), ('PB', 'O'), ('or', 'O'), ('ethanol', 'O'), ('inducible', 'O'), ('P450', 'O'), ('isoenzymes', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('its', 'O'), ('neurobehavioral', 'O'), ('toxicity', 'B'), ('.', 'O'))"
Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .,"(('Absolute', 'O'), ('and', 'O'), ('attributable', 'O'), ('risk', 'O'), ('of', 'O'), ('venous', 'B'), ('thromboembolism', 'I'), ('in', 'O'), ('women', 'O'), ('on', 'O'), ('combined', 'O'), ('cyproterone', 'O'), ('acetate', 'O'), ('and', 'O'), ('ethinylestradiol', 'O'), ('.', 'O'))"
"OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .","(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('achieve', 'O'), ('absolute', 'O'), ('risk', 'O'), ('estimates', 'O'), ('of', 'O'), ('venous', 'B'), ('thromboembolism', 'I'), ('(', 'O'), ('VTE', 'B'), (')', 'O'), ('among', 'O'), ('women', 'O'), ('on', 'O'), ('cyproterone', 'O'), ('acetate', 'O'), ('plus', 'O'), ('ethinylestradiol', 'O'), ('(', 'O'), ('CPA', 'O'), ('/', 'O'), ('EE', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('among', 'O'), ('women', 'O'), ('on', 'O'), ('combined', 'O'), ('oral', 'O'), ('contraceptives', 'O'), ('(', 'O'), ('COCs', 'O'), (')', 'O'), ('.', 'O'))"
"METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .","(('METHODS', 'O'), (':', 'O'), ('From', 'O'), ('the', 'O'), ('Danish', 'O'), ('National', 'O'), ('Register', 'O'), ('of', 'O'), ('Patients', 'O'), ('(', 'O'), ('NRP', 'O'), (')', 'O'), (',', 'O'), ('1996', 'O'), ('to', 'O'), ('1998', 'O'), (',', 'O'), ('the', 'O'), ('records', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('million', 'O'), ('Danish', 'O'), ('women', 'O'), (',', 'O'), ('ages', 'O'), ('15', 'O'), ('to', 'O'), ('44', 'O'), ('years', 'O'), (',', 'O'), ('were', 'O'), ('searched', 'O'), ('for', 'O'), ('evidence', 'O'), ('of', 'O'), ('VTE', 'B'), ('.', 'O'))"
"RESULTS : During the time frame of the study , 330 women were found to have had VTE while on COCs .","(('RESULTS', 'O'), (':', 'O'), ('During', 'O'), ('the', 'O'), ('time', 'O'), ('frame', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), (',', 'O'), ('330', 'O'), ('women', 'O'), ('were', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('had', 'O'), ('VTE', 'B'), ('while', 'O'), ('on', 'O'), ('COCs', 'O'), ('.', 'O'))"
"The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .","(('The', 'O'), ('corresponding', 'O'), ('absolute', 'O'), ('risk', 'O'), ('of', 'O'), ('VTE', 'B'), ('was', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('(', 'O'), ('range', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), (')', 'O'), ('per', 'O'), ('10', 'O'), ('000', 'O'), ('women', 'O'), ('years', 'O'), ('among', 'O'), ('the', 'O'), ('women', 'O'), ('on', 'O'), ('COCs', 'O'), (',', 'O'), ('4', 'O'), ('.', 'O'), ('2', 'O'), ('(', 'O'), ('range', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('2', 'O'), ('-', 'O'), ('5', 'O'), ('.', 'O'), ('2', 'O'), (')', 'O'), ('per', 'O'), ('10', 'O'), ('000', 'O'), ('women', 'O'), ('years', 'O'), ('among', 'O'), ('women', 'O'), ('on', 'O'), ('levonorgestrel', 'O'), ('-', 'O'), ('containing', 'O'), ('COCs', 'O'), (',', 'O'), ('and', 'O'), ('3', 'O'), ('.', 'O'), ('1', 'O'), ('(', 'O'), ('range', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('3', 'O'), ('-', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), (')', 'O'), ('per', 'O'), ('10', 'O'), ('000', 'O'), ('women', 'O'), ('years', 'O'), ('among', 'O'), ('the', 'O'), ('women', 'O'), ('on', 'O'), ('CPA', 'O'), ('/', 'O'), ('EE', 'O'), ('.', 'O'))"
CONCLUSION : Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .,"(('CONCLUSION', 'O'), (':', 'O'), ('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('the', 'O'), ('absolute', 'O'), ('risk', 'O'), ('of', 'O'), ('VTE', 'B'), ('among', 'O'), ('Danish', 'O'), ('women', 'O'), ('on', 'O'), ('COCs', 'O'), ('is', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('among', 'O'), ('women', 'O'), ('taking', 'O'), ('CPA', 'O'), ('/', 'O'), ('EE', 'O'), ('.', 'O'))"
BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .,"(('BACKGROUND', 'O'), (':', 'O'), ('Analysis', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('for', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drugs', 'O'), ('(', 'O'), ('NSAIDs', 'O'), (')', 'O'), ('suggests', 'O'), ('that', 'O'), ('a', 'O'), ('low', 'O'), ('incidence', 'O'), ('of', 'O'), ('developmental', 'B'), ('anomalies', 'I'), ('occurs', 'O'), ('in', 'O'), ('rats', 'O'), ('given', 'O'), ('NSAIDs', 'O'), ('on', 'O'), ('specific', 'O'), ('days', 'O'), ('during', 'O'), ('organogenesis', 'O'), ('.', 'O'))"
"Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ . Teratology 4 : 15 - 24 , 1971 ) .","(('Aspirin', 'O'), ('(', 'O'), ('acetylsalicylic', 'O'), ('acid', 'O'), ('[', 'O'), ('ASA', 'O'), (']', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('irreversible', 'O'), ('cyclooxygenase', 'O'), ('1', 'O'), ('and', 'O'), ('2', 'O'), ('inhibitor', 'O'), (',', 'O'), ('induces', 'O'), ('developmental', 'B'), ('anomalies', 'I'), ('when', 'O'), ('administered', 'O'), ('to', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('on', 'O'), ('gestational', 'O'), ('day', 'O'), ('(', 'O'), ('GD', 'O'), (')', 'O'), ('9', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('or', 'O'), ('11', 'O'), ('(', 'O'), ('Kimmel', 'O'), ('CA', 'O'), (',', 'O'), ('Wilson', 'O'), ('JG', 'O'), (',', 'O'), ('Schumacher', 'O'), ('HJ', 'O'), ('.', 'O'), ('Teratology', 'O'), ('4', 'O'), (':', 'O'), ('15', 'O'), ('-', 'O'), ('24', 'O'), (',', 'O'), ('1971', 'O'), (')', 'O'), ('.', 'O'))"
"Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .","(('Objectives', 'O'), ('of', 'O'), ('the', 'O'), ('current', 'O'), ('study', 'O'), ('were', 'O'), ('to', 'O'), ('compare', 'O'), ('results', 'O'), ('between', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('(', 'O'), ('SD', 'O'), (')', 'O'), ('and', 'O'), ('Wistar', 'O'), ('strains', 'O'), ('when', 'O'), ('ASA', 'O'), ('is', 'O'), ('administered', 'O'), ('on', 'O'), ('GD', 'O'), ('9', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('or', 'O'), ('11', 'O'), (';', 'O'), ('to', 'O'), ('compare', 'O'), ('the', 'O'), ('malformation', 'O'), ('patterns', 'O'), ('following', 'O'), ('single', 'O'), ('and', 'O'), ('multiple', 'O'), ('dosings', 'O'), ('during', 'O'), ('organogenesis', 'O'), ('in', 'O'), ('SD', 'O'), ('rats', 'O'), (';', 'O'), ('and', 'O'), ('to', 'O'), ('test', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('maternal', 'O'), ('gastrointestinal', 'B'), ('toxicity', 'I'), ('confounds', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('low', 'O'), ('incidence', 'O'), ('malformations', 'B'), ('with', 'O'), ('ASA', 'O'), ('when', 'O'), ('a', 'O'), ('multiple', 'O'), ('dosing', 'O'), ('paradigm', 'O'), ('is', 'O'), ('used', 'O'), ('.', 'O'))"
"RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('literature', 'O'), ('evaluation', 'O'), ('suggested', 'O'), ('that', 'O'), ('NSAIDs', 'O'), ('induce', 'O'), ('ventricular', 'B'), ('septal', 'I'), ('defects', 'I'), ('(', 'O'), ('VSDs', 'B'), (')', 'O'), ('and', 'O'), ('midline', 'B'), ('defects', 'I'), ('(', 'O'), ('MDs', 'B'), (')', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('diaphragmatic', 'B'), ('hernia', 'I'), ('(', 'O'), ('DH', 'B'), (')', 'O'), (',', 'O'), ('MDs', 'B'), (',', 'O'), ('and', 'O'), ('VSDs', 'B'), ('in', 'O'), ('rabbits', 'O'), ('(', 'O'), ('Cook', 'O'), ('JC', 'O'), ('et', 'O'), ('al', 'O'), ('.', 'O'), (',', 'O'), ('2003', 'O'), (')', 'O'), (';', 'O'), ('hence', 'O'), (',', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('focused', 'O'), ('on', 'O'), ('these', 'O'), ('malformations', 'B'), (',', 'O'), ('even', 'O'), ('though', 'O'), ('ASA', 'O'), ('induces', 'O'), ('several', 'O'), ('other', 'O'), ('low', 'O'), ('-', 'O'), ('incidence', 'O'), ('malformations', 'B'), ('.', 'O'))"
CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('High', 'O'), ('concordance', 'O'), ('in', 'O'), ('major', 'O'), ('developmental', 'B'), ('anomalies', 'I'), ('between', 'O'), ('Wistar', 'O'), ('and', 'O'), ('SD', 'O'), ('rats', 'O'), ('were', 'O'), ('noted', 'O'), ('with', 'O'), ('the', 'O'), ('exception', 'O'), ('of', 'O'), ('VSD', 'B'), ('in', 'O'), ('the', 'O'), ('SD', 'O'), ('rats', 'O'), ('and', 'O'), ('hydrocephalus', 'B'), ('in', 'O'), ('the', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('.', 'O'))"
The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .,"(('The', 'O'), ('most', 'O'), ('common', 'O'), ('adverse', 'O'), ('effects', 'O'), ('were', 'O'), ('nausea', 'B'), ('and', 'O'), ('vomiting', 'B'), ('in', 'O'), ('the', 'O'), ('flumazenil', 'O'), ('group', 'O'), ('and', 'O'), ('nausea', 'B'), ('and', 'O'), ('injection', 'O'), ('-', 'O'), ('site', 'O'), ('pain', 'B'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O'))"
Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .,"(('Methylphenidate', 'O'), ('-', 'O'), ('induced', 'O'), ('obsessive', 'B'), ('-', 'I'), ('compulsive', 'I'), ('symptoms', 'I'), ('in', 'O'), ('an', 'O'), ('elderly', 'O'), ('man', 'O'), ('.', 'O'))"
An 82 - year - old man with treatment - resistant depression and early Alzheimer ' s disease was started on methylphenidate .,"(('An', 'O'), ('82', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('treatment', 'B'), ('-', 'I'), ('resistant', 'I'), ('depression', 'I'), ('and', 'O'), ('early', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('was', 'O'), ('started', 'O'), ('on', 'O'), ('methylphenidate', 'O'), ('.', 'O'))"
Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .,"(('Significant', 'O'), ('obsessive', 'B'), ('-', 'I'), ('compulsive', 'I'), ('behavior', 'I'), ('ensued', 'O'), ('but', 'O'), ('diminished', 'O'), ('over', 'O'), ('several', 'O'), ('weeks', 'O'), ('when', 'O'), ('methylphenidate', 'O'), ('was', 'O'), ('replaced', 'O'), ('by', 'O'), ('fluvoxamine', 'O'), ('.', 'O'))"
"The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .","(('The', 'O'), ('patient', 'O'), ('had', 'O'), ('no', 'O'), ('prior', 'O'), ('psychiatric', 'B'), ('history', 'O'), (',', 'O'), ('but', 'O'), ('he', 'O'), ('had', 'O'), ('a', 'O'), ('sister', 'O'), ('with', 'O'), ('obsessive', 'B'), ('-', 'I'), ('compulsive', 'I'), ('disorder', 'I'), ('.', 'O'))"
Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .,"(('Ciprofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('and', 'O'), ('autoimmune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('.', 'O'))"
Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .,"(('Ciprofloxacin', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('several', 'O'), ('side', 'O'), ('effects', 'O'), ('including', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('and', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('.', 'O'))"
"In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .","(('In', 'O'), ('this', 'O'), ('report', 'O'), (',', 'O'), ('we', 'O'), ('describe', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('ciprofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('and', 'O'), ('autoimmune', 'B'), ('hemolytic', 'I'), ('anemia', 'I'), ('.', 'O'))"
Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .,"(('Hemolytic', 'B'), ('anemia', 'I'), ('improved', 'O'), ('after', 'O'), ('stopping', 'O'), ('the', 'O'), ('drug', 'O'), ('and', 'O'), ('initiation', 'O'), ('of', 'O'), ('steroid', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .","(('Unfortunately', 'O'), (',', 'O'), ('acute', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('was', 'O'), ('irreversible', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), ('developed', 'O'), ('end', 'B'), ('-', 'I'), ('stage', 'I'), ('renal', 'I'), ('disease', 'I'), ('.', 'O'))"
Potential deleterious effect of furosemide in radiocontrast nephropathy .,"(('Potential', 'O'), ('deleterious', 'O'), ('effect', 'O'), ('of', 'O'), ('furosemide', 'O'), ('in', 'O'), ('radiocontrast', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('efficacy', 'O'), ('of', 'O'), ('furosemide', 'O'), ('in', 'O'), ('addition', 'O'), ('to', 'O'), ('intravenous', 'O'), ('fluids', 'O'), ('in', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('radiocontrast', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
"18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .","(('18', 'O'), ('patients', 'O'), (',', 'O'), ('referred', 'O'), ('to', 'O'), ('a', 'O'), ('radiocontrast', 'O'), ('study', 'O'), (',', 'O'), ('considered', 'O'), ('at', 'O'), ('risk', 'O'), ('because', 'O'), ('of', 'O'), ('preexisting', 'O'), ('renal', 'B'), ('insufficiency', 'I'), (',', 'O'), ('were', 'O'), ('enrolled', 'O'), ('in', 'O'), ('a', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('controlled', 'O'), ('trial', 'O'), (',', 'O'), ('performed', 'O'), ('at', 'O'), ('the', 'O'), ('secondary', 'O'), ('care', 'O'), ('center', 'O'), ('of', 'O'), ('a', 'O'), ('1', 'O'), (',', 'O'), ('100', 'O'), ('-', 'O'), ('bed', 'O'), ('private', 'O'), ('university', 'O'), ('hospital', 'O'), ('.', 'O'))"
"Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .","(('Renal', 'B'), ('function', 'I'), ('significantly', 'I'), ('deteriorated', 'I'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('pretreated', 'O'), ('with', 'O'), ('furosemide', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('005', 'O'), ('by', 'O'), ('ANOVA', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('rise', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('from', 'O'), ('145', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('13', 'O'), ('to', 'O'), ('182', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('16', 'O'), ('mumol', 'O'), ('/', 'O'), ('l', 'O'), ('at', 'O'), ('24', 'O'), ('h', 'O'), (',', 'O'), ('while', 'O'), ('no', 'O'), ('change', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('(', 'O'), ('from', 'O'), ('141', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('to', 'O'), ('142', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('7', 'O'), ('mumol', 'O'), ('/', 'O'), ('l', 'O'), (')', 'O'), ('.', 'O'))"
Renal failure was associated with weight loss in the furosemide - treated group .,"(('Renal', 'B'), ('failure', 'I'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('weight', 'B'), ('loss', 'I'), ('in', 'O'), ('the', 'O'), ('furosemide', 'O'), ('-', 'O'), ('treated', 'O'), ('group', 'O'), ('.', 'O'))"
Furosemide may be deleterious in the prevention of radiocontrast nephropathy .,"(('Furosemide', 'O'), ('may', 'O'), ('be', 'O'), ('deleterious', 'O'), ('in', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('radiocontrast', 'O'), ('nephropathy', 'B'), ('.', 'O'))"
Progestational agents and blood coagulation .,"(('Progestational', 'O'), ('agents', 'O'), ('and', 'O'), ('blood', 'B'), ('coagulation', 'I'), ('.', 'O'))"
Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .,"(('Thromboembolic', 'B'), ('and', 'O'), ('other', 'O'), ('complications', 'O'), ('of', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('therapy', 'O'), ('in', 'O'), ('relationship', 'O'), ('to', 'O'), ('pretreatment', 'O'), ('levels', 'O'), ('of', 'O'), ('blood', 'B'), ('coagulation', 'I'), ('factors', 'O'), (':', 'O'), ('summary', 'O'), ('report', 'O'), ('of', 'O'), ('a', 'O'), ('ten', 'O'), ('-', 'O'), ('year', 'O'), ('study', 'O'), ('.', 'O'))"
"Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .","(('Significant', 'O'), ('increases', 'O'), ('in', 'O'), ('certain', 'O'), ('factors', 'O'), ('of', 'O'), ('the', 'O'), ('blood', 'B'), ('coagulation', 'I'), ('and', 'O'), ('fibrinolysin', 'O'), ('systems', 'O'), ('(', 'O'), ('factors', 'O'), ('I', 'O'), (',', 'O'), ('II', 'O'), (',', 'O'), ('VII', 'O'), (',', 'O'), ('VIII', 'O'), (',', 'O'), ('IX', 'O'), (',', 'O'), ('and', 'O'), ('X', 'O'), ('and', 'O'), ('plasminogen', 'O'), (')', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('the', 'O'), ('treated', 'O'), ('groups', 'O'), ('.', 'O'))"
"All four had an abnormal blood coagulation profile , suggesting "" hypercoagulability "" before initiation of therapy .","(('All', 'O'), ('four', 'O'), ('had', 'O'), ('an', 'O'), ('abnormal', 'O'), ('blood', 'B'), ('coagulation', 'I'), ('profile', 'O'), (',', 'O'), ('suggesting', 'O'), ('""', 'O'), ('hypercoagulability', 'B'), ('""', 'O'), ('before', 'O'), ('initiation', 'O'), ('of', 'O'), ('therapy', 'O'), ('.', 'O'))"
"One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .","(('One', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), ('developed', 'O'), ('a', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('before', 'O'), ('receiving', 'O'), ('any', 'O'), ('medication', 'O'), (',', 'O'), ('shortly', 'O'), ('after', 'O'), ('the', 'O'), ('base', 'O'), ('-', 'O'), ('line', 'O'), ('values', 'O'), ('were', 'O'), ('obtained', 'O'), ('.', 'O'))"
Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .,"(('Previous', 'O'), ('studies', 'O'), ('suggested', 'O'), ('the', 'O'), ('possiblility', 'O'), ('of', 'O'), ('increased', 'O'), ('propensity', 'O'), ('for', 'O'), ('thromboembolic', 'B'), ('episodes', 'I'), ('in', 'O'), ('patients', 'O'), ('possessing', 'O'), ('the', 'O'), ('A', 'O'), ('antigen', 'O'), ('.', 'O'))"
Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .,"(('Orthostatic', 'B'), ('hypotension', 'I'), ('occurs', 'O'), ('following', 'O'), ('alpha', 'O'), ('2', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('blockade', 'O'), ('in', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('-', 'O'), ('pretreated', 'O'), ('conscious', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('.', 'O'))"
Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .,"(('Studies', 'O'), ('were', 'O'), ('performed', 'O'), ('to', 'O'), ('evaluate', 'O'), ('whether', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treatment', 'O'), ('alters', 'O'), ('the', 'O'), ('alpha', 'O'), ('2', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('function', 'O'), ('for', 'O'), ('orthostatic', 'O'), ('control', 'O'), ('of', 'O'), ('arterial', 'O'), ('blood', 'O'), ('pressure', 'O'), ('in', 'O'), ('conscious', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('(', 'O'), ('SHR', 'O'), (')', 'O'), ('.', 'O'))"
Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .,"(('Orthostatic', 'B'), ('hypotension', 'I'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('the', 'O'), ('average', 'O'), ('decrease', 'O'), ('(', 'O'), ('%', 'O'), (')', 'O'), ('in', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('(', 'O'), ('MAP', 'O'), ('femoral', 'O'), (')', 'O'), ('over', 'O'), ('the', 'O'), ('60', 'O'), ('-', 'O'), ('s', 'O'), ('tilt', 'O'), ('period', 'O'), ('.', 'O'))"
"However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('head', 'O'), ('-', 'O'), ('up', 'O'), ('tilt', 'O'), ('induced', 'O'), ('orthostatic', 'B'), ('hypotension', 'I'), ('in', 'O'), ('the', 'O'), ('SHR', 'O'), ('treated', 'O'), ('with', 'O'), ('prazosin', 'O'), ('(', 'O'), ('-', 'O'), ('16', 'O'), ('%', 'O'), ('MAP', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('the', 'O'), ('SHR', 'O'), ('treated', 'O'), ('with', 'O'), ('rauwolscine', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('+', 'O'), ('2', 'O'), ('%', 'O'), ('MAP', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), ('.', 'O'))"
Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .,"(('Head', 'O'), ('-', 'O'), ('up', 'O'), ('tilts', 'O'), ('in', 'O'), ('these', 'O'), ('rats', 'O'), ('did', 'O'), ('not', 'O'), ('produce', 'O'), ('orthostatic', 'B'), ('hypotension', 'I'), ('when', 'O'), ('performed', 'O'), ('either', 'O'), ('prior', 'O'), ('to', 'O'), ('or', 'O'), ('after', 'O'), ('acute', 'O'), ('dosing', 'O'), ('of', 'O'), ('prazosin', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('mg', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .","(('The', 'O'), ('pressor', 'O'), ('responses', 'O'), ('and', 'O'), ('bradycardia', 'B'), ('to', 'O'), ('the', 'O'), ('alpha', 'O'), ('1', 'O'), ('-', 'O'), ('agonist', 'O'), ('cirazoline', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('and', 'O'), ('2', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('alpha', 'O'), ('2', 'O'), ('-', 'O'), ('agonist', 'O'), ('Abbott', 'O'), ('-', 'O'), ('53693', 'O'), ('(', 'O'), ('1', 'O'), ('and', 'O'), ('3', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('noradrenaline', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('were', 'O'), ('determined', 'O'), ('in', 'O'), ('conscious', 'O'), ('SHR', 'O'), ('with', 'O'), ('and', 'O'), ('without', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('pretreatment', 'O'), ('.', 'O'))"
Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .,"(('Both', 'O'), ('the', 'O'), ('pressor', 'O'), ('and', 'O'), ('bradycardia', 'B'), ('effects', 'O'), ('of', 'O'), ('cirazoline', 'O'), ('were', 'O'), ('abolished', 'O'), ('in', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treated', 'O'), ('SHR', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('4', 'O'), (')', 'O'), ('as', 'O'), ('compared', 'O'), ('to', 'O'), ('the', 'O'), ('untreated', 'O'), ('SHR', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('4', 'O'), (')', 'O'), ('.', 'O'))"
"On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('the', 'O'), ('pressor', 'O'), ('effects', 'O'), ('of', 'O'), ('Abbott', 'O'), ('-', 'O'), ('53693', 'O'), ('were', 'O'), ('similar', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('of', 'O'), ('SHR', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('accompanying', 'O'), ('bradycardia', 'B'), ('was', 'O'), ('greater', 'O'), ('in', 'O'), ('SHR', 'O'), ('with', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treatment', 'O'), ('than', 'O'), ('without', 'O'), ('such', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )","(('Furthermore', 'O'), (',', 'O'), ('the', 'O'), ('bradycardia', 'B'), ('that', 'O'), ('accompanied', 'O'), ('the', 'O'), ('noradrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('pressor', 'O'), ('effect', 'O'), ('in', 'O'), ('SHR', 'O'), ('was', 'O'), ('similar', 'O'), ('with', 'O'), ('and', 'O'), ('without', 'O'), ('chronic', 'O'), ('prazosin', 'O'), ('treatment', 'O'), ('despite', 'O'), ('a', 'O'), ('47', 'O'), ('-', 'O'), ('71', 'O'), ('%', 'O'), ('reduction', 'O'), ('of', 'O'), ('the', 'O'), ('pressor', 'O'), ('effect', 'O'), ('in', 'O'), ('chronic', 'O'), ('alpha', 'O'), ('1', 'O'), ('-', 'O'), ('receptor', 'O'), ('blocked', 'O'), ('SHR', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('400', 'O'), ('WORDS', 'O'), (')', 'O'))"
Hemolytic - uremic syndrome associated with ingestion of quinine .,"(('Hemolytic', 'B'), ('-', 'I'), ('uremic', 'I'), ('syndrome', 'I'), ('associated', 'O'), ('with', 'O'), ('ingestion', 'O'), ('of', 'O'), ('quinine', 'O'), ('.', 'O'))"
"Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .","(('Hemolytic', 'B'), ('-', 'I'), ('uremic', 'I'), ('syndrome', 'I'), ('following', 'O'), ('quinine', 'O'), ('ingestion', 'O'), ('is', 'O'), ('a', 'O'), ('newly', 'O'), ('described', 'O'), ('phenomenon', 'O'), (',', 'O'), ('with', 'O'), ('just', 'O'), ('two', 'O'), ('previous', 'O'), ('descriptions', 'O'), ('of', 'O'), ('4', 'O'), ('cases', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .,"(('Quinine', 'O'), ('-', 'O'), ('associated', 'O'), ('hemolytic', 'B'), ('-', 'I'), ('uremic', 'I'), ('syndrome', 'I'), ('probably', 'O'), ('occurs', 'O'), ('more', 'O'), ('often', 'O'), ('than', 'O'), ('is', 'O'), ('recognized', 'O'), ('.', 'O'))"
Amnestic syndrome associated with propranolol toxicity : a case report .,"(('Amnestic', 'B'), ('syndrome', 'I'), ('associated', 'O'), ('with', 'O'), ('propranolol', 'O'), ('toxicity', 'B'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .,"(('An', 'O'), ('elderly', 'O'), ('woman', 'O'), ('developed', 'O'), ('an', 'O'), ('Alzheimer', 'B'), ('-', 'O'), ('like', 'O'), ('subacute', 'O'), ('dementia', 'B'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('propranolol', 'O'), ('toxicity', 'B'), ('.', 'O'))"
There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .,"(('There', 'O'), ('is', 'O'), ('evidence', 'O'), ('that', 'O'), ('cerebral', 'O'), ('reactions', 'O'), ('to', 'O'), ('drug', 'O'), ('toxicity', 'B'), ('can', 'O'), ('exhibit', 'O'), ('patterns', 'O'), ('that', 'O'), ('suggest', 'O'), ('highly', 'O'), ('selective', 'O'), ('involvement', 'O'), ('of', 'O'), ('functional', 'O'), ('subdivisions', 'O'), ('of', 'O'), ('the', 'O'), ('brain', 'O'), ('.', 'O'))"
Cefotetan - induced immune hemolytic anemia .,"(('Cefotetan', 'O'), ('-', 'O'), ('induced', 'O'), ('immune', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('.', 'O'))"
Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .,"(('Immune', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('drug', 'O'), ('-', 'O'), ('adsorption', 'O'), ('mechanism', 'O'), ('has', 'O'), ('been', 'O'), ('described', 'O'), ('primarily', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('penicillins', 'O'), ('and', 'O'), ('first', 'O'), ('-', 'O'), ('generation', 'O'), ('cephalosporins', 'O'), ('.', 'O'))"
We describe a patient who developed anemia while receiving intravenous cefotetan .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('anemia', 'B'), ('while', 'O'), ('receiving', 'O'), ('intravenous', 'O'), ('cefotetan', 'O'), ('.', 'O'))"
"These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .","(('These', 'O'), ('observations', 'O'), (',', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('clinical', 'O'), ('and', 'O'), ('laboratory', 'O'), ('evidence', 'O'), ('of', 'O'), ('extravascular', 'O'), ('hemolysis', 'B'), (',', 'O'), ('are', 'O'), ('consistent', 'O'), ('with', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), (',', 'O'), ('possibly', 'O'), ('involving', 'O'), ('both', 'O'), ('drug', 'O'), ('-', 'O'), ('adsorption', 'O'), ('and', 'O'), ('autoantibody', 'O'), ('formation', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .,"(('Use', 'O'), ('of', 'O'), ('dexamethasone', 'O'), ('with', 'O'), ('mesna', 'O'), ('for', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('.', 'O'))"
AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .,"(('AIM', 'O'), (':', 'O'), ('Hemorrhagic', 'B'), ('cystitis', 'I'), ('(', 'O'), ('HC', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('limiting', 'O'), ('side', 'O'), ('-', 'O'), ('effect', 'O'), ('of', 'O'), ('chemotherapy', 'O'), ('with', 'O'), ('ifosfamide', 'O'), ('(', 'O'), ('IFS', 'O'), (')', 'O'), ('.', 'O'))"
All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .,"(('All', 'O'), ('-', 'O'), ('trans', 'O'), ('-', 'O'), ('retinoic', 'O'), ('acid', 'O'), ('-', 'O'), ('induced', 'O'), ('erythema', 'B'), ('nodosum', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('acute', 'B'), ('promyelocytic', 'I'), ('leukemia', 'I'), ('.', 'O'))"
Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .,"(('Erythema', 'B'), ('nodosum', 'I'), ('associated', 'O'), ('with', 'O'), ('all', 'O'), ('-', 'O'), ('trans', 'O'), ('-', 'O'), ('retinoic', 'O'), ('acid', 'O'), ('(', 'O'), ('ATRA', 'O'), (')', 'O'), ('for', 'O'), ('acute', 'B'), ('promyelocytic', 'I'), ('leukemia', 'I'), ('(', 'O'), ('APL', 'B'), (')', 'O'), ('is', 'O'), ('very', 'O'), ('rare', 'O'), ('.', 'O'))"
We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .,"(('We', 'O'), ('describe', 'O'), ('four', 'O'), ('patients', 'O'), ('with', 'O'), ('classic', 'O'), ('APL', 'B'), ('who', 'O'), ('developed', 'O'), ('erythema', 'B'), ('nodosum', 'I'), ('during', 'O'), ('ATRA', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .","(('Fever', 'B'), ('and', 'O'), ('subsequent', 'O'), ('multiple', 'O'), ('painful', 'B'), ('erythematous', 'B'), ('nodules', 'I'), ('over', 'O'), ('extremities', 'O'), ('developed', 'O'), ('on', 'O'), ('D11', 'O'), (',', 'O'), ('D16', 'O'), (',', 'O'), ('D17', 'O'), (',', 'O'), ('and', 'O'), ('D19', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('after', 'O'), ('ATRA', 'O'), ('therapy', 'O'), ('.', 'O'))"
The skin biopsy taken from each patient was consistent with erythema nodosum .,"(('The', 'O'), ('skin', 'O'), ('biopsy', 'O'), ('taken', 'O'), ('from', 'O'), ('each', 'O'), ('patient', 'O'), ('was', 'O'), ('consistent', 'O'), ('with', 'O'), ('erythema', 'B'), ('nodosum', 'I'), ('.', 'O'))"
ATRA seemed to be the most possible etiology of erythema nodosum in our patients .,"(('ATRA', 'O'), ('seemed', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('most', 'O'), ('possible', 'O'), ('etiology', 'O'), ('of', 'O'), ('erythema', 'B'), ('nodosum', 'I'), ('in', 'O'), ('our', 'O'), ('patients', 'O'), ('.', 'O'))"
Short - term use of steroid is very effective in ATRA - induced erythema nodosum .,"(('Short', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('of', 'O'), ('steroid', 'O'), ('is', 'O'), ('very', 'O'), ('effective', 'O'), ('in', 'O'), ('ATRA', 'O'), ('-', 'O'), ('induced', 'O'), ('erythema', 'B'), ('nodosum', 'I'), ('.', 'O'))"
"Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .","(('Loreclezole', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('exerted', 'O'), ('a', 'O'), ('significant', 'O'), ('protective', 'O'), ('action', 'O'), ('in', 'O'), ('amygdala', 'O'), ('-', 'O'), ('kindled', 'O'), ('rats', 'O'), (',', 'O'), ('reducing', 'O'), ('both', 'O'), ('seizure', 'B'), ('and', 'O'), ('afterdischarge', 'O'), ('durations', 'O'), ('.', 'O'))"
Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .,"(('Mitochondrial', 'O'), ('DNA', 'O'), ('and', 'O'), ('its', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('products', 'O'), ('are', 'O'), ('defective', 'O'), ('in', 'O'), ('doxorubicin', 'O'), ('nephrosis', 'B'), ('.', 'O'))"
BACKGROUND : Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .,"(('BACKGROUND', 'O'), (':', 'O'), ('Doxorubicin', 'O'), ('induces', 'O'), ('a', 'O'), ('self', 'O'), ('-', 'O'), ('perpetuating', 'O'), ('nephropathy', 'B'), ('characterized', 'O'), ('by', 'O'), ('early', 'O'), ('glomerular', 'B'), ('and', 'I'), ('late', 'I'), ('-', 'I'), ('onset', 'I'), ('tubular', 'I'), ('lesions', 'I'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
We investigated the potential role of mitochondrial injury in the onset of these lesions .,"(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('potential', 'O'), ('role', 'O'), ('of', 'O'), ('mitochondrial', 'B'), ('injury', 'I'), ('in', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('these', 'O'), ('lesions', 'O'), ('.', 'O'))"
Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .,"(('Glomerular', 'B'), ('and', 'I'), ('tubular', 'I'), ('injury', 'I'), ('was', 'O'), ('monitored', 'O'), ('and', 'O'), ('correlated', 'O'), ('to', 'O'), ('the', 'O'), ('activity', 'O'), ('or', 'O'), ('expression', 'O'), ('of', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('components', 'O'), ('.', 'O'))"
"RESULTS : The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), (""'"", 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), ('group', 'O'), ('had', 'O'), ('significant', 'O'), ('glomerular', 'B'), ('and', 'I'), ('tubular', 'I'), ('lesions', 'I'), (',', 'O'), ('depressed', 'O'), ('activities', 'O'), ('of', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('NADH', 'O'), ('dehydrogenase', 'O'), ('and', 'O'), ('cytochrome', 'O'), ('-', 'O'), ('c', 'O'), ('oxidase', 'O'), ('(', 'O'), ('COX', 'O'), (')', 'O'), ('and', 'O'), ('increased', 'O'), ('citrate', 'O'), ('synthase', 'O'), ('activity', 'O'), ('.', 'O'))"
"In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .","(('In', 'O'), (""'"", 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), (""'"", 'O'), ('rats', 'O'), (',', 'O'), ('there', 'O'), ('were', 'O'), ('fewer', 'O'), ('tubular', 'B'), ('lesions', 'I'), (',', 'O'), ('but', 'O'), ('similar', 'O'), ('numbers', 'O'), ('of', 'O'), ('glomerular', 'B'), ('lesions', 'I'), ('activity', 'O'), ('.', 'O'))"
"Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I .","(('Among', 'O'), ('all', 'O'), ('animals', 'O'), (',', 'O'), ('glomerular', 'B'), ('and', 'I'), ('tubular', 'I'), ('injury', 'I'), ('were', 'O'), ('inversely', 'O'), ('correlated', 'O'), ('with', 'O'), ('mtDNA', 'O'), ('levels', 'O'), (',', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('activities', 'O'), ('and', 'O'), ('with', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('the', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('subunit', 'O'), ('COX', 'O'), ('-', 'O'), ('I', 'O'), ('.', 'O'))"
CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('for', 'O'), ('quantitative', 'O'), ('and', 'O'), ('qualitative', 'O'), ('mtDNA', 'O'), ('alterations', 'O'), ('through', 'O'), ('the', 'O'), ('reduction', 'O'), ('of', 'O'), ('mtDNA', 'O'), ('-', 'O'), ('encoded', 'O'), ('respiratory', 'O'), ('chain', 'O'), ('function', 'O'), ('and', 'O'), ('induction', 'O'), ('of', 'O'), ('superoxide', 'O'), ('in', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('renal', 'B'), ('lesions', 'I'), ('.', 'O'))"
"A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .","(('A', 'O'), ('randomized', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('crossover', 'O'), ('study', 'O'), ('of', 'O'), ('ephedrine', 'O'), ('for', 'O'), ('SSRI', 'O'), ('-', 'O'), ('induced', 'O'), ('female', 'O'), ('sexual', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
"The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .","(('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('ephedrine', 'O'), (',', 'O'), ('an', 'O'), ('alpha', 'O'), ('-', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('agonist', 'O'), ('previously', 'O'), ('shown', 'O'), ('to', 'O'), ('enhance', 'O'), ('genital', 'O'), ('blood', 'O'), ('flow', 'O'), ('in', 'O'), ('women', 'O'), (',', 'O'), ('has', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('in', 'O'), ('reversing', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('sexual', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?,"(('Does', 'O'), ('hormone', 'O'), ('therapy', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('have', 'O'), ('a', 'O'), ('detrimental', 'B'), ('effect', 'I'), ('on', 'I'), ('memory', 'I'), ('and', 'I'), ('cognition', 'I'), ('?', 'O'))"
This pilot study examines whether hormone therapy for breast cancer affects cognition .,"(('This', 'O'), ('pilot', 'O'), ('study', 'O'), ('examines', 'O'), ('whether', 'O'), ('hormone', 'O'), ('therapy', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('affects', 'O'), ('cognition', 'O'), ('.', 'O'))"
"Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .","(('Patients', 'O'), ('participating', 'O'), ('in', 'O'), ('a', 'O'), ('randomised', 'O'), ('trial', 'O'), ('of', 'O'), ('anastrozole', 'O'), (',', 'O'), ('tamoxifen', 'O'), ('alone', 'O'), ('or', 'O'), ('combined', 'O'), ('(', 'O'), ('ATAC', 'O'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('94', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('group', 'O'), ('of', 'O'), ('women', 'O'), ('without', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('35', 'O'), (')', 'O'), ('completed', 'O'), ('a', 'O'), ('battery', 'O'), ('of', 'O'), ('neuropsychological', 'O'), ('measures', 'O'), ('.', 'O'))"
The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .,"(('The', 'O'), ('results', 'O'), ('showed', 'O'), ('specific', 'O'), ('impairments', 'O'), ('in', 'O'), ('processing', 'O'), ('speed', 'O'), ('and', 'O'), ('verbal', 'O'), ('memory', 'O'), ('in', 'O'), ('women', 'O'), ('receiving', 'O'), ('hormonal', 'O'), ('therapy', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .,"(('Doxorubicin', 'O'), ('is', 'O'), ('an', 'O'), ('anti', 'O'), ('-', 'O'), ('tumor', 'B'), ('agent', 'O'), ('that', 'O'), ('represses', 'O'), ('cardiac', 'O'), ('-', 'O'), ('specific', 'O'), ('gene', 'O'), ('expression', 'O'), ('and', 'O'), ('induces', 'O'), ('myocardial', 'O'), ('cell', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .,"(('These', 'O'), ('findings', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('overexpression', 'O'), ('of', 'O'), ('p300', 'O'), ('protects', 'O'), ('cardiac', 'O'), ('myocytes', 'O'), ('from', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('apoptosis', 'O'), ('and', 'O'), ('reduces', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('acute', 'O'), ('heart', 'B'), ('failure', 'I'), ('in', 'O'), ('adult', 'O'), ('mice', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
Methimazole - induced cholestatic jaundice .,"(('Methimazole', 'O'), ('-', 'O'), ('induced', 'O'), ('cholestatic', 'B'), ('jaundice', 'I'), ('.', 'O'))"
A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .,"(('A', 'O'), ('43', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('had', 'O'), ('severe', 'O'), ('jaundice', 'B'), ('and', 'O'), ('itching', 'B'), ('1', 'O'), ('month', 'O'), ('after', 'O'), ('receiving', 'O'), ('methimazole', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('tid', 'O'), (')', 'O'), ('and', 'O'), ('propranolol', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('tid', 'O'), (')', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('hyperthyroidism', 'B'), ('.', 'O'))"
The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .,"(('The', 'O'), ('patient', 'O'), ('continued', 'O'), ('treatment', 'O'), ('for', 'O'), ('another', 'O'), ('4', 'O'), ('days', 'O'), ('after', 'O'), ('the', 'O'), ('appearance', 'O'), ('of', 'O'), ('jaundice', 'B'), ('until', 'O'), ('she', 'O'), ('finished', 'O'), ('both', 'O'), ('medications', 'O'), ('.', 'O'))"
"When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .","(('When', 'O'), ('seen', 'O'), ('at', 'O'), ('the', 'O'), ('emergency', 'O'), ('department', 'O'), ('2', 'O'), ('weeks', 'O'), ('later', 'O'), (',', 'O'), ('she', 'O'), ('still', 'O'), ('had', 'O'), ('severe', 'O'), ('icterus', 'B'), (',', 'O'), ('pruritus', 'B'), (',', 'O'), ('and', 'O'), ('hyperbilirubinemia', 'B'), (',', 'O'), ('formed', 'O'), ('mainly', 'O'), ('of', 'O'), ('the', 'O'), ('conjugated', 'O'), ('fraction', 'O'), ('.', 'O'))"
"Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .","(('Methimazole', 'O'), ('-', 'O'), ('induced', 'O'), ('cholestasis', 'B'), ('was', 'O'), ('diagnosed', 'O'), (',', 'O'), ('and', 'O'), ('propranolol', 'O'), ('therapy', 'O'), ('was', 'O'), ('resumed', 'O'), ('.', 'O'))"
"In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .","(('In', 'O'), ('rare', 'O'), ('cases', 'O'), ('within', 'O'), ('the', 'O'), ('first', 'O'), ('few', 'O'), ('weeks', 'O'), ('of', 'O'), ('therapy', 'O'), (',', 'O'), ('this', 'O'), ('drug', 'O'), ('can', 'O'), ('cause', 'O'), ('severe', 'O'), ('and', 'O'), ('reversible', 'O'), ('cholestatic', 'B'), ('jaundice', 'I'), ('.', 'O'))"
Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert ' s disease ) .,"(('Atrial', 'B'), ('fibrillation', 'I'), ('following', 'O'), ('chemotherapy', 'O'), ('for', 'O'), ('stage', 'O'), ('IIIE', 'O'), ('diffuse', 'O'), ('large', 'O'), ('B', 'O'), ('-', 'O'), ('cell', 'O'), ('gastric', 'B'), ('lymphoma', 'I'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), ('(', 'O'), ('Steinert', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (')', 'O'), ('.', 'O'))"
"The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .","(('The', 'O'), ('authors', 'O'), ('describe', 'O'), ('the', 'O'), ('unusual', 'O'), ('association', 'O'), ('between', 'O'), ('diffuse', 'O'), ('B', 'O'), ('-', 'O'), ('cell', 'O'), ('gastric', 'B'), ('lymphoma', 'I'), ('and', 'O'), ('myotonic', 'B'), ('dystrophy', 'I'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('form', 'O'), ('of', 'O'), ('adult', 'O'), ('muscular', 'B'), ('dystrophy', 'I'), (',', 'O'), ('and', 'O'), ('sudden', 'O'), ('atrial', 'B'), ('fibrillation', 'I'), ('following', 'O'), ('one', 'O'), ('cycle', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('based', 'O'), ('chemotherapy', 'O'), ('in', 'O'), ('the', 'O'), ('same', 'O'), ('patient', 'O'), ('.', 'O'))"
Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .,"(('Atrial', 'B'), ('fibrillation', 'I'), ('or', 'O'), ('other', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('are', 'O'), ('unusual', 'O'), ('complications', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('chemotherapy', 'O'), ('.', 'O'))"
The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .,"(('The', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('intrinsically', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('aggressive', 'O'), ('chemotherapy', 'O'), ('employed', 'O'), ('could', 'O'), ('function', 'O'), ('as', 'O'), ('a', 'O'), ('triggering', 'O'), ('factor', 'O'), ('for', 'O'), ('the', 'O'), ('arrhythmia', 'B'), ('in', 'O'), ('the', 'O'), ('predisposed', 'O'), ('myocardium', 'O'), ('of', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .,"(('Hypersensitivity', 'B'), ('immune', 'O'), ('reaction', 'O'), ('as', 'O'), ('a', 'O'), ('mechanism', 'O'), ('for', 'O'), ('dilevalol', 'O'), ('-', 'O'), ('associated', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('lymphocyte', 'O'), ('reactivity', 'O'), ('to', 'O'), ('dilevalol', 'O'), ('and', 'O'), ('to', 'O'), ('serum', 'O'), ('containing', 'O'), ('putative', 'O'), ('ex', 'O'), ('vivo', 'O'), ('dilevalol', 'O'), ('antigens', 'O'), ('or', 'O'), ('metabolites', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('dilevalol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('.', 'O'))"
PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .,"(('PATIENT', 'O'), (':', 'O'), ('A', 'O'), ('58', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('a', 'O'), ('clinical', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('dilevalol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('.', 'O'))"
"CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('methodology', 'O'), ('used', 'O'), ('allowed', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('lymphocyte', 'O'), ('sensitization', 'O'), ('to', 'O'), ('sera', 'O'), ('containing', 'O'), ('ex', 'O'), ('vivo', 'O'), ('-', 'O'), ('prepared', 'O'), ('dilevalol', 'O'), ('antigens', 'O'), (',', 'O'), ('suggesting', 'O'), ('the', 'O'), ('involvement', 'O'), ('of', 'O'), ('an', 'O'), ('immunologic', 'O'), ('mechanism', 'O'), ('in', 'O'), ('dilevalol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('.', 'O'))"
Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .,"(('Increased', 'O'), ('expression', 'O'), ('and', 'O'), ('apical', 'O'), ('targeting', 'O'), ('of', 'O'), ('renal', 'O'), ('ENaC', 'O'), ('subunits', 'O'), ('in', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Nephrotic syndrome is often accompanied by sodium retention and generalized edema .,"(('Nephrotic', 'B'), ('syndrome', 'I'), ('is', 'O'), ('often', 'O'), ('accompanied', 'O'), ('by', 'O'), ('sodium', 'O'), ('retention', 'O'), ('and', 'O'), ('generalized', 'O'), ('edema', 'B'), ('.', 'O'))"
"After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .","(('After', 'O'), ('7', 'O'), ('days', 'O'), (',', 'O'), ('PAN', 'O'), ('treatment', 'O'), ('induced', 'O'), ('significant', 'O'), ('proteinuria', 'B'), (',', 'O'), ('hypoalbuminemia', 'B'), (',', 'O'), ('decreased', 'O'), ('urinary', 'O'), ('sodium', 'O'), ('excretion', 'O'), (',', 'O'), ('and', 'O'), ('extensive', 'O'), ('ascites', 'B'), ('.', 'O'))"
"In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('increased', 'O'), ('or', 'O'), ('sustained', 'O'), ('expression', 'O'), ('of', 'O'), ('ENaC', 'O'), ('subunits', 'O'), ('combined', 'O'), ('with', 'O'), ('increased', 'O'), ('apical', 'O'), ('targeting', 'O'), ('in', 'O'), ('the', 'O'), ('DCT2', 'O'), (',', 'O'), ('connecting', 'O'), ('tubule', 'O'), (',', 'O'), ('and', 'O'), ('collecting', 'O'), ('duct', 'O'), ('are', 'O'), ('likely', 'O'), ('to', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('sodium', 'O'), ('retention', 'O'), ('associated', 'O'), ('with', 'O'), ('PAN', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
A resurgence of interest in the surgical treatment of Parkinson ' s disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .,"(('A', 'O'), ('resurgence', 'O'), ('of', 'O'), ('interest', 'O'), ('in', 'O'), ('the', 'O'), ('surgical', 'O'), ('treatment', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('(', 'O'), ('PD', 'B'), (')', 'O'), ('came', 'O'), ('with', 'O'), ('the', 'O'), ('rediscovery', 'O'), ('of', 'O'), ('posteroventral', 'O'), ('pallidotomy', 'O'), ('by', 'O'), ('Laitinen', 'O'), ('in', 'O'), ('1985', 'O'), ('.', 'O'))"
"Laitinen ' s procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .","(('Laitinen', 'O'), (""'"", 'O'), ('s', 'O'), ('procedure', 'O'), ('improved', 'O'), ('most', 'O'), ('symptoms', 'O'), ('in', 'O'), ('drug', 'O'), ('-', 'O'), ('resistant', 'O'), ('PD', 'B'), (',', 'O'), ('which', 'O'), ('engendered', 'O'), ('wide', 'O'), ('interest', 'O'), ('in', 'O'), ('the', 'O'), ('neurosurgical', 'O'), ('community', 'O'), ('.', 'O'))"
"According to the literature pallidotomy improves the "" on "" symptoms of PD , such as dyskinesias , as well as the "" off "" symptoms , such as rigidity , bradykinesia , and on - off fluctuations .","(('According', 'O'), ('to', 'O'), ('the', 'O'), ('literature', 'O'), ('pallidotomy', 'O'), ('improves', 'O'), ('the', 'O'), ('""', 'O'), ('on', 'O'), ('""', 'O'), ('symptoms', 'O'), ('of', 'O'), ('PD', 'B'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('dyskinesias', 'B'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('the', 'O'), ('""', 'O'), ('off', 'O'), ('""', 'O'), ('symptoms', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('rigidity', 'B'), (',', 'O'), ('bradykinesia', 'B'), (',', 'O'), ('and', 'O'), ('on', 'O'), ('-', 'O'), ('off', 'O'), ('fluctuations', 'O'), ('.', 'O'))"
"Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .","(('Pallidal', 'O'), ('stimulation', 'O'), ('improves', 'O'), ('bradykinesia', 'B'), ('and', 'O'), ('rigidity', 'B'), ('to', 'O'), ('a', 'O'), ('minor', 'O'), ('extent', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('its', 'O'), ('strength', 'O'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('in', 'O'), ('improving', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('.', 'O'))"
"Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the "" freezing "" phenomenon in the lower limbs at the same time .","(('Stimulation', 'O'), ('often', 'O'), ('produces', 'O'), ('an', 'O'), ('improvement', 'O'), ('in', 'O'), ('the', 'O'), ('hyper', 'B'), ('-', 'I'), ('or', 'I'), ('dyskinetic', 'I'), ('upper', 'O'), ('limbs', 'O'), (',', 'O'), ('but', 'O'), ('increases', 'O'), ('the', 'O'), ('""', 'O'), ('freezing', 'O'), ('""', 'O'), ('phenomenon', 'O'), ('in', 'O'), ('the', 'O'), ('lower', 'O'), ('limbs', 'O'), ('at', 'O'), ('the', 'O'), ('same', 'O'), ('time', 'O'), ('.', 'O'))"
Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .,"(('Effects', 'O'), ('of', 'O'), ('the', 'O'), ('cyclooxygenase', 'O'), ('-', 'O'), ('2', 'O'), ('specific', 'O'), ('inhibitor', 'O'), ('valdecoxib', 'O'), ('versus', 'O'), ('nonsteroidal', 'O'), ('antiinflammatory', 'O'), ('agents', 'O'), ('and', 'O'), ('placebo', 'O'), ('on', 'O'), ('cardiovascular', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('arthritis', 'B'), ('.', 'O'))"
There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .,"(('There', 'O'), ('have', 'O'), ('been', 'O'), ('concerns', 'O'), ('that', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('cardiovascular', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('may', 'O'), ('be', 'O'), ('higher', 'O'), ('with', 'O'), ('cyclooxygenase', 'O'), ('(', 'O'), ('COX', 'O'), (')', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('specific', 'O'), ('inhibitors', 'O'), ('than', 'O'), ('nonselective', 'O'), ('nonsteroidal', 'O'), ('antiinflammatory', 'O'), ('drugs', 'O'), ('(', 'O'), ('NSAIDs', 'O'), (')', 'O'), ('.', 'O'))"
"We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .","(('We', 'O'), ('evaluated', 'O'), ('cardiovascular', 'O'), ('event', 'O'), ('data', 'O'), ('for', 'O'), ('valdecoxib', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('COX', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('specific', 'O'), ('inhibitor', 'O'), ('in', 'O'), ('approximately', 'O'), ('8000', 'O'), ('patients', 'O'), ('with', 'O'), ('osteoarthritis', 'B'), ('and', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('treated', 'O'), ('with', 'O'), ('this', 'O'), ('agent', 'O'), ('in', 'O'), ('randomized', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O'))"
"The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('cardiovascular', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('(', 'O'), ('cardiac', 'O'), (',', 'O'), ('cerebrovascular', 'O'), ('and', 'O'), ('peripheral', 'O'), ('vascular', 'O'), (',', 'O'), ('or', 'O'), ('arterial', 'O'), ('thrombotic', 'B'), (')', 'O'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('analyzing', 'O'), ('pooled', 'O'), ('valdecoxib', 'O'), ('(', 'O'), ('10', 'O'), ('-', 'O'), ('80', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), (',', 'O'), ('nonselective', 'O'), ('NSAID', 'O'), ('(', 'O'), ('diclofenac', 'O'), ('75', 'O'), ('mg', 'O'), ('bid', 'O'), (',', 'O'), ('ibuprofen', 'O'), ('800', 'O'), ('mg', 'O'), ('tid', 'O'), (',', 'O'), ('or', 'O'), ('naproxen', 'O'), ('500', 'O'), ('mg', 'O'), ('bid', 'O'), (')', 'O'), ('and', 'O'), ('placebo', 'O'), ('data', 'O'), ('from', 'O'), ('10', 'O'), ('randomized', 'O'), ('osteoarthritis', 'B'), ('and', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('trials', 'O'), ('that', 'O'), ('were', 'O'), ('6', 'O'), ('-', 'O'), ('52', 'O'), ('weeks', 'O'), ('in', 'O'), ('duration', 'O'), ('.', 'O'))"
"Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .","(('Crude', 'O'), ('and', 'O'), ('exposure', 'O'), ('-', 'O'), ('adjusted', 'O'), ('incidences', 'O'), ('of', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('were', 'O'), ('similar', 'O'), ('for', 'O'), ('valdecoxib', 'O'), (',', 'O'), ('NSAIDs', 'O'), (',', 'O'), ('and', 'O'), ('placebo', 'O'), ('.', 'O'))"
The risk of serious thrombotic events was also similar for each valdecoxib dose .,"(('The', 'O'), ('risk', 'O'), ('of', 'O'), ('serious', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('was', 'O'), ('also', 'O'), ('similar', 'O'), ('for', 'O'), ('each', 'O'), ('valdecoxib', 'O'), ('dose', 'O'), ('.', 'O'))"
"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .","(('Thrombotic', 'B'), ('risk', 'O'), ('was', 'O'), ('consistently', 'O'), ('higher', 'O'), ('for', 'O'), ('users', 'O'), ('of', 'O'), ('aspirin', 'O'), ('users', 'O'), ('than', 'O'), ('nonusers', 'O'), ('of', 'O'), ('aspirin', 'O'), ('(', 'O'), ('placebo', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('vs', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), (';', 'O'), ('valdecoxib', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('vs', 'O'), ('.', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (';', 'O'), ('NSAIDs', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('vs', 'O'), ('.', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .,"(('Short', 'O'), ('-', 'O'), ('and', 'O'), ('intermediate', 'O'), ('-', 'O'), ('term', 'O'), ('treatment', 'O'), ('with', 'O'), ('therapeutic', 'O'), ('(', 'O'), ('10', 'O'), ('or', 'O'), ('20', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), ('and', 'O'), ('supratherapeutic', 'O'), ('(', 'O'), ('40', 'O'), ('or', 'O'), ('80', 'O'), ('mg', 'O'), ('daily', 'O'), (')', 'O'), ('valdecoxib', 'O'), ('doses', 'O'), ('was', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('thrombotic', 'B'), ('events', 'O'), ('relative', 'O'), ('to', 'O'), ('nonselective', 'O'), ('NSAIDs', 'O'), ('or', 'O'), ('placebo', 'O'), ('in', 'O'), ('osteoarthritis', 'B'), ('and', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('patients', 'O'), ('in', 'O'), ('controlled', 'O'), ('clinical', 'O'), ('trials', 'O'), ('.', 'O'))"
Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .,"(('Hypersensitivity', 'B'), ('myocarditis', 'B'), ('complicating', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), ('heart', 'O'), ('.', 'O'))"
The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .,"(('The', 'O'), ('present', 'O'), ('report', 'O'), ('describes', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('eosinophilic', 'B'), ('myocarditis', 'I'), ('complicating', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), ('.', 'O'))"
"The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .","(('The', 'O'), ('47', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('female', 'O'), ('patient', 'O'), (',', 'O'), ('known', 'O'), ('to', 'O'), ('have', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), (',', 'O'), ('was', 'O'), ('admitted', 'O'), ('with', 'O'), ('biventricular', 'B'), ('failure', 'I'), ('and', 'O'), ('managed', 'O'), ('aggressively', 'O'), ('with', 'O'), ('dobutamine', 'O'), ('infusion', 'O'), ('and', 'O'), ('other', 'O'), ('drugs', 'O'), ('while', 'O'), ('being', 'O'), ('assessed', 'O'), ('for', 'O'), ('heart', 'O'), ('transplantation', 'O'), ('.', 'O'))"
"On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .","(('On', 'O'), ('transthoracic', 'O'), ('echocardiogram', 'O'), (',', 'O'), ('she', 'O'), ('had', 'O'), ('moderate', 'O'), ('left', 'B'), ('ventricular', 'I'), ('dysfunction', 'I'), ('with', 'O'), ('regional', 'O'), ('variability', 'O'), ('and', 'O'), ('moderate', 'O'), ('mitral', 'B'), ('regurgitation', 'I'), ('.', 'O'))"
The recipient ' s heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .,"(('The', 'O'), ('recipient', 'O'), (""'"", 'O'), ('s', 'O'), ('heart', 'O'), ('showed', 'O'), ('the', 'O'), ('features', 'O'), ('of', 'O'), ('apical', 'O'), ('hypertrophic', 'B'), ('cardiomyopathy', 'I'), ('and', 'O'), ('myocarditis', 'B'), ('with', 'O'), ('abundant', 'O'), ('eosinophils', 'O'), ('.', 'O'))"
Myocarditis is rare and eosinophilic myocarditis is rarer .,"(('Myocarditis', 'B'), ('is', 'O'), ('rare', 'O'), ('and', 'O'), ('eosinophilic', 'B'), ('myocarditis', 'I'), ('is', 'O'), ('rarer', 'O'), ('.', 'O'))"
It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .,"(('It', 'O'), ('is', 'O'), ('likely', 'O'), ('that', 'O'), ('the', 'O'), ('hypersensitivity', 'B'), ('(', 'O'), ('eosinophilic', 'B'), (')', 'O'), ('myocarditis', 'B'), ('was', 'O'), ('related', 'O'), ('to', 'O'), ('dobutamine', 'O'), ('infusion', 'O'), ('therapy', 'O'), ('.', 'O'))"
Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .,"(('Eosinophilic', 'B'), ('myocarditis', 'I'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('an', 'O'), ('incidence', 'O'), ('of', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('to', 'O'), ('7', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('in', 'O'), ('explanted', 'O'), ('hearts', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('multidrug', 'O'), ('therapy', 'O'), ('.', 'O'))"
Time trends in warfarin - associated hemorrhage .,"(('Time', 'O'), ('trends', 'O'), ('in', 'O'), ('warfarin', 'O'), ('-', 'O'), ('associated', 'O'), ('hemorrhage', 'B'), ('.', 'O'))"
"The annual incidence of warfarin - related bleeding at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .","(('The', 'O'), ('annual', 'O'), ('incidence', 'O'), ('of', 'O'), ('warfarin', 'O'), ('-', 'O'), ('related', 'O'), ('bleeding', 'B'), ('at', 'O'), ('Brigham', 'O'), ('and', 'O'), ('Women', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), ('increased', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('97', 'O'), ('/', 'O'), ('1', 'O'), (',', 'O'), ('000', 'O'), ('patient', 'O'), ('admissions', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('time', 'O'), ('period', 'O'), ('(', 'O'), ('January', 'O'), ('1995', 'O'), ('to', 'O'), ('October', 'O'), ('1998', 'O'), (')', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('19', 'O'), ('/', 'O'), ('1', 'O'), (',', 'O'), ('000', 'O'), ('patient', 'O'), ('admissions', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('time', 'O'), ('period', 'O'), ('(', 'O'), ('November', 'O'), ('1998', 'O'), ('to', 'O'), ('August', 'O'), ('2002', 'O'), (')', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('.', 'O'))"
"The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .","(('The', 'O'), ('proportion', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('major', 'O'), ('and', 'O'), ('intracranial', 'B'), ('bleeding', 'I'), ('increased', 'O'), ('from', 'O'), ('20', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('time', 'O'), ('period', 'O'), (',', 'O'), ('to', 'O'), ('33', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('and', 'O'), ('7', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('second', 'O'), ('.', 'O'))"
Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .,"(('Yohimbine', 'O'), ('treatment', 'O'), ('of', 'O'), ('sexual', 'B'), ('side', 'I'), ('effects', 'I'), ('induced', 'O'), ('by', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('blockers', 'O'), ('.', 'O'))"
A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .,"(('A', 'O'), ('single', 'O'), ('case', 'O'), ('report', 'O'), ('suggests', 'O'), ('that', 'O'), ('yohimbine', 'O'), ('may', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('the', 'O'), ('sexual', 'B'), ('side', 'I'), ('effects', 'I'), ('of', 'O'), ('clomipramine', 'O'), ('.', 'O'))"
This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .,"(('This', 'O'), ('study', 'O'), ('evaluated', 'O'), ('yohimbine', 'O'), ('as', 'O'), ('a', 'O'), ('treatment', 'O'), ('for', 'O'), ('the', 'O'), ('sexual', 'B'), ('side', 'I'), ('effects', 'I'), ('caused', 'O'), ('by', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('blockers', 'O'), ('.', 'O'))"
"METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .","(('METHOD', 'O'), (':', 'O'), ('Six', 'O'), ('patients', 'O'), ('with', 'O'), ('either', 'O'), ('obsessive', 'B'), ('compulsive', 'I'), ('disorder', 'I'), (',', 'O'), ('trichotillomania', 'B'), (',', 'O'), ('anxiety', 'B'), (',', 'O'), ('or', 'O'), ('affective', 'B'), ('disorders', 'I'), ('who', 'O'), ('suffered', 'O'), ('sexual', 'B'), ('side', 'I'), ('effects', 'I'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('blockers', 'O'), ('were', 'O'), ('given', 'O'), ('yohimbine', 'O'), ('on', 'O'), ('a', 'O'), ('p', 'O'), ('.', 'O'), ('r', 'O'), ('.', 'O'), ('n', 'O'), ('.', 'O'), ('basis', 'O'), ('in', 'O'), ('an', 'O'), ('open', 'O'), ('clinical', 'O'), ('trial', 'O'), ('.', 'O'))"
"Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .","(('Side', 'O'), ('effects', 'O'), ('of', 'O'), ('yohimbine', 'O'), ('included', 'O'), ('excessive', 'O'), ('sweating', 'O'), (',', 'O'), ('increased', 'O'), ('anxiety', 'B'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('wound', 'O'), ('-', 'O'), ('up', 'O'), ('feeling', 'O'), ('in', 'O'), ('some', 'O'), ('patients', 'O'), ('.', 'O'))"
CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('indicate', 'O'), ('that', 'O'), ('yohimbine', 'O'), ('may', 'O'), ('be', 'O'), ('an', 'O'), ('effective', 'O'), ('treatment', 'O'), ('for', 'O'), ('the', 'O'), ('sexual', 'B'), ('side', 'I'), ('effects', 'I'), ('caused', 'O'), ('by', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('blockers', 'O'), ('.', 'O'))"
Hemorrhagic cystitis complicating bone marrow transplantation .,"(('Hemorrhagic', 'B'), ('cystitis', 'I'), ('complicating', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('.', 'O'))"
Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .,"(('Hemorrhagic', 'B'), ('cystitis', 'I'), ('is', 'O'), ('a', 'O'), ('potentially', 'O'), ('serious', 'O'), ('complication', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cyclophosphamide', 'O'), ('therapy', 'O'), ('administered', 'O'), ('before', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('.', 'O'))"
"In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .","(('In', 'O'), ('an', 'O'), ('attempt', 'O'), ('to', 'O'), ('obviate', 'O'), ('the', 'O'), ('inconvenience', 'O'), ('of', 'O'), ('bladder', 'O'), ('irrigation', 'O'), (',', 'O'), ('we', 'O'), ('conducted', 'O'), ('a', 'O'), ('feasibility', 'O'), ('trial', 'O'), ('of', 'O'), ('uroprophylaxis', 'O'), ('with', 'O'), ('mesna', 'O'), (',', 'O'), ('which', 'O'), ('neutralizes', 'O'), ('the', 'O'), ('hepatic', 'O'), ('metabolite', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('that', 'O'), ('causes', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('.', 'O'))"
"Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .","(('Of', 'O'), ('97', 'O'), ('patients', 'O'), ('who', 'O'), ('received', 'O'), ('standard', 'O'), ('prophylaxis', 'O'), (',', 'O'), ('4', 'O'), ('had', 'O'), ('symptomatic', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('.', 'O'))"
"In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('two', 'O'), ('of', 'O'), ('four', 'O'), ('consecutive', 'O'), ('patients', 'O'), ('who', 'O'), ('received', 'O'), ('mesna', 'O'), ('uroprophylaxis', 'O'), ('before', 'O'), ('allogeneic', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('had', 'O'), ('severe', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('for', 'O'), ('at', 'O'), ('least', 'O'), ('2', 'O'), ('weeks', 'O'), ('.', 'O'))"
"Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .","(('Because', 'O'), ('of', 'O'), ('this', 'O'), ('suboptimal', 'O'), ('result', 'O'), (',', 'O'), ('we', 'O'), ('resumed', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('bladder', 'O'), ('irrigation', 'O'), ('and', 'O'), ('forced', 'O'), ('hydration', 'O'), ('to', 'O'), ('minimize', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('.', 'O'))"
"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .","(('Consensus', 'O'), ('statement', 'O'), ('concerning', 'O'), ('cardiotoxicity', 'B'), ('occurring', 'O'), ('during', 'O'), ('haematopoietic', 'O'), ('stem', 'O'), ('cell', 'O'), ('transplantation', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('autoimmune', 'B'), ('diseases', 'I'), (',', 'O'), ('with', 'O'), ('special', 'O'), ('reference', 'O'), ('to', 'O'), ('systemic', 'B'), ('sclerosis', 'I'), ('and', 'O'), ('multiple', 'B'), ('sclerosis', 'I'), ('.', 'O'))"
Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .,"(('Autologous', 'O'), ('haematopoietic', 'O'), ('stem', 'O'), ('cell', 'O'), ('transplantation', 'O'), ('is', 'O'), ('now', 'O'), ('a', 'O'), ('feasible', 'O'), ('and', 'O'), ('effective', 'O'), ('treatment', 'O'), ('for', 'O'), ('selected', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('autoimmune', 'B'), ('diseases', 'I'), ('.', 'O'))"
This is primarily due to complications related to either the stage of the disease at transplant or due to infections .,"(('This', 'O'), ('is', 'O'), ('primarily', 'O'), ('due', 'O'), ('to', 'O'), ('complications', 'O'), ('related', 'O'), ('to', 'O'), ('either', 'O'), ('the', 'O'), ('stage', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('at', 'O'), ('transplant', 'O'), ('or', 'O'), ('due', 'O'), ('to', 'O'), ('infections', 'B'), ('.', 'O'))"
The number of deaths related to cardiac toxicity is low .,"(('The', 'O'), ('number', 'O'), ('of', 'O'), ('deaths', 'O'), ('related', 'O'), ('to', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('is', 'O'), ('low', 'O'), ('.', 'O'))"
"However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .","(('However', 'O'), (',', 'O'), ('caution', 'O'), ('is', 'O'), ('required', 'O'), ('when', 'O'), ('cyclophosphamide', 'O'), ('or', 'O'), ('anthracyclines', 'O'), ('such', 'O'), ('as', 'O'), ('mitoxantrone', 'O'), ('are', 'O'), ('used', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('possible', 'O'), ('underlying', 'O'), ('heart', 'B'), ('damage', 'I'), (',', 'O'), ('for', 'O'), ('example', 'O'), (',', 'O'), ('systemic', 'B'), ('sclerosis', 'I'), ('patients', 'O'), ('.', 'O'))"
"The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .","(('The', 'O'), ('object', 'O'), ('of', 'O'), ('the', 'O'), ('meeting', 'O'), ('was', 'O'), ('to', 'O'), ('analyse', 'O'), ('existing', 'O'), ('data', 'O'), (',', 'O'), ('both', 'O'), ('published', 'O'), ('or', 'O'), ('available', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('European', 'O'), ('Group', 'O'), ('for', 'O'), ('Blood', 'O'), ('and', 'O'), ('Marrow', 'O'), ('Transplantation', 'O'), ('autoimmune', 'B'), ('disease', 'I'), ('database', 'O'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('propose', 'O'), ('a', 'O'), ('safe', 'O'), ('approach', 'O'), ('to', 'O'), ('such', 'O'), ('patients', 'O'), ('.', 'O'))"
Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?,"(('Does', 'O'), ('supplemental', 'O'), ('vitamin', 'O'), ('C', 'O'), ('increase', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('risk', 'O'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('diabetes', 'B'), ('?', 'O'))"
These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .,"(('These', 'O'), ('observations', 'O'), ('led', 'O'), ('us', 'O'), ('to', 'O'), ('hypothesize', 'O'), ('that', 'O'), ('a', 'O'), ('high', 'O'), ('intake', 'O'), ('of', 'O'), ('vitamin', 'O'), ('C', 'O'), ('in', 'O'), ('diabetic', 'B'), ('persons', 'O'), ('might', 'O'), ('promote', 'O'), ('atherosclerosis', 'B'), ('.', 'O'))"
OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('objective', 'O'), ('was', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('relation', 'O'), ('between', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('and', 'O'), ('mortality', 'O'), ('from', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('.', 'O'))"
"DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .","(('DESIGN', 'O'), (':', 'O'), ('We', 'O'), ('studied', 'O'), ('the', 'O'), ('relation', 'O'), ('between', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('and', 'O'), ('mortality', 'O'), ('from', 'O'), ('total', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('281', 'O'), (')', 'O'), (',', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('175', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('stroke', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('57', 'O'), (')', 'O'), ('in', 'O'), ('1923', 'O'), ('postmenopausal', 'O'), ('women', 'O'), ('who', 'O'), ('reported', 'O'), ('being', 'O'), ('diabetic', 'B'), ('at', 'O'), ('baseline', 'O'), ('.', 'O'))"
"Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y .","(('Diet', 'O'), ('was', 'O'), ('assessed', 'O'), ('with', 'O'), ('a', 'O'), ('food', 'O'), ('-', 'O'), ('frequency', 'O'), ('questionnaire', 'O'), ('at', 'O'), ('baseline', 'O'), (',', 'O'), ('and', 'O'), ('subjects', 'O'), ('initially', 'O'), ('free', 'O'), ('of', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('were', 'O'), ('prospectively', 'O'), ('followed', 'O'), ('for', 'O'), ('15', 'O'), ('y', 'O'), ('.', 'O'))"
"RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .","(('RESULTS', 'O'), (':', 'O'), ('After', 'O'), ('adjustment', 'O'), ('for', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('risk', 'O'), ('factors', 'O'), (',', 'O'), ('type', 'O'), ('of', 'O'), ('diabetes', 'B'), ('medication', 'O'), ('used', 'O'), (',', 'O'), ('duration', 'O'), ('of', 'O'), ('diabetes', 'B'), (',', 'O'), ('and', 'O'), ('intakes', 'O'), ('of', 'O'), ('folate', 'O'), (',', 'O'), ('vitamin', 'O'), ('E', 'O'), (',', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('carotene', 'O'), (',', 'O'), ('the', 'O'), ('adjusted', 'O'), ('relative', 'O'), ('risks', 'O'), ('of', 'O'), ('total', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('mortality', 'O'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('97', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('11', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('47', 'O'), (',', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('84', 'O'), ('(', 'O'), ('P', 'O'), ('for', 'O'), ('trend', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('across', 'O'), ('quintiles', 'O'), ('of', 'O'), ('total', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('from', 'O'), ('food', 'O'), ('and', 'O'), ('supplements', 'O'), ('.', 'O'))"
"Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .","(('Adjusted', 'O'), ('relative', 'O'), ('risks', 'O'), ('of', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('81', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('99', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('26', 'O'), (',', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('91', 'O'), ('(', 'O'), ('P', 'O'), ('for', 'O'), ('trend', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('and', 'O'), ('of', 'O'), ('stroke', 'B'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('52', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('23', 'O'), (',', 'O'), ('2', 'O'), ('.', 'O'), ('22', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('57', 'O'), ('(', 'O'), ('P', 'O'), ('for', 'O'), ('trend', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .,"(('Vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('was', 'O'), ('unrelated', 'O'), ('to', 'O'), ('mortality', 'O'), ('from', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('in', 'O'), ('the', 'O'), ('nondiabetic', 'O'), ('subjects', 'O'), ('at', 'O'), ('baseline', 'O'), ('.', 'O'))"
CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .,"(('CONCLUSION', 'O'), (':', 'O'), ('A', 'O'), ('high', 'O'), ('vitamin', 'O'), ('C', 'O'), ('intake', 'O'), ('from', 'O'), ('supplements', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), ('mortality', 'O'), ('in', 'O'), ('postmenopausal', 'O'), ('women', 'O'), ('with', 'O'), ('diabetes', 'B'), ('.', 'O'))"
Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .,"(('Optical', 'O'), ('coherence', 'O'), ('tomography', 'O'), ('can', 'O'), ('measure', 'O'), ('axonal', 'O'), ('loss', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('ethambutol', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
"PURPOSE : To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .","(('PURPOSE', 'O'), (':', 'O'), ('To', 'O'), ('map', 'O'), ('and', 'O'), ('identify', 'O'), ('the', 'O'), ('pattern', 'O'), (',', 'O'), ('in', 'O'), ('vivo', 'O'), (',', 'O'), ('of', 'O'), ('axonal', 'B'), ('degeneration', 'I'), ('in', 'O'), ('ethambutol', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('using', 'O'), ('optical', 'O'), ('coherence', 'O'), ('tomography', 'O'), ('(', 'O'), ('OCT', 'O'), (')', 'O'), ('.', 'O'))"
Ethambutol is an antimycobacterial agent often used to treat tuberculosis .,"(('Ethambutol', 'O'), ('is', 'O'), ('an', 'O'), ('antimycobacterial', 'O'), ('agent', 'O'), ('often', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('tuberculosis', 'B'), ('.', 'O'))"
"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .","(('A', 'O'), ('serious', 'O'), ('complication', 'O'), ('of', 'O'), ('ethambutol', 'O'), ('is', 'O'), ('an', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('that', 'O'), ('impairs', 'O'), ('visual', 'O'), ('acuity', 'O'), (',', 'O'), ('contrast', 'O'), ('sensitivity', 'O'), (',', 'O'), ('and', 'O'), ('color', 'O'), ('vision', 'O'), ('.', 'O'))"
"However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .","(('However', 'O'), (',', 'O'), ('early', 'O'), ('on', 'O'), (',', 'O'), ('when', 'O'), ('the', 'O'), ('toxic', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('is', 'O'), ('mild', 'O'), ('and', 'O'), ('partly', 'O'), ('reversible', 'O'), (',', 'O'), ('the', 'O'), ('funduscopic', 'O'), ('findings', 'O'), ('are', 'O'), ('often', 'O'), ('subtle', 'O'), ('and', 'O'), ('easy', 'O'), ('to', 'O'), ('miss', 'O'), ('.', 'O'))"
"METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .","(('METHODS', 'O'), (':', 'O'), ('Three', 'O'), ('subjects', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('ethambutol', 'O'), ('(', 'O'), ('EMB', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('of', 'O'), ('short', 'O'), ('-', 'O'), (',', 'O'), ('intermediate', 'O'), ('-', 'O'), (',', 'O'), ('and', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('visual', 'B'), ('deficits', 'I'), ('were', 'O'), ('administered', 'O'), ('a', 'O'), ('full', 'O'), ('neuro', 'O'), ('-', 'O'), ('ophthalmologic', 'O'), ('examination', 'O'), ('including', 'O'), ('visual', 'O'), ('acuity', 'O'), (',', 'O'), ('color', 'O'), ('vision', 'O'), (',', 'O'), ('contrast', 'O'), ('sensitivity', 'O'), (',', 'O'), ('and', 'O'), ('fundus', 'O'), ('examination', 'O'), ('.', 'O'))"
"In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .","(('In', 'O'), ('all', 'O'), ('subjects', 'O'), ('with', 'O'), ('history', 'O'), ('of', 'O'), ('EMB', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('mean', 'O'), ('loss', 'O'), ('of', 'O'), ('72', 'O'), ('%', 'O'), ('nerve', 'O'), ('fiber', 'O'), ('layer', 'O'), ('thickness', 'O'), ('in', 'O'), ('the', 'O'), ('temporal', 'O'), ('quadrant', 'O'), ('(', 'O'), ('patient', 'O'), ('A', 'O'), (',', 'O'), ('with', 'O'), ('eventual', 'O'), ('recovery', 'O'), ('of', 'O'), ('visual', 'O'), ('acuity', 'O'), ('and', 'O'), ('fields', 'O'), (',', 'O'), ('58', 'O'), ('%', 'O'), ('loss', 'O'), (';', 'O'), ('patient', 'O'), ('B', 'O'), (',', 'O'), ('with', 'O'), ('intermediate', 'O'), ('visual', 'B'), ('deficits', 'I'), (',', 'O'), ('68', 'O'), ('%', 'O'), ('loss', 'O'), (';', 'O'), ('patient', 'O'), ('C', 'O'), (',', 'O'), ('with', 'O'), ('chronic', 'O'), ('visual', 'B'), ('deficits', 'I'), (',', 'O'), ('90', 'O'), ('%', 'O'), ('loss', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('an', 'O'), ('average', 'O'), ('mean', 'O'), ('optic', 'O'), ('nerve', 'O'), ('thickness', 'O'), ('of', 'O'), ('26', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('16', 'O'), ('microm', 'O'), ('.', 'O'))"
"In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .","(('In', 'O'), ('both', 'O'), ('sets', 'O'), ('(', 'O'), ('four', 'O'), (')', 'O'), ('of', 'O'), ('eyes', 'O'), ('of', 'O'), ('the', 'O'), ('subjects', 'O'), ('with', 'O'), ('persistent', 'O'), ('visual', 'B'), ('deficits', 'I'), ('(', 'O'), ('patients', 'O'), ('B', 'O'), ('and', 'O'), ('C', 'O'), (')', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('an', 'O'), ('average', 'O'), ('loss', 'O'), ('of', 'O'), ('79', 'O'), ('%', 'O'), ('of', 'O'), ('nerve', 'O'), ('fiber', 'O'), ('thickness', 'O'), ('in', 'O'), ('the', 'O'), ('temporal', 'O'), ('quadrant', 'O'), ('.', 'O'))"
CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('OCT', 'O'), ('results', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('with', 'O'), ('EMB', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('show', 'O'), ('considerable', 'O'), ('loss', 'O'), ('especially', 'O'), ('of', 'O'), ('the', 'O'), ('temporal', 'O'), ('fibers', 'O'), ('.', 'O'))"
This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .,"(('This', 'O'), ('is', 'O'), ('consistent', 'O'), ('with', 'O'), ('prior', 'O'), ('histopathological', 'O'), ('studies', 'O'), ('that', 'O'), ('show', 'O'), ('predominant', 'O'), ('loss', 'O'), ('of', 'O'), ('parvo', 'O'), ('-', 'O'), ('cellular', 'O'), ('axons', 'O'), ('(', 'O'), ('or', 'O'), ('small', 'O'), ('-', 'O'), ('caliber', 'O'), ('axons', 'O'), (')', 'O'), ('within', 'O'), ('the', 'O'), ('papillo', 'O'), ('-', 'O'), ('macular', 'O'), ('bundle', 'O'), ('in', 'O'), ('toxic', 'O'), ('or', 'O'), ('hereditary', 'O'), ('optic', 'B'), ('neuropathies', 'I'), ('.', 'O'))"
OCT can be a valuable tool in the quantitative analysis of optic neuropathies .,"(('OCT', 'O'), ('can', 'O'), ('be', 'O'), ('a', 'O'), ('valuable', 'O'), ('tool', 'O'), ('in', 'O'), ('the', 'O'), ('quantitative', 'O'), ('analysis', 'O'), ('of', 'O'), ('optic', 'B'), ('neuropathies', 'I'), ('.', 'O'))"
"Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .","(('Additionally', 'O'), (',', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('management', 'O'), ('of', 'O'), ('EMB', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('important', 'O'), ('to', 'O'), ('properly', 'O'), ('manage', 'O'), ('ethambutol', 'O'), ('dosing', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('renal', 'B'), ('impairment', 'I'), ('and', 'O'), ('to', 'O'), ('achieve', 'O'), ('proper', 'O'), ('transition', 'O'), ('to', 'O'), ('a', 'O'), ('maintenance', 'O'), ('dose', 'O'), ('once', 'O'), ('an', 'O'), ('appropriate', 'O'), ('loading', 'O'), ('dose', 'O'), ('has', 'O'), ('been', 'O'), ('reached', 'O'), ('.', 'O'))"
Hypoxia in renal disease with proteinuria and / or glomerular hypertension .,"(('Hypoxia', 'B'), ('in', 'O'), ('renal', 'B'), ('disease', 'I'), ('with', 'O'), ('proteinuria', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('glomerular', 'O'), ('hypertension', 'B'), ('.', 'O'))"
"In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .","(('In', 'O'), ('this', 'O'), ('study', 'O'), (',', 'O'), ('we', 'O'), ('developed', 'O'), ('a', 'O'), ('new', 'O'), ('hypoxia', 'B'), ('-', 'O'), ('responsive', 'O'), ('reporter', 'O'), ('vector', 'O'), ('using', 'O'), ('a', 'O'), ('hypoxia', 'B'), ('-', 'O'), ('responsive', 'O'), ('element', 'O'), ('of', 'O'), ('the', 'O'), ('5', 'O'), (""'"", 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('untranslated', 'O'), ('region', 'O'), ('and', 'O'), ('generated', 'O'), ('a', 'O'), ('novel', 'O'), ('hypoxia', 'B'), ('-', 'O'), ('sensing', 'O'), ('transgenic', 'O'), ('rat', 'O'), ('.', 'O'))"
We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .,"(('We', 'O'), ('then', 'O'), ('applied', 'O'), ('this', 'O'), ('animal', 'O'), ('model', 'O'), ('to', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('tubulointerstitial', 'O'), ('hypoxia', 'B'), ('in', 'O'), ('the', 'O'), ('diseased', 'B'), ('kidney', 'I'), ('.', 'O'))"
"With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .","(('With', 'O'), ('this', 'O'), ('model', 'O'), (',', 'O'), ('we', 'O'), ('were', 'O'), ('able', 'O'), ('to', 'O'), ('identify', 'O'), ('diffuse', 'O'), ('cortical', 'O'), ('hypoxia', 'B'), ('in', 'O'), ('the', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('and', 'O'), ('focal', 'O'), ('and', 'O'), ('segmental', 'O'), ('hypoxia', 'B'), ('in', 'O'), ('the', 'O'), ('remnant', 'O'), ('kidney', 'O'), ('model', 'O'), ('.', 'O'))"
"Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .","(('Expression', 'O'), ('of', 'O'), ('the', 'O'), ('hypoxia', 'B'), ('-', 'O'), ('responsive', 'O'), ('transgene', 'O'), ('increased', 'O'), ('throughout', 'O'), ('the', 'O'), ('observation', 'O'), ('period', 'O'), (',', 'O'), ('reaching', 'O'), ('2', 'O'), ('.', 'O'), ('2', 'O'), ('-', 'O'), ('fold', 'O'), ('at', 'O'), ('2', 'O'), ('weeks', 'O'), ('in', 'O'), ('the', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('model', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('6', 'O'), ('-', 'O'), ('fold', 'O'), ('at', 'O'), ('4', 'O'), ('weeks', 'O'), ('in', 'O'), ('the', 'O'), ('remnant', 'O'), ('kidney', 'O'), ('model', 'O'), (',', 'O'), ('whereas', 'O'), ('that', 'O'), ('of', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('showed', 'O'), ('a', 'O'), ('mild', 'O'), ('decrease', 'O'), (',', 'O'), ('reflecting', 'O'), ('distinct', 'O'), ('behaviors', 'O'), ('of', 'O'), ('the', 'O'), ('two', 'O'), ('genes', 'O'), ('.', 'O'))"
The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .,"(('The', 'O'), ('degree', 'O'), ('of', 'O'), ('hypoxia', 'B'), ('showed', 'O'), ('a', 'O'), ('positive', 'O'), ('correlation', 'O'), ('with', 'O'), ('microscopic', 'O'), ('tubulointerstitial', 'B'), ('injury', 'I'), ('in', 'O'), ('both', 'O'), ('models', 'O'), ('.', 'O'))"
We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .,"(('We', 'O'), ('propose', 'O'), ('here', 'O'), ('a', 'O'), ('possible', 'O'), ('pathological', 'O'), ('tie', 'O'), ('between', 'O'), ('chronic', 'O'), ('tubulointerstitial', 'O'), ('hypoxia', 'B'), ('and', 'O'), ('progressive', 'O'), ('glomerular', 'B'), ('diseases', 'I'), ('.', 'O'))"
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C .,"(('Adequate', 'O'), ('timing', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('reduction', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('hemolysis', 'B'), ('during', 'O'), ('combination', 'O'), ('therapy', 'O'), ('of', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('for', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('.', 'O'))"
BACKGROUND : Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .,"(('BACKGROUND', 'O'), (':', 'O'), ('Hemolytic', 'B'), ('anemia', 'I'), ('is', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('major', 'O'), ('adverse', 'O'), ('events', 'O'), ('of', 'O'), ('the', 'O'), ('combination', 'O'), ('therapy', 'O'), ('of', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('.', 'O'))"
"Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .","(('Because', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('related', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), (',', 'O'), ('dose', 'O'), ('reduction', 'O'), ('is', 'O'), ('a', 'O'), ('common', 'O'), ('event', 'O'), ('in', 'O'), ('this', 'O'), ('therapy', 'O'), ('.', 'O'))"
In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .,"(('In', 'O'), ('this', 'O'), ('clinical', 'O'), ('retrospective', 'O'), ('cohort', 'O'), ('study', 'O'), ('we', 'O'), ('have', 'O'), ('examined', 'O'), ('the', 'O'), ('suitable', 'O'), ('timing', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('reduction', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('hemolysis', 'B'), ('during', 'O'), ('combination', 'O'), ('therapy', 'O'), ('.', 'O'))"
"METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .","(('METHODS', 'O'), (':', 'O'), ('Thirty', 'O'), ('-', 'O'), ('seven', 'O'), ('of', 'O'), ('160', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('HCV', 'O'), ('-', 'O'), ('genotype', 'O'), ('1b', 'O'), (',', 'O'), ('had', 'O'), ('high', 'O'), ('virus', 'O'), ('load', 'O'), (',', 'O'), ('and', 'O'), ('received', 'O'), ('24', 'O'), ('-', 'O'), ('week', 'O'), ('combination', 'O'), ('therapy', 'O'), ('developed', 'O'), ('anemia', 'B'), ('with', 'O'), ('hemoglobin', 'O'), ('level', 'O'), ('<', 'O'), ('10', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('or', 'O'), ('anemia', 'B'), ('-', 'O'), ('related', 'O'), ('signs', 'O'), ('during', 'O'), ('therapy', 'O'), ('.', 'O'))"
"However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .","(('However', 'O'), (',', 'O'), ('10', 'O'), ('of', 'O'), ('37', 'O'), ('patients', 'O'), ('with', 'O'), ('reduction', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('could', 'O'), ('not', 'O'), ('continue', 'O'), ('combination', 'O'), ('therapy', 'O'), ('because', 'O'), ('their', 'O'), ('<', 'O'), ('8', 'O'), ('.', 'O'), ('5', 'O'), ('g', 'O'), ('/', 'O'), ('dl', 'O'), ('hemoglobin', 'O'), ('values', 'O'), ('decreased', 'O'), ('to', 'O'), ('or', 'O'), ('anemia', 'B'), ('-', 'O'), ('related', 'O'), ('severe', 'O'), ('side', 'O'), ('effects', 'O'), ('occurred', 'O'), ('(', 'O'), ('group', 'O'), ('B', 'O'), (')', 'O'), ('.', 'O'))"
Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .,"(('Aging', 'O'), ('process', 'O'), ('of', 'O'), ('epithelial', 'O'), ('cells', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('prostate', 'O'), ('lateral', 'O'), ('lobe', 'O'), ('in', 'O'), ('experimental', 'O'), ('hyperprolactinemia', 'B'), ('induced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
"The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .","(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('influence', 'O'), ('of', 'O'), ('hyperprolactinemia', 'B'), (',', 'O'), ('induced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('(', 'O'), ('HAL', 'O'), (')', 'O'), ('on', 'O'), ('age', 'O'), ('related', 'O'), ('morphology', 'O'), ('and', 'O'), ('function', 'O'), ('changes', 'O'), ('of', 'O'), ('epithelial', 'O'), ('cells', 'O'), ('in', 'O'), ('rat', 'O'), ('prostate', 'O'), ('lateral', 'O'), ('lobe', 'O'), ('.', 'O'))"
"Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .","(('Light', 'O'), ('microscopy', 'O'), ('visualized', 'O'), ('the', 'O'), ('following', 'O'), (':', 'O'), ('hypertrophy', 'B'), ('and', 'O'), ('epithelium', 'O'), ('hyperplasia', 'B'), ('of', 'O'), ('the', 'O'), ('glandular', 'O'), ('ducts', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('increased', 'O'), ('PCNA', 'O'), ('expression', 'O'), ('.', 'O'))"
Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .,"(('Relation', 'O'), ('of', 'O'), ('perfusion', 'O'), ('defects', 'O'), ('observed', 'O'), ('with', 'O'), ('myocardial', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('to', 'O'), ('the', 'O'), ('severity', 'O'), ('of', 'O'), ('coronary', 'B'), ('stenosis', 'I'), (':', 'O'), ('correlation', 'O'), ('with', 'O'), ('thallium', 'O'), ('-', 'O'), ('201', 'O'), ('single', 'O'), ('-', 'O'), ('photon', 'O'), ('emission', 'O'), ('tomography', 'O'), ('.', 'O'))"
It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .,"(('It', 'O'), ('has', 'O'), ('been', 'O'), ('previously', 'O'), ('shown', 'O'), ('that', 'O'), ('myocardial', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('is', 'O'), ('a', 'O'), ('valuable', 'O'), ('technique', 'O'), ('for', 'O'), ('delineating', 'O'), ('regions', 'O'), ('of', 'O'), ('myocardial', 'O'), ('underperfusion', 'O'), ('secondary', 'O'), ('to', 'O'), ('coronary', 'B'), ('occlusion', 'I'), ('and', 'O'), ('to', 'O'), ('critical', 'O'), ('coronary', 'B'), ('stenoses', 'I'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('hyperemic', 'B'), ('stimulation', 'O'), ('.', 'O'))"
The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .,"(('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('myocardial', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('performed', 'O'), ('with', 'O'), ('a', 'O'), ('stable', 'O'), ('solution', 'O'), ('of', 'O'), ('sonicated', 'O'), ('albumin', 'O'), ('could', 'O'), ('detect', 'O'), ('regions', 'O'), ('of', 'O'), ('myocardial', 'O'), ('underperfusion', 'O'), ('resulting', 'O'), ('from', 'O'), ('various', 'O'), ('degrees', 'O'), ('of', 'O'), ('coronary', 'B'), ('stenosis', 'I'), ('.', 'O'))"
"During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .","(('During', 'O'), ('a', 'O'), ('transient', 'O'), ('(', 'O'), ('20', 'O'), ('-', 'O'), ('s', 'O'), (')', 'O'), ('coronary', 'B'), ('occlusion', 'I'), (',', 'O'), ('a', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('was', 'O'), ('observed', 'O'), ('with', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('in', 'O'), ('14', 'O'), ('of', 'O'), ('the', 'O'), ('15', 'O'), ('dogs', 'O'), ('in', 'O'), ('which', 'O'), ('the', 'O'), ('occlusion', 'O'), ('was', 'O'), ('produced', 'O'), ('.', 'O'))"
"During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .","(('During', 'O'), ('dipyridamole', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperemia', 'B'), (',', 'O'), ('12', 'O'), ('of', 'O'), ('the', 'O'), ('16', 'O'), ('dogs', 'O'), ('with', 'O'), ('a', 'O'), ('partial', 'O'), ('coronary', 'B'), ('stenosis', 'I'), ('had', 'O'), ('a', 'O'), ('visible', 'O'), ('area', 'O'), ('of', 'O'), ('hypoperfusion', 'O'), ('by', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('.', 'O'))"
The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .,"(('The', 'O'), ('four', 'O'), ('dogs', 'O'), ('without', 'O'), ('a', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('had', 'O'), ('a', 'O'), ('stenosis', 'O'), ('that', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('mild', 'O'), ('(', 'O'), ('0', 'O'), ('%', 'O'), ('to', 'O'), ('50', 'O'), ('%', 'O'), (')', 'O'), ('reduction', 'O'), ('in', 'O'), ('dipyridamole', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperemia', 'B'), ('.', 'O'))"
Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .,"(('Thallium', 'O'), ('-', 'O'), ('201', 'O'), ('SPECT', 'O'), ('demonstrated', 'O'), ('a', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('in', 'O'), ('all', 'O'), ('14', 'O'), ('dogs', 'O'), ('analyzed', 'O'), ('during', 'O'), ('dipyridamole', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperemia', 'B'), (';', 'O'), ('the', 'O'), ('size', 'O'), ('of', 'O'), ('the', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('correlated', 'O'), ('with', 'O'), ('the', 'O'), ('anatomic', 'O'), ('area', 'O'), ('at', 'O'), ('risk', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('58', 'O'), (';', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('and', 'O'), ('with', 'O'), ('the', 'O'), ('perfusion', 'O'), ('defect', 'O'), ('by', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('(', 'O'), ('r', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('58', 'O'), (';', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('.', 'O'))"
"Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .","(('Thus', 'O'), (',', 'O'), ('myocardial', 'O'), ('contrast', 'O'), ('echocardiography', 'O'), ('can', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('visualize', 'O'), ('and', 'O'), ('quantitate', 'O'), ('the', 'O'), ('amount', 'O'), ('of', 'O'), ('jeopardized', 'O'), ('myocardium', 'O'), ('during', 'O'), ('moderate', 'O'), ('to', 'O'), ('severe', 'O'), ('degrees', 'O'), ('of', 'O'), ('coronary', 'B'), ('stenosis', 'I'), ('.', 'O'))"
The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .,"(('The', 'O'), ('activation', 'O'), ('of', 'O'), ('spinal', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartate', 'O'), ('receptors', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('degeneration', 'O'), ('of', 'O'), ('spinal', 'O'), ('motor', 'O'), ('neurons', 'O'), ('induced', 'O'), ('by', 'O'), ('neuraxial', 'O'), ('morphine', 'O'), ('after', 'O'), ('a', 'O'), ('noninjurious', 'O'), ('interval', 'O'), ('of', 'O'), ('spinal', 'B'), ('cord', 'I'), ('ischemia', 'I'), ('.', 'O'))"
We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .,"(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('the', 'O'), ('degeneration', 'O'), ('of', 'O'), ('spinal', 'O'), ('motor', 'O'), ('neurons', 'O'), ('and', 'O'), ('activation', 'O'), ('of', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('d', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (')', 'O'), ('receptors', 'O'), ('after', 'O'), ('neuraxial', 'O'), ('morphine', 'O'), ('following', 'O'), ('a', 'O'), ('noninjurious', 'O'), ('interval', 'O'), ('of', 'O'), ('aortic', 'B'), ('occlusion', 'I'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .,"(('Spinal', 'B'), ('cord', 'I'), ('ischemia', 'I'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('aortic', 'B'), ('occlusion', 'I'), ('for', 'O'), ('6', 'O'), ('min', 'O'), ('with', 'O'), ('a', 'O'), ('balloon', 'O'), ('catheter', 'O'), ('.', 'O'))"
We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .,"(('We', 'O'), ('suggest', 'O'), ('that', 'O'), ('opioids', 'O'), ('may', 'O'), ('be', 'O'), ('neurotoxic', 'B'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('of', 'O'), ('spinal', 'B'), ('cord', 'I'), ('ischemia', 'I'), ('via', 'O'), ('NMDA', 'O'), ('receptor', 'O'), ('activation', 'O'), ('.', 'O'))"
Acute low back pain during intravenous administration of amiodarone : a report of two cases .,"(('Acute', 'O'), ('low', 'B'), ('back', 'I'), ('pain', 'I'), ('during', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('amiodarone', 'O'), (':', 'O'), ('a', 'O'), ('report', 'O'), ('of', 'O'), ('two', 'O'), ('cases', 'O'), ('.', 'O'))"
Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .,"(('Amiodarone', 'O'), ('represents', 'O'), ('an', 'O'), ('effective', 'O'), ('antiarrhythmic', 'O'), ('drug', 'O'), ('for', 'O'), ('cardioversion', 'O'), ('of', 'O'), ('recent', 'O'), ('-', 'O'), ('onset', 'O'), ('atrial', 'B'), ('fibrillation', 'I'), ('(', 'O'), ('AF', 'B'), (')', 'O'), ('and', 'O'), ('maintenance', 'O'), ('of', 'O'), ('sinus', 'O'), ('rhythm', 'O'), ('.', 'O'))"
"We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .","(('We', 'O'), ('briefly', 'O'), ('describe', 'O'), ('two', 'O'), ('patients', 'O'), ('suffering', 'O'), ('from', 'O'), ('recent', 'O'), ('-', 'O'), ('onset', 'O'), ('atrial', 'B'), ('fibrillation', 'I'), (',', 'O'), ('who', 'O'), ('experienced', 'O'), ('an', 'O'), ('acute', 'O'), ('devastating', 'O'), ('low', 'B'), ('back', 'I'), ('pain', 'I'), ('a', 'O'), ('few', 'O'), ('minutes', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('intravenous', 'O'), ('amiodarone', 'O'), ('loading', 'O'), ('.', 'O'))"
"Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .","(('Quantitative', 'O'), ('drug', 'O'), ('levels', 'O'), ('in', 'O'), ('stimulant', 'O'), ('psychosis', 'B'), (':', 'O'), ('relationship', 'O'), ('to', 'O'), ('symptom', 'O'), ('severity', 'O'), (',', 'O'), ('catecholamines', 'O'), ('and', 'O'), ('hyperkinesia', 'B'), ('.', 'O'))"
"To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .","(('To', 'O'), ('examine', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('quantitative', 'O'), ('stimulant', 'O'), ('drug', 'O'), ('levels', 'O'), (',', 'O'), ('catecholamines', 'O'), (',', 'O'), ('and', 'O'), ('psychotic', 'B'), ('symptoms', 'I'), (',', 'O'), ('nineteen', 'O'), ('patients', 'O'), ('in', 'O'), ('a', 'O'), ('psychiatric', 'B'), ('emergency', 'O'), ('service', 'O'), ('with', 'O'), ('a', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('amphetamine', 'O'), ('-', 'O'), ('or', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('were', 'O'), ('interviewed', 'O'), (',', 'O'), ('and', 'O'), ('plasma', 'O'), ('and', 'O'), ('urine', 'O'), ('were', 'O'), ('collected', 'O'), ('for', 'O'), ('quantitative', 'O'), ('assays', 'O'), ('of', 'O'), ('stimulant', 'O'), ('drug', 'O'), ('and', 'O'), ('catecholamine', 'O'), ('metabolite', 'O'), ('levels', 'O'), ('.', 'O'))"
"Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .","(('Although', 'O'), ('many', 'O'), ('other', 'O'), ('factors', 'O'), ('such', 'O'), ('as', 'O'), ('sensitization', 'O'), ('may', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), (',', 'O'), ('intensity', 'O'), ('of', 'O'), ('stimulant', 'O'), ('-', 'O'), ('induced', 'O'), ('psychotic', 'B'), ('symptoms', 'I'), ('and', 'O'), ('stereotypies', 'B'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('at', 'O'), ('least', 'O'), ('in', 'O'), ('part', 'O'), ('dose', 'O'), ('-', 'O'), ('related', 'O'), ('.', 'O'))"
CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .,"(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('42', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('white', 'O'), ('man', 'O'), ('developed', 'O'), ('acute', 'O'), ('hypertension', 'B'), ('with', 'O'), ('severe', 'O'), ('headache', 'B'), ('and', 'O'), ('vomiting', 'B'), ('2', 'O'), ('hours', 'O'), ('after', 'O'), ('the', 'O'), ('first', 'O'), ('doses', 'O'), ('of', 'O'), ('amisulpride', 'O'), ('100', 'O'), ('mg', 'O'), ('and', 'O'), ('tiapride', 'O'), ('100', 'O'), ('mg', 'O'), ('.', 'O'))"
"In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .","(('In', 'O'), ('our', 'O'), ('case', 'O'), (',', 'O'), ('use', 'O'), ('of', 'O'), ('the', 'O'), ('Naranjo', 'O'), ('probability', 'O'), ('scale', 'O'), ('indicated', 'O'), ('a', 'O'), ('possible', 'O'), ('relationship', 'O'), ('between', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('crisis', 'O'), ('and', 'O'), ('amisulpride', 'O'), ('and', 'O'), ('tiapride', 'O'), ('therapy', 'O'), ('.', 'O'))"
"CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .","(('CONCLUSIONS', 'O'), (':', 'O'), ('As', 'O'), ('of', 'O'), ('March', 'O'), ('24', 'O'), (',', 'O'), ('2005', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('reported', 'O'), ('case', 'O'), ('of', 'O'), ('amisulpride', 'O'), ('-', 'O'), ('and', 'O'), ('tiapride', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertensive', 'B'), ('crisis', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('pheochromocytoma', 'B'), ('.', 'O'))"
"Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .","(('Minor', 'O'), ('neurological', 'B'), ('dysfunction', 'I'), (',', 'O'), ('cognitive', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('somatic', 'O'), ('development', 'O'), ('at', 'O'), ('the', 'O'), ('age', 'O'), ('of', 'O'), ('3', 'O'), ('to', 'O'), ('7', 'O'), ('years', 'O'), ('after', 'O'), ('dexamethasone', 'O'), ('treatment', 'O'), ('in', 'O'), ('very', 'O'), ('-', 'O'), ('low', 'O'), ('birth', 'O'), ('-', 'O'), ('weight', 'O'), ('infants', 'O'), ('.', 'O'))"
"The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .","(('The', 'O'), ('objective', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('minor', 'O'), ('neurological', 'B'), ('dysfunction', 'I'), (',', 'O'), ('cognitive', 'O'), ('development', 'O'), (',', 'O'), ('and', 'O'), ('somatic', 'O'), ('development', 'O'), ('after', 'O'), ('dexamethasone', 'O'), ('therapy', 'O'), ('in', 'O'), ('very', 'O'), ('-', 'O'), ('low', 'O'), ('-', 'O'), ('birthweight', 'O'), ('infants', 'O'), ('.', 'O'))"
"Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .","(('Exclusion', 'O'), ('criteria', 'O'), ('were', 'O'), ('asphyxia', 'B'), (',', 'O'), ('malformations', 'B'), (',', 'O'), ('major', 'O'), ('surgical', 'O'), ('interventions', 'O'), (',', 'O'), ('small', 'O'), ('for', 'O'), ('gestational', 'O'), ('age', 'O'), (',', 'O'), ('intraventricular', 'O'), ('haemorrhage', 'B'), ('grades', 'O'), ('III', 'O'), ('and', 'O'), ('IV', 'O'), (',', 'O'), ('periventricular', 'B'), ('leukomalacia', 'I'), (',', 'O'), ('and', 'O'), ('severe', 'O'), ('psychomotor', 'B'), ('retardation', 'I'), ('.', 'O'))"
Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .,"(('Each', 'O'), ('child', 'O'), ('was', 'O'), ('examined', 'O'), ('by', 'O'), ('a', 'O'), ('neuropediatrician', 'O'), ('for', 'O'), ('minor', 'O'), ('neurological', 'B'), ('dysfunctions', 'I'), ('and', 'O'), ('tested', 'O'), ('by', 'O'), ('a', 'O'), ('psychologist', 'O'), ('for', 'O'), ('cognitive', 'O'), ('development', 'O'), ('with', 'O'), ('a', 'O'), ('Kaufman', 'O'), ('Assessment', 'O'), ('Battery', 'O'), ('for', 'O'), ('Children', 'O'), ('and', 'O'), ('a', 'O'), ('Draw', 'O'), ('-', 'O'), ('a', 'O'), ('-', 'O'), ('Man', 'O'), ('Test', 'O'), ('.', 'O'))"
"After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .","(('After', 'O'), ('dexamethasone', 'O'), ('treatment', 'O'), (',', 'O'), ('children', 'O'), ('showed', 'O'), ('a', 'O'), ('higher', 'O'), ('rate', 'O'), ('of', 'O'), ('minor', 'O'), ('neurological', 'B'), ('dysfunctions', 'I'), ('.', 'O'))"
"Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .","(('Valproic', 'O'), ('acid', 'O'), ('I', 'O'), (':', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), ('biomarkers', 'O'), (',', 'O'), ('liver', 'B'), ('toxicity', 'I'), (',', 'O'), ('and', 'O'), ('valproic', 'O'), ('acid', 'O'), ('metabolite', 'O'), ('levels', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .","(('To', 'O'), ('determine', 'O'), ('whether', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('temporal', 'O'), ('relationship', 'O'), ('between', 'O'), ('VPA', 'O'), ('-', 'O'), ('associated', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('and', 'O'), ('hepatotoxicity', 'B'), (',', 'O'), ('adult', 'O'), ('male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('treated', 'O'), ('ip', 'O'), ('with', 'O'), ('VPA', 'O'), ('(', 'O'), ('500', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('saline', 'O'), ('(', 'O'), ('vehicle', 'O'), (')', 'O'), ('once', 'O'), ('daily', 'O'), ('for', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('7', 'O'), (',', 'O'), ('10', 'O'), (',', 'O'), ('or', 'O'), ('14', 'O'), ('days', 'O'), ('.', 'O'))"
Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .,"(('Liver', 'B'), ('toxicity', 'I'), ('was', 'O'), ('evaluated', 'O'), ('based', 'O'), ('on', 'O'), ('serum', 'O'), ('levels', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('glutathione', 'O'), ('S', 'O'), ('-', 'O'), ('transferase', 'O'), ('(', 'O'), ('alpha', 'O'), ('-', 'O'), ('GST', 'O'), (')', 'O'), ('and', 'O'), ('by', 'O'), ('histology', 'O'), ('.', 'O'))"
"Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .","(('Serum', 'O'), ('alpha', 'O'), ('-', 'O'), ('GST', 'O'), ('levels', 'O'), ('were', 'O'), ('significantly', 'O'), ('elevated', 'O'), ('by', 'O'), ('day', 'O'), ('4', 'O'), (',', 'O'), ('which', 'O'), ('corresponded', 'O'), ('to', 'O'), ('hepatotoxicity', 'B'), ('as', 'O'), ('shown', 'O'), ('by', 'O'), ('the', 'O'), ('increasing', 'O'), ('incidence', 'O'), ('of', 'O'), ('inflammation', 'B'), ('of', 'O'), ('the', 'O'), ('liver', 'O'), ('capsule', 'O'), (',', 'O'), ('necrosis', 'B'), (',', 'O'), ('and', 'O'), ('steatosis', 'B'), ('throughout', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
"Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .","(('Overall', 'O'), (',', 'O'), ('these', 'O'), ('findings', 'O'), ('indicate', 'O'), ('that', 'O'), ('VPA', 'O'), ('treatment', 'O'), ('results', 'O'), ('in', 'O'), ('oxidative', 'O'), ('stress', 'O'), (',', 'O'), ('as', 'O'), ('measured', 'O'), ('by', 'O'), ('levels', 'O'), ('of', 'O'), ('15', 'O'), ('-', 'O'), ('F', 'O'), ('(', 'O'), ('2t', 'O'), (')', 'O'), ('-', 'O'), ('IsoP', 'O'), (',', 'O'), ('which', 'O'), ('precedes', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('necrosis', 'B'), (',', 'O'), ('steatosis', 'B'), (',', 'O'), ('and', 'O'), ('elevated', 'O'), ('levels', 'O'), ('of', 'O'), ('serum', 'O'), ('alpha', 'O'), ('-', 'O'), ('GST', 'O'), ('.', 'O'))"
Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .,"(('Assessment', 'O'), ('of', 'O'), ('perinatal', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('and', 'O'), ('rubella', 'B'), ('prevention', 'O'), ('in', 'O'), ('New', 'O'), ('Hampshire', 'O'), ('delivery', 'O'), ('hospitals', 'O'), ('.', 'O'))"
OBJECTIVE : To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('current', 'O'), ('performance', 'O'), ('on', 'O'), ('recommended', 'O'), ('perinatal', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('and', 'O'), ('rubella', 'B'), ('prevention', 'O'), ('practices', 'O'), ('in', 'O'), ('New', 'O'), ('Hampshire', 'O'), ('.', 'O'))"
"Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .","(('Assessment', 'O'), ('was', 'O'), ('done', 'O'), ('on', 'O'), ('the', 'O'), ('following', 'O'), (':', 'O'), ('prenatal', 'O'), ('screening', 'O'), ('for', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('and', 'O'), ('rubella', 'B'), (',', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('vaccine', 'O'), ('birth', 'O'), ('dose', 'O'), ('to', 'O'), ('all', 'O'), ('infants', 'O'), (',', 'O'), ('administration', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('to', 'O'), ('infants', 'O'), ('who', 'O'), ('were', 'O'), ('born', 'O'), ('to', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('-', 'O'), ('positive', 'O'), ('mothers', 'O'), (',', 'O'), ('rubella', 'B'), ('immunity', 'O'), (',', 'O'), ('and', 'O'), ('administration', 'O'), ('of', 'O'), ('in', 'O'), ('-', 'O'), ('hospital', 'O'), ('postpartum', 'O'), ('rubella', 'B'), ('vaccine', 'O'), ('to', 'O'), ('rubella', 'B'), ('nonimmune', 'O'), ('women', 'O'), ('.', 'O'))"
RESULTS : Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .,"(('RESULTS', 'O'), (':', 'O'), ('Prenatal', 'O'), ('screening', 'O'), ('rates', 'O'), ('for', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('(', 'O'), ('98', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('rubella', 'B'), ('(', 'O'), ('99', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('high', 'O'), ('.', 'O'))"
Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .,"(('Hepatitis', 'B'), ('B', 'I'), ('vaccine', 'O'), ('birth', 'O'), ('dose', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('76', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('all', 'O'), ('infants', 'O'), ('.', 'O'))"
All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .,"(('All', 'O'), ('infants', 'O'), ('who', 'O'), ('were', 'O'), ('born', 'O'), ('to', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('-', 'O'), ('positive', 'O'), ('mothers', 'O'), ('also', 'O'), ('received', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('.', 'O'))"
Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .,"(('Multivariate', 'O'), ('logistic', 'O'), ('regression', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('month', 'O'), ('of', 'O'), ('delivery', 'O'), ('and', 'O'), ('infant', 'O'), ('birth', 'O'), ('weight', 'O'), ('were', 'O'), ('independent', 'O'), ('predictors', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('vaccination', 'O'), ('.', 'O'))"
CONCLUSION : This study documents good compliance in New Hampshire ' s birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .,"(('CONCLUSION', 'O'), (':', 'O'), ('This', 'O'), ('study', 'O'), ('documents', 'O'), ('good', 'O'), ('compliance', 'O'), ('in', 'O'), ('New', 'O'), ('Hampshire', 'O'), (""'"", 'O'), ('s', 'O'), ('birthing', 'O'), ('hospitals', 'O'), ('with', 'O'), ('national', 'O'), ('guidelines', 'O'), ('for', 'O'), ('perinatal', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('and', 'O'), ('rubella', 'B'), ('prevention', 'O'), ('and', 'O'), ('highlights', 'O'), ('potential', 'O'), ('areas', 'O'), ('for', 'O'), ('improvement', 'O'), ('.', 'O'))"
Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .,"(('Succinylcholine', 'O'), ('-', 'O'), ('induced', 'O'), ('masseter', 'B'), ('muscle', 'I'), ('rigidity', 'I'), ('during', 'O'), ('bronchoscopic', 'O'), ('removal', 'O'), ('of', 'O'), ('a', 'O'), ('tracheal', 'O'), ('foreign', 'O'), ('body', 'O'), ('.', 'O'))"
Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .,"(('Masseter', 'B'), ('muscle', 'I'), ('rigidity', 'I'), ('during', 'O'), ('general', 'O'), ('anesthesia', 'O'), ('is', 'O'), ('considered', 'O'), ('an', 'O'), ('early', 'O'), ('warning', 'O'), ('sign', 'O'), ('of', 'O'), ('a', 'O'), ('possible', 'O'), ('episode', 'O'), ('of', 'O'), ('malignant', 'B'), ('hyperthermia', 'I'), ('.', 'O'))"
The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .,"(('The', 'O'), ('decision', 'O'), ('whether', 'O'), ('to', 'O'), ('continue', 'O'), ('or', 'O'), ('discontinue', 'O'), ('the', 'O'), ('procedure', 'O'), ('depends', 'O'), ('on', 'O'), ('the', 'O'), ('urgency', 'O'), ('of', 'O'), ('the', 'O'), ('surgery', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('masseter', 'B'), ('muscle', 'I'), ('rigidity', 'I'), ('.', 'O'))"
"Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .","(('Here', 'O'), (',', 'O'), ('we', 'O'), ('describe', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('severe', 'O'), ('masseter', 'B'), ('muscle', 'I'), ('rigidity', 'I'), ('(', 'O'), ('jaw', 'B'), ('of', 'I'), ('steel', 'I'), (')', 'O'), ('after', 'O'), ('succinylcholine', 'O'), ('(', 'O'), ('Sch', 'O'), (')', 'O'), ('administration', 'O'), ('during', 'O'), ('general', 'O'), ('anesthetic', 'O'), ('management', 'O'), ('for', 'O'), ('rigid', 'O'), ('bronchoscopic', 'O'), ('removal', 'O'), ('of', 'O'), ('a', 'O'), ('tracheal', 'O'), ('foreign', 'O'), ('body', 'O'), ('.', 'O'))"
Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .,"(('Anesthesia', 'O'), ('was', 'O'), ('continued', 'O'), ('uneventfully', 'O'), ('with', 'O'), ('propofol', 'O'), ('infusion', 'O'), ('while', 'O'), ('all', 'O'), ('facilities', 'O'), ('were', 'O'), ('available', 'O'), ('to', 'O'), ('detect', 'O'), ('and', 'O'), ('treat', 'O'), ('malignant', 'B'), ('hyperthermia', 'I'), ('.', 'O'))"
Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .,"(('Dexrazoxane', 'O'), ('protects', 'O'), ('against', 'O'), ('myelosuppression', 'B'), ('from', 'O'), ('the', 'O'), ('DNA', 'O'), ('cleavage', 'O'), ('-', 'O'), ('enhancing', 'O'), ('drugs', 'O'), ('etoposide', 'O'), ('and', 'O'), ('daunorubicin', 'O'), ('but', 'O'), ('not', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
"PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .","(('PURPOSE', 'O'), (':', 'O'), ('The', 'O'), ('anthracyclines', 'O'), ('daunorubicin', 'O'), ('and', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('the', 'O'), ('epipodophyllotoxin', 'O'), ('etoposide', 'O'), ('are', 'O'), ('potent', 'O'), ('DNA', 'O'), ('cleavage', 'O'), ('-', 'O'), ('enhancing', 'O'), ('drugs', 'O'), ('that', 'O'), ('are', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('clinical', 'O'), ('oncology', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('myelosuppression', 'B'), ('and', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('limit', 'O'), ('their', 'O'), ('use', 'O'), ('.', 'O'))"
Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .,"(('Dexrazoxane', 'O'), ('(', 'O'), ('ICRF', 'O'), ('-', 'O'), ('187', 'O'), (')', 'O'), ('is', 'O'), ('recommended', 'O'), ('for', 'O'), ('protection', 'O'), ('against', 'O'), ('anthracycline', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .","(('EXPERIMENTAL', 'O'), ('DESIGN', 'O'), (':', 'O'), ('Because', 'O'), ('of', 'O'), ('their', 'O'), ('widespread', 'O'), ('use', 'O'), (',', 'O'), ('the', 'O'), ('hematologic', 'B'), ('toxicity', 'I'), ('following', 'O'), ('coadministration', 'O'), ('of', 'O'), ('dexrazoxane', 'O'), ('and', 'O'), ('these', 'O'), ('three', 'O'), ('structurally', 'O'), ('different', 'O'), ('DNA', 'O'), ('cleavage', 'O'), ('enhancers', 'O'), ('was', 'O'), ('investigated', 'O'), (':', 'O'), ('Sensitivity', 'O'), ('of', 'O'), ('human', 'O'), ('and', 'O'), ('murine', 'O'), ('blood', 'O'), ('progenitor', 'O'), ('cells', 'O'), ('to', 'O'), ('etoposide', 'O'), (',', 'O'), ('daunorubicin', 'O'), (',', 'O'), ('and', 'O'), ('doxorubicin', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('dexrazoxane', 'O'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('granulocyte', 'O'), ('-', 'O'), ('macrophage', 'O'), ('colony', 'O'), ('forming', 'O'), ('assays', 'O'), ('.', 'O'))"
"RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .","(('RESULTS', 'O'), (':', 'O'), ('Nontoxic', 'O'), ('doses', 'O'), ('of', 'O'), ('dexrazoxane', 'O'), ('reduced', 'O'), ('myelosuppression', 'B'), ('and', 'O'), ('weight', 'B'), ('loss', 'I'), ('from', 'O'), ('daunorubicin', 'O'), ('and', 'O'), ('etoposide', 'O'), ('in', 'O'), ('mice', 'O'), ('and', 'O'), ('antagonized', 'O'), ('their', 'O'), ('antiproliferative', 'O'), ('effects', 'O'), ('in', 'O'), ('the', 'O'), ('colony', 'O'), ('assay', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('dexrazoxane', 'O'), ('neither', 'O'), ('reduced', 'O'), ('myelosuppression', 'B'), (',', 'O'), ('weight', 'B'), ('loss', 'I'), (',', 'O'), ('nor', 'O'), ('the', 'O'), ('in', 'O'), ('vitro', 'O'), ('cytotoxicity', 'B'), ('from', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .,"(('Clinical', 'O'), ('trials', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('brain', 'O'), ('metastases', 'B'), ('combining', 'O'), ('dexrazoxane', 'O'), ('and', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('etoposide', 'O'), ('is', 'O'), ('ongoing', 'O'), ('with', 'O'), ('the', 'O'), ('aim', 'O'), ('of', 'O'), ('improving', 'O'), ('efficacy', 'O'), ('without', 'O'), ('aggravating', 'O'), ('hematologic', 'B'), ('toxicity', 'I'), ('.', 'O'))"
Assessment of the onset and persistence of amnesia during procedural sedation with propofol .,"(('Assessment', 'O'), ('of', 'O'), ('the', 'O'), ('onset', 'O'), ('and', 'O'), ('persistence', 'O'), ('of', 'O'), ('amnesia', 'B'), ('during', 'O'), ('procedural', 'O'), ('sedation', 'O'), ('with', 'O'), ('propofol', 'O'), ('.', 'O'))"
The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .,"(('The', 'O'), ('mean', 'O'), ('highest', 'O'), ('BIS', 'O'), ('score', 'O'), ('corresponding', 'O'), ('to', 'O'), ('the', 'O'), ('inability', 'B'), ('to', 'I'), ('repeat', 'I'), ('words', 'I'), ('was', 'O'), ('81', 'O'), ('.', 'O'), ('5', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('=', 'O'), ('78', 'O'), ('.', 'O'), ('1', 'O'), ('to', 'O'), ('84', 'O'), ('.', 'O'), ('8', 'O'), (')', 'O'), ('.', 'O'))"
Amiodarone pulmonary toxicity .,"(('Amiodarone', 'O'), ('pulmonary', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .","(('Amiodarone', 'O'), ('is', 'O'), ('an', 'O'), ('effective', 'O'), ('antiarrhythmic', 'O'), ('agent', 'O'), ('whose', 'O'), ('utility', 'O'), ('is', 'O'), ('limited', 'O'), ('by', 'O'), ('many', 'O'), ('side', 'O'), ('-', 'O'), ('effects', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('problematic', 'O'), ('being', 'O'), ('pneumonitis', 'B'), ('.', 'O'))"
The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .,"(('The', 'O'), ('pulmonary', 'B'), ('toxicity', 'I'), ('of', 'O'), ('amiodarone', 'O'), ('is', 'O'), ('thought', 'O'), ('to', 'O'), ('result', 'O'), ('from', 'O'), ('direct', 'O'), ('injury', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('intracellular', 'O'), ('accumulation', 'O'), ('of', 'O'), ('phospholipid', 'O'), ('and', 'O'), ('T', 'O'), ('cell', 'O'), ('-', 'O'), ('mediated', 'O'), ('hypersensitivity', 'B'), ('pneumonitis', 'I'), ('.', 'O'))"
The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .,"(('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('radiographic', 'O'), ('features', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('-', 'O'), ('induced', 'O'), ('pulmonary', 'B'), ('toxicity', 'I'), ('are', 'O'), ('characteristic', 'O'), ('but', 'O'), ('nonspecific', 'O'), ('.', 'O'))"
"The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .","(('The', 'O'), ('diagnosis', 'O'), ('depends', 'O'), ('on', 'O'), ('exclusion', 'O'), ('of', 'O'), ('other', 'O'), ('entities', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('heart', 'B'), ('failure', 'I'), (',', 'O'), ('infection', 'B'), (',', 'O'), ('and', 'O'), ('malignancy', 'B'), ('.', 'O'))"
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .,"(('Two', 'O'), ('prodrugs', 'O'), ('of', 'O'), ('potent', 'O'), ('and', 'O'), ('selective', 'O'), ('GluR5', 'O'), ('kainate', 'O'), ('receptor', 'O'), ('antagonists', 'O'), ('actives', 'O'), ('in', 'O'), ('three', 'O'), ('animal', 'O'), ('models', 'O'), ('of', 'O'), ('pain', 'B'), ('.', 'O'))"
"Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .","(('Their', 'O'), ('ester', 'O'), ('prodrugs', 'O'), ('6', 'O'), ('and', 'O'), ('8', 'O'), ('were', 'O'), ('orally', 'O'), ('active', 'O'), ('in', 'O'), ('three', 'O'), ('models', 'O'), ('of', 'O'), ('pain', 'B'), (':', 'O'), ('reversal', 'O'), ('of', 'O'), ('formalin', 'O'), ('-', 'O'), ('induced', 'O'), ('paw', 'O'), ('licking', 'O'), (',', 'O'), ('carrageenan', 'O'), ('-', 'O'), ('induced', 'O'), ('thermal', 'B'), ('hyperalgesia', 'I'), (',', 'O'), ('and', 'O'), ('capsaicin', 'O'), ('-', 'O'), ('induced', 'O'), ('mechanical', 'B'), ('hyperalgesia', 'I'), ('.', 'O'))"
Possible azithromycin - associated hiccups .,"(('Possible', 'O'), ('azithromycin', 'O'), ('-', 'O'), ('associated', 'O'), ('hiccups', 'B'), ('.', 'O'))"
OBJECTIVE : To report a case of persistent hiccups associated by azithromycin therapy .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('persistent', 'O'), ('hiccups', 'B'), ('associated', 'O'), ('by', 'O'), ('azithromycin', 'O'), ('therapy', 'O'), ('.', 'O'))"
CASE SUMMARY : A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .,"(('CASE', 'O'), ('SUMMARY', 'O'), (':', 'O'), ('A', 'O'), ('76', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('presented', 'O'), ('with', 'O'), ('persistent', 'O'), ('hiccups', 'B'), ('after', 'O'), ('beginning', 'O'), ('azithromycin', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('pharyngitis', 'B'), ('.', 'O'))"
Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .,"(('Discontinuation', 'O'), ('of', 'O'), ('azithromycin', 'O'), ('and', 'O'), ('therapy', 'O'), ('with', 'O'), ('baclofen', 'O'), ('finally', 'O'), ('resolved', 'O'), ('hiccups', 'B'), ('.', 'O'))"
No organic cause of hiccups was identified despite extensive investigation .,"(('No', 'O'), ('organic', 'O'), ('cause', 'O'), ('of', 'O'), ('hiccups', 'B'), ('was', 'O'), ('identified', 'O'), ('despite', 'O'), ('extensive', 'O'), ('investigation', 'O'), ('.', 'O'))"
DISCUSSION : Pharmacotherapeutic agents have been uncommonly associated with hiccups .,"(('DISCUSSION', 'O'), (':', 'O'), ('Pharmacotherapeutic', 'O'), ('agents', 'O'), ('have', 'O'), ('been', 'O'), ('uncommonly', 'O'), ('associated', 'O'), ('with', 'O'), ('hiccups', 'B'), ('.', 'O'))"
"Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .","(('Corticosteroids', 'O'), ('(', 'O'), ('dexamethasone', 'O'), ('and', 'O'), ('methylprednisolone', 'O'), (')', 'O'), (',', 'O'), ('benzodiazepines', 'O'), ('(', 'O'), ('midazolam', 'O'), (')', 'O'), ('and', 'O'), ('general', 'O'), ('anaesthesia', 'O'), ('have', 'O'), ('been', 'O'), ('the', 'O'), ('specific', 'O'), ('agents', 'O'), ('mentioned', 'O'), ('most', 'O'), ('frequently', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('as', 'O'), ('being', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('hiccups', 'B'), ('.', 'O'))"
Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .,"(('Few', 'O'), ('cases', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('hiccups', 'B'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('related', 'O'), ('to', 'O'), ('macrolide', 'O'), ('antimicrobials', 'O'), ('.', 'O'))"
"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .","(('Using', 'O'), ('the', 'O'), ('Naranjo', 'O'), ('adverse', 'O'), ('effect', 'O'), ('reaction', 'O'), ('probability', 'O'), ('scale', 'O'), ('this', 'O'), ('event', 'O'), ('could', 'O'), ('be', 'O'), ('classified', 'O'), ('as', 'O'), ('possible', 'O'), ('(', 'O'), ('score', 'O'), ('5', 'O'), ('points', 'O'), (')', 'O'), (',', 'O'), ('mostly', 'O'), ('because', 'O'), ('of', 'O'), ('the', 'O'), ('close', 'O'), ('temporal', 'O'), ('sequence', 'O'), (',', 'O'), ('previous', 'O'), ('reports', 'O'), ('on', 'O'), ('this', 'O'), ('reaction', 'O'), ('with', 'O'), ('other', 'O'), ('macrolides', 'O'), ('and', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('any', 'O'), ('alternative', 'O'), ('explanation', 'O'), ('for', 'O'), ('hiccups', 'B'), ('.', 'O'))"
Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .,"(('Our', 'O'), ('hypothesis', 'O'), ('is', 'O'), ('that', 'O'), ('a', 'O'), ('vagal', 'O'), ('mechanism', 'O'), ('mediated', 'O'), ('by', 'O'), ('azithromycin', 'O'), ('could', 'O'), ('be', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('hiccups', 'B'), ('in', 'O'), ('our', 'O'), ('patient', 'O'), ('.', 'O'))"
CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Diagnosis', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('hiccups', 'B'), ('is', 'O'), ('difficult', 'O'), ('and', 'O'), ('often', 'O'), ('achieved', 'O'), ('only', 'O'), ('by', 'O'), ('a', 'O'), ('process', 'O'), ('of', 'O'), ('elimination', 'O'), ('.', 'O'))"
"However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .","(('However', 'O'), (',', 'O'), ('macrolide', 'O'), ('antimicrobials', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('hiccups', 'B'), ('and', 'O'), ('vagal', 'O'), ('mechanism', 'O'), ('could', 'O'), ('explain', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('this', 'O'), ('side', 'O'), ('-', 'O'), ('effect', 'O'), ('.', 'O'))"
Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .,"(('Calcium', 'O'), ('carbonate', 'O'), ('toxicity', 'B'), (':', 'O'), ('the', 'O'), ('updated', 'O'), ('milk', 'B'), ('-', 'I'), ('alkali', 'I'), ('syndrome', 'I'), (';', 'O'), ('report', 'O'), ('of', 'O'), ('3', 'O'), ('cases', 'O'), ('and', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
OBJECTIVE : To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('describe', 'O'), ('3', 'O'), ('patients', 'O'), ('with', 'O'), ('calcium', 'O'), ('carbonate', 'O'), ('-', 'O'), ('induced', 'O'), ('hypercalcemia', 'B'), ('and', 'O'), ('gain', 'O'), ('insights', 'O'), ('into', 'O'), ('the', 'O'), ('cause', 'O'), ('and', 'O'), ('management', 'O'), ('of', 'O'), ('the', 'O'), ('milk', 'B'), ('-', 'I'), ('alkali', 'I'), ('syndrome', 'I'), ('.', 'O'))"
METHODS : We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .,"(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('report', 'O'), ('the', 'O'), ('clinical', 'O'), ('and', 'O'), ('laboratory', 'O'), ('data', 'O'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('who', 'O'), ('presented', 'O'), ('with', 'O'), ('severe', 'O'), ('hypercalcemia', 'B'), ('(', 'O'), ('corrected', 'O'), ('serum', 'O'), ('calcium', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('14', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), (')', 'O'), ('and', 'O'), ('review', 'O'), ('the', 'O'), ('pertinent', 'O'), ('literature', 'O'), ('on', 'O'), ('milk', 'B'), ('-', 'I'), ('alkali', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"RESULTS : The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('3', 'O'), ('patients', 'O'), ('had', 'O'), ('acute', 'B'), ('renal', 'I'), ('insufficiency', 'I'), (',', 'O'), ('relative', 'O'), ('metabolic', 'B'), ('alkalosis', 'I'), (',', 'O'), ('and', 'O'), ('low', 'O'), ('parathyroid', 'O'), ('hormone', 'O'), ('(', 'O'), ('PTH', 'O'), (')', 'O'), (',', 'O'), ('PTH', 'O'), ('-', 'O'), ('related', 'O'), ('peptide', 'O'), (',', 'O'), ('and', 'O'), ('1', 'O'), (',', 'O'), ('25', 'O'), ('-', 'O'), ('dihydroxyvitamin', 'O'), ('D', 'O'), ('concentrations', 'O'), ('.', 'O'))"
"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .","(('The', 'O'), ('2', 'O'), ('patients', 'O'), ('with', 'O'), ('the', 'O'), ('higher', 'O'), ('serum', 'O'), ('calcium', 'O'), ('concentrations', 'O'), ('received', 'O'), ('pamidronate', 'O'), ('intravenously', 'O'), ('(', 'O'), ('60', 'O'), ('and', 'O'), ('30', 'O'), ('mg', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), (',', 'O'), ('which', 'O'), ('caused', 'O'), ('severe', 'O'), ('hypocalcemia', 'B'), ('.', 'O'))"
"In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('our', 'O'), ('highlighted', 'O'), ('cases', 'O'), (',', 'O'), ('we', 'O'), ('review', 'O'), ('the', 'O'), ('history', 'O'), (',', 'O'), ('classification', 'O'), (',', 'O'), ('pathophysiologic', 'O'), ('features', 'O'), (',', 'O'), ('and', 'O'), ('treatment', 'O'), ('of', 'O'), ('milk', 'B'), ('-', 'I'), ('alkali', 'I'), ('syndrome', 'I'), ('and', 'O'), ('summarize', 'O'), ('the', 'O'), ('cases', 'O'), ('reported', 'O'), ('from', 'O'), ('early', 'O'), ('1995', 'O'), ('to', 'O'), ('November', 'O'), ('2003', 'O'), ('.', 'O'))"
CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .,"(('CONCLUSION', 'O'), (':', 'O'), ('Milk', 'B'), ('-', 'I'), ('alkali', 'I'), ('syndrome', 'I'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('common', 'O'), ('cause', 'O'), ('of', 'O'), ('unexplained', 'O'), ('hypercalcemia', 'B'), ('and', 'O'), ('can', 'O'), ('be', 'O'), ('precipitated', 'O'), ('by', 'O'), ('small', 'O'), ('amounts', 'O'), ('of', 'O'), ('orally', 'O'), ('ingested', 'O'), ('calcium', 'O'), ('carbonate', 'O'), ('in', 'O'), ('susceptible', 'O'), ('persons', 'O'), ('.', 'O'))"
"Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .","(('Pamidronate', 'O'), ('treatment', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('considerable', 'O'), ('risk', 'O'), ('for', 'O'), ('hypocalcemia', 'B'), (',', 'O'), ('even', 'O'), ('in', 'O'), ('cases', 'O'), ('of', 'O'), ('initially', 'O'), ('severe', 'O'), ('hypercalcemia', 'B'), ('.', 'O'))"
Warfarin - induced leukocytoclastic vasculitis .,"(('Warfarin', 'O'), ('-', 'O'), ('induced', 'O'), ('leukocytoclastic', 'B'), ('vasculitis', 'I'), ('.', 'O'))"
"Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .","(('Leukocytoclastic', 'B'), ('vasculitis', 'I'), ('(', 'O'), ('LV', 'B'), (')', 'O'), ('is', 'O'), ('primarily', 'O'), ('a', 'O'), ('cutaneous', 'B'), ('small', 'I'), ('vessel', 'I'), ('vasculitis', 'I'), (',', 'O'), ('though', 'O'), ('systemic', 'O'), ('involvement', 'O'), ('may', 'O'), ('be', 'O'), ('encountered', 'O'), ('.', 'O'))"
All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .,"(('All', 'O'), ('4', 'O'), ('patients', 'O'), ('presented', 'O'), ('with', 'O'), ('skin', 'B'), ('eruptions', 'I'), ('that', 'O'), ('developed', 'O'), ('after', 'O'), ('receiving', 'O'), ('warfarin', 'O'), ('for', 'O'), ('several', 'O'), ('years', 'O'), ('.', 'O'))"
"The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .","(('The', 'O'), ('results', 'O'), ('of', 'O'), ('skin', 'B'), ('lesion', 'I'), ('biopsies', 'O'), ('were', 'O'), ('available', 'O'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), (',', 'O'), ('confirming', 'O'), ('LV', 'B'), ('Cutaneous', 'I'), ('lesions', 'I'), ('resolved', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('after', 'O'), ('warfarin', 'O'), ('was', 'O'), ('discontinued', 'O'), ('.', 'O'))"
Cocaine - induced brainstem seizures and behavior .,"(('Cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('brainstem', 'O'), ('seizures', 'B'), ('and', 'O'), ('behavior', 'O'), ('.', 'O'))"
"The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , "" beating drum "" behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .","(('The', 'O'), ('abnormal', 'O'), ('behaviors', 'O'), ('were', 'O'), ('yawning', 'O'), (',', 'O'), ('retrocollis', 'O'), (',', 'O'), ('hyperactivity', 'B'), (',', 'O'), ('hypersensitivity', 'B'), (',', 'O'), ('""', 'O'), ('beating', 'O'), ('drum', 'O'), ('""', 'O'), ('behavior', 'O'), (',', 'O'), ('squealing', 'O'), (',', 'O'), ('head', 'O'), ('bobbing', 'O'), (',', 'O'), ('circling', 'O'), (',', 'O'), ('sniffing', 'O'), (',', 'O'), ('abnormal', 'O'), ('posturing', 'O'), (',', 'O'), ('and', 'O'), ('facial', 'O'), ('twitching', 'O'), ('.', 'O'))"
"Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .","(('Hypersensitivity', 'B'), ('to', 'O'), ('various', 'O'), ('auditory', 'O'), (',', 'O'), ('tactile', 'O'), (',', 'O'), ('and', 'O'), ('visual', 'O'), ('stimulation', 'O'), ('was', 'O'), ('present', 'O'), ('and', 'O'), ('shifts', 'O'), ('in', 'O'), ('the', 'O'), ('brainstem', 'O'), ('ambient', 'O'), ('power', 'O'), ('spectral', 'O'), ('frequency', 'O'), ('occurred', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('tactile', 'O'), ('stimulation', 'O'), ('.', 'O'))"
rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .,"(('rTMS', 'O'), ('of', 'O'), ('supplementary', 'O'), ('motor', 'O'), ('area', 'O'), ('modulates', 'O'), ('therapy', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('in', 'O'), ('Parkinson', 'B'), ('disease', 'I'), ('.', 'O'))"
The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .,"(('The', 'O'), ('neural', 'O'), ('mechanisms', 'O'), ('and', 'O'), ('circuitry', 'O'), ('involved', 'O'), ('in', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesia', 'B'), ('are', 'O'), ('unclear', 'O'), ('.', 'O'))"
"Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .","(('Using', 'O'), ('repetitive', 'O'), ('transcranial', 'O'), ('magnetic', 'O'), ('stimulation', 'O'), ('(', 'O'), ('rTMS', 'O'), (')', 'O'), ('over', 'O'), ('the', 'O'), ('supplementary', 'O'), ('motor', 'O'), ('area', 'O'), ('(', 'O'), ('SMA', 'O'), (')', 'O'), ('in', 'O'), ('a', 'O'), ('group', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('advanced', 'O'), ('Parkinson', 'B'), ('disease', 'I'), (',', 'O'), ('the', 'O'), ('authors', 'O'), ('investigated', 'O'), ('whether', 'O'), ('modulation', 'O'), ('of', 'O'), ('SMA', 'O'), ('excitability', 'O'), ('may', 'O'), ('result', 'O'), ('in', 'O'), ('a', 'O'), ('modification', 'O'), ('of', 'O'), ('a', 'O'), ('dyskinetic', 'B'), ('state', 'O'), ('induced', 'O'), ('by', 'O'), ('continuous', 'O'), ('apomorphine', 'O'), ('infusion', 'O'), ('.', 'O'))"
"rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .","(('rTMS', 'O'), ('at', 'O'), ('1', 'O'), ('Hz', 'O'), ('was', 'O'), ('observed', 'O'), ('to', 'O'), ('markedly', 'O'), ('reduce', 'O'), ('drug', 'B'), ('-', 'I'), ('induced', 'I'), ('dyskinesias', 'I'), (',', 'O'), ('whereas', 'O'), ('5', 'O'), ('-', 'O'), ('Hz', 'O'), ('rTMS', 'O'), ('induced', 'O'), ('a', 'O'), ('slight', 'O'), ('but', 'O'), ('not', 'O'), ('significant', 'O'), ('increase', 'O'), ('.', 'O'))"
Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .,"(('Intracavitary', 'O'), ('chemotherapy', 'O'), ('(', 'O'), ('paclitaxel', 'O'), ('/', 'O'), ('carboplatin', 'O'), ('liquid', 'O'), ('crystalline', 'O'), ('cubic', 'O'), ('phases', 'O'), (')', 'O'), ('for', 'O'), ('recurrent', 'O'), ('glioblastoma', 'B'), ('-', 'O'), ('-', 'O'), ('clinical', 'O'), ('observations', 'O'), ('.', 'O'))"
Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .,"(('Human', 'O'), ('malignant', 'O'), ('brain', 'B'), ('tumors', 'I'), ('have', 'O'), ('a', 'O'), ('poor', 'O'), ('prognosis', 'O'), ('in', 'O'), ('spite', 'O'), ('of', 'O'), ('surgery', 'O'), ('and', 'O'), ('radiation', 'O'), ('therapy', 'O'), ('.', 'O'))"
"For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .","(('For', 'O'), ('human', 'O'), ('glioblastoma', 'B'), ('recurrences', 'O'), (',', 'O'), ('the', 'O'), ('feasibility', 'O'), (',', 'O'), ('safety', 'O'), (',', 'O'), ('and', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('surgical', 'O'), ('intracavitary', 'O'), ('application', 'O'), ('of', 'O'), ('paclitaxel', 'O'), ('and', 'O'), ('carboplatin', 'O'), ('encapsulated', 'O'), ('by', 'O'), ('liquid', 'O'), ('crystalline', 'O'), ('cubic', 'O'), ('phases', 'O'), ('are', 'O'), ('examined', 'O'), ('in', 'O'), ('a', 'O'), ('pilot', 'O'), ('study', 'O'), ('.', 'O'))"
A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .,"(('A', 'O'), ('total', 'O'), ('of', 'O'), ('12', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('recurrence', 'O'), ('of', 'O'), ('a', 'O'), ('glioblastoma', 'B'), ('multiforme', 'O'), ('underwent', 'O'), ('re', 'O'), ('-', 'O'), ('resection', 'O'), ('and', 'O'), ('received', 'O'), ('an', 'O'), ('intracavitary', 'O'), ('application', 'O'), ('of', 'O'), ('paclitaxel', 'O'), ('and', 'O'), ('carboplatin', 'O'), ('cubic', 'O'), ('phases', 'O'), ('in', 'O'), ('different', 'O'), ('dosages', 'O'), ('.', 'O'))"
"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .","(('Six', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('received', 'O'), ('more', 'O'), ('than', 'O'), ('15', 'O'), ('mg', 'O'), ('paclitaxel', 'O'), ('and', 'O'), ('suffered', 'O'), ('from', 'O'), ('moderate', 'O'), ('to', 'O'), ('severe', 'O'), ('brain', 'B'), ('edema', 'I'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('remaining', 'O'), ('patients', 'O'), ('received', 'O'), ('only', 'O'), ('a', 'O'), ('total', 'O'), ('of', 'O'), ('15', 'O'), ('mg', 'O'), ('paclitaxel', 'O'), ('.', 'O'))"
"In the latter group , brain edema was markedly reduced and dealt medically .","(('In', 'O'), ('the', 'O'), ('latter', 'O'), ('group', 'O'), (',', 'O'), ('brain', 'B'), ('edema', 'I'), ('was', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('and', 'O'), ('dealt', 'O'), ('medically', 'O'), ('.', 'O'))"
"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .","(('Intracavitary', 'O'), ('chemotherapy', 'O'), ('in', 'O'), ('recurrent', 'O'), ('glioblastoma', 'B'), ('using', 'O'), ('cubic', 'O'), ('phases', 'O'), ('is', 'O'), ('feasible', 'O'), ('and', 'O'), ('safe', 'O'), (',', 'O'), ('yet', 'O'), ('the', 'O'), ('clinical', 'O'), ('benefit', 'O'), ('remains', 'O'), ('to', 'O'), ('be', 'O'), ('examined', 'O'), ('in', 'O'), ('a', 'O'), ('clinical', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('.', 'O'))"
Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .,"(('Lamotrigine', 'O'), ('associated', 'O'), ('with', 'O'), ('exacerbation', 'O'), ('or', 'O'), ('de', 'O'), ('novo', 'O'), ('myoclonus', 'B'), ('in', 'O'), ('idiopathic', 'B'), ('generalized', 'I'), ('epilepsies', 'I'), ('.', 'O'))"
Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .,"(('Five', 'O'), ('patients', 'O'), ('with', 'O'), ('idiopathic', 'B'), ('generalized', 'I'), ('epilepsies', 'I'), ('(', 'O'), ('IGE', 'B'), (')', 'O'), ('treated', 'O'), ('with', 'O'), ('lamotrigine', 'O'), ('(', 'O'), ('LTG', 'O'), (')', 'O'), ('experienced', 'O'), ('exacerbation', 'O'), ('or', 'O'), ('de', 'O'), ('novo', 'O'), ('appearance', 'O'), ('of', 'O'), ('myoclonic', 'B'), ('jerks', 'I'), ('(', 'O'), ('MJ', 'B'), (')', 'O'), ('.', 'O'))"
"In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .","(('In', 'O'), ('two', 'O'), ('patients', 'O'), (',', 'O'), ('LTG', 'O'), ('exacerbated', 'O'), ('MJ', 'B'), ('in', 'O'), ('a', 'O'), ('delayed', 'O'), ('but', 'O'), ('more', 'O'), ('severe', 'O'), ('manner', 'O'), (',', 'O'), ('with', 'O'), ('myoclonic', 'B'), ('status', 'I'), ('that', 'O'), ('only', 'O'), ('ceased', 'O'), ('after', 'O'), ('LTG', 'O'), ('withdrawal', 'O'), ('.', 'O'))"
Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .,"(('Absence', 'O'), ('of', 'O'), ('acute', 'O'), ('cerebral', 'O'), ('vasoconstriction', 'O'), ('after', 'O'), ('cocaine', 'O'), ('-', 'O'), ('associated', 'O'), ('subarachnoid', 'B'), ('hemorrhage', 'I'), ('.', 'O'))"
"INTRODUCTION : Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .","(('INTRODUCTION', 'O'), (':', 'O'), ('Cocaine', 'O'), ('use', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('neurovascular', 'B'), ('complications', 'I'), (',', 'O'), ('including', 'O'), ('arterial', 'O'), ('vasoconstriction', 'O'), ('and', 'O'), ('vasculitis', 'B'), ('.', 'O'))"
Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .,"(('Information', 'O'), ('on', 'O'), ('these', 'O'), ('effects', 'O'), ('could', 'O'), ('be', 'O'), ('obtained', 'O'), ('from', 'O'), ('angiograms', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('cocaine', 'O'), ('-', 'O'), ('associated', 'O'), ('subarachnoid', 'B'), ('hemorrhage', 'I'), ('(', 'O'), ('SAH', 'B'), (')', 'O'), ('who', 'O'), ('underwent', 'O'), ('angiography', 'O'), ('shortly', 'O'), ('after', 'O'), ('cocaine', 'O'), ('use', 'O'), ('.', 'O'))"
CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .,"(('CONCLUSION', 'O'), (':', 'O'), ('No', 'O'), ('quantitative', 'O'), ('evidence', 'O'), ('for', 'O'), ('narrowing', 'O'), ('of', 'O'), ('large', 'O'), ('cerebral', 'O'), ('arteries', 'O'), ('or', 'O'), ('qualitative', 'O'), ('angiographic', 'O'), ('evidence', 'O'), ('for', 'O'), ('distal', 'O'), ('narrowing', 'O'), ('or', 'O'), ('vasculitis', 'B'), ('could', 'O'), ('be', 'O'), ('found', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('underwent', 'O'), ('angiography', 'O'), ('after', 'O'), ('aneurysmal', 'B'), ('SAH', 'B'), ('associated', 'O'), ('with', 'O'), ('cocaine', 'O'), ('use', 'O'), ('.', 'O'))"
Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .,"(('Methamphetamine', 'O'), ('causes', 'O'), ('alterations', 'O'), ('in', 'O'), ('the', 'O'), ('MAP', 'O'), ('kinase', 'O'), ('-', 'O'), ('related', 'O'), ('pathways', 'O'), ('in', 'O'), ('the', 'O'), ('brains', 'O'), ('of', 'O'), ('mice', 'O'), ('that', 'O'), ('display', 'O'), ('increased', 'O'), ('aggressiveness', 'B'), ('.', 'O'))"
"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .","(('Aggressive', 'B'), ('behaviors', 'I'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('suffer', 'O'), ('from', 'O'), ('some', 'O'), ('psychiatric', 'B'), ('disorders', 'I'), (',', 'O'), ('and', 'O'), ('are', 'O'), ('common', 'O'), ('in', 'O'), ('methamphetamine', 'O'), ('(', 'O'), ('METH', 'O'), (')', 'O'), ('abusers', 'O'), ('.', 'O'))"
"Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .","(('Herein', 'O'), (',', 'O'), ('we', 'O'), ('report', 'O'), ('that', 'O'), ('multiple', 'O'), ('(', 'O'), ('but', 'O'), ('not', 'O'), ('single', 'O'), (')', 'O'), ('injections', 'O'), ('of', 'O'), ('METH', 'O'), ('significantly', 'O'), ('increased', 'O'), ('aggressiveness', 'B'), ('in', 'O'), ('male', 'O'), ('CD', 'O'), ('-', 'O'), ('1', 'O'), ('mice', 'O'), ('.', 'O'))"
This increase in aggressiveness was not secondary to METH - induced hyperactivity .,"(('This', 'O'), ('increase', 'O'), ('in', 'O'), ('aggressiveness', 'B'), ('was', 'O'), ('not', 'O'), ('secondary', 'O'), ('to', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperactivity', 'B'), ('.', 'O'))"
These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('alterations', 'O'), ('in', 'O'), ('MAP', 'O'), ('kinase', 'O'), ('-', 'O'), ('related', 'O'), ('pathways', 'O'), ('in', 'O'), ('the', 'O'), ('prefronto', 'O'), ('-', 'O'), ('striatal', 'O'), ('circuitries', 'O'), ('might', 'O'), ('be', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('manifestation', 'O'), ('of', 'O'), ('aggressive', 'B'), ('behaviors', 'I'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
Amisulpride related tic - like symptoms in an adolescent schizophrenic .,"(('Amisulpride', 'O'), ('related', 'O'), ('tic', 'B'), ('-', 'I'), ('like', 'I'), ('symptoms', 'I'), ('in', 'O'), ('an', 'O'), ('adolescent', 'O'), ('schizophrenic', 'B'), ('.', 'O'))"
"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .","(('Tic', 'B'), ('disorders', 'I'), ('can', 'O'), ('be', 'O'), ('effectively', 'O'), ('treated', 'O'), ('by', 'O'), ('atypical', 'O'), ('antipsychotics', 'O'), ('such', 'O'), ('as', 'O'), ('risperidone', 'O'), (',', 'O'), ('olanzapine', 'O'), ('and', 'O'), ('ziprasidone', 'O'), ('.', 'O'))"
"However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .","(('However', 'O'), (',', 'O'), ('there', 'O'), ('are', 'O'), ('two', 'O'), ('case', 'O'), ('reports', 'O'), ('that', 'O'), ('show', 'O'), ('tic', 'B'), ('-', 'I'), ('like', 'I'), ('symptoms', 'I'), (',', 'O'), ('including', 'O'), ('motor', 'O'), ('and', 'O'), ('phonic', 'O'), ('variants', 'O'), (',', 'O'), ('occurring', 'O'), ('during', 'O'), ('treatment', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('or', 'O'), ('clozapine', 'O'), ('.', 'O'))"
We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .,"(('We', 'O'), ('present', 'O'), ('a', 'O'), ('15', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('girl', 'O'), ('schizophrenic', 'B'), ('who', 'O'), ('developed', 'O'), ('frequent', 'O'), ('involuntary', 'B'), ('eye', 'I'), ('-', 'I'), ('blinking', 'I'), ('movements', 'I'), ('after', 'O'), ('5', 'O'), ('months', 'O'), ('of', 'O'), ('amisulpride', 'O'), ('treatment', 'O'), ('(', 'O'), ('1000', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), (')', 'O'), ('.', 'O'))"
The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .,"(('The', 'O'), ('tic', 'B'), ('-', 'I'), ('like', 'I'), ('symptoms', 'I'), ('resolved', 'O'), ('completely', 'O'), ('after', 'O'), ('we', 'O'), ('reduced', 'O'), ('the', 'O'), ('dose', 'O'), ('of', 'O'), ('amisulpride', 'O'), ('down', 'O'), ('to', 'O'), ('800', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), ('.', 'O'))"
"However , her psychosis recurred after the dose reduction .","(('However', 'O'), (',', 'O'), ('her', 'O'), ('psychosis', 'B'), ('recurred', 'O'), ('after', 'O'), ('the', 'O'), ('dose', 'O'), ('reduction', 'O'), ('.', 'O'))"
No more tic - like symptoms or other side effects have been reported .,"(('No', 'O'), ('more', 'O'), ('tic', 'B'), ('-', 'I'), ('like', 'I'), ('symptoms', 'I'), ('or', 'O'), ('other', 'O'), ('side', 'O'), ('effects', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .","(('Together', 'O'), ('with', 'O'), ('previously', 'O'), ('reported', 'O'), ('cases', 'O'), (',', 'O'), ('our', 'O'), ('patient', 'O'), ('suggests', 'O'), ('that', 'O'), ('tic', 'B'), ('-', 'I'), ('like', 'I'), ('symptoms', 'I'), ('might', 'O'), ('occur', 'O'), ('in', 'O'), ('certain', 'O'), ('vulnerable', 'O'), ('individuals', 'O'), ('during', 'O'), ('treatment', 'O'), ('with', 'O'), ('atypical', 'O'), ('antipsychotics', 'O'), ('such', 'O'), ('as', 'O'), ('quetiapine', 'O'), (',', 'O'), ('clozapine', 'O'), (',', 'O'), ('or', 'O'), ('amisulpride', 'O'), ('.', 'O'))"
Chloroquine related complete heart block with blindness : case report .,"(('Chloroquine', 'O'), ('related', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('with', 'O'), ('blindness', 'B'), (':', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .","(('A', 'O'), ('27', 'O'), ('-', 'O'), ('year', 'O'), ('old', 'O'), ('African', 'O'), ('woman', 'O'), ('with', 'O'), ('history', 'O'), ('of', 'O'), ('regular', 'O'), ('chloroquine', 'O'), ('ingestion', 'O'), ('presented', 'O'), ('with', 'O'), ('progressive', 'O'), ('deterioration', 'B'), ('of', 'I'), ('vision', 'I'), (',', 'O'), ('easy', 'O'), ('fatiguability', 'B'), (',', 'O'), ('dyspnoea', 'B'), (',', 'O'), ('dizziness', 'B'), ('progressing', 'O'), ('to', 'O'), ('syncopal', 'B'), ('attacks', 'I'), ('.', 'O'))"
"Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .","(('Ophthalmological', 'O'), ('assessment', 'O'), ('revealed', 'O'), ('features', 'O'), ('of', 'O'), ('chloroquine', 'O'), ('retinopathy', 'B'), (',', 'O'), ('cardiac', 'O'), ('assessment', 'O'), ('revealed', 'O'), ('features', 'O'), ('of', 'O'), ('heart', 'B'), ('failure', 'I'), ('and', 'O'), ('a', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('with', 'O'), ('right', 'B'), ('bundle', 'I'), ('branch', 'I'), ('block', 'I'), ('pattern', 'O'), ('.', 'O'))"
The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .,"(('The', 'O'), ('heart', 'B'), ('block', 'I'), ('was', 'O'), ('treated', 'O'), ('by', 'O'), ('pacemaker', 'O'), ('insertion', 'O'), ('and', 'O'), ('the', 'O'), ('heart', 'B'), ('failure', 'I'), ('resolved', 'O'), ('spontaneously', 'O'), ('following', 'O'), ('chloroquine', 'O'), ('discontinuation', 'O'), ('.', 'O'))"
"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .","(('Although', 'O'), ('suprofen', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('in', 'O'), ('greater', 'O'), ('than', 'O'), ('100', 'O'), ('subjects', 'O'), (',', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('damage', 'O'), ('remains', 'O'), ('unclear', 'O'), ('.', 'O'))"
The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .,"(('The', 'O'), ('direct', 'O'), ('nephrotoxic', 'B'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('15', 'O'), ('mg', 'O'), ('of', 'O'), ('suprofen', 'O'), ('were', 'O'), ('compared', 'O'), ('in', 'O'), ('the', 'O'), ('recirculating', 'O'), ('isolated', 'O'), ('rat', 'O'), ('kidney', 'O'), ('perfused', 'O'), ('with', 'O'), ('cell', 'O'), ('-', 'O'), ('free', 'O'), ('buffer', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('the', 'O'), ('addition', 'O'), ('of', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('dL', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('.', 'O'))"
"In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .","(('In', 'O'), ('summary', 'O'), (',', 'O'), ('suprofen', 'O'), ('causes', 'O'), ('acute', 'B'), ('declines', 'I'), ('in', 'I'), ('renal', 'I'), ('function', 'I'), (',', 'O'), ('most', 'O'), ('likely', 'O'), ('by', 'O'), ('directly', 'O'), ('altering', 'O'), ('the', 'O'), ('intrarenal', 'O'), ('distribution', 'O'), ('of', 'O'), ('uric', 'O'), ('acid', 'O'), ('.', 'O'))"
Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .,"(('Microinjection', 'O'), ('of', 'O'), ('ritanserin', 'O'), ('into', 'O'), ('the', 'O'), ('CA1', 'O'), ('region', 'O'), ('of', 'O'), ('hippocampus', 'O'), ('improves', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('in', 'O'), ('adult', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('ritanserin', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HT2', 'O'), ('antagonist', 'O'), (')', 'O'), ('on', 'O'), ('scopolamine', 'O'), ('(', 'O'), ('muscarinic', 'O'), ('cholinergic', 'O'), ('antagonist', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('in', 'O'), ('Morris', 'O'), ('water', 'O'), ('maze', 'O'), ('(', 'O'), ('MWM', 'O'), (')', 'O'), ('was', 'O'), ('investigated', 'O'), ('.', 'O'))"
Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .,"(('Our', 'O'), ('findings', 'O'), ('show', 'O'), ('that', 'O'), ('microinjection', 'O'), ('of', 'O'), ('ritanserin', 'O'), ('into', 'O'), ('the', 'O'), ('CA1', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('improves', 'O'), ('the', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .,"(('PTU', 'O'), ('-', 'O'), ('associated', 'O'), ('vasculitis', 'B'), ('in', 'O'), ('a', 'O'), ('girl', 'O'), ('with', 'O'), ('Turner', 'B'), ('Syndrome', 'I'), ('and', 'O'), ('Graves', 'B'), (""'"", 'I'), ('disease', 'I'), ('.', 'O'))"
"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .","(('Palpable', 'O'), ('purpura', 'B'), ('is', 'O'), ('a', 'O'), ('concerning', 'O'), ('clinical', 'O'), ('finding', 'O'), ('in', 'O'), ('pediatric', 'O'), ('patients', 'O'), ('and', 'O'), ('can', 'O'), ('have', 'O'), ('many', 'O'), ('causes', 'O'), (',', 'O'), ('including', 'O'), ('infectious', 'O'), ('and', 'O'), ('autoimmune', 'O'), ('processes', 'O'), ('.', 'O'))"
"A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .","(('A', 'O'), ('rare', 'O'), ('cause', 'O'), (',', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('vasculitis', 'B'), (',', 'O'), ('may', 'O'), ('result', 'O'), ('from', 'O'), ('the', 'O'), ('production', 'O'), ('of', 'O'), ('antineutrophil', 'O'), ('cytoplasmic', 'O'), ('antibodies', 'O'), ('(', 'O'), ('ANCAs', 'O'), (')', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('a', 'O'), ('medication', 'O'), ('.', 'O'))"
We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('girl', 'O'), ('with', 'O'), ('Turner', 'B'), ('syndrome', 'I'), ('and', 'O'), ('Graves', 'B'), (""'"", 'I'), ('disease', 'I'), ('who', 'O'), ('presented', 'O'), ('with', 'O'), ('palpable', 'O'), ('purpuric', 'B'), ('lesions', 'I'), ('.', 'O'))"
"The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .","(('The', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('propylthiouracil', 'O'), ('(', 'O'), ('PTU', 'O'), (')', 'O'), ('-', 'O'), ('associated', 'O'), ('vasculitis', 'B'), ('was', 'O'), ('made', 'O'), ('by', 'O'), ('observation', 'O'), ('of', 'O'), ('consistent', 'O'), ('clinical', 'O'), ('features', 'O'), (',', 'O'), ('the', 'O'), ('detection', 'O'), ('of', 'O'), ('elevated', 'O'), ('ANA', 'O'), ('and', 'O'), ('ANCA', 'O'), ('in', 'O'), ('the', 'O'), ('blood', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('observed', 'O'), ('clinical', 'O'), ('resolution', 'O'), ('of', 'O'), ('symptoms', 'O'), ('following', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('PTU', 'O'), ('.', 'O'))"
"Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .","(('Subsequent', 'O'), ('treatment', 'O'), ('of', 'O'), ('persistent', 'O'), ('hyperthyroidism', 'B'), ('with', 'O'), ('radioablation', 'O'), ('did', 'O'), ('not', 'O'), ('result', 'O'), ('in', 'O'), ('an', 'O'), ('exacerbation', 'O'), ('of', 'O'), ('the', 'O'), ('vasculitis', 'B'), (',', 'O'), ('a', 'O'), ('complication', 'O'), ('described', 'O'), ('in', 'O'), ('prior', 'O'), ('case', 'O'), ('reports', 'O'), ('.', 'O'))"
Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .,"(('Daidzein', 'O'), ('activates', 'O'), ('choline', 'O'), ('acetyltransferase', 'O'), ('from', 'O'), ('MC', 'O'), ('-', 'O'), ('IXC', 'O'), ('cells', 'O'), ('and', 'O'), ('improves', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
"The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer ' s disease ( AD ) .","(('The', 'O'), ('choline', 'O'), ('acetyltransferase', 'O'), ('(', 'O'), ('ChAT', 'O'), (')', 'O'), ('activator', 'O'), (',', 'O'), ('which', 'O'), ('enhances', 'O'), ('cholinergic', 'O'), ('transmission', 'O'), ('via', 'O'), ('an', 'O'), ('augmentation', 'O'), ('of', 'O'), ('the', 'O'), ('enzymatic', 'O'), ('production', 'O'), ('of', 'O'), ('acetylcholine', 'O'), ('(', 'O'), ('ACh', 'O'), (')', 'O'), (',', 'O'), ('is', 'O'), ('an', 'O'), ('important', 'O'), ('factor', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('(', 'O'), ('AD', 'B'), (')', 'O'), ('.', 'O'))"
"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('daidzein', 'O'), ('from', 'O'), ('Pueraria', 'O'), ('thunbergiana', 'O'), ('on', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('impairments', 'B'), ('of', 'I'), ('learning', 'I'), ('and', 'I'), ('memory', 'I'), (',', 'O'), ('we', 'O'), ('conducted', 'O'), ('a', 'O'), ('series', 'O'), ('of', 'O'), ('in', 'O'), ('vivo', 'O'), ('tests', 'O'), ('.', 'O'))"
"Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .","(('Administration', 'O'), ('of', 'O'), ('daidzein', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), (')', 'O'), ('to', 'O'), ('mice', 'O'), ('was', 'O'), ('shown', 'O'), ('significantly', 'O'), ('to', 'O'), ('reverse', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), (',', 'O'), ('according', 'O'), ('to', 'O'), ('the', 'O'), ('results', 'O'), ('of', 'O'), ('a', 'O'), ('Y', 'O'), ('-', 'O'), ('maze', 'O'), ('test', 'O'), ('.', 'O'))"
"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .","(('These', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('daidzein', 'O'), ('might', 'O'), ('play', 'O'), ('a', 'O'), ('role', 'O'), ('in', 'O'), ('acetylcholine', 'O'), ('biosynthesis', 'O'), ('as', 'O'), ('a', 'O'), ('ChAT', 'O'), ('activator', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('it', 'O'), ('also', 'O'), ('ameliorates', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .,"(('Urinary', 'O'), ('symptoms', 'O'), ('and', 'O'), ('quality', 'O'), ('of', 'O'), ('life', 'O'), ('changes', 'O'), ('in', 'O'), ('Thai', 'O'), ('women', 'O'), ('with', 'O'), ('overactive', 'B'), ('bladder', 'I'), ('after', 'O'), ('tolterodine', 'O'), ('treatment', 'O'), ('.', 'O'))"
OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .,"(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('study', 'O'), ('the', 'O'), ('urinary', 'O'), ('symptoms', 'O'), ('and', 'O'), ('quality', 'O'), ('of', 'O'), ('life', 'O'), ('changes', 'O'), ('in', 'O'), ('Thai', 'O'), ('women', 'O'), ('with', 'O'), ('overactive', 'B'), ('bladder', 'I'), ('(', 'O'), ('OAB', 'B'), (')', 'O'), ('after', 'O'), ('tolterodine', 'O'), ('treatment', 'O'), ('.', 'O'))"
The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .,"(('The', 'O'), ('most', 'O'), ('common', 'O'), ('side', 'O'), ('effect', 'O'), ('was', 'O'), ('dry', 'B'), ('month', 'I'), ('in', 'O'), ('5', 'O'), ('cases', 'O'), ('(', 'O'), ('16', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), (')', 'O'), ('with', 'O'), ('2', 'O'), ('cases', 'O'), ('reporting', 'O'), ('a', 'O'), ('moderate', 'O'), ('degree', 'O'), ('and', 'O'), ('1', 'O'), ('case', 'O'), ('with', 'O'), ('severe', 'O'), ('degree', 'O'), ('.', 'O'))"
Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .,"(('Only', 'O'), ('one', 'O'), ('case', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('withdrew', 'O'), ('from', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('severe', 'O'), ('dry', 'B'), ('mouth', 'I'), ('.', 'O'))"
Remifentanil pretreatment reduces myoclonus after etomidate .,"(('Remifentanil', 'O'), ('pretreatment', 'O'), ('reduces', 'O'), ('myoclonus', 'B'), ('after', 'O'), ('etomidate', 'O'), ('.', 'O'))"
STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .,"(('STUDY', 'O'), ('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('compare', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('remifentanil', 'O'), ('1', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('and', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('gender', 'O'), ('on', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('myoclonus', 'B'), ('after', 'O'), ('anesthesia', 'O'), ('induction', 'O'), ('with', 'O'), ('etomidate', 'O'), ('.', 'O'))"
"The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .","(('The', 'O'), ('grade', 'O'), ('of', 'O'), ('sedation', 'O'), ('(', 'O'), ('none', 'O'), (',', 'O'), ('mild', 'O'), (',', 'O'), ('moderate', 'O'), (',', 'O'), ('severe', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B'), (',', 'O'), ('pruritus', 'B'), (',', 'O'), ('and', 'O'), ('apnea', 'B'), ('were', 'O'), ('recorded', 'O'), ('after', 'O'), ('injection', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('.', 'O'))"
MAIN RESULTS : The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .,"(('MAIN', 'O'), ('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('myoclonus', 'B'), ('was', 'O'), ('significantly', 'O'), ('lower', 'O'), ('in', 'O'), ('the', 'O'), ('remifentanil', 'O'), ('group', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('(', 'O'), ('70', 'O'), ('%', 'O'), (')', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .","(('None', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('experienced', 'O'), ('sedation', 'O'), (',', 'O'), ('apnea', 'B'), (',', 'O'), ('nausea', 'B'), (',', 'O'), ('or', 'O'), ('pruritus', 'B'), ('after', 'O'), ('injection', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('.', 'O'))"
"In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .","(('In', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), (',', 'O'), ('male', 'O'), ('patients', 'O'), ('were', 'O'), ('associated', 'O'), ('with', 'O'), ('significantly', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('myoclonus', 'B'), ('after', 'O'), ('etomidate', 'O'), ('administration', 'O'), ('.', 'O'))"
"CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .","(('CONCLUSION', 'O'), (':', 'O'), ('Pretreatment', 'O'), ('with', 'O'), ('remifentanil', 'O'), ('1', 'O'), ('microg', 'O'), ('/', 'O'), ('kg', 'O'), ('reduced', 'O'), ('myoclonus', 'B'), ('after', 'O'), ('etomidate', 'O'), ('induction', 'O'), ('without', 'O'), ('side', 'O'), ('effects', 'O'), ('such', 'O'), ('as', 'O'), ('sedation', 'O'), (',', 'O'), ('apnea', 'B'), (',', 'O'), ('nausea', 'B'), (',', 'O'), ('or', 'O'), ('pruritus', 'B'), ('.', 'O'))"
Men experience increased incidence of myoclonus than women after etomidate administration .,"(('Men', 'O'), ('experience', 'O'), ('increased', 'O'), ('incidence', 'O'), ('of', 'O'), ('myoclonus', 'B'), ('than', 'O'), ('women', 'O'), ('after', 'O'), ('etomidate', 'O'), ('administration', 'O'), ('.', 'O'))"
"Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .","(('Although', 'O'), ('3', 'O'), (',', 'O'), ('4', 'O'), ('-', 'O'), ('methylenedioxymethamphetamine', 'O'), ('(', 'O'), ('MDMA', 'O'), ('or', 'O'), ('ecstasy', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('damage', 'O'), ('brain', 'O'), ('serotonin', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), (')', 'O'), ('neurons', 'O'), ('in', 'O'), ('animals', 'O'), ('and', 'O'), ('possibly', 'O'), ('humans', 'O'), (',', 'O'), ('little', 'O'), ('is', 'O'), ('known', 'O'), ('about', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('consequences', 'O'), ('of', 'O'), ('MDMA', 'O'), ('-', 'O'), ('induced', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('neurotoxic', 'B'), ('lesions', 'I'), ('on', 'O'), ('functions', 'O'), ('in', 'O'), ('which', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('is', 'O'), ('involved', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('cognitive', 'O'), ('function', 'O'), ('.', 'O'))"
"In contrast , no evidence of memory impairment was observed in moderate MDMA users .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('memory', 'B'), ('impairment', 'I'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('moderate', 'O'), ('MDMA', 'O'), ('users', 'O'), ('.', 'O'))"
"While the use of MDMA in quantities that may be considered "" moderate "" is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .","(('While', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('MDMA', 'O'), ('in', 'O'), ('quantities', 'O'), ('that', 'O'), ('may', 'O'), ('be', 'O'), ('considered', 'O'), ('""', 'O'), ('moderate', 'O'), ('""', 'O'), ('is', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('impaired', 'B'), ('memory', 'I'), ('functioning', 'I'), (',', 'O'), ('heavy', 'O'), ('use', 'O'), ('of', 'O'), ('MDMA', 'O'), ('use', 'O'), ('may', 'O'), ('lead', 'O'), ('to', 'O'), ('long', 'O'), ('lasting', 'O'), ('memory', 'B'), ('impairments', 'I'), ('.', 'O'))"
Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .,"(('Role', 'O'), ('of', 'O'), ('mangiferin', 'O'), ('on', 'O'), ('biochemical', 'O'), ('alterations', 'O'), ('and', 'O'), ('antioxidant', 'O'), ('status', 'O'), ('in', 'O'), ('isoproterenol', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .","(('(', 'O'), ('Anacardiaceae', 'O'), (')', 'O'), (',', 'O'), ('on', 'O'), ('isoproterenol', 'O'), ('(', 'O'), ('ISPH', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('(', 'O'), ('MI', 'B'), (')', 'O'), ('in', 'O'), ('rats', 'O'), ('through', 'O'), ('its', 'O'), ('antioxidative', 'O'), ('mechanism', 'O'), ('.', 'O'))"
"Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .","(('Subcutaneous', 'O'), ('injection', 'O'), ('of', 'O'), ('ISPH', 'O'), ('(', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), ('in', 'O'), ('1', 'O'), ('ml', 'O'), ('saline', 'O'), (')', 'O'), ('to', 'O'), ('rats', 'O'), ('for', 'O'), ('2', 'O'), ('consecutive', 'O'), ('days', 'O'), ('caused', 'O'), ('myocardial', 'B'), ('damage', 'I'), ('in', 'O'), ('rat', 'O'), ('heart', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('the', 'O'), ('increased', 'O'), ('activity', 'O'), ('of', 'O'), ('serum', 'O'), ('lactate', 'O'), ('dehydrogenase', 'O'), ('(', 'O'), ('LDH', 'O'), (')', 'O'), ('and', 'O'), ('creatine', 'O'), ('phosphokinase', 'O'), ('isoenzymes', 'O'), ('(', 'O'), ('CK', 'O'), ('-', 'O'), ('MB', 'O'), (')', 'O'), (',', 'O'), ('increased', 'O'), ('uric', 'O'), ('acid', 'O'), ('level', 'O'), ('and', 'O'), ('reduced', 'O'), ('plasma', 'O'), ('iron', 'O'), ('binding', 'O'), ('capacity', 'O'), ('.', 'O'))"
The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .,"(('The', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('mangiferin', 'O'), ('was', 'O'), ('analyzed', 'O'), ('by', 'O'), ('triphenyl', 'O'), ('tetrazolium', 'O'), ('chloride', 'O'), ('(', 'O'), ('TTC', 'O'), (')', 'O'), ('test', 'O'), ('used', 'O'), ('for', 'O'), ('macroscopic', 'O'), ('enzyme', 'O'), ('mapping', 'O'), ('assay', 'O'), ('of', 'O'), ('the', 'O'), ('ischemic', 'B'), ('myocardium', 'I'), ('.', 'O'))"
"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .","(('From', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('it', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('mangiferin', 'O'), ('exerts', 'O'), ('a', 'O'), ('beneficial', 'O'), ('effect', 'O'), ('against', 'O'), ('ISPH', 'O'), ('-', 'O'), ('induced', 'O'), ('MI', 'B'), ('due', 'O'), ('to', 'O'), ('its', 'O'), ('antioxidant', 'O'), ('potential', 'O'), (',', 'O'), ('which', 'O'), ('regulated', 'O'), ('the', 'O'), ('tissues', 'O'), ('defense', 'O'), ('system', 'O'), ('against', 'O'), ('cardiac', 'B'), ('damage', 'I'), ('.', 'O'))"
"Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .","(('Randomised', 'O'), ('clinical', 'O'), ('trials', 'O'), ('and', 'O'), ('observational', 'O'), ('studies', 'O'), ('have', 'O'), ('shown', 'O'), ('an', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('myocardial', 'B'), ('infarction', 'I'), (',', 'O'), ('stroke', 'B'), (',', 'O'), ('hypertension', 'B'), ('and', 'O'), ('heart', 'B'), ('failure', 'I'), ('during', 'O'), ('treatment', 'O'), ('with', 'O'), ('cyclooxygenase', 'O'), ('inhibitors', 'O'), ('.', 'O'))"
"Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .","(('Diagnostic', 'O'), ('markers', 'O'), ('such', 'O'), ('as', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('pro', 'O'), ('brain', 'O'), ('natriuretic', 'O'), ('peptide', 'O'), ('(', 'O'), ('NT', 'O'), ('-', 'O'), ('proBNP', 'O'), (')', 'O'), ('or', 'O'), ('high', 'O'), ('-', 'O'), ('sensitive', 'O'), ('C', 'O'), ('-', 'O'), ('reactive', 'O'), ('protein', 'O'), ('might', 'O'), ('help', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('identification', 'O'), ('of', 'O'), ('patients', 'O'), ('at', 'O'), ('risk', 'O'), (',', 'O'), ('thus', 'O'), ('avoiding', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('serious', 'O'), ('cardiovascular', 'B'), ('toxicity', 'I'), ('.', 'O'))"
Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .,"(('Pilocarpine', 'O'), ('seizures', 'B'), ('cause', 'O'), ('age', 'O'), ('-', 'O'), ('dependent', 'O'), ('impairment', 'B'), ('in', 'I'), ('auditory', 'I'), ('location', 'I'), ('discrimination', 'I'), ('.', 'O'))"
Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .,"(('Children', 'O'), ('who', 'O'), ('have', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('have', 'O'), ('continuous', 'O'), ('or', 'O'), ('rapidly', 'O'), ('repeating', 'O'), ('seizures', 'B'), ('that', 'O'), ('may', 'O'), ('be', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('and', 'O'), ('may', 'O'), ('cause', 'O'), ('life', 'O'), ('-', 'O'), ('long', 'O'), ('changes', 'O'), ('in', 'O'), ('brain', 'O'), ('and', 'O'), ('behavior', 'O'), ('.', 'O'))"
The extent to which status epilepticus causes deficits in auditory discrimination is unknown .,"(('The', 'O'), ('extent', 'O'), ('to', 'O'), ('which', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('causes', 'O'), ('deficits', 'B'), ('in', 'I'), ('auditory', 'I'), ('discrimination', 'I'), ('is', 'O'), ('unknown', 'O'), ('.', 'O'))"
A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .,"(('A', 'O'), ('naturalistic', 'O'), ('auditory', 'O'), ('location', 'O'), ('discrimination', 'O'), ('method', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('evaluate', 'O'), ('this', 'O'), ('question', 'O'), ('using', 'O'), ('an', 'O'), ('animal', 'O'), ('model', 'O'), ('of', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('.', 'O'))"
"Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .","(('Pilocarpine', 'O'), ('on', 'O'), ('either', 'O'), ('day', 'O'), ('induced', 'O'), ('status', 'B'), ('epilepticus', 'I'), (';', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('at', 'O'), ('P45', 'O'), ('resulted', 'O'), ('in', 'O'), ('CA3', 'O'), ('cell', 'O'), ('loss', 'O'), ('and', 'O'), ('spontaneous', 'O'), ('seizures', 'B'), (',', 'O'), ('whereas', 'O'), ('P20', 'O'), ('rats', 'O'), ('had', 'O'), ('no', 'O'), ('cell', 'O'), ('loss', 'O'), ('or', 'O'), ('spontaneous', 'O'), ('seizures', 'B'), ('.', 'O'))"
"In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .","(('In', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('(', 'O'), ('P20', 'O'), (')', 'O'), ('rats', 'O'), (',', 'O'), ('acquisition', 'O'), ('of', 'O'), ('the', 'O'), ('sound', 'O'), ('-', 'O'), ('source', 'O'), ('location', 'O'), ('discrimination', 'O'), ('was', 'O'), ('moderately', 'O'), ('impaired', 'O'), ('.', 'O'))"
Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .,"(('Status', 'B'), ('epilepticus', 'I'), ('(', 'O'), ('P45', 'O'), (')', 'O'), ('rats', 'O'), ('failed', 'O'), ('to', 'O'), ('acquire', 'O'), ('either', 'O'), ('sound', 'O'), ('-', 'O'), ('source', 'O'), ('location', 'O'), ('or', 'O'), ('sound', 'O'), ('-', 'O'), ('silence', 'O'), ('discriminations', 'O'), ('.', 'O'))"
"Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .","(('Status', 'B'), ('epilepticus', 'I'), ('in', 'O'), ('rat', 'O'), ('causes', 'O'), ('an', 'O'), ('age', 'O'), ('-', 'O'), ('dependent', 'O'), (',', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('impairment', 'B'), ('in', 'I'), ('auditory', 'I'), ('discrimination', 'I'), ('.', 'O'))"
This impairment may explain one cause of impaired auditory location discrimination in humans .,"(('This', 'O'), ('impairment', 'O'), ('may', 'O'), ('explain', 'O'), ('one', 'O'), ('cause', 'O'), ('of', 'O'), ('impaired', 'B'), ('auditory', 'I'), ('location', 'I'), ('discrimination', 'I'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .,"(('Nerve', 'O'), ('growth', 'O'), ('factor', 'O'), ('and', 'O'), ('prostaglandins', 'O'), ('in', 'O'), ('the', 'O'), ('urine', 'O'), ('of', 'O'), ('female', 'O'), ('patients', 'O'), ('with', 'O'), ('overactive', 'B'), ('bladder', 'I'), ('.', 'O'))"
Definition and management of anemia in patients infected with hepatitis C virus .,"(('Definition', 'O'), ('and', 'O'), ('management', 'O'), ('of', 'O'), ('anemia', 'B'), ('in', 'O'), ('patients', 'O'), ('infected', 'B'), ('with', 'I'), ('hepatitis', 'I'), ('C', 'I'), ('virus', 'I'), ('.', 'O'))"
"Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .","(('Chronic', 'B'), ('infection', 'I'), ('with', 'I'), ('hepatitis', 'I'), ('C', 'I'), ('virus', 'I'), ('(', 'O'), ('HCV', 'O'), (')', 'O'), ('can', 'O'), ('progress', 'O'), ('to', 'O'), ('cirrhosis', 'B'), (',', 'O'), ('hepatocellular', 'B'), ('carcinoma', 'I'), (',', 'O'), ('and', 'O'), ('end', 'B'), ('-', 'I'), ('stage', 'I'), ('liver', 'I'), ('disease', 'I'), ('.', 'O'))"
The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .,"(('The', 'O'), ('current', 'O'), ('best', 'O'), ('treatment', 'O'), ('for', 'O'), ('HCV', 'B'), ('infection', 'I'), ('is', 'O'), ('combination', 'O'), ('therapy', 'O'), ('with', 'O'), ('pegylated', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('.', 'O'))"
"Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .","(('Although', 'O'), ('this', 'O'), ('regimen', 'O'), ('produces', 'O'), ('sustained', 'O'), ('virologic', 'O'), ('responses', 'O'), ('(', 'O'), ('SVRs', 'O'), (')', 'O'), ('in', 'O'), ('approximately', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('it', 'O'), ('can', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('potentially', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('.', 'O'))"
"Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .","(('Hemoglobin', 'O'), ('concentrations', 'O'), ('decrease', 'O'), ('mainly', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('induced', 'O'), ('hemolysis', 'B'), (',', 'O'), ('and', 'O'), ('this', 'O'), ('anemia', 'B'), ('can', 'O'), ('be', 'O'), ('problematic', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('HCV', 'B'), ('infection', 'I'), (',', 'O'), ('especially', 'O'), ('those', 'O'), ('who', 'O'), ('have', 'O'), ('comorbid', 'O'), ('renal', 'B'), ('or', 'I'), ('cardiovascular', 'I'), ('disorders', 'I'), ('.', 'O'))"
"In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .","(('In', 'O'), ('general', 'O'), (',', 'O'), ('anemia', 'B'), ('can', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), (',', 'O'), ('and', 'O'), ('may', 'O'), ('have', 'O'), ('negative', 'O'), ('effects', 'O'), ('on', 'O'), ('cerebral', 'O'), ('function', 'O'), ('and', 'O'), ('quality', 'O'), ('of', 'O'), ('life', 'O'), ('.', 'O'))"
"Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .","(('Although', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('associated', 'O'), ('anemia', 'B'), ('can', 'O'), ('be', 'O'), ('reversed', 'O'), ('by', 'O'), ('dose', 'O'), ('reduction', 'O'), ('or', 'O'), ('discontinuation', 'O'), (',', 'O'), ('this', 'O'), ('approach', 'O'), ('compromises', 'O'), ('outcomes', 'O'), ('by', 'O'), ('significantly', 'O'), ('decreasing', 'O'), ('SVR', 'O'), ('rates', 'O'), ('.', 'O'))"
Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .,"(('Recombinant', 'O'), ('human', 'O'), ('erythropoietin', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('to', 'O'), ('manage', 'O'), ('ribavirin', 'O'), ('-', 'O'), ('associated', 'O'), ('anemia', 'B'), ('but', 'O'), ('has', 'O'), ('other', 'O'), ('potential', 'O'), ('disadvantages', 'O'), ('.', 'O'))"
"Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .","(('Viramidine', 'O'), (',', 'O'), ('a', 'O'), ('liver', 'O'), ('-', 'O'), ('targeting', 'O'), ('prodrug', 'O'), ('of', 'O'), ('ribavirin', 'O'), (',', 'O'), ('has', 'O'), ('the', 'O'), ('potential', 'O'), ('to', 'O'), ('maintain', 'O'), ('the', 'O'), ('virologic', 'O'), ('efficacy', 'O'), ('of', 'O'), ('ribavirin', 'O'), ('while', 'O'), ('decreasing', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('.', 'O'))"
This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .,"(('This', 'O'), ('study', 'O'), ('examined', 'O'), ('the', 'O'), ('utility', 'O'), ('of', 'O'), ('biometry', 'O'), ('for', 'O'), ('detecting', 'O'), ('alcohol', 'O'), ('-', 'O'), ('related', 'O'), ('fetal', 'O'), ('growth', 'B'), ('impairment', 'I'), ('.', 'O'))"
Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .,"(('Analyses', 'O'), ('of', 'O'), ('covariance', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('whether', 'O'), ('there', 'O'), ('were', 'O'), ('differences', 'O'), ('between', 'O'), ('groups', 'O'), ('after', 'O'), ('controlling', 'O'), ('for', 'O'), ('influences', 'O'), ('of', 'O'), ('gestational', 'O'), ('age', 'O'), ('and', 'O'), ('drug', 'B'), ('abuse', 'I'), ('.', 'O'))"
Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .,"(('Any', 'O'), ('alcohol', 'O'), ('consumption', 'O'), ('postpregnancy', 'O'), ('recognition', 'O'), ('among', 'O'), ('the', 'O'), ('heavy', 'O'), ('drinkers', 'O'), ('resulted', 'O'), ('in', 'O'), ('reduced', 'B'), ('cerebellar', 'I'), ('growth', 'I'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('decreased', 'B'), ('cranial', 'I'), ('to', 'I'), ('body', 'I'), ('growth', 'I'), ('in', 'O'), ('comparison', 'O'), ('with', 'O'), ('women', 'O'), ('who', 'O'), ('either', 'O'), ('quit', 'O'), ('drinking', 'O'), ('or', 'O'), ('who', 'O'), ('were', 'O'), ('nondrinkers', 'O'), ('.', 'O'))"
Ethambutol - associated optic neuropathy .,"(('Ethambutol', 'O'), ('-', 'O'), ('associated', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
"INTRODUCTION : Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .","(('INTRODUCTION', 'O'), (':', 'O'), ('Ethambutol', 'O'), ('is', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('tuberculosis', 'B'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('still', 'O'), ('prevalent', 'O'), ('in', 'O'), ('Southeast', 'O'), ('Asia', 'O'), (',', 'O'), ('and', 'O'), ('can', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('permanent', 'O'), ('visual', 'B'), ('loss', 'I'), ('.', 'O'))"
CLINICAL PICTURE : Three patients with ethambutol - associated toxic optic neuropathy are described .,"(('CLINICAL', 'O'), ('PICTURE', 'O'), (':', 'O'), ('Three', 'O'), ('patients', 'O'), ('with', 'O'), ('ethambutol', 'O'), ('-', 'O'), ('associated', 'O'), ('toxic', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
"All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .","(('All', 'O'), ('3', 'O'), ('patients', 'O'), ('had', 'O'), ('loss', 'B'), ('of', 'I'), ('central', 'I'), ('visual', 'I'), ('acuity', 'I'), (',', 'I'), ('colour', 'I'), ('vision', 'I'), ('(', 'I'), ('Ishihara', 'I'), (')', 'I'), ('and', 'I'), ('visual', 'I'), ('field', 'I'), ('.', 'O'))"
"The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .","(('The', 'O'), ('visual', 'B'), ('field', 'I'), ('loss', 'I'), ('had', 'O'), ('a', 'O'), ('bitemporal', 'O'), ('flavour', 'O'), (',', 'O'), ('suggesting', 'O'), ('involvement', 'O'), ('of', 'O'), ('the', 'O'), ('optic', 'O'), ('chiasm', 'O'), ('.', 'O'))"
OUTCOME : All 3 patients had some permanent loss of visual function .,"(('OUTCOME', 'O'), (':', 'O'), ('All', 'O'), ('3', 'O'), ('patients', 'O'), ('had', 'O'), ('some', 'O'), ('permanent', 'O'), ('loss', 'B'), ('of', 'I'), ('visual', 'I'), ('function', 'I'), ('.', 'O'))"
CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Ethambutol', 'O'), ('usage', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('permanent', 'O'), ('visual', 'B'), ('loss', 'I'), ('and', 'O'), ('should', 'O'), ('be', 'O'), ('avoided', 'O'), ('if', 'O'), ('possible', 'O'), ('or', 'O'), ('used', 'O'), ('with', 'O'), ('caution', 'O'), ('and', 'O'), ('proper', 'O'), ('ophthalmological', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('.', 'O'))"
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .,"(('Possible', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('related', 'O'), ('to', 'O'), ('concomitant', 'O'), ('treatment', 'O'), ('with', 'O'), ('paroxetine', 'O'), ('and', 'O'), ('alprazolam', 'O'), ('.', 'O'))"
"A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .","(('A', 'O'), ('74', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('depressive', 'B'), ('symptoms', 'I'), ('was', 'O'), ('admitted', 'O'), ('to', 'O'), ('a', 'O'), ('psychiatric', 'B'), ('hospital', 'O'), ('due', 'O'), ('to', 'O'), ('insomnia', 'B'), (',', 'O'), ('loss', 'B'), ('of', 'I'), ('appetite', 'I'), (',', 'O'), ('exhaustion', 'O'), (',', 'O'), ('and', 'O'), ('agitation', 'B'), ('.', 'O'))"
"On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .","(('On', 'O'), ('the', 'O'), ('10th', 'O'), ('day', 'O'), ('of', 'O'), ('paroxetine', 'O'), ('and', 'O'), ('alprazolam', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('exhibited', 'O'), ('marked', 'O'), ('psychomotor', 'B'), ('retardation', 'I'), (',', 'O'), ('disorientation', 'O'), (',', 'O'), ('and', 'O'), ('severe', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('with', 'O'), ('tremors', 'B'), ('.', 'O'))"
"The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe extrapyramidal symptoms .","(('The', 'O'), ('patient', 'O'), ('had', 'O'), ('a', 'O'), ('fever', 'B'), ('(', 'O'), ('38', 'O'), ('.', 'O'), ('2', 'O'), ('degrees', 'O'), ('C', 'O'), (')', 'O'), (',', 'O'), ('fluctuating', 'O'), ('blood', 'O'), ('pressure', 'O'), ('(', 'O'), ('between', 'O'), ('165', 'O'), ('/', 'O'), ('90', 'O'), ('and', 'O'), ('130', 'O'), ('/', 'O'), ('70', 'O'), ('mg', 'O'), ('mm', 'O'), ('Hg', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('severe', 'O'), ('extrapyramidal', 'B'), ('symptoms', 'I'), ('.', 'O'))"
"7 days later , the fever disappeared and the patient ' s serum CPK levels were normalized ( 175 IU / L ) .","(('7', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('the', 'O'), ('fever', 'B'), ('disappeared', 'O'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('serum', 'O'), ('CPK', 'O'), ('levels', 'O'), ('were', 'O'), ('normalized', 'O'), ('(', 'O'), ('175', 'O'), ('IU', 'O'), ('/', 'O'), ('L', 'O'), (')', 'O'), ('.', 'O'))"
"This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .","(('This', 'O'), ('patient', 'O'), ('presented', 'O'), ('with', 'O'), ('symptoms', 'O'), ('of', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('(', 'O'), ('NMS', 'B'), (')', 'O'), (',', 'O'), ('thus', 'O'), ('demonstrating', 'O'), ('that', 'O'), ('NMS', 'B'), ('-', 'O'), ('like', 'O'), ('symptoms', 'O'), ('can', 'O'), ('occur', 'O'), ('after', 'O'), ('combined', 'O'), ('paroxetine', 'O'), ('and', 'O'), ('alprazolam', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .","(('Several', 'O'), ('risk', 'O'), ('factors', 'O'), ('for', 'O'), ('NMS', 'B'), ('should', 'O'), ('be', 'O'), ('noted', 'O'), ('in', 'O'), ('elderly', 'O'), ('depressive', 'B'), ('patients', 'O'), ('whose', 'O'), ('symptoms', 'O'), ('often', 'O'), ('include', 'O'), ('dehydration', 'B'), (',', 'O'), ('agitation', 'B'), (',', 'O'), ('malnutrition', 'B'), (',', 'O'), ('and', 'O'), ('exhaustion', 'O'), ('.', 'O'))"
Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .,"(('Careful', 'O'), ('therapeutic', 'O'), ('intervention', 'O'), ('is', 'O'), ('necessary', 'O'), ('in', 'O'), ('cases', 'O'), ('involving', 'O'), ('elderly', 'O'), ('patients', 'O'), ('who', 'O'), ('suffer', 'O'), ('from', 'O'), ('depression', 'B'), ('.', 'O'))"
Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .,"(('Down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('transporter', 'O'), ('function', 'O'), ('induced', 'O'), ('by', 'O'), ('chronic', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('linking', 'O'), ('to', 'O'), ('the', 'O'), ('alteration', 'O'), ('of', 'O'), ('sensitivity', 'O'), ('of', 'O'), ('local', 'O'), ('-', 'O'), ('anesthetics', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('and', 'O'), ('the', 'O'), ('counteraction', 'O'), ('by', 'O'), ('co', 'O'), ('-', 'O'), ('administration', 'O'), ('with', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('.', 'O'))"
Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .,"(('Alterations', 'O'), ('of', 'O'), ('norepinephrine', 'O'), ('transporter', 'O'), ('(', 'O'), ('NET', 'O'), (')', 'O'), ('function', 'O'), ('by', 'O'), ('chronic', 'O'), ('inhibition', 'O'), ('of', 'O'), ('NET', 'O'), ('in', 'O'), ('relation', 'O'), ('to', 'O'), ('sensitization', 'O'), ('to', 'O'), ('seizures', 'B'), ('induce', 'O'), ('by', 'O'), ('cocaine', 'O'), ('and', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .,"(('Daily', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('appearance', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('and', 'O'), ('decreased', 'O'), ('that', 'O'), ('of', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .,"(('Co', 'O'), ('-', 'O'), ('administration', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('with', 'O'), ('desipramine', 'O'), ('reversed', 'O'), ('the', 'O'), ('changes', 'O'), ('of', 'O'), ('convulsive', 'B'), ('activity', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('and', 'O'), ('cocaine', 'O'), ('induced', 'O'), ('by', 'O'), ('repeated', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('.', 'O'))"
These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .,"(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('down', 'O'), ('-', 'O'), ('regulation', 'O'), ('of', 'O'), ('hippocampal', 'O'), ('NET', 'O'), ('induced', 'O'), ('by', 'O'), ('chronic', 'O'), ('administration', 'O'), ('of', 'O'), ('desipramine', 'O'), ('may', 'O'), ('be', 'O'), ('relevant', 'O'), ('to', 'O'), ('desipramine', 'O'), ('-', 'O'), ('induced', 'O'), ('sensitization', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('convulsions', 'B'), ('.', 'O'))"
Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .,"(('Desipramine', 'O'), ('-', 'O'), ('induced', 'O'), ('sensitization', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('seizures', 'B'), ('may', 'O'), ('have', 'O'), ('a', 'O'), ('mechanism', 'O'), ('distinct', 'O'), ('from', 'O'), ('kindling', 'O'), ('resulting', 'O'), ('from', 'O'), ('repeated', 'O'), ('administration', 'O'), ('of', 'O'), ('cocaine', 'O'), ('.', 'O'))"
Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .,"(('Atorvastatin', 'O'), ('prevented', 'O'), ('and', 'O'), ('reversed', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .","(('To', 'O'), ('assess', 'O'), ('the', 'O'), ('antioxidant', 'O'), ('effects', 'O'), ('of', 'O'), ('atorvastatin', 'O'), ('(', 'O'), ('atorva', 'O'), (')', 'O'), ('on', 'O'), ('dexamethasone', 'O'), ('(', 'O'), ('dex', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), (',', 'O'), ('60', 'O'), ('male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('treated', 'O'), ('with', 'O'), ('atorva', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), ('or', 'O'), ('tap', 'O'), ('water', 'O'), ('for', 'O'), ('15', 'O'), ('days', 'O'), ('.', 'O'))"
"Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .","(('Atorva', 'O'), ('reversed', 'O'), ('dex', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('(', 'O'), ('129', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mmHg', 'O'), (',', 'O'), ('vs', 'O'), ('.', 'O'), ('135', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('mmHg', 'O'), ('P', 'O'), (""'"", 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('decreased', 'O'), ('plasma', 'O'), ('superoxide', 'O'), ('(', 'O'), ('7931', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('392', 'O'), ('.', 'O'), ('8', 'O'), ('dex', 'O'), (',', 'O'), ('1187', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('441', 'O'), ('.', 'O'), ('2', 'O'), ('atorva', 'O'), ('+', 'O'), ('dex', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('.', 'O'))"
"Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .","(('Thus', 'O'), (',', 'O'), ('atorvastatin', 'O'), ('prevented', 'O'), ('and', 'O'), ('reversed', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .,"(('Peripheral', 'B'), ('neuropathy', 'I'), ('caused', 'O'), ('by', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('treatment', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('acute', 'B'), ('myeloid', 'I'), ('leukemia', 'I'), ('.', 'O'))"
"The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .","(('The', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('toxicity', 'B'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('is', 'O'), ('well', 'O'), ('recognized', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('toxicity', 'B'), ('of', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('in', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('has', 'O'), ('been', 'O'), ('infrequently', 'O'), ('reported', 'O'), ('.', 'O'))"
A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .,"(('A', 'O'), ('49', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('Japanese', 'O'), ('man', 'O'), ('was', 'O'), ('diagnosed', 'O'), ('with', 'O'), ('acute', 'B'), ('myeloid', 'I'), ('leukemia', 'I'), ('.', 'O'))"
"The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .","(('The', 'O'), ('first', 'O'), ('course', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('resulted', 'O'), ('in', 'O'), ('no', 'O'), ('unusual', 'O'), ('symptoms', 'O'), (',', 'O'), ('but', 'O'), ('on', 'O'), ('day', 'O'), ('21', 'O'), ('of', 'O'), ('the', 'O'), ('second', 'O'), ('course', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('complained', 'O'), ('of', 'O'), ('numbness', 'B'), ('in', 'O'), ('his', 'O'), ('right', 'O'), ('foot', 'O'), ('.', 'O'))"
Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .,"(('Electromyogram', 'O'), ('and', 'O'), ('nerve', 'O'), ('-', 'O'), ('conduction', 'O'), ('studies', 'O'), ('showed', 'O'), ('peripheral', 'B'), ('neuropathy', 'I'), ('in', 'O'), ('both', 'O'), ('peroneal', 'O'), ('nerves', 'O'), ('.', 'O'))"
"This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .","(('This', 'O'), ('neuropathy', 'B'), ('was', 'O'), ('gradually', 'O'), ('resolving', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('after', 'O'), ('the', 'O'), ('patient', 'O'), ('received', 'O'), ('allogeneic', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), (',', 'O'), ('the', 'O'), ('symptoms', 'O'), ('worsened', 'O'), (',', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('graft', 'B'), ('-', 'I'), ('versus', 'I'), ('-', 'I'), ('host', 'I'), ('disease', 'I'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('symptoms', 'O'), ('subsequently', 'O'), ('responded', 'O'), ('to', 'O'), ('methylprednisolone', 'O'), ('.', 'O'))"
"Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .","(('Although', 'O'), ('the', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('peripheral', 'B'), ('neuropathy', 'I'), ('are', 'O'), ('still', 'O'), ('unclear', 'O'), (',', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('cytosine', 'O'), ('arabinoside', 'O'), ('is', 'O'), ('a', 'O'), ('therapy', 'O'), ('that', 'O'), ('is', 'O'), ('potentially', 'O'), ('toxic', 'O'), ('to', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), (',', 'O'), ('and', 'O'), ('auto', 'O'), ('/', 'O'), ('alloimmunity', 'O'), ('may', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('these', 'O'), ('mechanisms', 'O'), ('.', 'O'))"
Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .,"(('Effect', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('tocopherol', 'O'), ('and', 'O'), ('deferoxamine', 'O'), ('on', 'O'), ('methamphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .,"(('Methamphetamine', 'O'), ('(', 'O'), ('MA', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('dopaminergic', 'O'), ('neurotoxicity', 'B'), ('is', 'O'), ('believed', 'O'), ('to', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('increased', 'O'), ('formation', 'O'), ('of', 'O'), ('free', 'O'), ('radicals', 'O'), ('.', 'O'))"
"This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .","(('This', 'O'), ('study', 'O'), ('examined', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('tocopherol', 'O'), ('(', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('scavenger', 'O'), ('of', 'O'), ('reactive', 'O'), ('oxygen', 'O'), ('species', 'O'), (',', 'O'), ('and', 'O'), ('deferoxamine', 'O'), ('(', 'O'), ('DFO', 'O'), (')', 'O'), (',', 'O'), ('an', 'O'), ('iron', 'O'), ('chelator', 'O'), (',', 'O'), ('on', 'O'), ('the', 'O'), ('MA', 'O'), ('-', 'O'), ('induced', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .,"(('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('and', 'O'), ('DFO', 'O'), ('attenuated', 'O'), ('the', 'O'), ('MA', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperthermia', 'B'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('the', 'O'), ('alterations', 'O'), ('in', 'O'), ('the', 'O'), ('locomotor', 'O'), ('activity', 'O'), ('.', 'O'))"
This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .,"(('This', 'O'), ('suggests', 'O'), ('that', 'O'), ('alpha', 'O'), ('-', 'O'), ('TC', 'O'), ('and', 'O'), ('DFO', 'O'), ('ameliorate', 'O'), ('the', 'O'), ('MA', 'O'), ('-', 'O'), ('induced', 'O'), ('neuronal', 'B'), ('damage', 'I'), ('by', 'O'), ('decreasing', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('.', 'O'))"
Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .,"(('Blockade', 'O'), ('of', 'O'), ('both', 'O'), ('D', 'O'), ('-', 'O'), ('1', 'O'), ('and', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('dopamine', 'O'), ('receptors', 'O'), ('may', 'O'), ('induce', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .,"(('The', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('dopamine', 'O'), ('antagonists', 'O'), ('has', 'O'), ('been', 'O'), ('tested', 'O'), ('and', 'O'), ('the', 'O'), ('possible', 'O'), ('dopamine', 'O'), ('subtypes', 'O'), ('involved', 'O'), ('in', 'O'), ('catalepsy', 'B'), ('was', 'O'), ('determined', 'O'), ('.', 'O'))"
"Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .","(('Dopamine', 'O'), ('antagonist', 'O'), ('fluphenazine', 'O'), (',', 'O'), ('D', 'O'), ('-', 'O'), ('1', 'O'), ('antagonist', 'O'), ('SCH', 'O'), ('23390', 'O'), ('or', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('antagonist', 'O'), ('sulpiride', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .,"(('Combination', 'O'), ('of', 'O'), ('SCH', 'O'), ('23390', 'O'), ('with', 'O'), ('sulpiride', 'O'), ('did', 'O'), ('not', 'O'), ('induce', 'O'), ('catalepsy', 'B'), ('potentiation', 'O'), ('.', 'O'))"
"D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .","(('D', 'O'), ('-', 'O'), ('1', 'O'), ('agonist', 'O'), ('SKF', 'O'), ('38393', 'O'), ('or', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('agonist', 'O'), ('quinpirole', 'O'), ('decreased', 'O'), ('the', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('fluphenazine', 'O'), (',', 'O'), ('SCH', 'O'), ('23390', 'O'), ('or', 'O'), ('sulpiride', 'O'), ('.', 'O'))"
Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .,"(('Combination', 'O'), ('of', 'O'), ('SKF', 'O'), ('38393', 'O'), ('with', 'O'), ('quinpirole', 'O'), ('did', 'O'), ('not', 'O'), ('cause', 'O'), ('potentiated', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('on', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('dopamine', 'O'), ('antagonists', 'O'), ('.', 'O'))"
"The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .","(('The', 'O'), ('data', 'O'), ('may', 'O'), ('indicate', 'O'), ('that', 'O'), ('although', 'O'), ('D', 'O'), ('-', 'O'), ('2', 'O'), ('receptor', 'O'), ('blockade', 'O'), ('is', 'O'), ('involved', 'O'), ('in', 'O'), ('catalepsy', 'B'), (',', 'O'), ('the', 'O'), ('D', 'O'), ('-', 'O'), ('1', 'O'), ('receptor', 'O'), ('may', 'O'), ('plan', 'O'), ('a', 'O'), ('role', 'O'), ('.', 'O'))"
Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .,"(('Sustained', 'O'), ('clinical', 'O'), ('improvement', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('decompensated', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('virus', 'O'), ('-', 'O'), ('related', 'O'), ('cirrhosis', 'B'), ('after', 'O'), ('treatment', 'O'), ('with', 'O'), ('lamivudine', 'O'), ('monotherapy', 'O'), ('.', 'O'))"
"Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .","(('Hepatitis', 'B'), ('B', 'I'), ('virus', 'I'), ('(', 'I'), ('HBV', 'I'), (')', 'I'), ('infection', 'I'), (',', 'O'), ('which', 'O'), ('causes', 'O'), ('liver', 'B'), ('cirrhosis', 'I'), ('and', 'O'), ('hepatocellular', 'B'), ('carcinoma', 'I'), (',', 'O'), ('remains', 'O'), ('a', 'O'), ('major', 'O'), ('health', 'O'), ('problem', 'O'), ('in', 'O'), ('Asian', 'O'), ('countries', 'O'), ('.', 'O'))"
"In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .","(('In', 'O'), ('this', 'O'), ('report', 'O'), (',', 'O'), ('we', 'O'), ('encountered', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('decompensated', 'O'), ('HBV', 'O'), ('-', 'O'), ('related', 'O'), ('cirrhosis', 'B'), ('who', 'O'), ('exhibited', 'O'), ('the', 'O'), ('dramatic', 'O'), ('improvements', 'O'), ('after', 'O'), ('antiviral', 'O'), ('therapy', 'O'), ('.', 'O'))"
"The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .","(('The', 'O'), ('administration', 'O'), ('of', 'O'), ('lamivudine', 'O'), ('to', 'O'), ('patients', 'O'), ('with', 'O'), ('HBV', 'O'), ('-', 'O'), ('related', 'O'), ('cirrhosis', 'B'), (',', 'O'), ('like', 'O'), ('our', 'O'), ('present', 'O'), ('case', 'O'), (',', 'O'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('as', 'O'), ('an', 'O'), ('initial', 'O'), ('medical', 'O'), ('therapeutic', 'O'), ('option', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('countries', 'O'), ('where', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('is', 'O'), ('not', 'O'), ('reliably', 'O'), ('available', 'O'), ('.', 'O'))"
Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .,"(('Antiarrhythmic', 'O'), ('effects', 'O'), ('of', 'O'), ('optical', 'O'), ('isomers', 'O'), ('of', 'O'), ('cibenzoline', 'O'), ('on', 'O'), ('canine', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .,"(('Antiarrhythmic', 'O'), ('effects', 'O'), ('of', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('and', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('were', 'O'), ('examined', 'O'), ('using', 'O'), ('two', 'O'), ('canine', 'O'), ('ventricular', 'B'), ('arrhythmia', 'I'), ('models', 'O'), ('.', 'O'))"
"Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .","(('Digitalis', 'O'), ('arrhythmia', 'B'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('suppressed', 'O'), ('by', 'O'), ('Na', 'O'), ('channel', 'O'), ('blockers', 'O'), (',', 'O'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('intermittent', 'O'), ('intravenous', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('injection', 'O'), ('of', 'O'), ('ouabain', 'O'), ('in', 'O'), ('pentobarbital', 'O'), ('-', 'O'), ('anesthetized', 'O'), ('dogs', 'O'), ('.', 'O'))"
"Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .","(('Adrenaline', 'B'), ('arrhythmia', 'I'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('suppressed', 'O'), ('by', 'O'), ('Ca', 'O'), ('channel', 'O'), ('blockers', 'O'), (',', 'O'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('adrenaline', 'O'), ('infusion', 'O'), ('in', 'O'), ('halothane', 'O'), ('-', 'O'), ('anesthetized', 'O'), ('dogs', 'O'), ('.', 'O'))"
"Ten and 5 mg / kg i . v . ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .","(('Ten', 'O'), ('and', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('suppressed', 'O'), ('digitalis', 'O'), ('-', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmias', 'B'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .","(('The', 'O'), ('minimum', 'O'), ('effective', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('of', 'O'), ('(', 'O'), ('+', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('for', 'O'), ('digitalis', 'O'), ('-', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmias', 'B'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('micrograms', 'O'), ('/', 'O'), ('ml', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SD', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), ('.', 'O'))"
"A lower dose of 1 mg / kg i . v . of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .","(('A', 'O'), ('lower', 'O'), ('dose', 'O'), ('of', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('of', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('suppressed', 'O'), ('the', 'O'), ('digitalis', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmia', 'B'), (',', 'O'), ('whereas', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('was', 'O'), ('needed', 'O'), ('to', 'O'), ('suppress', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmias', 'B'), ('.', 'O'))"
"The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .","(('The', 'O'), ('minimum', 'O'), ('effective', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('of', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('cibenzoline', 'O'), ('for', 'O'), ('digitalis', 'O'), ('-', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmia', 'B'), ('were', 'O'), ('0', 'O'), ('.', 'O'), ('06', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('04', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('micrograms', 'O'), ('/', 'O'), ('ml', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SD', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('6', 'O'), (')', 'O'), ('.', 'O'))"
AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .,"(('AIM', 'O'), (':', 'O'), ('Widespread', 'O'), ('use', 'O'), ('of', 'O'), ('mannitol', 'O'), ('to', 'O'), ('reduce', 'O'), ('brain', 'B'), ('edema', 'I'), ('and', 'O'), ('lower', 'O'), ('elevated', 'B'), ('ICP', 'I'), ('in', 'O'), ('brain', 'B'), ('tumor', 'I'), ('patients', 'O'), ('continues', 'O'), ('to', 'O'), ('be', 'O'), ('afflicted', 'O'), ('by', 'O'), ('the', 'O'), ('so', 'O'), ('-', 'O'), ('called', 'O'), ('rebound', 'O'), ('phenomenon', 'O'), ('.', 'O'))"
As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .,"(('As', 'O'), ('a', 'O'), ('contribution', 'O'), ('to', 'O'), ('this', 'O'), ('issue', 'O'), ('we', 'O'), ('decided', 'O'), ('to', 'O'), ('research', 'O'), ('the', 'O'), ('possible', 'O'), ('passage', 'O'), ('of', 'O'), ('mannitol', 'O'), ('into', 'O'), ('the', 'O'), ('brain', 'O'), ('after', 'O'), ('administration', 'O'), ('to', 'O'), ('21', 'O'), ('brain', 'B'), ('tumor', 'I'), ('patients', 'O'), ('.', 'O'))"
"METHODS : Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .","(('METHODS', 'O'), (':', 'O'), ('Mannitol', 'O'), ('(', 'O'), ('18', 'O'), ('%', 'O'), ('solution', 'O'), (';', 'O'), ('1', 'O'), ('g', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('was', 'O'), ('administered', 'O'), ('as', 'O'), ('a', 'O'), ('bolus', 'O'), ('to', 'O'), ('patients', 'O'), ('(', 'O'), ('ten', 'O'), ('had', 'O'), ('malignant', 'B'), ('glioma', 'I'), (',', 'O'), ('seven', 'O'), ('brain', 'O'), ('metastases', 'B'), ('and', 'O'), ('four', 'O'), ('meningioma', 'B'), (')', 'O'), ('about', 'O'), ('30', 'O'), ('minutes', 'O'), ('before', 'O'), ('craniotomy', 'O'), ('.', 'O'))"
"CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('of', 'O'), ('our', 'O'), ('study', 'O'), ('show', 'O'), ('that', 'O'), ('even', 'O'), ('after', 'O'), ('a', 'O'), ('single', 'O'), ('bolus', 'O'), (',', 'O'), ('mannitol', 'O'), ('may', 'O'), ('leak', 'O'), ('through', 'O'), ('the', 'O'), ('altered', 'O'), ('BBB', 'O'), ('near', 'O'), ('gliomas', 'B'), (',', 'O'), ('reversing', 'O'), ('the', 'O'), ('initial', 'O'), ('plasma', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('blood', 'O'), ('osmotic', 'O'), ('gradient', 'O'), (',', 'O'), ('aggravating', 'O'), ('peritumoral', 'O'), ('edema', 'B'), ('and', 'O'), ('promoting', 'O'), ('rebound', 'O'), ('of', 'O'), ('ICP', 'O'), ('.', 'O'))"
Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .,"(('Placebo', 'O'), ('-', 'O'), ('level', 'O'), ('incidence', 'O'), ('of', 'O'), ('extrapyramidal', 'B'), ('symptoms', 'I'), ('(', 'O'), ('EPS', 'B'), (')', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('in', 'O'), ('controlled', 'O'), ('studies', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('bipolar', 'B'), ('mania', 'I'), ('.', 'O'))"
"OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('extrapyramidal', 'B'), ('symptoms', 'I'), ('(', 'O'), ('EPS', 'B'), (')', 'O'), (',', 'O'), ('including', 'O'), ('akathisia', 'B'), (',', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('bipolar', 'B'), ('mania', 'I'), ('.', 'O'))"
"Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .","(('Extrapyramidal', 'B'), ('symptoms', 'I'), ('were', 'O'), ('evaluated', 'O'), ('using', 'O'), ('the', 'O'), ('Simpson', 'O'), ('-', 'O'), ('Angus', 'O'), ('Scale', 'O'), ('(', 'O'), ('SAS', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('Barnes', 'O'), ('Akathisia', 'O'), ('Rating', 'O'), ('Scale', 'O'), ('(', 'O'), ('BARS', 'O'), (')', 'O'), (',', 'O'), ('adverse', 'O'), ('event', 'O'), ('reports', 'O'), ('and', 'O'), ('anticholinergic', 'O'), ('drug', 'O'), ('usage', 'O'), ('.', 'O'))"
"RESULTS : The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('EPS', 'B'), ('-', 'O'), ('related', 'O'), ('adverse', 'O'), ('events', 'O'), (',', 'O'), ('including', 'O'), ('akathisia', 'B'), (',', 'O'), ('was', 'O'), ('no', 'O'), ('different', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('monotherapy', 'O'), ('(', 'O'), ('12', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('with', 'O'), ('placebo', 'O'), ('(', 'O'), ('13', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .","(('Similarly', 'O'), (',', 'O'), ('EPS', 'B'), ('-', 'O'), ('related', 'O'), ('adverse', 'O'), ('events', 'O'), ('with', 'O'), ('QTP', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), ('(', 'O'), ('21', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('were', 'O'), ('no', 'O'), ('different', 'O'), ('than', 'O'), ('with', 'O'), ('PBO', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), ('(', 'O'), ('19', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .","(('Adverse', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('EPS', 'B'), ('occurred', 'O'), ('in', 'O'), ('59', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('haloperidol', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('99', 'O'), (')', 'O'), ('monotherapy', 'O'), (',', 'O'), ('whereas', 'O'), ('26', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('lithium', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('98', 'O'), (')', 'O'), ('monotherapy', 'O'), ('experienced', 'O'), ('adverse', 'O'), ('events', 'O'), ('related', 'O'), ('to', 'O'), ('EPS', 'B'), ('.', 'O'))"
"The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('akathisia', 'B'), ('was', 'O'), ('low', 'O'), ('and', 'O'), ('similar', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('monotherapy', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('placebo', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('with', 'O'), ('QTP', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('PBO', 'O'), ('+', 'O'), ('Li', 'O'), ('/', 'O'), ('DVP', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .","(('Lithium', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('significantly', 'O'), ('higher', 'O'), ('incidence', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('of', 'O'), ('tremor', 'B'), ('(', 'O'), ('18', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('quetiapine', 'O'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (';', 'O'), ('cerebellar', 'O'), ('tremor', 'B'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('a', 'O'), ('known', 'O'), ('adverse', 'O'), ('effect', 'O'), ('of', 'O'), ('lithium', 'O'), (',', 'O'), ('may', 'O'), ('have', 'O'), ('contributed', 'O'), ('to', 'O'), ('the', 'O'), ('elevated', 'O'), ('rate', 'O'), ('of', 'O'), ('tremor', 'B'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .","(('Haloperidol', 'O'), ('induced', 'O'), ('a', 'O'), ('significantly', 'O'), ('higher', 'O'), ('incidence', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('of', 'O'), ('akathisia', 'B'), ('(', 'O'), ('33', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('versus', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('tremor', 'B'), ('(', 'O'), ('30', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('versus', 'O'), ('7', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('extrapyramidal', 'B'), ('syndrome', 'I'), ('(', 'O'), ('35', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('versus', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('quetiapine', 'O'), ('.', 'O'))"
"CONCLUSIONS : In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('bipolar', 'B'), ('mania', 'I'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('EPS', 'B'), (',', 'O'), ('including', 'O'), ('akathisia', 'B'), (',', 'O'), ('with', 'O'), ('quetiapine', 'O'), ('therapy', 'O'), ('is', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('with', 'O'), ('placebo', 'O'), ('.', 'O'))"
Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .,"(('Intravenous', 'O'), ('phenytoin', 'O'), ('was', 'O'), ('administered', 'O'), ('during', 'O'), ('the', 'O'), ('later', 'O'), ('part', 'O'), ('of', 'O'), ('the', 'O'), ('surgery', 'O'), ('for', 'O'), ('seizure', 'B'), ('prophylaxis', 'O'), ('.', 'O'))"
"Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .","(('Following', 'O'), ('phenytoin', 'O'), ('administration', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('developed', 'O'), ('acute', 'O'), ('severe', 'O'), ('bradycardia', 'B'), (',', 'O'), ('refractory', 'O'), ('to', 'O'), ('atropine', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('.', 'O'))"
The cardiac depressant actions of phenytoin and hypothermia can be additive .,"(('The', 'O'), ('cardiac', 'O'), ('depressant', 'O'), ('actions', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('and', 'O'), ('hypothermia', 'B'), ('can', 'O'), ('be', 'O'), ('additive', 'O'), ('.', 'O'))"
Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .,"(('Administration', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('hypothermia', 'B'), ('may', 'O'), ('lead', 'O'), ('to', 'O'), ('an', 'O'), ('adverse', 'O'), ('cardiac', 'O'), ('event', 'O'), ('in', 'O'), ('children', 'O'), ('.', 'O'))"
Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .,"(('Valproate', 'O'), ('-', 'O'), ('induced', 'O'), ('chorea', 'B'), ('and', 'O'), ('encephalopathy', 'B'), ('in', 'O'), ('atypical', 'O'), ('nonketotic', 'B'), ('hyperglycinemia', 'I'), ('.', 'O'))"
Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .,"(('Nonketotic', 'B'), ('hyperglycinemia', 'I'), ('is', 'O'), ('a', 'O'), ('disorder', 'B'), ('of', 'I'), ('amino', 'I'), ('acid', 'I'), ('metabolism', 'I'), ('in', 'O'), ('which', 'O'), ('a', 'O'), ('defect', 'O'), ('in', 'O'), ('the', 'O'), ('glycine', 'O'), ('cleavage', 'O'), ('system', 'O'), ('leads', 'O'), ('to', 'O'), ('an', 'O'), ('accumulation', 'O'), ('of', 'O'), ('glycine', 'O'), ('in', 'O'), ('the', 'O'), ('brain', 'O'), ('and', 'O'), ('other', 'O'), ('body', 'O'), ('compartments', 'O'), ('.', 'O'))"
"In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .","(('In', 'O'), ('the', 'O'), ('classical', 'O'), ('form', 'O'), ('it', 'O'), ('presents', 'O'), ('as', 'O'), ('neonatal', 'O'), ('apnea', 'B'), (',', 'O'), ('intractable', 'O'), ('seizures', 'B'), (',', 'O'), ('and', 'O'), ('hypotonia', 'B'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('significant', 'O'), ('psychomotor', 'B'), ('retardation', 'I'), ('.', 'O'))"
"This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .","(('This', 'O'), ('report', 'O'), ('describes', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('mild', 'O'), ('language', 'B'), ('delay', 'I'), ('and', 'O'), ('mental', 'B'), ('retardation', 'I'), (',', 'O'), ('who', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('nonketotic', 'B'), ('hyperglycinemia', 'I'), ('following', 'O'), ('her', 'O'), ('presentation', 'O'), ('with', 'O'), ('acute', 'O'), ('encephalopathy', 'B'), ('and', 'O'), ('chorea', 'B'), ('shortly', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('valproate', 'O'), ('therapy', 'O'), ('.', 'O'))"
Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .,"(('Delayed', 'O'), ('institution', 'O'), ('of', 'O'), ('hypertension', 'B'), ('during', 'O'), ('focal', 'O'), ('cerebral', 'B'), ('ischemia', 'I'), (':', 'O'), ('effect', 'O'), ('on', 'O'), ('brain', 'B'), ('edema', 'I'), ('.', 'O'))"
The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('instituted', 'O'), ('after', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('h', 'O'), ('delay', 'O'), ('following', 'O'), ('middle', 'B'), ('cerebral', 'I'), ('artery', 'I'), ('occlusion', 'I'), ('(', 'O'), ('MCAO', 'B'), (')', 'O'), ('on', 'O'), ('brain', 'B'), ('edema', 'I'), ('formation', 'O'), ('and', 'O'), ('histochemical', 'O'), ('injury', 'O'), ('was', 'O'), ('studied', 'O'), ('.', 'O'))"
"Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .","(('Under', 'O'), ('isoflurane', 'O'), ('anesthesia', 'O'), (',', 'O'), ('the', 'O'), ('MCA', 'O'), ('of', 'O'), ('14', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('was', 'O'), ('occluded', 'O'), ('.', 'O'))"
"In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .","(('In', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('group', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('7', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('MAP', 'O'), ('was', 'O'), ('elevated', 'O'), ('by', 'O'), ('25', 'O'), ('-', 'O'), ('30', 'O'), ('mm', 'O'), ('Hg', 'O'), ('beginning', 'O'), ('2', 'O'), ('h', 'O'), ('after', 'O'), ('MCAO', 'B'), ('.', 'O'))"
The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .,"(('The', 'O'), ('brains', 'O'), ('were', 'O'), ('sectioned', 'O'), ('along', 'O'), ('coronal', 'O'), ('planes', 'O'), ('spanning', 'O'), ('the', 'O'), ('distribution', 'O'), ('of', 'O'), ('ischemia', 'B'), ('produced', 'O'), ('by', 'O'), ('MCAO', 'B'), ('.', 'O'))"
Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .,"(('Specific', 'O'), ('gravity', 'O'), ('(', 'O'), ('SG', 'O'), (')', 'O'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('the', 'O'), ('subcortex', 'O'), ('and', 'O'), ('in', 'O'), ('two', 'O'), ('sites', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('(', 'O'), ('core', 'O'), ('and', 'O'), ('periphery', 'O'), ('of', 'O'), ('the', 'O'), ('ischemic', 'B'), ('territory', 'O'), (')', 'O'), ('.', 'O'))"
"The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .","(('The', 'O'), ('extent', 'O'), ('of', 'O'), ('neuronal', 'B'), ('injury', 'I'), ('was', 'O'), ('determined', 'O'), ('by', 'O'), ('2', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('triphenyltetrazolium', 'O'), ('staining', 'O'), ('.', 'O'))"
"In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .","(('In', 'O'), ('the', 'O'), ('ischemic', 'B'), ('core', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('difference', 'O'), ('in', 'O'), ('SG', 'O'), ('in', 'O'), ('the', 'O'), ('subcortex', 'O'), ('and', 'O'), ('cortex', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
"In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / - 0 . 001 vs 1 . 039 + / - 0 . 001 , P less than 0 . 05 ) .","(('In', 'O'), ('the', 'O'), ('periphery', 'O'), ('of', 'O'), ('the', 'O'), ('ischemic', 'B'), ('territory', 'O'), (',', 'O'), ('SG', 'O'), ('in', 'O'), ('the', 'O'), ('cortex', 'O'), ('was', 'O'), ('greater', 'O'), ('(', 'O'), ('less', 'O'), ('edema', 'B'), ('accumulation', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('group', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('041', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), ('vs', 'O'), ('1', 'O'), ('.', 'O'), ('039', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (',', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .","(('The', 'O'), ('area', 'O'), ('of', 'O'), ('histochemical', 'O'), ('injury', 'O'), ('(', 'O'), ('as', 'O'), ('a', 'O'), ('percent', 'O'), ('of', 'O'), ('the', 'O'), ('cross', 'O'), ('-', 'O'), ('sectional', 'O'), ('area', 'O'), ('of', 'O'), ('the', 'O'), ('hemisphere', 'O'), (')', 'O'), ('was', 'O'), ('less', 'O'), ('in', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('group', 'O'), ('(', 'O'), ('33', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('%', 'O'), ('vs', 'O'), ('21', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('%', 'O'), (',', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .","(('The', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('phenylephrine', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('instituted', 'O'), ('2', 'O'), ('h', 'O'), ('after', 'O'), ('MCAO', 'B'), ('does', 'O'), ('not', 'O'), ('aggravate', 'O'), ('edema', 'B'), ('in', 'O'), ('the', 'O'), ('ischemic', 'B'), ('core', 'O'), (',', 'O'), ('that', 'O'), ('it', 'O'), ('improves', 'O'), ('edema', 'B'), ('in', 'O'), ('the', 'O'), ('periphery', 'O'), ('of', 'O'), ('the', 'O'), ('ischemic', 'B'), ('territory', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('it', 'O'), ('reduces', 'O'), ('the', 'O'), ('area', 'O'), ('of', 'O'), ('histochemical', 'O'), ('neuronal', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
"Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .","(('Behavioral', 'O'), ('measures', 'O'), ('included', 'O'), ('locomotion', 'O'), (',', 'O'), ('irritability', 'B'), (',', 'O'), ('copulation', 'O'), (',', 'O'), ('partner', 'O'), ('preference', 'O'), (',', 'O'), ('and', 'O'), ('aggression', 'B'), ('.', 'O'))"
"Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .","(('Animals', 'O'), ('were', 'O'), ('tested', 'O'), ('for', 'O'), ('aggression', 'B'), ('in', 'O'), ('their', 'O'), ('home', 'O'), ('cage', 'O'), (',', 'O'), ('both', 'O'), ('with', 'O'), ('and', 'O'), ('without', 'O'), ('physical', 'O'), ('provocation', 'O'), ('(', 'O'), ('mild', 'O'), ('tail', 'O'), ('pinch', 'O'), (')', 'O'), ('.', 'O'))"
"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .","(('Chronic', 'O'), ('exposure', 'O'), ('to', 'O'), ('PCPA', 'O'), ('alone', 'O'), ('significantly', 'O'), ('decreased', 'O'), ('locomotor', 'O'), ('activity', 'O'), ('and', 'O'), ('increased', 'O'), ('irritability', 'B'), ('but', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('sexual', 'O'), ('behavior', 'O'), (',', 'O'), ('partner', 'O'), ('preference', 'O'), (',', 'O'), ('or', 'O'), ('aggression', 'B'), ('.', 'O'))"
"T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .","(('T', 'O'), ('alone', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('locomotion', 'O'), (',', 'O'), ('irritability', 'B'), (',', 'O'), ('or', 'O'), ('sexual', 'O'), ('behavior', 'O'), ('but', 'O'), ('increased', 'O'), ('partner', 'O'), ('preference', 'O'), ('and', 'O'), ('aggression', 'B'), ('.', 'O'))"
"Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .","(('Based', 'O'), ('on', 'O'), ('these', 'O'), ('data', 'O'), (',', 'O'), ('it', 'O'), ('can', 'O'), ('be', 'O'), ('speculated', 'O'), ('that', 'O'), ('pubertal', 'O'), ('AAS', 'O'), ('users', 'O'), ('with', 'O'), ('low', 'O'), ('central', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('may', 'O'), ('be', 'O'), ('especially', 'O'), ('prone', 'O'), ('to', 'O'), ('exhibit', 'O'), ('aggressive', 'B'), ('behavior', 'I'), ('.', 'O'))"
"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .","(('Earlier', 'O'), ('studies', 'O'), ('have', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('antagonism', 'O'), ('of', 'O'), ('sigma1', 'O'), ('receptors', 'O'), ('attenuates', 'O'), ('the', 'O'), ('convulsive', 'B'), (',', 'O'), ('lethal', 'O'), (',', 'O'), ('locomotor', 'O'), ('stimulatory', 'O'), ('and', 'O'), ('rewarding', 'O'), ('actions', 'O'), ('of', 'O'), ('cocaine', 'O'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .","(('In', 'O'), ('behavioral', 'O'), ('studies', 'O'), (',', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('Swiss', 'O'), ('Webster', 'O'), ('mice', 'O'), ('with', 'O'), ('UMB24', 'O'), ('or', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('SM', 'O'), ('21', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('and', 'O'), ('locomotor', 'O'), ('activity', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('lethality', 'O'), ('.', 'O'))"
Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .,"(('Cardiac', 'B'), ('arrest', 'I'), ('in', 'O'), ('a', 'O'), ('child', 'O'), ('with', 'O'), ('cerebral', 'B'), ('palsy', 'I'), ('undergoing', 'O'), ('sevoflurane', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), ('after', 'O'), ('preoperative', 'O'), ('clonidine', 'O'), ('.', 'O'))"
"We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .","(('We', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('5', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('child', 'O'), ('with', 'O'), ('cerebral', 'B'), ('palsy', 'I'), ('and', 'O'), ('seizure', 'B'), ('disorder', 'I'), (',', 'O'), ('receiving', 'O'), ('clonidine', 'O'), ('for', 'O'), ('restlessness', 'B'), (',', 'O'), ('who', 'O'), ('presented', 'O'), ('for', 'O'), ('placement', 'O'), ('of', 'O'), ('a', 'O'), ('baclofen', 'O'), ('pump', 'O'), ('.', 'O'))"
"Without the knowledge of the medical personnel , the patient ' s mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .","(('Without', 'O'), ('the', 'O'), ('knowledge', 'O'), ('of', 'O'), ('the', 'O'), ('medical', 'O'), ('personnel', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('mother', 'O'), ('administered', 'O'), ('three', 'O'), ('doses', 'O'), ('of', 'O'), ('clonidine', 'O'), ('during', 'O'), ('the', 'O'), ('evening', 'O'), ('before', 'O'), ('and', 'O'), ('morning', 'O'), ('of', 'O'), ('surgery', 'O'), ('to', 'O'), ('reduce', 'O'), ('anxiety', 'B'), ('.', 'O'))"
"During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .","(('During', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('developed', 'O'), ('bradycardia', 'B'), ('and', 'O'), ('hypotension', 'B'), ('requiring', 'O'), ('cardiac', 'O'), ('resuscitation', 'O'), ('.', 'O'))"
There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .,"(('There', 'O'), ('are', 'O'), ('no', 'O'), ('previous', 'O'), ('reports', 'O'), ('of', 'O'), ('clonidine', 'O'), ('-', 'O'), ('associated', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('in', 'O'), ('a', 'O'), ('child', 'O'), ('undergoing', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .,"(('Angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('(', 'O'), ('ACE', 'O'), (')', 'O'), ('inhibitor', 'O'), ('-', 'O'), ('associated', 'O'), ('angioedema', 'B'), ('of', 'O'), ('the', 'O'), ('stomach', 'O'), ('and', 'O'), ('small', 'O'), ('intestine', 'O'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .","(('This', 'O'), ('is', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('on', 'O'), ('a', 'O'), ('45', 'O'), ('-', 'O'), ('year', 'O'), ('old', 'O'), ('African', 'O'), ('-', 'O'), ('American', 'O'), ('female', 'O'), ('with', 'O'), ('newly', 'O'), ('diagnosed', 'O'), ('hypertension', 'B'), (',', 'O'), ('who', 'O'), ('was', 'O'), ('started', 'O'), ('on', 'O'), ('a', 'O'), ('combination', 'O'), ('pill', 'O'), ('of', 'O'), ('amlodipine', 'O'), ('/', 'O'), ('benazapril', 'O'), ('10', 'O'), ('/', 'O'), ('5', 'O'), ('mg', 'O'), ('.', 'O'))"
"The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .","(('The', 'O'), ('very', 'O'), ('next', 'O'), ('day', 'O'), (',', 'O'), ('she', 'O'), ('presented', 'O'), ('at', 'O'), ('the', 'O'), ('emergency', 'O'), ('room', 'O'), ('(', 'O'), ('ER', 'O'), (')', 'O'), ('with', 'O'), ('abdominal', 'B'), ('pain', 'I'), (',', 'O'), ('nausea', 'B'), ('and', 'O'), ('vomiting', 'B'), ('.', 'O'))"
"Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .","(('Angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('inhibitor', 'O'), ('(', 'O'), ('ACEI', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('angioedema', 'B'), ('was', 'O'), ('suspected', 'O'), (',', 'O'), ('and', 'O'), ('anti', 'O'), ('-', 'O'), ('hypertensive', 'B'), ('medications', 'O'), ('were', 'O'), ('discontinued', 'O'), ('.', 'O'))"
"Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .","(('Her', 'O'), ('symptoms', 'O'), ('improved', 'O'), ('within', 'O'), ('the', 'O'), ('next', 'O'), ('24', 'O'), ('hours', 'O'), (',', 'O'), ('and', 'O'), ('repeat', 'O'), ('CT', 'O'), ('after', 'O'), ('72', 'O'), ('hours', 'O'), ('revealed', 'O'), ('marked', 'O'), ('improvement', 'O'), ('in', 'O'), ('stomach', 'O'), ('and', 'O'), ('small', 'O'), ('bowel', 'O'), ('thickening', 'O'), ('and', 'O'), ('resolution', 'O'), ('of', 'O'), ('ascites', 'B'), ('.', 'O'))"
"The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .","(('The', 'O'), ('recognition', 'O'), ('of', 'O'), ('angiotensin', 'O'), ('-', 'O'), ('converting', 'O'), ('enzyme', 'O'), ('(', 'O'), ('ACE', 'O'), (')', 'O'), ('and', 'O'), ('angiotensin', 'O'), ('receptor', 'O'), ('blocker', 'O'), ('(', 'O'), ('ARB', 'O'), (')', 'O'), ('intestinal', 'B'), ('angioedema', 'I'), ('constitutes', 'O'), ('a', 'O'), ('challenge', 'O'), ('to', 'O'), ('primary', 'O'), ('care', 'O'), ('physicians', 'O'), (',', 'O'), ('internists', 'O'), (',', 'O'), ('emergency', 'O'), ('room', 'O'), ('personal', 'O'), ('and', 'O'), ('surgeons', 'O'), ('.', 'O'))"
Carbamazepine - induced cardiac dysfunction .,"(('Carbamazepine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
"A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .","(('A', 'O'), ('patient', 'O'), ('with', 'O'), ('sinus', 'O'), ('bradycardia', 'B'), ('and', 'O'), ('atrioventricular', 'B'), ('block', 'I'), (',', 'O'), ('induced', 'O'), ('by', 'O'), ('carbamazepine', 'O'), (',', 'O'), ('prompted', 'O'), ('an', 'O'), ('extensive', 'O'), ('literature', 'O'), ('review', 'O'), ('of', 'O'), ('all', 'O'), ('previously', 'O'), ('reported', 'O'), ('cases', 'O'), ('.', 'O'))"
"From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .","(('From', 'O'), ('the', 'O'), ('analysis', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), (',', 'O'), ('two', 'O'), ('distinct', 'O'), ('forms', 'O'), ('of', 'O'), ('carbamazepine', 'O'), ('-', 'O'), ('associated', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('emerged', 'O'), ('.', 'O'))"
One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .,"(('One', 'O'), ('patient', 'O'), ('group', 'O'), ('developed', 'O'), ('sinus', 'B'), ('tachycardias', 'I'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('of', 'O'), ('a', 'O'), ('massive', 'O'), ('carbamazepine', 'O'), ('overdose', 'B'), ('.', 'O'))"
"The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .","(('The', 'O'), ('second', 'O'), ('group', 'O'), ('consisted', 'O'), ('almost', 'O'), ('exclusively', 'O'), ('of', 'O'), ('elderly', 'O'), ('women', 'O'), ('who', 'O'), ('developed', 'O'), ('potentially', 'O'), ('life', 'O'), ('-', 'O'), ('threatening', 'O'), ('bradyarrhythmias', 'B'), ('or', 'O'), ('atrioventricular', 'B'), ('conduction', 'I'), ('delay', 'I'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('either', 'O'), ('therapeutic', 'O'), ('or', 'O'), ('modestly', 'O'), ('elevated', 'O'), ('carbamazepine', 'O'), ('serum', 'O'), ('levels', 'O'), ('.', 'O'))"
"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .","(('Because', 'O'), ('carbamazepine', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('many', 'O'), ('neurologic', 'O'), ('and', 'O'), ('psychiatric', 'B'), ('conditions', 'O'), (',', 'O'), ('the', 'O'), ('recognition', 'O'), ('of', 'O'), ('the', 'O'), ('latter', 'O'), ('syndrome', 'O'), ('has', 'O'), ('important', 'O'), ('implications', 'O'), ('for', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('.', 'O'))"
Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .,"(('Detection', 'O'), ('of', 'O'), ('abnormal', 'O'), ('cardiac', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('activity', 'O'), ('in', 'O'), ('adriamycin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('with', 'O'), ('iodine', 'O'), ('-', 'O'), ('125', 'O'), ('-', 'O'), ('metaiodobenzylguanidine', 'O'), ('.', 'O'))"
"Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .","(('Using', 'O'), ('a', 'O'), ('rat', 'O'), ('model', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('we', 'O'), ('tested', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('abnormal', 'O'), ('cardiac', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('activity', 'O'), ('may', 'O'), ('appear', 'O'), ('and', 'O'), ('be', 'O'), ('exacerbated', 'O'), ('dose', 'O'), ('-', 'O'), ('dependently', 'O'), ('in', 'O'), ('adriamycin', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .","(('The', 'O'), ('degree', 'O'), ('of', 'O'), ('vacuolar', 'B'), ('degeneration', 'I'), ('of', 'I'), ('myocardial', 'I'), ('cells', 'I'), ('was', 'O'), ('analyzed', 'O'), ('in', 'O'), ('relation', 'O'), ('to', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('treatment', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('once', 'O'), ('a', 'O'), ('week', 'O'), (')', 'O'), ('.', 'O'))"
The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .,"(('The', 'O'), ('appearance', 'O'), ('of', 'O'), ('impaired', 'O'), ('cardiac', 'O'), ('adrenergic', 'O'), ('neuron', 'O'), ('activity', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('slight', 'O'), ('myocardial', 'B'), ('impairment', 'I'), ('(', 'O'), ('scattered', 'O'), ('or', 'O'), ('focal', 'O'), ('vacuolar', 'B'), ('degeneration', 'I'), (')', 'O'), ('indicates', 'O'), ('that', 'O'), ('MIBG', 'O'), ('scintigraphy', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('method', 'O'), ('for', 'O'), ('detection', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .,"(('Syncope', 'B'), ('and', 'O'), ('QT', 'B'), ('prolongation', 'I'), ('among', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('methadone', 'O'), ('for', 'O'), ('heroin', 'O'), ('dependence', 'O'), ('in', 'O'), ('the', 'O'), ('city', 'O'), ('of', 'O'), ('Copenhagen', 'O'), ('.', 'O'))"
Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .,"(('Prolongation', 'O'), ('of', 'O'), ('the', 'O'), ('QT', 'O'), ('interval', 'O'), ('in', 'O'), ('the', 'O'), ('ECG', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('(', 'O'), ('TdP', 'B'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('methadone', 'O'), ('users', 'O'), ('.', 'O'))"
"As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .","(('As', 'O'), ('heroin', 'O'), ('addicts', 'O'), ('sometimes', 'O'), ('faint', 'O'), ('while', 'O'), ('using', 'O'), ('illicit', 'O'), ('drugs', 'O'), (',', 'O'), ('doctors', 'O'), ('might', 'O'), ('attribute', 'O'), ('too', 'O'), ('many', 'O'), ('episodes', 'O'), ('of', 'O'), ('syncope', 'B'), ('to', 'O'), ('illicit', 'O'), ('drug', 'O'), ('use', 'O'), ('and', 'O'), ('thereby', 'O'), ('underestimate', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('TdP', 'B'), ('in', 'O'), ('this', 'O'), ('special', 'O'), ('population', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('high', 'O'), ('mortality', 'O'), ('in', 'O'), ('this', 'O'), ('population', 'O'), ('may', 'O'), (',', 'O'), ('in', 'O'), ('part', 'O'), (',', 'O'), ('be', 'O'), ('caused', 'O'), ('by', 'O'), ('the', 'O'), ('proarrhythmic', 'O'), ('effect', 'O'), ('of', 'O'), ('methadone', 'O'), ('.', 'O'))"
All participants were interviewed about any experience of syncope .,"(('All', 'O'), ('participants', 'O'), ('were', 'O'), ('interviewed', 'O'), ('about', 'O'), ('any', 'O'), ('experience', 'O'), ('of', 'O'), ('syncope', 'B'), ('.', 'O'))"
"The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .","(('The', 'O'), ('association', 'O'), ('between', 'O'), ('opioid', 'O'), ('dose', 'O'), ('and', 'O'), ('QT', 'O'), (',', 'O'), ('and', 'O'), ('methadone', 'O'), ('dose', 'O'), ('and', 'O'), ('reporting', 'O'), ('of', 'O'), ('syncope', 'B'), ('was', 'O'), ('assessed', 'O'), ('using', 'O'), ('multivariate', 'O'), ('linear', 'O'), ('regression', 'O'), ('and', 'O'), ('logistic', 'O'), ('regression', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .","(('Among', 'O'), ('the', 'O'), ('subjects', 'O'), ('treated', 'O'), ('with', 'O'), ('methadone', 'O'), (',', 'O'), ('28', 'O'), ('%', 'O'), ('men', 'O'), ('and', 'O'), ('32', 'O'), ('%', 'O'), ('women', 'O'), ('had', 'O'), ('prolonged', 'B'), ('QTc', 'I'), ('interval', 'I'), ('.', 'O'))"
A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .,"(('A', 'O'), ('50', 'O'), ('mg', 'O'), ('higher', 'O'), ('methadone', 'O'), ('dose', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), (')', 'O'), ('times', 'O'), ('higher', 'O'), ('odds', 'O'), ('for', 'O'), ('syncope', 'B'), ('.', 'O'))"
CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Methadone', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('QT', 'B'), ('prolongation', 'I'), ('and', 'O'), ('higher', 'O'), ('reporting', 'O'), ('of', 'O'), ('syncope', 'B'), ('in', 'O'), ('a', 'O'), ('population', 'O'), ('of', 'O'), ('heroin', 'O'), ('addicts', 'O'), ('.', 'O'))"
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .,"(('Neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('induced', 'O'), ('by', 'O'), ('ziprasidone', 'O'), ('on', 'O'), ('the', 'O'), ('second', 'O'), ('day', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .,"(('Neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('(', 'O'), ('NMS', 'B'), (')', 'O'), ('is', 'O'), ('the', 'O'), ('rarest', 'O'), ('and', 'O'), ('most', 'O'), ('serious', 'O'), ('of', 'O'), ('the', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('(', 'O'), ('NMS', 'B'), (')', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('ziprasidone', 'O'), ('.', 'O'))"
The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .,"(('The', 'O'), ('patient', 'O'), ('is', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('male', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('schizophrenia', 'B'), ('who', 'O'), ('developed', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('of', 'O'), ('NMS', 'B'), ('after', 'O'), ('2', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('an', 'O'), ('80', 'O'), ('-', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), ('dose', 'O'), ('of', 'O'), ('orally', 'O'), ('administrated', 'O'), ('ziprasidone', 'O'), ('.', 'O'))"
Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .,"(('Peripheral', 'O'), ('iron', 'O'), ('dextran', 'O'), ('induced', 'O'), ('degeneration', 'B'), ('of', 'I'), ('dopaminergic', 'I'), ('neurons', 'I'), ('in', 'O'), ('rat', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('.', 'O'))"
Iron accumulation is considered to be involved in the pathogenesis of Parkinson ' s disease .,"(('Iron', 'O'), ('accumulation', 'O'), ('is', 'O'), ('considered', 'O'), ('to', 'O'), ('be', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .","(('To', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('peripheral', 'O'), ('iron', 'O'), ('overload', 'O'), ('and', 'O'), ('dopaminergic', 'O'), ('neuron', 'O'), ('loss', 'O'), ('in', 'O'), ('rat', 'O'), ('substantia', 'O'), ('nigra', 'O'), ('(', 'O'), ('SN', 'O'), (')', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('we', 'O'), ('used', 'O'), ('fast', 'O'), ('cyclic', 'O'), ('voltammetry', 'O'), (',', 'O'), ('tyrosine', 'O'), ('hydroxylase', 'O'), ('(', 'O'), ('TH', 'O'), (')', 'O'), ('immunohistochemistry', 'O'), (',', 'O'), ('Perls', 'O'), (""'"", 'O'), ('iron', 'O'), ('staining', 'O'), (',', 'O'), ('and', 'O'), ('high', 'O'), ('performance', 'O'), ('liquid', 'O'), ('chromatography', 'O'), ('-', 'O'), ('electrochemical', 'O'), ('detection', 'O'), ('to', 'O'), ('study', 'O'), ('the', 'O'), ('degeneration', 'B'), ('of', 'I'), ('dopaminergic', 'I'), ('neurons', 'I'), ('and', 'O'), ('increased', 'O'), ('iron', 'O'), ('content', 'O'), ('in', 'O'), ('the', 'O'), ('SN', 'O'), ('of', 'O'), ('iron', 'O'), ('dextran', 'O'), ('overloaded', 'O'), ('animals', 'O'), ('.', 'O'))"
"These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('peripheral', 'O'), ('iron', 'O'), ('dextran', 'O'), ('can', 'O'), ('increase', 'O'), ('the', 'O'), ('iron', 'O'), ('level', 'O'), ('in', 'O'), ('the', 'O'), ('SN', 'O'), (',', 'O'), ('where', 'O'), ('excessive', 'O'), ('iron', 'O'), ('causes', 'O'), ('the', 'O'), ('degeneration', 'B'), ('of', 'I'), ('dopaminergic', 'I'), ('neurons', 'I'), ('.', 'O'))"
"The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .","(('The', 'O'), ('development', 'O'), ('of', 'O'), ('schizophrenia', 'B'), ('may', 'O'), ('include', 'O'), ('an', 'O'), ('early', 'O'), ('neurodevelopmental', 'O'), ('stress', 'O'), ('component', 'O'), ('which', 'O'), ('increases', 'O'), ('vulnerability', 'O'), ('to', 'O'), ('later', 'O'), ('stressful', 'O'), ('life', 'O'), ('events', 'O'), (',', 'O'), ('in', 'O'), ('combination', 'O'), ('leading', 'O'), ('to', 'O'), ('overt', 'O'), ('disease', 'O'), ('.', 'O'))"
Amphetamine - induced locomotor hyperactivity was similar in all groups .,"(('Amphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('locomotor', 'B'), ('hyperactivity', 'I'), ('was', 'O'), ('similar', 'O'), ('in', 'O'), ('all', 'O'), ('groups', 'O'), ('.', 'O'))"
An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .,"(('An', 'O'), ('extremely', 'O'), ('rare', 'O'), ('case', 'O'), ('of', 'O'), ('delusional', 'B'), ('parasitosis', 'I'), ('in', 'O'), ('a', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('patient', 'O'), ('during', 'O'), ('pegylated', 'O'), ('interferon', 'O'), ('alpha', 'O'), ('-', 'O'), ('2b', 'O'), ('and', 'O'), ('ribavirin', 'O'), ('treatment', 'O'), ('.', 'O'))"
"During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .","(('During', 'O'), ('treatment', 'O'), ('of', 'O'), ('chronic', 'B'), ('hepatitis', 'I'), ('C', 'I'), ('patients', 'O'), ('with', 'O'), ('interferon', 'O'), ('and', 'O'), ('ribavirin', 'O'), (',', 'O'), ('a', 'O'), ('lot', 'O'), ('of', 'O'), ('side', 'O'), ('effects', 'O'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
Twenty - three percent to 44 % of patients develop depression .,"(('Twenty', 'O'), ('-', 'O'), ('three', 'O'), ('percent', 'O'), ('to', 'O'), ('44', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('develop', 'O'), ('depression', 'B'), ('.', 'O'))"
A minority of patients evolve to psychosis .,"(('A', 'O'), ('minority', 'O'), ('of', 'O'), ('patients', 'O'), ('evolve', 'O'), ('to', 'O'), ('psychosis', 'B'), ('.', 'O'))"
"Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .","(('Phenobarbital', 'O'), ('(', 'O'), ('PB', 'O'), (')', 'O'), ('has', 'O'), ('a', 'O'), ('reputation', 'O'), ('for', 'O'), ('safety', 'O'), (',', 'O'), ('and', 'O'), ('it', 'O'), ('is', 'O'), ('commonly', 'O'), ('believed', 'O'), ('that', 'O'), ('PB', 'O'), ('-', 'O'), ('related', 'O'), ('increases', 'O'), ('in', 'O'), ('serum', 'O'), ('aminotransferase', 'O'), ('levels', 'O'), ('do', 'O'), ('not', 'O'), ('indicate', 'O'), ('or', 'O'), ('predict', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('significant', 'O'), ('chronic', 'O'), ('liver', 'B'), ('disease', 'I'), ('.', 'O'))"
"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .","(('Here', 'O'), ('we', 'O'), ('report', 'O'), ('of', 'O'), ('two', 'O'), ('adult', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('long', 'O'), ('history', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('treated', 'O'), ('with', 'O'), ('PB', 'O'), ('who', 'O'), ('died', 'O'), ('suddenly', 'O'), (':', 'O'), ('one', 'O'), ('as', 'O'), ('consequence', 'O'), ('of', 'O'), ('cardiac', 'B'), ('arrest', 'I'), (',', 'O'), ('the', 'O'), ('other', 'O'), ('of', 'O'), ('acute', 'O'), ('bronchopneumonia', 'B'), ('.', 'O'))"
"At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .","(('At', 'O'), ('autopsy', 'O'), (',', 'O'), ('analysis', 'O'), ('of', 'O'), ('liver', 'O'), ('parenchyma', 'O'), ('revealed', 'O'), ('rich', 'O'), ('portal', 'O'), ('inflammatory', 'O'), ('infiltrate', 'O'), (',', 'O'), ('which', 'O'), ('consisted', 'O'), ('of', 'O'), ('mixed', 'O'), ('eosinophil', 'O'), ('and', 'O'), ('monocyte', 'O'), ('cells', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('several', 'O'), ('foci', 'O'), ('of', 'O'), ('necrosis', 'B'), ('surrounded', 'O'), ('by', 'O'), ('a', 'O'), ('hard', 'O'), ('ring', 'O'), ('of', 'O'), ('non', 'O'), ('-', 'O'), ('specific', 'O'), ('granulomatous', 'O'), ('tissue', 'O'), ('.', 'O'))"
"Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .","(('Our', 'O'), ('findings', 'O'), ('illustrate', 'O'), ('that', 'O'), ('PB', 'O'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('chronic', 'O'), ('liver', 'B'), ('damage', 'I'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('lead', 'O'), ('to', 'O'), ('more', 'O'), ('serious', 'O'), ('and', 'O'), ('deleterious', 'O'), ('consequences', 'O'), ('.', 'O'))"
"For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .","(('For', 'O'), ('this', 'O'), ('reason', 'O'), (',', 'O'), ('each', 'O'), ('clinician', 'O'), ('should', 'O'), ('recognize', 'O'), ('this', 'O'), ('entity', 'O'), ('in', 'O'), ('the', 'O'), ('differential', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('PB', 'O'), ('-', 'O'), ('related', 'O'), ('asymptomatic', 'O'), ('chronic', 'B'), ('hepatic', 'I'), ('enzyme', 'I'), ('dysfunction', 'I'), ('.', 'O'))"
Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .,"(('Delayed', 'O'), ('leukoencephalopathy', 'B'), ('with', 'O'), ('stroke', 'B'), ('-', 'O'), ('like', 'O'), ('presentation', 'O'), ('in', 'O'), ('chemotherapy', 'O'), ('recipients', 'O'), ('.', 'O'))"
"BACKGROUND : A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .","(('BACKGROUND', 'O'), (':', 'O'), ('A', 'O'), ('transient', 'O'), ('leukoencephalopathy', 'B'), ('mimicking', 'O'), ('cerebrovascular', 'B'), ('accident', 'I'), ('has', 'O'), ('been', 'O'), ('described', 'O'), ('as', 'O'), ('a', 'O'), ('complication', 'O'), ('of', 'O'), ('chemotherapy', 'O'), (',', 'O'), ('most', 'O'), ('commonly', 'O'), ('in', 'O'), ('recipients', 'O'), ('of', 'O'), ('intrathecal', 'O'), ('methotrexate', 'O'), ('for', 'O'), ('childhood', 'O'), ('leukaemia', 'B'), ('.', 'O'))"
METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .,"(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('reviewed', 'O'), ('the', 'O'), ('medical', 'O'), ('literature', 'O'), ('for', 'O'), ('single', 'O'), ('reports', 'O'), ('and', 'O'), ('case', 'O'), ('series', 'O'), ('of', 'O'), ('patients', 'O'), ('presenting', 'O'), ('with', 'O'), ('stroke', 'B'), ('-', 'O'), ('like', 'O'), ('episodes', 'O'), ('while', 'O'), ('receiving', 'O'), ('systemic', 'O'), ('or', 'O'), ('intrathecal', 'O'), ('chemotherapy', 'O'), ('.', 'O'))"
"RESULTS : We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .","(('RESULTS', 'O'), (':', 'O'), ('We', 'O'), ('identified', 'O'), ('27', 'O'), ('reports', 'O'), ('of', 'O'), ('toxic', 'O'), ('leukoencephalopathy', 'B'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('methotrexate', 'O'), ('(', 'O'), ('intrathecal', 'O'), (',', 'O'), ('systemic', 'O'), (')', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('fluorouracil', 'O'), ('and', 'O'), ('its', 'O'), ('derivative', 'O'), ('carmofur', 'O'), (',', 'O'), ('and', 'O'), ('capecitabine', 'O'), ('.', 'O'))"
"Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .","(('Diffusion', 'O'), ('weighted', 'O'), ('imaging', 'O'), ('(', 'O'), ('DWI', 'O'), (')', 'O'), ('of', 'O'), ('all', 'O'), ('patients', 'O'), ('revealed', 'O'), ('well', 'O'), ('demarcated', 'O'), ('hyperintense', 'O'), ('lesions', 'B'), ('within', 'I'), ('the', 'I'), ('subcortical', 'I'), ('white', 'I'), ('matter', 'I'), ('of', 'O'), ('the', 'O'), ('cerebral', 'O'), ('hemispheres', 'O'), ('and', 'O'), ('the', 'O'), ('corpus', 'O'), ('callosum', 'O'), (',', 'O'), ('corresponding', 'O'), ('to', 'O'), ('areas', 'O'), ('of', 'O'), ('decreased', 'O'), ('proton', 'O'), ('diffusion', 'O'), ('on', 'O'), ('apparent', 'O'), ('diffusion', 'O'), ('coefficient', 'O'), ('(', 'O'), ('ADC', 'O'), (')', 'O'), ('maps', 'O'), ('(', 'O'), ('available', 'O'), ('in', 'O'), ('21', 'O'), ('/', 'O'), ('27', 'O'), ('patients', 'O'), (')', 'O'), ('.', 'O'))"
"However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .","(('However', 'O'), (',', 'O'), ('fluid', 'O'), ('attenuated', 'O'), ('inversion', 'O'), ('recovery', 'O'), ('(', 'O'), ('FLAIR', 'O'), (')', 'O'), ('sequences', 'O'), ('frequently', 'O'), ('revealed', 'O'), ('persistent', 'O'), ('white', 'B'), ('matter', 'I'), ('abnormalities', 'I'), ('.', 'O'))"
CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Several', 'O'), ('pathophysiological', 'O'), ('models', 'O'), ('of', 'O'), ('delayed', 'O'), ('leukoencephalopathy', 'B'), ('after', 'O'), ('exposure', 'O'), ('to', 'O'), ('intrathecal', 'O'), ('or', 'O'), ('systemic', 'O'), ('chemotherapy', 'O'), ('have', 'O'), ('been', 'O'), ('proposed', 'O'), ('.', 'O'))"
DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .,"(('DWI', 'O'), ('findings', 'O'), ('in', 'O'), ('this', 'O'), ('cohort', 'O'), ('are', 'O'), ('indicative', 'O'), ('of', 'O'), ('cytotoxic', 'B'), ('oedema', 'I'), ('within', 'I'), ('cerebral', 'I'), ('white', 'I'), ('matter', 'I'), ('and', 'O'), ('lend', 'O'), ('support', 'O'), ('to', 'O'), ('an', 'O'), ('at', 'O'), ('least', 'O'), ('partially', 'O'), ('reversible', 'O'), ('metabolic', 'O'), ('derangement', 'O'), ('as', 'O'), ('the', 'O'), ('basis', 'O'), ('for', 'O'), ('this', 'O'), ('syndrome', 'O'), ('.', 'O'))"
Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .,"(('Prenatal', 'O'), ('exposure', 'O'), ('to', 'O'), ('fluoxetine', 'O'), ('induces', 'O'), ('fetal', 'B'), ('pulmonary', 'I'), ('hypertension', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .,"(('Epidemiological', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('fluoxetine', 'O'), ('exposure', 'O'), ('prenatally', 'O'), ('increases', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('persistent', 'O'), ('pulmonary', 'B'), ('hypertension', 'I'), ('syndrome', 'I'), ('of', 'O'), ('the', 'O'), ('newborn', 'O'), ('.', 'O'))"
"The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .","(('The', 'O'), ('mechanism', 'O'), ('responsible', 'O'), ('for', 'O'), ('this', 'O'), ('effect', 'O'), ('is', 'O'), ('unclear', 'O'), ('and', 'O'), ('paradoxical', 'O'), (',', 'O'), ('considering', 'O'), ('the', 'O'), ('current', 'O'), ('evidence', 'O'), ('of', 'O'), ('a', 'O'), ('pulmonary', 'B'), ('hypertension', 'I'), ('protective', 'O'), ('fluoxetine', 'O'), ('effect', 'O'), ('in', 'O'), ('adult', 'O'), ('rodents', 'O'), ('.', 'O'))"
"As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .","(('As', 'O'), ('compared', 'O'), ('with', 'O'), ('controls', 'O'), (',', 'O'), ('fluoxetine', 'O'), ('exposure', 'O'), ('resulted', 'O'), ('in', 'O'), ('fetal', 'B'), ('pulmonary', 'I'), ('hypertension', 'I'), ('as', 'O'), ('evidenced', 'O'), ('by', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('weight', 'O'), ('ratio', 'O'), ('of', 'O'), ('the', 'O'), ('right', 'O'), ('ventricle', 'O'), ('to', 'O'), ('the', 'O'), ('left', 'O'), ('ventricle', 'O'), ('plus', 'O'), ('septum', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), ('and', 'O'), ('by', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('pulmonary', 'O'), ('arterial', 'O'), ('medial', 'O'), ('thickness', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSIONS : In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('contrast', 'O'), ('to', 'O'), ('the', 'O'), ('adult', 'O'), (',', 'O'), ('fluoxetine', 'O'), ('exposure', 'O'), ('in', 'O'), ('utero', 'O'), ('induces', 'O'), ('pulmonary', 'B'), ('hypertension', 'I'), ('in', 'O'), ('the', 'O'), ('fetal', 'O'), ('rat', 'O'), ('as', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('a', 'O'), ('developmentally', 'O'), ('regulated', 'O'), ('increase', 'O'), ('in', 'O'), ('pulmonary', 'O'), ('vascular', 'O'), ('smooth', 'O'), ('muscle', 'O'), ('proliferation', 'O'), ('.', 'O'))"
Disulfiram - induced transient optic and peripheral neuropathy : a case report .,"(('Disulfiram', 'O'), ('-', 'O'), ('induced', 'O'), ('transient', 'O'), ('optic', 'B'), ('and', 'I'), ('peripheral', 'I'), ('neuropathy', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .,"(('AIM', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('optic', 'B'), ('and', 'I'), ('peripheral', 'I'), ('neuropathy', 'I'), ('after', 'O'), ('chronic', 'O'), ('use', 'O'), ('of', 'O'), ('disulfiram', 'O'), ('for', 'O'), ('alcohol', 'B'), ('dependence', 'I'), ('management', 'O'), ('.', 'O'))"
RESULTS : A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .,"(('RESULTS', 'O'), (':', 'O'), ('A', 'O'), ('57', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('male', 'O'), ('presented', 'O'), ('with', 'O'), ('gradual', 'O'), ('loss', 'B'), ('of', 'I'), ('vision', 'I'), ('in', 'O'), ('both', 'O'), ('eyes', 'O'), ('with', 'O'), ('intermittent', 'O'), ('headaches', 'B'), ('for', 'O'), ('2', 'O'), ('months', 'O'), ('.', 'O'))"
He also complained of paraesthesia with numbness in both feet .,"(('He', 'O'), ('also', 'O'), ('complained', 'O'), ('of', 'O'), ('paraesthesia', 'B'), ('with', 'O'), ('numbness', 'B'), ('in', 'O'), ('both', 'O'), ('feet', 'O'), ('.', 'O'))"
He had been taking disulfiram for alcohol dependence for the preceding 3 years .,"(('He', 'O'), ('had', 'O'), ('been', 'O'), ('taking', 'O'), ('disulfiram', 'O'), ('for', 'O'), ('alcohol', 'B'), ('dependence', 'I'), ('for', 'O'), ('the', 'O'), ('preceding', 'O'), ('3', 'O'), ('years', 'O'), ('.', 'O'))"
OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('report', 'O'), ('the', 'O'), ('incidence', 'O'), ('and', 'O'), ('management', 'O'), ('of', 'O'), ('elevated', 'B'), ('intraocular', 'I'), ('pressure', 'I'), ('(', 'O'), ('IOP', 'O'), (')', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('uveitis', 'B'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('fluocinolone', 'O'), ('acetonide', 'O'), ('(', 'O'), ('FA', 'O'), (')', 'O'), ('intravitreal', 'O'), ('implant', 'O'), ('.', 'O'))"
Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .,"(('Myocardial', 'O'), ('Fas', 'O'), ('ligand', 'O'), ('expression', 'O'), ('increases', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
"BACKGROUND : Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .","(('BACKGROUND', 'O'), (':', 'O'), ('Dilated', 'B'), ('cardiomyopathy', 'I'), ('(', 'O'), ('DCM', 'B'), (')', 'O'), ('and', 'O'), ('myocarditis', 'B'), ('occur', 'O'), ('in', 'O'), ('many', 'O'), ('HIV', 'B'), ('-', 'I'), ('infected', 'I'), ('individuals', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('symptomatic', 'O'), ('heart', 'B'), ('failure', 'I'), ('in', 'O'), ('up', 'O'), ('to', 'O'), ('5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
"Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .","(('Highly', 'O'), ('active', 'O'), ('antiretroviral', 'O'), ('therapy', 'O'), ('(', 'O'), ('HAART', 'O'), (')', 'O'), ('has', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('of', 'O'), ('acquired', 'B'), ('immunodeficiency', 'I'), ('syndrome', 'I'), ('(', 'O'), ('AIDS', 'B'), (')', 'O'), (',', 'O'), ('but', 'O'), ('has', 'O'), ('resulted', 'O'), ('in', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('cardiac', 'B'), ('and', 'I'), ('skeletal', 'I'), ('myopathies', 'I'), ('.', 'O'))"
"In contrast , AZT - treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('AZT', 'O'), ('-', 'O'), ('treated', 'O'), ('FasL', 'O'), ('Tg', 'O'), ('mice', 'O'), ('developed', 'O'), ('cardiac', 'B'), ('dilation', 'I'), ('and', 'O'), ('depressed', 'O'), ('cardiac', 'O'), ('function', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), (',', 'O'), ('with', 'O'), ('concomitant', 'O'), ('inflammatory', 'O'), ('infiltration', 'O'), ('of', 'O'), ('both', 'O'), ('ventricles', 'O'), ('.', 'O'))"
"CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('expression', 'O'), ('of', 'O'), ('Fas', 'O'), ('ligand', 'O'), ('in', 'O'), ('the', 'O'), ('myocardium', 'O'), (',', 'O'), ('as', 'O'), ('identified', 'O'), ('in', 'O'), ('HIV', 'O'), ('-', 'O'), ('positive', 'O'), ('patients', 'O'), (',', 'O'), ('might', 'O'), ('increase', 'O'), ('the', 'O'), ('susceptibility', 'O'), ('to', 'O'), ('HAART', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('due', 'O'), ('to', 'O'), ('activation', 'O'), ('of', 'O'), ('apoptotic', 'O'), ('pathways', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('cardiac', 'B'), ('dilation', 'I'), ('and', 'I'), ('dysfunction', 'I'), ('.', 'O'))"
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .,"(('Gastrointestinal', 'O'), ('tolerability', 'O'), ('of', 'O'), ('etoricoxib', 'O'), ('in', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('patients', 'O'), (':', 'O'), ('results', 'O'), ('of', 'O'), ('the', 'O'), ('etoricoxib', 'O'), ('vs', 'O'), ('diclofenac', 'O'), ('sodium', 'O'), ('gastrointestinal', 'O'), ('tolerability', 'O'), ('and', 'O'), ('effectiveness', 'O'), ('trial', 'O'), ('(', 'O'), ('EDGE', 'O'), ('-', 'O'), ('II', 'O'), (')', 'O'), ('.', 'O'))"
"OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .","(('OBJECTIVE', 'O'), (':', 'O'), ('A', 'O'), ('randomised', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('study', 'O'), ('to', 'O'), ('compare', 'O'), ('the', 'O'), ('gastrointestinal', 'O'), ('(', 'O'), ('GI', 'O'), (')', 'O'), ('tolerability', 'O'), (',', 'O'), ('safety', 'O'), ('and', 'O'), ('efficacy', 'O'), ('of', 'O'), ('etoricoxib', 'O'), ('and', 'O'), ('diclofenac', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('(', 'O'), ('RA', 'B'), (')', 'O'), ('.', 'O'))"
"General safety was also assessed , including adjudicated thrombotic cardiovascular event data .","(('General', 'O'), ('safety', 'O'), ('was', 'O'), ('also', 'O'), ('assessed', 'O'), (',', 'O'), ('including', 'O'), ('adjudicated', 'O'), ('thrombotic', 'B'), ('cardiovascular', 'I'), ('event', 'O'), ('data', 'O'), ('.', 'O'))"
The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('discontinuations', 'O'), ('for', 'O'), ('hypertension', 'B'), ('-', 'O'), ('related', 'O'), ('and', 'O'), ('oedema', 'B'), ('-', 'O'), ('related', 'O'), ('AEs', 'O'), ('were', 'O'), ('significantly', 'O'), ('higher', 'O'), ('with', 'O'), ('etoricoxib', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), ('respectively', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('diclofenac', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('respectively', 'O'), (';', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), ('for', 'O'), ('hypertension', 'B'), ('and', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), ('for', 'O'), ('oedema', 'B'), (')', 'O'), ('.', 'O'))"
Reduction of pain during induction with target - controlled propofol and remifentanil .,"(('Reduction', 'O'), ('of', 'O'), ('pain', 'B'), ('during', 'O'), ('induction', 'O'), ('with', 'O'), ('target', 'O'), ('-', 'O'), ('controlled', 'O'), ('propofol', 'O'), ('and', 'O'), ('remifentanil', 'O'), ('.', 'O'))"
BACKGROUND : Pain on injection of propofol is unpleasant .,"(('BACKGROUND', 'O'), (':', 'O'), ('Pain', 'B'), ('on', 'O'), ('injection', 'O'), ('of', 'O'), ('propofol', 'O'), ('is', 'O'), ('unpleasant', 'O'), ('.', 'O'))"
We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .,"(('We', 'O'), ('hypothesized', 'O'), ('that', 'O'), ('propofol', 'O'), ('infusion', 'O'), ('pain', 'B'), ('might', 'O'), ('be', 'O'), ('prevented', 'O'), ('by', 'O'), ('infusing', 'O'), ('remifentanil', 'O'), ('before', 'O'), ('starting', 'O'), ('the', 'O'), ('propofol', 'O'), ('infusion', 'O'), ('in', 'O'), ('a', 'O'), ('clinical', 'O'), ('setting', 'O'), ('where', 'O'), ('target', 'O'), ('-', 'O'), ('controlled', 'O'), ('infusions', 'O'), ('(', 'O'), ('TCI', 'O'), (')', 'O'), ('of', 'O'), ('both', 'O'), ('drugs', 'O'), ('were', 'O'), ('used', 'O'), ('.', 'O'))"
"A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .","(('A', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), ('trial', 'O'), ('was', 'O'), ('performed', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('effect', 'O'), ('-', 'O'), ('site', 'O'), ('concentration', 'O'), ('(', 'O'), ('Ce', 'O'), (')', 'O'), ('of', 'O'), ('remifentanil', 'O'), ('to', 'O'), ('prevent', 'O'), ('the', 'O'), ('pain', 'B'), ('without', 'O'), ('producing', 'O'), ('complications', 'O'), ('.', 'O'))"
"Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .","(('Remifentanil', 'O'), ('-', 'O'), ('related', 'O'), ('complications', 'O'), ('were', 'O'), ('assessed', 'O'), ('during', 'O'), ('the', 'O'), ('remifentanil', 'O'), ('infusion', 'O'), (',', 'O'), ('and', 'O'), ('pain', 'B'), ('caused', 'O'), ('by', 'O'), ('propofol', 'O'), ('was', 'O'), ('evaluated', 'O'), ('using', 'O'), ('a', 'O'), ('four', 'O'), ('-', 'O'), ('point', 'O'), ('scale', 'O'), ('during', 'O'), ('the', 'O'), ('propofol', 'O'), ('infusion', 'O'), ('.', 'O'))"
"RESULTS : The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('pain', 'B'), ('was', 'O'), ('significantly', 'O'), ('lower', 'O'), ('in', 'O'), ('Groups', 'O'), ('R4', 'O'), ('and', 'O'), ('R6', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('and', 'O'), ('R2', 'O'), ('groups', 'O'), ('(', 'O'), ('12', 'O'), ('/', 'O'), ('32', 'O'), ('and', 'O'), ('6', 'O'), ('/', 'O'), ('31', 'O'), ('vs', 'O'), ('26', 'O'), ('/', 'O'), ('31', 'O'), ('and', 'O'), ('25', 'O'), ('/', 'O'), ('32', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .,"(('Pain', 'B'), ('was', 'O'), ('less', 'O'), ('severe', 'O'), ('in', 'O'), ('Groups', 'O'), ('R4', 'O'), ('and', 'O'), ('R6', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('and', 'O'), ('R2', 'O'), ('groups', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"However , both incidence and severity of pain were not different between Groups R4 and R6 .","(('However', 'O'), (',', 'O'), ('both', 'O'), ('incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('pain', 'B'), ('were', 'O'), ('not', 'O'), ('different', 'O'), ('between', 'O'), ('Groups', 'O'), ('R4', 'O'), ('and', 'O'), ('R6', 'O'), ('.', 'O'))"
"CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .","(('CONCLUSIONS', 'O'), (':', 'O'), ('During', 'O'), ('induction', 'O'), ('of', 'O'), ('anaesthesia', 'O'), ('with', 'O'), ('TCI', 'O'), ('of', 'O'), ('propofol', 'O'), ('and', 'O'), ('remifentanil', 'O'), (',', 'O'), ('a', 'O'), ('significant', 'O'), ('reduction', 'O'), ('in', 'O'), ('propofol', 'O'), ('infusion', 'O'), ('pain', 'B'), ('was', 'O'), ('achieved', 'O'), ('without', 'O'), ('significant', 'O'), ('complications', 'O'), ('by', 'O'), ('prior', 'O'), ('administration', 'O'), ('of', 'O'), ('remifentanil', 'O'), ('at', 'O'), ('a', 'O'), ('target', 'O'), ('Ce', 'O'), ('of', 'O'), ('4', 'O'), ('ng', 'O'), ('ml', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .","(('Dexmedetomidine', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('trend', 'O'), ('towards', 'O'), ('improved', 'O'), ('cardiac', 'O'), ('outcomes', 'O'), (';', 'O'), ('all', 'O'), ('-', 'O'), ('cause', 'O'), ('mortality', 'O'), ('(', 'O'), ('OR', 'O'), ('0', 'O'), ('.', 'O'), ('27', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), ('-', 'O'), ('7', 'O'), ('.', 'O'), ('13', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('44', 'O'), (')', 'O'), (',', 'O'), ('non', 'O'), ('-', 'O'), ('fatal', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('(', 'O'), ('OR', 'O'), ('0', 'O'), ('.', 'O'), ('26', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('04', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('60', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('14', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('myocardial', 'B'), ('ischaemia', 'I'), ('(', 'O'), ('OR', 'O'), ('0', 'O'), ('.', 'O'), ('65', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('0', 'O'), ('.', 'O'), ('26', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('63', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('36', 'O'), (')', 'O'), ('.', 'O'))"
"Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .","(('Peri', 'O'), ('-', 'O'), ('operative', 'O'), ('hypotension', 'B'), ('(', 'O'), ('26', 'O'), ('%', 'O'), (',', 'O'), ('OR', 'O'), ('3', 'O'), ('.', 'O'), ('80', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('91', 'O'), ('-', 'O'), ('7', 'O'), ('.', 'O'), ('54', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('and', 'O'), ('bradycardia', 'B'), ('(', 'O'), ('17', 'O'), ('%', 'O'), (',', 'O'), ('OR', 'O'), ('5', 'O'), ('.', 'O'), ('45', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('2', 'O'), ('.', 'O'), ('98', 'O'), ('-', 'O'), ('9', 'O'), ('.', 'O'), ('95', 'O'), (',', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('00001', 'O'), (')', 'O'), ('were', 'O'), ('significantly', 'O'), ('increased', 'O'), ('.', 'O'))"
An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .,"(('An', 'O'), ('anticholinergic', 'O'), ('did', 'O'), ('not', 'O'), ('reduce', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('bradycardia', 'B'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('43', 'O'), (')', 'O'), ('.', 'O'))"
Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .,"(('Myocardial', 'B'), ('infarction', 'I'), ('in', 'O'), ('pregnancy', 'O'), ('associated', 'O'), ('with', 'O'), ('clomiphene', 'O'), ('citrate', 'O'), ('for', 'O'), ('ovulation', 'O'), ('induction', 'O'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .","(('Spontaneous', 'O'), ('coronary', 'B'), ('thrombosis', 'I'), ('or', 'O'), ('thromboembolism', 'B'), ('with', 'O'), ('subsequent', 'O'), ('clot', 'O'), ('lysis', 'O'), ('has', 'O'), ('been', 'O'), ('suggested', 'O'), ('as', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('causes', 'O'), ('of', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('(', 'O'), ('MI', 'B'), (')', 'O'), ('during', 'O'), ('pregnancy', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('subsequently', 'O'), ('normal', 'O'), ('coronary', 'O'), ('angiogram', 'O'), ('.', 'O'))"
CASE : A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .,"(('CASE', 'O'), (':', 'O'), ('A', 'O'), ('33', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('a', 'O'), ('5', 'O'), ('-', 'O'), ('week', 'O'), ('gestation', 'O'), ('had', 'O'), ('recently', 'O'), ('received', 'O'), ('CC', 'O'), ('for', 'O'), ('ovulation', 'O'), ('induction', 'O'), ('and', 'O'), ('presented', 'O'), ('with', 'O'), ('chest', 'B'), ('pain', 'I'), ('.', 'O'))"
An electrocardiogram showed a lateral and anterior wall myocardial infarction .,"(('An', 'O'), ('electrocardiogram', 'O'), ('showed', 'O'), ('a', 'O'), ('lateral', 'O'), ('and', 'O'), ('anterior', 'O'), ('wall', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('.', 'O'))"
"At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .","(('At', 'O'), ('the', 'O'), ('time', 'O'), ('of', 'O'), ('admission', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('at', 'O'), ('high', 'O'), ('risk', 'O'), ('of', 'O'), ('radiation', 'B'), ('injury', 'I'), ('to', 'O'), ('the', 'O'), ('fetus', 'O'), (',', 'O'), ('so', 'O'), ('a', 'O'), ('coronary', 'O'), ('angiogram', 'O'), ('was', 'O'), ('postponed', 'O'), ('until', 'O'), ('the', 'O'), ('second', 'O'), ('trimester', 'O'), ('.', 'O'))"
CONCLUSION : This appears to be the first reported case documenting a possible association between CC and myocardial infarction .,"(('CONCLUSION', 'O'), (':', 'O'), ('This', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('first', 'O'), ('reported', 'O'), ('case', 'O'), ('documenting', 'O'), ('a', 'O'), ('possible', 'O'), ('association', 'O'), ('between', 'O'), ('CC', 'O'), ('and', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('.', 'O'))"
Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .,"(('Reverse', 'O'), ('or', 'O'), ('inverted', 'O'), ('left', 'B'), ('ventricular', 'I'), ('apical', 'I'), ('ballooning', 'I'), ('syndrome', 'I'), ('(', 'O'), ('reverse', 'O'), ('Takotsubo', 'B'), ('cardiomyopathy', 'I'), (')', 'O'), ('in', 'O'), ('a', 'O'), ('young', 'O'), ('woman', 'O'), ('in', 'O'), ('the', 'O'), ('setting', 'O'), ('of', 'O'), ('amphetamine', 'O'), ('use', 'O'), ('.', 'O'))"
"Transient left ventricular apical ballooning syndrome was first described in Japan as "" Takotsubo cardiomyopathy . "" This syndrome has been identified in many other countries .","(('Transient', 'O'), ('left', 'B'), ('ventricular', 'I'), ('apical', 'I'), ('ballooning', 'I'), ('syndrome', 'I'), ('was', 'O'), ('first', 'O'), ('described', 'O'), ('in', 'O'), ('Japan', 'O'), ('as', 'O'), ('""', 'O'), ('Takotsubo', 'B'), ('cardiomyopathy', 'I'), ('.', 'O'), ('""', 'O'), ('This', 'O'), ('syndrome', 'O'), ('has', 'O'), ('been', 'O'), ('identified', 'O'), ('in', 'O'), ('many', 'O'), ('other', 'O'), ('countries', 'O'), ('.', 'O'))"
"In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .","(('In', 'O'), ('this', 'O'), ('article', 'O'), (',', 'O'), ('we', 'O'), ('report', 'O'), ('an', 'O'), ('interesting', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('young', 'O'), ('woman', 'O'), ('who', 'O'), ('presented', 'O'), ('with', 'O'), ('this', 'O'), ('rare', 'O'), ('type', 'O'), ('of', 'O'), ('reverse', 'O'), ('apical', 'B'), ('ballooning', 'I'), ('syndrome', 'I'), ('occurring', 'O'), ('after', 'O'), ('amphetamine', 'O'), ('use', 'O'), ('.', 'O'))"
"Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .","(('Results', 'O'), ('of', 'O'), ('a', 'O'), ('comparative', 'O'), (',', 'O'), ('phase', 'O'), ('III', 'O'), (',', 'O'), ('12', 'O'), ('-', 'O'), ('week', 'O'), (',', 'O'), ('multicenter', 'O'), (',', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('assessment', 'O'), ('of', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('tolerability', 'O'), ('of', 'O'), ('a', 'O'), ('fixed', 'O'), ('-', 'O'), ('dose', 'O'), ('combination', 'O'), ('of', 'O'), ('telmisartan', 'O'), ('and', 'O'), ('amlodipine', 'O'), ('versus', 'O'), ('amlodipine', 'O'), ('monotherapy', 'O'), ('in', 'O'), ('Indian', 'O'), ('adults', 'O'), ('with', 'O'), ('stage', 'O'), ('II', 'O'), ('hypertension', 'B'), ('.', 'O'))"
OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('tolerability', 'O'), ('of', 'O'), ('a', 'O'), ('new', 'O'), ('fixed', 'O'), ('-', 'O'), ('dose', 'O'), ('combination', 'O'), ('(', 'O'), ('FDC', 'O'), (')', 'O'), ('of', 'O'), ('telmisartan', 'O'), ('40', 'O'), ('mg', 'O'), ('+', 'O'), ('amlodipine', 'O'), ('5', 'O'), ('mg', 'O'), ('(', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('amlodipine', 'O'), ('5', 'O'), ('-', 'O'), ('mg', 'O'), ('monotherapy', 'O'), ('(', 'O'), ('A', 'O'), (')', 'O'), ('in', 'O'), ('adult', 'O'), ('Indian', 'O'), ('patients', 'O'), ('with', 'O'), ('stage', 'O'), ('II', 'O'), ('hypertension', 'B'), ('.', 'O'))"
"METHODS : This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .","(('METHODS', 'O'), (':', 'O'), ('This', 'O'), ('comparative', 'O'), (',', 'O'), ('Phase', 'O'), ('III', 'O'), (',', 'O'), ('12', 'O'), ('-', 'O'), ('week', 'O'), (',', 'O'), ('multicenter', 'O'), (',', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('study', 'O'), ('was', 'O'), ('conducted', 'O'), ('in', 'O'), ('Indian', 'O'), ('patients', 'O'), ('aged', 'O'), ('18', 'O'), ('to', 'O'), ('65', 'O'), ('years', 'O'), ('with', 'O'), ('established', 'O'), ('stage', 'O'), ('II', 'O'), ('hypertension', 'B'), ('.', 'O'))"
"Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .","(('Peripheral', 'O'), ('edema', 'B'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('8', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('patients', 'O'), ('(', 'O'), ('9', 'O'), ('/', 'O'), ('106', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('group', 'O'), ('compared', 'O'), ('with', 'O'), ('13', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('(', 'O'), ('14', 'O'), ('/', 'O'), ('104', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('A', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('cough', 'B'), ('was', 'O'), ('reported', 'O'), ('in', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('patients', 'O'), ('(', 'O'), ('4', 'O'), ('/', 'O'), ('106', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('group', 'O'), ('and', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('(', 'O'), ('1', 'O'), ('/', 'O'), ('104', 'O'), (')', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('A', 'O'), ('group', 'O'), (';', 'O'), ('these', 'O'), ('differences', 'O'), ('did', 'O'), ('not', 'O'), ('reach', 'O'), ('statistical', 'O'), ('significance', 'O'), ('.', 'O'))"
"The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .","(('The', 'O'), ('incidences', 'O'), ('of', 'O'), ('headache', 'B'), (',', 'O'), ('dizziness', 'B'), (',', 'O'), ('and', 'O'), ('diarrhea', 'B'), ('were', 'O'), ('similar', 'O'), ('between', 'O'), ('the', 'O'), ('2', 'O'), ('groups', 'O'), ('.', 'O'))"
"CONCLUSIONS : Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .","(('CONCLUSIONS', 'O'), (':', 'O'), ('Among', 'O'), ('these', 'O'), ('Indian', 'O'), ('patients', 'O'), ('with', 'O'), ('stage', 'O'), ('II', 'O'), ('hypertension', 'B'), (',', 'O'), ('the', 'O'), ('FDC', 'O'), ('of', 'O'), ('T', 'O'), ('+', 'O'), ('A', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('significantly', 'O'), ('more', 'O'), ('effective', 'O'), (',', 'O'), ('with', 'O'), ('regard', 'O'), ('to', 'O'), ('BP', 'O'), ('reductions', 'O'), (',', 'O'), ('than', 'O'), ('A', 'O'), (',', 'O'), ('and', 'O'), ('both', 'O'), ('treatments', 'O'), ('were', 'O'), ('well', 'O'), ('tolerated', 'O'), ('.', 'O'))"
OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .,"(('OBJECTIVES', 'O'), (':', 'O'), ('The', 'O'), ('objectives', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('were', 'O'), ('to', 'O'), ('examine', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('APOE', 'O'), ('epsilon4', 'O'), ('and', 'O'), ('subjective', 'O'), ('effects', 'O'), ('of', 'O'), ('trihexyphenidyl', 'O'), ('on', 'O'), ('measures', 'O'), ('reflecting', 'O'), ('sedation', 'O'), ('and', 'O'), ('confusion', 'B'), ('and', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('trihexyphenidyl', 'O'), ('-', 'O'), ('induced', 'O'), ('subjective', 'O'), ('effects', 'O'), ('and', 'O'), ('objective', 'O'), ('memory', 'O'), ('performance', 'O'), ('.', 'O'))"
An evaluation of amikacin nephrotoxicity in the hematology / oncology population .,"(('An', 'O'), ('evaluation', 'O'), ('of', 'O'), ('amikacin', 'O'), ('nephrotoxicity', 'B'), ('in', 'O'), ('the', 'O'), ('hematology', 'O'), ('/', 'O'), ('oncology', 'O'), ('population', 'O'), ('.', 'O'))"
Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .,"(('Amikacin', 'O'), ('is', 'O'), ('an', 'O'), ('aminoglycoside', 'O'), ('commonly', 'O'), ('used', 'O'), ('to', 'O'), ('provide', 'O'), ('empirical', 'O'), ('double', 'O'), ('gram', 'O'), ('-', 'O'), ('negative', 'O'), ('treatment', 'O'), ('for', 'O'), ('febrile', 'B'), ('neutropenia', 'I'), ('and', 'O'), ('other', 'O'), ('suspected', 'O'), ('infections', 'B'), ('.', 'O'))"
"To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .","(('To', 'O'), ('evaluate', 'O'), ('amikacin', 'O'), ('-', 'O'), ('associated', 'O'), ('nephrotoxicity', 'B'), ('in', 'O'), ('an', 'O'), ('adult', 'O'), ('hematology', 'O'), ('/', 'O'), ('oncology', 'O'), ('population', 'O'), (',', 'O'), ('a', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('open', 'O'), ('-', 'O'), ('label', 'O'), ('trial', 'O'), ('was', 'O'), ('conducted', 'O'), ('at', 'O'), ('a', 'O'), ('university', 'O'), ('-', 'O'), ('affiliated', 'O'), ('medical', 'O'), ('center', 'O'), ('.', 'O'))"
Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .,"(('Forty', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('diagnosis', 'O'), ('consistent', 'O'), ('with', 'O'), ('a', 'O'), ('hematologic', 'B'), ('/', 'I'), ('oncologic', 'I'), ('disorder', 'I'), ('that', 'O'), ('required', 'O'), ('treatment', 'O'), ('with', 'O'), ('an', 'O'), ('aminoglycoside', 'O'), ('were', 'O'), ('randomized', 'O'), ('to', 'O'), ('either', 'O'), ('conventional', 'O'), ('or', 'O'), ('extended', 'O'), ('-', 'O'), ('interval', 'O'), ('amikacin', 'O'), ('.', 'O'))"
The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .,"(('The', 'O'), ('occurrence', 'O'), ('of', 'O'), ('nephrotoxicity', 'B'), ('by', 'O'), ('means', 'O'), ('of', 'O'), ('an', 'O'), ('increase', 'O'), ('in', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('and', 'O'), ('evaluation', 'O'), ('of', 'O'), ('efficacy', 'O'), ('via', 'O'), ('amikacin', 'O'), ('serum', 'O'), ('concentrations', 'O'), ('with', 'O'), ('respective', 'O'), ('pathogens', 'O'), ('were', 'O'), ('assessed', 'O'), ('.', 'O'))"
"The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .","(('The', 'O'), ('occurrence', 'O'), ('of', 'O'), ('nephrotoxicity', 'B'), ('was', 'O'), ('similar', 'O'), ('between', 'O'), ('the', 'O'), ('conventional', 'O'), ('and', 'O'), ('extended', 'O'), ('-', 'O'), ('interval', 'O'), ('groups', 'O'), (',', 'O'), ('at', 'O'), ('10', 'O'), ('%', 'O'), ('and', 'O'), ('5', 'O'), ('%', 'O'), (',', 'O'), ('respectively', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('1', 'O'), ('.', 'O'), ('00', 'O'), (')', 'O'), ('.', 'O'))"
"The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .","(('The', 'O'), ('occurrence', 'O'), ('of', 'O'), ('nephrotoxicity', 'B'), ('was', 'O'), ('similar', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('dosing', 'O'), ('regimens', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('distribution', 'O'), ('of', 'O'), ('risk', 'O'), ('factors', 'O'), ('was', 'O'), ('variable', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('.', 'O'))"
"Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .","(('Although', 'O'), ('dexmedetomidine', 'O'), ('sedation', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('16', 'O'), ('%', 'O'), ('incidence', 'O'), ('of', 'O'), ('bradycardia', 'B'), (',', 'O'), ('all', 'O'), ('concomitant', 'O'), ('mean', 'O'), ('arterial', 'O'), ('blood', 'O'), ('pressures', 'O'), ('were', 'O'), ('within', 'O'), ('20', 'O'), ('%', 'O'), ('of', 'O'), ('age', 'O'), ('-', 'O'), ('adjusted', 'O'), ('normal', 'O'), ('range', 'O'), ('and', 'O'), ('oxygen', 'O'), ('saturations', 'O'), ('were', 'O'), ('95', 'O'), ('%', 'O'), ('or', 'O'), ('higher', 'O'), ('.', 'O'))"
Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .,"(('Hepatotoxicity', 'B'), ('associated', 'O'), ('with', 'O'), ('sulfasalazine', 'O'), ('in', 'O'), ('inflammatory', 'O'), ('arthritis', 'B'), (':', 'O'), ('A', 'O'), ('case', 'O'), ('series', 'O'), ('from', 'O'), ('a', 'O'), ('local', 'O'), ('surveillance', 'O'), ('of', 'O'), ('serious', 'O'), ('adverse', 'O'), ('events', 'O'), ('.', 'O'))"
We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .,"(('We', 'O'), ('report', 'O'), ('an', 'O'), ('investigation', 'O'), ('from', 'O'), ('a', 'O'), ('local', 'O'), ('surveillance', 'O'), ('for', 'O'), ('serious', 'O'), ('adverse', 'O'), ('drug', 'O'), ('reactions', 'O'), ('associated', 'O'), ('with', 'O'), ('disease', 'O'), ('modifying', 'O'), ('anti', 'O'), ('-', 'O'), ('rheumatic', 'O'), ('drugs', 'O'), ('that', 'O'), ('was', 'O'), ('triggered', 'O'), ('by', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('liver', 'B'), ('failure', 'I'), ('in', 'O'), ('two', 'O'), ('of', 'O'), ('our', 'O'), ('patients', 'O'), ('.', 'O'))"
"Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .","(('Patients', 'O'), (""'"", 'O'), (',', 'O'), ('who', 'O'), ('had', 'O'), ('hepatotoxicity', 'B'), ('on', 'O'), ('sulfasalazine', 'O'), ('and', 'O'), ('met', 'O'), ('a', 'O'), ('definition', 'O'), ('of', 'O'), ('a', 'O'), ('serious', 'O'), ('ADR', 'O'), (',', 'O'), ('were', 'O'), ('identified', 'O'), ('.', 'O'))"
The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .,"(('The', 'O'), ('likely', 'O'), ('frequency', 'O'), ('of', 'O'), ('hepatotoxicity', 'B'), ('with', 'O'), ('sulfasalazine', 'O'), ('was', 'O'), ('estimated', 'O'), ('by', 'O'), ('making', 'O'), ('a', 'O'), ('series', 'O'), ('of', 'O'), ('conservative', 'O'), ('assumptions', 'O'), ('.', 'O'))"
"Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .","(('Eight', 'O'), ('patients', 'O'), ('were', 'O'), ('hospitalised', 'O'), (',', 'O'), ('two', 'O'), ('in', 'O'), ('hepatic', 'B'), ('failure', 'I'), ('-', 'O'), ('one', 'O'), ('died', 'O'), ('after', 'O'), ('a', 'O'), ('liver', 'O'), ('transplant', 'O'), ('.', 'O'))"
"Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .","(('Seven', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('skin', 'B'), ('rash', 'I'), (',', 'O'), ('three', 'O'), ('eosinophilia', 'B'), ('and', 'O'), ('one', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('.', 'O'))"
Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .,"(('Drug', 'O'), ('-', 'O'), ('related', 'O'), ('hepatotoxicity', 'B'), ('was', 'O'), ('judged', 'O'), ('probable', 'O'), ('or', 'O'), ('highly', 'O'), ('probable', 'O'), ('in', 'O'), ('8', 'O'), ('patients', 'O'), ('.', 'O'))"
The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .,"(('The', 'O'), ('likely', 'O'), ('frequency', 'O'), ('of', 'O'), ('serious', 'O'), ('hepatotoxicity', 'B'), ('with', 'O'), ('sulfasalazine', 'O'), ('was', 'O'), ('estimated', 'O'), ('at', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('treated', 'O'), ('patients', 'O'), ('.', 'O'))"
CONCLUSION : Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .,"(('CONCLUSION', 'O'), (':', 'O'), ('Serious', 'O'), ('hepatotoxicity', 'B'), ('associated', 'O'), ('with', 'O'), ('sulfasalazine', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('under', 'O'), ('-', 'O'), ('appreciated', 'O'), ('and', 'O'), ('intensive', 'O'), ('monitoring', 'O'), ('and', 'O'), ('vigilance', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('6', 'O'), ('weeks', 'O'), ('of', 'O'), ('treatment', 'O'), ('is', 'O'), ('especially', 'O'), ('important', 'O'), ('.', 'O'))"
Complete atrioventricular block secondary to lithium therapy .,"(('Complete', 'O'), ('atrioventricular', 'B'), ('block', 'I'), ('secondary', 'O'), ('to', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('.', 'O'))"
Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .,"(('Sinus', 'B'), ('node', 'I'), ('dysfunction', 'I'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('most', 'O'), ('frequently', 'O'), ('among', 'O'), ('the', 'O'), ('adverse', 'O'), ('cardiovascular', 'O'), ('effects', 'O'), ('of', 'O'), ('lithium', 'O'), ('.', 'O'))"
"In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('case', 'O'), (',', 'O'), ('complete', 'O'), ('atrioventricular', 'B'), ('(', 'I'), ('AV', 'I'), (')', 'I'), ('block', 'I'), ('with', 'O'), ('syncopal', 'B'), ('attacks', 'I'), ('developed', 'O'), ('secondary', 'O'), ('to', 'O'), ('lithium', 'O'), ('therapy', 'O'), (',', 'O'), ('necessitating', 'O'), ('permanent', 'O'), ('pacemaker', 'O'), ('implantation', 'O'), ('.', 'O'))"
Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .,"(('Exaggerated', 'O'), ('expression', 'O'), ('of', 'O'), ('inflammatory', 'O'), ('mediators', 'O'), ('in', 'O'), ('vasoactive', 'O'), ('intestinal', 'O'), ('polypeptide', 'O'), ('knockout', 'O'), ('(', 'O'), ('VIP', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('cyclophosphamide', 'O'), ('(', 'O'), ('CYP', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('cystitis', 'B'), ('.', 'O'))"
VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .,"(('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('exhibit', 'O'), ('altered', 'O'), ('bladder', 'O'), ('function', 'O'), ('and', 'O'), ('neurochemical', 'O'), ('properties', 'O'), ('in', 'O'), ('micturition', 'O'), ('pathways', 'O'), ('after', 'O'), ('cyclophosphamide', 'O'), ('(', 'O'), ('CYP', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('cystitis', 'B'), ('.', 'O'))"
"Given VIP ' s role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .","(('Given', 'O'), ('VIP', 'O'), (""'"", 'O'), ('s', 'O'), ('role', 'O'), ('as', 'O'), ('an', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('mediator', 'O'), (',', 'O'), ('we', 'O'), ('hypothesized', 'O'), ('that', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('would', 'O'), ('exhibit', 'O'), ('enhanced', 'O'), ('inflammatory', 'O'), ('mediator', 'O'), ('expression', 'O'), ('after', 'O'), ('cystitis', 'B'), ('.', 'O'))"
A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .,"(('A', 'O'), ('mouse', 'O'), ('inflammatory', 'O'), ('cytokine', 'O'), ('and', 'O'), ('receptor', 'O'), ('RT2', 'O'), ('profiler', 'O'), ('array', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('regulated', 'O'), ('transcripts', 'O'), ('in', 'O'), ('the', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('of', 'O'), ('wild', 'O'), ('type', 'O'), ('(', 'O'), ('WT', 'O'), (')', 'O'), ('and', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('or', 'O'), ('without', 'O'), ('CYP', 'O'), ('-', 'O'), ('induced', 'O'), ('cystitis', 'B'), ('(', 'O'), ('150', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (';', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (';', 'O'), ('48', 'O'), ('h', 'O'), (')', 'O'), ('.', 'O'))"
"The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .","(('The', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('in', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('bladder', 'B'), ('inflammation', 'I'), (',', 'O'), ('inflammatory', 'O'), ('mediators', 'O'), ('are', 'O'), ('increased', 'O'), ('above', 'O'), ('that', 'O'), ('observed', 'O'), ('in', 'O'), ('WT', 'O'), ('with', 'O'), ('CYP', 'O'), ('.', 'O'))"
This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .,"(('This', 'O'), ('shift', 'O'), ('in', 'O'), ('balance', 'O'), ('may', 'O'), ('contribute', 'O'), ('to', 'O'), ('increased', 'O'), ('bladder', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('VIP', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('with', 'O'), ('bladder', 'B'), ('inflammation', 'I'), ('and', 'O'), ('altered', 'O'), ('neurochemical', 'O'), ('expression', 'O'), ('in', 'O'), ('micturition', 'O'), ('pathways', 'O'), ('.', 'O'))"
"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .","(('Oxytocin', 'O'), ('is', 'O'), ('a', 'O'), ('commonly', 'O'), ('used', 'O'), ('uterotonic', 'O'), ('that', 'O'), ('can', 'O'), ('cause', 'O'), ('significant', 'O'), ('and', 'O'), ('even', 'O'), ('fatal', 'O'), ('hypotension', 'B'), (',', 'O'), ('particularly', 'O'), ('when', 'O'), ('given', 'O'), ('as', 'O'), ('a', 'O'), ('bolus', 'O'), ('.', 'O'))"
The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .,"(('The', 'O'), ('resulting', 'O'), ('hypotension', 'B'), ('can', 'O'), ('be', 'O'), ('produced', 'O'), ('by', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('systemic', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('or', 'O'), ('cardiac', 'O'), ('output', 'O'), ('through', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('venous', 'O'), ('return', 'O'), ('.', 'O'))"
"Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .","(('Parturients', 'O'), ('with', 'O'), ('normal', 'O'), ('volume', 'O'), ('status', 'O'), (',', 'O'), ('heart', 'O'), ('valves', 'O'), ('and', 'O'), ('pulmonary', 'O'), ('vasculature', 'O'), ('most', 'O'), ('often', 'O'), ('respond', 'O'), ('to', 'O'), ('this', 'O'), ('hypotension', 'B'), ('with', 'O'), ('a', 'O'), ('compensatory', 'O'), ('increase', 'O'), ('in', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('stroke', 'B'), ('volume', 'O'), ('.', 'O'))"
Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .,"(('Oxytocin', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('at', 'O'), ('cesarean', 'O'), ('delivery', 'O'), ('may', 'O'), ('be', 'O'), ('incorrectly', 'O'), ('attributed', 'O'), ('to', 'O'), ('blood', 'B'), ('loss', 'I'), ('.', 'O'))"
"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .","(('Hypotension', 'B'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('oxytocin', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('systemic', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('and', 'O'), ('a', 'O'), ('compensatory', 'O'), ('increase', 'O'), ('in', 'O'), ('stroke', 'B'), ('volume', 'O'), (',', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('cardiac', 'O'), ('output', 'O'), ('.', 'O'))"
Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .,"(('Pulse', 'O'), ('power', 'O'), ('analysis', 'O'), ('may', 'O'), ('be', 'O'), ('helpful', 'O'), ('in', 'O'), ('determining', 'O'), ('the', 'O'), ('etiology', 'O'), ('of', 'O'), ('and', 'O'), ('treating', 'O'), ('hypotension', 'B'), ('during', 'O'), ('cesarean', 'O'), ('delivery', 'O'), ('under', 'O'), ('neuraxial', 'O'), ('anesthesia', 'O'), ('.', 'O'))"
Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .,"(('Protective', 'O'), ('effects', 'O'), ('of', 'O'), ('antithrombin', 'O'), ('on', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('nephrosis', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .","(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('antithrombin', 'O'), (',', 'O'), ('a', 'O'), ('plasma', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('coagulation', 'O'), ('factors', 'O'), (',', 'O'), ('in', 'O'), ('rats', 'O'), ('with', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrosis', 'B'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('an', 'O'), ('experimental', 'O'), ('model', 'O'), ('of', 'O'), ('human', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .,"(('Treatment', 'O'), ('with', 'O'), ('antithrombin', 'O'), ('attenuated', 'O'), ('the', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('hematological', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .,"(('Puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('hyperlipidemia', 'B'), ('were', 'O'), ('also', 'O'), ('suppressed', 'O'), ('.', 'O'))"
"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .","(('Histopathological', 'O'), ('examination', 'O'), ('revealed', 'O'), ('severe', 'O'), ('renal', 'B'), ('damage', 'I'), ('such', 'O'), ('as', 'O'), ('proteinaceous', 'O'), ('casts', 'O'), ('in', 'O'), ('tubuli', 'O'), ('and', 'O'), ('tubular', 'O'), ('expansion', 'O'), ('in', 'O'), ('the', 'O'), ('kidney', 'O'), ('of', 'O'), ('control', 'O'), ('rats', 'O'), (',', 'O'), ('while', 'O'), ('an', 'O'), ('improvement', 'O'), ('of', 'O'), ('the', 'O'), ('damage', 'O'), ('was', 'O'), ('seen', 'O'), ('in', 'O'), ('antithrombin', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('thrombin', 'O'), ('plays', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .,"(('Treatment', 'O'), ('with', 'O'), ('antithrombin', 'O'), ('may', 'O'), ('be', 'O'), ('clinically', 'O'), ('effective', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Heparin - induced thrombocytopenia after liver transplantation .,"(('Heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .,"(('BACKGROUND', 'O'), (':', 'O'), ('Unfractionated', 'O'), ('heparin', 'O'), ('sodium', 'O'), ('(', 'O'), ('UFH', 'O'), (')', 'O'), ('or', 'O'), ('low', 'O'), ('-', 'O'), ('molecular', 'O'), ('weight', 'O'), ('heparin', 'O'), ('(', 'O'), ('LMWH', 'O'), (')', 'O'), ('is', 'O'), ('used', 'O'), ('in', 'O'), ('anticoagulant', 'O'), ('protocols', 'O'), ('at', 'O'), ('several', 'O'), ('institutions', 'O'), ('to', 'O'), ('prevent', 'O'), ('thrombosis', 'B'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('.', 'O'))"
"Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .","(('Heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('(', 'O'), ('HIT', 'B'), (')', 'O'), ('is', 'O'), ('an', 'O'), ('adverse', 'O'), ('immune', 'O'), ('-', 'O'), ('mediated', 'O'), ('reaction', 'O'), ('to', 'O'), ('heparin', 'O'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('platelet', 'O'), ('count', 'O'), ('decreases', 'O'), ('of', 'O'), ('more', 'O'), ('than', 'O'), ('50', 'O'), ('%', 'O'), ('.', 'O'))"
"The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .","(('The', 'O'), ('frequencies', 'O'), ('of', 'O'), ('HIT', 'B'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('and', 'O'), ('platelet', 'O'), ('factor', 'O'), ('4', 'O'), ('/', 'O'), ('heparin', 'O'), ('-', 'O'), ('reactive', 'O'), ('antibody', 'O'), ('(', 'O'), ('HIT', 'B'), ('antibody', 'O'), (')', 'O'), ('positivity', 'O'), ('in', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('patients', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('are', 'O'), ('unknown', 'O'), ('.', 'O'))"
HIT antibody levels were measured the day before surgery and on POD 7 and 14 .,"(('HIT', 'B'), ('antibody', 'O'), ('levels', 'O'), ('were', 'O'), ('measured', 'O'), ('the', 'O'), ('day', 'O'), ('before', 'O'), ('surgery', 'O'), ('and', 'O'), ('on', 'O'), ('POD', 'O'), ('7', 'O'), ('and', 'O'), ('14', 'O'), ('.', 'O'))"
"Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .","(('Two', 'O'), ('patients', 'O'), ('developed', 'O'), ('hepatic', 'O'), ('artery', 'O'), ('thrombosis', 'B'), ('on', 'O'), ('POD', 'O'), ('11', 'O'), ('and', 'O'), ('19', 'O'), (',', 'O'), ('respectively', 'O'), (',', 'O'), ('although', 'O'), ('they', 'O'), ('were', 'O'), ('HIT', 'B'), ('antibody', 'O'), ('-', 'O'), ('negative', 'O'), ('and', 'O'), ('their', 'O'), ('platelet', 'O'), ('counts', 'O'), ('were', 'O'), ('stable', 'O'), ('.', 'O'))"
The heparin - induced platelet aggregation test was negative in these patients .,"(('The', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('test', 'O'), ('was', 'O'), ('negative', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('.', 'O'))"
"The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .","(('The', 'O'), ('percentage', 'O'), ('of', 'O'), ('HIT', 'B'), ('antibody', 'O'), ('-', 'O'), ('positive', 'O'), ('patients', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('preoperatively', 'O'), (',', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('on', 'O'), ('POD', 'O'), ('7', 'O'), (',', 'O'), ('and', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('on', 'O'), ('POD', 'O'), ('14', 'O'), ('.', 'O'))"
None of the subjects / patients developed UFH - related HIT .,"(('None', 'O'), ('of', 'O'), ('the', 'O'), ('subjects', 'O'), ('/', 'O'), ('patients', 'O'), ('developed', 'O'), ('UFH', 'O'), ('-', 'O'), ('related', 'O'), ('HIT', 'B'), ('.', 'O'))"
"CONCLUSIONS : In our series , the occurrence of HIT after liver transplantation was uncommon .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('our', 'O'), ('series', 'O'), (',', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('HIT', 'B'), ('after', 'O'), ('liver', 'O'), ('transplantation', 'O'), ('was', 'O'), ('uncommon', 'O'), ('.', 'O'))"
Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .,"(('Doxorubicin', 'O'), ('cardiomyopathy', 'B'), ('-', 'O'), ('induced', 'O'), ('inflammation', 'B'), ('and', 'O'), ('apoptosis', 'O'), ('are', 'O'), ('attenuated', 'O'), ('by', 'O'), ('gene', 'O'), ('deletion', 'O'), ('of', 'O'), ('the', 'O'), ('kinin', 'O'), ('B1', 'O'), ('receptor', 'O'), ('.', 'O'))"
"Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .","(('Clinical', 'O'), ('use', 'O'), ('of', 'O'), ('the', 'O'), ('anthracycline', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('DOX', 'O'), (')', 'O'), ('is', 'O'), ('limited', 'O'), ('by', 'O'), ('its', 'O'), ('cardiotoxic', 'B'), ('effects', 'O'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('attributed', 'O'), ('to', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
"To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('possible', 'O'), ('role', 'O'), ('of', 'O'), ('the', 'O'), ('kinin', 'O'), ('B1', 'O'), ('receptor', 'O'), ('(', 'O'), ('B1R', 'O'), (')', 'O'), ('during', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('DOX', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('we', 'O'), ('studied', 'O'), ('B1R', 'O'), ('knockout', 'O'), ('mice', 'O'), ('(', 'O'), ('B1R', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), (')', 'O'), ('by', 'O'), ('investigating', 'O'), ('cardiac', 'O'), ('inflammation', 'B'), ('and', 'O'), ('apoptosis', 'O'), ('after', 'O'), ('induction', 'O'), ('of', 'O'), ('DOX', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .,"(('DOX', 'O'), ('control', 'O'), ('mice', 'O'), ('showed', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('measured', 'O'), ('by', 'O'), ('pressure', 'O'), ('-', 'O'), ('volume', 'O'), ('loops', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
"This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .","(('This', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('reduced', 'O'), ('activation', 'O'), ('state', 'O'), ('of', 'O'), ('AKT', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('an', 'O'), ('increased', 'O'), ('bax', 'O'), ('/', 'O'), ('bcl2', 'O'), ('ratio', 'O'), ('in', 'O'), ('Western', 'O'), ('blots', 'O'), (',', 'O'), ('indicating', 'O'), ('cardiac', 'B'), ('apoptosis', 'I'), ('.', 'O'))"
"In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .","(('In', 'O'), ('DOX', 'O'), ('B1R', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), (',', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), ('was', 'O'), ('improved', 'O'), ('compared', 'O'), ('to', 'O'), ('DOX', 'O'), ('control', 'O'), ('mice', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('normalization', 'O'), ('of', 'O'), ('the', 'O'), ('bax', 'O'), ('/', 'O'), ('bcl', 'O'), ('-', 'O'), ('2', 'O'), ('ratio', 'O'), ('and', 'O'), ('interleukin', 'O'), ('6', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('AKT', 'O'), ('activation', 'O'), ('state', 'O'), ('.', 'O'))"
These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('B1R', 'O'), ('is', 'O'), ('detrimental', 'O'), ('in', 'O'), ('DOX', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('that', 'O'), ('it', 'O'), ('mediates', 'O'), ('the', 'O'), ('inflammatory', 'O'), ('response', 'O'), ('and', 'O'), ('apoptosis', 'O'), ('.', 'O'))"
These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .,"(('These', 'O'), ('insights', 'O'), ('might', 'O'), ('have', 'O'), ('useful', 'O'), ('implications', 'O'), ('for', 'O'), ('future', 'O'), ('studies', 'O'), ('utilizing', 'O'), ('B1R', 'O'), ('antagonists', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('human', 'O'), ('DOX', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .,"(('Detailed', 'O'), ('spectral', 'O'), ('profile', 'O'), ('analysis', 'O'), ('of', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('epileptiform', 'B'), ('activity', 'I'), ('in', 'O'), ('anesthetized', 'O'), ('rats', 'O'), ('.', 'O'))"
Penicillin model is a widely used experimental model for epilepsy research .,"(('Penicillin', 'O'), ('model', 'O'), ('is', 'O'), ('a', 'O'), ('widely', 'O'), ('used', 'O'), ('experimental', 'O'), ('model', 'O'), ('for', 'O'), ('epilepsy', 'B'), ('research', 'O'), ('.', 'O'))"
In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .,"(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('we', 'O'), ('aimed', 'O'), ('to', 'O'), ('portray', 'O'), ('a', 'O'), ('detailed', 'O'), ('spectral', 'O'), ('analysis', 'O'), ('of', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('epileptiform', 'B'), ('activity', 'I'), ('in', 'O'), ('comparison', 'O'), ('with', 'O'), ('basal', 'O'), ('brain', 'O'), ('activity', 'O'), ('in', 'O'), ('anesthetized', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('.', 'O'))"
"After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .","(('After', 'O'), ('a', 'O'), ('short', 'O'), ('period', 'O'), ('of', 'O'), ('basal', 'O'), ('activity', 'O'), ('recording', 'O'), (',', 'O'), ('epileptic', 'B'), ('focus', 'O'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('injecting', 'O'), ('400IU', 'O'), ('/', 'O'), ('2', 'O'), ('microl', 'O'), ('penicillin', 'O'), ('-', 'O'), ('G', 'O'), ('potassium', 'O'), ('into', 'O'), ('the', 'O'), ('left', 'O'), ('lateral', 'O'), ('ventricle', 'O'), ('while', 'O'), ('the', 'O'), ('cortical', 'O'), ('activity', 'O'), ('was', 'O'), ('continuously', 'O'), ('recorded', 'O'), ('.', 'O'))"
"Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .","(('Basal', 'O'), ('activity', 'O'), (',', 'O'), ('latent', 'O'), ('period', 'O'), ('and', 'O'), ('the', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('epileptiform', 'B'), ('activity', 'I'), ('periods', 'O'), ('were', 'O'), ('then', 'O'), ('analyzed', 'O'), ('using', 'O'), ('both', 'O'), ('conventional', 'O'), ('methods', 'O'), ('and', 'O'), ('spectral', 'O'), ('analysis', 'O'), ('.', 'O'))"
"Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .","(('Our', 'O'), ('results', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('most', 'O'), ('affected', 'O'), ('frequency', 'O'), ('bands', 'O'), ('were', 'O'), ('delta', 'O'), (',', 'O'), ('theta', 'O'), (',', 'O'), ('beta', 'O'), ('-', 'O'), ('2', 'O'), ('and', 'O'), ('gamma', 'O'), ('-', 'O'), ('2', 'O'), ('bands', 'O'), ('during', 'O'), ('the', 'O'), ('epileptiform', 'B'), ('activity', 'I'), ('and', 'O'), ('there', 'O'), ('were', 'O'), ('marked', 'O'), ('differences', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('spectral', 'O'), ('densities', 'O'), ('between', 'O'), ('three', 'O'), ('investigated', 'O'), ('episodes', 'O'), ('(', 'O'), ('basal', 'O'), ('activity', 'O'), (',', 'O'), ('latent', 'O'), ('period', 'O'), ('and', 'O'), ('epileptiform', 'B'), ('activity', 'I'), (')', 'O'), ('.', 'O'))"
High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .,"(('High', 'O'), ('fat', 'O'), ('diet', 'O'), ('-', 'O'), ('fed', 'O'), ('obese', 'B'), ('rats', 'O'), ('are', 'O'), ('highly', 'O'), ('sensitive', 'O'), ('to', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .","(('Often', 'O'), (',', 'O'), ('chemotherapy', 'O'), ('by', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('Adriamycin', 'O'), (')', 'O'), ('is', 'O'), ('limited', 'O'), ('due', 'O'), ('to', 'O'), ('life', 'O'), ('threatening', 'O'), ('cardiotoxicity', 'B'), ('in', 'O'), ('patients', 'O'), ('during', 'O'), ('and', 'O'), ('posttherapy', 'O'), ('.', 'O'))"
"Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .","(('Recently', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('moderate', 'O'), ('diet', 'O'), ('restriction', 'O'), ('remarkably', 'O'), ('protects', 'O'), ('against', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .","(('In', 'O'), ('the', 'O'), ('current', 'O'), ('study', 'O'), (',', 'O'), ('we', 'O'), ('investigated', 'O'), ('whether', 'O'), ('a', 'O'), ('physiological', 'O'), ('intervention', 'O'), ('by', 'O'), ('feeding', 'O'), ('40', 'O'), ('%', 'O'), ('high', 'O'), ('fat', 'O'), ('diet', 'O'), ('(', 'O'), ('HFD', 'O'), (')', 'O'), (',', 'O'), ('which', 'O'), ('induces', 'O'), ('obesity', 'B'), ('in', 'O'), ('male', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('(', 'O'), ('250', 'O'), ('-', 'O'), ('275', 'O'), ('g', 'O'), (')', 'O'), (',', 'O'), ('sensitizes', 'O'), ('to', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .","(('A', 'O'), ('LD', 'O'), ('(', 'O'), ('10', 'O'), (')', 'O'), ('dose', 'O'), ('(', 'O'), ('8', 'O'), ('mg', 'O'), ('doxorubicin', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('ip', 'O'), (')', 'O'), ('administered', 'O'), ('on', 'O'), ('day', 'O'), ('43', 'O'), ('of', 'O'), ('the', 'O'), ('HFD', 'O'), ('feeding', 'O'), ('regimen', 'O'), ('led', 'O'), ('to', 'O'), ('higher', 'O'), ('cardiotoxicity', 'B'), (',', 'O'), ('cardiac', 'B'), ('dysfunction', 'I'), (',', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), (',', 'O'), ('and', 'O'), ('80', 'O'), ('%', 'O'), ('mortality', 'O'), ('in', 'O'), ('the', 'O'), ('obese', 'B'), ('(', 'O'), ('OB', 'B'), (')', 'O'), ('rats', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('any', 'O'), ('significant', 'O'), ('renal', 'B'), ('or', 'I'), ('hepatic', 'I'), ('toxicity', 'I'), ('.', 'O'))"
"In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('HFD', 'O'), ('-', 'O'), ('induced', 'O'), ('obese', 'B'), ('rats', 'O'), ('are', 'O'), ('highly', 'O'), ('sensitized', 'O'), ('to', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('by', 'O'), ('substantially', 'O'), ('downregulating', 'O'), ('cardiac', 'O'), ('mitochondrial', 'O'), ('ATP', 'O'), ('generation', 'O'), (',', 'O'), ('increasing', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('and', 'O'), ('downregulating', 'O'), ('the', 'O'), ('JAK', 'O'), ('/', 'O'), ('STAT3', 'O'), ('pathway', 'O'), ('.', 'O'))"
Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .,"(('Isoproterenol', 'O'), ('induces', 'O'), ('primary', 'O'), ('loss', 'O'), ('of', 'O'), ('dystrophin', 'O'), ('in', 'O'), ('rat', 'O'), ('hearts', 'O'), (':', 'O'), ('correlation', 'O'), ('with', 'O'), ('myocardial', 'B'), ('injury', 'I'), ('.', 'O'))"
"The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .","(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('isoproterenol', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('damage', 'I'), ('is', 'O'), ('unknown', 'O'), (',', 'O'), ('but', 'O'), ('a', 'O'), ('mismatch', 'O'), ('of', 'O'), ('oxygen', 'O'), ('supply', 'O'), ('vs', 'O'), ('.', 'O'), ('demand', 'O'), ('following', 'O'), ('coronary', 'O'), ('hypotension', 'B'), ('and', 'O'), ('myocardial', 'B'), ('hyperactivity', 'I'), ('is', 'O'), ('the', 'O'), ('best', 'O'), ('explanation', 'O'), ('for', 'O'), ('the', 'O'), ('complex', 'O'), ('morphological', 'O'), ('alterations', 'O'), ('observed', 'O'), ('.', 'O'))"
"These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .","(('These', 'O'), ('changes', 'O'), (',', 'O'), ('related', 'O'), ('to', 'O'), ('ischaemic', 'B'), ('injury', 'I'), (',', 'O'), ('explain', 'O'), ('the', 'O'), ('severe', 'O'), ('alterations', 'O'), ('in', 'O'), ('the', 'O'), ('structural', 'O'), ('integrity', 'O'), ('of', 'O'), ('the', 'O'), ('sarcolemma', 'O'), ('of', 'O'), ('cardiomyocytes', 'O'), ('and', 'O'), ('hence', 'O'), ('severe', 'O'), ('and', 'O'), ('irreversible', 'O'), ('injury', 'O'), ('induced', 'O'), ('by', 'O'), ('isoproterenol', 'O'), ('.', 'O'))"
Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .,"(('Etiologic', 'O'), ('factors', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('liver', 'B'), ('tumors', 'I'), ('associated', 'O'), ('with', 'O'), ('oral', 'O'), ('contraceptives', 'O'), ('.', 'O'))"
"Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .","(('Within', 'O'), ('the', 'O'), ('last', 'O'), ('several', 'O'), ('years', 'O'), (',', 'O'), ('previously', 'O'), ('rare', 'O'), ('liver', 'B'), ('tumors', 'I'), ('have', 'O'), ('been', 'O'), ('seen', 'O'), ('in', 'O'), ('young', 'O'), ('women', 'O'), ('using', 'O'), ('oral', 'O'), ('contraceptive', 'O'), ('steroids', 'O'), ('.', 'O'))"
"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .","(('The', 'O'), ('Registry', 'O'), ('for', 'O'), ('Liver', 'B'), ('Tumors', 'I'), ('Associated', 'O'), ('with', 'O'), ('Oral', 'O'), ('Contraceptives', 'O'), ('at', 'O'), ('the', 'O'), ('University', 'O'), ('of', 'O'), ('California', 'O'), (',', 'O'), ('Irvine', 'O'), (',', 'O'), ('has', 'O'), ('clearly', 'O'), ('identified', 'O'), ('27', 'O'), ('cases', 'O'), ('.', 'O'))"
"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .","(('Common', 'O'), ('to', 'O'), ('these', 'O'), ('71', 'O'), ('cases', 'O'), ('has', 'O'), ('been', 'O'), ('a', 'O'), ('histopathologic', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('focal', 'B'), ('nodular', 'I'), ('hyperplasia', 'I'), (',', 'O'), ('adenoma', 'B'), (',', 'O'), ('hamartoma', 'B'), (',', 'O'), ('and', 'O'), ('hepatoma', 'B'), ('.', 'O'))"
"Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .","(('Four', 'O'), ('patients', 'O'), ('developed', 'O'), ('transient', 'O'), ('microscopic', 'O'), ('hematuria', 'B'), ('at', 'O'), ('400', 'O'), (',', 'O'), ('450', 'O'), (',', 'O'), ('and', 'O'), ('500', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('.', 'O'))"
There were no instances of macroscopic hematuria .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('instances', 'O'), ('of', 'O'), ('macroscopic', 'O'), ('hematuria', 'B'), ('.', 'O'))"
"At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .","(('At', 'O'), ('550', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), (',', 'O'), ('three', 'O'), ('patients', 'O'), ('experienced', 'O'), ('nonurologic', 'O'), ('toxicity', 'B'), (';', 'O'), ('confusion', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('Grade', 'O'), ('2', 'O'), ('leukopenia', 'B'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .","(('The', 'O'), ('frequency', 'O'), ('and', 'O'), ('predictability', 'O'), ('of', 'O'), ('hematuria', 'B'), ('are', 'O'), ('not', 'O'), ('precise', 'O'), (',', 'O'), ('and', 'O'), ('at', 'O'), ('least', 'O'), ('daily', 'O'), ('monitoring', 'O'), ('by', 'O'), ('urine', 'O'), ('Hematest', 'O'), ('is', 'O'), ('essential', 'O'), (',', 'O'), ('adding', 'O'), ('Mesna', 'O'), ('to', 'O'), ('the', 'O'), ('infusate', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('persistent', 'O'), ('hematuria', 'B'), ('.', 'O'))"
A case of ventricular tachycardia related to caffeine pretreatment .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('related', 'O'), ('to', 'O'), ('caffeine', 'O'), ('pretreatment', 'O'), ('.', 'O'))"
"Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .","(('Suboptimal', 'O'), ('seizure', 'B'), ('duration', 'O'), ('is', 'O'), ('commonly', 'O'), ('encountered', 'O'), ('in', 'O'), ('electroconvulsive', 'O'), ('therapy', 'O'), ('practice', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('older', 'O'), ('patients', 'O'), ('with', 'O'), ('higher', 'O'), ('seizure', 'B'), ('thresholds', 'O'), ('.', 'O'))"
Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .,"(('Intravenous', 'O'), ('caffeine', 'O'), ('is', 'O'), ('commonly', 'O'), ('used', 'O'), ('to', 'O'), ('improve', 'O'), ('seizure', 'B'), ('duration', 'O'), ('and', 'O'), ('quality', 'O'), ('in', 'O'), ('such', 'O'), ('patients', 'O'), ('and', 'O'), ('is', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), ('aside', 'O'), ('from', 'O'), ('occasional', 'O'), ('reports', 'O'), ('of', 'O'), ('relatively', 'O'), ('benign', 'O'), ('ventricular', 'B'), ('ectopy', 'I'), ('.', 'O'))"
We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('no', 'O'), ('previous', 'O'), ('history', 'O'), ('of', 'O'), ('cardiac', 'B'), ('disease', 'I'), ('or', 'O'), ('arrhythmia', 'B'), ('who', 'O'), ('developed', 'O'), ('sustained', 'O'), ('bigeminy', 'O'), ('and', 'O'), ('2', 'O'), ('brief', 'O'), ('runs', 'O'), ('of', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('after', 'O'), ('caffeine', 'O'), ('administration', 'O'), ('.', 'O'))"
"Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .","(('Although', 'O'), ('intravenous', 'O'), ('caffeine', 'O'), ('is', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), (',', 'O'), ('the', 'O'), ('clinician', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('the', 'O'), ('potential', 'O'), ('for', 'O'), ('unpredictable', 'O'), ('and', 'O'), ('serious', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .,"(('Fatal', 'O'), ('haemopericardium', 'B'), ('and', 'O'), ('gastrointestinal', 'B'), ('haemorrhage', 'I'), ('due', 'O'), ('to', 'O'), ('possible', 'O'), ('interaction', 'O'), ('of', 'O'), ('cranberry', 'O'), ('juice', 'O'), ('with', 'O'), ('warfarin', 'O'), ('.', 'O'))"
We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('fatal', 'O'), ('internal', 'O'), ('haemorrhage', 'B'), ('in', 'O'), ('an', 'O'), ('elderly', 'O'), ('man', 'O'), ('who', 'O'), ('consumed', 'O'), ('only', 'O'), ('cranberry', 'O'), ('juice', 'O'), ('for', 'O'), ('two', 'O'), ('weeks', 'O'), ('while', 'O'), ('maintaining', 'O'), ('his', 'O'), ('usual', 'O'), ('dosage', 'O'), ('of', 'O'), ('warfarin', 'O'), ('.', 'O'))"
Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .,"(('Effect', 'O'), ('of', 'O'), ('increasing', 'O'), ('intraperitoneal', 'O'), ('infusion', 'O'), ('rates', 'O'), ('on', 'O'), ('bupropion', 'O'), ('hydrochloride', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .,"(('BACKGROUND', 'O'), (':', 'O'), ('It', 'O'), ('is', 'O'), ('not', 'O'), ('known', 'O'), ('if', 'O'), ('there', 'O'), ('is', 'O'), ('a', 'O'), ('relationship', 'O'), ('between', 'O'), ('input', 'O'), ('rate', 'O'), ('and', 'O'), ('incidence', 'O'), ('of', 'O'), ('bupropion', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
"METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .","(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('varying', 'O'), ('the', 'O'), ('intraperitoneal', 'O'), ('infusion', 'O'), ('rates', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('a', 'O'), ('known', 'O'), ('convulsive', 'B'), ('dose', 'O'), ('50', 'O'), ('(', 'O'), ('CD50', 'O'), (')', 'O'), (',', 'O'), ('on', 'O'), ('the', 'O'), ('incidence', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('bupropion', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('in', 'O'), ('the', 'O'), ('Swiss', 'O'), ('albino', 'O'), ('mice', 'O'), ('.', 'O'))"
"The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .","(('The', 'O'), ('number', 'O'), (',', 'O'), ('time', 'O'), ('of', 'O'), ('onset', 'O'), (',', 'O'), ('duration', 'O'), ('and', 'O'), ('the', 'O'), ('intensity', 'O'), ('of', 'O'), ('the', 'O'), ('convulsions', 'B'), ('or', 'O'), ('absence', 'O'), ('of', 'O'), ('convulsions', 'B'), ('were', 'O'), ('recorded', 'O'), ('.', 'O'))"
RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('results', 'O'), ('showed', 'O'), ('that', 'O'), ('IP', 'O'), ('administration', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('by', 'O'), ('bolus', 'O'), ('injection', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('in', 'O'), ('6', 'O'), ('out', 'O'), ('of', 'O'), ('10', 'O'), ('mice', 'O'), ('(', 'O'), ('60', 'O'), ('%', 'O'), ('of', 'O'), ('convulsing', 'O'), ('mice', 'O'), (')', 'O'), ('in', 'O'), ('group', 'O'), ('1', 'O'), ('.', 'O'))"
Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .,"(('Logistic', 'O'), ('regression', 'O'), ('analysis', 'O'), ('revealed', 'O'), ('that', 'O'), ('infusion', 'O'), ('time', 'O'), ('was', 'O'), ('significant', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0004', 'O'), (';', 'O'), ('odds', 'O'), ('ratio', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('974', 'O'), (')', 'O'), ('and', 'O'), ('increasing', 'O'), ('the', 'O'), ('IP', 'O'), ('infusion', 'O'), ('time', 'O'), ('of', 'O'), ('bupropion', 'O'), ('HCl', 'O'), ('120', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('91', 'O'), ('%', 'O'), ('reduced', 'O'), ('odds', 'O'), ('of', 'O'), ('convulsions', 'B'), ('at', 'O'), ('infusion', 'O'), ('times', 'O'), ('of', 'O'), ('15', 'O'), ('to', 'O'), ('90', 'O'), ('min', 'O'), ('compared', 'O'), ('to', 'O'), ('bolus', 'O'), ('injection', 'O'), ('.', 'O'))"
Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .,"(('Further', 'O'), ('increase', 'O'), ('in', 'O'), ('infusion', 'O'), ('time', 'O'), ('resulted', 'O'), ('in', 'O'), ('further', 'O'), ('reduction', 'O'), ('in', 'O'), ('the', 'O'), ('odds', 'O'), ('of', 'O'), ('convulsions', 'B'), ('to', 'O'), ('99', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('reduction', 'O'), ('at', 'O'), ('240', 'O'), ('min', 'O'), ('.', 'O'))"
"CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .","(('CONCLUSION', 'O'), (':', 'O'), ('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('demonstration', 'O'), ('of', 'O'), ('an', 'O'), ('inverse', 'O'), ('relationship', 'O'), ('between', 'O'), ('infusion', 'O'), ('time', 'O'), ('of', 'O'), ('a', 'O'), ('fixed', 'O'), ('and', 'O'), ('convulsive', 'B'), ('dose', 'O'), ('of', 'O'), ('bupropion', 'O'), ('and', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('convulsions', 'B'), ('in', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('is', 'O'), ('novel', 'O'), ('.', 'O'))"
Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .,"(('Graft', 'B'), ('-', 'I'), ('versus', 'I'), ('-', 'I'), ('host', 'I'), ('disease', 'I'), ('prophylaxis', 'O'), ('with', 'O'), ('everolimus', 'O'), ('and', 'O'), ('tacrolimus', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('high', 'O'), ('incidence', 'O'), ('of', 'O'), ('sinusoidal', 'B'), ('obstruction', 'I'), ('syndrome', 'I'), ('and', 'O'), ('microangiopathy', 'B'), (':', 'O'), ('results', 'O'), ('of', 'O'), ('the', 'O'), ('EVTAC', 'O'), ('trial', 'O'), ('.', 'O'))"
A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .,"(('A', 'O'), ('calcineurin', 'O'), ('inhibitor', 'O'), ('combined', 'O'), ('with', 'O'), ('methotrexate', 'O'), ('is', 'O'), ('the', 'O'), ('standard', 'O'), ('prophylaxis', 'O'), ('for', 'O'), ('graft', 'B'), ('-', 'I'), ('versus', 'I'), ('-', 'I'), ('host', 'I'), ('disease', 'I'), ('(', 'O'), ('GVHD', 'B'), (')', 'O'), ('after', 'O'), ('allogeneic', 'O'), ('hematopoietic', 'O'), ('stem', 'O'), ('cell', 'O'), ('transplantation', 'O'), ('(', 'O'), ('HSCT', 'O'), (')', 'O'), ('.', 'O'))"
"We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .","(('We', 'O'), ('report', 'O'), ('on', 'O'), ('a', 'O'), ('combination', 'O'), ('of', 'O'), ('everolimus', 'O'), ('and', 'O'), ('tacrolimus', 'O'), ('in', 'O'), ('24', 'O'), ('patients', 'O'), ('(', 'O'), ('median', 'O'), ('age', 'O'), (',', 'O'), ('62', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('either', 'O'), ('myelodysplastic', 'B'), ('syndrome', 'I'), ('(', 'O'), ('MDS', 'B'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('17', 'O'), (')', 'O'), ('or', 'O'), ('acute', 'B'), ('myeloid', 'I'), ('leukemia', 'I'), ('(', 'O'), ('AML', 'B'), (';', 'O'), ('n', 'O'), ('=', 'O'), ('7', 'O'), (')', 'O'), ('undergoing', 'O'), ('intensive', 'O'), ('conditioning', 'O'), ('followed', 'O'), ('by', 'O'), ('HSCT', 'O'), ('from', 'O'), ('related', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('4', 'O'), (')', 'O'), ('or', 'O'), ('unrelated', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('20', 'O'), (')', 'O'), ('donors', 'O'), ('.', 'O'))"
"All patients engrafted , and only 1 patient experienced grade IV mucositis .","(('All', 'O'), ('patients', 'O'), ('engrafted', 'O'), (',', 'O'), ('and', 'O'), ('only', 'O'), ('1', 'O'), ('patient', 'O'), ('experienced', 'O'), ('grade', 'O'), ('IV', 'O'), ('mucositis', 'B'), ('.', 'O'))"
"Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .","(('Transplantation', 'B'), ('-', 'I'), ('associated', 'I'), ('microangiopathy', 'I'), ('(', 'O'), ('TMA', 'B'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('7', 'O'), ('patients', 'O'), ('(', 'O'), ('29', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('2', 'O'), ('cases', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
"The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .","(('The', 'O'), ('study', 'O'), ('was', 'O'), ('terminated', 'O'), ('prematurely', 'O'), ('because', 'O'), ('an', 'O'), ('additional', 'O'), ('6', 'O'), ('patients', 'O'), ('(', 'O'), ('25', 'O'), ('%', 'O'), (')', 'O'), ('developed', 'O'), ('sinusoidal', 'B'), ('obstruction', 'I'), ('syndrome', 'I'), ('(', 'O'), ('SOS', 'B'), (')', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('fatal', 'O'), ('in', 'O'), ('2', 'O'), ('cases', 'O'), ('.', 'O'))"
"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .","(('Although', 'O'), ('this', 'O'), ('new', 'O'), ('combination', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('effective', 'O'), ('as', 'O'), ('a', 'O'), ('prophylactic', 'O'), ('regimen', 'O'), ('for', 'O'), ('acute', 'O'), ('GVHD', 'B'), (',', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('TMA', 'B'), ('and', 'O'), ('SOS', 'B'), ('is', 'O'), ('considerably', 'O'), ('higher', 'O'), ('than', 'O'), ('seen', 'O'), ('with', 'O'), ('other', 'O'), ('regimens', 'O'), ('.', 'O'))"
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .,"(('Longitudinal', 'O'), ('assessment', 'O'), ('of', 'O'), ('air', 'O'), ('conduction', 'O'), ('audiograms', 'O'), ('in', 'O'), ('a', 'O'), ('phase', 'O'), ('III', 'O'), ('clinical', 'O'), ('trial', 'O'), ('of', 'O'), ('difluoromethylornithine', 'O'), ('and', 'O'), ('sulindac', 'O'), ('for', 'O'), ('prevention', 'O'), ('of', 'O'), ('sporadic', 'O'), ('colorectal', 'B'), ('adenomas', 'I'), ('.', 'O'))"
"Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .","(('Temporary', 'O'), ('hearing', 'B'), ('loss', 'I'), ('is', 'O'), ('a', 'O'), ('known', 'O'), ('toxicity', 'B'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('DFMO', 'O'), (',', 'O'), ('thus', 'O'), ('a', 'O'), ('comprehensive', 'O'), ('approach', 'O'), ('was', 'O'), ('developed', 'O'), ('to', 'O'), ('analyze', 'O'), ('serial', 'O'), ('air', 'O'), ('conduction', 'O'), ('audiograms', 'O'), ('.', 'O'))"
There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('significant', 'O'), ('difference', 'O'), ('in', 'O'), ('the', 'O'), ('proportion', 'O'), ('of', 'O'), ('subjects', 'O'), ('in', 'O'), ('the', 'O'), ('DFMO', 'O'), ('plus', 'O'), ('sulindac', 'O'), ('group', 'O'), ('who', 'O'), ('experienced', 'O'), ('clinically', 'O'), ('significant', 'O'), ('hearing', 'B'), ('loss', 'I'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), ('.', 'O'))"
"The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .","(('The', 'O'), ('estimated', 'O'), ('attributable', 'O'), ('risk', 'O'), ('of', 'O'), ('ototoxicity', 'B'), ('from', 'O'), ('exposure', 'O'), ('to', 'O'), ('the', 'O'), ('drug', 'O'), ('is', 'O'), ('8', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('0', 'O'), ('%', 'O'), ('to', 'O'), ('18', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('12', 'O'), (')', 'O'), ('.', 'O'))"
Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .,"(('Proteinase', 'O'), ('3', 'O'), ('-', 'O'), ('antineutrophil', 'O'), ('cytoplasmic', 'O'), ('antibody', 'O'), ('-', 'O'), ('(', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), (')', 'O'), ('positive', 'O'), ('necrotizing', 'O'), ('glomerulonephritis', 'B'), ('after', 'O'), ('restarting', 'O'), ('sulphasalazine', 'O'), ('treatment', 'O'), ('.', 'O'))"
"A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .","(('A', 'O'), ('59', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('ulcerative', 'B'), ('colitis', 'I'), ('developed', 'O'), ('red', 'B'), ('eyes', 'I'), (',', 'O'), ('pleural', 'B'), ('effusion', 'I'), (',', 'O'), ('eosinophilia', 'B'), ('and', 'O'), ('urinary', 'B'), ('abnormalities', 'I'), ('after', 'O'), ('restarting', 'O'), ('of', 'O'), ('sulphasalazine', 'O'), ('treatment', 'O'), ('.', 'O'))"
"PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .","(('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), ('titer', 'O'), ('was', 'O'), ('250', 'O'), ('and', 'O'), ('1', 'O'), (',', 'O'), ('070', 'O'), ('EU', 'O'), ('in', 'O'), ('pleural', 'B'), ('effusions', 'I'), ('on', 'O'), ('right', 'O'), ('and', 'O'), ('left', 'O'), ('side', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .","(('Although', 'O'), ('cessation', 'O'), ('of', 'O'), ('sulphasalazine', 'O'), ('treatment', 'O'), ('resulted', 'O'), ('in', 'O'), ('improvements', 'O'), ('in', 'O'), ('fever', 'B'), (',', 'O'), ('red', 'B'), ('eyes', 'I'), (',', 'O'), ('chest', 'B'), ('pain', 'I'), (',', 'O'), ('titer', 'O'), ('of', 'O'), ('C', 'O'), ('-', 'O'), ('reactive', 'O'), ('protein', 'O'), ('and', 'O'), ('volume', 'O'), ('of', 'O'), ('the', 'O'), ('pleural', 'B'), ('effusions', 'I'), (',', 'O'), ('we', 'O'), ('initiated', 'O'), ('steroid', 'O'), ('therapy', 'O'), (',', 'O'), ('because', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), ('titer', 'O'), ('rose', 'O'), ('to', 'O'), ('320', 'O'), ('EU', 'O'), (',', 'O'), ('eosinophil', 'O'), ('count', 'O'), ('increased', 'O'), ('to', 'O'), ('1', 'O'), (',', 'O'), ('100', 'O'), ('cells', 'O'), ('/', 'O'), ('microl', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('pleural', 'B'), ('effusion', 'I'), ('remained', 'O'), ('.', 'O'))"
"One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .","(('One', 'O'), ('month', 'O'), ('after', 'O'), ('steroid', 'O'), ('therapy', 'O'), (',', 'O'), ('the', 'O'), ('pleural', 'B'), ('effusion', 'I'), ('disappeared', 'O'), (',', 'O'), ('and', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), ('titer', 'O'), ('normalized', 'O'), ('3', 'O'), ('months', 'O'), ('later', 'O'), ('.', 'O'))"
This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .,"(('This', 'O'), ('case', 'O'), ('suggests', 'O'), ('that', 'O'), ('sulphasalazine', 'O'), ('can', 'O'), ('induce', 'O'), ('PR3', 'O'), ('-', 'O'), ('ANCA', 'O'), ('-', 'O'), ('positive', 'O'), ('necrotizing', 'O'), ('glomerulonephritis', 'B'), ('.', 'O'))"
Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson ' s disease .,"(('Comparison', 'O'), ('of', 'O'), ('unilateral', 'O'), ('pallidotomy', 'O'), ('and', 'O'), ('subthalamotomy', 'O'), ('findings', 'O'), ('in', 'O'), ('advanced', 'O'), ('idiopathic', 'B'), ('Parkinson', 'I'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson ' s disease ( PD ) refractory to medical treatment was designed .","(('A', 'O'), ('prospective', 'O'), (',', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('pilot', 'O'), ('study', 'O'), ('to', 'O'), ('compare', 'O'), ('the', 'O'), ('results', 'O'), ('of', 'O'), ('stereotactic', 'O'), ('unilateral', 'O'), ('pallidotomy', 'O'), ('and', 'O'), ('subthalamotomy', 'O'), ('in', 'O'), ('advanced', 'O'), ('idiopathic', 'B'), ('Parkinson', 'I'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('(', 'O'), ('PD', 'B'), (')', 'O'), ('refractory', 'O'), ('to', 'O'), ('medical', 'O'), ('treatment', 'O'), ('was', 'O'), ('designed', 'O'), ('.', 'O'))"
"Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .","(('Ten', 'O'), ('consecutive', 'O'), ('patients', 'O'), ('(', 'O'), ('mean', 'O'), ('age', 'O'), (',', 'O'), ('58', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('8', 'O'), ('years', 'O'), (';', 'O'), ('7', 'O'), ('men', 'O'), (',', 'O'), ('3', 'O'), ('women', 'O'), (')', 'O'), ('with', 'O'), ('similar', 'O'), ('characteristics', 'O'), ('at', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('disease', 'O'), ('(', 'O'), ('mean', 'O'), ('disease', 'O'), ('time', 'O'), (',', 'O'), ('8', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('years', 'O'), (')', 'O'), (',', 'O'), ('disabling', 'O'), ('motor', 'O'), ('fluctuations', 'O'), ('(', 'O'), ('Hoehn', 'O'), ('_', 'O'), ('Yahr', 'O'), ('stage', 'O'), ('3', 'O'), ('-', 'O'), ('5', 'O'), ('in', 'O'), ('off', 'O'), ('-', 'O'), ('drug', 'O'), ('phases', 'O'), (')', 'O'), ('and', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('were', 'O'), ('selected', 'O'), ('.', 'O'))"
"Clinical evaluation included the use of the Unified Parkinson ' s Disease Rating Scale ( UPDRS ) , Hoehn _ Yahr score and Schwab England activities of daily living ( ADL ) score in ' on ' - and ' off ' - drug conditions before surgery and 6 months after surgery .","(('Clinical', 'O'), ('evaluation', 'O'), ('included', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('the', 'O'), ('Unified', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('Disease', 'I'), ('Rating', 'O'), ('Scale', 'O'), ('(', 'O'), ('UPDRS', 'O'), (')', 'O'), (',', 'O'), ('Hoehn', 'O'), ('_', 'O'), ('Yahr', 'O'), ('score', 'O'), ('and', 'O'), ('Schwab', 'O'), ('England', 'O'), ('activities', 'O'), ('of', 'O'), ('daily', 'O'), ('living', 'O'), ('(', 'O'), ('ADL', 'O'), (')', 'O'), ('score', 'O'), ('in', 'O'), (""'"", 'O'), ('on', 'O'), (""'"", 'O'), ('-', 'O'), ('and', 'O'), (""'"", 'O'), ('off', 'O'), (""'"", 'O'), ('-', 'O'), ('drug', 'O'), ('conditions', 'O'), ('before', 'O'), ('surgery', 'O'), ('and', 'O'), ('6', 'O'), ('months', 'O'), ('after', 'O'), ('surgery', 'O'), ('.', 'O'))"
There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .,"(('There', 'O'), ('was', 'O'), ('statistically', 'O'), ('significant', 'O'), ('improvement', 'O'), ('in', 'O'), ('all', 'O'), ('contralateral', 'O'), ('major', 'O'), ('parkinsonian', 'B'), ('motor', 'O'), ('signs', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), ('followed', 'O'), ('for', 'O'), ('6', 'O'), ('months', 'O'), ('.', 'O'))"
The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .,"(('The', 'O'), ('findings', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('suggest', 'O'), ('that', 'O'), ('lesions', 'O'), ('of', 'O'), ('the', 'O'), ('unilateral', 'O'), ('STN', 'O'), ('and', 'O'), ('GPi', 'O'), ('are', 'O'), ('equally', 'O'), ('effective', 'O'), ('treatment', 'O'), ('for', 'O'), ('patients', 'O'), ('with', 'O'), ('advanced', 'O'), ('PD', 'B'), ('refractory', 'O'), ('to', 'O'), ('medical', 'O'), ('treatment', 'O'), ('.', 'O'))"
A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .,"(('A', 'O'), ('clinical', 'O'), ('trial', 'O'), ('was', 'O'), ('initiated', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('recommended', 'O'), ('dose', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('bortezomib', 'O'), ('and', 'O'), ('dexamethasone', 'O'), ('as', 'O'), ('induction', 'O'), ('treatment', 'O'), ('before', 'O'), ('stem', 'O'), ('cell', 'O'), ('transplantation', 'O'), ('for', 'O'), ('younger', 'O'), ('patients', 'O'), ('with', 'O'), ('newly', 'O'), ('diagnosed', 'O'), ('multiple', 'B'), ('myeloma', 'I'), ('(', 'O'), ('MM', 'B'), (')', 'O'), ('.', 'O'))"
The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .,"(('The', 'O'), ('most', 'O'), ('frequent', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('hematological', 'B'), ('and', 'I'), ('gastrointestinal', 'I'), ('toxicities', 'I'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('neuropathy', 'B'), ('.', 'O'))"
Naloxone reversal of hypotension due to captopril overdose .,"(('Naloxone', 'O'), ('reversal', 'O'), ('of', 'O'), ('hypotension', 'B'), ('due', 'O'), ('to', 'O'), ('captopril', 'O'), ('overdose', 'B'), ('.', 'O'))"
The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .,"(('The', 'O'), ('opioid', 'O'), ('antagonist', 'O'), ('naloxone', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('block', 'O'), ('or', 'O'), ('reverse', 'O'), ('the', 'O'), ('hypotensive', 'B'), ('actions', 'O'), ('of', 'O'), ('captopril', 'O'), ('.', 'O'))"
"We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .","(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('an', 'O'), ('intentional', 'O'), ('captopril', 'O'), ('overdose', 'B'), (',', 'O'), ('manifested', 'O'), ('by', 'O'), ('marked', 'O'), ('hypotension', 'B'), (',', 'O'), ('that', 'O'), ('resolved', 'O'), ('promptly', 'O'), ('with', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('naloxone', 'O'), ('.', 'O'))"
"To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .","(('To', 'O'), ('our', 'O'), ('knowledge', 'O'), (',', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('reported', 'O'), ('case', 'O'), ('of', 'O'), ('captopril', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('treated', 'O'), ('with', 'O'), ('naloxone', 'O'), ('.', 'O'))"
Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .,"(('Our', 'O'), ('experience', 'O'), ('demonstrates', 'O'), ('a', 'O'), ('possible', 'O'), ('role', 'O'), ('of', 'O'), ('naloxone', 'O'), ('in', 'O'), ('the', 'O'), ('reversal', 'O'), ('of', 'O'), ('hypotension', 'B'), ('resulting', 'O'), ('from', 'O'), ('captopril', 'O'), ('.', 'O'))"
"Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .","(('Recently', 'O'), (',', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('commercial', 'O'), ('lots', 'O'), ('of', 'O'), ('heparin', 'O'), ('products', 'O'), ('were', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('contaminated', 'O'), ('with', 'O'), ('an', 'O'), ('oversulfated', 'O'), ('chondroitin', 'O'), ('sulfate', 'O'), ('(', 'O'), ('OSCS', 'O'), (')', 'O'), ('derivative', 'O'), ('that', 'O'), ('could', 'O'), ('elicit', 'O'), ('a', 'O'), ('hypotensive', 'B'), ('response', 'O'), ('in', 'O'), ('pigs', 'O'), ('following', 'O'), ('a', 'O'), ('single', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('infusion', 'O'), ('.', 'O'))"
"Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .","(('Using', 'O'), ('both', 'O'), ('contaminated', 'O'), ('heparin', 'O'), ('products', 'O'), ('and', 'O'), ('the', 'O'), ('synthetically', 'O'), ('produced', 'O'), ('derivative', 'O'), (',', 'O'), ('we', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('OSCS', 'O'), ('produces', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('hypotension', 'B'), ('in', 'O'), ('pigs', 'O'), ('.', 'O'))"
5 flourouracil - induced apical ballooning syndrome : a case report .,"(('5', 'O'), ('flourouracil', 'O'), ('-', 'O'), ('induced', 'O'), ('apical', 'B'), ('ballooning', 'I'), ('syndrome', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .,"(('The', 'O'), ('apical', 'B'), ('ballooning', 'I'), ('syndrome', 'I'), ('(', 'O'), ('ABS', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('recently', 'O'), ('described', 'O'), ('stress', 'O'), ('-', 'O'), ('mediated', 'O'), ('acute', 'B'), ('cardiac', 'I'), ('syndrome', 'I'), ('characterized', 'O'), ('by', 'O'), ('transient', 'O'), ('wall', 'O'), ('-', 'O'), ('motion', 'O'), ('abnormalities', 'O'), ('involving', 'O'), ('the', 'O'), ('apex', 'O'), ('and', 'O'), ('midventricle', 'O'), ('with', 'O'), ('hyperkinesis', 'B'), ('of', 'O'), ('the', 'O'), ('basal', 'O'), ('left', 'O'), ('ventricular', 'O'), ('(', 'O'), ('LV', 'O'), (')', 'O'), ('segments', 'O'), ('without', 'O'), ('obstructive', 'O'), ('epicardial', 'B'), ('coronary', 'I'), ('disease', 'I'), ('.', 'O'))"
We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .,"(('We', 'O'), ('describe', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('woman', 'O'), ('who', 'O'), ('developed', 'O'), ('the', 'O'), ('syndrome', 'O'), ('after', 'O'), ('chemotherapy', 'O'), ('for', 'O'), ('metastatic', 'O'), ('cancer', 'B'), ('.', 'O'))"
"A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .","(('A', 'O'), ('79', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('presented', 'O'), ('with', 'O'), ('typical', 'O'), ('ischemic', 'B'), ('chest', 'B'), ('pain', 'I'), (',', 'O'), ('elevated', 'O'), ('cardiac', 'O'), ('enzymes', 'O'), ('with', 'O'), ('significant', 'O'), ('ST', 'O'), ('-', 'O'), ('segment', 'O'), ('abnormalities', 'O'), ('on', 'O'), ('her', 'O'), ('electrocardiogram', 'O'), ('.', 'O'))"
She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .,"(('She', 'O'), ('underwent', 'O'), ('recent', 'O'), ('chemotherapy', 'O'), ('with', 'O'), ('fluorouracil', 'O'), ('for', 'O'), ('metastatic', 'O'), ('colorectal', 'B'), ('cancer', 'I'), ('.', 'O'))"
Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .,"(('Echocardiography', 'O'), ('revealed', 'O'), ('a', 'O'), ('wall', 'O'), ('-', 'O'), ('motion', 'O'), ('abnormality', 'O'), ('involving', 'O'), ('the', 'O'), ('apical', 'O'), ('and', 'O'), ('periapical', 'O'), ('segments', 'O'), ('which', 'O'), ('appeared', 'O'), ('akinetic', 'B'), ('.', 'O'))"
"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .","(('Pathogenetic', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('cardiac', 'B'), ('complications', 'I'), ('in', 'O'), ('cancer', 'B'), ('patients', 'O'), ('undergoing', 'O'), ('chemotherapy', 'O'), ('include', 'O'), ('coronary', 'B'), ('vasospasm', 'I'), (',', 'O'), ('endothelial', 'O'), ('damage', 'O'), ('and', 'O'), ('consequent', 'O'), ('thrombus', 'B'), ('formation', 'O'), ('.', 'O'))"
"In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .","(('In', 'O'), ('our', 'O'), ('patient', 'O'), (',', 'O'), ('both', 'O'), ('supraphysiologic', 'O'), ('levels', 'O'), ('of', 'O'), ('plasma', 'O'), ('catecholamines', 'O'), ('and', 'O'), ('stress', 'O'), ('related', 'O'), ('neuropeptides', 'O'), ('caused', 'O'), ('by', 'O'), ('cancer', 'B'), ('diagnosis', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('chemotherapy', 'O'), ('may', 'O'), ('have', 'O'), ('contributed', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('ABS', 'B'), ('.', 'O'))"
Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .,"(('Rapid', 'O'), ('reversal', 'O'), ('of', 'O'), ('anticoagulation', 'O'), ('reduces', 'O'), ('hemorrhage', 'B'), ('volume', 'O'), ('in', 'O'), ('a', 'O'), ('mouse', 'O'), ('model', 'O'), ('of', 'O'), ('warfarin', 'O'), ('-', 'O'), ('associated', 'O'), ('intracerebral', 'B'), ('hemorrhage', 'I'), ('.', 'O'))"
Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .,"(('Warfarin', 'O'), ('-', 'O'), ('associated', 'O'), ('intracerebral', 'B'), ('hemorrhage', 'I'), ('(', 'O'), ('W', 'O'), ('-', 'O'), ('ICH', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('severe', 'O'), ('type', 'O'), ('of', 'O'), ('stroke', 'B'), ('.', 'O'))"
There is no consensus on the optimal treatment for W - ICH .,"(('There', 'O'), ('is', 'O'), ('no', 'O'), ('consensus', 'O'), ('on', 'O'), ('the', 'O'), ('optimal', 'O'), ('treatment', 'O'), ('for', 'O'), ('W', 'O'), ('-', 'O'), ('ICH', 'B'), ('.', 'O'))"
"Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .","(('Second', 'O'), (',', 'O'), ('a', 'O'), ('stereotactic', 'O'), ('injection', 'O'), ('of', 'O'), ('collagenase', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('induce', 'O'), ('hemorrhage', 'B'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('striatum', 'O'), ('.', 'O'))"
"Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .","(('Twenty', 'O'), ('-', 'O'), ('four', 'O'), ('hours', 'O'), ('after', 'O'), ('hemorrhage', 'B'), ('induction', 'O'), (',', 'O'), ('hemorrhagic', 'O'), ('blood', 'O'), ('volume', 'O'), ('was', 'O'), ('quantified', 'O'), ('using', 'O'), ('a', 'O'), ('photometric', 'O'), ('hemoglobin', 'O'), ('assay', 'O'), ('.', 'O'))"
"In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .","(('In', 'O'), ('the', 'O'), ('saline', 'O'), ('group', 'O'), (',', 'O'), ('45', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('mice', 'O'), ('developed', 'O'), ('large', 'O'), ('hematomas', 'B'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), (',', 'O'), ('>', 'O'), ('15', 'O'), ('microL', 'O'), (')', 'O'), ('.', 'O'))"
We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .,"(('We', 'O'), ('provide', 'O'), ('experimental', 'O'), ('data', 'O'), ('suggesting', 'O'), ('PCC', 'O'), ('to', 'O'), ('be', 'O'), ('an', 'O'), ('effective', 'O'), ('acute', 'O'), ('treatment', 'O'), ('for', 'O'), ('W', 'O'), ('-', 'O'), ('ICH', 'B'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('reducing', 'O'), ('hemorrhagic', 'O'), ('blood', 'O'), ('volume', 'O'), ('.', 'O'))"
Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .,"(('Future', 'O'), ('studies', 'O'), ('are', 'O'), ('needed', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('therapeutic', 'O'), ('potential', 'O'), ('emerging', 'O'), ('from', 'O'), ('our', 'O'), ('finding', 'O'), ('for', 'O'), ('human', 'O'), ('W', 'O'), ('-', 'O'), ('ICH', 'B'), ('.', 'O'))"
"BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .","(('BACKGROUND', 'O'), (':', 'O'), ('Hormone', 'O'), ('therapy', 'O'), ('(', 'O'), ('HT', 'O'), (')', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('for', 'O'), ('controlling', 'O'), ('menopausal', 'O'), ('symptoms', 'O'), ('and', 'O'), ('has', 'O'), ('also', 'O'), ('been', 'O'), ('used', 'O'), ('for', 'O'), ('the', 'O'), ('management', 'O'), ('and', 'O'), ('prevention', 'O'), ('of', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), (',', 'O'), ('osteoporosis', 'B'), ('and', 'O'), ('dementia', 'B'), ('in', 'O'), ('older', 'O'), ('women', 'O'), ('.', 'O'))"
"OBJECTIVES : To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .","(('OBJECTIVES', 'O'), (':', 'O'), ('To', 'O'), ('assess', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('HT', 'O'), ('on', 'O'), ('mortality', 'O'), (',', 'O'), ('cardiovascular', 'O'), ('outcomes', 'O'), (',', 'O'), ('cancer', 'B'), (',', 'O'), ('gallbladder', 'B'), ('disease', 'I'), (',', 'O'), ('cognition', 'O'), (',', 'O'), ('fractures', 'B'), ('and', 'O'), ('quality', 'O'), ('of', 'O'), ('life', 'O'), ('.', 'O'))"
"In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year ' s use ) , stroke ( after three years ) , breast cancer and gallbladder disease .","(('In', 'O'), ('relatively', 'O'), ('healthy', 'O'), ('women', 'O'), (',', 'O'), ('combined', 'O'), ('continuous', 'O'), ('HT', 'O'), ('significantly', 'O'), ('increased', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('venous', 'B'), ('thrombo', 'I'), ('-', 'I'), ('embolism', 'I'), ('or', 'O'), ('coronary', 'O'), ('event', 'O'), ('(', 'O'), ('after', 'O'), ('one', 'O'), ('year', 'O'), (""'"", 'O'), ('s', 'O'), ('use', 'O'), (')', 'O'), (',', 'O'), ('stroke', 'B'), ('(', 'O'), ('after', 'O'), ('three', 'O'), ('years', 'O'), (')', 'O'), (',', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('gallbladder', 'B'), ('disease', 'I'), ('.', 'O'))"
"Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .","(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('oestrogen', 'O'), ('-', 'O'), ('only', 'O'), ('HT', 'O'), ('significantly', 'O'), ('increased', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('venous', 'B'), ('thrombo', 'I'), ('-', 'I'), ('embolism', 'I'), (',', 'O'), ('stroke', 'B'), ('and', 'O'), ('gallbladder', 'B'), ('disease', 'I'), ('(', 'O'), ('after', 'O'), ('one', 'O'), ('to', 'O'), ('two', 'O'), ('years', 'O'), (',', 'O'), ('three', 'O'), ('years', 'O'), ('and', 'O'), ('seven', 'O'), ('years', 'O'), (""'"", 'O'), ('use', 'O'), ('respectively', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('significantly', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
"The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .","(('The', 'O'), ('only', 'O'), ('statistically', 'O'), ('significant', 'O'), ('benefits', 'O'), ('of', 'O'), ('HT', 'O'), ('were', 'O'), ('a', 'O'), ('decreased', 'O'), ('incidence', 'O'), ('of', 'O'), ('fractures', 'B'), ('and', 'O'), ('(', 'O'), ('for', 'O'), ('combined', 'O'), ('HT', 'O'), (')', 'O'), ('colon', 'B'), ('cancer', 'I'), (',', 'O'), ('with', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('.', 'O'))"
"Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .","(('Among', 'O'), ('women', 'O'), ('aged', 'O'), ('over', 'O'), ('65', 'O'), ('who', 'O'), ('were', 'O'), ('relatively', 'O'), ('healthy', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), ('generally', 'O'), ('fit', 'O'), (',', 'O'), ('without', 'O'), ('overt', 'O'), ('disease', 'O'), (')', 'O'), ('and', 'O'), ('taking', 'O'), ('continuous', 'O'), ('combined', 'O'), ('HT', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('dementia', 'B'), ('.', 'O'))"
"Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .","(('Among', 'O'), ('women', 'O'), ('with', 'O'), ('cardiovascular', 'B'), ('disease', 'I'), (',', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('of', 'O'), ('combined', 'O'), ('continuous', 'O'), ('HT', 'O'), ('significantly', 'O'), ('increased', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('venous', 'B'), ('thrombo', 'I'), ('-', 'I'), ('embolism', 'I'), ('.', 'O'), ('One', 'O'), ('trial', 'O'), ('analysed', 'O'), ('subgroups', 'O'), ('of', 'O'), ('2839', 'O'), ('relatively', 'O'), ('healthy', 'O'), ('50', 'O'), ('to', 'O'), ('59', 'O'), ('year', 'O'), ('old', 'O'), ('women', 'O'), ('taking', 'O'), ('combined', 'O'), ('continuous', 'O'), ('HT', 'O'), ('and', 'O'), ('1637', 'O'), ('taking', 'O'), ('oestrogen', 'O'), ('-', 'O'), ('only', 'O'), ('HT', 'O'), (',', 'O'), ('versus', 'O'), ('similar', 'O'), ('-', 'O'), ('sized', 'O'), ('placebo', 'O'), ('groups', 'O'), ('.', 'O'))"
"The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .","(('The', 'O'), ('only', 'O'), ('significantly', 'O'), ('increased', 'O'), ('risk', 'O'), ('reported', 'O'), ('was', 'O'), ('for', 'O'), ('venous', 'B'), ('thrombo', 'I'), ('-', 'I'), ('embolism', 'I'), ('in', 'O'), ('women', 'O'), ('taking', 'O'), ('combined', 'O'), ('continuous', 'O'), ('HT', 'O'), (':', 'O'), ('their', 'O'), ('absolute', 'O'), ('risk', 'O'), ('remained', 'O'), ('low', 'O'), (',', 'O'), ('at', 'O'), ('less', 'O'), ('than', 'O'), ('1', 'O'), ('/', 'O'), ('500', 'O'), ('.', 'O'))"
Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .,"(('Acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('AIDS', 'B'), ('on', 'O'), ('tenofovir', 'O'), ('while', 'O'), ('receiving', 'O'), ('prolonged', 'O'), ('vancomycin', 'O'), ('course', 'O'), ('for', 'O'), ('osteomyelitis', 'B'), ('.', 'O'))"
Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .,"(('Renal', 'B'), ('failure', 'I'), ('developed', 'O'), ('after', 'O'), ('a', 'O'), ('prolonged', 'O'), ('course', 'O'), ('of', 'O'), ('vancomycin', 'O'), ('therapy', 'O'), ('in', 'O'), ('2', 'O'), ('patients', 'O'), ('who', 'O'), ('were', 'O'), ('receiving', 'O'), ('tenofovir', 'O'), ('disoproxil', 'O'), ('fumarate', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('an', 'O'), ('antiretroviral', 'O'), ('regimen', 'O'), ('.', 'O'))"
Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .,"(('Tenofovir', 'O'), ('has', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('Fanconi', 'B'), ('syndrome', 'I'), ('and', 'O'), ('renal', 'B'), ('insufficiency', 'I'), ('because', 'O'), ('of', 'O'), ('its', 'O'), ('effects', 'O'), ('on', 'O'), ('the', 'O'), ('proximal', 'O'), ('renal', 'O'), ('tubule', 'O'), ('.', 'O'))"
Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .,"(('Vancomycin', 'O'), ('nephrotoxicity', 'B'), ('is', 'O'), ('infrequent', 'O'), ('but', 'O'), ('may', 'O'), ('result', 'O'), ('from', 'O'), ('coadministration', 'O'), ('with', 'O'), ('a', 'O'), ('nephrotoxic', 'B'), ('agent', 'O'), ('.', 'O'))"
Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .,"(('Clinicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('that', 'O'), ('tenofovir', 'O'), ('may', 'O'), ('raise', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('renal', 'B'), ('failure', 'I'), ('during', 'O'), ('prolonged', 'O'), ('administration', 'O'), ('of', 'O'), ('vancomycin', 'O'), ('.', 'O'))"
"Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .","(('Pyrazinamide', 'O'), ('can', 'O'), ('have', 'O'), ('adverse', 'O'), ('effects', 'O'), ('such', 'O'), ('as', 'O'), ('hepatic', 'B'), ('toxicity', 'I'), (',', 'O'), ('hyperuricemia', 'B'), ('or', 'O'), ('digestive', 'O'), ('disorders', 'O'), ('.', 'O'))"
"We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .","(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('reversible', 'O'), ('olfactory', 'B'), ('disorder', 'I'), ('related', 'O'), ('to', 'O'), ('pyrazinamide', 'O'), ('in', 'O'), ('a', 'O'), ('woman', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('positive', 'O'), ('rechallenge', 'O'), ('.', 'O'))"
Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .,"(('Mice', 'O'), ('lacking', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), ('are', 'O'), ('resistant', 'O'), ('to', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('polyuria', 'B'), ('.', 'O'))"
Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .,"(('Cyclooxygenase', 'O'), ('-', 'O'), ('2', 'O'), ('activity', 'O'), ('is', 'O'), ('required', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('polyuria', 'B'), ('.', 'O'))"
The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .,"(('The', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('assess', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('polyuria', 'B'), ('in', 'O'), ('mice', 'O'), ('deficient', 'O'), ('in', 'O'), ('microsomal', 'O'), ('prostaglandin', 'O'), ('E', 'O'), ('synthase', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .,"(('A', 'O'), ('2', 'O'), ('-', 'O'), ('wk', 'O'), ('administration', 'O'), ('of', 'O'), ('LiCl', 'O'), ('(', 'O'), ('4', 'O'), ('mmol', 'O'), ('.', 'O'), ('kg', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'), ('day', 'O'), ('(', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('ip', 'O'), (')', 'O'), ('in', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), ('mice', 'O'), ('led', 'O'), ('to', 'O'), ('a', 'O'), ('marked', 'O'), ('polyuria', 'B'), ('with', 'O'), ('hyposmotic', 'O'), ('urine', 'O'), ('.', 'O'))"
"In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), ('mice', 'O'), ('were', 'O'), ('largely', 'O'), ('resistant', 'O'), ('to', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('polyuria', 'B'), ('and', 'O'), ('a', 'O'), ('urine', 'O'), ('concentrating', 'O'), ('defect', 'O'), (',', 'O'), ('accompanied', 'O'), ('by', 'O'), ('nearly', 'O'), ('complete', 'O'), ('blockade', 'O'), ('of', 'O'), ('high', 'O'), ('urine', 'O'), ('PGE', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('and', 'O'), ('cAMP', 'O'), ('output', 'O'), ('.', 'O'))"
We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('mPGES', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('derived', 'O'), ('PGE', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('mediates', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('polyuria', 'B'), ('likely', 'O'), ('via', 'O'), ('inhibition', 'O'), ('of', 'O'), ('AQP2', 'O'), ('and', 'O'), ('NKCC2', 'O'), ('expression', 'O'), ('.', 'O'))"
Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .,"(('Preservation', 'O'), ('of', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('during', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('with', 'O'), ('fenoldopam', 'O'), ('in', 'O'), ('dogs', 'O'), ('.', 'O'))"
The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .,"(('The', 'O'), ('introduction', 'O'), ('of', 'O'), ('drugs', 'O'), ('that', 'O'), ('could', 'O'), ('induce', 'O'), ('hypotension', 'B'), ('with', 'O'), ('different', 'O'), ('pharmacological', 'O'), ('actions', 'O'), ('would', 'O'), ('be', 'O'), ('advantageous', 'O'), ('because', 'O'), ('side', 'O'), ('effects', 'O'), ('unique', 'O'), ('to', 'O'), ('a', 'O'), ('specific', 'O'), ('drug', 'O'), ('could', 'O'), ('be', 'O'), ('minimized', 'O'), ('by', 'O'), ('selecting', 'O'), ('appropriate', 'O'), ('therapy', 'O'), ('.', 'O'))"
The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .,"(('The', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('fenoldopam', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('induce', 'O'), ('hypotension', 'B'), ('and', 'O'), ('preserve', 'O'), ('blood', 'O'), ('flow', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('was', 'O'), ('tested', 'O'), ('.', 'O'))"
Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .,"(('Renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('(', 'O'), ('RBF', 'O'), (')', 'O'), ('increased', 'O'), ('during', 'O'), ('fenoldopam', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('11', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('7', 'O'), ('per', 'O'), ('cent', 'O'), ('and', 'O'), ('decreased', 'O'), ('21', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), ('per', 'O'), ('cent', 'O'), ('during', 'O'), ('sodium', 'O'), ('nitroprusside', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .,"(('Sodium', 'O'), ('nitroprusside', 'O'), ('is', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('selective', 'O'), ('arteriolar', 'O'), ('and', 'O'), ('venous', 'O'), ('vasodilator', 'O'), ('that', 'O'), ('can', 'O'), ('produce', 'O'), ('redistribution', 'O'), ('of', 'O'), ('blood', 'O'), ('flow', 'O'), ('away', 'O'), ('from', 'O'), ('the', 'O'), ('kidney', 'O'), ('during', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .,"(('Fenoldopam', 'O'), ('is', 'O'), ('a', 'O'), ('selective', 'O'), ('dopamine', 'O'), ('-', 'O'), ('1', 'O'), ('(', 'O'), ('DA1', 'O'), (')', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('that', 'O'), ('causes', 'O'), ('vasodilatation', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('and', 'O'), ('other', 'O'), ('organs', 'O'), ('with', 'O'), ('DA1', 'O'), ('receptors', 'O'), ('and', 'O'), ('preserves', 'O'), ('blood', 'O'), ('flow', 'O'), ('to', 'O'), ('the', 'O'), ('kidney', 'O'), ('during', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
Seizures associated with levofloxacin : case presentation and literature review .,"(('Seizures', 'B'), ('associated', 'O'), ('with', 'O'), ('levofloxacin', 'O'), (':', 'O'), ('case', 'O'), ('presentation', 'O'), ('and', 'O'), ('literature', 'O'), ('review', 'O'), ('.', 'O'))"
"PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .","(('PURPOSE', 'O'), (':', 'O'), ('We', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('seizures', 'B'), ('shortly', 'O'), ('after', 'O'), ('initiating', 'O'), ('treatment', 'O'), ('with', 'O'), ('levofloxacin', 'O'), ('and', 'O'), ('to', 'O'), ('discuss', 'O'), ('the', 'O'), ('potential', 'O'), ('drug', 'O'), ('-', 'O'), ('drug', 'O'), ('interactions', 'O'), ('related', 'O'), ('to', 'O'), ('the', 'O'), ('inhibition', 'O'), ('of', 'O'), ('cytochrome', 'O'), ('P450', 'O'), ('(', 'O'), ('CYP', 'O'), (')', 'O'), ('1A2', 'O'), ('in', 'O'), ('this', 'O'), ('case', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('in', 'O'), ('other', 'O'), ('cases', 'O'), (',', 'O'), ('of', 'O'), ('levofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
RESULTS : Six cases of levofloxacin - induced seizures have been reported in the literature .,"(('RESULTS', 'O'), (':', 'O'), ('Six', 'O'), ('cases', 'O'), ('of', 'O'), ('levofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .","(('Acute', 'O'), ('analgesic', 'O'), ('and', 'O'), ('antiinflammatory', 'O'), ('activities', 'O'), ('were', 'O'), ('ascertained', 'O'), ('using', 'O'), ('acetic', 'O'), ('acid', 'O'), ('induced', 'O'), ('writhing', 'B'), ('model', 'O'), ('(', 'O'), ('mice', 'O'), (')', 'O'), ('and', 'O'), ('carrageenan', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('paw', 'O'), ('edema', 'B'), ('model', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .","(('This', 'O'), ('study', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('pilocarpine', 'O'), ('and', 'O'), ('explore', 'O'), ('the', 'O'), ('underlying', 'O'), ('ionic', 'O'), ('mechanism', 'O'), (',', 'O'), ('using', 'O'), ('both', 'O'), ('aconitine', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('and', 'O'), ('ouabain', 'O'), ('-', 'O'), ('induced', 'O'), ('guinea', 'O'), ('pig', 'O'), ('arrhythmia', 'B'), ('models', 'O'), ('.', 'O'))"
"The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .","(('The', 'O'), ('current', 'O'), ('data', 'O'), ('showed', 'O'), ('that', 'O'), ('pilocarpine', 'O'), ('significantly', 'O'), ('delayed', 'O'), ('onset', 'O'), ('of', 'O'), ('arrhythmias', 'B'), (',', 'O'), ('decreased', 'O'), ('the', 'O'), ('time', 'O'), ('course', 'O'), ('of', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('and', 'I'), ('fibrillation', 'I'), (',', 'O'), ('reduced', 'O'), ('arrhythmia', 'B'), ('score', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('the', 'O'), ('survival', 'O'), ('time', 'O'), ('of', 'O'), ('arrhythmic', 'B'), ('rats', 'O'), ('and', 'O'), ('guinea', 'O'), ('pigs', 'O'), ('.', 'O'))"
Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .,"(('Effect', 'O'), ('of', 'O'), ('methanolic', 'O'), ('extract', 'O'), ('of', 'O'), ('Hibiscus', 'O'), ('rosa', 'O'), ('sinensis', 'O'), ('(', 'O'), ('100', 'O'), ('-', 'O'), ('300', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('was', 'O'), ('studied', 'O'), ('on', 'O'), ('reserpine', 'O'), ('-', 'O'), ('induced', 'O'), ('orofacial', 'O'), ('dyskinesia', 'B'), ('and', 'O'), ('neurochemical', 'O'), ('alterations', 'O'), ('.', 'O'))"
The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .,"(('The', 'O'), ('results', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('suggested', 'O'), ('that', 'O'), ('Hibiscus', 'O'), ('rosa', 'O'), ('sinensis', 'O'), ('had', 'O'), ('a', 'O'), ('protective', 'O'), ('role', 'O'), ('against', 'O'), ('reserpine', 'O'), ('-', 'O'), ('induced', 'O'), ('orofacial', 'O'), ('dyskinesia', 'B'), ('and', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('.', 'O'))"
Dynamic response of blood vessel in acute renal failure .,"(('Dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessel', 'O'), ('in', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .","(('In', 'O'), ('this', 'O'), ('study', 'O'), ('we', 'O'), ('postulated', 'O'), ('that', 'O'), ('during', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('induced', 'O'), ('by', 'O'), ('gentamicin', 'O'), ('the', 'O'), ('transient', 'O'), ('or', 'O'), ('dynamic', 'O'), ('response', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('could', 'O'), ('be', 'O'), ('affected', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('antioxidants', 'O'), ('can', 'O'), ('prevent', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('dynamic', 'O'), ('responses', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('.', 'O'))"
Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .,"(('Reversible', 'O'), ('myocardial', 'B'), ('hypertrophy', 'I'), ('induced', 'O'), ('by', 'O'), ('tacrolimus', 'O'), ('in', 'O'), ('a', 'O'), ('pediatric', 'O'), ('heart', 'O'), ('transplant', 'O'), ('recipient', 'O'), (':', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"However , adverse effects include cardiac toxicity .","(('However', 'O'), (',', 'O'), ('adverse', 'O'), ('effects', 'O'), ('include', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('.', 'O'))"
Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .,"(('Herein', 'O'), ('we', 'O'), ('describe', 'O'), ('transient', 'O'), ('myocardial', 'B'), ('hypertrophy', 'I'), ('induced', 'O'), ('by', 'O'), ('tacrolimus', 'O'), ('after', 'O'), ('heart', 'O'), ('transplantation', 'O'), ('.', 'O'))"
The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .,"(('The', 'O'), ('hypertrophy', 'B'), ('caused', 'O'), ('no', 'O'), ('clinical', 'O'), ('symptoms', 'O'), ('but', 'O'), ('was', 'O'), ('noted', 'O'), ('because', 'O'), ('of', 'O'), ('elevation', 'O'), ('of', 'O'), ('plasma', 'O'), ('brain', 'O'), ('natriuretic', 'O'), ('peptide', 'O'), ('concentration', 'O'), ('and', 'O'), ('confirmed', 'O'), ('at', 'O'), ('echocardiography', 'O'), ('.', 'O'))"
"Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .","(('Initially', 'O'), (',', 'O'), ('allograft', 'O'), ('rejection', 'O'), ('was', 'O'), ('feared', 'O'), (';', 'O'), ('however', 'O'), (',', 'O'), ('myocardial', 'O'), ('biopsy', 'O'), ('samples', 'O'), ('revealed', 'O'), ('only', 'O'), ('interstitial', 'O'), ('edema', 'B'), ('and', 'O'), ('mild', 'O'), ('myocardial', 'B'), ('hypertrophy', 'I'), (';', 'O'), ('neither', 'O'), ('cellular', 'O'), ('nor', 'O'), ('humoral', 'O'), ('rejection', 'O'), ('was', 'O'), ('detected', 'O'), ('.', 'O'))"
"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .","(('Myocardial', 'B'), ('hypertrophy', 'I'), ('completely', 'O'), ('resolved', 'O'), ('upon', 'O'), ('reducing', 'O'), ('the', 'O'), ('target', 'O'), ('concentration', 'O'), ('of', 'O'), ('tacrolimus', 'O'), ('and', 'O'), ('did', 'O'), ('not', 'O'), ('recur', 'O'), (',', 'O'), ('as', 'O'), ('confirmed', 'O'), ('at', 'O'), ('echocardiography', 'O'), ('and', 'O'), ('myocardial', 'O'), ('biopsy', 'O'), ('.', 'O'))"
"Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .","(('Thus', 'O'), (',', 'O'), ('we', 'O'), ('conclude', 'O'), ('that', 'O'), ('tacrolimus', 'O'), ('induces', 'O'), ('reversible', 'O'), ('myocardial', 'B'), ('hypertrophy', 'I'), ('.', 'O'))"
Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .,"(('Nimodipine', 'O'), ('prevents', 'O'), ('memory', 'B'), ('impairment', 'I'), ('caused', 'O'), ('by', 'O'), ('nitroglycerin', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('adult', 'O'), ('mice', 'O'), ('.', 'O'))"
BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .,"(('BACKGROUND', 'O'), (':', 'O'), ('Hypotension', 'B'), ('and', 'O'), ('a', 'O'), ('resultant', 'O'), ('decrease', 'O'), ('in', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('have', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('cognitive', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .,"(('We', 'O'), ('tested', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('nimodipine', 'O'), ('(', 'O'), ('NIMO', 'O'), (')', 'O'), ('administered', 'O'), ('at', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('nitroglycerin', 'O'), ('(', 'O'), ('NTG', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('would', 'O'), ('preserve', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('associative', 'O'), ('memory', 'O'), ('.', 'O'))"
The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .,"(('The', 'O'), ('extent', 'O'), ('of', 'O'), ('hypotension', 'B'), ('and', 'O'), ('changes', 'O'), ('in', 'O'), ('brain', 'O'), ('tissue', 'O'), ('oxygenation', 'O'), ('(', 'O'), ('PbtO', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('were', 'O'), ('studied', 'O'), ('in', 'O'), ('a', 'O'), ('separate', 'O'), ('group', 'O'), ('of', 'O'), ('animals', 'O'), ('.', 'O'))"
"Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .","(('Mice', 'O'), ('subjected', 'O'), ('to', 'O'), ('hypotensive', 'B'), ('episodes', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('in', 'O'), ('latency', 'O'), ('time', 'O'), ('(', 'O'), ('178', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('156', 'O'), ('s', 'O'), (')', 'O'), ('compared', 'O'), ('with', 'O'), ('those', 'O'), ('injected', 'O'), ('with', 'O'), ('saline', 'O'), (',', 'O'), ('NTG', 'O'), ('+', 'O'), ('NIMO', 'O'), (',', 'O'), ('or', 'O'), ('delayed', 'O'), ('NTG', 'O'), ('(', 'O'), ('580', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('81', 'O'), ('s', 'O'), (',', 'O'), ('557', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('67', 'O'), ('s', 'O'), (',', 'O'), ('and', 'O'), ('493', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('146', 'O'), ('s', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
"CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .","(('CONCLUSION', 'O'), (':', 'O'), ('In', 'O'), ('a', 'O'), ('PA', 'O'), ('retention', 'O'), ('paradigm', 'O'), (',', 'O'), ('the', 'O'), ('injection', 'O'), ('of', 'O'), ('NTG', 'O'), ('immediately', 'O'), ('after', 'O'), ('learning', 'O'), ('produced', 'O'), ('a', 'O'), ('significant', 'O'), ('impairment', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('associative', 'O'), ('memory', 'O'), ('in', 'O'), ('mice', 'O'), (',', 'O'), ('whereas', 'O'), ('delayed', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('.', 'O'))"
NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .,"(('NIMO', 'O'), ('attenuated', 'O'), ('the', 'O'), ('disruption', 'O'), ('in', 'O'), ('consolidation', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('memory', 'O'), ('caused', 'O'), ('by', 'O'), ('NTG', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('improve', 'O'), ('latency', 'O'), ('in', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .","(('The', 'O'), ('observed', 'O'), ('effect', 'O'), ('of', 'O'), ('NIMO', 'O'), ('may', 'O'), ('have', 'O'), ('been', 'O'), ('attributable', 'O'), ('to', 'O'), ('the', 'O'), ('preservation', 'O'), ('of', 'O'), ('calcium', 'O'), ('homeostasis', 'O'), ('during', 'O'), ('hypotension', 'B'), (',', 'O'), ('because', 'O'), ('there', 'O'), ('were', 'O'), ('no', 'O'), ('differences', 'O'), ('in', 'O'), ('the', 'O'), ('PbtO', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('indices', 'O'), ('among', 'O'), ('groups', 'O'), ('.', 'O'))"
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson ' s disease .,"(('Metabotropic', 'O'), ('glutamate', 'O'), ('7', 'O'), ('receptor', 'O'), ('subtype', 'O'), ('modulates', 'O'), ('motor', 'O'), ('symptoms', 'O'), ('in', 'O'), ('rodent', 'O'), ('models', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson ' s disease ( PD ) .,"(('Metabotropic', 'O'), ('glutamate', 'O'), ('(', 'O'), ('mGlu', 'O'), (')', 'O'), ('receptors', 'O'), ('modulate', 'O'), ('synaptic', 'O'), ('transmission', 'O'), ('in', 'O'), ('the', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('and', 'O'), ('represent', 'O'), ('promising', 'O'), ('therapeutic', 'O'), ('targets', 'O'), ('for', 'O'), ('symptomatic', 'O'), ('treatment', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('(', 'O'), ('PD', 'B'), (')', 'O'), ('.', 'O'))"
"Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .","(('Among', 'O'), ('the', 'O'), ('eight', 'O'), ('mGlu', 'O'), ('receptor', 'O'), ('subtypes', 'O'), (',', 'O'), ('mGlu7', 'O'), ('receptor', 'O'), ('is', 'O'), ('prominently', 'O'), ('expressed', 'O'), ('in', 'O'), ('the', 'O'), ('basal', 'O'), ('ganglia', 'O'), (',', 'O'), ('but', 'O'), ('its', 'O'), ('role', 'O'), ('in', 'O'), ('restoring', 'O'), ('motor', 'O'), ('function', 'O'), ('in', 'O'), ('animal', 'O'), ('models', 'O'), ('of', 'O'), ('PD', 'B'), ('is', 'O'), ('not', 'O'), ('known', 'O'), ('.', 'O'))"
"The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('N', 'O'), (',', 'O'), ('N', 'O'), (""'"", 'O'), ('-', 'O'), ('dibenzhydrylethane', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), ('-', 'O'), ('diamine', 'O'), ('dihydrochloride', 'O'), ('(', 'O'), ('AMN082', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('first', 'O'), ('selective', 'O'), ('allosteric', 'O'), ('activator', 'O'), ('of', 'O'), ('mGlu7', 'O'), ('receptors', 'O'), (',', 'O'), ('were', 'O'), ('thus', 'O'), ('tested', 'O'), ('in', 'O'), ('different', 'O'), ('rodent', 'O'), ('models', 'O'), ('of', 'O'), ('PD', 'B'), ('.', 'O'))"
"Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .","(('Here', 'O'), (',', 'O'), ('we', 'O'), ('show', 'O'), ('that', 'O'), ('oral', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('or', 'O'), ('intrastriatal', 'O'), ('administration', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('and', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('nmol', 'O'), (')', 'O'), ('of', 'O'), ('AMN082', 'O'), ('reverses', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .","(('In', 'O'), ('a', 'O'), ('more', 'O'), ('complex', 'O'), ('task', 'O'), ('commonly', 'O'), ('used', 'O'), ('to', 'O'), ('evaluate', 'O'), ('major', 'O'), ('akinetic', 'B'), ('symptoms', 'O'), ('of', 'O'), ('PD', 'B'), ('patients', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('AMN082', 'O'), ('reverses', 'O'), ('the', 'O'), ('increased', 'O'), ('reaction', 'O'), ('time', 'O'), ('to', 'O'), ('respond', 'O'), ('to', 'O'), ('a', 'O'), ('cue', 'O'), ('of', 'O'), ('bilateral', 'O'), ('6', 'O'), ('-', 'O'), ('OHDA', 'O'), ('-', 'O'), ('lesioned', 'O'), ('rats', 'O'), ('.', 'O'))"
"In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('AMN082', 'O'), ('reduces', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('a', 'O'), ('mGlu7', 'O'), ('receptor', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), ('in', 'O'), ('wild', 'O'), ('-', 'O'), ('type', 'O'), ('but', 'O'), ('not', 'O'), ('mGlu7', 'O'), ('receptor', 'O'), ('knockout', 'O'), ('mice', 'O'), ('.', 'O'))"
Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .,"(('Higher', 'O'), ('doses', 'O'), ('of', 'O'), ('AMN082', 'O'), ('(', 'O'), ('10', 'O'), ('and', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), (')', 'O'), ('have', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('same', 'O'), ('models', 'O'), ('of', 'O'), ('PD', 'B'), ('.', 'O'))"
Sorafenib - induced acute myocardial infarction due to coronary artery spasm .,"(('Sorafenib', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('due', 'O'), ('to', 'O'), ('coronary', 'B'), ('artery', 'I'), ('spasm', 'I'), ('.', 'O'))"
A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .,"(('A', 'O'), ('65', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('advanced', 'O'), ('renal', 'B'), ('cell', 'I'), ('carcinoma', 'I'), ('was', 'O'), ('admitted', 'O'), ('due', 'O'), ('to', 'O'), ('continuing', 'O'), ('chest', 'B'), ('pain', 'I'), ('at', 'O'), ('rest', 'O'), ('.', 'O'))"
He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .,"(('He', 'O'), ('was', 'O'), ('diagnosed', 'O'), ('with', 'O'), ('non', 'O'), ('-', 'O'), ('ST', 'O'), ('-', 'O'), ('elevation', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('by', 'O'), ('laboratory', 'O'), ('data', 'O'), ('and', 'O'), ('electrocardiogram', 'O'), ('.', 'O'))"
Enhanced heart magnetic resonance imaging also showed subendocardial infarction .,"(('Enhanced', 'O'), ('heart', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('imaging', 'O'), ('also', 'O'), ('showed', 'O'), ('subendocardial', 'B'), ('infarction', 'I'), ('.', 'O'))"
Coronary artery spasm was induced by a provocative test .,"(('Coronary', 'B'), ('artery', 'I'), ('spasm', 'I'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('a', 'O'), ('provocative', 'O'), ('test', 'O'), ('.', 'O'))"
Addition of oral nicorandil reduced his symptoms and maintained stable angina status .,"(('Addition', 'O'), ('of', 'O'), ('oral', 'O'), ('nicorandil', 'O'), ('reduced', 'O'), ('his', 'O'), ('symptoms', 'O'), ('and', 'O'), ('maintained', 'O'), ('stable', 'B'), ('angina', 'I'), ('status', 'O'), ('.', 'O'))"
We report the first case of sorafenib - induced coronary artery spasm .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('first', 'O'), ('case', 'O'), ('of', 'O'), ('sorafenib', 'O'), ('-', 'O'), ('induced', 'O'), ('coronary', 'B'), ('artery', 'I'), ('spasm', 'I'), ('.', 'O'))"
"On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('the', 'O'), ('Rho', 'O'), ('/', 'O'), ('ROCK', 'O'), ('pathway', 'O'), ('has', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('coronary', 'B'), ('artery', 'I'), ('spasm', 'I'), ('.', 'O'))"
"Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .","(('Tacrine', 'O'), (',', 'O'), ('administered', 'O'), ('in', 'O'), ('LiCl', 'O'), ('pre', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), (',', 'O'), ('induces', 'O'), ('electrocorticographic', 'O'), ('seizures', 'B'), ('and', 'O'), ('delayed', 'O'), ('hippocampal', 'B'), ('damage', 'I'), ('.', 'O'))"
"All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .","(('All', 'O'), ('the', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('tacrine', 'O'), ('-', 'O'), ('loaded', 'O'), ('nanoparticles', 'O'), ('showed', 'O'), ('an', 'O'), ('earlier', 'O'), ('outcome', 'O'), ('of', 'O'), ('CNS', 'O'), ('adverse', 'O'), ('symptoms', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), ('epileptic', 'B'), ('onset', 'O'), (',', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('those', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('the', 'O'), ('free', 'O'), ('compound', 'O'), ('(', 'O'), ('10', 'O'), ('min', 'O'), ('vs', 'O'), ('.', 'O'), ('22', 'O'), ('min', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
"In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('tacrine', 'O'), ('-', 'O'), ('loaded', 'O'), ('nanoparticles', 'O'), ('administration', 'O'), ('induced', 'O'), ('damage', 'B'), ('of', 'I'), ('neuronal', 'I'), ('cells', 'I'), ('in', 'O'), ('CA1', 'O'), ('field', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('in', 'O'), ('all', 'O'), ('treated', 'O'), ('animals', 'O'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('saline', 'O'), ('solution', 'O'), ('of', 'O'), ('tacrine', 'O'), ('only', 'O'), ('in', 'O'), ('60', 'O'), ('%', 'O'), ('of', 'O'), ('animals', 'O'), ('.', 'O'))"
"In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('the', 'O'), ('evaluation', 'O'), ('of', 'O'), ('time', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('onset', 'O'), ('of', 'O'), ('symptoms', 'O'), ('and', 'O'), ('the', 'O'), ('severity', 'O'), ('of', 'O'), ('neurodegenerative', 'O'), ('processes', 'O'), ('induced', 'O'), ('by', 'O'), ('the', 'O'), ('tacrine', 'O'), ('-', 'O'), ('lithium', 'O'), ('model', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), (',', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('evaluate', 'O'), ('preliminarily', 'O'), ('the', 'O'), ('capability', 'O'), ('of', 'O'), ('a', 'O'), ('drug', 'O'), ('delivery', 'O'), ('system', 'O'), ('to', 'O'), ('trespass', 'O'), ('(', 'O'), ('or', 'O'), ('not', 'O'), (')', 'O'), ('the', 'O'), ('BBB', 'O'), ('in', 'O'), ('vivo', 'O'), ('.', 'O'))"
High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .,"(('High', 'O'), ('-', 'O'), ('dose', 'O'), ('tranexamic', 'O'), ('Acid', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('nonischemic', 'O'), ('clinical', 'O'), ('seizures', 'B'), ('in', 'O'), ('cardiac', 'O'), ('surgical', 'O'), ('patients', 'O'), ('.', 'O'))"
"BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .","(('BACKGROUND', 'O'), (':', 'O'), ('In', 'O'), ('2', 'O'), ('separate', 'O'), ('centers', 'O'), (',', 'O'), ('we', 'O'), ('observed', 'O'), ('a', 'O'), ('notable', 'O'), ('increase', 'O'), ('in', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('postoperative', 'O'), ('convulsive', 'B'), ('seizures', 'B'), ('from', 'O'), ('1', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('to', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('in', 'O'), ('patients', 'O'), ('having', 'O'), ('undergone', 'O'), ('major', 'O'), ('cardiac', 'O'), ('surgical', 'O'), ('procedures', 'O'), ('.', 'O'))"
The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('this', 'O'), ('review', 'O'), ('was', 'O'), ('to', 'O'), ('perform', 'O'), ('a', 'O'), ('retrospective', 'O'), ('analysis', 'O'), ('to', 'O'), ('examine', 'O'), ('whether', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('relation', 'O'), ('between', 'O'), ('TXA', 'O'), ('usage', 'O'), ('and', 'O'), ('seizures', 'B'), ('after', 'O'), ('cardiac', 'O'), ('surgery', 'O'), ('.', 'O'))"
METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .,"(('METHODS', 'O'), (':', 'O'), ('An', 'O'), ('in', 'O'), ('-', 'O'), ('depth', 'O'), ('chart', 'O'), ('review', 'O'), ('was', 'O'), ('undertaken', 'O'), ('in', 'O'), ('all', 'O'), ('24', 'O'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('perioperative', 'O'), ('seizures', 'B'), ('.', 'O'))"
"RESULTS : Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .","(('RESULTS', 'O'), (':', 'O'), ('Twenty', 'O'), ('-', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('24', 'O'), ('patients', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('evidence', 'O'), ('of', 'O'), ('new', 'O'), ('cerebral', 'B'), ('ischemic', 'I'), ('injury', 'I'), (',', 'O'), ('but', 'O'), ('seizures', 'B'), ('were', 'O'), ('likely', 'O'), ('due', 'O'), ('to', 'O'), ('ischemic', 'B'), ('brain', 'I'), ('injury', 'I'), ('in', 'O'), ('3', 'O'), ('patients', 'O'), ('.', 'O'))"
All patients with seizures did not have permanent neurological abnormalities .,"(('All', 'O'), ('patients', 'O'), ('with', 'O'), ('seizures', 'B'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('permanent', 'O'), ('neurological', 'B'), ('abnormalities', 'I'), ('.', 'O'))"
"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .","(('All', 'O'), ('24', 'O'), ('patients', 'O'), ('with', 'O'), ('seizures', 'B'), ('received', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('TXA', 'O'), ('intraoperatively', 'O'), ('ranging', 'O'), ('from', 'O'), ('61', 'O'), ('to', 'O'), ('259', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('had', 'O'), ('a', 'O'), ('mean', 'O'), ('age', 'O'), ('of', 'O'), ('69', 'O'), ('.', 'O'), ('9', 'O'), ('years', 'O'), (',', 'O'), ('and', 'O'), ('21', 'O'), ('of', 'O'), ('24', 'O'), ('had', 'O'), ('undergone', 'O'), ('open', 'O'), ('chamber', 'O'), ('rather', 'O'), ('than', 'O'), ('coronary', 'O'), ('bypass', 'O'), ('procedures', 'O'), ('.', 'O'))"
"No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .","(('No', 'O'), ('evidence', 'O'), ('of', 'O'), ('brain', 'B'), ('ischemic', 'I'), (',', 'O'), ('metabolic', 'O'), (',', 'O'), ('or', 'O'), ('hyperthermia', 'B'), ('-', 'O'), ('induced', 'O'), ('causes', 'O'), ('for', 'O'), ('their', 'O'), ('seizures', 'B'), ('was', 'O'), ('apparent', 'O'), ('.', 'O'))"
CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .,"(('CONCLUSION', 'O'), (':', 'O'), ('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('use', 'O'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('TXA', 'O'), ('in', 'O'), ('older', 'O'), ('patients', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('cardiopulmonary', 'O'), ('bypass', 'O'), ('and', 'O'), ('open', 'O'), ('-', 'O'), ('chamber', 'O'), ('cardiac', 'O'), ('surgery', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('clinical', 'O'), ('seizures', 'B'), ('in', 'O'), ('susceptible', 'O'), ('patients', 'O'), ('.', 'O'))"
Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .,"(('Electrocardiographic', 'O'), ('changes', 'O'), ('and', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('psychotropic', 'O'), ('drugs', 'O'), ('.', 'O'))"
"Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .","(('Although', 'O'), ('most', 'O'), ('patients', 'O'), ('were', 'O'), ('receiving', 'O'), ('several', 'O'), ('drugs', 'O'), (',', 'O'), ('Mellaril', 'O'), ('(', 'O'), ('thioridazine', 'O'), (')', 'O'), ('appeared', 'O'), ('to', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('five', 'O'), ('cases', 'O'), ('of', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('which', 'O'), ('was', 'O'), ('fatal', 'O'), ('in', 'O'), ('a', 'O'), ('35', 'O'), ('year', 'O'), ('old', 'O'), ('woman', 'O'), ('.', 'O'))"
Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .,"(('Supraventricular', 'B'), ('tachycardia', 'I'), ('developed', 'O'), ('in', 'O'), ('one', 'O'), ('patient', 'O'), ('receiving', 'O'), ('Thorazine', 'O'), ('(', 'O'), ('chlorpromazine', 'O'), (')', 'O'), ('.', 'O'))"
Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .,"(('Aventyl', 'O'), ('(', 'O'), ('nortriptyline', 'O'), (')', 'O'), ('and', 'O'), ('Elavil', 'O'), ('(', 'O'), ('amitriptyline', 'O'), (')', 'O'), ('each', 'O'), ('produced', 'O'), ('left', 'B'), ('bundle', 'I'), ('branch', 'I'), ('block', 'I'), ('in', 'O'), ('a', 'O'), ('73', 'O'), ('year', 'O'), ('old', 'O'), ('woman', 'O'), ('.', 'O'))"
The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .,"(('The', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('responded', 'O'), ('to', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('and', 'O'), ('to', 'O'), ('direct', 'O'), ('current', 'O'), ('electric', 'O'), ('shock', 'O'), (';', 'O'), ('ventricular', 'O'), ('pacing', 'O'), ('was', 'O'), ('required', 'O'), ('in', 'O'), ('some', 'O'), ('instances', 'O'), ('and', 'O'), ('intravenous', 'O'), ('administration', 'O'), ('of', 'O'), ('propranolol', 'O'), ('combined', 'O'), ('with', 'O'), ('ventricular', 'O'), ('pacing', 'O'), ('in', 'O'), ('one', 'O'), ('.', 'O'))"
The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .,"(('The', 'O'), ('tachyarrhythmias', 'B'), ('generally', 'O'), ('subsided', 'O'), ('within', 'O'), ('48', 'O'), ('hours', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('drugs', 'O'), ('was', 'O'), ('stopped', 'O'), ('.', 'O'))"
Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .,"(('Five', 'O'), ('of', 'O'), ('the', 'O'), ('eight', 'O'), ('patients', 'O'), ('were', 'O'), ('50', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('or', 'O'), ('younger', 'O'), (';', 'O'), ('only', 'O'), ('one', 'O'), ('clearly', 'O'), ('had', 'O'), ('antecedent', 'O'), ('heart', 'B'), ('disease', 'I'), ('.', 'O'))"
Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .,"(('Major', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('are', 'O'), ('a', 'O'), ('potential', 'O'), ('hazard', 'O'), ('in', 'O'), ('patients', 'O'), ('without', 'O'), ('heart', 'B'), ('disease', 'I'), ('who', 'O'), ('are', 'O'), ('receiving', 'O'), ('customary', 'O'), ('therapeutic', 'O'), ('doses', 'O'), ('of', 'O'), ('psychotropic', 'O'), ('drugs', 'O'), ('.', 'O'))"
A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .,"(('A', 'O'), ('prospective', 'O'), ('clinical', 'O'), ('trial', 'O'), ('is', 'O'), ('suggested', 'O'), ('to', 'O'), ('quantify', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('cardiac', 'B'), ('complications', 'I'), ('to', 'O'), ('patients', 'O'), ('receiving', 'O'), ('phenothiazines', 'O'), ('or', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('drugs', 'O'), ('.', 'O'))"
"We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .","(('We', 'O'), ('have', 'O'), ('used', 'O'), ('a', 'O'), ('murine', 'O'), ('model', 'O'), ('of', 'O'), ('AIDS', 'B'), (',', 'O'), ('infection', 'B'), ('of', 'O'), ('female', 'O'), ('C57BL', 'O'), ('/', 'O'), ('6', 'O'), ('mice', 'O'), ('with', 'O'), ('LP', 'O'), ('-', 'O'), ('BM5', 'O'), ('murine', 'O'), ('leukaemia', 'B'), ('(', 'O'), ('MuLV', 'O'), (')', 'O'), ('virus', 'O'), (',', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('anaemia', 'B'), ('is', 'O'), ('due', 'O'), (',', 'O'), ('in', 'O'), ('part', 'O'), (',', 'O'), ('to', 'O'), ('decreased', 'O'), ('responsiveness', 'O'), ('of', 'O'), ('erythropoietic', 'O'), ('precursors', 'O'), ('(', 'O'), ('BFU', 'O'), ('-', 'O'), ('e', 'O'), (')', 'O'), ('to', 'O'), ('erythropoietin', 'O'), ('(', 'O'), ('EPO', 'O'), (')', 'O'), ('.', 'O'))"
Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .,"(('Sedation', 'O'), ('depth', 'O'), ('during', 'O'), ('spinal', 'O'), ('anesthesia', 'O'), ('and', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('postoperative', 'B'), ('delirium', 'I'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('hip', 'B'), ('fracture', 'I'), ('repair', 'O'), ('.', 'O'))"
OBJECTIVE : To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('determine', 'O'), ('whether', 'O'), ('limiting', 'O'), ('intraoperative', 'O'), ('sedation', 'O'), ('depth', 'O'), ('during', 'O'), ('spinal', 'O'), ('anesthesia', 'O'), ('for', 'O'), ('hip', 'B'), ('fracture', 'I'), ('repair', 'O'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('can', 'O'), ('decrease', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('postoperative', 'B'), ('delirium', 'I'), ('.', 'O'))"
"PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .","(('PATIENTS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('performed', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('randomized', 'O'), ('controlled', 'O'), ('trial', 'O'), ('at', 'O'), ('an', 'O'), ('academic', 'O'), ('medical', 'O'), ('center', 'O'), ('of', 'O'), ('elderly', 'O'), ('patients', 'O'), ('(', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('65', 'O'), ('years', 'O'), (')', 'O'), ('without', 'O'), ('preoperative', 'O'), ('delirium', 'B'), ('or', 'O'), ('severe', 'O'), ('dementia', 'B'), ('who', 'O'), ('underwent', 'O'), ('hip', 'B'), ('fracture', 'I'), ('repair', 'O'), ('under', 'O'), ('spinal', 'O'), ('anesthesia', 'O'), ('with', 'O'), ('propofol', 'O'), ('sedation', 'O'), ('.', 'O'))"
"The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57 [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .","(('The', 'O'), ('prevalence', 'O'), ('of', 'O'), ('postoperative', 'B'), ('delirium', 'I'), ('was', 'O'), ('significantly', 'O'), ('lower', 'O'), ('in', 'O'), ('the', 'O'), ('light', 'O'), ('sedation', 'O'), ('group', 'O'), ('(', 'O'), ('11', 'O'), ('/', 'O'), ('57', 'O'), ('[', 'O'), ('19', 'O'), ('%', 'O'), (']', 'O'), ('vs', 'O'), ('23', 'O'), ('/', 'O'), ('57', 'O'), ('[', 'O'), ('40', 'O'), ('%', 'O'), (']', 'O'), ('in', 'O'), ('the', 'O'), ('deep', 'O'), ('sedation', 'O'), ('group', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('1', 'O'), ('incident', 'O'), ('of', 'O'), ('delirium', 'B'), ('will', 'O'), ('be', 'O'), ('prevented', 'O'), ('for', 'O'), ('every', 'O'), ('4', 'O'), ('.', 'O'), ('7', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('light', 'O'), ('sedation', 'O'), ('.', 'O'))"
The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .,"(('The', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('SD', 'O'), ('number', 'O'), ('of', 'O'), ('days', 'O'), ('of', 'O'), ('delirium', 'B'), ('during', 'O'), ('hospitalization', 'O'), ('was', 'O'), ('lower', 'O'), ('in', 'O'), ('the', 'O'), ('light', 'O'), ('sedation', 'O'), ('group', 'O'), ('than', 'O'), ('in', 'O'), ('the', 'O'), ('deep', 'O'), ('sedation', 'O'), ('group', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('days', 'O'), ('vs', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('4', 'O'), ('.', 'O'), ('0', 'O'), ('days', 'O'), (';', 'O'), ('P', 'O'), ('=', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSION : The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('use', 'O'), ('of', 'O'), ('light', 'O'), ('propofol', 'O'), ('sedation', 'O'), ('decreased', 'O'), ('the', 'O'), ('prevalence', 'O'), ('of', 'O'), ('postoperative', 'B'), ('delirium', 'I'), ('by', 'O'), ('50', 'O'), ('%', 'O'), ('compared', 'O'), ('with', 'O'), ('deep', 'O'), ('sedation', 'O'), ('.', 'O'))"
"Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .","(('Limiting', 'O'), ('depth', 'O'), ('of', 'O'), ('sedation', 'O'), ('during', 'O'), ('spinal', 'O'), ('anesthesia', 'O'), ('is', 'O'), ('a', 'O'), ('simple', 'O'), (',', 'O'), ('safe', 'O'), (',', 'O'), ('and', 'O'), ('cost', 'O'), ('-', 'O'), ('effective', 'O'), ('intervention', 'O'), ('for', 'O'), ('preventing', 'O'), ('postoperative', 'B'), ('delirium', 'I'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('that', 'O'), ('could', 'O'), ('be', 'O'), ('widely', 'O'), ('and', 'O'), ('readily', 'O'), ('adopted', 'O'), ('.', 'O'))"
The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .,"(('The', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('in', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
"OBJECTIVE : Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .","(('OBJECTIVE', 'O'), (':', 'O'), ('Diabetic', 'B'), ('nephropathy', 'I'), ('is', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('major', 'O'), ('causes', 'O'), ('of', 'O'), ('renal', 'B'), ('failure', 'I'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('accompanied', 'O'), ('by', 'O'), ('the', 'O'), ('production', 'O'), ('of', 'O'), ('reactive', 'O'), ('oxygen', 'O'), ('species', 'O'), ('(', 'O'), ('ROS', 'O'), (')', 'O'), ('.', 'O'))"
"Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .","(('Here', 'O'), (',', 'O'), ('we', 'O'), ('report', 'O'), ('our', 'O'), ('findings', 'O'), ('demonstrating', 'O'), ('a', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('against', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
"RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .","(('RESEARCH', 'O'), ('DESIGN', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('explore', 'O'), ('the', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('against', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('using', 'O'), ('human', 'O'), ('kidney', 'O'), ('biopsy', 'O'), ('tissues', 'O'), ('from', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('patients', 'O'), (',', 'O'), ('a', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('model', 'O'), ('in', 'O'), ('Nrf2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), (',', 'O'), ('and', 'O'), ('cultured', 'O'), ('human', 'O'), ('mesangial', 'O'), ('cells', 'O'), ('.', 'O'))"
RESULTS : The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .,"(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('glomeruli', 'O'), ('of', 'O'), ('human', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('patients', 'O'), ('were', 'O'), ('under', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('and', 'O'), ('had', 'O'), ('elevated', 'O'), ('Nrf2', 'O'), ('levels', 'O'), ('.', 'O'))"
"In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .","(('In', 'O'), ('the', 'O'), ('animal', 'O'), ('study', 'O'), (',', 'O'), ('Nrf2', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('to', 'O'), ('be', 'O'), ('crucial', 'O'), ('in', 'O'), ('ameliorating', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('renal', 'B'), ('damage', 'I'), ('.', 'O'))"
This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .,"(('This', 'O'), ('is', 'O'), ('evident', 'O'), ('by', 'O'), ('Nrf2', 'O'), ('(', 'O'), ('-', 'O'), ('/', 'O'), ('-', 'O'), (')', 'O'), ('mice', 'O'), ('having', 'O'), ('higher', 'O'), ('ROS', 'O'), ('production', 'O'), ('and', 'O'), ('suffering', 'O'), ('from', 'O'), ('greater', 'O'), ('oxidative', 'O'), ('DNA', 'O'), ('damage', 'O'), ('and', 'O'), ('renal', 'B'), ('injury', 'I'), ('compared', 'O'), ('with', 'O'), ('Nrf2', 'O'), ('(', 'O'), ('+', 'O'), ('/', 'O'), ('+', 'O'), (')', 'O'), ('mice', 'O'), ('.', 'O'))"
"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .","(('Mechanistic', 'O'), ('studies', 'O'), ('in', 'O'), ('both', 'O'), ('in', 'O'), ('vivo', 'O'), ('and', 'O'), ('in', 'O'), ('vitro', 'O'), ('systems', 'O'), ('showed', 'O'), ('that', 'O'), ('the', 'O'), ('Nrf2', 'O'), ('-', 'O'), ('mediated', 'O'), ('protection', 'O'), ('against', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('is', 'O'), (',', 'O'), ('at', 'O'), ('least', 'O'), (',', 'O'), ('partially', 'O'), ('through', 'O'), ('inhibition', 'O'), ('of', 'O'), ('transforming', 'O'), ('growth', 'O'), ('factor', 'O'), ('-', 'O'), ('beta1', 'O'), ('(', 'O'), ('TGF', 'O'), ('-', 'O'), ('beta1', 'O'), (')', 'O'), ('and', 'O'), ('reduction', 'O'), ('of', 'O'), ('extracellular', 'O'), ('matrix', 'O'), ('production', 'O'), ('.', 'O'))"
"CONCLUSIONS : This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .","(('CONCLUSIONS', 'O'), (':', 'O'), ('This', 'O'), ('work', 'O'), ('clearly', 'O'), ('indicates', 'O'), ('a', 'O'), ('protective', 'O'), ('role', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('in', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('dietary', 'O'), ('or', 'O'), ('therapeutic', 'O'), ('activation', 'O'), ('of', 'O'), ('Nrf2', 'O'), ('could', 'O'), ('be', 'O'), ('used', 'O'), ('as', 'O'), ('a', 'O'), ('strategy', 'O'), ('to', 'O'), ('prevent', 'O'), ('or', 'O'), ('slow', 'O'), ('down', 'O'), ('the', 'O'), ('progression', 'O'), ('of', 'O'), ('diabetic', 'B'), ('nephropathy', 'I'), ('.', 'O'))"
Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .,"(('Metformin', 'O'), ('prevents', 'O'), ('experimental', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('induced', 'O'), ('nephropathy', 'B'), ('by', 'O'), ('a', 'O'), ('mitochondria', 'O'), ('-', 'O'), ('dependent', 'O'), ('pathway', 'O'), ('.', 'O'))"
The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .,"(('The', 'O'), ('antidiabetic', 'O'), ('drug', 'O'), ('metformin', 'O'), ('can', 'O'), ('diminish', 'O'), ('apoptosis', 'O'), ('induced', 'O'), ('by', 'O'), ('oxidative', 'O'), ('stress', 'O'), ('in', 'O'), ('endothelial', 'O'), ('cells', 'O'), ('and', 'O'), ('prevent', 'O'), ('vascular', 'B'), ('dysfunction', 'I'), ('even', 'O'), ('in', 'O'), ('nondiabetic', 'O'), ('patients', 'O'), ('.', 'O'))"
Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .,"(('Here', 'O'), ('we', 'O'), ('tested', 'O'), ('whether', 'O'), ('it', 'O'), ('has', 'O'), ('a', 'O'), ('beneficial', 'O'), ('effect', 'O'), ('in', 'O'), ('a', 'O'), ('rat', 'O'), ('model', 'O'), ('of', 'O'), ('gentamicin', 'O'), ('toxicity', 'B'), ('.', 'O'))"
Metformin treatment fully blocked gentamicin - mediated acute renal failure .,"(('Metformin', 'O'), ('treatment', 'O'), ('fully', 'O'), ('blocked', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('mediated', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .,"(('These', 'O'), ('in', 'O'), ('vivo', 'O'), ('markers', 'O'), ('of', 'O'), ('kidney', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('their', 'O'), ('correction', 'O'), ('by', 'O'), ('metformin', 'O'), ('were', 'O'), ('complemented', 'O'), ('by', 'O'), ('in', 'O'), ('vitro', 'O'), ('studies', 'O'), ('of', 'O'), ('mitochondrial', 'O'), ('function', 'O'), ('.', 'O'))"
"Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .","(('Thus', 'O'), (',', 'O'), ('our', 'O'), ('study', 'O'), ('suggests', 'O'), ('that', 'O'), ('pleiotropic', 'O'), ('effects', 'O'), ('of', 'O'), ('metformin', 'O'), ('can', 'O'), ('lessen', 'O'), ('gentamicin', 'O'), ('nephrotoxicity', 'B'), ('and', 'O'), ('improve', 'O'), ('mitochondrial', 'O'), ('homeostasis', 'O'), ('.', 'O'))"
Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .,"(('Risk', 'O'), ('of', 'O'), ('nephropathy', 'B'), ('after', 'O'), ('consumption', 'O'), ('of', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('media', 'O'), ('by', 'O'), ('children', 'O'), ('undergoing', 'O'), ('cardiac', 'O'), ('angiography', 'O'), (':', 'O'), ('a', 'O'), ('prospective', 'O'), ('study', 'O'), ('.', 'O'))"
"Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .","(('Despite', 'O'), ('increasing', 'O'), ('reports', 'O'), ('on', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('media', 'O'), ('-', 'O'), ('induced', 'O'), ('nephropathy', 'B'), ('(', 'O'), ('CIN', 'B'), (')', 'O'), ('in', 'O'), ('hospitalized', 'O'), ('adult', 'O'), ('patients', 'O'), ('during', 'O'), ('cardiac', 'O'), ('procedures', 'O'), (',', 'O'), ('the', 'O'), ('studies', 'O'), ('in', 'O'), ('pediatrics', 'O'), ('are', 'O'), ('limited', 'O'), (',', 'O'), ('with', 'O'), ('even', 'O'), ('less', 'O'), ('focus', 'O'), ('on', 'O'), ('possible', 'O'), ('predisposing', 'O'), ('factors', 'O'), ('and', 'O'), ('preventive', 'O'), ('measures', 'O'), ('for', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('cardiac', 'O'), ('angiography', 'O'), ('.', 'O'))"
"This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .","(('This', 'O'), ('prospective', 'O'), ('study', 'O'), ('determined', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('CIN', 'B'), ('for', 'O'), ('two', 'O'), ('nonionic', 'O'), ('contrast', 'O'), ('media', 'O'), ('(', 'O'), ('CM', 'O'), (')', 'O'), (',', 'O'), ('iopromide', 'O'), ('and', 'O'), ('iohexol', 'O'), (',', 'O'), ('among', 'O'), ('80', 'O'), ('patients', 'O'), ('younger', 'O'), ('than', 'O'), ('18', 'O'), ('years', 'O'), ('and', 'O'), ('compared', 'O'), ('the', 'O'), ('rates', 'O'), ('for', 'O'), ('this', 'O'), ('complication', 'O'), ('in', 'O'), ('relation', 'O'), ('to', 'O'), ('the', 'O'), ('type', 'O'), ('and', 'O'), ('dosage', 'O'), ('of', 'O'), ('CM', 'O'), ('and', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('cyanosis', 'B'), ('.', 'O'))"
"Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .","(('Risk', 'O'), ('of', 'O'), ('renal', 'B'), ('failure', 'I'), (',', 'O'), ('Injury', 'B'), ('to', 'I'), ('the', 'I'), ('kidney', 'I'), (',', 'O'), ('Failure', 'B'), ('of', 'I'), ('kidney', 'I'), ('function', 'I'), (',', 'O'), ('Loss', 'B'), ('of', 'I'), ('kidney', 'I'), ('function', 'I'), (',', 'O'), ('and', 'O'), ('End', 'O'), ('-', 'O'), ('stage', 'O'), ('renal', 'B'), ('damage', 'I'), ('(', 'O'), ('RIFLE', 'O'), ('criteria', 'O'), (')', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('define', 'O'), ('CIN', 'B'), ('and', 'O'), ('its', 'O'), ('incidence', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('population', 'O'), ('.', 'O'))"
"Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .","(('Accordingly', 'O'), (',', 'O'), ('among', 'O'), ('the', 'O'), ('15', 'O'), ('CIN', 'B'), ('patients', 'O'), ('(', 'O'), ('18', 'O'), ('.', 'O'), ('75', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('7', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('in', 'O'), ('group', 'O'), ('A', 'O'), ('had', 'O'), ('increased', 'O'), ('risk', 'O'), ('and', 'O'), ('3', 'O'), ('.', 'O'), ('75', 'O'), ('%', 'O'), ('had', 'O'), ('renal', 'B'), ('injury', 'I'), (',', 'O'), ('whereas', 'O'), ('5', 'O'), ('%', 'O'), ('of', 'O'), ('group', 'O'), ('B', 'O'), ('had', 'O'), ('increased', 'O'), ('risk', 'O'), ('and', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('had', 'O'), ('renal', 'B'), ('injury', 'I'), ('.', 'O'))"
"Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .","(('Among', 'O'), ('the', 'O'), ('15', 'O'), ('patients', 'O'), ('with', 'O'), ('CIN', 'B'), (',', 'O'), ('6', 'O'), ('had', 'O'), ('cyanotic', 'O'), ('congenital', 'B'), ('heart', 'I'), ('diseases', 'I'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('incidence', 'O'), ('did', 'O'), ('not', 'O'), ('differ', 'O'), ('significantly', 'O'), ('from', 'O'), ('that', 'O'), ('for', 'O'), ('the', 'O'), ('noncyanotic', 'O'), ('patients', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('243', 'O'), (')', 'O'), ('.', 'O'))"
"The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .","(('The', 'O'), ('incidence', 'O'), ('depends', 'O'), ('on', 'O'), ('dosage', 'O'), ('but', 'O'), ('not', 'O'), ('on', 'O'), ('the', 'O'), ('type', 'O'), ('of', 'O'), ('consumed', 'O'), ('nonionic', 'O'), ('CM', 'O'), (',', 'O'), ('nor', 'O'), ('on', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('cyanosis', 'B'), (',', 'O'), ('and', 'O'), ('although', 'O'), ('CIN', 'B'), ('usually', 'O'), ('is', 'O'), ('reversible', 'O'), (',', 'O'), ('more', 'O'), ('concern', 'O'), ('is', 'O'), ('needed', 'O'), ('for', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('such', 'O'), ('a', 'O'), ('complication', 'O'), ('in', 'O'), ('children', 'O'), ('.', 'O'))"
Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .,"(('Renal', 'O'), ('function', 'O'), ('and', 'O'), ('hemodynamics', 'O'), ('during', 'O'), ('prolonged', 'O'), ('isoflurane', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('isoflurane', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('on', 'O'), ('glomerular', 'O'), ('function', 'O'), ('and', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('20', 'O'), ('human', 'O'), ('subjects', 'O'), ('.', 'O'))"
Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .,"(('Hypotension', 'B'), ('was', 'O'), ('induced', 'O'), ('for', 'O'), ('236', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('15', 'O'), ('.', 'O'), ('1', 'O'), ('min', 'O'), ('by', 'O'), ('increasing', 'O'), ('the', 'O'), ('isoflurane', 'O'), ('inspired', 'O'), ('concentration', 'O'), ('to', 'O'), ('maintain', 'O'), ('a', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('of', 'O'), ('59', 'O'), ('.', 'O'), ('8', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('4', 'O'), ('mmHg', 'O'), ('.', 'O'))"
GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .,"(('GFR', 'O'), ('and', 'O'), ('ERPF', 'O'), ('decreased', 'O'), ('with', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('anesthesia', 'O'), ('but', 'O'), ('not', 'O'), ('significantly', 'O'), ('more', 'O'), ('during', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .","(('Renal', 'O'), ('vascular', 'O'), ('resistance', 'O'), ('increased', 'O'), ('during', 'O'), ('anesthesia', 'O'), ('but', 'O'), ('decreased', 'O'), ('when', 'O'), ('hypotension', 'B'), ('was', 'O'), ('induced', 'O'), (',', 'O'), ('allowing', 'O'), ('the', 'O'), ('maintenance', 'O'), ('of', 'O'), ('renal', 'O'), ('blood', 'O'), ('flow', 'O'), ('.', 'O'))"
We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('renal', 'O'), ('compensatory', 'O'), ('mechanisms', 'O'), ('are', 'O'), ('preserved', 'O'), ('during', 'O'), ('isoflurane', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('and', 'O'), ('that', 'O'), ('renal', 'O'), ('function', 'O'), ('and', 'O'), ('hemodynamics', 'O'), ('quickly', 'O'), ('return', 'O'), ('to', 'O'), ('normal', 'O'), ('when', 'O'), ('normotension', 'O'), ('is', 'O'), ('resumed', 'O'), ('.', 'O'))"
Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .,"(('Many', 'O'), ('authors', 'O'), ('described', 'O'), ('the', 'O'), ('effects', 'O'), ('on', 'O'), ('the', 'O'), ('fetus', 'O'), ('of', 'O'), ('maternal', 'O'), ('cocaine', 'B'), ('abuse', 'I'), ('during', 'O'), ('pregnancy', 'O'), ('.', 'O'))"
Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .,"(('Vasoconstriction', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('common', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('leading', 'O'), ('to', 'O'), ('a', 'O'), ('wide', 'O'), ('range', 'O'), ('of', 'O'), ('fetal', 'B'), ('anomalies', 'I'), ('.', 'O'))"
"We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .","(('We', 'O'), ('report', 'O'), ('on', 'O'), ('an', 'O'), ('infant', 'O'), ('with', 'O'), ('multiple', 'B'), ('cranial', 'I'), ('-', 'I'), ('nerve', 'I'), ('involvement', 'I'), ('attributable', 'O'), ('to', 'O'), ('brainstem', 'B'), ('dysgenesis', 'I'), (',', 'O'), ('born', 'O'), ('to', 'O'), ('a', 'O'), ('cocaine', 'B'), ('-', 'I'), ('addicted', 'I'), ('mother', 'O'), ('.', 'O'))"
OBJECTIVE : The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('on', 'O'), ('trabecular', 'O'), ('bone', 'O'), ('mineral', 'O'), ('density', 'O'), ('(', 'O'), ('BMD', 'O'), (')', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescents', 'O'), ('.', 'O'))"
RESULTS : Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .,"(('RESULTS', 'O'), (':', 'O'), ('Hyperprolactinemia', 'B'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('49', 'O'), ('%', 'O'), ('of', 'O'), ('83', 'O'), ('boys', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('41', 'O'), (')', 'O'), ('treated', 'O'), ('with', 'O'), ('risperidone', 'O'), ('for', 'O'), ('a', 'O'), ('mean', 'O'), ('of', 'O'), ('2', 'O'), ('.', 'O'), ('9', 'O'), ('years', 'O'), ('.', 'O'))"
Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .,"(('Serum', 'O'), ('testosterone', 'O'), ('concentration', 'O'), ('increased', 'O'), ('with', 'O'), ('pubertal', 'O'), ('status', 'O'), ('but', 'O'), ('was', 'O'), ('not', 'O'), ('affected', 'O'), ('by', 'O'), ('hyperprolactinemia', 'B'), ('.', 'O'))"
"Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .","(('Of', 'O'), ('13', 'O'), ('documented', 'O'), ('fractures', 'B'), (',', 'O'), ('3', 'O'), ('occurred', 'O'), ('after', 'O'), ('risperidone', 'O'), ('and', 'O'), ('SSRIs', 'O'), ('were', 'O'), ('started', 'O'), (',', 'O'), ('and', 'O'), ('none', 'O'), ('occurred', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('hyperprolactinemia', 'B'), ('.', 'O'))"
CONCLUSIONS : This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('This', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('study', 'O'), ('to', 'O'), ('link', 'O'), ('risperidone', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperprolactinemia', 'B'), ('and', 'O'), ('SSRI', 'O'), ('treatment', 'O'), ('to', 'O'), ('lower', 'O'), ('BMD', 'O'), ('in', 'O'), ('children', 'O'), ('and', 'O'), ('adolescents', 'O'), ('.', 'O'))"
"RATIONALE AND OBJECTIVES : The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .","(('RATIONALE', 'O'), ('AND', 'O'), ('OBJECTIVES', 'O'), (':', 'O'), ('The', 'O'), ('light', 'O'), ('-', 'O'), ('enhanced', 'O'), ('startle', 'B'), ('paradigm', 'O'), ('(', 'O'), ('LES', 'O'), (')', 'O'), ('is', 'O'), ('suggested', 'O'), ('to', 'O'), ('model', 'O'), ('anxiety', 'B'), (',', 'O'), ('because', 'O'), ('of', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('specific', 'O'), ('cue', 'O'), ('and', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('effect', 'O'), ('.', 'O'))"
Rosaceiform dermatitis associated with topical tacrolimus treatment .,"(('Rosaceiform', 'O'), ('dermatitis', 'B'), ('associated', 'O'), ('with', 'O'), ('topical', 'O'), ('tacrolimus', 'O'), ('treatment', 'O'), ('.', 'O'))"
We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .,"(('We', 'O'), ('describe', 'O'), ('herein', 'O'), ('3', 'O'), ('patients', 'O'), ('who', 'O'), ('developed', 'O'), ('rosacea', 'B'), ('-', 'O'), ('like', 'O'), ('dermatitis', 'B'), ('eruptions', 'B'), ('while', 'O'), ('using', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('%', 'O'), ('or', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('%', 'O'), ('tacrolimus', 'O'), ('ointment', 'O'), ('for', 'O'), ('facial', 'B'), ('dermatitis', 'I'), ('.', 'O'))"
"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .","(('Continuous', 'O'), ('topical', 'O'), ('use', 'O'), ('of', 'O'), ('immunomodulators', 'O'), ('such', 'O'), ('as', 'O'), ('tacrolimus', 'O'), ('or', 'O'), ('pimecrolimus', 'O'), ('should', 'O'), ('be', 'O'), ('regarded', 'O'), ('as', 'O'), ('a', 'O'), ('potential', 'O'), ('cause', 'O'), ('of', 'O'), ('rosaceiform', 'O'), ('dermatitis', 'B'), (',', 'O'), ('although', 'O'), ('many', 'O'), ('cases', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .,"(('Coenzyme', 'O'), ('Q10', 'O'), ('treatment', 'O'), ('ameliorates', 'O'), ('acute', 'O'), ('cisplatin', 'O'), ('nephrotoxicity', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .,"(('The', 'O'), ('nephroprotective', 'O'), ('effect', 'O'), ('of', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('was', 'O'), ('investigated', 'O'), ('in', 'O'), ('mice', 'O'), ('with', 'O'), ('acute', 'B'), ('renal', 'I'), ('injury', 'I'), ('induced', 'O'), ('by', 'O'), ('a', 'O'), ('single', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('cisplatin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .","(('Coenzyme', 'O'), ('Q10', 'O'), ('significantly', 'O'), ('compensated', 'O'), ('deficits', 'O'), ('in', 'O'), ('the', 'O'), ('antioxidant', 'O'), ('defense', 'O'), ('mechanisms', 'O'), ('(', 'O'), ('reduced', 'O'), ('glutathione', 'O'), ('level', 'O'), ('and', 'O'), ('superoxide', 'O'), ('dismutase', 'O'), ('activity', 'O'), (')', 'O'), (',', 'O'), ('suppressed', 'O'), ('lipid', 'O'), ('peroxidation', 'O'), (',', 'O'), ('decreased', 'O'), ('the', 'O'), ('elevations', 'O'), ('of', 'O'), ('tumor', 'B'), ('necrosis', 'B'), ('factor', 'O'), ('-', 'O'), ('alpha', 'O'), (',', 'O'), ('nitric', 'O'), ('oxide', 'O'), ('and', 'O'), ('platinum', 'O'), ('ion', 'O'), ('concentration', 'O'), (',', 'O'), ('and', 'O'), ('attenuated', 'O'), ('the', 'O'), ('reductions', 'O'), ('of', 'O'), ('selenium', 'O'), ('and', 'O'), ('zinc', 'O'), ('ions', 'O'), ('in', 'O'), ('renal', 'O'), ('tissue', 'O'), ('resulted', 'O'), ('from', 'O'), ('cisplatin', 'O'), ('administration', 'O'), ('.', 'O'))"
"Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .","(('Also', 'O'), (',', 'O'), ('histopathological', 'O'), ('renal', 'B'), ('tissue', 'I'), ('damage', 'I'), ('mediated', 'O'), ('by', 'O'), ('cisplatin', 'O'), ('was', 'O'), ('ameliorated', 'O'), ('by', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('treatment', 'O'), ('.', 'O'))"
It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .,"(('It', 'O'), ('was', 'O'), ('concluded', 'O'), ('that', 'O'), ('coenzyme', 'O'), ('Q10', 'O'), ('represents', 'O'), ('a', 'O'), ('potential', 'O'), ('therapeutic', 'O'), ('option', 'O'), ('to', 'O'), ('protect', 'O'), ('against', 'O'), ('acute', 'O'), ('cisplatin', 'O'), ('nephrotoxicity', 'B'), ('commonly', 'O'), ('encountered', 'O'), ('in', 'O'), ('clinical', 'O'), ('practice', 'O'), ('.', 'O'))"
Reversible cholestasis with bile duct injury following azathioprine therapy .,"(('Reversible', 'O'), ('cholestasis', 'B'), ('with', 'O'), ('bile', 'B'), ('duct', 'I'), ('injury', 'I'), ('following', 'O'), ('azathioprine', 'O'), ('therapy', 'O'), ('.', 'O'))"
"A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .","(('A', 'O'), ('67', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), (',', 'O'), ('with', 'O'), ('primary', 'O'), ('polymyositis', 'B'), ('and', 'O'), ('without', 'O'), ('previous', 'O'), ('evidence', 'O'), ('of', 'O'), ('liver', 'B'), ('disease', 'I'), (',', 'O'), ('developed', 'O'), ('clinical', 'O'), ('and', 'O'), ('biochemical', 'O'), ('features', 'O'), ('of', 'O'), ('severe', 'O'), ('cholestasis', 'B'), ('3', 'O'), ('months', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('azathioprine', 'O'), ('therapy', 'O'), ('.', 'O'))"
Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .,"(('Liver', 'O'), ('biopsy', 'O'), ('showed', 'O'), ('cholestasis', 'B'), ('with', 'O'), ('both', 'O'), ('cytological', 'O'), ('and', 'O'), ('architectural', 'O'), ('alterations', 'O'), ('of', 'O'), ('interlobular', 'O'), ('bile', 'O'), ('ducts', 'O'), ('.', 'O'))"
It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .,"(('It', 'O'), ('is', 'O'), ('believed', 'O'), ('that', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('reported', 'O'), ('case', 'O'), ('of', 'O'), ('reversible', 'O'), ('azathioprine', 'O'), ('-', 'O'), ('induced', 'O'), ('cholestasis', 'B'), ('associated', 'O'), ('with', 'O'), ('histological', 'O'), ('evidence', 'O'), ('of', 'O'), ('bile', 'B'), ('duct', 'I'), ('injury', 'I'), ('.', 'O'))"
Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .,"(('Dopamine', 'O'), ('is', 'O'), ('not', 'O'), ('essential', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('methamphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
"It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .","(('It', 'O'), ('is', 'O'), ('widely', 'O'), ('believed', 'O'), ('that', 'O'), ('dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), ('mediates', 'O'), ('methamphetamine', 'O'), ('(', 'O'), ('METH', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('toxicity', 'B'), ('to', 'O'), ('brain', 'O'), ('dopaminergic', 'O'), ('neurons', 'O'), (',', 'O'), ('because', 'O'), ('drugs', 'O'), ('that', 'O'), ('interfere', 'O'), ('with', 'O'), ('DA', 'O'), ('neurotransmission', 'O'), ('decrease', 'O'), ('toxicity', 'B'), (',', 'O'), ('whereas', 'O'), ('drugs', 'O'), ('that', 'O'), ('increase', 'O'), ('DA', 'O'), ('neurotransmission', 'O'), ('enhance', 'O'), ('toxicity', 'B'), ('.', 'O'))"
Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .,"(('Here', 'O'), ('we', 'O'), ('show', 'O'), ('that', 'O'), ('the', 'O'), ('recently', 'O'), ('reported', 'O'), ('ability', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('dihydroxyphenylalanine', 'O'), ('to', 'O'), ('reverse', 'O'), ('the', 'O'), ('protective', 'O'), ('effect', 'O'), ('of', 'O'), ('alpha', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('para', 'O'), ('-', 'O'), ('tyrosine', 'O'), ('on', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('DA', 'O'), ('neurotoxicity', 'B'), ('is', 'O'), ('also', 'O'), ('confounded', 'O'), ('by', 'O'), ('drug', 'O'), ('effects', 'O'), ('on', 'O'), ('body', 'O'), ('temperature', 'O'), ('.', 'O'))"
"Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .","(('Further', 'O'), (',', 'O'), ('we', 'O'), ('show', 'O'), ('that', 'O'), ('mice', 'O'), ('genetically', 'O'), ('engineered', 'O'), ('to', 'O'), ('be', 'O'), ('deficient', 'O'), ('in', 'O'), ('brain', 'O'), ('DA', 'O'), ('develop', 'O'), ('METH', 'O'), ('neurotoxicity', 'B'), (',', 'O'), ('as', 'O'), ('long', 'O'), ('as', 'O'), ('the', 'O'), ('thermic', 'O'), ('effects', 'O'), ('of', 'O'), ('METH', 'O'), ('are', 'O'), ('preserved', 'O'), ('.', 'O'))"
"In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('we', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('mice', 'O'), ('genetically', 'O'), ('engineered', 'O'), ('to', 'O'), ('have', 'O'), ('unilateral', 'O'), ('brain', 'O'), ('DA', 'O'), ('deficits', 'O'), ('develop', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('dopaminergic', 'B'), ('deficits', 'I'), ('that', 'O'), ('are', 'O'), ('of', 'O'), ('comparable', 'O'), ('magnitude', 'O'), ('on', 'O'), ('both', 'O'), ('sides', 'O'), ('of', 'O'), ('the', 'O'), ('brain', 'O'), ('.', 'O'))"
"Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .","(('Taken', 'O'), ('together', 'O'), (',', 'O'), ('these', 'O'), ('findings', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('DA', 'O'), ('is', 'O'), ('not', 'O'), ('essential', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('dopaminergic', 'O'), ('neurotoxicity', 'B'), ('and', 'O'), ('suggest', 'O'), ('that', 'O'), ('mechanisms', 'O'), ('independent', 'O'), ('of', 'O'), ('DA', 'O'), ('warrant', 'O'), ('more', 'O'), ('intense', 'O'), ('investigation', 'O'), ('.', 'O'))"
Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .,"(('Swallowing', 'O'), ('-', 'O'), ('induced', 'O'), ('atrial', 'B'), ('tachyarrhythmia', 'I'), ('triggered', 'O'), ('by', 'O'), ('salbutamol', 'O'), (':', 'O'), ('case', 'O'), ('report', 'O'), ('and', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('.', 'O'))"
"On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .","(('On', 'O'), ('electrocardiogram', 'O'), (',', 'O'), ('episodes', 'O'), ('of', 'O'), ('atrial', 'B'), ('tachyarrhythmia', 'I'), ('were', 'O'), ('recorded', 'O'), ('immediately', 'O'), ('after', 'O'), ('swallowing', 'O'), (';', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('Holter', 'O'), ('monitoring', 'O'), ('recorded', 'O'), ('several', 'O'), ('events', 'O'), ('.', 'O'))"
"The arrhythmia resolved after therapy with atenolol , but recurred a year later .","(('The', 'O'), ('arrhythmia', 'B'), ('resolved', 'O'), ('after', 'O'), ('therapy', 'O'), ('with', 'O'), ('atenolol', 'O'), (',', 'O'), ('but', 'O'), ('recurred', 'O'), ('a', 'O'), ('year', 'O'), ('later', 'O'), ('.', 'O'))"
"After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .","(('After', 'O'), ('stopping', 'O'), ('the', 'O'), ('beta', 'O'), ('-', 'O'), ('agonist', 'O'), (',', 'O'), ('and', 'O'), ('after', 'O'), ('a', 'O'), ('week', 'O'), ('with', 'O'), ('the', 'O'), ('atenolol', 'O'), (',', 'O'), ('the', 'O'), ('arrhythmia', 'B'), ('disappeared', 'O'), ('.', 'O'))"
DISCUSSION : Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .,"(('DISCUSSION', 'O'), (':', 'O'), ('Swallowing', 'O'), ('-', 'O'), ('induced', 'O'), ('atrial', 'B'), ('tachyarrhythmia', 'I'), ('(', 'O'), ('SIAT', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('rare', 'O'), ('phenomenon', 'O'), ('.', 'O'))"
"It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .","(('It', 'O'), ('discusses', 'O'), ('demographics', 'O'), (',', 'O'), ('clinical', 'O'), ('characteristics', 'O'), ('and', 'O'), ('types', 'O'), ('of', 'O'), ('arrhythmia', 'B'), (',', 'O'), ('postulated', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('SIAT', 'B'), (',', 'O'), ('and', 'O'), ('different', 'O'), ('treatment', 'O'), ('possibilities', 'O'), ('such', 'O'), ('as', 'O'), ('medications', 'O'), (',', 'O'), ('surgery', 'O'), (',', 'O'), ('and', 'O'), ('radiofrequency', 'O'), ('catheter', 'O'), ('ablation', 'O'), ('(', 'O'), ('RFCA', 'O'), (')', 'O'), ('.', 'O'))"
"Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .","(('Although', 'O'), ('it', 'O'), ('is', 'O'), ('difficult', 'O'), ('to', 'O'), ('define', 'O'), ('causality', 'O'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('logical', 'O'), ('to', 'O'), ('think', 'O'), ('that', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('agonist', 'O'), ('like', 'O'), ('salbutamol', 'O'), ('(', 'O'), ('known', 'O'), ('to', 'O'), ('induce', 'O'), ('tachycardia', 'B'), (')', 'O'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('trigger', 'O'), ('of', 'O'), ('adrenergic', 'O'), ('reflexes', 'O'), ('originating', 'O'), ('in', 'O'), ('the', 'O'), ('esophagus', 'O'), ('while', 'O'), ('swallowing', 'O'), ('and', 'O'), ('that', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('blocker', 'O'), ('such', 'O'), ('as', 'O'), ('atenolol', 'O'), ('(', 'O'), ('that', 'O'), ('blocks', 'O'), ('the', 'O'), ('adrenergic', 'O'), ('activity', 'O'), (')', 'O'), ('may', 'O'), ('relieve', 'O'), ('it', 'O'), ('.', 'O'))"
The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .,"(('The', 'O'), ('ability', 'O'), ('of', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('to', 'O'), ('reverse', 'O'), ('or', 'O'), ('prevent', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('function', 'O'), ('caused', 'O'), ('by', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('mellitus', 'I'), ('.', 'O'))"
The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('on', 'O'), ('in', 'O'), ('vivo', 'O'), ('and', 'O'), ('in', 'O'), ('vitro', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('function', 'O'), ('in', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('diabetic', 'B'), ('rats', 'O'), ('were', 'O'), ('investigated', 'O'), ('.', 'O'))"
"Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .","(('Diabetes', 'B'), ('of', 'O'), ('2', 'O'), ('months', 'O'), ('duration', 'O'), ('resulted', 'O'), ('in', 'O'), ('decreases', 'O'), ('in', 'O'), ('body', 'O'), ('weight', 'O'), ('and', 'O'), ('increases', 'O'), ('in', 'O'), ('fluid', 'O'), ('consumption', 'O'), (',', 'O'), ('urine', 'O'), ('volume', 'O'), (',', 'O'), ('frequency', 'O'), ('of', 'O'), ('micturition', 'O'), (',', 'O'), ('and', 'O'), ('average', 'O'), ('volume', 'O'), ('per', 'O'), ('micturition', 'O'), (';', 'O'), ('effects', 'O'), ('which', 'O'), ('were', 'O'), ('prevented', 'O'), ('by', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .","(('Insulin', 'O'), ('treatment', 'O'), ('also', 'O'), ('prevented', 'O'), ('the', 'O'), ('increases', 'O'), ('in', 'O'), ('contractile', 'O'), ('responses', 'O'), ('of', 'O'), ('bladder', 'O'), ('body', 'O'), ('strips', 'O'), ('from', 'O'), ('diabetic', 'B'), ('rats', 'O'), ('to', 'O'), ('nerve', 'O'), ('stimulation', 'O'), (',', 'O'), ('ATP', 'O'), (',', 'O'), ('and', 'O'), ('bethanechol', 'O'), ('.', 'O'))"
"Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .","(('Diabetes', 'B'), ('of', 'O'), ('4', 'O'), ('months', 'O'), ('duration', 'O'), ('also', 'O'), ('resulted', 'O'), ('in', 'O'), ('decreases', 'O'), ('in', 'O'), ('body', 'O'), ('weight', 'O'), (',', 'O'), ('and', 'O'), ('increases', 'O'), ('in', 'O'), ('fluid', 'O'), ('consumption', 'O'), (',', 'O'), ('urine', 'O'), ('volume', 'O'), (',', 'O'), ('frequency', 'O'), ('of', 'O'), ('micturition', 'O'), (',', 'O'), ('and', 'O'), ('average', 'O'), ('volume', 'O'), ('per', 'O'), ('micturition', 'O'), (',', 'O'), ('effects', 'O'), ('which', 'O'), ('were', 'O'), ('reversed', 'O'), ('by', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('for', 'O'), ('the', 'O'), ('final', 'O'), ('2', 'O'), ('months', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .","(('Insulin', 'O'), ('treatment', 'O'), ('reversed', 'O'), ('the', 'O'), ('increases', 'O'), ('in', 'O'), ('contractile', 'O'), ('responses', 'O'), ('of', 'O'), ('bladder', 'O'), ('body', 'O'), ('strips', 'O'), ('from', 'O'), ('diabetic', 'B'), ('rats', 'O'), ('to', 'O'), ('nerve', 'O'), ('stimulation', 'O'), (',', 'O'), ('ATP', 'O'), (',', 'O'), ('and', 'O'), ('bethanechol', 'O'), ('.', 'O'))"
The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .,"(('The', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('on', 'O'), ('urinary', 'O'), ('bladder', 'O'), ('function', 'O'), ('are', 'O'), ('both', 'O'), ('prevented', 'O'), ('and', 'O'), ('reversed', 'O'), ('by', 'O'), ('insulin', 'O'), ('treatment', 'O'), ('.', 'O'))"
Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .,"(('Glutamatergic', 'O'), ('neurotransmission', 'O'), ('mediated', 'O'), ('by', 'O'), ('NMDA', 'O'), ('receptors', 'O'), ('in', 'O'), ('the', 'O'), ('inferior', 'O'), ('colliculus', 'O'), ('can', 'O'), ('modulate', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .,"(('The', 'O'), ('present', 'O'), ('study', 'O'), ('examined', 'O'), ('the', 'O'), ('influence', 'O'), ('of', 'O'), ('excitatory', 'O'), ('amino', 'O'), ('acid', 'O'), ('-', 'O'), ('mediated', 'O'), ('mechanisms', 'O'), ('in', 'O'), ('the', 'O'), ('IC', 'O'), ('on', 'O'), ('the', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('the', 'O'), ('dopamine', 'O'), ('receptor', 'O'), ('blocker', 'O'), ('haloperidol', 'O'), ('administered', 'O'), ('systemically', 'O'), ('(', 'O'), ('1', 'O'), ('or', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .","(('Haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('was', 'O'), ('challenged', 'O'), ('with', 'O'), ('prior', 'O'), ('intracollicular', 'O'), ('microinjections', 'O'), ('of', 'O'), ('glutamate', 'O'), ('NMDA', 'O'), ('receptor', 'O'), ('antagonists', 'O'), (',', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), ('(', 'O'), ('15', 'O'), ('or', 'O'), ('30', 'O'), ('mmol', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (')', 'O'), ('and', 'O'), ('AP7', 'O'), ('(', 'O'), ('10', 'O'), ('or', 'O'), ('20', 'O'), ('nmol', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (')', 'O'), (',', 'O'), ('or', 'O'), ('of', 'O'), ('the', 'O'), ('NMDA', 'O'), ('receptor', 'O'), ('agonist', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('d', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (',', 'O'), ('20', 'O'), ('or', 'O'), ('30', 'O'), ('nmol', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), (')', 'O'), ('.', 'O'))"
"The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .","(('The', 'O'), ('results', 'O'), ('showed', 'O'), ('that', 'O'), ('intracollicular', 'O'), ('microinjection', 'O'), ('of', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), ('and', 'O'), ('AP7', 'O'), ('previous', 'O'), ('to', 'O'), ('systemic', 'O'), ('injections', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('the', 'O'), ('catalepsy', 'B'), (',', 'O'), ('as', 'O'), ('indicated', 'O'), ('by', 'O'), ('a', 'O'), ('reduced', 'O'), ('latency', 'O'), ('to', 'O'), ('step', 'O'), ('down', 'O'), ('from', 'O'), ('a', 'O'), ('horizontal', 'O'), ('bar', 'O'), ('.', 'O'))"
These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('glutamate', 'O'), ('-', 'O'), ('mediated', 'O'), ('mechanisms', 'O'), ('in', 'O'), ('the', 'O'), ('neural', 'O'), ('circuits', 'O'), ('at', 'O'), ('the', 'O'), ('IC', 'O'), ('level', 'O'), ('influence', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('participate', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('motor', 'O'), ('activity', 'O'), ('.', 'O'))"
Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .,"(('Severe', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('patient', 'O'), ('on', 'O'), ('amiodarone', 'O'), ('presenting', 'O'), ('with', 'O'), ('myxedemic', 'B'), ('coma', 'I'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .,"(('This', 'O'), ('is', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('of', 'O'), ('myxedema', 'B'), ('coma', 'I'), ('secondary', 'O'), ('to', 'O'), ('amiodarone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypothyroidism', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('severe', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('(', 'O'), ('CHF', 'B'), (')', 'O'), ('.', 'O'))"
"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .","(('Patients', 'O'), ('with', 'O'), ('CHF', 'B'), ('on', 'O'), ('amiodarone', 'O'), ('may', 'O'), ('suffer', 'O'), ('serious', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('from', 'O'), ('hypothyroidism', 'B'), (',', 'O'), ('and', 'O'), ('thus', 'O'), ('may', 'O'), ('deserve', 'O'), ('closer', 'O'), ('follow', 'O'), ('up', 'O'), ('for', 'O'), ('thyroid', 'O'), ('stimulating', 'O'), ('hormone', 'O'), ('(', 'O'), ('TSH', 'O'), (')', 'O'), ('levels', 'O'), ('.', 'O'))"
This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .,"(('This', 'O'), ('case', 'O'), ('report', 'O'), ('carries', 'O'), ('an', 'O'), ('important', 'O'), ('clinical', 'O'), ('application', 'O'), ('given', 'O'), ('the', 'O'), ('frequent', 'O'), ('usage', 'O'), ('of', 'O'), ('amiodarone', 'O'), ('among', 'O'), ('CHF', 'B'), ('patients', 'O'), ('.', 'O'))"
"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .","(('The', 'O'), ('myriad', 'O'), ('clinical', 'O'), ('presentation', 'O'), ('of', 'O'), ('myxedema', 'B'), ('coma', 'I'), ('and', 'O'), ('its', 'O'), ('serious', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('stresses', 'O'), ('the', 'O'), ('need', 'O'), ('to', 'O'), ('suspect', 'O'), ('this', 'O'), ('clinical', 'O'), ('syndrome', 'O'), ('among', 'O'), ('CHF', 'B'), ('patients', 'O'), ('presenting', 'O'), ('with', 'O'), ('hypotension', 'B'), (',', 'O'), ('weakness', 'B'), ('or', 'O'), ('other', 'O'), ('unexplained', 'O'), ('symptoms', 'O'), ('.', 'O'))"
"Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer ' s disease in male rats .","(('Effects', 'O'), ('of', 'O'), ('active', 'O'), ('constituents', 'O'), ('of', 'O'), ('Crocus', 'O'), ('sativus', 'O'), ('L', 'O'), ('.', 'O'), (',', 'O'), ('crocin', 'O'), ('on', 'O'), ('streptozocin', 'O'), ('-', 'O'), ('induced', 'O'), ('model', 'O'), ('of', 'O'), ('sporadic', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('.', 'O'))"
"In the present study , the effect of crocins on sporadic Alzheimer ' s disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('crocins', 'O'), ('on', 'O'), ('sporadic', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('induced', 'O'), ('by', 'O'), ('intracerebroventricular', 'O'), ('(', 'O'), ('icv', 'O'), (')', 'O'), ('streptozocin', 'O'), ('(', 'O'), ('STZ', 'O'), (')', 'O'), ('in', 'O'), ('male', 'O'), ('rats', 'O'), ('was', 'O'), ('investigated', 'O'), ('.', 'O'))"
"In Alzheimer ' s disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .","(('In', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('groups', 'O'), (',', 'O'), ('rats', 'O'), ('were', 'O'), ('injected', 'O'), ('with', 'O'), ('STZ', 'O'), ('-', 'O'), ('icv', 'O'), ('bilaterally', 'O'), ('(', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('first', 'O'), ('day', 'O'), ('and', 'O'), ('3', 'O'), ('days', 'O'), ('later', 'O'), (',', 'O'), ('a', 'O'), ('similar', 'O'), ('STZ', 'O'), ('-', 'O'), ('icv', 'O'), ('application', 'O'), ('was', 'O'), ('repeated', 'O'), ('.', 'O'))"
"In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('crocin', 'O'), ('in', 'O'), ('the', 'O'), ('mentioned', 'O'), ('dose', 'O'), ('could', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('learning', 'B'), ('and', 'I'), ('memory', 'I'), ('impairment', 'I'), ('in', 'O'), ('treated', 'O'), ('STZ', 'O'), ('-', 'O'), ('injected', 'O'), ('group', 'O'), ('in', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('test', 'O'), ('.', 'O'))"
"CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer ' s disease .","(('CONCLUSION', 'O'), (':', 'O'), ('Therefore', 'O'), (',', 'O'), ('these', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('the', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('crocin', 'O'), ('(', 'O'), ('30', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('antagonizing', 'O'), ('the', 'O'), ('cognitive', 'B'), ('deficits', 'I'), ('caused', 'O'), ('by', 'O'), ('STZ', 'O'), ('-', 'O'), ('icv', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('its', 'O'), ('potential', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('neurodegenerative', 'B'), ('diseases', 'I'), ('such', 'O'), ('as', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .,"(('Serotonin', 'O'), ('6', 'O'), ('receptor', 'O'), ('gene', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('methamphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('in', 'O'), ('a', 'O'), ('Japanese', 'O'), ('population', 'O'), ('.', 'O'))"
BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .,"(('BACKGROUND', 'O'), (':', 'O'), ('Altered', 'O'), ('serotonergic', 'O'), ('neural', 'O'), ('transmission', 'O'), ('is', 'O'), ('hypothesized', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('susceptibility', 'O'), ('factor', 'O'), ('for', 'O'), ('psychotic', 'B'), ('disorders', 'I'), ('such', 'O'), ('as', 'O'), ('schizophrenia', 'B'), ('.', 'O'))"
"The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .","(('The', 'O'), ('serotonin', 'O'), ('6', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('HT6', 'O'), (')', 'O'), ('receptor', 'O'), ('is', 'O'), ('therapeutically', 'O'), ('targeted', 'O'), ('by', 'O'), ('several', 'O'), ('second', 'O'), ('generation', 'O'), ('antipsychotics', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('clozapine', 'O'), ('and', 'O'), ('olanzapine', 'O'), (',', 'O'), ('and', 'O'), ('d', 'O'), ('-', 'O'), ('amphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperactivity', 'B'), ('in', 'O'), ('rats', 'O'), ('is', 'O'), ('corrected', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('a', 'O'), ('selective', 'O'), ('5', 'O'), ('-', 'O'), ('HT6', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('.', 'O'))"
"These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .","(('These', 'O'), ('animal', 'O'), ('models', 'O'), ('were', 'O'), ('considered', 'O'), ('to', 'O'), ('reflect', 'O'), ('the', 'O'), ('positive', 'O'), ('symptoms', 'O'), ('of', 'O'), ('schizophrenia', 'B'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('above', 'O'), ('evidence', 'O'), ('suggests', 'O'), ('that', 'O'), ('altered', 'O'), ('5', 'O'), ('-', 'O'), ('HT6', 'O'), ('receptors', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('pathophysiology', 'O'), ('of', 'O'), ('psychotic', 'B'), ('disorders', 'I'), ('.', 'O'))"
The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .,"(('The', 'O'), ('symptoms', 'O'), ('of', 'O'), ('methamphetamine', 'O'), ('(', 'O'), ('METH', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('are', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('of', 'O'), ('paranoid', 'B'), ('type', 'I'), ('schizophrenia', 'I'), ('.', 'O'))"
"Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .","(('Therefore', 'O'), (',', 'O'), ('we', 'O'), ('conducted', 'O'), ('an', 'O'), ('analysis', 'O'), ('of', 'O'), ('the', 'O'), ('association', 'O'), ('of', 'O'), ('the', 'O'), ('5', 'O'), ('-', 'O'), ('HT6', 'O'), ('gene', 'O'), ('(', 'O'), ('HTR6', 'O'), (')', 'O'), ('with', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('.', 'O'))"
"METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .","(('METHOD', 'O'), (':', 'O'), ('Using', 'O'), ('five', 'O'), ('tagging', 'O'), ('SNPs', 'O'), ('(', 'O'), ('rs6693503', 'O'), (',', 'O'), ('rs1805054', 'O'), (',', 'O'), ('rs4912138', 'O'), (',', 'O'), ('rs3790757', 'O'), ('and', 'O'), ('rs9659997', 'O'), (')', 'O'), (',', 'O'), ('we', 'O'), ('conducted', 'O'), ('a', 'O'), ('genetic', 'O'), ('association', 'O'), ('analysis', 'O'), ('of', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('samples', 'O'), ('(', 'O'), ('197', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('patients', 'O'), ('and', 'O'), ('337', 'O'), ('controls', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('Japanese', 'O'), ('population', 'O'), ('.', 'O'))"
RESULTS : rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .,"(('RESULTS', 'O'), (':', 'O'), ('rs6693503', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('allele', 'O'), ('/', 'O'), ('genotype', 'O'), ('-', 'O'), ('wise', 'O'), ('analysis', 'O'), ('.', 'O'))"
"In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .","(('In', 'O'), ('the', 'O'), ('haplotype', 'O'), ('-', 'O'), ('wise', 'O'), ('analysis', 'O'), (',', 'O'), ('we', 'O'), ('detected', 'O'), ('an', 'O'), ('association', 'O'), ('between', 'O'), ('two', 'O'), ('markers', 'O'), ('(', 'O'), ('rs6693503', 'O'), ('and', 'O'), ('rs1805054', 'O'), (')', 'O'), ('and', 'O'), ('three', 'O'), ('markers', 'O'), ('(', 'O'), ('rs6693503', 'O'), (',', 'O'), ('rs1805054', 'O'), ('and', 'O'), ('rs4912138', 'O'), (')', 'O'), ('in', 'O'), ('HTR6', 'O'), ('and', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('patients', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .,"(('CONCLUSION', 'O'), (':', 'O'), ('HTR6', 'O'), ('may', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('pathophysiology', 'O'), ('of', 'O'), ('METH', 'O'), ('-', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('in', 'O'), ('the', 'O'), ('Japanese', 'O'), ('population', 'O'), ('.', 'O'))"
Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .,"(('Neural', 'O'), ('correlates', 'O'), ('of', 'O'), ('S', 'O'), ('-', 'O'), ('ketamine', 'O'), ('induced', 'O'), ('psychosis', 'B'), ('during', 'O'), ('overt', 'O'), ('continuous', 'O'), ('verbal', 'O'), ('fluency', 'O'), ('.', 'O'))"
The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .,"(('The', 'O'), ('glutamatergic', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (')', 'O'), ('receptor', 'O'), ('has', 'O'), ('been', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('pathophysiology', 'O'), ('of', 'O'), ('schizophrenia', 'B'), ('.', 'O'))"
"Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .","(('Administered', 'O'), ('to', 'O'), ('healthy', 'O'), ('volunteers', 'O'), (',', 'O'), ('a', 'O'), ('subanesthetic', 'O'), ('dose', 'O'), ('of', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('competitive', 'O'), ('NMDA', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('ketamine', 'O'), ('leads', 'O'), ('to', 'O'), ('psychopathological', 'O'), ('symptoms', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('observed', 'O'), ('in', 'O'), ('schizophrenia', 'B'), ('.', 'O'))"
"In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .","(('In', 'O'), ('patients', 'O'), ('with', 'O'), ('schizophrenia', 'B'), (',', 'O'), ('ketamine', 'O'), ('exacerbates', 'O'), ('the', 'O'), ('core', 'O'), ('symptoms', 'O'), ('of', 'O'), ('illness', 'O'), (',', 'O'), ('supporting', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('of', 'O'), ('a', 'O'), ('glutamatergic', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
Ketamine elicited psychosis like psychopathology .,"(('Ketamine', 'O'), ('elicited', 'O'), ('psychosis', 'B'), ('like', 'O'), ('psychopathology', 'O'), ('.', 'O'))"
"Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .","(('Ketamine', 'O'), ('induces', 'O'), ('activation', 'O'), ('changes', 'O'), ('in', 'O'), ('healthy', 'O'), ('subjects', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('schizophrenia', 'B'), (',', 'O'), ('particularly', 'O'), ('in', 'O'), ('frontal', 'O'), ('and', 'O'), ('temporal', 'O'), ('brain', 'O'), ('regions', 'O'), ('.', 'O'))"
Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .,"(('Our', 'O'), ('results', 'O'), ('provide', 'O'), ('further', 'O'), ('support', 'O'), ('for', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('of', 'O'), ('an', 'O'), ('NMDA', 'O'), ('receptor', 'O'), ('dysfunction', 'O'), ('in', 'O'), ('the', 'O'), ('pathophysiology', 'O'), ('of', 'O'), ('schizophrenia', 'B'), ('.', 'O'))"
Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .,"(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('prognosis', 'O'), ('for', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('prognosis', 'O'), ('for', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('remains', 'O'), ('unknown', 'O'), ('.', 'O'))"
AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .,"(('AIM', 'O'), (':', 'O'), ('To', 'O'), ('examine', 'O'), ('whether', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('increases', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('mortality', 'O'), ('.', 'O'))"
"METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .","(('METHODS', 'O'), (':', 'O'), ('We', 'O'), ('followed', 'O'), ('up', 'O'), ('all', 'O'), ('transplant', 'O'), ('-', 'O'), ('free', 'O'), ('survivors', 'O'), ('of', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('injury', 'I'), (',', 'O'), ('hospitalized', 'O'), ('in', 'O'), ('a', 'O'), ('Danish', 'O'), ('national', 'O'), ('referral', 'O'), ('centre', 'O'), ('during', 'O'), ('1984', 'O'), ('-', 'O'), ('2004', 'O'), ('.', 'O'))"
We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .,"(('We', 'O'), ('compared', 'O'), ('age', 'O'), ('-', 'O'), ('specific', 'O'), ('mortality', 'O'), ('rates', 'O'), ('from', 'O'), ('1', 'O'), ('year', 'O'), ('post', 'O'), ('-', 'O'), ('discharge', 'O'), ('through', 'O'), ('2008', 'O'), ('between', 'O'), ('those', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('liver', 'B'), ('injury', 'I'), ('led', 'O'), ('to', 'O'), ('an', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('and', 'O'), ('those', 'O'), ('in', 'O'), ('whom', 'O'), ('it', 'O'), ('did', 'O'), ('not', 'O'), ('.', 'O'))"
"On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .","(('On', 'O'), ('average', 'O'), (',', 'O'), ('age', 'O'), ('-', 'O'), ('specific', 'O'), ('mortality', 'O'), ('rates', 'O'), ('were', 'O'), ('slightly', 'O'), ('higher', 'O'), ('for', 'O'), ('the', 'O'), ('101', 'O'), ('patients', 'O'), ('whose', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('had', 'O'), ('caused', 'O'), ('an', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('(', 'O'), ('adjusted', 'O'), ('mortality', 'O'), ('rate', 'O'), ('ratio', 'O'), ('=', 'O'), ('1', 'O'), ('.', 'O'), ('70', 'O'), (',', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), ('1', 'O'), ('.', 'O'), ('02', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('85', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('association', 'O'), ('was', 'O'), ('age', 'O'), ('-', 'O'), ('dependent', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('survivors', 'O'), ('of', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('died', 'O'), ('of', 'O'), ('liver', 'B'), ('disease', 'I'), (',', 'O'), ('whereas', 'O'), ('suicides', 'O'), ('were', 'O'), ('frequent', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
These observations speak against long - term effects of acute liver failure .,"(('These', 'O'), ('observations', 'O'), ('speak', 'O'), ('against', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('effects', 'O'), ('of', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
"More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .","(('More', 'O'), ('likely', 'O'), (',', 'O'), ('the', 'O'), ('elevated', 'O'), ('mortality', 'O'), ('rate', 'O'), ('ratio', 'O'), ('resulted', 'O'), ('from', 'O'), ('incomplete', 'O'), ('adjustment', 'O'), ('for', 'O'), ('the', 'O'), ('greater', 'O'), ('prevalence', 'O'), ('of', 'O'), ('substance', 'B'), ('abuse', 'I'), ('among', 'O'), ('survivors', 'O'), ('of', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Paracetamol', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('did', 'O'), ('not', 'O'), ('affect', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('mortality', 'O'), ('.', 'O'))"
"Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .","(('Clinical', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('may', 'O'), ('be', 'O'), ('justified', 'O'), ('by', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('liver', 'B'), ('failure', 'I'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('liver', 'B'), ('failure', 'I'), ('itself', 'O'), ('.', 'O'))"
In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson ' s disease .,"(('In', 'O'), ('vivo', 'O'), ('characterization', 'O'), ('of', 'O'), ('a', 'O'), ('dual', 'O'), ('adenosine', 'O'), ('A2A', 'O'), ('/', 'O'), ('A1', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('in', 'O'), ('animal', 'O'), ('models', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson ' s disease is described .,"(('The', 'O'), ('in', 'O'), ('vivo', 'O'), ('characterization', 'O'), ('of', 'O'), ('a', 'O'), ('dual', 'O'), ('adenosine', 'O'), ('A', 'O'), ('(', 'O'), ('2A', 'O'), (')', 'O'), ('/', 'O'), ('A', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('in', 'O'), ('several', 'O'), ('animal', 'O'), ('models', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('is', 'O'), ('described', 'O'), ('.', 'O'))"
"Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced","(('Compound', 'O'), ('1', 'O'), ('is', 'O'), ('a', 'O'), ('potent', 'O'), ('A', 'O'), ('(', 'O'), ('2A', 'O'), (')', 'O'), ('/', 'O'), ('A', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('in', 'O'), ('vitro', 'O'), ('(', 'O'), ('A', 'O'), ('(', 'O'), ('2A', 'O'), (')', 'O'), ('K', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), ('=', 'O'), ('4', 'O'), ('.', 'O'), ('1', 'O'), ('nM', 'O'), (';', 'O'), ('A', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('K', 'O'), ('(', 'O'), ('i', 'O'), (')', 'O'), ('=', 'O'), ('17', 'O'), ('.', 'O'), ('0', 'O'), ('nM', 'O'), (')', 'O'), ('that', 'O'), ('has', 'O'), ('excellent', 'O'), ('activity', 'O'), (',', 'O'), ('after', 'O'), ('oral', 'O'), ('administration', 'O'), (',', 'O'), ('across', 'O'), ('a', 'O'), ('number', 'O'), ('of', 'O'), ('animal', 'O'), ('models', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('including', 'O'), ('mouse', 'O'), ('and', 'O'), ('rat', 'O'), ('models', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), (',', 'O'), ('mouse', 'O'), ('model', 'O'), ('of', 'O'), ('reserpine', 'O'), ('-', 'O'), ('induced', 'O'), ('akinesia', 'B'), (',', 'O'), ('rat', 'O'), ('6', 'O'), ('-', 'O'), ('hydroxydopamine', 'O'), ('(', 'O'), ('6', 'O'), ('-', 'O'), ('OHDA', 'O'), (')', 'O'), ('lesion', 'O'), ('model', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'))"
Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .,"(('Effects', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampal', 'O'), ('deep', 'O'), ('brain', 'O'), ('stimulation', 'O'), ('on', 'O'), ('cortical', 'O'), ('epileptic', 'B'), ('discharges', 'O'), ('in', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('epilepsy', 'B'), ('model', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .","(('AIM', 'O'), (':', 'O'), ('Experimental', 'O'), ('and', 'O'), ('clinical', 'O'), ('studies', 'O'), ('have', 'O'), ('revealed', 'O'), ('that', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('can', 'O'), ('control', 'O'), ('epileptic', 'B'), ('activity', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('action', 'O'), ('is', 'O'), ('obscure', 'O'), ('and', 'O'), ('optimal', 'O'), ('stimulation', 'O'), ('parameters', 'O'), ('are', 'O'), ('not', 'O'), ('clearly', 'O'), ('defined', 'O'), ('.', 'O'))"
The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .,"(('The', 'O'), ('aim', 'O'), ('was', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('high', 'O'), ('frequency', 'O'), ('hippocampal', 'O'), ('stimulation', 'O'), ('on', 'O'), ('cortical', 'O'), ('epileptic', 'B'), ('activity', 'O'), ('in', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('epilepsy', 'B'), ('model', 'O'), ('.', 'O'))"
RESULTS : High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .,"(('RESULTS', 'O'), (':', 'O'), ('High', 'O'), ('frequency', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('suppressed', 'O'), ('the', 'O'), ('acute', 'O'), ('penicillin', 'O'), ('-', 'O'), ('induced', 'O'), ('cortical', 'O'), ('epileptic', 'B'), ('activity', 'O'), ('independent', 'O'), ('from', 'O'), ('stimulus', 'O'), ('intensity', 'O'), ('.', 'O'))"
CONCLUSION : Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .,"(('CONCLUSION', 'O'), (':', 'O'), ('Our', 'O'), ('results', 'O'), ('revealed', 'O'), ('that', 'O'), ('continuous', 'O'), ('high', 'O'), ('frequency', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampus', 'O'), ('suppressed', 'O'), ('acute', 'O'), ('cortical', 'O'), ('epileptic', 'B'), ('activity', 'O'), ('effectively', 'O'), ('without', 'O'), ('causing', 'O'), ('secondary', 'O'), ('epileptic', 'B'), ('discharges', 'O'), ('.', 'O'))"
These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .,"(('These', 'O'), ('results', 'O'), ('are', 'O'), ('important', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('defining', 'O'), ('the', 'O'), ('optimal', 'O'), ('parameters', 'O'), ('of', 'O'), ('hippocampal', 'O'), ('DBS', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('epilepsy', 'B'), ('.', 'O'))"
CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .,"(('CCNU', 'O'), ('(', 'O'), ('lomustine', 'O'), (')', 'O'), ('toxicity', 'B'), ('in', 'O'), ('dogs', 'O'), (':', 'O'), ('a', 'O'), ('retrospective', 'O'), ('study', 'O'), ('(', 'O'), ('2002', 'O'), ('-', 'O'), ('07', 'O'), (')', 'O'), ('.', 'O'))"
"OBJECTIVE : To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .","(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('describe', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('haematological', 'B'), (',', 'I'), ('renal', 'I'), (',', 'I'), ('hepatic', 'I'), ('and', 'I'), ('gastrointestinal', 'I'), ('toxicities', 'I'), ('in', 'O'), ('tumour', 'O'), ('-', 'O'), ('bearing', 'O'), ('dogs', 'O'), ('receiving', 'O'), ('1', 'O'), ('-', 'O'), ('(', 'O'), ('2', 'O'), ('-', 'O'), ('chloroethyl', 'O'), (')', 'O'), ('-', 'O'), ('3', 'O'), ('-', 'O'), ('cyclohexyl', 'O'), ('-', 'O'), ('1', 'O'), ('-', 'O'), ('nitrosourea', 'O'), ('(', 'O'), ('CCNU', 'O'), (')', 'O'), ('.', 'O'))"
"RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .","(('RESULTS', 'O'), (':', 'O'), ('Of', 'O'), ('the', 'O'), ('206', 'O'), ('dogs', 'O'), ('treated', 'O'), ('with', 'O'), ('CCNU', 'O'), (',', 'O'), ('185', 'O'), ('met', 'O'), ('the', 'O'), ('inclusion', 'O'), ('criteria', 'O'), ('for', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('class', 'O'), ('of', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .","(('CCNU', 'O'), ('was', 'O'), ('used', 'O'), ('most', 'O'), ('commonly', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('lymphoma', 'B'), (',', 'O'), ('mast', 'B'), ('cell', 'I'), ('tumour', 'I'), (',', 'O'), ('brain', 'B'), ('tumour', 'I'), (',', 'O'), ('histiocytic', 'B'), ('tumours', 'I'), ('and', 'O'), ('epitheliotropic', 'B'), ('lymphoma', 'I'), ('.', 'O'))"
"Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .","(('Throughout', 'O'), ('treatment', 'O'), (',', 'O'), ('56', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('of', 'O'), ('dogs', 'O'), ('experienced', 'O'), ('neutropenia', 'B'), (',', 'O'), ('34', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('experienced', 'O'), ('anaemia', 'B'), ('and', 'O'), ('14', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('experienced', 'O'), ('thrombocytopenia', 'B'), ('.', 'O'))"
"Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .","(('Gastrointestinal', 'B'), ('toxicosis', 'I'), ('was', 'O'), ('detected', 'O'), ('in', 'O'), ('37', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('of', 'O'), ('dogs', 'O'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('common', 'O'), ('sign', 'O'), ('of', 'O'), ('which', 'O'), ('was', 'O'), ('vomiting', 'B'), ('(', 'O'), ('24', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .","(('Potential', 'O'), ('renal', 'O'), ('toxicity', 'B'), ('and', 'O'), ('elevated', 'O'), ('alanine', 'O'), ('transaminase', 'O'), ('(', 'O'), ('ALT', 'O'), (')', 'O'), ('concentration', 'O'), ('were', 'O'), ('reported', 'O'), ('in', 'O'), ('12', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('and', 'O'), ('48', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), ('of', 'O'), ('dogs', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
The incidence of hepatic failure was 1 . 2 % .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('hepatic', 'B'), ('failure', 'I'), ('was', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('.', 'O'))"
"CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .","(('CONCLUSIONS', 'O'), (':', 'O'), ('CCNU', 'O'), ('-', 'O'), ('associated', 'O'), ('toxicity', 'B'), ('in', 'O'), ('dogs', 'O'), ('is', 'O'), ('common', 'O'), (',', 'O'), ('but', 'O'), ('is', 'O'), ('usually', 'O'), ('not', 'O'), ('life', 'O'), ('threatening', 'O'), ('.', 'O'))"
A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .,"(('A', 'O'), ('report', 'O'), ('is', 'O'), ('given', 'O'), ('on', 'O'), ('an', 'O'), ('83', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('female', 'O'), ('who', 'O'), ('acquired', 'O'), ('central', 'O'), ('vein', 'B'), ('thrombosis', 'I'), ('in', 'O'), ('her', 'O'), ('seeing', 'O'), ('eye', 'O'), ('one', 'O'), ('day', 'O'), ('after', 'O'), ('having', 'O'), ('started', 'O'), ('topical', 'O'), ('medication', 'O'), ('with', 'O'), ('dipivalyl', 'O'), ('epinephrine', 'O'), ('for', 'O'), ('advanced', 'O'), ('glaucoma', 'B'), ('discovered', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('eye', 'O'), ('.', 'O'))"
Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .,"(('Benzylacyclouridine', 'O'), ('reverses', 'O'), ('azidothymidine', 'O'), ('-', 'O'), ('induced', 'O'), ('marrow', 'B'), ('suppression', 'I'), ('without', 'O'), ('impairment', 'O'), ('of', 'O'), ('anti', 'O'), ('-', 'O'), ('human', 'O'), ('immunodeficiency', 'B'), ('virus', 'O'), ('activity', 'O'), ('.', 'O'))"
"Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .","(('Because', 'O'), ('of', 'O'), ('the', 'O'), ('clinical', 'O'), ('toxicities', 'B'), ('associated', 'O'), ('with', 'O'), ('chronic', 'O'), ('Urd', 'O'), ('administration', 'O'), (',', 'O'), ('the', 'O'), ('ability', 'O'), ('of', 'O'), ('benzylacyclouridine', 'O'), ('(', 'O'), ('BAU', 'O'), (')', 'O'), ('to', 'O'), ('effect', 'O'), (',', 'O'), ('in', 'O'), ('vivo', 'O'), (',', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('anemia', 'B'), ('and', 'O'), ('leukopenia', 'B'), ('was', 'O'), ('assessed', 'O'), ('.', 'O'))"
"This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .","(('This', 'O'), ('agent', 'O'), ('inhibits', 'O'), ('Urd', 'O'), ('catabolism', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('vivo', 'O'), (',', 'O'), ('increases', 'O'), ('the', 'O'), ('plasma', 'O'), ('concentration', 'O'), ('of', 'O'), ('Urd', 'O'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('manner', 'O'), (',', 'O'), ('without', 'O'), ('Urd', 'O'), ('-', 'O'), ('related', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .","(('In', 'O'), ('mice', 'O'), ('rendered', 'O'), ('anemic', 'B'), ('and', 'O'), ('leukopenic', 'B'), ('by', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('AZT', 'O'), ('for', 'O'), ('28', 'O'), ('days', 'O'), ('in', 'O'), ('drinking', 'O'), ('water', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('mL', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('continued', 'O'), ('administration', 'O'), ('of', 'O'), ('AZT', 'O'), ('plus', 'O'), ('daily', 'O'), ('BAU', 'O'), ('(', 'O'), ('300', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('orally', 'O'), (')', 'O'), ('partially', 'O'), ('reversed', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('anemia', 'B'), ('and', 'O'), ('leukopenia', 'B'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), (',', 'O'), ('increased', 'O'), ('peripheral', 'O'), ('reticulocytes', 'O'), ('(', 'O'), ('to', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), (',', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), (',', 'O'), ('increased', 'O'), ('cellularity', 'O'), ('in', 'O'), ('the', 'O'), ('marrow', 'O'), (',', 'O'), ('and', 'O'), ('improved', 'O'), ('megaloblastosis', 'B'), ('.', 'O'))"
"When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .","(('When', 'O'), ('coadministered', 'O'), ('with', 'O'), ('AZT', 'O'), ('from', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('drug', 'O'), ('administration', 'O'), (',', 'O'), ('BAU', 'O'), ('reduced', 'O'), ('AZT', 'O'), ('-', 'O'), ('induced', 'O'), ('marrow', 'B'), ('toxicity', 'I'), ('.', 'O'))"
Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .,"(('Lethal', 'O'), ('anuria', 'B'), ('complicating', 'O'), ('high', 'O'), ('dose', 'O'), ('ifosfamide', 'O'), ('chemotherapy', 'O'), ('in', 'O'), ('a', 'O'), ('breast', 'B'), ('cancer', 'I'), ('patient', 'O'), ('with', 'O'), ('an', 'O'), ('impaired', 'B'), ('renal', 'I'), ('function', 'I'), ('.', 'O'))"
"A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .","(('A', 'O'), ('sixty', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('advanced', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('previously', 'O'), ('treated', 'O'), ('with', 'O'), ('cisplatin', 'O'), (',', 'O'), ('developed', 'O'), ('an', 'O'), ('irreversible', 'O'), ('lethal', 'O'), ('renal', 'B'), ('failure', 'I'), ('with', 'O'), ('anuria', 'B'), (',', 'O'), ('the', 'O'), ('day', 'O'), ('after', 'O'), ('5', 'O'), ('g', 'O'), ('/', 'O'), ('m2', 'O'), ('bolus', 'O'), ('ifosfamide', 'O'), ('.', 'O'))"
Postrenal failure was excluded by echography .,"(('Postrenal', 'B'), ('failure', 'I'), ('was', 'O'), ('excluded', 'O'), ('by', 'O'), ('echography', 'O'), ('.', 'O'))"
"A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .","(('A', 'O'), ('prerenal', 'O'), ('component', 'O'), ('could', 'O'), ('have', 'O'), ('contributed', 'O'), ('to', 'O'), ('renal', 'B'), ('failure', 'I'), ('because', 'O'), ('of', 'O'), ('a', 'O'), ('transient', 'O'), ('hypotension', 'B'), (',', 'O'), ('due', 'O'), ('to', 'O'), ('an', 'O'), ('increasing', 'O'), ('ascitis', 'O'), (',', 'O'), ('occurring', 'O'), ('just', 'O'), ('before', 'O'), ('anuria', 'B'), ('.', 'O'))"
Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .,"(('Ifosfamide', 'O'), ('is', 'O'), ('a', 'O'), ('known', 'O'), ('nephrotoxic', 'B'), ('drug', 'O'), ('with', 'O'), ('demonstrated', 'O'), ('tubulopathies', 'B'), ('.', 'O'))"
"We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .","(('We', 'O'), ('strongly', 'O'), ('suspect', 'O'), ('that', 'O'), ('this', 'O'), ('lethal', 'O'), ('anuria', 'B'), ('was', 'O'), ('mainly', 'O'), ('due', 'O'), ('to', 'O'), ('ifosfamide', 'O'), (',', 'O'), ('occurring', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('having', 'O'), ('received', 'O'), ('previous', 'O'), ('cisplatin', 'O'), ('chemotherapy', 'O'), ('and', 'O'), ('with', 'O'), ('poor', 'O'), ('kidney', 'O'), ('perfusion', 'O'), ('due', 'O'), ('to', 'O'), ('transient', 'O'), ('hypotension', 'B'), ('.', 'O'))"
We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .,"(('We', 'O'), ('recommend', 'O'), ('careful', 'O'), ('use', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('in', 'O'), ('patients', 'O'), ('pretreated', 'O'), ('with', 'O'), ('nephrotoxic', 'B'), ('chemotherapy', 'O'), ('and', 'O'), ('inadequate', 'O'), ('renal', 'O'), ('perfusion', 'O'), ('.', 'O'))"
The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('intrathecal', 'O'), ('administration', 'O'), ('of', 'O'), ('prostaglandins', 'O'), ('on', 'O'), ('pain', 'B'), ('responses', 'O'), ('in', 'O'), ('conscious', 'O'), ('mice', 'O'), ('were', 'O'), ('evaluated', 'O'), ('by', 'O'), ('using', 'O'), ('hot', 'O'), ('plate', 'O'), ('and', 'O'), ('acetic', 'O'), ('acid', 'O'), ('writhing', 'O'), ('tests', 'O'), ('.', 'O'))"
"Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .","(('Conversely', 'O'), (',', 'O'), ('prostaglandin', 'O'), ('E2', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperalgesia', 'B'), ('was', 'O'), ('blocked', 'O'), ('by', 'O'), ('AH6809', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('500', 'O'), ('ng', 'O'), (')', 'O'), ('but', 'O'), ('not', 'O'), ('by', 'O'), ('the', 'O'), ('substance', 'O'), ('P', 'O'), ('antagonist', 'O'), ('.', 'O'))"
Prostaglandin F2 alpha had little effect on pain responses .,"(('Prostaglandin', 'O'), ('F2', 'O'), ('alpha', 'O'), ('had', 'O'), ('little', 'O'), ('effect', 'O'), ('on', 'O'), ('pain', 'B'), ('responses', 'O'), ('.', 'O'))"
"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .","(('These', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('both', 'O'), ('prostaglandin', 'O'), ('D2', 'O'), ('and', 'O'), ('prostaglandin', 'O'), ('E2', 'O'), ('exert', 'O'), ('hyperalgesia', 'B'), ('in', 'O'), ('the', 'O'), ('spinal', 'O'), ('cord', 'O'), (',', 'O'), ('but', 'O'), ('in', 'O'), ('different', 'O'), ('ways', 'O'), ('.', 'O'))"
D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .,"(('D', 'O'), ('-', 'O'), ('Penicillamine', 'O'), ('caused', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('in', 'O'), ('1', 'O'), ('patient', 'O'), ('and', 'O'), ('milder', 'O'), ('reversible', 'O'), ('proteinuria', 'B'), ('in', 'O'), ('3', 'O'), ('other', 'O'), ('patients', 'O'), (';', 'O'), ('none', 'O'), ('developed', 'O'), ('renal', 'B'), ('insufficiency', 'I'), ('.', 'O'))"
Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .,"(('Cerebral', 'B'), ('sinus', 'I'), ('thrombosis', 'I'), ('as', 'O'), ('a', 'O'), ('potential', 'O'), ('hazard', 'O'), ('of', 'O'), ('antifibrinolytic', 'O'), ('treatment', 'O'), ('in', 'O'), ('menorrhagia', 'B'), ('.', 'O'))"
We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .,"(('We', 'O'), ('describe', 'O'), ('a', 'O'), ('42', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('who', 'O'), ('developed', 'O'), ('superior', 'O'), ('sagittal', 'B'), ('and', 'I'), ('left', 'I'), ('transverse', 'I'), ('sinus', 'I'), ('thrombosis', 'I'), ('associated', 'O'), ('with', 'O'), ('prolonged', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), ('therapy', 'O'), ('for', 'O'), ('menorrhagia', 'B'), ('.', 'O'))"
This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .,"(('This', 'O'), ('antifibrinolytic', 'O'), ('agent', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('menorrhagia', 'B'), ('to', 'O'), ('promote', 'O'), ('clotting', 'O'), ('and', 'O'), ('reduce', 'O'), ('blood', 'B'), ('loss', 'I'), ('.', 'O'))"
"Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .","(('Although', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('thromboembolic', 'B'), ('disease', 'I'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('during', 'O'), ('treatment', 'O'), ('with', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), (',', 'O'), ('cerebral', 'B'), ('sinus', 'I'), ('thrombosis', 'I'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('previously', 'O'), ('described', 'O'), ('.', 'O'))"
Seizure activity with imipenem therapy : incidence and risk factors .,"(('Seizure', 'B'), ('activity', 'O'), ('with', 'O'), ('imipenem', 'O'), ('therapy', 'O'), (':', 'O'), ('incidence', 'O'), ('and', 'O'), ('risk', 'O'), ('factors', 'O'), ('.', 'O'))"
Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .,"(('Two', 'O'), ('elderly', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('either', 'O'), ('cerebral', 'B'), ('vascular', 'I'), ('accident', 'I'), ('(', 'O'), ('CVA', 'B'), (')', 'O'), ('or', 'O'), ('head', 'B'), ('trauma', 'I'), ('and', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('renal', 'B'), ('disease', 'I'), ('developed', 'O'), ('seizures', 'B'), ('while', 'O'), ('receiving', 'O'), ('maximum', 'O'), ('doses', 'O'), ('of', 'O'), ('imipenem', 'O'), ('/', 'O'), ('cilastatin', 'O'), ('.', 'O'))"
Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .,"(('Neither', 'O'), ('patient', 'O'), ('had', 'O'), ('reported', 'O'), ('previous', 'O'), ('seizures', 'B'), ('or', 'O'), ('seizure', 'B'), ('-', 'O'), ('like', 'O'), ('activity', 'O'), ('nor', 'O'), ('was', 'O'), ('receiving', 'O'), ('anticonvulsant', 'O'), ('agents', 'O'), ('.', 'O'))"
All seizures were controlled with therapeutic doses of phenytoin .,"(('All', 'O'), ('seizures', 'B'), ('were', 'O'), ('controlled', 'O'), ('with', 'O'), ('therapeutic', 'O'), ('doses', 'O'), ('of', 'O'), ('phenytoin', 'O'), ('.', 'O'))"
Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .,"(('Both', 'O'), ('patients', 'O'), ('had', 'O'), ('received', 'O'), ('maximum', 'O'), ('doses', 'O'), ('of', 'O'), ('other', 'O'), ('beta', 'O'), ('-', 'O'), ('lactam', 'O'), ('antibiotics', 'O'), ('without', 'O'), ('evidence', 'O'), ('of', 'O'), ('seizure', 'B'), ('activity', 'O'), ('.', 'O'))"
Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .,"(('Midline', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('nerves', 'O'), ('in', 'O'), ('rat', 'O'), ('medulla', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('hypotensive', 'B'), ('effect', 'O'), ('of', 'O'), ('methyldopa', 'O'), ('.', 'O'))"
Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .,"(('Previous', 'O'), ('experiments', 'O'), ('in', 'O'), ('this', 'O'), ('laboratory', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('microinjection', 'O'), ('of', 'O'), ('methyldopa', 'O'), ('onto', 'O'), ('the', 'O'), ('ventrolateral', 'O'), ('cells', 'O'), ('of', 'O'), ('the', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('medulla', 'O'), ('elicits', 'O'), ('a', 'O'), ('hypotensive', 'B'), ('response', 'O'), ('mediated', 'O'), ('by', 'O'), ('a', 'O'), ('projection', 'O'), ('descending', 'O'), ('into', 'O'), ('the', 'O'), ('spinal', 'O'), ('cord', 'O'), ('.', 'O'))"
"In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .","(('In', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), (',', 'O'), ('stroke', 'B'), ('-', 'O'), ('prone', 'O'), ('rats', 'O'), (',', 'O'), ('microinjection', 'O'), ('of', 'O'), ('methyldopa', 'O'), ('into', 'O'), ('the', 'O'), ('area', 'O'), ('of', 'O'), ('the', 'O'), ('midline', 'O'), ('B3', 'O'), ('serotonin', 'O'), ('cell', 'O'), ('group', 'O'), ('in', 'O'), ('the', 'O'), ('ventral', 'O'), ('medulla', 'O'), ('caused', 'O'), ('a', 'O'), ('potent', 'O'), ('hypotension', 'B'), ('of', 'O'), ('30', 'O'), ('-', 'O'), ('40', 'O'), ('mm', 'O'), ('Hg', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('maximal', 'O'), ('2', 'O'), ('-', 'O'), ('3', 'O'), ('h', 'O'), ('after', 'O'), ('administration', 'O'), ('and', 'O'), ('was', 'O'), ('abolished', 'O'), ('by', 'O'), ('the', 'O'), ('serotonin', 'O'), ('neurotoxin', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('dihydroxytryptamine', 'O'), ('(', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DHT', 'O'), (')', 'O'), ('injected', 'O'), ('intracerebroventricularly', 'O'), ('.', 'O'))"
"However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .","(('However', 'O'), (',', 'O'), ('intraspinal', 'O'), ('injection', 'O'), ('of', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DHT', 'O'), ('to', 'O'), ('produce', 'O'), ('a', 'O'), ('more', 'O'), ('selective', 'O'), ('lesion', 'O'), ('of', 'O'), ('only', 'O'), ('descending', 'O'), ('serotonin', 'O'), ('projections', 'O'), ('in', 'O'), ('the', 'O'), ('spinal', 'O'), ('cord', 'O'), ('did', 'O'), ('not', 'O'), ('affect', 'O'), ('this', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .","(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('therefore', 'O'), ('that', 'O'), (',', 'O'), ('unlike', 'O'), ('the', 'O'), ('ventrolateral', 'O'), ('B3', 'O'), ('cells', 'O'), ('which', 'O'), ('mediate', 'O'), ('a', 'O'), ('methyldopa', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('via', 'O'), ('descending', 'O'), ('projections', 'O'), (',', 'O'), ('the', 'O'), ('midline', 'O'), ('serotonin', 'O'), ('B3', 'O'), ('cells', 'O'), ('in', 'O'), ('the', 'O'), ('medulla', 'O'), ('contribute', 'O'), ('to', 'O'), ('the', 'O'), ('hypotensive', 'B'), ('action', 'O'), ('of', 'O'), ('methyldopa', 'O'), (',', 'O'), ('either', 'O'), ('by', 'O'), ('way', 'O'), ('of', 'O'), ('an', 'O'), ('ascending', 'O'), ('projection', 'O'), ('which', 'O'), ('does', 'O'), ('not', 'O'), ('pass', 'O'), ('through', 'O'), ('the', 'O'), ('median', 'O'), ('forebrain', 'O'), ('bundle', 'O'), (',', 'O'), ('or', 'O'), ('through', 'O'), ('a', 'O'), ('projection', 'O'), ('restricted', 'O'), ('to', 'O'), ('the', 'O'), ('caudal', 'O'), ('brainstem', 'O'), ('.', 'O'))"
Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .,"(('Antiarrhythmic', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('of', 'O'), ('cibenzoline', 'O'), ('on', 'O'), ('canine', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
"Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .","(('Using', 'O'), ('two', 'O'), ('-', 'O'), ('stage', 'O'), ('coronary', 'O'), ('ligation', 'O'), ('-', 'O'), (',', 'O'), ('digitalis', 'O'), ('-', 'O'), (',', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('canine', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), (',', 'O'), ('antiarrhythmic', 'O'), ('effects', 'O'), ('of', 'O'), ('cibenzoline', 'O'), ('were', 'O'), ('examined', 'O'), ('and', 'O'), ('the', 'O'), ('minimum', 'O'), ('effective', 'O'), ('plasma', 'O'), ('concentration', 'O'), ('for', 'O'), ('each', 'O'), ('arrhythmia', 'B'), ('model', 'O'), ('was', 'O'), ('determined', 'O'), ('.', 'O'))"
"Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / -","(('Cibenzoline', 'O'), ('suppressed', 'O'), ('all', 'O'), ('the', 'O'), ('arrhythmias', 'B'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('minimum', 'O'), ('effective', 'O'), ('plasma', 'O'), ('concentrations', 'O'), ('for', 'O'), ('arrhythmias', 'B'), ('induced', 'O'), ('by', 'O'), ('24', 'O'), ('-', 'O'), ('h', 'O'), ('coronary', 'O'), ('ligation', 'O'), (',', 'O'), ('48', 'O'), ('-', 'O'), ('h', 'O'), ('coronary', 'O'), ('ligation', 'O'), (',', 'O'), ('digitalis', 'O'), (',', 'O'), ('and', 'O'), ('adrenaline', 'O'), ('were', 'O'), ('1', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('9', 'O'), ('(', 'O'), ('by', 'O'), ('8', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('(', 'O'), ('by', 'O'), ('8', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('(', 'O'), ('by', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('3', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'))"
The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .,"(('The', 'O'), ('concentration', 'O'), ('for', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('arrhythmia', 'B'), ('was', 'O'), ('significantly', 'O'), ('higher', 'O'), ('than', 'O'), ('those', 'O'), ('for', 'O'), ('the', 'O'), ('other', 'O'), ('types', 'O'), ('of', 'O'), ('arrhythmias', 'B'), ('.', 'O'))"
"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .","(('Because', 'O'), ('cibenzoline', 'O'), ('had', 'O'), ('only', 'O'), ('weak', 'O'), ('hypotensive', 'B'), ('and', 'O'), ('sinus', 'O'), ('node', 'O'), ('depressive', 'B'), ('effects', 'O'), ('and', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('orally', 'O'), ('active', 'O'), ('when', 'O'), ('given', 'O'), ('to', 'O'), ('coronary', 'O'), ('ligation', 'O'), ('arrhythmia', 'B'), ('dogs', 'O'), (',', 'O'), ('its', 'O'), ('clinical', 'O'), ('usefulness', 'O'), ('is', 'O'), ('expected', 'O'), ('.', 'O'))"
"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .","(('Although', 'O'), ('there', 'O'), ('have', 'O'), ('been', 'O'), ('anecdotal', 'O'), ('reports', 'O'), ('of', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), ('associated', 'O'), ('with', 'O'), ('fluorouracil', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), (')', 'O'), ('therapy', 'O'), (',', 'O'), ('this', 'O'), ('phenomenon', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('studied', 'O'), ('in', 'O'), ('a', 'O'), ('systematic', 'O'), ('fashion', 'O'), ('.', 'O'))"
We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .,"(('We', 'O'), ('prospectively', 'O'), ('performed', 'O'), ('continuous', 'O'), ('ambulatory', 'O'), ('ECG', 'O'), ('monitoring', 'O'), ('on', 'O'), ('25', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('for', 'O'), ('treatment', 'O'), ('of', 'O'), ('solid', 'O'), ('tumors', 'B'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('ischemic', 'B'), ('ST', 'O'), ('changes', 'O'), ('.', 'O'))"
Anginal episodes were rare : only one patient had angina ( during 5 - FU infusion ) .,"(('Anginal', 'B'), ('episodes', 'O'), ('were', 'O'), ('rare', 'O'), (':', 'O'), ('only', 'O'), ('one', 'O'), ('patient', 'O'), ('had', 'O'), ('angina', 'B'), ('(', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), (')', 'O'), ('.', 'O'))"
The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('ischemic', 'B'), ('episodes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), ('prior', 'O'), ('to', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('v', 'O'), ('0', 'O'), ('.', 'O'), ('13', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('ECG', 'O'), ('changes', 'O'), ('was', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('minutes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('before', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('v', 'O'), ('1', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('minutes', 'O'), ('per', 'O'), ('patient', 'O'), ('per', 'O'), ('hour', 'O'), ('during', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
ECG changes were more common among patients with known coronary artery disease .,"(('ECG', 'O'), ('changes', 'O'), ('were', 'O'), ('more', 'O'), ('common', 'O'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('known', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('.', 'O'))"
"There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .","(('There', 'O'), ('were', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('sudden', 'B'), ('death', 'I'), (',', 'O'), ('both', 'O'), ('of', 'O'), ('which', 'O'), ('occurred', 'O'), ('at', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('chemotherapy', 'O'), ('course', 'O'), ('.', 'O'))"
"We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .","(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('infusion', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('silent', 'O'), ('ST', 'O'), ('segment', 'O'), ('deviation', 'O'), ('suggestive', 'O'), ('of', 'O'), ('ischemia', 'B'), (',', 'O'), ('particularly', 'O'), ('among', 'O'), ('patients', 'O'), ('with', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('.', 'O'))"
"Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .","(('Our', 'O'), ('study', 'O'), ('group', 'O'), ('consisted', 'O'), ('of', 'O'), ('74', 'O'), ('HIV', 'O'), ('-', 'O'), ('positive', 'O'), ('homosexual', 'O'), ('men', 'O'), ('belonging', 'O'), ('to', 'O'), ('groups', 'O'), ('II', 'O'), ('B', 'O'), (',', 'O'), ('III', 'O'), ('and', 'O'), ('IV', 'O'), ('C2', 'O'), ('from', 'O'), ('the', 'O'), ('Centers', 'O'), ('for', 'O'), ('Disease', 'O'), ('Control', 'O'), ('(', 'O'), ('CDC', 'O'), (')', 'O'), ('classification', 'O'), ('of', 'O'), ('HIV', 'B'), ('disease', 'I'), ('.', 'O'))"
"Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .","(('Symptomatic', 'O'), ('adverse', 'O'), ('effects', 'O'), ('were', 'O'), ('present', 'O'), ('in', 'O'), ('96', 'O'), ('%', 'O'), ('of', 'O'), ('subjects', 'O'), (',', 'O'), ('most', 'O'), ('commonly', 'O'), ('nausea', 'B'), ('(', 'O'), ('64', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('fatigue', 'B'), ('(', 'O'), ('55', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('headache', 'B'), ('(', 'O'), ('49', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .,"(('National', 'O'), ('project', 'O'), ('on', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('mother', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('infant', 'O'), ('infection', 'B'), ('by', 'I'), ('hepatitis', 'I'), ('B', 'I'), ('virus', 'I'), ('in', 'O'), ('Japan', 'O'), ('.', 'O'))"
"In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .","(('In', 'O'), ('Japan', 'O'), (',', 'O'), ('a', 'O'), ('nationwide', 'O'), ('prevention', 'O'), ('program', 'O'), ('against', 'O'), ('mother', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('infant', 'O'), ('infection', 'B'), ('by', 'I'), ('hepatitis', 'I'), ('B', 'I'), ('virus', 'I'), ('(', 'O'), ('HBV', 'O'), (')', 'O'), ('started', 'O'), ('in', 'O'), ('1985', 'O'), ('.', 'O'))"
These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .,"(('These', 'O'), ('infants', 'O'), ('are', 'O'), ('treated', 'O'), ('with', 'O'), ('two', 'O'), ('injections', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('(', 'O'), ('HBIG', 'O'), (')', 'O'), ('and', 'O'), ('at', 'O'), ('least', 'O'), ('three', 'O'), ('injections', 'O'), ('of', 'O'), ('plasma', 'O'), ('derived', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('vaccine', 'O'), ('.', 'O'))"
"Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .","(('Intradermal', 'O'), ('injection', 'O'), ('of', 'O'), ('mu', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('delta', 'O'), ('or', 'O'), ('kappa', 'O'), ('opioid', 'O'), ('-', 'O'), ('agonists', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('produced', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('inhibition', 'O'), ('of', 'O'), ('prostaglandin', 'O'), ('E2', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperalgesia', 'B'), ('.', 'O'))"
"Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .","(('Morphine', 'O'), ('did', 'O'), ('not', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('alter', 'O'), ('the', 'O'), ('hyperalgesia', 'B'), ('induced', 'O'), ('by', 'O'), ('8', 'O'), ('-', 'O'), ('bromo', 'O'), ('cyclic', 'O'), ('adenosine', 'O'), ('monophosphate', 'O'), ('.', 'O'))"
Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .,"(('Involvement', 'O'), ('of', 'O'), ('locus', 'O'), ('coeruleus', 'O'), ('and', 'O'), ('noradrenergic', 'O'), ('neurotransmission', 'O'), ('in', 'O'), ('fentanyl', 'O'), ('-', 'O'), ('induced', 'O'), ('muscular', 'B'), ('rigidity', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .","(('Whereas', 'O'), ('muscular', 'B'), ('rigidity', 'I'), ('is', 'O'), ('a', 'O'), ('well', 'O'), ('-', 'O'), ('known', 'O'), ('side', 'O'), ('effect', 'O'), ('that', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('fentanyl', 'O'), ('anesthesia', 'O'), (',', 'O'), ('a', 'O'), ('paucity', 'O'), ('of', 'O'), ('information', 'O'), ('exists', 'O'), ('with', 'O'), ('regard', 'O'), ('to', 'O'), ('its', 'O'), ('underlying', 'O'), ('mechanism', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'), ('.', 'O'))"
"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .","(('Such', 'O'), ('an', 'O'), ('induced', 'O'), ('muscular', 'B'), ('rigidity', 'I'), ('by', 'O'), ('the', 'O'), ('narcotic', 'O'), ('agent', 'O'), ('was', 'O'), ('significantly', 'O'), ('antagonized', 'O'), ('or', 'O'), ('even', 'O'), ('reduced', 'O'), ('by', 'O'), ('prior', 'O'), ('electrolytic', 'O'), ('lesions', 'O'), ('of', 'O'), ('the', 'O'), ('locus', 'O'), ('coeruleus', 'O'), ('or', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('blocker', 'O'), (',', 'O'), ('prazosin', 'O'), ('.', 'O'))"
It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .,"(('It', 'O'), ('is', 'O'), ('speculated', 'O'), ('that', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('muscular', 'B'), ('rigidity', 'I'), ('by', 'O'), ('fentanyl', 'O'), ('may', 'O'), ('involve', 'O'), ('the', 'O'), ('coerulospinal', 'O'), ('noradrenergic', 'O'), ('fibers', 'O'), ('to', 'O'), ('the', 'O'), ('spinal', 'O'), ('motoneurons', 'O'), ('.', 'O'))"
"Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .","(('Dexmedetomidine', 'O'), (',', 'O'), ('acting', 'O'), ('through', 'O'), ('central', 'O'), ('alpha', 'O'), ('-', 'O'), ('2', 'O'), ('adrenoceptors', 'O'), (',', 'O'), ('prevents', 'O'), ('opiate', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .,"(('The', 'O'), ('highly', 'O'), ('-', 'O'), ('selective', 'O'), ('alpha', 'O'), ('-', 'O'), ('2', 'O'), ('adrenergic', 'O'), ('agonist', 'O'), ('dexmedetomidine', 'O'), ('(', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), (')', 'O'), ('is', 'O'), ('capable', 'O'), ('of', 'O'), ('inducing', 'O'), ('muscle', 'B'), ('flaccidity', 'I'), ('and', 'O'), ('anesthesia', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('dogs', 'O'), ('.', 'O'))"
Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .,"(('Intense', 'O'), ('generalized', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('is', 'O'), ('an', 'O'), ('undesirable', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('potent', 'O'), ('opiate', 'O'), ('agonists', 'O'), ('.', 'O'))"
"Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .","(('Although', 'O'), ('the', 'O'), ('neurochemistry', 'O'), ('of', 'O'), ('opiate', 'O'), ('-', 'O'), ('induced', 'O'), ('rigidity', 'B'), ('has', 'O'), ('yet', 'O'), ('to', 'O'), ('be', 'O'), ('fully', 'O'), ('elucidated', 'O'), (',', 'O'), ('recent', 'O'), ('work', 'O'), ('suggests', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('a', 'O'), ('central', 'O'), ('adrenergic', 'O'), ('mechanism', 'O'), ('.', 'O'))"
"In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('authors', 'O'), ('determined', 'O'), ('if', 'O'), ('treatment', 'O'), ('with', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('prevents', 'O'), ('the', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('caused', 'O'), ('by', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('alfentanil', 'O'), ('anesthesia', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('prevented', 'O'), ('alfentanil', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('in', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('fashion', 'O'), ('.', 'O'))"
"The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('The', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('D', 'O'), ('-', 'O'), ('MED', 'O'), ('animals', 'O'), ('were', 'O'), ('flaccid', 'O'), (',', 'O'), ('akinetic', 'B'), (',', 'O'), ('and', 'O'), ('lacked', 'O'), ('a', 'O'), ('startle', 'B'), ('response', 'O'), ('during', 'O'), ('the', 'O'), ('entire', 'O'), ('experimental', 'O'), ('period', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .,"(('A', 'O'), ('repeated', 'O'), ('treatment', 'O'), ('with', 'O'), ('fluvoxamine', 'O'), ('(', 'O'), ('twice', 'O'), ('daily', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), (')', 'O'), ('potentiated', 'O'), ('in', 'O'), ('mice', 'O'), ('and', 'O'), ('in', 'O'), ('rats', 'O'), ('(', 'O'), ('weaker', 'O'), (')', 'O'), ('the', 'O'), ('amphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperactivity', 'B'), ('.', 'O'))"
The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .,"(('The', 'O'), ('hyperactivity', 'B'), ('induced', 'O'), ('by', 'O'), ('nomifensine', 'O'), ('in', 'O'), ('mice', 'O'), ('remained', 'O'), ('unaffected', 'O'), ('by', 'O'), ('fluvoxamine', 'O'), ('.', 'O'))"
"Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .","(('Protective', 'O'), ('effect', 'O'), ('of', 'O'), ('a', 'O'), ('specific', 'O'), ('platelet', 'O'), ('-', 'O'), ('activating', 'O'), ('factor', 'O'), ('antagonist', 'O'), (',', 'O'), ('BN', 'O'), ('52021', 'O'), (',', 'O'), ('on', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiovascular', 'B'), ('impairments', 'I'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .","(('Administration', 'O'), ('of', 'O'), ('the', 'O'), ('local', 'O'), ('anaesthetic', 'O'), ('bupivacaine', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('or', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('to', 'O'), ('rats', 'O'), ('elicited', 'O'), ('a', 'O'), ('marked', 'O'), ('decrease', 'B'), ('of', 'I'), ('mean', 'I'), ('arterial', 'I'), ('blood', 'I'), ('pressure', 'I'), ('(', 'I'), ('MBP', 'I'), (')', 'I'), ('and', 'I'), ('heart', 'I'), ('rate', 'I'), ('(', 'I'), ('HR', 'I'), (')', 'I'), ('leading', 'O'), ('to', 'O'), ('death', 'O'), ('(', 'O'), ('in', 'O'), ('67', 'O'), ('%', 'O'), ('or', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('animals', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
"Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the decrease of MBP and HR .","(('Intravenous', 'O'), ('injection', 'O'), ('of', 'O'), ('the', 'O'), ('specific', 'O'), ('platelet', 'O'), ('-', 'O'), ('activating', 'O'), ('factor', 'O'), ('(', 'O'), ('PAF', 'O'), (')', 'O'), ('antagonist', 'O'), ('BN', 'O'), ('52021', 'O'), ('(', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('30', 'O'), ('min', 'O'), ('before', 'O'), ('bupivacaine', 'O'), ('administration', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('suppressed', 'O'), ('both', 'O'), ('the', 'O'), ('decrease', 'B'), ('of', 'I'), ('MBP', 'I'), ('and', 'I'), ('HR', 'I'), ('.', 'O'))"
"When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .","(('When', 'O'), ('BN', 'O'), ('52021', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('was', 'O'), ('injected', 'O'), ('immediately', 'O'), ('after', 'O'), ('bupivacaine', 'O'), ('(', 'O'), ('2', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('partial', 'O'), ('reversion', 'O'), ('of', 'O'), ('the', 'O'), ('decrease', 'B'), ('of', 'I'), ('MBP', 'I'), ('and', 'I'), ('HR', 'I'), ('was', 'O'), ('observed', 'O'), (',', 'O'), ('whereas', 'O'), ('the', 'O'), ('dose', 'O'), ('of', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('was', 'O'), ('ineffective', 'O'), ('.', 'O'))"
"Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .","(('Since', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('BN', 'O'), ('52021', 'O'), (',', 'O'), ('at', 'O'), ('all', 'O'), ('doses', 'O'), ('studied', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('alter', 'O'), ('MBP', 'O'), ('and', 'O'), ('HR', 'O'), ('at', 'O'), ('the', 'O'), ('doses', 'O'), ('used', 'O'), (',', 'O'), ('the', 'O'), ('bulk', 'O'), ('of', 'O'), ('these', 'O'), ('results', 'O'), ('clearly', 'O'), ('demonstrate', 'O'), ('a', 'O'), ('protective', 'O'), ('action', 'O'), ('of', 'O'), ('BN', 'O'), ('52021', 'O'), (',', 'O'), ('a', 'O'), ('specific', 'O'), ('antagonist', 'O'), ('of', 'O'), ('PAF', 'O'), (',', 'O'), ('against', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiovascular', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .","(('Thus', 'O'), (',', 'O'), ('consistent', 'O'), ('with', 'O'), ('its', 'O'), ('direct', 'O'), ('effect', 'O'), ('on', 'O'), ('heart', 'O'), (',', 'O'), ('PAF', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('implicated', 'O'), ('in', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiovascular', 'B'), ('alterations', 'I'), ('.', 'O'))"
The epidemiology of the acute flank pain syndrome from suprofen .,"(('The', 'O'), ('epidemiology', 'O'), ('of', 'O'), ('the', 'O'), ('acute', 'O'), ('flank', 'B'), ('pain', 'I'), ('syndrome', 'O'), ('from', 'O'), ('suprofen', 'O'), ('.', 'O'))"
"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .","(('Until', 'O'), ('physicians', 'O'), ('began', 'O'), ('reporting', 'O'), ('an', 'O'), ('unusual', 'O'), ('acute', 'O'), ('flank', 'B'), ('pain', 'I'), ('syndrome', 'O'), ('to', 'O'), ('the', 'O'), ('spontaneous', 'O'), ('reporting', 'O'), ('system', 'O'), (',', 'O'), ('700', 'O'), (',', 'O'), ('000', 'O'), ('persons', 'O'), ('used', 'O'), ('the', 'O'), ('drug', 'O'), ('in', 'O'), ('the', 'O'), ('United', 'O'), ('States', 'O'), ('.', 'O'))"
"Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17","(('Case', 'O'), ('patients', 'O'), ('were', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('be', 'O'), ('men', 'O'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), (';', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('2', 'O'), ('-', 'O'), ('12', 'O'), ('.', 'O'), ('1', 'O'), (')', 'O'), (',', 'O'), ('suffer', 'O'), ('from', 'O'), ('hay', 'B'), ('fever', 'I'), ('and', 'O'), ('asthma', 'B'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('-', 'O'), ('11', 'O'), ('.', 'O'), ('9', 'O'), (')', 'O'), (';', 'O'), ('to', 'O'), ('participate', 'O'), ('in', 'O'), ('regular', 'O'), ('exercise', 'O'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), (';', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('30', 'O'), ('.', 'O'), ('7', 'O'), (')', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('Nautilus', 'O'), ('equipment', 'O'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('02', 'O'), (')', 'O'), (';', 'O'), ('and', 'O'), ('to', 'O'), ('use', 'O'), ('alcohol', 'O'), ('(', 'O'), ('odds', 'O'), ('ratio', 'O'), (',', 'O'), ('4', 'O'), ('.', 'O'), ('4', 'O'), (';', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('1', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('17', 'O'))"
"Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .","(('Possible', 'O'), ('risk', 'O'), ('factors', 'O'), ('included', 'O'), ('young', 'O'), ('age', 'O'), (',', 'O'), ('concurrent', 'O'), ('use', 'O'), ('of', 'O'), ('other', 'O'), ('analgesic', 'O'), ('agents', 'O'), ('(', 'O'), ('especially', 'O'), ('ibuprofen', 'O'), (')', 'O'), (',', 'O'), ('preexisting', 'O'), ('renal', 'B'), ('disease', 'I'), (',', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('kidney', 'B'), ('stones', 'I'), (',', 'O'), ('a', 'O'), ('history', 'O'), ('of', 'O'), ('gout', 'B'), (',', 'O'), ('a', 'O'), ('recent', 'O'), ('increase', 'O'), ('in', 'O'), ('activity', 'O'), (',', 'O'), ('a', 'O'), ('recent', 'O'), ('increase', 'O'), ('in', 'O'), ('sun', 'O'), ('exposure', 'O'), (',', 'O'), ('and', 'O'), ('residence', 'O'), ('in', 'O'), ('the', 'O'), ('Sunbelt', 'O'), ('.', 'O'))"
Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .,"(('Phlorizin', 'O'), ('-', 'O'), ('induced', 'O'), ('glycosuria', 'B'), ('does', 'O'), ('not', 'O'), ('prevent', 'O'), ('gentamicin', 'O'), ('nephrotoxicity', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .","(('Because', 'O'), ('rats', 'O'), ('with', 'O'), ('streptozotocin', 'O'), ('-', 'O'), ('induced', 'O'), ('diabetes', 'B'), ('mellitus', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('have', 'O'), ('a', 'O'), ('high', 'O'), ('solute', 'O'), ('diuresis', 'O'), ('(', 'O'), ('glycosuria', 'B'), ('of', 'O'), ('10', 'O'), ('to', 'O'), ('12', 'O'), ('g', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), (',', 'O'), ('we', 'O'), ('have', 'O'), ('suggested', 'O'), ('that', 'O'), ('this', 'O'), ('may', 'O'), ('in', 'O'), ('part', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('their', 'O'), ('resistance', 'O'), ('to', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('(', 'O'), ('ARF', 'B'), (')', 'O'), ('.', 'O'))"
The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .,"(('The', 'O'), ('protection', 'O'), ('from', 'O'), ('gentamicin', 'O'), ('nephrotoxicity', 'B'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('non', 'O'), ('-', 'O'), ('diabetic', 'B'), ('rats', 'O'), ('with', 'O'), ('chronic', 'O'), ('solute', 'O'), ('diuresis', 'O'), ('induced', 'O'), ('by', 'O'), ('blockage', 'O'), ('of', 'O'), ('tubular', 'O'), ('glucose', 'O'), ('reabsorption', 'O'), ('with', 'O'), ('phlorizin', 'O'), ('(', 'O'), ('P', 'O'), (')', 'O'), ('.', 'O'))"
DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .,"(('DM', 'B'), ('rats', 'O'), ('with', 'O'), ('mild', 'O'), ('glycosuria', 'B'), ('(', 'O'), ('similar', 'O'), ('in', 'O'), ('degree', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('the', 'O'), ('P', 'O'), ('treated', 'O'), ('animals', 'O'), (')', 'O'), ('were', 'O'), ('also', 'O'), ('studied', 'O'), ('.', 'O'))"
"In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .","(('In', 'O'), ('Group', 'O'), ('I', 'O'), (',', 'O'), ('P', 'O'), ('induced', 'O'), ('a', 'O'), ('moderate', 'O'), ('and', 'O'), ('stable', 'O'), ('glycosuria', 'B'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('g', 'O'), ('/', 'O'), ('day', 'O'), (',', 'O'), ('SE', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('no', 'O'), ('functional', 'O'), ('or', 'O'), ('morphologic', 'O'), ('evidence', 'O'), ('of', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('(', 'O'), ('baseline', 'O'), ('CCr', 'O'), ('2', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('ml', 'O'), ('/', 'O'), ('min', 'O'), (',', 'O'), ('undetectable', 'O'), ('lysozymuria', 'O'), (')', 'O'), ('or', 'O'), ('damage', 'O'), ('(', 'O'), ('tubular', 'B'), ('necrosis', 'I'), ('score', 'O'), ('[', 'O'), ('maximum', 'O'), ('4', 'O'), (']', 'O'), (',', 'O'), ('zero', 'O'), (')', 'O'), ('.', 'O'))"
"In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .","(('In', 'O'), ('Group', 'O'), ('II', 'O'), (',', 'O'), ('P', 'O'), ('did', 'O'), ('not', 'O'), ('prevent', 'O'), ('gentamicin', 'O'), ('-', 'O'), ('ARF', 'B'), ('(', 'O'), ('maximal', 'O'), ('decrease', 'O'), ('in', 'O'), ('CCr', 'O'), ('at', 'O'), ('day', 'O'), ('9', 'O'), ('.', 'O'), ('89', 'O'), ('%', 'O'), (',', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (';', 'O'), ('peak', 'O'), ('lysozymuria', 'O'), (',', 'O'), ('1863', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('321', 'O'), ('micrograms', 'O'), ('/', 'O'), ('day', 'O'), (';', 'O'), ('and', 'O'), ('tubular', 'B'), ('necrosis', 'I'), ('score', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('These', 'O'), ('values', 'O'), ('were', 'O'), ('not', 'O'), ('different', 'O'), ('from', 'O'), ('those', 'O'), ('of', 'O'), ('Group', 'O'), ('III', 'O'), (':', 'O'), ('maximal', 'O'), ('decrease', 'O'), ('in', 'O'), ('CCr', 'O'), ('73', 'O'), ('%', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('lysozymuria', 'O'), (',', 'O'), ('2147', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('701', 'O'), ('micrograms', 'O'), ('/', 'O'), ('day', 'O'), (';', 'O'), ('tubular', 'B'), ('necrosis', 'I'), ('score', 'O'), (',', 'O'), ('3', 'O'), ('.', 'O'), ('8', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
"Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .","(('Catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('combinations', 'O'), ('of', 'O'), ('ketamine', 'O'), ('and', 'O'), ('morphine', 'O'), (':', 'O'), ('potentiation', 'O'), (',', 'O'), ('antagonism', 'O'), (',', 'O'), ('tolerance', 'O'), ('and', 'O'), ('cross', 'O'), ('-', 'O'), ('tolerance', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .,"(('Previous', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('both', 'O'), ('ketamine', 'O'), ('and', 'O'), ('morphine', 'O'), ('induced', 'O'), ('analgesia', 'B'), ('and', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .","(('Latency', 'O'), ('to', 'O'), ('the', 'O'), ('loss', 'O'), ('of', 'O'), ('righting', 'O'), ('reflex', 'O'), (',', 'O'), ('rigidity', 'B'), ('and', 'O'), ('behavior', 'O'), ('on', 'O'), ('recovery', 'O'), (',', 'O'), ('reflected', 'O'), ('the', 'O'), ('relative', 'O'), ('predominance', 'O'), ('of', 'O'), ('ketamine', 'O'), ('or', 'O'), ('morphine', 'O'), ('in', 'O'), ('each', 'O'), ('combination', 'O'), ('.', 'O'))"
"While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .","(('While', 'O'), ('the', 'O'), ('mutual', 'O'), ('potentiation', 'O'), (',', 'O'), ('antagonism', 'O'), ('and', 'O'), ('tolerance', 'O'), ('suggest', 'O'), ('common', 'O'), ('mechanisms', 'O'), ('for', 'O'), ('the', 'O'), ('induced', 'O'), ('catalepsy', 'B'), (',', 'O'), ('differences', 'O'), ('in', 'O'), ('latency', 'O'), (',', 'O'), ('rigidity', 'B'), ('and', 'O'), ('behavior', 'O'), (',', 'O'), ('asymmetry', 'O'), ('of', 'O'), ('cross', 'O'), ('-', 'O'), ('tolerance', 'O'), ('and', 'O'), ('a', 'O'), ('widely', 'O'), ('-', 'O'), ('different', 'O'), ('ID50', 'O'), ('for', 'O'), ('naloxone', 'O'), ('would', 'O'), ('argue', 'O'), ('against', 'O'), ('an', 'O'), ('action', 'O'), ('at', 'O'), ('a', 'O'), ('single', 'O'), ('opioid', 'O'), ('site', 'O'), ('.', 'O'))"
Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .,"(('Hydrocortisone', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertension', 'B'), ('in', 'O'), ('humans', 'O'), (':', 'O'), ('pressor', 'O'), ('responsiveness', 'O'), ('and', 'O'), ('sympathetic', 'O'), ('function', 'O'), ('.', 'O'))"
"Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .","(('Although', 'O'), ('diastolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('remained', 'O'), ('unchanged', 'O'), (',', 'O'), ('systolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('increased', 'O'), ('from', 'O'), ('119', 'O'), ('to', 'O'), ('135', 'O'), ('mm', 'O'), ('Hg', 'O'), ('(', 'O'), ('SED', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'B'), ('cardiac', 'I'), ('output', 'I'), ('(', 'O'), ('5', 'O'), ('.', 'O'), ('85', 'O'), ('-', 'O'), ('7', 'O'), ('.', 'O'), ('73', 'O'), ('l', 'O'), ('/', 'O'), ('min', 'O'), (',', 'O'), ('SED', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('46', 'O'), (',', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS ),"(('The', 'O'), ('rise', 'B'), ('in', 'I'), ('resting', 'I'), ('blood', 'I'), ('pressure', 'I'), ('with', 'O'), ('hydrocortisone', 'O'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'B'), ('cardiac', 'I'), ('output', 'I'), ('(', 'O'), ('presumably', 'O'), ('due', 'O'), ('to', 'O'), ('increased', 'O'), ('blood', 'O'), ('volume', 'O'), (')', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
Neuromuscular blockade with magnesium sulfate and nifedipine .,"(('Neuromuscular', 'B'), ('blockade', 'I'), ('with', 'O'), ('magnesium', 'O'), ('sulfate', 'O'), ('and', 'O'), ('nifedipine', 'O'), ('.', 'O'))"
A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .,"(('A', 'O'), ('patient', 'O'), ('who', 'O'), ('received', 'O'), ('tocolysis', 'O'), ('with', 'O'), ('nifedipine', 'O'), ('developed', 'O'), ('neuromuscular', 'B'), ('blockade', 'I'), ('after', 'O'), ('500', 'O'), ('mg', 'O'), ('of', 'O'), ('magnesium', 'O'), ('sulfate', 'O'), ('was', 'O'), ('administered', 'O'), ('.', 'O'))"
This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .,"(('This', 'O'), ('reaction', 'O'), ('demonstrates', 'O'), ('that', 'O'), ('nifedipine', 'O'), ('can', 'O'), ('seriously', 'O'), ('potentiate', 'O'), ('the', 'O'), ('toxicity', 'B'), ('of', 'O'), ('magnesium', 'O'), ('.', 'O'))"
Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .,"(('Chronic', 'O'), ('carbamazepine', 'O'), ('inhibits', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('seizures', 'B'), ('kindled', 'O'), ('by', 'O'), ('cocaine', 'O'), ('and', 'O'), ('lidocaine', 'O'), ('.', 'O'))"
The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('carbamazepine', 'O'), ('(', 'O'), ('CBZ', 'O'), (')', 'O'), ('treatment', 'O'), ('on', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('kindled', 'O'), ('seizures', 'B'), ('and', 'O'), ('lethality', 'O'), ('were', 'O'), ('evaluated', 'O'), ('in', 'O'), ('different', 'O'), ('stages', 'O'), ('of', 'O'), ('the', 'O'), ('kindling', 'O'), ('process', 'O'), ('and', 'O'), ('under', 'O'), ('different', 'O'), ('methods', 'O'), ('of', 'O'), ('CBZ', 'O'), ('administration', 'O'), ('.', 'O'))"
"Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .","(('Chronic', 'O'), ('oral', 'O'), ('CBZ', 'O'), ('inhibited', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('both', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('and', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), (',', 'O'), ('but', 'O'), ('had', 'O'), ('little', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('fully', 'O'), ('developed', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('seizures', 'B'), ('.', 'O'))"
Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .,"(('Chronic', 'O'), ('CBZ', 'O'), ('also', 'O'), ('decreased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('seizure', 'B'), ('-', 'O'), ('related', 'O'), ('mortality', 'O'), ('in', 'O'), ('the', 'O'), ('cocaine', 'O'), ('-', 'O'), ('injected', 'O'), ('rats', 'O'), ('.', 'O'))"
Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .,"(('Acute', 'O'), ('CBZ', 'O'), ('over', 'O'), ('a', 'O'), ('range', 'O'), ('of', 'O'), ('doses', 'O'), ('(', 'O'), ('15', 'O'), ('-', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('completed', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('kindled', 'O'), ('or', 'O'), ('acute', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .,"(('Repeated', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), ('injection', 'O'), ('of', 'O'), ('CBZ', 'O'), ('(', 'O'), ('15', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('also', 'O'), ('was', 'O'), ('without', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('lidocaine', 'O'), ('-', 'O'), ('or', 'O'), ('cocaine', 'O'), ('-', 'O'), ('kindled', 'O'), ('seizures', 'B'), ('.', 'O'))"
The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .,"(('The', 'O'), ('differential', 'O'), ('effects', 'O'), ('of', 'O'), ('CBZ', 'O'), ('depending', 'O'), ('upon', 'O'), ('stage', 'O'), ('of', 'O'), ('seizure', 'B'), ('development', 'O'), ('suggest', 'O'), ('that', 'O'), ('distinct', 'O'), ('mechanisms', 'O'), ('underlie', 'O'), ('the', 'O'), ('development', 'O'), ('versus', 'O'), ('maintenance', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('kindled', 'O'), ('seizures', 'B'), ('.', 'O'))"
"Magnetic resonance imaging of cerebral venous thrombosis secondary to "" low - dose "" birth control pills .","(('Magnetic', 'O'), ('resonance', 'O'), ('imaging', 'O'), ('of', 'O'), ('cerebral', 'O'), ('venous', 'B'), ('thrombosis', 'I'), ('secondary', 'O'), ('to', 'O'), ('""', 'O'), ('low', 'O'), ('-', 'O'), ('dose', 'O'), ('""', 'O'), ('birth', 'O'), ('control', 'O'), ('pills', 'O'), ('.', 'O'))"
A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .,"(('A', 'O'), ('dystonia', 'B'), ('-', 'O'), ('like', 'O'), ('syndrome', 'O'), ('after', 'O'), ('neuropeptide', 'O'), ('(', 'O'), ('MSH', 'O'), ('/', 'O'), ('ACTH', 'O'), (')', 'O'), ('stimulation', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('locus', 'O'), ('ceruleus', 'O'), ('.', 'O'))"
"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .","(('The', 'O'), ('movement', 'B'), ('disorder', 'I'), ('investigated', 'O'), ('in', 'O'), ('these', 'O'), ('studies', 'O'), ('has', 'O'), ('some', 'O'), ('features', 'O'), ('in', 'O'), ('common', 'O'), ('with', 'O'), ('human', 'O'), ('idiopathic', 'O'), ('dystonia', 'B'), (',', 'O'), ('and', 'O'), ('information', 'O'), ('obtained', 'O'), ('in', 'O'), ('these', 'O'), ('studies', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('potential', 'O'), ('clinical', 'O'), ('benefit', 'O'), ('.', 'O'))"
"However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or","(('However', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('not', 'O'), ('certain', 'O'), ('as', 'O'), ('to', 'O'), ('the', 'O'), ('following', 'O'), (':', 'O'), ('(', 'O'), ('a', 'O'), (')', 'O'), ('what', 'O'), ('receptors', 'O'), ('were', 'O'), ('stimulated', 'O'), ('by', 'O'), ('the', 'O'), ('ACTH', 'O'), ('N', 'O'), ('-', 'O'), ('terminal', 'O'), ('fragments', 'O'), ('at', 'O'), ('the', 'O'), ('LC', 'O'), ('that', 'O'), ('resulted', 'O'), ('in', 'O'), ('this', 'O'), ('disorder', 'O'), (';', 'O'), ('(', 'O'), ('b', 'O'), (')', 'O'), ('whether', 'O'), ('NE', 'O'), (',', 'O'), ('released', 'O'), ('onto', 'O'), ('Purkinje', 'O'), ('cell', 'O'), ('synapses', 'O'), ('located', 'O'), ('at', 'O'), ('terminals', 'O'), ('of', 'O'), ('the', 'O'), ('ceruleo', 'O'), ('-', 'O'), ('cerebellar', 'O'), ('pathway', 'O'), (',', 'O'), ('did', 'O'), ('indeed', 'O'), ('cause', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('depression', 'B'), ('at', 'O'), ('Purkinje', 'O'), ('cell', 'O'), ('synapses', 'O'), ('(', 'O'), ('previously', 'O'), ('described', 'O'), ('by', 'O'), ('others', 'O'), (')', 'O'), ('that', 'O'), ('resulted', 'O'), ('in', 'O'), ('the', 'O'), ('long', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('movement', 'B'), ('disorder', 'I'), (';', 'O'), ('(', 'O'), ('c', 'O'), (')', 'O'), ('whether', 'O'), ('the', 'O'), ('inhibition', 'O'), ('of', 'O'), ('inhibitory', 'O'), ('Purkinje', 'O'), ('cells', 'O'), ('resulted', 'O'), ('in', 'O'), ('disinhibition', 'O'), ('or', 'O'))"
Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .,"(('Enhanced', 'O'), ('stimulus', 'O'), ('-', 'O'), ('induced', 'O'), ('neurotransmitter', 'O'), ('overflow', 'O'), ('in', 'O'), ('epinephrine', 'O'), ('-', 'O'), ('induced', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('is', 'O'), ('not', 'O'), ('mediated', 'O'), ('by', 'O'), ('prejunctional', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('activation', 'O'), ('.', 'O'))"
GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .,"(('GABA', 'O'), ('involvement', 'O'), ('in', 'O'), ('naloxone', 'O'), ('induced', 'O'), ('reversal', 'O'), ('of', 'O'), ('respiratory', 'B'), ('paralysis', 'I'), ('produced', 'O'), ('by', 'O'), ('thiopental', 'O'), ('.', 'O'))"
"No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .","(('No', 'O'), ('agent', 'O'), ('is', 'O'), ('yet', 'O'), ('available', 'O'), ('to', 'O'), ('reverse', 'O'), ('respiratory', 'B'), ('paralysis', 'I'), ('produced', 'O'), ('by', 'O'), ('CNS', 'O'), ('depressants', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('general', 'O'), ('anesthetics', 'O'), ('.', 'O'))"
In this study naloxone reversed respiratory paralysis induced by thiopental in rats .,"(('In', 'O'), ('this', 'O'), ('study', 'O'), ('naloxone', 'O'), ('reversed', 'O'), ('respiratory', 'B'), ('paralysis', 'I'), ('induced', 'O'), ('by', 'O'), ('thiopental', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"50 mg / kg , i . v . thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .","(('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('thiopental', 'O'), ('produced', 'O'), ('respiratory', 'B'), ('arrest', 'I'), ('with', 'O'), ('further', 'O'), ('increase', 'O'), ('in', 'O'), ('GABA', 'O'), ('and', 'O'), ('decrease', 'O'), ('in', 'O'), ('glutamate', 'O'), ('again', 'O'), ('in', 'O'), ('cortex', 'O'), ('and', 'O'), ('brain', 'O'), ('stem', 'O'), ('without', 'O'), ('affecting', 'O'), ('any', 'O'), ('of', 'O'), ('the', 'O'), ('amino', 'O'), ('acids', 'O'), ('studied', 'O'), ('in', 'O'), ('four', 'O'), ('regions', 'O'), ('of', 'O'), ('rat', 'O'), ('brain', 'O'), ('.', 'O'))"
"Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .","(('Naloxone', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), (')', 'O'), ('reversed', 'O'), ('respiratory', 'B'), ('paralysis', 'I'), (',', 'O'), ('glutamate', 'O'), ('and', 'O'), ('GABA', 'O'), ('levels', 'O'), ('to', 'O'), ('control', 'O'), ('values', 'O'), ('in', 'O'), ('brain', 'O'), ('stem', 'O'), ('and', 'O'), ('cortex', 'O'), ('with', 'O'), ('no', 'O'), ('changes', 'O'), ('in', 'O'), ('caudate', 'O'), ('or', 'O'), ('cerebellum', 'O'), ('.', 'O'))"
These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .,"(('These', 'O'), ('data', 'O'), ('suggest', 'O'), ('naloxone', 'O'), ('reverses', 'O'), ('respiratory', 'B'), ('paralysis', 'I'), ('produced', 'O'), ('by', 'O'), ('thiopental', 'O'), ('and', 'O'), ('involves', 'O'), ('GABA', 'O'), ('in', 'O'), ('its', 'O'), ('action', 'O'), ('.', 'O'))"
Diazepam facilitates reflex bradycardia in conscious rats .,"(('Diazepam', 'O'), ('facilitates', 'O'), ('reflex', 'O'), ('bradycardia', 'B'), ('in', 'O'), ('conscious', 'O'), ('rats', 'O'), ('.', 'O'))"
"Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .","(('Also', 'O'), (',', 'O'), ('reflex', 'O'), ('bradycardia', 'B'), ('was', 'O'), ('produced', 'O'), ('in', 'O'), ('rats', 'O'), ('by', 'O'), ('intravenous', 'O'), ('infusion', 'O'), ('of', 'O'), ('adrenaline', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('25', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('micrograms', 'O'), ('kg', 'O'), ('-', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
"Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .","(('Intravenous', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('the', 'O'), ('rats', 'O'), ('with', 'O'), ('diazepam', 'O'), (',', 'O'), ('although', 'O'), ('causing', 'O'), ('no', 'O'), ('change', 'O'), ('in', 'O'), ('the', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('pressor', 'O'), ('effect', 'O'), (',', 'O'), ('did', 'O'), ('enhance', 'O'), ('the', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('reflex', 'O'), ('bradycardia', 'B'), ('.', 'O'))"
"However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('diazepam', 'O'), ('enhancement', 'O'), ('of', 'O'), ('adrenaline', 'O'), ('-', 'O'), ('induced', 'O'), ('reflex', 'O'), ('bradycardia', 'B'), ('was', 'O'), ('antagonized', 'O'), ('by', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('rats', 'O'), ('with', 'O'), ('an', 'O'), ('intravenous', 'O'), ('dose', 'O'), ('of', 'O'), ('picrotoxin', 'O'), ('(', 'O'), ('an', 'O'), ('agent', 'O'), ('blocks', 'O'), ('chloride', 'O'), ('channels', 'O'), ('by', 'O'), ('binding', 'O'), ('to', 'O'), ('sites', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('benzodiazepine', 'O'), ('-', 'O'), ('GABA', 'O'), ('-', 'O'), ('chloride', 'O'), ('channel', 'O'), ('macromolecular', 'O'), ('complex', 'O'), (')', 'O'), ('.', 'O'))"
The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .,"(('The', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('diazepam', 'O'), ('acts', 'O'), ('through', 'O'), ('the', 'O'), ('benzodiazepine', 'O'), ('-', 'O'), ('GABA', 'O'), ('-', 'O'), ('chloride', 'O'), ('channel', 'O'), ('macromolecular', 'O'), ('complex', 'O'), ('within', 'O'), ('the', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('to', 'O'), ('facilitate', 'O'), ('reflex', 'O'), ('bradycardia', 'B'), ('mediated', 'O'), ('through', 'O'), ('baroreceptor', 'O'), ('reflexes', 'O'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('an', 'O'), ('acute', 'O'), ('increase', 'O'), ('in', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('.', 'O'))"
Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .,"(('Initial', 'O'), ('potassium', 'O'), ('loss', 'O'), ('and', 'O'), ('hypokalaemia', 'B'), ('during', 'O'), ('chlorthalidone', 'O'), ('administration', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('essential', 'O'), ('hypertension', 'B'), (':', 'O'), ('the', 'O'), ('influence', 'O'), ('of', 'O'), ('dietary', 'O'), ('sodium', 'O'), ('restriction', 'O'), ('.', 'O'))"
"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .","(('To', 'O'), ('investigate', 'O'), ('the', 'O'), ('initial', 'O'), ('potassium', 'O'), ('loss', 'O'), ('and', 'O'), ('development', 'O'), ('of', 'O'), ('hypokalaemia', 'B'), ('during', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('an', 'O'), ('oral', 'O'), ('diuretic', 'O'), (',', 'O'), ('metabolic', 'O'), ('balance', 'O'), ('studies', 'O'), ('were', 'O'), ('performed', 'O'), ('in', 'O'), ('ten', 'O'), ('patients', 'O'), ('with', 'O'), ('essential', 'O'), ('hypertension', 'B'), ('who', 'O'), ('had', 'O'), ('shown', 'O'), ('hypokalaemia', 'B'), ('under', 'O'), ('prior', 'O'), ('oral', 'O'), ('diuretic', 'O'), ('treatment', 'O'), ('.', 'O'))"
Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .,"(('Reversal', 'O'), ('of', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('by', 'O'), ('novel', 'O'), ('aryl', 'O'), ('-', 'O'), ('piperazine', 'O'), ('anxiolytic', 'O'), ('drugs', 'O'), ('.', 'O'))"
"The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .","(('The', 'O'), ('novel', 'O'), ('anxiolytic', 'O'), ('drug', 'O'), (',', 'O'), ('buspirone', 'O'), (',', 'O'), ('reverses', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .,"(('A', 'O'), ('series', 'O'), ('of', 'O'), ('aryl', 'O'), ('-', 'O'), ('piperazine', 'O'), ('analogues', 'O'), ('of', 'O'), ('buspirone', 'O'), ('and', 'O'), ('other', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptaminergic', 'O'), ('agonists', 'O'), ('were', 'O'), ('tested', 'O'), ('for', 'O'), ('their', 'O'), ('ability', 'O'), ('to', 'O'), ('reverse', 'O'), ('haloperidol', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .,"(('Those', 'O'), ('drugs', 'O'), ('with', 'O'), ('strong', 'O'), ('affinity', 'O'), ('for', 'O'), ('5', 'O'), ('-', 'O'), ('hydroxytryptamine1a', 'O'), ('receptors', 'O'), ('were', 'O'), ('able', 'O'), ('to', 'O'), ('reverse', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
"However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .","(('However', 'O'), (',', 'O'), ('inhibition', 'O'), ('of', 'O'), ('postsynaptic', 'O'), ('5', 'O'), ('-', 'O'), ('HT', 'O'), ('receptors', 'O'), ('neither', 'O'), ('inhibited', 'O'), ('nor', 'O'), ('potentiated', 'O'), ('reversal', 'O'), ('of', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('leaves', 'O'), ('open', 'O'), ('the', 'O'), ('question', 'O'), ('as', 'O'), ('to', 'O'), ('the', 'O'), ('site', 'O'), ('or', 'O'), ('mechanism', 'O'), ('for', 'O'), ('this', 'O'), ('effect', 'O'), ('.', 'O'))"
Induction of ventricular fibrillation and decrease of aortic pressure .,"(('Induction', 'O'), ('of', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('and', 'O'), ('decrease', 'O'), ('of', 'O'), ('aortic', 'O'), ('pressure', 'O'), ('.', 'O'))"
Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .,"(('Frequencies', 'O'), ('of', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('were', 'O'), ('significantly', 'O'), ('lower', 'O'), ('(', 'O'), ('p', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('after', 'O'), ('iopentol', 'O'), ('(', 'O'), ('0', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('iohexol', 'O'), ('(', 'O'), ('3', 'O'), ('%', 'O'), (')', 'O'), ('than', 'O'), ('after', 'O'), ('metrizoate', 'O'), ('(', 'O'), ('22', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .,"(('It', 'O'), ('has', 'O'), ('been', 'O'), ('suggested', 'O'), ('that', 'O'), ('adenylate', 'O'), ('cyclase', 'O'), ('inhibition', 'O'), ('may', 'O'), ('be', 'O'), ('important', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('both', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), ('and', 'O'), ('hypothyroidism', 'B'), ('during', 'O'), ('lithium', 'O'), ('treatment', 'O'), ('.', 'O'))"
Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .,"(('Impaired', 'O'), ('Umax', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('both', 'O'), ('euthyroid', 'O'), ('and', 'O'), ('hypothyroid', 'B'), ('patients', 'O'), ('while', 'O'), ('some', 'O'), ('hypothyroid', 'B'), ('patients', 'O'), ('concentrated', 'O'), ('their', 'O'), ('urine', 'O'), ('well', 'O'), ('.', 'O'))"
Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .,"(('Remodelling', 'O'), ('of', 'O'), ('nerve', 'O'), ('structure', 'O'), ('in', 'O'), ('experimental', 'O'), ('isoniazid', 'O'), ('neuropathy', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .,"(('The', 'O'), ('neuropathy', 'B'), ('caused', 'O'), ('by', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('isoniazid', 'O'), ('in', 'O'), ('rats', 'O'), ('was', 'O'), ('studied', 'O'), ('with', 'O'), ('a', 'O'), ('computer', 'O'), ('-', 'O'), ('assisted', 'O'), ('morphometric', 'O'), ('method', 'O'), ('.', 'O'))"
"Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .","(('Multicenter', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('multiple', 'O'), ('-', 'O'), ('dose', 'O'), (',', 'O'), ('parallel', 'O'), ('-', 'O'), ('groups', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('trial', 'O'), ('of', 'O'), ('azelastine', 'O'), (',', 'O'), ('chlorpheniramine', 'O'), (',', 'O'), ('and', 'O'), ('placebo', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('spring', 'B'), ('allergic', 'I'), ('rhinitis', 'I'), ('.', 'O'))"
"Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .","(('Azelastine', 'O'), (',', 'O'), ('a', 'O'), ('novel', 'O'), ('antiallergic', 'O'), ('medication', 'O'), (',', 'O'), ('was', 'O'), ('compared', 'O'), ('with', 'O'), ('chlorpheniramine', 'O'), ('maleate', 'O'), ('and', 'O'), ('placebo', 'O'), ('for', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('spring', 'B'), ('allergic', 'I'), ('rhinitis', 'I'), ('in', 'O'), ('a', 'O'), ('multicenter', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), (',', 'O'), ('multiple', 'O'), ('-', 'O'), ('dose', 'O'), (',', 'O'), ('parallel', 'O'), ('-', 'O'), ('groups', 'O'), ('study', 'O'), ('.', 'O'))"
"Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .","(('Subjects', 'O'), ('ranged', 'O'), ('in', 'O'), ('age', 'O'), ('from', 'O'), ('18', 'O'), ('to', 'O'), ('60', 'O'), ('years', 'O'), ('of', 'O'), ('age', 'O'), ('and', 'O'), ('had', 'O'), ('at', 'O'), ('least', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('year', 'O'), ('history', 'O'), ('of', 'O'), ('spring', 'B'), ('allergic', 'I'), ('rhinitis', 'I'), (',', 'O'), ('confirmed', 'O'), ('by', 'O'), ('positive', 'O'), ('skin', 'O'), ('test', 'O'), ('to', 'O'), ('spring', 'O'), ('aeroallergens', 'O'), ('.', 'O'))"
Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .,"(('Drowsiness', 'B'), ('and', 'O'), ('altered', 'B'), ('taste', 'I'), ('perception', 'I'), ('were', 'O'), ('increased', 'O'), ('significantly', 'O'), ('over', 'O'), ('placebo', 'O'), ('only', 'O'), ('in', 'O'), ('the', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('azelastine', 'O'), ('group', 'O'), ('.', 'O'))"
"Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .","(('Azelastine', 'O'), ('appears', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('safe', 'O'), (',', 'O'), ('efficacious', 'O'), ('medication', 'O'), ('for', 'O'), ('seasonal', 'B'), ('allergic', 'I'), ('rhinitis', 'I'), ('.', 'O'))"
Toxicity due to remission inducing drugs in rheumatoid arthritis .,"(('Toxicity', 'B'), ('due', 'O'), ('to', 'O'), ('remission', 'O'), ('inducing', 'O'), ('drugs', 'O'), ('in', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .,"(('Twenty', 'O'), ('-', 'O'), ('five', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('(', 'O'), ('RA', 'B'), (')', 'O'), ('who', 'O'), ('developed', 'O'), ('toxicity', 'B'), ('while', 'O'), ('taking', 'O'), ('remission', 'O'), ('inducing', 'O'), ('drugs', 'O'), ('and', 'O'), ('30', 'O'), ('without', 'O'), ('toxicity', 'B'), ('were', 'O'), ('studied', 'O'), ('for', 'O'), ('possible', 'O'), ('associations', 'O'), ('with', 'O'), ('class', 'O'), ('I', 'O'), ('and', 'O'), ('II', 'O'), ('HLA', 'O'), ('antigens', 'O'), ('.', 'O'))"
"A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .","(('A', 'O'), ('strong', 'O'), ('association', 'O'), ('has', 'O'), ('been', 'O'), ('found', 'O'), ('between', 'O'), ('nephritis', 'B'), ('and', 'O'), ('dermatitis', 'B'), ('due', 'O'), ('to', 'O'), ('Tiopronin', 'O'), ('(', 'O'), ('a', 'O'), ('D', 'O'), ('-', 'O'), ('Penicillamine', 'O'), ('like', 'O'), ('compound', 'O'), (')', 'O'), ('and', 'O'), ('class', 'O'), ('I', 'O'), ('antigens', 'O'), ('B35', 'O'), ('-', 'O'), ('Cw4', 'O'), (',', 'O'), ('and', 'O'), ('between', 'O'), ('dermatitis', 'B'), ('due', 'O'), ('to', 'O'), ('gold', 'O'), ('thiosulphate', 'O'), ('and', 'O'), ('B35', 'O'), ('.', 'O'))"
Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .,"(('Compared', 'O'), ('to', 'O'), ('healthy', 'O'), ('controls', 'O'), ('a', 'O'), ('lower', 'O'), ('DR5', 'O'), ('frequency', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('RA', 'B'), ('except', 'O'), ('for', 'O'), ('the', 'O'), ('Tiopronin', 'O'), ('related', 'O'), ('nephritis', 'B'), ('group', 'O'), ('.', 'O'))"
Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .,"(('Transient', 'O'), ('contralateral', 'B'), ('rotation', 'I'), ('following', 'O'), ('unilateral', 'O'), ('substantia', 'B'), ('nigra', 'I'), ('lesion', 'I'), ('reflects', 'O'), ('susceptibility', 'O'), ('of', 'O'), ('the', 'O'), ('nigrostriatal', 'O'), ('system', 'O'), ('to', 'O'), ('exhaustion', 'O'), ('by', 'O'), ('amphetamine', 'O'), ('.', 'O'))"
"Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .","(('Following', 'O'), ('unilateral', 'O'), ('6', 'O'), ('-', 'O'), ('OHDA', 'O'), ('induced', 'O'), ('SN', 'B'), ('lesion', 'I'), (',', 'O'), ('a', 'O'), ('transient', 'O'), ('period', 'O'), ('of', 'O'), ('contralateral', 'B'), ('rotation', 'I'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('precede', 'O'), ('the', 'O'), ('predominant', 'O'), ('ipsilateral', 'B'), ('circling', 'I'), ('.', 'O'))"
"In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('clarify', 'O'), ('the', 'O'), ('nature', 'O'), ('of', 'O'), ('this', 'O'), ('initial', 'O'), ('contralateral', 'B'), ('rotation', 'I'), ('we', 'O'), ('examined', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('duration', 'O'), ('of', 'O'), ('recovery', 'O'), ('period', 'O'), ('after', 'O'), ('the', 'O'), ('lesion', 'O'), (',', 'O'), ('on', 'O'), ('amphetamine', 'O'), ('-', 'O'), ('induced', 'O'), ('rotational', 'B'), ('behavior', 'I'), ('.', 'O'))"
Mitomycin C associated hemolytic uremic syndrome .,"(('Mitomycin', 'O'), ('C', 'O'), ('associated', 'O'), ('hemolytic', 'B'), ('uremic', 'I'), ('syndrome', 'I'), ('.', 'O'))"
Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .,"(('Mitomycin', 'O'), ('C', 'O'), ('associated', 'O'), ('Hemolytic', 'B'), ('Uremic', 'I'), ('Syndrome', 'I'), ('(', 'O'), ('HUS', 'B'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('potentially', 'O'), ('fatal', 'O'), ('but', 'O'), ('uncommon', 'O'), ('condition', 'O'), ('that', 'O'), ('is', 'O'), ('not', 'O'), ('yet', 'O'), ('widely', 'O'), ('recognised', 'O'), ('.', 'O'))"
"It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .","(('It', 'O'), ('consists', 'O'), ('of', 'O'), ('microangiopathic', 'O'), ('hemolytic', 'B'), ('anemia', 'I'), (',', 'O'), ('thrombocytopenia', 'B'), ('and', 'O'), ('progressive', 'O'), ('renal', 'B'), ('failure', 'I'), ('associated', 'O'), ('with', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('treatment', 'O'), ('and', 'O'), ('affects', 'O'), ('about', 'O'), ('10', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('this', 'O'), ('agent', 'O'), ('.', 'O'))"
The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .,"(('The', 'O'), ('renal', 'B'), ('failure', 'I'), ('usually', 'O'), ('develops', 'O'), ('about', 'O'), ('8', 'O'), ('-', 'O'), ('10', 'O'), ('mth', 'O'), ('after', 'O'), ('start', 'O'), ('of', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('treatment', 'O'), ('and', 'O'), ('the', 'O'), ('mortality', 'O'), ('is', 'O'), ('approximately', 'O'), ('60', 'O'), ('%', 'O'), ('from', 'O'), ('renal', 'B'), ('failure', 'I'), ('or', 'O'), ('pulmonary', 'B'), ('edema', 'I'), ('.', 'O'))"
"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .","(('Renal', 'B'), ('lesions', 'I'), ('are', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('seen', 'O'), ('in', 'O'), ('idiopathic', 'O'), ('HUS', 'B'), ('and', 'O'), ('include', 'O'), ('arteriolar', 'O'), ('fibrin', 'O'), ('thrombi', 'B'), (',', 'O'), ('expanded', 'O'), ('subendothelial', 'O'), ('zones', 'O'), ('in', 'O'), ('glomerular', 'O'), ('capillary', 'O'), ('walls', 'O'), (',', 'O'), ('ischemic', 'B'), ('wrinkling', 'O'), ('of', 'O'), ('glomerular', 'O'), ('basement', 'O'), ('membranes', 'O'), ('and', 'O'), ('mesangiolysis', 'O'), ('.', 'O'))"
We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .,"(('We', 'O'), ('describe', 'O'), ('the', 'O'), ('clinical', 'O'), ('course', 'O'), ('and', 'O'), ('pathological', 'O'), ('findings', 'O'), ('in', 'O'), ('a', 'O'), ('65', 'O'), ('yr', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('gastric', 'B'), ('adenocarcinoma', 'I'), ('who', 'O'), ('developed', 'O'), ('renal', 'B'), ('failure', 'I'), ('and', 'O'), ('thrombocytopenia', 'B'), ('while', 'O'), ('on', 'O'), ('treatment', 'O'), ('with', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('and', 'O'), ('died', 'O'), ('in', 'O'), ('pulmonary', 'B'), ('edema', 'I'), ('.', 'O'))"
Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .,"(('Ketanserin', 'O'), ('pretreatment', 'O'), ('reverses', 'O'), ('alfentanil', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('.', 'O'))"
"Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .","(('Systemic', 'O'), ('pretreatment', 'O'), ('with', 'O'), ('ketanserin', 'O'), (',', 'O'), ('a', 'O'), ('relatively', 'O'), ('specific', 'O'), ('type', 'O'), ('-', 'O'), ('2', 'O'), ('serotonin', 'O'), ('receptor', 'O'), ('antagonist', 'O'), (',', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('the', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('produced', 'O'), ('in', 'O'), ('rats', 'O'), ('by', 'O'), ('the', 'O'), ('potent', 'O'), ('short', 'O'), ('-', 'O'), ('acting', 'O'), ('opiate', 'O'), ('agonist', 'O'), ('alfentanil', 'O'), ('.', 'O'))"
"Following placement of subcutaneous electrodes in each animal ' s left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .","(('Following', 'O'), ('placement', 'O'), ('of', 'O'), ('subcutaneous', 'O'), ('electrodes', 'O'), ('in', 'O'), ('each', 'O'), ('animal', 'O'), (""'"", 'O'), ('s', 'O'), ('left', 'O'), ('gastrocnemius', 'O'), ('muscle', 'O'), (',', 'O'), ('rigidity', 'B'), ('was', 'O'), ('assessed', 'O'), ('by', 'O'), ('analyzing', 'O'), ('root', 'O'), ('-', 'O'), ('mean', 'O'), ('-', 'O'), ('square', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('.', 'O'))"
Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .,"(('Chlordiazepoxide', 'O'), ('at', 'O'), ('doses', 'O'), ('up', 'O'), ('to', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('failed', 'O'), ('to', 'O'), ('significantly', 'O'), ('influence', 'O'), ('the', 'O'), ('rigidity', 'B'), ('produced', 'O'), ('by', 'O'), ('alfentanil', 'O'), ('.', 'O'))"
"Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .","(('Despite', 'O'), ('the', 'O'), ('absence', 'O'), ('of', 'O'), ('rigidity', 'B'), (',', 'O'), ('animals', 'O'), ('that', 'O'), ('received', 'O'), ('ketanserin', 'O'), ('(', 'O'), ('greater', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('31', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('followed', 'O'), ('by', 'O'), ('alfentanil', 'O'), ('were', 'O'), ('motionless', 'O'), (',', 'O'), ('flaccid', 'O'), (',', 'O'), ('and', 'O'), ('less', 'O'), ('responsive', 'O'), ('to', 'O'), ('external', 'O'), ('stimuli', 'O'), ('than', 'O'), ('were', 'O'), ('animals', 'O'), ('receiving', 'O'), ('alfentanil', 'O'), ('alone', 'O'), ('.', 'O'))"
"These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .","(('These', 'O'), ('results', 'O'), (',', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('previous', 'O'), ('work', 'O'), (',', 'O'), ('suggest', 'O'), ('that', 'O'), ('muscle', 'B'), ('rigidity', 'I'), (',', 'O'), ('a', 'O'), ('clinically', 'O'), ('relevant', 'O'), ('side', 'O'), ('-', 'O'), ('effect', 'O'), ('of', 'O'), ('parenteral', 'O'), ('narcotic', 'O'), ('administration', 'O'), (',', 'O'), ('may', 'O'), ('be', 'O'), ('partly', 'O'), ('mediated', 'O'), ('via', 'O'), ('serotonergic', 'O'), ('pathways', 'O'), ('.', 'O'))"
"Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .","(('Pretreatment', 'O'), ('with', 'O'), ('type', 'O'), ('-', 'O'), ('2', 'O'), ('serotonin', 'O'), ('antagonists', 'O'), ('may', 'O'), ('be', 'O'), ('clinically', 'O'), ('useful', 'O'), ('in', 'O'), ('attenuating', 'O'), ('opiate', 'O'), ('-', 'O'), ('induced', 'O'), ('rigidity', 'B'), (',', 'O'), ('although', 'O'), ('further', 'O'), ('studies', 'O'), ('will', 'O'), ('be', 'O'), ('necessary', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('interaction', 'O'), ('of', 'O'), ('possibly', 'O'), ('enhanced', 'O'), ('CNS', 'O'), (',', 'O'), ('cardiovascular', 'B'), (',', 'I'), ('and', 'I'), ('respiratory', 'I'), ('depression', 'I'), ('.', 'O'))"
"The patient ' s subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .","(('The', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('subjective', 'O'), ('assessment', 'O'), ('of', 'O'), ('mood', 'O'), ('rating', 'O'), (',', 'O'), ('an', 'O'), ('objective', 'O'), ('test', 'O'), ('of', 'O'), ('performance', 'O'), (',', 'O'), ('a', 'O'), ('test', 'O'), ('for', 'O'), ('amnesia', 'B'), (',', 'O'), ('and', 'O'), ('vital', 'O'), ('signs', 'O'), ('were', 'O'), ('recorded', 'O'), ('for', 'O'), ('up', 'O'), ('to', 'O'), ('300', 'O'), ('min', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('trial', 'O'), ('drug', 'O'), ('.', 'O'))"
"No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .","(('No', 'O'), ('significant', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('two', 'O'), ('groups', 'O'), ('were', 'O'), ('observed', 'O'), ('for', 'O'), ('mood', 'O'), ('rating', 'O'), (',', 'O'), ('amnesia', 'B'), (',', 'O'), ('or', 'O'), ('vital', 'O'), ('signs', 'O'), ('.', 'O'))"
Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .,"(('Prolonged', 'O'), ('administration', 'O'), ('of', 'O'), ('female', 'O'), ('sex', 'O'), ('hormones', 'O'), ('is', 'O'), ('a', 'O'), ('possible', 'O'), ('cause', 'O'), ('of', 'O'), ('chorea', 'B'), ('in', 'O'), ('women', 'O'), ('who', 'O'), ('have', 'O'), ('not', 'O'), ('previously', 'O'), ('had', 'O'), ('chorea', 'B'), ('or', 'O'), ('rheumatic', 'B'), ('fever', 'I'), ('.', 'O'))"
Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .,"(('Co', 'O'), ('-', 'O'), ('carcinogenic', 'B'), ('effect', 'O'), ('of', 'O'), ('retinyl', 'O'), ('acetate', 'O'), ('on', 'O'), ('forestomach', 'B'), ('carcinogenesis', 'I'), ('of', 'O'), ('male', 'O'), ('F344', 'O'), ('rats', 'O'), ('induced', 'O'), ('with', 'O'), ('butylated', 'O'), ('hydroxyanisole', 'O'), ('.', 'O'))"
The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat forestomach tumorigenesis was examined .,"(('The', 'O'), ('potential', 'O'), ('modifying', 'O'), ('effect', 'O'), ('of', 'O'), ('retinyl', 'O'), ('acetate', 'O'), ('(', 'O'), ('RA', 'O'), (')', 'O'), ('on', 'O'), ('butylated', 'O'), ('hydroxyanisole', 'O'), ('(', 'O'), ('BHA', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('forestomach', 'B'), ('tumorigenesis', 'I'), ('was', 'O'), ('examined', 'O'), ('.', 'O'))"
"In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .","(('In', 'O'), ('groups', 'O'), ('given', 'O'), ('2', 'O'), ('%', 'O'), ('BHA', 'O'), (',', 'O'), ('although', 'O'), ('marked', 'O'), ('hyperplastic', 'O'), ('changes', 'O'), ('of', 'O'), ('the', 'O'), ('forestomach', 'O'), ('epithelium', 'O'), ('were', 'O'), ('observed', 'O'), ('in', 'O'), ('all', 'O'), ('animals', 'O'), (',', 'O'), ('co', 'O'), ('-', 'O'), ('administration', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('%', 'O'), ('RA', 'O'), ('significantly', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('increased', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('forestomach', 'B'), ('tumors', 'I'), ('(', 'O'), ('squamous', 'B'), ('cell', 'I'), ('papilloma', 'I'), ('and', 'O'), ('carcinoma', 'B'), (')', 'O'), ('to', 'O'), ('60', 'O'), ('%', 'O'), ('(', 'O'), ('9', 'O'), ('/', 'O'), ('15', 'O'), (',', 'O'), ('2', 'O'), ('rats', 'O'), ('with', 'O'), ('carcinoma', 'B'), (')', 'O'), ('from', 'O'), ('15', 'O'), ('%', 'O'), ('(', 'O'), ('3', 'O'), ('/', 'O'), ('20', 'O'), (',', 'O'), ('one', 'O'), ('rat', 'O'), ('with', 'O'), ('carcinoma', 'B'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('group', 'O'), ('given', 'O'), ('RA', 'O'), ('-', 'O'), ('free', 'O'), ('water', 'O'), ('.', 'O'))"
"In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .","(('In', 'O'), ('rats', 'O'), ('given', 'O'), ('1', 'O'), ('%', 'O'), ('BHA', 'O'), (',', 'O'), ('RA', 'O'), ('co', 'O'), ('-', 'O'), ('administered', 'O'), ('at', 'O'), ('a', 'O'), ('dose', 'O'), ('of', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('or', 'O'), ('0', 'O'), ('.', 'O'), ('25', 'O'), ('%', 'O'), ('showed', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('enhancing', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('the', 'O'), ('BHA', 'O'), ('-', 'O'), ('induced', 'O'), ('epithelial', 'B'), ('hyperplasia', 'I'), ('.', 'O'))"
These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .,"(('These', 'O'), ('findings', 'O'), ('indicate', 'O'), ('that', 'O'), ('RA', 'O'), ('acted', 'O'), ('as', 'O'), ('a', 'O'), ('co', 'O'), ('-', 'O'), ('carcinogen', 'O'), ('in', 'O'), ('the', 'O'), ('BHA', 'O'), ('forestomach', 'B'), ('carcinogenesis', 'I'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .,"(('A', 'O'), ('prospective', 'O'), ('study', 'O'), ('on', 'O'), ('the', 'O'), ('dose', 'O'), ('dependency', 'O'), ('of', 'O'), ('cardiotoxicity', 'B'), ('induced', 'O'), ('by', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('.', 'O'))"
"Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .","(('Since', 'O'), ('1975', 'O'), ('mitomycin', 'O'), ('C', 'O'), ('(', 'O'), ('MMC', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('suggested', 'O'), ('to', 'O'), ('be', 'O'), ('cardiotoxic', 'B'), (',', 'O'), ('especially', 'O'), ('when', 'O'), ('combined', 'O'), ('with', 'O'), ('or', 'O'), ('given', 'O'), ('following', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .,"(('One', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('developed', 'O'), ('cardiac', 'B'), ('failure', 'I'), ('after', 'O'), ('30', 'O'), ('mg', 'O'), ('m', 'O'), ('-', 'O'), ('2', 'O'), ('MMC', 'O'), ('and', 'O'), ('only', 'O'), ('150', 'O'), ('mg', 'O'), ('m', 'O'), ('-', 'O'), ('2', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
The cardiac failure was predicted by a drop in EF determined during a cold pressor test .,"(('The', 'O'), ('cardiac', 'B'), ('failure', 'I'), ('was', 'O'), ('predicted', 'O'), ('by', 'O'), ('a', 'O'), ('drop', 'O'), ('in', 'O'), ('EF', 'O'), ('determined', 'O'), ('during', 'O'), ('a', 'O'), ('cold', 'O'), ('pressor', 'O'), ('test', 'O'), ('.', 'O'))"
"None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .","(('None', 'O'), ('of', 'O'), ('the', 'O'), ('other', 'O'), ('patients', 'O'), ('developed', 'O'), ('clinical', 'O'), ('cardiotoxicity', 'B'), (',', 'O'), ('nor', 'O'), ('did', 'O'), ('the', 'O'), ('studied', 'O'), ('parameters', 'O'), ('change', 'O'), ('.', 'O'))"
"Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .","(('Based', 'O'), ('on', 'O'), ('the', 'O'), ('combined', 'O'), ('data', 'O'), ('from', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('and', 'O'), ('the', 'O'), ('literature', 'O'), (',', 'O'), ('we', 'O'), ('suggest', 'O'), ('that', 'O'), ('MMC', 'O'), ('-', 'O'), ('related', 'O'), ('cardiotoxicity', 'B'), ('is', 'O'), ('dose', 'O'), ('dependent', 'O'), (',', 'O'), ('occurring', 'O'), ('at', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('levels', 'O'), ('of', 'O'), ('30', 'O'), ('mg', 'O'), ('m', 'O'), ('-', 'O'), ('2', 'O'), ('or', 'O'), ('more', 'O'), (',', 'O'), ('mainly', 'O'), ('in', 'O'), ('patients', 'O'), ('also', 'O'), ('(', 'O'), ('previously', 'O'), ('or', 'O'), ('simultaneously', 'O'), (')', 'O'), ('treated', 'O'), ('with', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .,"(('Reversible', 'O'), ('cerebral', 'B'), ('lesions', 'I'), ('associated', 'O'), ('with', 'O'), ('tiazofurin', 'O'), ('usage', 'O'), (':', 'O'), ('MR', 'O'), ('demonstration', 'O'), ('.', 'O'))"
We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .,"(('We', 'O'), ('report', 'O'), ('our', 'O'), ('results', 'O'), ('with', 'O'), ('magnetic', 'O'), ('resonance', 'O'), ('(', 'O'), ('MR', 'O'), (')', 'O'), ('in', 'O'), ('demonstrating', 'O'), ('reversible', 'O'), ('cerebral', 'B'), ('abnormalities', 'I'), ('concurrent', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .,"(('Receptor', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('nicotine', 'O'), ('-', 'O'), ('induced', 'O'), ('locomotor', 'B'), ('hyperactivity', 'I'), ('in', 'O'), ('chronic', 'O'), ('nicotine', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('.', 'O'))"
"These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('chronic', 'O'), ('nicotine', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('develop', 'O'), ('locomotor', 'B'), ('hyperactivity', 'I'), ('in', 'O'), ('response', 'O'), ('to', 'O'), ('nicotine', 'O'), ('initially', 'O'), ('due', 'O'), ('to', 'O'), ('increases', 'O'), ('of', 'O'), ('both', 'O'), ('the', 'O'), ('density', 'O'), ('of', 'O'), ('nicotinic', 'O'), ('receptors', 'O'), ('and', 'O'), ('DA', 'O'), ('concentration', 'O'), (',', 'O'), ('followed', 'O'), ('by', 'O'), ('inducing', 'O'), ('DA', 'O'), ('receptor', 'O'), ('supersensitivity', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('.', 'O'))"
St .,"(('St', 'B'), ('.', 'I'))"
"Anthony ' s fire , then and now : a case report and historical review .","(('Anthony', 'B'), (""'"", 'I'), ('s', 'I'), ('fire', 'I'), (',', 'O'), ('then', 'O'), ('and', 'O'), ('now', 'O'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('and', 'O'), ('historical', 'O'), ('review', 'O'), ('.', 'O'))"
"A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .","(('A', 'O'), ('rare', 'O'), ('case', 'O'), ('of', 'O'), ('morbid', 'O'), ('vasospasm', 'B'), (',', 'O'), ('together', 'O'), ('with', 'O'), ('striking', 'O'), ('angiographic', 'O'), ('findings', 'O'), (',', 'O'), ('is', 'O'), ('described', 'O'), ('secondary', 'O'), ('to', 'O'), ('the', 'O'), ('ingestion', 'O'), ('of', 'O'), ('methysergide', 'O'), ('by', 'O'), ('a', 'O'), ('48', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('.', 'O'))"
"A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .","(('A', 'O'), ('discussion', 'O'), ('of', 'O'), ('the', 'O'), ('history', 'O'), ('of', 'O'), ('ergot', 'O'), ('includes', 'O'), ('its', 'O'), ('original', 'O'), ('discovery', 'O'), (',', 'O'), ('the', 'O'), ('epidemics', 'O'), ('of', 'O'), ('gangrene', 'B'), ('that', 'O'), ('it', 'O'), ('has', 'O'), ('caused', 'O'), ('through', 'O'), ('the', 'O'), ('ages', 'O'), ('and', 'O'), ('its', 'O'), ('past', 'O'), ('and', 'O'), ('present', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('migraine', 'B'), ('headache', 'I'), ('.', 'O'))"
"Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St .","(('Despite', 'O'), ('the', 'O'), ('advent', 'O'), ('of', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blockers', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('antagonists', 'O'), (',', 'O'), ('ergot', 'O'), ('preparations', 'O'), ('continue', 'O'), ('to', 'O'), ('play', 'O'), ('a', 'O'), ('major', 'O'), ('role', 'O'), ('in', 'O'), ('migraine', 'B'), ('therapy', 'O'), (',', 'O'), ('so', 'O'), ('that', 'O'), ('the', 'O'), ('danger', 'O'), ('of', 'O'), ('St', 'B'), ('.', 'I'))"
Anthony ' s fire persists .,"(('Anthony', 'B'), (""'"", 'I'), ('s', 'I'), ('fire', 'I'), ('persists', 'O'), ('.', 'O'))"
Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .,"(('Group', 'O'), ('II', 'O'), ('also', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'O'), ('of', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('secondary', 'O'), ('to', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('therapy', 'O'), ('with', 'O'), ('cyclosporine', 'O'), ('.', 'O'))"
We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .,"(('We', 'O'), ('think', 'O'), ('that', 'O'), ('even', 'O'), ('these', 'O'), ('lower', 'O'), ('dosages', 'O'), ('of', 'O'), ('cyclosporine', 'O'), ('can', 'O'), ('cause', 'O'), ('chronic', 'O'), ('nephrotoxicity', 'B'), ('and', 'O'), ('that', 'O'), ('further', 'O'), ('modification', 'O'), ('of', 'O'), ('the', 'O'), ('immunosuppressive', 'O'), ('regimen', 'O'), ('is', 'O'), ('required', 'O'), ('to', 'O'), ('completely', 'O'), ('abolish', 'O'), ('this', 'O'), ('toxic', 'O'), ('side', 'O'), ('effect', 'O'), ('.', 'O'))"
Ethopropazine and benztropine in neuroleptic - induced parkinsonism .,"(('Ethopropazine', 'O'), ('and', 'O'), ('benztropine', 'O'), ('in', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('parkinsonism', 'B'), ('.', 'O'))"
In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .,"(('In', 'O'), ('a', 'O'), ('12', 'O'), ('-', 'O'), ('week', 'O'), ('controlled', 'O'), ('study', 'O'), ('ethopropazine', 'O'), ('was', 'O'), ('compared', 'O'), ('to', 'O'), ('benztropine', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('parkinsonism', 'B'), ('induced', 'O'), ('by', 'O'), ('fluphenazine', 'O'), ('enanthate', 'O'), ('in', 'O'), ('60', 'O'), ('schizophrenic', 'B'), ('outpatients', 'O'), ('.', 'O'))"
"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .","(('Ethopropazine', 'O'), ('and', 'O'), ('benztropine', 'O'), ('were', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('equally', 'O'), ('effective', 'O'), ('in', 'O'), ('controlling', 'O'), ('parkinsonian', 'B'), ('symptoms', 'I'), ('and', 'O'), ('were', 'O'), ('as', 'O'), ('efficacious', 'O'), ('as', 'O'), ('procyclidine', 'O'), (',', 'O'), ('their', 'O'), ('previous', 'O'), ('antiparkinsonian', 'O'), ('drug', 'O'), ('.', 'O'))"
"However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .","(('However', 'O'), (',', 'O'), ('benztropine', 'O'), ('treated', 'O'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('significant', 'O'), ('increase', 'O'), ('in', 'O'), ('tardive', 'B'), ('dyskinesia', 'I'), ('compared', 'O'), ('to', 'O'), ('their', 'O'), ('condition', 'O'), ('during', 'O'), ('procyclindine', 'O'), ('treatment', 'O'), (',', 'O'), ('and', 'O'), ('significantly', 'O'), ('more', 'O'), ('anxiety', 'B'), ('and', 'O'), ('depression', 'B'), ('than', 'O'), ('ethopropazine', 'O'), ('treated', 'O'), ('patients', 'O'), ('.', 'O'))"
"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .","(('This', 'O'), ('suggests', 'O'), ('that', 'O'), ('benztropine', 'O'), ('is', 'O'), ('not', 'O'), ('the', 'O'), ('anticholinergic', 'O'), ('drug', 'O'), ('of', 'O'), ('choice', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('parkinsonian', 'B'), ('symptoms', 'I'), (',', 'O'), ('because', 'O'), ('of', 'O'), ('its', 'O'), ('more', 'O'), ('toxic', 'O'), ('central', 'O'), ('and', 'O'), ('peripheral', 'O'), ('atropinic', 'O'), ('effect', 'O'), ('.', 'O'))"
Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .,"(('Quinidine', 'O'), ('phenylethylbarbiturate', 'O'), ('-', 'O'), ('induced', 'O'), ('fulminant', 'O'), ('hepatitis', 'B'), ('in', 'O'), ('a', 'O'), ('pregnant', 'O'), ('woman', 'O'), ('.', 'O'))"
We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('19', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('Laotian', 'O'), ('patient', 'O'), ('affected', 'O'), ('by', 'O'), ('fulminant', 'O'), ('hepatitis', 'B'), ('during', 'O'), ('the', 'O'), ('third', 'O'), ('trimester', 'O'), ('of', 'O'), ('her', 'O'), ('pregnancy', 'O'), ('after', 'O'), ('a', 'O'), ('1', 'O'), ('-', 'O'), ('month', 'O'), ('administration', 'O'), ('of', 'O'), ('quinidine', 'O'), ('phenylethylbarbiturate', 'O'), ('.', 'O'))"
Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .,"(('Quinidine', 'O'), ('itself', 'O'), ('or', 'O'), ('phenylethylbarbiturate', 'O'), ('may', 'O'), ('be', 'O'), ('responsible', 'O'), ('for', 'O'), ('fulminant', 'O'), ('hepatitis', 'B'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('.', 'O'))"
Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .,"(('Mechanisms', 'O'), ('of', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('induced', 'O'), ('by', 'O'), ('epinephrine', 'O'), (':', 'O'), ('comparison', 'O'), ('with', 'O'), ('exercise', 'O'), ('-', 'O'), ('induced', 'O'), ('ischemia', 'B'), ('.', 'O'))"
The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .,"(('The', 'O'), ('role', 'O'), ('of', 'O'), ('epinephrine', 'O'), ('in', 'O'), ('eliciting', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('was', 'O'), ('examined', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('.', 'O'))"
Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .,"(('Objective', 'O'), ('signs', 'O'), ('of', 'O'), ('ischemia', 'B'), ('and', 'O'), ('factors', 'O'), ('increasing', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('consumption', 'O'), ('were', 'O'), ('compared', 'O'), ('during', 'O'), ('epinephrine', 'O'), ('infusion', 'O'), ('and', 'O'), ('supine', 'O'), ('bicycle', 'O'), ('exercise', 'O'), ('.', 'O'))"
Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .,"(('Both', 'O'), ('epinephrine', 'O'), ('and', 'O'), ('exercise', 'O'), ('produced', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('as', 'O'), ('evidenced', 'O'), ('by', 'O'), ('ST', 'O'), ('segment', 'O'), ('depression', 'B'), ('and', 'O'), ('angina', 'B'), ('.', 'O'))"
"However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('induced', 'O'), ('by', 'O'), ('epinephrine', 'O'), ('were', 'O'), ('significantly', 'O'), ('different', 'O'), ('from', 'O'), ('those', 'O'), ('of', 'O'), ('exercise', 'O'), ('.', 'O'))"
"Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .","(('Exercise', 'O'), ('-', 'O'), ('induced', 'O'), ('myocardial', 'B'), ('ischemia', 'I'), ('was', 'O'), ('marked', 'O'), ('predominantly', 'O'), ('by', 'O'), ('increased', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('rate', 'O'), ('-', 'O'), ('pressure', 'O'), ('product', 'O'), ('with', 'O'), ('a', 'O'), ('minor', 'O'), ('contribution', 'O'), ('of', 'O'), ('end', 'O'), ('-', 'O'), ('diastolic', 'O'), ('volume', 'O'), (',', 'O'), ('while', 'O'), ('epinephrine', 'O'), ('-', 'O'), ('induced', 'O'), ('ischemia', 'B'), ('was', 'O'), ('characterized', 'O'), ('by', 'O'), ('a', 'O'), ('marked', 'O'), ('increase', 'O'), ('in', 'O'), ('contractility', 'O'), ('and', 'O'), ('a', 'O'), ('less', 'O'), ('pronounced', 'O'), ('increase', 'O'), ('in', 'O'), ('heart', 'O'), ('rate', 'O'), ('and', 'O'), ('rate', 'O'), ('-', 'O'), ('pressure', 'O'), ('product', 'O'), ('.', 'O'))"
"These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .","(('These', 'O'), ('findings', 'O'), ('indicate', 'O'), ('that', 'O'), ('ischemia', 'B'), ('produced', 'O'), ('by', 'O'), ('epinephrine', 'O'), (',', 'O'), ('as', 'O'), ('may', 'O'), ('occur', 'O'), ('during', 'O'), ('states', 'O'), ('of', 'O'), ('emotional', 'O'), ('distress', 'O'), (',', 'O'), ('has', 'O'), ('a', 'O'), ('mechanism', 'O'), ('distinct', 'O'), ('from', 'O'), ('that', 'O'), ('due', 'O'), ('to', 'O'), ('physical', 'O'), ('exertion', 'O'), ('.', 'O'))"
"In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .","(('In', 'O'), ('early', 'O'), ('clinical', 'O'), ('studies', 'O'), ('with', 'O'), ('CB', 'O'), ('3717', 'O'), (',', 'O'), ('activity', 'O'), ('has', 'O'), ('been', 'O'), ('seen', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('ovarian', 'B'), ('cancer', 'I'), (',', 'O'), ('hepatoma', 'B'), (',', 'O'), ('and', 'O'), ('mesothelioma', 'B'), ('.', 'O'))"
"Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .","(('Toxicities', 'B'), ('included', 'O'), ('hepatotoxicity', 'B'), (',', 'O'), ('malaise', 'B'), (',', 'O'), ('and', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .,"(('Preliminary', 'O'), ('results', 'O'), ('at', 'O'), ('400', 'O'), ('and', 'O'), ('500', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('suggest', 'O'), ('that', 'O'), ('a', 'O'), ('reduction', 'O'), ('in', 'O'), ('nephrotoxicity', 'B'), ('may', 'O'), ('have', 'O'), ('been', 'O'), ('achieved', 'O'), ('with', 'O'), ('only', 'O'), ('1', 'O'), ('instance', 'O'), ('of', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('in', 'O'), ('10', 'O'), ('patients', 'O'), ('.', 'O'))"
Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .,"(('Type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('after', 'O'), ('needle', 'O'), ('-', 'O'), ('stick', 'O'), ('exposure', 'O'), (':', 'O'), ('prevention', 'O'), ('with', 'O'), ('hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('.', 'O'))"
"Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .","(('Hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('(', 'O'), ('HBIG', 'O'), (')', 'O'), ('and', 'O'), ('immune', 'O'), ('serum', 'O'), ('globulin', 'O'), ('(', 'O'), ('ISG', 'O'), (')', 'O'), ('were', 'O'), ('examined', 'O'), ('in', 'O'), ('a', 'O'), ('randomized', 'O'), (',', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('trial', 'O'), ('to', 'O'), ('assess', 'O'), ('their', 'O'), ('relative', 'O'), ('efficacies', 'O'), ('in', 'O'), ('preventing', 'O'), ('type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('after', 'O'), ('needle', 'O'), ('-', 'O'), ('stick', 'O'), ('exposure', 'O'), ('to', 'O'), ('hepatitis', 'O'), ('B', 'O'), ('surface', 'O'), ('antigen', 'O'), ('(', 'O'), ('HBsAG', 'O'), (')', 'O'), ('-', 'O'), ('positive', 'O'), ('donors', 'O'), ('.', 'O'))"
"Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .","(('Clinical', 'O'), ('hepatitis', 'B'), ('developed', 'O'), ('in', 'O'), ('1', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('of', 'O'), ('HBIG', 'O'), ('and', 'O'), ('in', 'O'), ('5', 'O'), ('.', 'O'), ('9', 'O'), ('%', 'O'), ('of', 'O'), ('ISG', 'O'), ('recipients', 'O'), ('(', 'O'), ('P', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('016', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('seroconversion', 'O'), ('(', 'O'), ('anti', 'O'), ('-', 'O'), ('HBs', 'O'), (')', 'O'), ('occurred', 'O'), ('in', 'O'), ('5', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('and', 'O'), ('20', 'O'), ('.', 'O'), ('7', 'O'), ('%', 'O'), ('of', 'O'), ('them', 'O'), ('respectively', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .,"(('Hepatitis', 'B'), ('B', 'I'), ('immune', 'O'), ('globulin', 'O'), ('remained', 'O'), ('significantly', 'O'), ('superior', 'O'), ('to', 'O'), ('ISG', 'O'), ('in', 'O'), ('preventing', 'O'), ('type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('even', 'O'), ('when', 'O'), ('the', 'O'), ('analysis', 'O'), ('was', 'O'), ('confined', 'O'), ('to', 'O'), ('these', 'O'), ('two', 'O'), ('high', 'O'), ('-', 'O'), ('risk', 'O'), ('subgroups', 'O'), ('.', 'O'))"
The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included .,"(('The', 'O'), ('efficacy', 'O'), ('of', 'O'), ('ISG', 'O'), ('in', 'O'), ('preventing', 'O'), ('type', 'B'), ('B', 'I'), ('hepatitis', 'I'), ('cannot', 'O'), ('be', 'O'), ('ascertained', 'O'), ('because', 'O'), ('a', 'O'), ('true', 'O'), ('placebo', 'O'), ('group', 'O'), ('was', 'O'), ('not', 'O'), ('included', 'O'), ('.', 'O'))"
Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .,"(('Production', 'O'), ('of', 'O'), ('autochthonous', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('in', 'O'), ('Lobund', 'O'), ('-', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('by', 'O'), ('treatments', 'O'), ('with', 'O'), ('N', 'O'), ('-', 'O'), ('nitroso', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methylurea', 'O'), ('and', 'O'), ('testosterone', 'O'), ('.', 'O'))"
"More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .","(('More', 'O'), ('than', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('Lobund', 'O'), ('-', 'O'), ('Wistar', 'O'), ('(', 'O'), ('L', 'O'), ('-', 'O'), ('W', 'O'), (')', 'O'), ('strain', 'O'), ('rats', 'O'), ('developed', 'O'), ('large', 'O'), (',', 'O'), ('palpable', 'O'), ('prostate', 'B'), ('adenocarcinomas', 'I'), ('(', 'O'), ('PAs', 'B'), (')', 'O'), ('following', 'O'), ('treatments', 'O'), ('with', 'O'), ('N', 'O'), ('-', 'O'), ('nitroso', 'O'), ('-', 'O'), ('N', 'O'), ('-', 'O'), ('methylurea', 'O'), ('(', 'O'), ('CAS', 'O'), (':', 'O'), ('684', 'O'), ('-', 'O'), ('93', 'O'), ('-', 'O'), ('5', 'O'), (')', 'O'), ('and', 'O'), ('testosterone', 'O'), ('propionate', 'O'), ('[', 'O'), ('(', 'O'), ('TP', 'O'), (')', 'O'), ('CAS', 'O'), (':', 'O'), ('57', 'O'), ('-', 'O'), ('85', 'O'), ('-', 'O'), ('2', 'O'), (']', 'O'), (',', 'O'), ('and', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('tumor', 'B'), ('-', 'O'), ('bearing', 'O'), ('rats', 'O'), ('manifested', 'O'), ('metastatic', 'O'), ('lesions', 'O'), ('.', 'O'))"
"In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .","(('In', 'O'), ('L', 'O'), ('-', 'O'), ('W', 'O'), ('rats', 'O'), (',', 'O'), ('TP', 'O'), ('acted', 'O'), ('as', 'O'), ('a', 'O'), ('tumor', 'B'), ('enhancement', 'O'), ('agent', 'O'), (',', 'O'), ('with', 'O'), ('primary', 'O'), ('emphasis', 'O'), ('on', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('.', 'O'))"
Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .,"(('Relative', 'O'), ('efficacy', 'O'), ('and', 'O'), ('toxicity', 'B'), ('of', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('tobramycin', 'O'), ('in', 'O'), ('oncology', 'O'), ('patients', 'O'), ('.', 'O'))"
We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .,"(('We', 'O'), ('prospectively', 'O'), ('compared', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('netilmicin', 'O'), ('sulfate', 'O'), ('or', 'O'), ('tobramycin', 'O'), ('sulfate', 'O'), ('in', 'O'), ('conjunction', 'O'), ('with', 'O'), ('piperacillin', 'O'), ('sodium', 'O'), ('in', 'O'), ('118', 'O'), ('immunocompromised', 'O'), ('patients', 'O'), ('with', 'O'), ('presumed', 'O'), ('severe', 'O'), ('infections', 'B'), ('.', 'O'))"
Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .,"(('Nephrotoxicity', 'B'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('similar', 'O'), ('proportion', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('tobramycin', 'O'), ('(', 'O'), ('17', 'O'), ('%', 'O'), ('vs', 'O'), ('11', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .,"(('Ototoxicity', 'B'), ('occurred', 'O'), ('in', 'O'), ('four', 'O'), ('(', 'O'), ('9', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('42', 'O'), ('netilmicin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('and', 'O'), ('in', 'O'), ('12', 'O'), ('(', 'O'), ('22', 'O'), ('%', 'O'), (')', 'O'), ('of', 'O'), ('54', 'O'), ('tobramycin', 'O'), ('and', 'O'), ('piperacillin', 'O'), ('-', 'O'), ('treated', 'O'), ('patients', 'O'), ('.', 'O'))"
We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('aminoglycoside', 'O'), ('-', 'O'), ('associated', 'O'), ('ototoxicity', 'B'), ('was', 'O'), ('less', 'O'), ('severe', 'O'), ('and', 'O'), ('more', 'O'), ('often', 'O'), ('reversible', 'O'), ('with', 'O'), ('netilmicin', 'O'), ('than', 'O'), ('with', 'O'), ('tobramycin', 'O'), ('.', 'O'))"
Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .,"(('Urinary', 'O'), ('enzymes', 'O'), ('and', 'O'), ('protein', 'O'), ('patterns', 'O'), ('as', 'O'), ('indicators', 'O'), ('of', 'O'), ('injury', 'B'), ('to', 'I'), ('different', 'I'), ('regions', 'I'), ('of', 'I'), ('the', 'I'), ('kidney', 'I'), ('.', 'O'))"
"Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .","(('Acute', 'B'), ('experimental', 'I'), ('models', 'I'), ('of', 'I'), ('renal', 'I'), ('damage', 'I'), ('to', 'O'), ('the', 'O'), ('proximal', 'O'), ('tubular', 'O'), (',', 'O'), ('glomerular', 'O'), (',', 'O'), ('and', 'O'), ('papillary', 'O'), ('regions', 'O'), ('of', 'O'), ('the', 'O'), ('rat', 'O'), ('were', 'O'), ('produced', 'O'), ('by', 'O'), ('administration', 'O'), ('of', 'O'), ('hexachloro', 'O'), ('-', 'O'), ('1', 'O'), (':', 'O'), ('3', 'O'), ('-', 'O'), ('butadiene', 'O'), ('(', 'O'), ('HCBD', 'O'), (')', 'O'), (',', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('PAN', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('2', 'O'), ('-', 'O'), ('bromoethylamine', 'O'), ('(', 'O'), ('BEA', 'O'), (')', 'O'), (',', 'O'), ('respectively', 'O'), ('.', 'O'))"
"Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .","(('Several', 'O'), ('routine', 'O'), ('indicators', 'O'), ('of', 'O'), ('nephrotoxicity', 'B'), (',', 'O'), ('the', 'O'), ('enzymes', 'O'), ('alkaline', 'O'), ('phosphatase', 'O'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('acetyl', 'O'), ('-', 'O'), ('beta', 'O'), ('-', 'O'), ('glucosaminidase', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('molecular', 'O'), ('weight', 'O'), ('of', 'O'), ('protein', 'B'), ('excretion', 'I'), ('were', 'O'), ('determined', 'O'), ('on', 'O'), ('urine', 'O'), ('samples', 'O'), ('.', 'O'))"
Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .,"(('Tubular', 'O'), ('damage', 'O'), ('produced', 'O'), ('by', 'O'), ('HCBD', 'O'), ('or', 'O'), ('BEA', 'O'), ('was', 'O'), ('discriminated', 'O'), ('both', 'O'), ('quantitatively', 'O'), ('and', 'O'), ('qualitatively', 'O'), ('from', 'O'), ('glomerular', 'B'), ('damage', 'I'), ('produced', 'O'), ('by', 'O'), ('PAN', 'O'), ('.', 'O'))"
"In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('protein', 'B'), ('excretion', 'I'), ('in', 'O'), ('tubular', 'O'), ('damage', 'O'), ('was', 'O'), ('raised', 'O'), ('only', 'O'), ('slightly', 'O'), ('and', 'O'), ('characterized', 'O'), ('by', 'O'), ('excretion', 'B'), ('of', 'I'), ('proteins', 'I'), ('of', 'O'), ('a', 'O'), ('wide', 'O'), ('range', 'O'), ('of', 'O'), ('molecular', 'O'), ('weights', 'O'), ('.', 'O'))"
It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .,"(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('both', 'O'), ('selective', 'O'), ('urinary', 'O'), ('enzymes', 'O'), ('and', 'O'), ('the', 'O'), ('molecular', 'O'), ('weight', 'O'), ('pattern', 'O'), ('of', 'O'), ('urinary', 'O'), ('proteins', 'O'), ('can', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('provide', 'O'), ('diagnostic', 'O'), ('information', 'O'), ('about', 'O'), ('the', 'O'), ('possible', 'O'), ('site', 'O'), ('of', 'O'), ('renal', 'B'), ('damage', 'I'), ('.', 'O'))"
"Twenty - six cases of Reye syndrome from The Children ' s Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .","(('Twenty', 'O'), ('-', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('Reye', 'B'), ('syndrome', 'I'), ('from', 'O'), ('The', 'O'), ('Children', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), (',', 'O'), ('Camperdown', 'O'), (',', 'O'), ('Australia', 'O'), (',', 'O'), ('occurring', 'O'), ('between', 'O'), ('1973', 'O'), ('and', 'O'), ('1982', 'O'), ('were', 'O'), ('reviewed', 'O'), ('.', 'O'))"
"Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .","(('Of', 'O'), ('these', 'O'), (',', 'O'), ('20', 'O'), ('cases', 'O'), ('met', 'O'), ('the', 'O'), ('US', 'O'), ('Public', 'O'), ('Health', 'O'), ('Service', 'O'), ('Centers', 'O'), ('for', 'O'), ('Disease', 'O'), ('Control', 'O'), ('criteria', 'O'), ('for', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('Reye', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .,"(('Pathologic', 'O'), ('confirmation', 'O'), ('of', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('Reye', 'B'), ('syndrome', 'I'), ('was', 'O'), ('accomplished', 'O'), ('in', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('cases', 'O'), ('.', 'O'))"
"The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('Reye', 'B'), ('syndrome', 'I'), ('in', 'O'), ('New', 'O'), ('South', 'O'), ('Wales', 'O'), (',', 'O'), ('Australia', 'O'), (',', 'O'), ('is', 'O'), ('estimated', 'O'), ('from', 'O'), ('this', 'O'), ('study', 'O'), ('to', 'O'), ('be', 'O'), ('approximately', 'O'), ('nine', 'O'), ('cases', 'O'), ('per', 'O'), ('1', 'O'), ('million', 'O'), ('children', 'O'), ('compared', 'O'), ('with', 'O'), ('recent', 'O'), ('US', 'O'), ('data', 'O'), ('of', 'O'), ('ten', 'O'), ('to', 'O'), ('20', 'O'), ('cases', 'O'), ('per', 'O'), ('1', 'O'), ('million', 'O'), ('children', 'O'), ('and', 'O'), ('three', 'O'), ('to', 'O'), ('seven', 'O'), ('cases', 'O'), ('per', 'O'), ('1', 'O'), ('million', 'O'), ('children', 'O'), ('in', 'O'), ('Great', 'O'), ('Britain', 'O'), ('.', 'O'))"
The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .,"(('The', 'O'), ('mortality', 'O'), ('for', 'O'), ('these', 'O'), ('Reye', 'B'), ('syndrome', 'I'), ('cases', 'O'), ('in', 'O'), ('Australia', 'O'), ('was', 'O'), ('45', 'O'), ('%', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('a', 'O'), ('32', 'O'), ('%', 'O'), ('case', 'O'), ('-', 'O'), ('fatality', 'O'), ('rate', 'O'), ('in', 'O'), ('the', 'O'), ('United', 'O'), ('States', 'O'), ('.', 'O'))"
"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .","(('Reye', 'B'), ('syndrome', 'I'), ('may', 'O'), ('be', 'O'), ('disappearing', 'O'), ('from', 'O'), ('Australia', 'O'), ('despite', 'O'), ('a', 'O'), ('total', 'O'), ('lack', 'O'), ('of', 'O'), ('association', 'O'), ('with', 'O'), ('salicylates', 'O'), ('or', 'O'), ('aspirin', 'O'), ('ingestion', 'O'), (',', 'O'), ('since', 'O'), ('there', 'O'), ('were', 'O'), ('no', 'O'), ('cases', 'O'), ('found', 'O'), ('at', 'O'), ('The', 'O'), ('Children', 'O'), (""'"", 'O'), ('s', 'O'), ('Hospital', 'O'), ('in', 'O'), ('1983', 'O'), (',', 'O'), ('1984', 'O'), (',', 'O'), ('or', 'O'), ('1985', 'O'), ('.', 'O'))"
Postpartum psychosis induced by bromocriptine .,"(('Postpartum', 'O'), ('psychosis', 'B'), ('induced', 'O'), ('by', 'O'), ('bromocriptine', 'O'), ('.', 'O'))"
"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .","(('Two', 'O'), ('multigravida', 'O'), ('patients', 'O'), ('with', 'O'), ('no', 'O'), ('prior', 'O'), ('psychiatric', 'B'), ('history', 'O'), ('were', 'O'), ('seen', 'O'), ('with', 'O'), ('postpartum', 'O'), ('psychosis', 'B'), (',', 'O'), ('having', 'O'), ('received', 'O'), ('bromocriptine', 'O'), ('for', 'O'), ('inhibition', 'B'), ('of', 'I'), ('lactation', 'I'), ('.', 'O'))"
Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson ' s disease .,"(('Bromocriptine', 'O'), ('given', 'O'), ('in', 'O'), ('high', 'O'), ('doses', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('psychosis', 'B'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('the', 'O'), ('drug', 'O'), ('for', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .,"(('These', 'O'), ('cases', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('bromocriptine', 'O'), ('may', 'O'), ('cause', 'O'), ('psychosis', 'B'), ('even', 'O'), ('when', 'O'), ('given', 'O'), ('in', 'O'), ('low', 'O'), ('doses', 'O'), ('.', 'O'))"
Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .,"(('Hyperglycemic', 'B'), ('acidotic', 'I'), ('coma', 'I'), ('and', 'O'), ('death', 'O'), ('in', 'O'), ('Kearns', 'B'), ('-', 'I'), ('Sayre', 'I'), ('syndrome', 'I'), ('.', 'O'))"
This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .,"(('This', 'O'), ('paper', 'O'), ('presents', 'O'), ('the', 'O'), ('clinical', 'O'), ('and', 'O'), ('metabolic', 'O'), ('findings', 'O'), ('in', 'O'), ('two', 'O'), ('young', 'O'), ('boys', 'O'), ('with', 'O'), ('long', 'O'), ('-', 'O'), ('standing', 'O'), ('Kearns', 'B'), ('-', 'I'), ('Sayre', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .","(('Following', 'O'), ('short', 'O'), ('exposure', 'O'), ('to', 'O'), ('oral', 'O'), ('prednisone', 'O'), (',', 'O'), ('both', 'O'), ('boys', 'O'), ('developed', 'O'), ('lethargy', 'B'), (',', 'O'), ('increasing', 'O'), ('somnolence', 'B'), (',', 'O'), ('polydipsia', 'B'), (',', 'O'), ('polyphagia', 'B'), (',', 'O'), ('and', 'O'), ('polyuria', 'B'), ('.', 'O'))"
"Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .","(('Both', 'O'), ('presented', 'O'), ('in', 'O'), ('the', 'O'), ('emergency', 'O'), ('room', 'O'), ('with', 'O'), ('profound', 'O'), ('coma', 'B'), (',', 'O'), ('hypotension', 'B'), (',', 'O'), ('severe', 'O'), ('hyperglycemia', 'B'), (',', 'O'), ('and', 'O'), ('acidosis', 'B'), ('.', 'O'))"
Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .,"(('Nonketotic', 'O'), ('lactic', 'B'), ('acidosis', 'I'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('one', 'O'), ('and', 'O'), ('ketosis', 'B'), ('without', 'O'), ('a', 'O'), ('known', 'O'), ('serum', 'O'), ('lactate', 'O'), ('level', 'O'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('.', 'O'))"
Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .,"(('Respiratory', 'B'), ('failure', 'I'), ('rapidly', 'O'), ('ensued', 'O'), ('and', 'O'), ('both', 'O'), ('patients', 'O'), ('expired', 'O'), ('in', 'O'), ('spite', 'O'), ('of', 'O'), ('efforts', 'O'), ('at', 'O'), ('resuscitation', 'O'), ('.', 'O'))"
We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .,"(('We', 'O'), ('believe', 'O'), ('these', 'O'), ('two', 'O'), ('cases', 'O'), ('represent', 'O'), ('a', 'O'), ('newly', 'O'), ('described', 'O'), ('and', 'O'), ('catastrophic', 'O'), ('metabolic', 'B'), ('-', 'I'), ('endocrine', 'I'), ('failure', 'I'), ('in', 'O'), ('the', 'O'), ('Kearns', 'B'), ('-', 'I'), ('Sayre', 'I'), ('syndrome', 'I'), ('.', 'O'))"
Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .,"(('Experimental', 'O'), ('cyclosporine', 'O'), ('nephrotoxicity', 'B'), (':', 'O'), ('risk', 'O'), ('of', 'O'), ('concomitant', 'O'), ('chemotherapy', 'O'), ('.', 'O'))"
The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .,"(('The', 'O'), ('role', 'O'), ('of', 'O'), ('cyclosporine', 'O'), ('(', 'O'), ('CSA', 'O'), (')', 'O'), ('alone', 'O'), ('or', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('various', 'O'), ('chemotherapeutics', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('was', 'O'), ('evaluated', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .","(('The', 'O'), ('combined', 'O'), ('administration', 'O'), ('of', 'O'), ('CSA', 'O'), ('and', 'O'), ('various', 'O'), ('chemotherapeutic', 'O'), ('drugs', 'O'), ('with', 'O'), ('a', 'O'), ('nephrotoxic', 'B'), ('potential', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('gentamicin', 'O'), ('(', 'O'), ('at', 'O'), ('therapeutic', 'O'), ('doses', 'O'), (')', 'O'), (',', 'O'), ('amphothericin', 'O'), ('B', 'O'), ('and', 'O'), ('ketoconazole', 'O'), (',', 'O'), ('which', 'O'), ('are', 'O'), ('frequently', 'O'), ('used', 'O'), ('in', 'O'), ('immunosuppressed', 'O'), ('patients', 'O'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('aggravate', 'O'), ('the', 'O'), ('CSA', 'O'), ('induced', 'O'), ('toxicity', 'B'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('model', 'O'), ('.', 'O'))"
"Gentamicin at toxic doses , however , increased CSA nephrotoxicity .","(('Gentamicin', 'O'), ('at', 'O'), ('toxic', 'O'), ('doses', 'O'), (',', 'O'), ('however', 'O'), (',', 'O'), ('increased', 'O'), ('CSA', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
"Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('nephrotoxicity', 'B'), ('induced', 'O'), ('by', 'O'), ('CSA', 'O'), ('has', 'O'), ('a', 'O'), ('different', 'O'), ('pathogenetic', 'O'), ('mechanism', 'O'), ('.', 'O'))"
"Diuretics , potassium and arrhythmias in hypertensive coronary disease .","(('Diuretics', 'O'), (',', 'O'), ('potassium', 'O'), ('and', 'O'), ('arrhythmias', 'B'), ('in', 'O'), ('hypertensive', 'B'), ('coronary', 'B'), ('disease', 'I'), ('.', 'O'))"
It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .,"(('It', 'O'), ('has', 'O'), ('been', 'O'), ('proposed', 'O'), ('that', 'O'), ('modest', 'O'), ('changes', 'O'), ('in', 'O'), ('plasma', 'O'), ('potassium', 'O'), ('can', 'O'), ('alter', 'O'), ('the', 'O'), ('tendency', 'O'), ('towards', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
"If this were so , patients with coronary artery disease might be especially susceptible .","(('If', 'O'), ('this', 'O'), ('were', 'O'), ('so', 'O'), (',', 'O'), ('patients', 'O'), ('with', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('might', 'O'), ('be', 'O'), ('especially', 'O'), ('susceptible', 'O'), ('.', 'O'))"
"Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .","(('Thus', 'O'), (',', 'O'), ('myocardial', 'O'), ('electrical', 'O'), ('excitability', 'O'), ('was', 'O'), ('measured', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('mild', 'O'), ('essential', 'O'), ('hypertension', 'B'), ('and', 'O'), ('known', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('after', 'O'), ('8', 'O'), ('weeks', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('a', 'O'), ('potassium', 'O'), ('-', 'O'), ('conserving', 'O'), ('diuretic', 'O'), ('(', 'O'), ('amiloride', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('similar', 'O'), ('period', 'O'), ('on', 'O'), ('a', 'O'), ('potassium', 'O'), ('-', 'O'), ('losing', 'O'), ('diuretic', 'O'), ('(', 'O'), ('chlorthalidone', 'O'), (')', 'O'), ('in', 'O'), ('a', 'O'), ('randomised', 'O'), ('study', 'O'), ('.', 'O'))"
"Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .","(('Compared', 'O'), ('to', 'O'), ('amiloride', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('chlorthalidone', 'O'), ('phase', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('increased', 'O'), ('frequency', 'O'), ('of', 'O'), ('ventricular', 'B'), ('ectopic', 'I'), ('beats', 'I'), ('(', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('Holter', 'O'), ('monitoring', 'O'), (')', 'O'), ('and', 'O'), ('a', 'O'), ('higher', 'O'), ('Lown', 'O'), ('grading', 'O'), (',', 'O'), ('increased', 'O'), ('upslope', 'O'), ('and', 'O'), ('duration', 'O'), ('of', 'O'), ('the', 'O'), ('monophasic', 'O'), ('action', 'O'), ('potential', 'O'), (',', 'O'), ('prolonged', 'O'), ('ventricular', 'O'), ('effective', 'O'), ('refractory', 'O'), ('period', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('electrical', 'O'), ('instability', 'O'), ('during', 'O'), ('programmed', 'O'), ('ventricular', 'O'), ('stimulation', 'O'), ('.', 'O'))"
"The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .","(('The', 'O'), ('above', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('because', 'O'), ('potassium', 'O'), ('-', 'O'), ('losing', 'O'), ('diuretic', 'O'), ('therapy', 'O'), ('can', 'O'), ('increase', 'O'), ('myocardial', 'O'), ('electrical', 'O'), ('excitability', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('ischaemic', 'B'), ('heart', 'I'), ('disease', 'I'), (',', 'O'), ('even', 'O'), ('minor', 'O'), ('falls', 'O'), ('in', 'O'), ('plasma', 'O'), ('potassium', 'O'), ('concentrations', 'O'), ('are', 'O'), ('probably', 'O'), ('best', 'O'), ('avoided', 'O'), ('in', 'O'), ('such', 'O'), ('patients', 'O'), ('.', 'O'))"
Transketolase abnormality in tolazamide - induced Wernicke ' s encephalopathy .,"(('Transketolase', 'O'), ('abnormality', 'O'), ('in', 'O'), ('tolazamide', 'O'), ('-', 'O'), ('induced', 'O'), ('Wernicke', 'B'), (""'"", 'I'), ('s', 'I'), ('encephalopathy', 'I'), ('.', 'O'))"
"We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .","(('We', 'O'), ('studied', 'O'), ('a', 'O'), ('thiamine', 'O'), ('-', 'O'), ('dependent', 'O'), ('enzyme', 'O'), (',', 'O'), ('transketolase', 'O'), (',', 'O'), ('from', 'O'), ('fibroblasts', 'O'), ('of', 'O'), ('a', 'O'), ('diabetic', 'B'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('Wernicke', 'B'), (""'"", 'I'), ('s', 'I'), ('encephalopathy', 'I'), ('when', 'O'), ('treated', 'O'), ('with', 'O'), ('tolazamide', 'O'), (',', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('delineate', 'O'), ('if', 'O'), ('this', 'O'), ('patient', 'O'), ('also', 'O'), ('had', 'O'), ('transketolase', 'O'), ('abnormality', 'O'), ('[', 'O'), ('high', 'O'), ('Km', 'O'), ('for', 'O'), ('thiamine', 'O'), ('pyrophosphate', 'O'), ('(', 'O'), ('TPP', 'O'), (')', 'O'), (']', 'O'), (',', 'O'), ('as', 'O'), ('previously', 'O'), ('reported', 'O'), ('in', 'O'), ('postalcoholic', 'O'), ('Wernicke', 'B'), ('-', 'I'), ('Korsakoff', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke ' s encephalopathy and from four normal controls .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('this', 'O'), ('patient', 'O'), (',', 'O'), ('we', 'O'), ('also', 'O'), ('studied', 'O'), ('this', 'O'), ('enzyme', 'O'), ('from', 'O'), ('three', 'O'), ('diabetic', 'B'), ('kindreds', 'O'), ('without', 'O'), ('any', 'O'), ('history', 'O'), ('of', 'O'), ('Wernicke', 'B'), (""'"", 'I'), ('s', 'I'), ('encephalopathy', 'I'), ('and', 'O'), ('from', 'O'), ('four', 'O'), ('normal', 'O'), ('controls', 'O'), ('.', 'O'))"
We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke ' s encephalopathy had abnormal transketolase as determined by its Km for TPP .,"(('We', 'O'), ('found', 'O'), ('that', 'O'), ('the', 'O'), ('above', 'O'), ('-', 'O'), ('mentioned', 'O'), ('patient', 'O'), ('and', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('diabetic', 'B'), ('kindreds', 'O'), ('with', 'O'), ('no', 'O'), ('history', 'O'), ('of', 'O'), ('Wernicke', 'B'), (""'"", 'I'), ('s', 'I'), ('encephalopathy', 'I'), ('had', 'O'), ('abnormal', 'O'), ('transketolase', 'O'), ('as', 'O'), ('determined', 'O'), ('by', 'O'), ('its', 'O'), ('Km', 'O'), ('for', 'O'), ('TPP', 'O'), ('.', 'O'))"
These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke ' s encephalopathy from the standpoint of transketolase abnormality .,"(('These', 'O'), ('data', 'O'), ('suggest', 'O'), ('a', 'O'), ('similarity', 'O'), ('between', 'O'), ('postalcoholic', 'O'), ('Wernicke', 'B'), ('-', 'I'), ('Korsakoff', 'I'), ('syndrome', 'I'), ('and', 'O'), ('the', 'O'), ('patient', 'O'), ('with', 'O'), ('tolazamide', 'O'), ('-', 'O'), ('induced', 'O'), ('Wernicke', 'B'), (""'"", 'I'), ('s', 'I'), ('encephalopathy', 'I'), ('from', 'O'), ('the', 'O'), ('standpoint', 'O'), ('of', 'O'), ('transketolase', 'O'), ('abnormality', 'O'), ('.', 'O'))"
Bradycardia due to trihexyphenidyl hydrochloride .,"(('Bradycardia', 'B'), ('due', 'O'), ('to', 'O'), ('trihexyphenidyl', 'O'), ('hydrochloride', 'O'), ('.', 'O'))"
"A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .","(('A', 'O'), ('chronic', 'O'), ('schizophrenic', 'B'), ('patient', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('an', 'O'), ('anticholinergic', 'O'), ('drug', 'O'), (',', 'O'), ('trihexyphenidyl', 'O'), ('hydrochloride', 'O'), ('.', 'O'))"
"The patient developed , paradoxically , sinus bradycardia .","(('The', 'O'), ('patient', 'O'), ('developed', 'O'), (',', 'O'), ('paradoxically', 'O'), (',', 'O'), ('sinus', 'O'), ('bradycardia', 'B'), ('.', 'O'))"
This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .,"(('This', 'O'), ('antidyskinetic', 'O'), ('drug', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('clinical', 'O'), ('psychiatric', 'B'), ('practice', 'O'), ('and', 'O'), ('physicians', 'O'), ('should', 'O'), ('be', 'O'), ('aware', 'O'), ('of', 'O'), ('this', 'O'), ('side', 'O'), ('effect', 'O'), ('.', 'O'))"
Post - operative rigidity after fentanyl administration .,"(('Post', 'O'), ('-', 'O'), ('operative', 'O'), ('rigidity', 'B'), ('after', 'O'), ('fentanyl', 'O'), ('administration', 'O'), ('.', 'O'))"
A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('thoraco', 'O'), ('-', 'O'), ('abdominal', 'O'), ('rigidity', 'B'), ('leading', 'O'), ('to', 'O'), ('respiratory', 'B'), ('failure', 'I'), ('is', 'O'), ('described', 'O'), ('in', 'O'), ('the', 'O'), ('post', 'O'), ('-', 'O'), ('operative', 'O'), ('period', 'O'), ('in', 'O'), ('an', 'O'), ('elderly', 'O'), ('patient', 'O'), ('who', 'O'), ('received', 'O'), ('a', 'O'), ('moderate', 'O'), ('dose', 'O'), ('of', 'O'), ('fentanyl', 'O'), ('.', 'O'))"
The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .,"(('The', 'O'), ('present', 'O'), ('work', 'O'), ('has', 'O'), ('been', 'O'), ('planned', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('elucidate', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('phenobarbital', 'O'), ('(', 'O'), ('PB', 'O'), (':', 'O'), ('15', 'O'), ('mg', 'O'), ('per', 'O'), ('rat', 'O'), ('of', 'O'), ('ingested', 'O'), ('dose', 'O'), (')', 'O'), ('on', 'O'), ('carcinogenesis', 'B'), ('when', 'O'), ('it', 'O'), ('is', 'O'), ('administered', 'O'), ('simultaneously', 'O'), ('with', 'O'), ('diethylnitrosamine', 'O'), ('(', 'O'), ('DEN', 'O'), (':', 'O'), ('10', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('.', 'O'))"
"In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .","(('In', 'O'), ('DEN', 'O'), ('+', 'O'), ('PB', 'O'), ('treated', 'O'), ('rats', 'O'), (',', 'O'), ('the', 'O'), ('survival', 'O'), ('was', 'O'), ('prolonged', 'O'), ('and', 'O'), ('the', 'O'), ('tumor', 'B'), ('incidence', 'O'), ('decreased', 'O'), ('as', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('results', 'O'), ('obtained', 'O'), ('by', 'O'), ('DEN', 'O'), ('alone', 'O'), ('.', 'O'))"
"It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .","(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('PB', 'O'), (',', 'O'), ('which', 'O'), ('promotes', 'O'), ('carcinogenesis', 'B'), ('when', 'O'), ('administered', 'O'), ('after', 'O'), ('the', 'O'), ('DEN', 'O'), ('treatment', 'O'), (',', 'O'), ('reduces', 'O'), ('the', 'O'), ('carcinogen', 'O'), ('effect', 'O'), ('when', 'O'), ('given', 'O'), ('simultaneously', 'O'), ('with', 'O'), ('DEN', 'O'), ('.', 'O'))"
This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .,"(('This', 'O'), (""'"", 'O'), ('anti', 'O'), ('-', 'O'), ('carcinogen', 'O'), (""'"", 'O'), ('effect', 'O'), ('acts', 'O'), ('on', 'O'), ('the', 'O'), ('initiation', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('on', 'O'), ('the', 'O'), ('promotion', 'O'), ('of', 'O'), ('the', 'O'), ('precancerous', 'B'), ('lesions', 'I'), ('.', 'O'))"
Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .,"(('Bilateral', 'B'), ('optic', 'I'), ('neuropathy', 'I'), ('due', 'O'), ('to', 'O'), ('combined', 'O'), ('ethambutol', 'O'), ('and', 'O'), ('isoniazid', 'O'), ('treatment', 'O'), ('.', 'O'))"
A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .,"(('A', 'O'), ('bilateral', 'B'), ('retrobulbar', 'I'), ('neuropathy', 'I'), ('with', 'O'), ('an', 'O'), ('unusual', 'O'), ('central', 'O'), ('bitemporal', 'O'), ('hemianopic', 'O'), ('scotoma', 'B'), ('was', 'O'), ('found', 'O'), ('.', 'O'))"
The hazards of optic nerve toxicity due to ethambutol are known .,"(('The', 'O'), ('hazards', 'O'), ('of', 'O'), ('optic', 'O'), ('nerve', 'O'), ('toxicity', 'B'), ('due', 'O'), ('to', 'O'), ('ethambutol', 'O'), ('are', 'O'), ('known', 'O'), ('.', 'O'))"
Vancomycin was curative in 95 % of 43 patients with proven infection .,"(('Vancomycin', 'O'), ('was', 'O'), ('curative', 'O'), ('in', 'O'), ('95', 'O'), ('%', 'O'), ('of', 'O'), ('43', 'O'), ('patients', 'O'), ('with', 'O'), ('proven', 'O'), ('infection', 'B'), ('.', 'O'))"
"Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .","(('Reactions', 'O'), ('included', 'O'), ('thrombophlebitis', 'B'), ('(', 'O'), ('20', 'O'), ('of', 'O'), ('54', 'O'), ('patients', 'O'), (')', 'O'), (',', 'O'), ('rash', 'B'), ('(', 'O'), ('4', 'O'), ('of', 'O'), ('54', 'O'), (')', 'O'), (',', 'O'), ('nephrotoxicity', 'B'), ('(', 'O'), ('4', 'O'), ('of', 'O'), ('50', 'O'), (')', 'O'), (',', 'O'), ('proteinuria', 'B'), ('(', 'O'), ('1', 'O'), ('of', 'O'), ('50', 'O'), (')', 'O'), ('and', 'O'), ('ototoxicity', 'B'), ('(', 'O'), ('1', 'O'), ('of', 'O'), ('11', 'O'), ('patients', 'O'), ('tested', 'O'), ('by', 'O'), ('audiometry', 'O'), (')', 'O'), ('.', 'O'))"
Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .,"(('Thrombophlebitis', 'B'), ('occurred', 'O'), ('only', 'O'), ('with', 'O'), ('infusion', 'O'), ('through', 'O'), ('peripheral', 'O'), ('cannulae', 'O'), (';', 'O'), ('nephrotoxicity', 'B'), ('and', 'O'), ('ototoxicity', 'B'), ('were', 'O'), ('confined', 'O'), ('to', 'O'), ('patients', 'O'), ('receiving', 'O'), ('an', 'O'), ('aminoglycoside', 'O'), ('plus', 'O'), ('vancomycin', 'O'), ('.', 'O'))"
"We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .","(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('vancomycin', 'O'), (',', 'O'), ('administered', 'O'), ('appropriately', 'O'), (',', 'O'), ('constitutes', 'O'), ('safe', 'O'), (',', 'O'), ('effective', 'O'), ('therapy', 'O'), ('for', 'O'), ('infections', 'B'), ('caused', 'O'), ('by', 'O'), ('susceptible', 'O'), ('bacteria', 'O'), ('.', 'O'))"
Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .,"(('Factors', 'O'), ('associated', 'O'), ('with', 'O'), ('nephrotoxicity', 'B'), ('and', 'O'), ('clinical', 'O'), ('outcome', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('amikacin', 'O'), ('.', 'O'))"
Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .,"(('Data', 'O'), ('from', 'O'), ('60', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('amikacin', 'O'), ('were', 'O'), ('analyzed', 'O'), ('for', 'O'), ('factors', 'O'), ('associated', 'O'), ('with', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
"When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .","(('When', 'O'), ('the', 'O'), ('parameters', 'O'), ('were', 'O'), ('examined', 'O'), ('individually', 'O'), (',', 'O'), ('duration', 'O'), ('of', 'O'), ('therapy', 'O'), ('and', 'O'), ('total', 'O'), ('AUC', 'O'), ('correlated', 'O'), ('significantly', 'O'), ('(', 'O'), ('P', 'O'), ('less', 'O'), ('than', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('with', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
"Based on this model and on Bayes ' theorem , the predictive accuracy of identifying "" nephrotoxic "" patients increased from 0 . 17 to 0 . 39 .","(('Based', 'O'), ('on', 'O'), ('this', 'O'), ('model', 'O'), ('and', 'O'), ('on', 'O'), ('Bayes', 'O'), (""'"", 'O'), ('theorem', 'O'), (',', 'O'), ('the', 'O'), ('predictive', 'O'), ('accuracy', 'O'), ('of', 'O'), ('identifying', 'O'), ('""', 'O'), ('nephrotoxic', 'B'), ('""', 'O'), ('patients', 'O'), ('increased', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('17', 'O'), ('to', 'O'), ('0', 'O'), ('.', 'O'), ('39', 'O'), ('.', 'O'))"
Cardiac toxicity of 5 - fluorouracil .,"(('Cardiac', 'B'), ('toxicity', 'I'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('fluorouracil', 'O'), ('.', 'O'))"
Report of a case of spontaneous angina .,"(('Report', 'O'), ('of', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('spontaneous', 'O'), ('angina', 'B'), ('.', 'O'))"
We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('colon', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('liver', 'O'), ('metastasis', 'B'), ('who', 'O'), ('presented', 'O'), ('chest', 'B'), ('pain', 'I'), ('after', 'O'), ('5', 'O'), ('-', 'O'), ('fluorouracil', 'O'), ('(', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), (')', 'O'), ('administration', 'O'), ('.', 'O'))"
"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal ' s angina , and chest pain promptly resolved with nifedipine .","(('Clinical', 'O'), ('electrocardiographic', 'O'), ('evolution', 'O'), ('was', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('observed', 'O'), ('in', 'O'), ('Prinzmetal', 'B'), (""'"", 'I'), ('s', 'I'), ('angina', 'I'), (',', 'O'), ('and', 'O'), ('chest', 'B'), ('pain', 'I'), ('promptly', 'O'), ('resolved', 'O'), ('with', 'O'), ('nifedipine', 'O'), ('.', 'O'))"
"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .","(('These', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('coronary', 'B'), ('spasm', 'I'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('cardiotoxicity', 'B'), ('due', 'O'), ('to', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('calcium', 'O'), ('antagonists', 'O'), ('may', 'O'), ('probably', 'O'), ('be', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('prevention', 'O'), ('or', 'O'), ('treatment', 'O'), ('of', 'O'), ('5', 'O'), ('-', 'O'), ('FU', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .,"(('Dose', 'O'), ('-', 'O'), ('related', 'O'), ('beneficial', 'O'), ('and', 'O'), ('adverse', 'O'), ('effects', 'O'), ('of', 'O'), ('dietary', 'O'), ('corticosterone', 'O'), ('on', 'O'), ('organophosphorus', 'O'), ('-', 'O'), ('induced', 'O'), ('delayed', 'O'), ('neuropathy', 'B'), ('in', 'O'), ('chickens', 'O'), ('.', 'O'))"
Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .,"(('Supplemented', 'O'), ('diets', 'O'), ('were', 'O'), ('continued', 'O'), ('until', 'O'), ('clinical', 'O'), ('signs', 'O'), ('and', 'O'), ('lesions', 'O'), ('of', 'O'), ('delayed', 'O'), ('neuropathy', 'B'), ('appeared', 'O'), ('.', 'O'))"
"Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .","(('Although', 'O'), ('low', 'O'), ('concentrations', 'O'), ('(', 'O'), ('less', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('50', 'O'), ('ppm', 'O'), (')', 'O'), ('of', 'O'), ('corticosterone', 'O'), ('had', 'O'), ('beneficial', 'O'), ('effects', 'O'), ('on', 'O'), ('TOTP', 'O'), ('-', 'O'), ('induced', 'O'), ('neuropathy', 'B'), (',', 'O'), ('greater', 'O'), ('than', 'O'), ('or', 'O'), ('equal', 'O'), ('to', 'O'), ('200', 'O'), ('ppm', 'O'), ('exacerbated', 'O'), ('clinical', 'O'), ('signs', 'O'), ('in', 'O'), ('chickens', 'O'), ('given', 'O'), ('either', 'O'), ('TOTP', 'O'), ('or', 'O'), ('DFP', 'O'), ('.', 'O'))"
Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .,"(('Amiodarone', 'O'), ('has', 'O'), ('proved', 'O'), ('very', 'O'), ('effective', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('otherwise', 'O'), ('resistant', 'O'), ('cardiac', 'O'), ('tachyarrhythmias', 'B'), ('.', 'O'))"
A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .,"(('A', 'O'), ('patient', 'O'), ('with', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('due', 'O'), ('to', 'O'), ('amiodarone', 'O'), ('treatment', 'O'), ('is', 'O'), ('presented', 'O'), ('below', 'O'), ('and', 'O'), ('a', 'O'), ('review', 'O'), ('of', 'O'), ('the', 'O'), ('hepatotoxicity', 'B'), ('of', 'O'), ('amiodarone', 'O'), ('is', 'O'), ('given', 'O'), ('.', 'O'))"
"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .","(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('solid', 'O'), ('evidence', 'O'), ('exists', 'O'), ('of', 'O'), ('hepatic', 'B'), ('injury', 'I'), ('due', 'O'), ('to', 'O'), ('amiodarone', 'O'), ('treatment', 'O'), (',', 'O'), ('including', 'O'), ('steatosis', 'B'), (',', 'O'), ('alterations', 'O'), ('resembling', 'O'), ('alcoholic', 'B'), ('hepatitis', 'I'), (',', 'O'), ('cholestatic', 'B'), ('hepatitis', 'I'), ('and', 'O'), ('micronodular', 'O'), ('cirrhosis', 'B'), ('of', 'I'), ('the', 'I'), ('liver', 'I'), ('.', 'O'))"
Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .,"(('Therapy', 'O'), ('should', 'O'), ('be', 'O'), ('discontinued', 'O'), ('on', 'O'), ('the', 'O'), ('suspicion', 'O'), ('of', 'O'), ('cholestatic', 'B'), ('injury', 'I'), ('or', 'O'), ('hepatomegaly', 'B'), ('.', 'O'))"
Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .,"(('Promotional', 'O'), ('effects', 'O'), ('of', 'O'), ('testosterone', 'O'), ('and', 'O'), ('dietary', 'O'), ('fat', 'O'), ('on', 'O'), ('prostate', 'O'), ('carcinogenesis', 'B'), ('in', 'O'), ('genetically', 'O'), ('susceptible', 'O'), ('rats', 'O'), ('.', 'O'))"
"Germfree ( GF ) Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .","(('Germfree', 'O'), ('(', 'O'), ('GF', 'O'), (')', 'O'), ('Lobund', 'O'), ('strain', 'O'), ('Wistar', 'O'), ('(', 'O'), ('LW', 'O'), (')', 'O'), ('rats', 'O'), (',', 'O'), ('fed', 'O'), ('vegetable', 'O'), ('diet', 'O'), ('L', 'O'), ('-', 'O'), ('485', 'O'), (',', 'O'), ('have', 'O'), ('developed', 'O'), ('prostate', 'B'), ('adenocarcinomas', 'I'), ('spontaneously', 'O'), ('(', 'O'), ('10', 'O'), ('%', 'O'), ('incidence', 'O'), (')', 'O'), ('at', 'O'), ('average', 'O'), ('age', 'O'), ('34', 'O'), ('months', 'O'), ('.', 'O'))"
"Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .","(('Conventional', 'O'), ('LW', 'O'), ('rats', 'O'), (',', 'O'), ('implanted', 'O'), ('with', 'O'), ('testosterone', 'O'), ('at', 'O'), ('age', 'O'), ('4', 'O'), ('months', 'O'), (',', 'O'), ('developed', 'O'), ('a', 'O'), ('higher', 'O'), ('incidence', 'O'), ('of', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('after', 'O'), ('an', 'O'), ('average', 'O'), ('interval', 'O'), ('of', 'O'), ('14', 'O'), ('months', 'O'), (':', 'O'), ('24', 'O'), ('%', 'O'), ('had', 'O'), ('developed', 'O'), ('gross', 'O'), ('tumors', 'B'), (',', 'O'), ('and', 'O'), ('40', 'O'), ('%', 'O'), ('when', 'O'), ('it', 'O'), ('included', 'O'), ('microscopic', 'O'), ('tumors', 'B'), ('.', 'O'))"
"Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .","(('Preliminary', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('testosterone', 'O'), ('-', 'O'), ('treated', 'O'), ('LW', 'O'), ('rats', 'O'), ('that', 'O'), ('were', 'O'), ('fed', 'O'), ('the', 'O'), ('same', 'O'), ('diet', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('supplemented', 'O'), ('with', 'O'), ('corn', 'O'), ('oil', 'O'), ('up', 'O'), ('to', 'O'), ('20', 'O'), ('%', 'O'), ('fat', 'O'), (',', 'O'), ('developed', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('after', 'O'), ('intervals', 'O'), ('of', 'O'), ('6', 'O'), ('-', 'O'), ('12', 'O'), ('months', 'O'), ('.', 'O'))"
Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .,"(('Aged', 'O'), ('GF', 'O'), ('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('(', 'O'), ('SD', 'O'), (')', 'O'), ('rats', 'O'), ('have', 'O'), ('not', 'O'), ('developed', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('spontaneously', 'O'), ('.', 'O'))"
Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .,"(('Experimental', 'O'), ('designs', 'O'), ('should', 'O'), ('consider', 'O'), ('genetic', 'O'), ('susceptibility', 'O'), ('as', 'O'), ('a', 'O'), ('basic', 'O'), ('prerequisite', 'O'), ('for', 'O'), ('studies', 'O'), ('on', 'O'), ('experimental', 'O'), ('prostate', 'B'), ('cancer', 'I'), ('.', 'O'))"
Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .,"(('Significant', 'O'), ('QTC', 'B'), ('prolongation', 'I'), ('occurred', 'O'), ('in', 'O'), ('30', 'O'), ('seconds', 'O'), ('to', 'O'), ('one', 'O'), ('minute', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('marked', 'O'), ('hypotension', 'B'), ('and', 'O'), ('elevation', 'O'), ('of', 'O'), ('cardiac', 'O'), ('output', 'O'), ('.', 'O'))"
"In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('muscle', 'B'), ('damage', 'I'), (',', 'O'), ('severe', 'O'), ('damage', 'O'), ('was', 'O'), ('also', 'O'), ('seen', 'O'), ('in', 'O'), ('harderian', 'O'), ('glands', 'O'), (',', 'O'), ('especially', 'O'), ('after', 'O'), ('exposure', 'O'), ('to', 'O'), ('mepivacaine', 'O'), ('and', 'O'), ('lidocaine', 'O'), ('plus', 'O'), ('epinephrine', 'O'), ('.', 'O'))"
"With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .","(('With', 'O'), ('these', 'O'), ('findings', 'O'), ('in', 'O'), ('rats', 'O'), (',', 'O'), ('it', 'O'), ('is', 'O'), ('hypothesized', 'O'), ('that', 'O'), ('the', 'O'), ('temporary', 'O'), ('diplopia', 'B'), ('sometimes', 'O'), ('seen', 'O'), ('in', 'O'), ('patients', 'O'), ('after', 'O'), ('ophthalmic', 'O'), ('surgery', 'O'), ('might', 'O'), ('be', 'O'), ('due', 'O'), ('to', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('to', 'O'), ('the', 'O'), ('extraocular', 'O'), ('muscles', 'O'), ('.', 'O'))"
Gentamicin nephropathy in a neonate .,"(('Gentamicin', 'O'), ('nephropathy', 'B'), ('in', 'O'), ('a', 'O'), ('neonate', 'O'), ('.', 'O'))"
The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .,"(('The', 'O'), ('clinical', 'O'), ('and', 'O'), ('autopsy', 'O'), ('findings', 'O'), ('in', 'O'), ('a', 'O'), ('premature', 'O'), ('baby', 'O'), ('who', 'O'), ('died', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('after', 'O'), ('therapy', 'O'), ('with', 'O'), ('gentamicin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('and', 'O'), ('penicillin', 'O'), ('are', 'O'), ('presented', 'O'), ('.', 'O'))"
The serum gentamicin concentration had reached toxic levels when anuria developed .,"(('The', 'O'), ('serum', 'O'), ('gentamicin', 'O'), ('concentration', 'O'), ('had', 'O'), ('reached', 'O'), ('toxic', 'O'), ('levels', 'O'), ('when', 'O'), ('anuria', 'B'), ('developed', 'O'), ('.', 'O'))"
Induction by paracetamol of bladder and liver tumours in the rat .,"(('Induction', 'O'), ('by', 'O'), ('paracetamol', 'O'), ('of', 'O'), ('bladder', 'B'), ('and', 'I'), ('liver', 'I'), ('tumours', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
"Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .","(('Papillomas', 'B'), ('of', 'O'), ('the', 'O'), ('transitional', 'O'), ('epithelium', 'O'), ('of', 'O'), ('the', 'O'), ('bladder', 'O'), ('developed', 'O'), ('in', 'O'), ('all', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('treated', 'O'), ('groups', 'O'), (',', 'O'), ('and', 'O'), ('three', 'O'), ('rats', 'O'), ('bore', 'O'), ('bladder', 'B'), ('carcinomas', 'I'), ('.', 'O'))"
"However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .","(('However', 'O'), (',', 'O'), ('significant', 'O'), ('yields', 'O'), ('of', 'O'), ('bladder', 'B'), ('tumours', 'I'), ('were', 'O'), ('only', 'O'), ('obtained', 'O'), ('from', 'O'), ('low', 'O'), ('dosage', 'O'), ('females', 'O'), ('and', 'O'), ('high', 'O'), ('dosage', 'O'), ('males', 'O'), ('.', 'O'))"
"Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .","(('Additionally', 'O'), (',', 'O'), ('20', 'O'), ('to', 'O'), ('25', 'O'), ('%', 'O'), ('of', 'O'), ('paracetamol', 'O'), ('-', 'O'), ('treated', 'O'), ('rats', 'O'), ('developed', 'O'), ('hyperplasia', 'B'), ('of', 'O'), ('the', 'O'), ('bladder', 'O'), ('epithelium', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('not', 'O'), ('coincident', 'O'), ('with', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('bladder', 'B'), ('calculi', 'I'), ('.', 'O'))"
Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .,"(('Transient', 'O'), ('hemiparesis', 'B'), (':', 'O'), ('a', 'O'), ('rare', 'O'), ('manifestation', 'O'), ('of', 'O'), ('diphenylhydantoin', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .","(('Among', 'O'), ('the', 'O'), ('common', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('diphenylhydantoin', 'O'), ('(', 'O'), ('DPH', 'O'), (')', 'O'), ('overdose', 'B'), (',', 'O'), ('the', 'O'), ('most', 'O'), ('frequently', 'O'), ('encountered', 'O'), ('neurological', 'O'), ('signs', 'O'), ('are', 'O'), ('those', 'O'), ('of', 'O'), ('cerebellar', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
Two patients are presented who suffered progressive hemiparesis due to DPH overdose .,"(('Two', 'O'), ('patients', 'O'), ('are', 'O'), ('presented', 'O'), ('who', 'O'), ('suffered', 'O'), ('progressive', 'O'), ('hemiparesis', 'B'), ('due', 'O'), ('to', 'O'), ('DPH', 'O'), ('overdose', 'B'), ('.', 'O'))"
It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .,"(('It', 'O'), ('is', 'O'), ('assumed', 'O'), ('that', 'O'), ('patients', 'O'), ('with', 'O'), ('some', 'O'), ('cerebral', 'B'), ('damage', 'I'), ('are', 'O'), ('liable', 'O'), ('to', 'O'), ('manifest', 'O'), ('DPH', 'O'), ('toxicity', 'B'), ('as', 'O'), ('focal', 'O'), ('neurological', 'O'), ('signs', 'O'), ('.', 'O'))"
Tiapride in levodopa - induced involuntary movements .,"(('Tiapride', 'O'), ('in', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('involuntary', 'B'), ('movements', 'I'), ('.', 'O'))"
"Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson ' s disease .","(('Tiapride', 'O'), (',', 'O'), ('a', 'O'), ('substituted', 'O'), ('benzamide', 'O'), ('derivative', 'O'), ('closely', 'O'), ('related', 'O'), ('to', 'O'), ('metoclopramide', 'O'), (',', 'O'), ('reduced', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('peak', 'O'), ('dose', 'O'), ('involuntary', 'B'), ('movements', 'I'), ('in', 'O'), ('16', 'O'), ('patients', 'O'), ('with', 'O'), ('idiopathic', 'B'), ('Parkinson', 'I'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"Tiapride had no effect on levodopa - induced early morning of "" off - period "" segmental dystonia .","(('Tiapride', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('early', 'O'), ('morning', 'O'), ('of', 'O'), ('""', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('""', 'O'), ('segmental', 'O'), ('dystonia', 'B'), ('.', 'O'))"
These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .,"(('These', 'O'), ('results', 'O'), ('fail', 'O'), ('to', 'O'), ('support', 'O'), ('the', 'O'), ('notion', 'O'), ('that', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('are', 'O'), ('caused', 'O'), ('by', 'O'), ('overstimulation', 'O'), ('of', 'O'), ('a', 'O'), ('separate', 'O'), ('group', 'O'), ('of', 'O'), ('dopamine', 'O'), ('receptors', 'O'), ('.', 'O'))"
Quinidine hepatitis .,"(('Quinidine', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
Liver biopsy showed active hepatitis .,"(('Liver', 'O'), ('biopsy', 'O'), ('showed', 'O'), ('active', 'O'), ('hepatitis', 'B'), ('.', 'O'))"
We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .,"(('We', 'O'), ('concluded', 'O'), ('that', 'O'), ('this', 'O'), ('patient', 'O'), ('had', 'O'), ('quinidine', 'O'), ('hepatotoxicity', 'B'), ('and', 'O'), ('believe', 'O'), ('that', 'O'), ('this', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('case', 'O'), ('reported', 'O'), ('with', 'O'), ('liver', 'O'), ('biopsy', 'O'), ('documentation', 'O'), ('.', 'O'))"
"This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .","(('This', 'O'), ('report', 'O'), ('also', 'O'), ('suggests', 'O'), ('that', 'O'), (',', 'O'), ('even', 'O'), ('after', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), (',', 'O'), ('the', 'O'), ('hepatic', 'B'), ('toxicity', 'I'), ('is', 'O'), ('reversible', 'O'), ('.', 'O'))"
Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .,"(('Arterial', 'O'), ('thromboembolism', 'B'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('systemic', 'O'), ('heparin', 'O'), ('therapy', 'O'), (':', 'O'), ('a', 'O'), ('complication', 'O'), ('associated', 'O'), ('with', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('.', 'O'))"
"Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .","(('Characteristic', 'O'), ('of', 'O'), ('the', 'O'), ('entity', 'O'), ('is', 'O'), ('arterial', 'B'), ('occlusion', 'I'), ('by', 'O'), ('platelet', 'O'), ('-', 'O'), ('fibrin', 'O'), ('thrombi', 'B'), ('with', 'O'), ('distal', 'O'), ('ischemia', 'B'), ('occurring', 'O'), ('four', 'O'), ('to', 'O'), ('twenty', 'O'), ('days', 'O'), ('after', 'O'), ('the', 'O'), ('initiation', 'O'), ('of', 'O'), ('heparin', 'O'), ('therapy', 'O'), (',', 'O'), ('preceded', 'O'), ('by', 'O'), ('profound', 'O'), ('thrombocytopenia', 'B'), ('with', 'O'), ('platelet', 'O'), ('counts', 'O'), ('in', 'O'), ('the', 'O'), ('range', 'O'), ('of', 'O'), ('30', 'O'), (',', 'O'), ('000', 'O'), ('to', 'O'), ('40', 'O'), (',', 'O'), ('000', 'O'), ('per', 'O'), ('cubic', 'O'), ('millimeter', 'O'), ('.', 'O'))"
"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .","(('The', 'O'), ('clinically', 'O'), ('apparent', 'O'), ('occlusion', 'O'), ('may', 'O'), ('be', 'O'), ('preceded', 'O'), ('by', 'O'), ('gastrointestinal', 'B'), ('and', 'I'), ('musculoskeletal', 'I'), ('symptoms', 'I'), ('that', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('ischemic', 'B'), ('in', 'O'), ('origin', 'O'), (',', 'O'), ('and', 'O'), ('might', 'O'), ('serve', 'O'), ('to', 'O'), ('warn', 'O'), ('the', 'O'), ('clinician', 'O'), ('of', 'O'), ('these', 'O'), ('complications', 'O'), ('.', 'O'))"
The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .,"(('The', 'O'), ('common', 'O'), ('factor', 'O'), ('relating', 'O'), ('thromboembolism', 'B'), ('and', 'O'), ('thrombocytopenia', 'B'), ('is', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('.', 'O'))"
Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .,"(('Its', 'O'), ('antiarrhythmic', 'O'), ('effectiveness', 'O'), ('surpasses', 'O'), ('that', 'O'), ('of', 'O'), ('propranolol', 'O'), ('and', 'O'), ('pindolol', 'O'), ('inhibiting', 'O'), ('the', 'O'), ('ouabain', 'O'), ('arrhythmia', 'B'), ('in', 'O'), ('dogs', 'O'), ('and', 'O'), ('cats', 'O'), ('.', 'O'))"
Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .,"(('Adverse', 'O'), ('reactions', 'O'), ('to', 'O'), ('bendrofluazide', 'O'), ('and', 'O'), ('propranolol', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('mild', 'O'), ('hypertension', 'B'), ('.', 'O'))"
Report of Medical Research Council Working Party on Mild to Moderate Hypertension .,"(('Report', 'O'), ('of', 'O'), ('Medical', 'O'), ('Research', 'O'), ('Council', 'O'), ('Working', 'O'), ('Party', 'O'), ('on', 'O'), ('Mild', 'O'), ('to', 'O'), ('Moderate', 'O'), ('Hypertension', 'B'), ('.', 'O'))"
"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .","(('Participants', 'O'), ('in', 'O'), ('the', 'O'), ('Medical', 'O'), ('Research', 'O'), ('Council', 'O'), ('treatment', 'O'), ('trial', 'O'), ('for', 'O'), ('mild', 'O'), ('hypertension', 'B'), ('are', 'O'), ('randomly', 'O'), ('allocated', 'O'), ('to', 'O'), ('one', 'O'), ('of', 'O'), ('four', 'O'), ('treatment', 'O'), ('groups', 'O'), (':', 'O'), ('bendrofluazide', 'O'), (',', 'O'), ('propranolol', 'O'), (',', 'O'), ('or', 'O'), ('a', 'O'), ('placebo', 'O'), ('for', 'O'), ('either', 'O'), ('of', 'O'), ('these', 'O'), ('drugs', 'O'), ('.', 'O'))"
"The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .","(('The', 'O'), ('results', 'O'), ('show', 'O'), ('an', 'O'), ('association', 'O'), ('between', 'O'), ('bendrofluazide', 'O'), ('treatment', 'O'), ('and', 'O'), ('impotence', 'B'), (',', 'O'), ('and', 'O'), ('impotence', 'B'), ('also', 'O'), ('occurred', 'O'), ('more', 'O'), ('frequently', 'O'), ('in', 'O'), ('patients', 'O'), ('taking', 'O'), ('propranolol', 'O'), ('than', 'O'), ('in', 'O'), ('those', 'O'), ('taking', 'O'), ('placebos', 'O'), ('.', 'O'))"
"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking propranolol .","(('Other', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('significantly', 'O'), ('linked', 'O'), ('with', 'O'), ('active', 'O'), ('drugs', 'O'), ('include', 'O'), ('impaired', 'B'), ('glucose', 'I'), ('tolerance', 'I'), ('in', 'O'), ('men', 'O'), ('and', 'O'), ('women', 'O'), ('and', 'O'), ('gout', 'B'), ('in', 'O'), ('men', 'O'), (',', 'O'), ('associated', 'O'), ('with', 'O'), ('bendrofluazide', 'O'), ('treatment', 'O'), (',', 'O'), ('and', 'O'), ('Raynaud', 'B'), (""'"", 'I'), ('s', 'I'), ('phenomenon', 'I'), ('and', 'O'), ('dyspnoea', 'B'), ('in', 'O'), ('men', 'O'), ('and', 'O'), ('women', 'O'), ('taking', 'O'), ('propranolol', 'O'), ('.', 'O'))"
No corneal disease is known to have occurred in the propranolol group .,"(('No', 'O'), ('corneal', 'B'), ('disease', 'I'), ('is', 'O'), ('known', 'O'), ('to', 'O'), ('have', 'O'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('propranolol', 'O'), ('group', 'O'), ('.', 'O'))"
"Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .","(('Serotonergic', 'O'), ('drugs', 'O'), (',', 'O'), ('benzodiazepines', 'O'), ('and', 'O'), ('baclofen', 'O'), ('block', 'O'), ('muscimol', 'O'), ('-', 'O'), ('induced', 'O'), ('myoclonic', 'B'), ('jerks', 'I'), ('in', 'O'), ('a', 'O'), ('strain', 'O'), ('of', 'O'), ('mice', 'O'), ('.', 'O'))"
"In male Swiss mice , muscimol produced myoclonic jerks .","(('In', 'O'), ('male', 'O'), ('Swiss', 'O'), ('mice', 'O'), (',', 'O'), ('muscimol', 'O'), ('produced', 'O'), ('myoclonic', 'B'), ('jerks', 'I'), ('.', 'O'))"
"Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .","(('Of', 'O'), ('the', 'O'), ('benzodiazepines', 'O'), (',', 'O'), ('clonazepam', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('several', 'O'), ('fold', 'O'), ('more', 'O'), ('potent', 'O'), ('than', 'O'), ('diazepam', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('-', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('in', 'O'), ('blocking', 'O'), ('the', 'O'), ('myoclonic', 'B'), ('jerks', 'I'), ('.', 'O'))"
"Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .","(('Considering', 'O'), ('the', 'O'), ('fact', 'O'), ('that', 'O'), ('5', 'O'), ('-', 'O'), ('HTP', 'O'), ('and', 'O'), ('the', 'O'), ('benzodiazepines', 'O'), ('have', 'O'), ('been', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('beneficial', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('clinical', 'O'), ('myoclonus', 'B'), (',', 'O'), ('the', 'O'), ('muscimol', 'O'), ('-', 'O'), ('induced', 'O'), ('myoclonus', 'B'), ('seems', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('satisfactory', 'O'), ('animal', 'O'), ('model', 'O'), ('that', 'O'), ('may', 'O'), ('prove', 'O'), ('useful', 'O'), ('for', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('new', 'O'), ('drug', 'O'), ('treatments', 'O'), ('for', 'O'), ('this', 'O'), ('condition', 'O'), ('.', 'O'))"
Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .,"(('Our', 'O'), ('present', 'O'), ('study', 'O'), ('indicated', 'O'), ('the', 'O'), ('possible', 'O'), ('value', 'O'), ('of', 'O'), ('MK', 'O'), ('-', 'O'), ('212', 'O'), ('and', 'O'), ('(', 'O'), ('-', 'O'), (')', 'O'), ('-', 'O'), ('baclofen', 'O'), ('in', 'O'), ('the', 'O'), ('management', 'O'), ('of', 'O'), ('clinical', 'O'), ('myoclonus', 'B'), ('.', 'O'))"
"Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .","(('Three', 'O'), ('patients', 'O'), ('with', 'O'), ('ischaemic', 'B'), ('heart', 'I'), ('disease', 'I'), ('developed', 'O'), ('profound', 'O'), ('cardiac', 'B'), ('failure', 'I'), (',', 'O'), ('hypotension', 'B'), ('and', 'O'), ('bradycardia', 'B'), ('during', 'O'), ('combined', 'O'), ('therapy', 'O'), ('with', 'O'), ('verapamil', 'O'), ('and', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenergic', 'O'), ('blocking', 'O'), ('drugs', 'O'), ('.', 'O'))"
"Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .","(('Nineteen', 'O'), ('patients', 'O'), ('had', 'O'), ('Zollinger', 'B'), ('-', 'I'), ('Ellison', 'I'), ('syndrome', 'I'), (',', 'O'), ('one', 'O'), ('patient', 'O'), ('had', 'O'), ('systemic', 'B'), ('mastocytosis', 'I'), (',', 'O'), ('and', 'O'), ('two', 'O'), ('patients', 'O'), ('had', 'O'), ('idiopathic', 'O'), ('hypersecretion', 'O'), ('.', 'O'))"
Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .,"(('Sixty', 'O'), ('percent', 'O'), ('of', 'O'), ('the', 'O'), ('males', 'O'), ('developed', 'O'), ('breast', 'O'), ('changes', 'O'), ('or', 'O'), ('impotence', 'B'), ('while', 'O'), ('taking', 'O'), ('cimetidine', 'O'), ('and', 'O'), ('in', 'O'), ('all', 'O'), ('cases', 'O'), ('these', 'O'), ('changes', 'O'), ('disappeared', 'O'), ('when', 'O'), ('cimetidine', 'O'), ('was', 'O'), ('replaced', 'O'), ('by', 'O'), ('ranitidine', 'O'), ('.', 'O'))"
"Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .","(('Treatment', 'O'), ('with', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('cimetidine', 'O'), ('(', 'O'), ('one', 'O'), ('to', 'O'), ('60', 'O'), ('months', 'O'), (';', 'O'), ('median', 'O'), (',', 'O'), ('11', 'O'), ('months', 'O'), (')', 'O'), ('or', 'O'), ('ranitidine', 'O'), ('(', 'O'), ('two', 'O'), ('to', 'O'), ('31', 'O'), ('months', 'O'), (';', 'O'), ('median', 'O'), (',', 'O'), ('14', 'O'), ('months', 'O'), (')', 'O'), ('was', 'O'), ('not', 'O'), ('associated', 'O'), ('with', 'O'), ('hepatic', 'B'), ('or', 'I'), ('hematologic', 'I'), ('toxicity', 'I'), ('or', 'O'), ('alterations', 'O'), ('of', 'O'), ('serum', 'O'), ('gastrin', 'O'), ('concentrations', 'O'), (',', 'O'), ('but', 'O'), ('ranitidine', 'O'), ('therapy', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('significantly', 'O'), ('lower', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('level', 'O'), ('than', 'O'), ('seen', 'O'), ('with', 'O'), ('cimetidine', 'O'), ('therapy', 'O'), ('.', 'O'))"
"In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .","(('In', 'O'), ('one', 'O'), ('patient', 'O'), (',', 'O'), ('enflurane', 'O'), ('administered', 'O'), ('during', 'O'), ('a', 'O'), ('donor', 'O'), ('nephrectomy', 'O'), ('resulted', 'O'), ('in', 'O'), ('unexpected', 'O'), ('partial', 'O'), ('motor', 'O'), ('seizures', 'B'), ('.', 'O'))"
"Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .","(('Until', 'O'), ('the', 'O'), ('cause', 'O'), ('of', 'O'), ('the', 'O'), ('seizures', 'B'), ('was', 'O'), ('correctly', 'O'), ('identified', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('inappropriately', 'O'), ('treated', 'O'), ('with', 'O'), ('anticonvulsants', 'O'), ('.', 'O'))"
"Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .","(('Two', 'O'), ('other', 'O'), ('patients', 'O'), ('suffered', 'O'), ('from', 'O'), ('partial', 'O'), (',', 'O'), ('complex', 'O'), ('and', 'O'), ('generalized', 'O'), ('seizures', 'B'), ('uncontrolled', 'O'), ('by', 'O'), ('medication', 'O'), ('.', 'O'))"
Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .,"(('Epileptic', 'B'), ('foci', 'O'), ('delineated', 'O'), ('and', 'O'), ('activated', 'O'), ('by', 'O'), ('enflurane', 'O'), ('were', 'O'), ('surgically', 'O'), ('ablated', 'O'), ('and', 'O'), ('the', 'O'), ('patients', 'O'), ('are', 'O'), ('now', 'O'), ('seizure', 'B'), ('-', 'O'), ('free', 'O'), ('.', 'O'))"
"On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('enflurane', 'O'), ('may', 'O'), ('prove', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('safe', 'O'), ('fast', 'O'), ('acting', 'O'), ('activator', 'O'), ('of', 'O'), ('epileptic', 'B'), ('foci', 'O'), ('during', 'O'), ('corticography', 'O'), ('or', 'O'), ('depth', 'O'), ('electrode', 'O'), ('intraoperative', 'O'), ('recordings', 'O'), ('.', 'O'))"
Development of isoproterenol - induced cardiac hypertrophy .,"(('Development', 'O'), ('of', 'O'), ('isoproterenol', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiac', 'B'), ('hypertrophy', 'I'), ('.', 'O'))"
The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .,"(('The', 'O'), ('development', 'O'), ('of', 'O'), ('cardiac', 'B'), ('hypertrophy', 'I'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('adult', 'O'), ('female', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('following', 'O'), ('daily', 'O'), ('subcutaneous', 'O'), ('injections', 'O'), ('of', 'O'), ('isoproterenol', 'O'), ('(', 'O'), ('ISO', 'O'), (')', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), (')', 'O'), ('.', 'O'))"
Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .,"(('Intraventricular', 'O'), ('pressures', 'O'), ('and', 'O'), ('coronary', 'O'), ('flow', 'O'), ('measures', 'O'), ('were', 'O'), ('similar', 'O'), ('for', 'O'), ('control', 'O'), ('and', 'O'), ('experimental', 'O'), ('animals', 'O'), ('following', 'O'), ('4', 'O'), ('days', 'O'), ('of', 'O'), ('developed', 'O'), ('hypertrophy', 'B'), ('.', 'O'))"
"However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .","(('However', 'O'), (',', 'O'), ('prolonged', 'O'), ('stimulation', 'O'), ('(', 'O'), ('8', 'O'), ('-', 'O'), ('12', 'O'), ('days', 'O'), (')', 'O'), ('appears', 'O'), ('to', 'O'), ('represent', 'O'), ('a', 'O'), ('complex', 'O'), ('integration', 'O'), ('of', 'O'), ('both', 'O'), ('cellular', 'O'), ('hypertrophy', 'B'), ('and', 'O'), ('hyperplasia', 'B'), ('within', 'O'), ('the', 'O'), ('heart', 'O'), ('.', 'O'))"
Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .,"(('Multiple', 'O'), ('side', 'O'), ('effects', 'O'), ('of', 'O'), ('penicillamine', 'O'), ('therapy', 'O'), ('in', 'O'), ('one', 'O'), ('patient', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
"Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .","(('Skin', 'B'), ('rashes', 'I'), (',', 'O'), ('proteinuria', 'B'), (',', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematosus', 'I'), (',', 'O'), ('polymyositis', 'B'), ('and', 'O'), ('myasthenia', 'B'), ('gravis', 'I'), ('have', 'O'), ('all', 'O'), ('been', 'O'), ('recorded', 'O'), ('as', 'O'), ('complications', 'O'), ('of', 'O'), ('penicillamine', 'O'), ('therapy', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
"The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with rheumatoid arthritis treated with penicillamine .","(('The', 'O'), ('skin', 'B'), ('lesion', 'I'), ('resembled', 'O'), ('elastosis', 'B'), ('perforans', 'I'), ('serpiginosa', 'I'), (',', 'O'), ('which', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('as', 'O'), ('a', 'O'), ('rare', 'O'), ('side', 'O'), ('effect', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('Wilson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('treated', 'O'), ('with', 'O'), ('penicillamine', 'O'), ('.', 'O'))"
One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .,"(('One', 'O'), ('case', 'O'), ('of', 'O'), ('acute', 'O'), ('hypercalcaemia', 'B'), ('and', 'O'), ('two', 'O'), ('of', 'O'), ('recurrent', 'O'), ('nephrolithiasis', 'B'), ('are', 'O'), ('reported', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('regularly', 'O'), ('consumed', 'O'), ('large', 'O'), ('amounts', 'O'), ('of', 'O'), ('calcium', 'O'), ('carbon', 'O'), ('-', 'O'), ('ate', 'O'), ('-', 'O'), ('sodium', 'O'), ('bicarbonate', 'O'), ('powders', 'O'), ('for', 'O'), ('more', 'O'), ('than', 'O'), ('20', 'O'), ('years', 'O'), ('.', 'O'))"
Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .,"(('Doxorubicin', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('left', 'O'), ('-', 'O'), ('sided', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('.', 'O'))"
Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .,"(('Two', 'O'), ('children', 'O'), ('with', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('of', 'O'), ('the', 'O'), ('left', 'O'), ('kidney', 'O'), ('experienced', 'O'), ('severe', 'O'), ('anthracycline', 'O'), ('cardiomyopathy', 'B'), ('after', 'O'), ('irradiation', 'O'), ('to', 'O'), ('the', 'O'), ('tumor', 'B'), ('bed', 'O'), ('and', 'O'), ('conventional', 'O'), ('dosage', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .,"(('The', 'O'), ('cardiomyopathy', 'B'), ('is', 'O'), ('attributed', 'O'), ('1', 'O'), (')', 'O'), ('to', 'O'), ('the', 'O'), ('fact', 'O'), ('that', 'O'), ('radiation', 'O'), ('fields', 'O'), ('for', 'O'), ('left', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('include', 'O'), ('the', 'O'), ('lower', 'O'), ('portion', 'O'), ('of', 'O'), ('the', 'O'), ('heart', 'O'), ('and', 'O'), ('2', 'O'), (')', 'O'), ('to', 'O'), ('the', 'O'), ('interaction', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('and', 'O'), ('irradiation', 'O'), ('on', 'O'), ('cardiac', 'O'), ('muscle', 'O'), ('.', 'O'))"
It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .,"(('It', 'O'), ('is', 'O'), ('recommended', 'O'), ('that', 'O'), ('doxorubicin', 'O'), ('dosage', 'O'), ('be', 'O'), ('sharply', 'O'), ('restricted', 'O'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('Wilms', 'B'), ('tumor', 'I'), ('of', 'O'), ('the', 'O'), ('left', 'O'), ('kidney', 'O'), ('who', 'O'), ('receive', 'O'), ('postoperative', 'O'), ('irradiation', 'O'), ('.', 'O'))"
Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .,"(('Calcitonin', 'O'), ('injection', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('potentiation', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('a', 'O'), ('partial', 'O'), ('prevention', 'O'), ('of', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('hyperactivity', 'B'), ('.', 'O'))"
"Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .","(('Pretreatment', 'O'), ('with', 'O'), ('naloxazone', 'O'), ('significantly', 'O'), ('blocked', 'O'), ('morphine', 'O'), ('analgesia', 'B'), (',', 'O'), ('catalepsy', 'B'), ('and', 'O'), ('hypothermia', 'B'), ('at', 'O'), ('a', 'O'), ('dose', 'O'), ('which', 'O'), ('completely', 'O'), ('eliminated', 'O'), ('high', 'O'), ('-', 'O'), ('affinity', 'O'), ('binding', 'O'), ('in', 'O'), ('brain', 'O'), ('membranes', 'O'), ('.', 'O'))"
"Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .","(('Moreover', 'O'), (',', 'O'), ('naloxazone', 'O'), ('significantly', 'O'), ('attenuated', 'O'), ('the', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('and', 'O'), ('respiratory', 'B'), ('depression', 'I'), (',', 'O'), ('whereas', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('bradycardia', 'B'), ('was', 'O'), ('less', 'O'), ('affected', 'O'), ('.', 'O'))"
Modification of drug action by hyperammonemia .,"(('Modification', 'O'), ('of', 'O'), ('drug', 'O'), ('action', 'O'), ('by', 'O'), ('hyperammonemia', 'B'), ('.', 'O'))"
"Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .","(('Thus', 'O'), (',', 'O'), ('hyperammonemia', 'B'), ('is', 'O'), ('capable', 'O'), ('of', 'O'), ('altering', 'O'), ('drug', 'O'), ('action', 'O'), ('and', 'O'), ('must', 'O'), ('be', 'O'), ('considered', 'O'), ('along', 'O'), ('with', 'O'), ('impaired', 'O'), ('drug', 'O'), ('metabolism', 'O'), ('in', 'O'), ('enhanced', 'O'), ('drug', 'O'), ('responses', 'O'), ('associated', 'O'), ('with', 'O'), ('liver', 'B'), ('disease', 'I'), ('.', 'O'))"
"Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .","(('Addition', 'O'), ('of', 'O'), ('excess', 'O'), ('calcium', 'O'), ('reversed', 'O'), ('the', 'O'), ('depression', 'B'), ('in', 'O'), ('both', 'O'), ('tissues', 'O'), (',', 'O'), ('but', 'O'), ('calcium', 'O'), ('-', 'O'), ('independent', 'O'), ('catecholamine', 'O'), ('release', 'O'), ('by', 'O'), ('acetaldehyde', 'O'), ('was', 'O'), ('not', 'O'), ('blocked', 'O'), ('by', 'O'), ('NH4Ac', 'O'), ('.', 'O'))"
The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .,"(('The', 'O'), ('data', 'O'), ('suggest', 'O'), ('that', 'O'), ('hyperammonemia', 'B'), ('exerts', 'O'), ('a', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blocking', 'O'), ('action', 'O'), ('which', 'O'), ('enhances', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('central', 'O'), ('nervous', 'O'), ('system', 'O'), ('depressants', 'O'), ('and', 'O'), ('certain', 'O'), ('opioid', 'O'), ('analgesics', 'O'), ('.', 'O'))"
Levodopa - induced dyskinesia and thalamotomy .,"(('Levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesia', 'B'), ('and', 'O'), ('thalamotomy', 'O'), ('.', 'O'))"
"Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .","(('Levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesia', 'B'), ('of', 'O'), ('the', 'O'), ('limbs', 'O'), ('in', 'O'), ('thirteen', 'O'), ('cases', 'O'), ('of', 'O'), ('Parkinsonism', 'B'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('choreic', 'O'), (',', 'O'), ('ballistic', 'O'), ('or', 'O'), ('dystonic', 'B'), ('in', 'O'), ('type', 'O'), (',', 'O'), ('was', 'O'), ('alleviated', 'O'), ('almost', 'O'), ('completely', 'O'), ('by', 'O'), ('stereotaxic', 'O'), ('surgery', 'O'), ('using', 'O'), ('a', 'O'), ('microelectrode', 'O'), ('technique', 'O'), ('for', 'O'), ('the', 'O'), ('ventralis', 'O'), ('oralis', 'O'), ('anterior', 'O'), ('and', 'O'), ('posterior', 'O'), ('nuclei', 'O'), ('of', 'O'), ('the', 'O'), ('thalamus', 'O'), (',', 'O'), ('but', 'O'), ('much', 'O'), ('less', 'O'), ('by', 'O'), ('the', 'O'), ('ventralis', 'O'), ('intermedius', 'O'), ('nucleus', 'O'), ('.', 'O'))"
Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .,"(('Control', 'O'), ('of', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('by', 'O'), ('thalamic', 'B'), ('lesions', 'I'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('routine', 'O'), ('treatment', 'O'), ('of', 'O'), ('Parkinsonism', 'B'), ('is', 'O'), ('discussed', 'O'), ('.', 'O'))"
Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .,"(('Treatment', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('urothelial', 'B'), ('toxicity', 'I'), ('by', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('sodium', 'O'), ('2', 'O'), ('-', 'O'), ('mercaptoethane', 'O'), ('sulphonate', 'O'), ('(', 'O'), ('MESNA', 'O'), (')', 'O'), ('to', 'O'), ('patients', 'O'), ('with', 'O'), ('inoperable', 'O'), ('lung', 'B'), ('cancer', 'I'), ('.', 'O'))"
The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .,"(('The', 'O'), ('protective', 'O'), ('effect', 'O'), ('of', 'O'), ('oral', 'O'), ('administration', 'O'), ('of', 'O'), ('the', 'O'), ('thiol', 'O'), ('compound', 'O'), ('sodium', 'O'), ('2', 'O'), ('-', 'O'), ('mercaptoethane', 'O'), ('sulphonate', 'O'), ('(', 'O'), ('MESNA', 'O'), (')', 'O'), ('against', 'O'), ('urothelial', 'B'), ('toxicity', 'I'), ('induced', 'O'), ('by', 'O'), ('ifosfamide', 'O'), ('(', 'O'), ('IF', 'O'), (')', 'O'), ('was', 'O'), ('tested', 'O'), ('in', 'O'), ('a', 'O'), ('group', 'O'), ('of', 'O'), ('45', 'O'), ('patients', 'O'), ('with', 'O'), ('inoperable', 'O'), ('lung', 'B'), ('cancer', 'I'), ('under', 'O'), ('treatment', 'O'), ('with', 'O'), ('IF', 'O'), ('(', 'O'), ('2250', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('on', 'O'), ('days', 'O'), ('2', 'O'), ('-', 'O'), ('5', 'O'), (')', 'O'), ('as', 'O'), ('part', 'O'), ('of', 'O'), ('a', 'O'), ('polychemotherapy', 'O'), ('regimen', 'O'), ('repeated', 'O'), ('in', 'O'), ('a', 'O'), ('4', 'O'), ('-', 'O'), ('week', 'O'), ('cycle', 'O'), ('.', 'O'))"
"In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .","(('In', 'O'), ('this', 'O'), ('group', 'O'), ('there', 'O'), ('were', 'O'), ('1', 'O'), ('complete', 'O'), ('and', 'O'), ('5', 'O'), ('partial', 'O'), ('remissions', 'O'), ('(', 'O'), ('total', 'O'), ('24', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('nearly', 'O'), ('all', 'O'), ('patients', 'O'), ('developed', 'O'), ('either', 'O'), ('gross', 'O'), ('haematuria', 'B'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('symptoms', 'O'), ('of', 'O'), ('bladder', 'B'), ('irritation', 'I'), ('(', 'O'), ('cystitis', 'B'), ('and', 'O'), ('pollakisuria', 'B'), (')', 'O'), ('.', 'O'))"
There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('appreciable', 'O'), ('differences', 'O'), ('between', 'O'), ('the', 'O'), ('MESNA', 'O'), ('series', 'O'), ('and', 'O'), ('the', 'O'), ('conventional', 'O'), ('prophylaxis', 'O'), ('series', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('either', 'O'), ('haematological', 'O'), ('or', 'O'), ('systemic', 'O'), ('toxicity', 'B'), ('of', 'O'), ('the', 'O'), ('cytostatic', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .","(('Myoclonic', 'B'), (',', 'I'), ('atonic', 'I'), (',', 'I'), ('and', 'I'), ('absence', 'I'), ('seizures', 'I'), ('following', 'O'), ('institution', 'O'), ('of', 'O'), ('carbamazepine', 'O'), ('therapy', 'O'), ('in', 'O'), ('children', 'O'), ('.', 'O'))"
"Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .","(('Five', 'O'), ('children', 'O'), (',', 'O'), ('aged', 'O'), ('3', 'O'), ('to', 'O'), ('11', 'O'), ('years', 'O'), (',', 'O'), ('treated', 'O'), ('with', 'O'), ('carbamazepine', 'O'), ('for', 'O'), ('epilepsy', 'B'), (',', 'O'), ('had', 'O'), ('an', 'O'), ('acute', 'O'), ('aberrant', 'O'), ('reaction', 'O'), ('characterized', 'O'), ('by', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('myoclonic', 'B'), (',', 'I'), ('atypical', 'I'), ('absence', 'I'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('atonic', 'I'), ('(', 'I'), ('minor', 'I'), ('motor', 'I'), (')', 'I'), ('seizures', 'I'), ('within', 'O'), ('a', 'O'), ('few', 'O'), ('days', 'O'), ('.', 'O'))"
"When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .","(('When', 'O'), ('the', 'O'), ('carbamazepine', 'O'), ('was', 'O'), ('discontinued', 'O'), (',', 'O'), ('two', 'O'), ('of', 'O'), ('the', 'O'), ('children', 'O'), ('returned', 'O'), ('to', 'O'), ('their', 'O'), ('former', 'O'), ('state', 'O'), ('very', 'O'), ('quickly', 'O'), (',', 'O'), ('two', 'O'), ('had', 'O'), ('the', 'O'), ('minor', 'O'), ('motor', 'O'), ('seizures', 'B'), ('resolve', 'O'), ('in', 'O'), ('3', 'O'), ('and', 'O'), ('6', 'O'), ('months', 'O'), (',', 'O'), ('and', 'O'), ('one', 'O'), ('had', 'O'), ('the', 'O'), ('seizures', 'B'), ('persist', 'O'), ('.', 'O'))"
The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .,"(('The', 'O'), ('child', 'O'), ('in', 'O'), ('whom', 'O'), ('the', 'O'), ('seizures', 'B'), ('persisted', 'O'), ('was', 'O'), ('later', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('ceroid', 'B'), ('lipofuscinosis', 'I'), ('.', 'O'))"
Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .,"(('Effect', 'O'), ('of', 'O'), ('prostaglandin', 'O'), ('synthetase', 'O'), ('inhibitors', 'O'), ('on', 'O'), ('experimentally', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .","(('To', 'O'), ('investigate', 'O'), ('the', 'O'), ('relationship', 'O'), ('of', 'O'), ('prostaglandins', 'O'), ('(', 'O'), ('PGs', 'O'), (')', 'O'), ('to', 'O'), ('seizure', 'B'), ('induction', 'O'), (',', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('six', 'O'), ('PG', 'O'), ('synthetase', 'O'), ('inhibitors', 'O'), ('on', 'O'), ('convulsions', 'B'), ('induced', 'O'), ('by', 'O'), ('flurothyl', 'O'), (',', 'O'), ('picrotoxin', 'O'), (',', 'O'), ('pentetrazol', 'O'), ('(', 'O'), ('PTZ', 'O'), (')', 'O'), (',', 'O'), ('electroshock', 'O'), ('or', 'O'), ('bicuculline', 'O'), ('were', 'O'), ('evaluated', 'O'), ('.', 'O'))"
"These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .","(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('PGs', 'O'), ('are', 'O'), ('involved', 'O'), ('in', 'O'), ('the', 'O'), ('mechanism', 'O'), ('(', 'O'), ('s', 'O'), (')', 'O'), ('underlying', 'O'), ('fluorthyl', 'O'), ('-', 'O'), ('and', 'O'), ('PTZ', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('picrotoxin', 'O'), ('-', 'O'), (',', 'O'), ('electroshock', 'O'), ('-', 'O'), (',', 'O'), ('or', 'O'), ('bicuculline', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .,"(('Valproic', 'O'), ('acid', 'O'), ('(', 'O'), ('VPA', 'O'), (')', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('24', 'O'), ('epileptic', 'B'), ('patients', 'O'), ('who', 'O'), ('were', 'O'), ('already', 'O'), ('being', 'O'), ('treated', 'O'), ('with', 'O'), ('other', 'O'), ('antiepileptic', 'O'), ('drugs', 'O'), ('.', 'O'))"
"Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .","(('Ammonia', 'O'), ('(', 'O'), ('NH3', 'O'), (')', 'O'), ('was', 'O'), ('higher', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), (',', 'O'), ('during', 'O'), ('continuous', 'O'), ('therapy', 'O'), (',', 'O'), ('complained', 'O'), ('of', 'O'), ('drowsiness', 'B'), ('(', 'O'), ('7', 'O'), ('patients', 'O'), (')', 'O'), ('than', 'O'), ('in', 'O'), ('those', 'O'), ('who', 'O'), ('were', 'O'), ('symptom', 'O'), ('-', 'O'), ('free', 'O'), ('(', 'O'), ('17', 'O'), ('patients', 'O'), (')', 'O'), (',', 'O'), ('although', 'O'), ('VPA', 'O'), ('plasma', 'O'), ('levels', 'O'), ('were', 'O'), ('similar', 'O'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .,"(('Effect', 'O'), ('of', 'O'), ('captopril', 'O'), ('on', 'O'), ('pre', 'O'), ('-', 'O'), ('existing', 'O'), ('and', 'O'), ('aminonucleoside', 'O'), ('-', 'O'), ('induced', 'O'), ('proteinuria', 'B'), ('in', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('.', 'O'))"
Proteinuria is a side effect of captopril treatment in hypertensive patients .,"(('Proteinuria', 'B'), ('is', 'O'), ('a', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('captopril', 'O'), ('treatment', 'O'), ('in', 'O'), ('hypertensive', 'B'), ('patients', 'O'), ('.', 'O'))"
The possibility of reproducing the same renal abnormality with captopril was examined in SHR .,"(('The', 'O'), ('possibility', 'O'), ('of', 'O'), ('reproducing', 'O'), ('the', 'O'), ('same', 'O'), ('renal', 'B'), ('abnormality', 'I'), ('with', 'O'), ('captopril', 'O'), ('was', 'O'), ('examined', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .,"(('Oral', 'O'), ('administration', 'O'), ('of', 'O'), ('captopril', 'O'), ('at', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('14', 'O'), ('days', 'O'), ('failed', 'O'), ('to', 'O'), ('aggravate', 'O'), ('proteinuria', 'B'), ('pre', 'O'), ('-', 'O'), ('existing', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
"Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .","(('Also', 'O'), (',', 'O'), ('captopril', 'O'), ('treatment', 'O'), ('failed', 'O'), ('to', 'O'), ('potentiate', 'O'), ('or', 'O'), ('facilitate', 'O'), ('development', 'O'), ('of', 'O'), ('massive', 'O'), ('proteinuria', 'B'), ('invoked', 'O'), ('by', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('in', 'O'), ('SHR', 'O'), ('.', 'O'))"
Complete heart block following a single dose of trazodone .,"(('Complete', 'O'), ('heart', 'B'), ('block', 'I'), ('following', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('trazodone', 'O'), ('.', 'O'))"
"Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .","(('Forty', 'O'), ('minutes', 'O'), ('after', 'O'), ('receiving', 'O'), ('a', 'O'), ('single', 'O'), ('starting', 'O'), ('dose', 'O'), ('of', 'O'), ('trazodone', 'O'), (',', 'O'), ('a', 'O'), ('patient', 'O'), ('developed', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('.', 'O'))"
Phenobarbital - induced dyskinesia in a neurologically - impaired child .,"(('Phenobarbital', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesia', 'B'), ('in', 'O'), ('a', 'O'), ('neurologically', 'B'), ('-', 'I'), ('impaired', 'I'), ('child', 'O'), ('.', 'O'))"
A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .,"(('A', 'O'), ('2', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('child', 'O'), ('with', 'O'), ('known', 'O'), ('neurologic', 'B'), ('impairment', 'I'), ('developed', 'O'), ('a', 'O'), ('dyskinesia', 'B'), ('soon', 'O'), ('after', 'O'), ('starting', 'O'), ('phenobarbital', 'O'), ('therapy', 'O'), ('for', 'O'), ('seizures', 'B'), ('.', 'O'))"
Known causes of movement disorders were eliminated after evaluation .,"(('Known', 'O'), ('causes', 'O'), ('of', 'O'), ('movement', 'B'), ('disorders', 'I'), ('were', 'O'), ('eliminated', 'O'), ('after', 'O'), ('evaluation', 'O'), ('.', 'O'))"
"On repeat challenge with phenobarbital , the dyskinesia recurred .","(('On', 'O'), ('repeat', 'O'), ('challenge', 'O'), ('with', 'O'), ('phenobarbital', 'O'), (',', 'O'), ('the', 'O'), ('dyskinesia', 'B'), ('recurred', 'O'), ('.', 'O'))"
Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .,"(('Phenobarbital', 'O'), ('should', 'O'), ('be', 'O'), ('added', 'O'), ('to', 'O'), ('the', 'O'), ('list', 'O'), ('of', 'O'), ('anticonvulsant', 'O'), ('drugs', 'O'), ('that', 'O'), ('can', 'O'), ('cause', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
"Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .","(('Heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), (',', 'O'), ('thrombosis', 'B'), (',', 'O'), ('and', 'O'), ('hemorrhage', 'B'), ('.', 'O'))"
Sixty - two patients with a heparin - induced thrombocytopenia are reported .,"(('Sixty', 'O'), ('-', 'O'), ('two', 'O'), ('patients', 'O'), ('with', 'O'), ('a', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombocytopenia', 'B'), ('are', 'O'), ('reported', 'O'), ('.', 'O'))"
"Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .","(('Clinical', 'O'), ('manifestations', 'O'), ('of', 'O'), ('this', 'O'), ('disorder', 'O'), ('include', 'O'), ('hemorrhage', 'B'), ('or', 'O'), (',', 'O'), ('more', 'O'), ('frequently', 'O'), (',', 'O'), ('thromboembolic', 'B'), ('events', 'O'), ('in', 'O'), ('patients', 'O'), ('receiving', 'O'), ('heparin', 'O'), ('.', 'O'))"
"Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient ' s plasma when heparin is added .","(('Laboratory', 'O'), ('testing', 'O'), ('has', 'O'), ('revealed', 'O'), ('a', 'B'), ('falling', 'I'), ('platelet', 'I'), ('count', 'I'), (',', 'O'), ('increased', 'O'), ('resistance', 'O'), ('to', 'O'), ('heparin', 'O'), (',', 'O'), ('and', 'O'), ('aggregation', 'O'), ('of', 'O'), ('platelets', 'O'), ('by', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('plasma', 'O'), ('when', 'O'), ('heparin', 'O'), ('is', 'O'), ('added', 'O'), ('.', 'O'))"
"The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .","(('The', 'O'), ('20', 'O'), ('deaths', 'O'), (',', 'O'), ('52', 'O'), ('hemorrhagic', 'B'), ('and', 'I'), ('thromboembolic', 'I'), ('complications', 'I'), (',', 'O'), ('and', 'O'), ('21', 'O'), ('surgical', 'O'), ('procedures', 'O'), ('to', 'O'), ('manage', 'O'), ('the', 'O'), ('complications', 'O'), ('confirm', 'O'), ('the', 'O'), ('seriousness', 'O'), ('of', 'O'), ('the', 'O'), ('disorder', 'O'), ('.', 'O'))"
"If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient ' s plasma , is indicated .","(('If', 'O'), ('the', 'O'), ('platelet', 'O'), ('count', 'O'), ('falls', 'O'), ('to', 'O'), ('less', 'O'), ('than', 'O'), ('100', 'O'), (',', 'O'), ('000', 'O'), ('/', 'O'), ('mm3', 'O'), (',', 'O'), ('while', 'O'), ('the', 'O'), ('patient', 'O'), ('is', 'O'), ('receiving', 'O'), ('heparin', 'O'), (',', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('testing', 'O'), (',', 'O'), ('using', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('plasma', 'O'), (',', 'O'), ('is', 'O'), ('indicated', 'O'), ('.', 'O'))"
Ventricular fibrillation from diatrizoate with and without chelating agents .,"(('Ventricular', 'B'), ('fibrillation', 'I'), ('from', 'O'), ('diatrizoate', 'O'), ('with', 'O'), ('and', 'O'), ('without', 'O'), ('chelating', 'O'), ('agents', 'O'), ('.', 'O'))"
The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .,"(('The', 'O'), ('toxicity', 'B'), ('of', 'O'), ('Renografin', 'O'), ('76', 'O'), ('%', 'O'), ('was', 'O'), ('compared', 'O'), ('with', 'O'), ('that', 'O'), ('of', 'O'), ('Hypaque', 'O'), ('76', 'O'), ('%', 'O'), ('by', 'O'), ('selective', 'O'), ('injection', 'O'), ('of', 'O'), ('each', 'O'), ('into', 'O'), ('the', 'O'), ('right', 'O'), ('coronary', 'O'), ('artery', 'O'), ('of', 'O'), ('dogs', 'O'), ('.', 'O'))"
"Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .","(('Ventricular', 'B'), ('fibrillation', 'I'), ('occurred', 'O'), ('significantly', 'O'), ('more', 'O'), ('often', 'O'), ('with', 'O'), ('Renografin', 'O'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('chelating', 'O'), ('agents', 'O'), ('contribute', 'O'), ('to', 'O'), ('toxicity', 'B'), ('in', 'O'), ('coronary', 'O'), ('angiography', 'O'), ('.', 'O'))"
Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .,"(('Long', 'O'), ('-', 'O'), ('term', 'O'), ('efficacy', 'O'), ('and', 'O'), ('toxicity', 'B'), ('of', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('amiodarone', 'O'), ('therapy', 'O'), ('for', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('or', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('.', 'O'))"
"Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .","(('Amiodarone', 'O'), ('was', 'O'), ('administered', 'O'), ('to', 'O'), ('154', 'O'), ('patients', 'O'), ('who', 'O'), ('had', 'O'), ('sustained', 'O'), (',', 'O'), ('symptomatic', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('(', 'O'), ('VT', 'B'), (')', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('118', 'O'), (')', 'O'), ('or', 'O'), ('a', 'O'), ('cardiac', 'B'), ('arrest', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('36', 'O'), (')', 'O'), ('and', 'O'), ('who', 'O'), ('were', 'O'), ('refractory', 'O'), ('to', 'O'), ('conventional', 'O'), ('antiarrhythmic', 'O'), ('drugs', 'O'), ('.', 'O'))"
Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .,"(('Sixty', 'O'), ('-', 'O'), ('nine', 'O'), ('percent', 'O'), ('of', 'O'), ('patients', 'O'), ('continued', 'O'), ('treatment', 'O'), ('with', 'O'), ('amiodarone', 'O'), ('and', 'O'), ('had', 'O'), ('no', 'O'), ('recurrence', 'O'), ('of', 'O'), ('symptomatic', 'O'), ('VT', 'B'), ('or', 'O'), ('ventricular', 'B'), ('fibrillation', 'I'), ('(', 'O'), ('VF', 'B'), (')', 'O'), ('over', 'O'), ('a', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('6', 'O'), ('to', 'O'), ('52', 'O'), ('months', 'O'), ('(', 'O'), ('mean', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('standard', 'O'), ('deviation', 'O'), ('14', 'O'), ('.', 'O'), ('2', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('8', 'O'), ('.', 'O'), ('2', 'O'), (')', 'O'), ('.', 'O'))"
"The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .","(('The', 'O'), ('most', 'O'), ('common', 'O'), ('symptomatic', 'O'), ('adverse', 'O'), ('reactions', 'O'), ('were', 'O'), ('tremor', 'B'), ('or', 'O'), ('ataxia', 'B'), ('(', 'O'), ('35', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('nausea', 'B'), ('and', 'O'), ('anorexia', 'B'), ('(', 'O'), ('8', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('visual', 'B'), ('halos', 'I'), ('or', 'I'), ('blurring', 'I'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), (',', 'O'), ('thyroid', 'B'), ('function', 'I'), ('abnormalities', 'I'), ('(', 'O'), ('6', 'O'), ('%', 'O'), (')', 'O'), ('and', 'O'), ('pulmonary', 'B'), ('interstitial', 'I'), ('infiltrates', 'I'), ('(', 'O'), ('5', 'O'), ('%', 'O'), (')', 'O'), ('.', 'O'))"
"Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .","(('Although', 'O'), ('large', 'O'), ('-', 'O'), ('dose', 'O'), ('amiodarone', 'O'), ('is', 'O'), ('highly', 'O'), ('effective', 'O'), ('in', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('treatment', 'O'), ('of', 'O'), ('VT', 'B'), ('or', 'O'), ('VF', 'B'), ('refractory', 'O'), ('to', 'O'), ('conventional', 'O'), ('antiarrhythmic', 'O'), ('drugs', 'O'), (',', 'O'), ('it', 'O'), ('causes', 'O'), ('significant', 'O'), ('toxicity', 'B'), ('in', 'O'), ('approximately', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('.', 'O'))"
Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?,"(('Why', 'O'), ('may', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), ('(', 'O'), ('EACA', 'O'), (')', 'O'), ('induce', 'O'), ('myopathy', 'B'), ('in', 'O'), ('man', 'O'), ('?', 'O'))"
A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('necrotizing', 'B'), ('myopathy', 'I'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('short', 'O'), ('epsilon', 'O'), ('-', 'O'), ('aminocaproic', 'O'), ('acid', 'O'), ('(', 'O'), ('EACA', 'O'), (')', 'O'), ('treatment', 'O'), ('in', 'O'), ('a', 'O'), ('72', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), ('with', 'O'), ('subarachnoid', 'B'), ('haemorrhage', 'I'), ('(', 'O'), ('SAH', 'B'), (')', 'O'), ('is', 'O'), ('described', 'O'), ('.', 'O'))"
Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .,"(('Cerebral', 'B'), ('hemorrhage', 'I'), ('associated', 'O'), ('with', 'O'), ('phenylpropanolamine', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('caffeine', 'O'), ('.', 'O'))"
Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .,"(('Phenylpropanolamine', 'O'), ('(', 'O'), ('PPA', 'O'), (')', 'O'), ('is', 'O'), ('a', 'O'), ('drug', 'O'), ('that', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('serious', 'O'), ('side', 'O'), ('effects', 'O'), ('including', 'O'), ('stroke', 'B'), ('.', 'O'))"
"In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .","(('In', 'O'), ('order', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('PPA', 'O'), ('/', 'O'), ('caffeine', 'O'), ('can', 'O'), ('lead', 'O'), ('to', 'O'), ('stroke', 'B'), ('in', 'O'), ('normotensive', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('hypertensive', 'B'), ('rats', 'O'), (',', 'O'), ('we', 'O'), ('administered', 'O'), ('the', 'O'), ('combination', 'O'), ('in', 'O'), ('six', 'O'), ('times', 'O'), ('the', 'O'), ('allowed', 'O'), ('human', 'O'), ('dose', 'O'), ('calculated', 'O'), ('on', 'O'), ('a', 'O'), ('per', 'O'), ('weight', 'O'), ('basis', 'O'), ('for', 'O'), ('the', 'O'), ('rats', 'O'), ('two', 'O'), ('times', 'O'), ('per', 'O'), ('day', 'O'), ('for', 'O'), ('five', 'O'), ('days', 'O'), ('.', 'O'))"
Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .,"(('Subarachnoid', 'B'), ('and', 'I'), ('cerebral', 'I'), ('hemorrhage', 'I'), ('was', 'O'), ('noted', 'O'), ('in', 'O'), ('18', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('.', 'O'))"
A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .,"(('A', 'O'), ('single', 'O'), ('PPA', 'O'), ('/', 'O'), ('caffeine', 'O'), ('administration', 'O'), ('(', 'O'), ('same', 'O'), ('dose', 'O'), (')', 'O'), ('lead', 'O'), ('to', 'O'), ('acute', 'O'), ('hypertension', 'B'), ('in', 'O'), ('both', 'O'), ('the', 'O'), ('normotensive', 'O'), ('and', 'O'), ('hypertensive', 'B'), ('animals', 'O'), ('.', 'O'))"
These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .,"(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('PPA', 'O'), ('/', 'O'), ('caffeine', 'O'), ('can', 'O'), ('lead', 'O'), ('to', 'O'), ('cerebral', 'B'), ('hemorrhage', 'I'), ('in', 'O'), ('previously', 'O'), ('hypertensive', 'B'), ('animals', 'O'), ('when', 'O'), ('administered', 'O'), ('in', 'O'), ('greater', 'O'), ('than', 'O'), ('the', 'O'), ('allowed', 'O'), ('dosage', 'O'), ('.', 'O'))"
Renal papillary necrosis due to naproxen .,"(('Renal', 'B'), ('papillary', 'I'), ('necrosis', 'I'), ('due', 'O'), ('to', 'O'), ('naproxen', 'O'), ('.', 'O'))"
"A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .","(('A', 'O'), ('31', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), (',', 'O'), ('who', 'O'), ('had', 'O'), ('previously', 'O'), ('been', 'O'), ('treated', 'O'), ('with', 'O'), ('sulindac', 'O'), (',', 'O'), ('fenoprofen', 'O'), ('calcium', 'O'), (',', 'O'), ('high', 'O'), ('dose', 'O'), ('salicylates', 'O'), ('and', 'O'), ('gold', 'O'), ('salts', 'O'), (',', 'O'), ('developed', 'O'), ('renal', 'B'), ('papillary', 'I'), ('necrosis', 'I'), ('(', 'O'), ('RPN', 'B'), (')', 'O'), ('4', 'O'), ('months', 'O'), ('after', 'O'), ('institution', 'O'), ('of', 'O'), ('naproxen', 'O'), ('therapy', 'O'), ('.', 'O'))"
No other factor predisposing to RPN could be discovered .,"(('No', 'O'), ('other', 'O'), ('factor', 'O'), ('predisposing', 'O'), ('to', 'O'), ('RPN', 'B'), ('could', 'O'), ('be', 'O'), ('discovered', 'O'), ('.', 'O'))"
We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .,"(('We', 'O'), ('review', 'O'), ('previous', 'O'), ('reports', 'O'), ('linking', 'O'), ('RPN', 'B'), ('to', 'O'), ('antiinflammatory', 'O'), ('drug', 'O'), ('use', 'O'), ('and', 'O'), ('discuss', 'O'), ('possible', 'O'), ('advantages', 'O'), ('of', 'O'), ('sulindac', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('experienced', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('from', 'O'), ('other', 'O'), ('antiinflammatory', 'O'), ('agents', 'O'), ('.', 'O'))"
"Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .","(('Thus', 'O'), (',', 'O'), ('aminoglycosides', 'O'), ('may', 'O'), ('act', 'O'), ('as', 'O'), ('nephrotoxicants', 'O'), ('at', 'O'), ('glomerular', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('tubular', 'O'), ('level', 'O'), ('inducing', 'O'), ('impairment', 'B'), ('of', 'I'), ('renal', 'I'), ('reabsorption', 'I'), ('and', 'O'), ('accumulation', 'O'), ('of', 'O'), ('proteins', 'O'), ('.', 'O'))"
Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .,"(('Induction', 'O'), ('of', 'O'), ('the', 'O'), ('obstructive', 'B'), ('sleep', 'I'), ('apnea', 'I'), ('syndrome', 'I'), ('in', 'O'), ('a', 'O'), ('woman', 'O'), ('by', 'O'), ('exogenous', 'O'), ('androgen', 'O'), ('administration', 'O'), ('.', 'O'))"
We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .,"(('We', 'O'), ('documented', 'O'), ('airway', 'O'), ('occlusion', 'O'), ('during', 'O'), ('sleep', 'O'), ('and', 'O'), ('an', 'O'), ('abnormally', 'O'), ('high', 'O'), ('supraglottic', 'O'), ('resistance', 'O'), ('while', 'O'), ('awake', 'O'), ('in', 'O'), ('a', 'O'), ('54', 'O'), ('-', 'O'), ('yr', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('who', 'O'), ('had', 'O'), ('developed', 'O'), ('physical', 'O'), ('changes', 'O'), ('and', 'O'), ('the', 'O'), ('syndrome', 'B'), ('of', 'I'), ('obstructive', 'I'), ('sleep', 'I'), ('apnea', 'I'), ('while', 'O'), ('being', 'O'), ('administered', 'O'), ('exogenous', 'O'), ('androgens', 'O'), ('.', 'O'))"
A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .,"(('A', 'O'), ('rechallenge', 'O'), ('with', 'O'), ('androgen', 'O'), ('produced', 'O'), ('symptoms', 'O'), ('of', 'O'), ('obstructive', 'B'), ('sleep', 'I'), ('apnea', 'I'), ('that', 'O'), ('abated', 'O'), ('upon', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('the', 'O'), ('hormone', 'O'), ('.', 'O'))"
Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .,"(('Previous', 'O'), ('reports', 'O'), ('have', 'O'), ('favored', 'O'), ('a', 'O'), ('role', 'O'), ('of', 'O'), ('androgens', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('sleep', 'B'), ('apnea', 'I'), ('.', 'O'))"
Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .,"(('Development', 'O'), ('of', 'O'), ('the', 'O'), ('obstructive', 'B'), ('sleep', 'I'), ('apnea', 'I'), ('syndrome', 'I'), ('must', 'O'), ('be', 'O'), ('considered', 'O'), ('a', 'O'), ('possible', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('androgen', 'O'), ('therapy', 'O'), ('.', 'O'))"
8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .,"(('8', 'O'), ('of', 'O'), ('the', 'O'), ('10', 'O'), ('monkeys', 'O'), ('developed', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('at', 'O'), ('an', 'O'), ('average', 'O'), ('cumulative', 'O'), ('adriamycin', 'O'), ('dose', 'O'), ('(', 'O'), ('310', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (')', 'O'), ('well', 'O'), ('below', 'O'), ('that', 'O'), ('considered', 'O'), ('the', 'O'), ('safe', 'O'), ('upper', 'O'), ('limit', 'O'), ('(', 'O'), ('550', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (')', 'O'), ('in', 'O'), ('man', 'O'), ('.', 'O'))"
"Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .","(('Histologically', 'O'), (',', 'O'), ('the', 'O'), ('myocardial', 'B'), ('lesions', 'I'), ('resembled', 'O'), ('those', 'O'), ('found', 'O'), ('in', 'O'), ('human', 'O'), ('anthracycline', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .,"(('1', 'O'), ('of', 'O'), ('the', 'O'), ('10', 'O'), ('monkeys', 'O'), ('developed', 'O'), ('acute', 'B'), ('myeloblastic', 'I'), ('leukemia', 'I'), ('after', 'O'), ('receiving', 'O'), ('324', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('of', 'O'), ('adriamycin', 'O'), (';', 'O'), ('the', 'O'), ('10th', 'O'), ('monkey', 'O'), ('is', 'O'), ('alive', 'O'), ('and', 'O'), ('well', 'O'), ('26', 'O'), ('months', 'O'), ('after', 'O'), ('the', 'O'), ('last', 'O'), ('dose', 'O'), ('of', 'O'), ('drug', 'O'), ('.', 'O'))"
"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('adriamycin', 'O'), ('is', 'O'), ('a', 'O'), ('more', 'O'), ('potent', 'O'), ('cardiotoxin', 'O'), ('in', 'O'), ('monkeys', 'O'), ('than', 'O'), ('in', 'O'), ('man', 'O'), (',', 'O'), ('and', 'O'), ('that', 'O'), ('leukemia', 'B'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('consequence', 'O'), ('of', 'O'), ('prolonged', 'O'), ('treatment', 'O'), ('with', 'O'), ('this', 'O'), ('drug', 'O'), ('.', 'O'))"
Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .,"(('Tricuspid', 'B'), ('valve', 'I'), ('regurgitation', 'I'), ('and', 'O'), ('lithium', 'O'), ('carbonate', 'O'), ('toxicity', 'B'), ('in', 'O'), ('a', 'O'), ('newborn', 'O'), ('infant', 'O'), ('.', 'O'))"
"A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .","(('A', 'O'), ('newborn', 'O'), ('with', 'O'), ('massive', 'O'), ('tricuspid', 'B'), ('regurgitation', 'I'), (',', 'O'), ('atrial', 'B'), ('flutter', 'I'), (',', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), (',', 'O'), ('and', 'O'), ('a', 'O'), ('high', 'O'), ('serum', 'O'), ('lithium', 'O'), ('level', 'O'), ('is', 'O'), ('described', 'O'), ('.', 'O'))"
"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .","(('This', 'O'), ('is', 'O'), ('the', 'O'), ('first', 'O'), ('patient', 'O'), ('to', 'O'), ('initially', 'O'), ('manifest', 'O'), ('tricuspid', 'B'), ('regurgitation', 'I'), ('and', 'O'), ('atrial', 'B'), ('flutter', 'I'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('11th', 'O'), ('described', 'O'), ('patient', 'O'), ('with', 'O'), ('cardiac', 'B'), ('disease', 'I'), ('among', 'O'), ('infants', 'O'), ('exposed', 'O'), ('to', 'O'), ('lithium', 'O'), ('compounds', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('trimester', 'O'), ('of', 'O'), ('pregnancy', 'O'), ('.', 'O'))"
Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .,"(('Lithium', 'O'), ('carbonate', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('factor', 'O'), ('in', 'O'), ('the', 'O'), ('increasing', 'O'), ('incidence', 'O'), ('of', 'O'), ('congenital', 'B'), ('heart', 'I'), ('disease', 'I'), ('when', 'O'), ('taken', 'O'), ('during', 'O'), ('early', 'O'), ('pregnancy', 'O'), ('.', 'O'))"
"It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .","(('It', 'O'), ('also', 'O'), ('causes', 'O'), ('neurologic', 'B'), ('depression', 'I'), (',', 'O'), ('cyanosis', 'B'), (',', 'O'), ('and', 'O'), ('cardiac', 'B'), ('arrhythmia', 'I'), ('when', 'O'), ('consumed', 'O'), ('prior', 'O'), ('to', 'O'), ('delivery', 'O'), ('.', 'O'))"
Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .,"(('Effects', 'O'), ('of', 'O'), ('the', 'O'), ('novel', 'O'), ('compound', 'O'), ('aniracetam', 'O'), ('(', 'O'), ('Ro', 'O'), ('13', 'O'), ('-', 'O'), ('5057', 'O'), (')', 'O'), ('upon', 'O'), ('impaired', 'B'), ('learning', 'I'), ('and', 'I'), ('memory', 'I'), ('in', 'O'), ('rodents', 'O'), ('.', 'O'))"
"The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3","(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('aniracetam', 'O'), ('(', 'O'), ('Ro', 'O'), ('13', 'O'), ('-', 'O'), ('5057', 'O'), (',', 'O'), ('1', 'O'), ('-', 'O'), ('anisoyl', 'O'), ('-', 'O'), ('2', 'O'), ('-', 'O'), ('pyrrolidinone', 'O'), (')', 'O'), ('was', 'O'), ('studied', 'O'), ('on', 'O'), ('various', 'O'), ('forms', 'O'), ('of', 'O'), ('experimentally', 'O'), ('impaired', 'B'), ('cognitive', 'I'), ('functions', 'I'), ('(', 'O'), ('learning', 'O'), ('and', 'O'), ('memory', 'O'), (')', 'O'), ('in', 'O'), ('rodents', 'O'), ('and', 'O'), ('produced', 'O'), ('the', 'O'), ('following', 'O'), ('effects', 'O'), (':', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('almost', 'O'), ('complete', 'O'), ('prevention', 'O'), ('of', 'O'), ('the', 'O'), ('incapacity', 'O'), ('to', 'O'), ('learn', 'O'), ('a', 'O'), ('discrete', 'O'), ('escape', 'O'), ('response', 'O'), ('in', 'O'), ('rats', 'O'), ('exposed', 'O'), ('to', 'O'), ('sublethal', 'O'), ('hypercapnia', 'B'), ('immediately', 'O'), ('before', 'O'), ('the', 'O'), ('acquisition', 'O'), ('session', 'O'), (';', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('partial', 'O'), ('(', 'O'), ('rats', 'O'), (')', 'O'), ('or', 'O'), ('complete', 'O'), ('(', 'O'), ('mice', 'O'), (')', 'O'), ('prevention', 'O'), ('of', 'O'), ('the', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('amnesia', 'B'), ('for', 'O'), ('a', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), (';', 'O'), ('(', 'O'), ('3', 'O'))"
") complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 )","((')', 'O'), ('complete', 'O'), ('protection', 'O'), ('against', 'O'), ('amnesia', 'B'), ('for', 'O'), ('a', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('in', 'O'), ('rats', 'O'), ('submitted', 'O'), ('to', 'O'), ('electroconvulsive', 'O'), ('shock', 'O'), ('immediately', 'O'), ('after', 'O'), ('avoidance', 'O'), ('acquisition', 'O'), (';', 'O'), ('(', 'O'), ('4', 'O'), (')', 'O'), ('prevention', 'O'), ('of', 'O'), ('the', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('retention', 'O'), ('-', 'O'), ('or', 'O'), ('retrieval', 'O'), ('-', 'O'), ('deficit', 'O'), ('for', 'O'), ('a', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('induced', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('mice', 'O'), ('by', 'O'), ('chloramphenicol', 'O'), ('or', 'O'), ('cycloheximide', 'O'), ('administered', 'O'), ('immediately', 'O'), ('after', 'O'), ('acquisition', 'O'), (';', 'O'), ('(', 'O'), ('5', 'O'), (')', 'O'), ('reversal', 'O'), (',', 'O'), ('when', 'O'), ('administered', 'O'), ('as', 'O'), ('late', 'O'), ('as', 'O'), ('1', 'O'), ('h', 'O'), ('before', 'O'), ('the', 'O'), ('retention', 'O'), ('test', 'O'), (',', 'O'), ('of', 'O'), ('the', 'O'), ('deficit', 'O'), ('in', 'O'), ('retention', 'O'), ('or', 'O'), ('retrieval', 'O'), ('of', 'O'), ('a', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('induced', 'O'), ('by', 'O'), ('cycloheximide', 'O'), ('injected', 'O'), ('2', 'O'), ('days', 'O'), ('previously', 'O'), (';', 'O'), ('(', 'O'), ('6', 'O'), (')', 'O'))"
These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .,"(('These', 'O'), ('improvements', 'O'), ('or', 'O'), ('normalizations', 'O'), ('of', 'O'), ('impaired', 'B'), ('cognitive', 'I'), ('functions', 'I'), ('were', 'O'), ('seen', 'O'), ('at', 'O'), ('oral', 'O'), ('aniracetam', 'O'), ('doses', 'O'), ('of', 'O'), ('10', 'O'), ('-', 'O'), ('100', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('.', 'O'))"
"The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .","(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('injected', 'O'), ('into', 'O'), ('the', 'O'), ('cerebral', 'O'), ('ventricles', 'O'), ('of', 'O'), ('group', 'O'), ('-', 'O'), ('housed', 'O'), ('unanaesthetized', 'O'), ('cats', 'O'), ('upon', 'O'), ('vocalization', 'O'), ('(', 'O'), ('rage', 'O'), (',', 'O'), ('hissing', 'O'), ('and', 'O'), ('snarling', 'O'), (')', 'O'), (',', 'O'), ('fighting', 'O'), ('(', 'O'), ('attack', 'O'), ('with', 'O'), ('paws', 'O'), ('and', 'O'), ('claws', 'O'), (',', 'O'), ('defense', 'O'), ('with', 'O'), ('paws', 'O'), ('and', 'O'), ('claws', 'O'), ('and', 'O'), ('biting', 'O'), (')', 'O'), (',', 'O'), ('mydriasis', 'B'), (',', 'O'), ('tremor', 'B'), ('and', 'O'), ('clonic', 'B'), ('-', 'I'), ('tonic', 'I'), ('convulsions', 'I'), ('produced', 'O'), ('by', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('injected', 'O'), ('similarly', 'O'), ('was', 'O'), ('investigated', 'O'), ('.', 'O'))"
"On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .","(('On', 'O'), ('the', 'O'), ('other', 'O'), ('hand', 'O'), (',', 'O'), ('mydriasis', 'B'), (',', 'O'), ('tremor', 'B'), ('and', 'O'), ('clonic', 'B'), ('-', 'I'), ('tonic', 'I'), ('convulsions', 'I'), ('evoked', 'O'), ('by', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('were', 'O'), ('not', 'O'), ('significantly', 'O'), ('changed', 'O'), ('by', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('.', 'O'))"
"It is apparent that calcium chloride can "" dissociate "" vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .","(('It', 'O'), ('is', 'O'), ('apparent', 'O'), ('that', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('can', 'O'), ('""', 'O'), ('dissociate', 'O'), ('""', 'O'), ('vocalization', 'O'), ('and', 'O'), ('fighting', 'O'), ('from', 'O'), ('autonomic', 'O'), ('and', 'O'), ('motor', 'O'), ('phenomena', 'O'), ('such', 'O'), ('as', 'O'), ('mydriasis', 'B'), (',', 'O'), ('tremor', 'B'), ('and', 'O'), ('clonic', 'B'), ('-', 'I'), ('tonic', 'I'), ('convulsions', 'I'), ('caused', 'O'), ('by', 'O'), ('carbachol', 'O'), ('and', 'O'), ('eserine', 'O'), ('.', 'O'))"
"Thiazide diuretics , hypokalemia and cardiac arrhythmias .","(('Thiazide', 'O'), ('diuretics', 'O'), (',', 'O'), ('hypokalemia', 'B'), ('and', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('.', 'O'))"
"We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .","(('We', 'O'), ('treated', 'O'), ('38', 'O'), ('patients', 'O'), ('(', 'O'), ('22', 'O'), ('low', 'O'), ('renin', 'O'), (',', 'O'), ('16', 'O'), ('normal', 'O'), ('renin', 'O'), (')', 'O'), ('with', 'O'), ('moderate', 'O'), ('diastolic', 'B'), ('hypertension', 'I'), ('with', 'O'), ('hydrochlorothiazide', 'O'), ('(', 'O'), ('HCTC', 'O'), (')', 'O'), ('administered', 'O'), ('on', 'O'), ('a', 'O'), ('twice', 'O'), ('daily', 'O'), ('schedule', 'O'), ('.', 'O'))"
Circulating lysosomal enzymes and acute hepatic necrosis .,"(('Circulating', 'O'), ('lysosomal', 'O'), ('enzymes', 'O'), ('and', 'O'), ('acute', 'B'), ('hepatic', 'I'), ('necrosis', 'I'), ('.', 'O'))"
"The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .","(('The', 'O'), ('activities', 'O'), ('of', 'O'), ('the', 'O'), ('lysosomal', 'O'), ('enzymes', 'O'), ('acid', 'O'), ('and', 'O'), ('neutral', 'O'), ('protease', 'O'), (',', 'O'), ('N', 'O'), ('-', 'O'), ('acetylglucosaminidase', 'O'), (',', 'O'), ('and', 'O'), ('acid', 'O'), ('phosphatase', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('the', 'O'), ('serum', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('fulminant', 'B'), ('hepatic', 'I'), ('failure', 'I'), ('.', 'O'))"
"Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .","(('Acid', 'O'), ('protease', 'O'), ('(', 'O'), ('cathepsin', 'O'), ('D', 'O'), (')', 'O'), ('activity', 'O'), ('was', 'O'), ('increased', 'O'), ('about', 'O'), ('tenfold', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('died', 'O'), ('and', 'O'), ('nearly', 'O'), ('fourfold', 'O'), ('in', 'O'), ('those', 'O'), ('who', 'O'), ('survived', 'O'), ('fulminant', 'B'), ('hepatic', 'I'), ('failure', 'I'), ('after', 'O'), ('paracetamol', 'O'), ('overdose', 'B'), (',', 'O'), ('whereas', 'O'), ('activities', 'O'), ('were', 'O'), ('increased', 'O'), ('equally', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('fulminant', 'B'), ('hepatic', 'I'), ('failure', 'I'), ('due', 'O'), ('to', 'O'), ('viral', 'B'), ('hepatitis', 'I'), ('whether', 'O'), ('or', 'O'), ('not', 'O'), ('they', 'O'), ('survived', 'O'), ('.', 'O'))"
Hepatic veno - occlusive disease caused by 6 - thioguanine .,"(('Hepatic', 'B'), ('veno', 'I'), ('-', 'I'), ('occlusive', 'I'), ('disease', 'I'), ('caused', 'O'), ('by', 'O'), ('6', 'O'), ('-', 'O'), ('thioguanine', 'O'), ('.', 'O'))"
Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .,"(('Clinically', 'O'), ('reversible', 'O'), ('veno', 'B'), ('-', 'I'), ('occlusive', 'I'), ('disease', 'I'), ('of', 'I'), ('the', 'I'), ('liver', 'I'), ('developed', 'O'), ('in', 'O'), ('a', 'O'), ('23', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('acute', 'B'), ('lymphocytic', 'I'), ('leukemia', 'I'), ('after', 'O'), ('10', 'O'), ('months', 'O'), ('of', 'O'), ('maintenance', 'O'), ('therapy', 'O'), ('with', 'O'), ('6', 'O'), ('-', 'O'), ('thioguanine', 'O'), ('.', 'O'))"
"Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .","(('Although', 'O'), ('this', 'O'), ('disease', 'O'), ('was', 'O'), ('clinically', 'O'), ('reversible', 'O'), (',', 'O'), ('some', 'O'), ('subintimal', 'O'), ('fibrosis', 'B'), ('about', 'O'), ('the', 'O'), ('terminal', 'O'), ('hepatic', 'O'), ('veins', 'O'), ('persisted', 'O'), ('.', 'O'))"
"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .","(('This', 'O'), ('case', 'O'), ('presented', 'O'), ('a', 'O'), ('unique', 'O'), ('opportunity', 'O'), ('to', 'O'), ('observe', 'O'), ('the', 'O'), ('histologic', 'O'), ('features', 'O'), ('of', 'O'), ('clinically', 'O'), ('reversible', 'O'), ('hepatic', 'B'), ('veno', 'I'), ('-', 'I'), ('occlusive', 'I'), ('disease', 'I'), ('over', 'O'), ('time', 'O'), (',', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('first', 'O'), ('case', 'O'), ('of', 'O'), ('veno', 'O'), ('-', 'O'), ('occlusive', 'O'), ('related', 'O'), ('solely', 'O'), ('to', 'O'), ('6', 'O'), ('-', 'O'), ('thioguanine', 'O'), ('.', 'O'))"
Chlorpropamide - induced optic neuropathy .,"(('Chlorpropamide', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('.', 'O'))"
A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .,"(('A', 'O'), ('65', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('adult', 'B'), ('-', 'I'), ('onset', 'I'), ('diabetes', 'I'), ('treated', 'O'), ('with', 'O'), ('chlorpropamide', 'O'), ('(', 'O'), ('Diabenese', 'O'), (')', 'O'), ('had', 'O'), ('a', 'O'), ('toxic', 'B'), ('optic', 'I'), ('neuropathy', 'I'), ('that', 'O'), ('resolved', 'O'), ('with', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('chlorpropamide', 'O'), ('therapy', 'O'), ('.', 'O'))"
"Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .","(('Visual', 'B'), ('loss', 'I'), ('occurs', 'O'), ('in', 'O'), ('diabetics', 'B'), ('for', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('reasons', 'O'), (',', 'O'), ('and', 'O'), ('accurate', 'O'), ('diagnosis', 'O'), ('is', 'O'), ('necessary', 'O'), ('to', 'O'), ('institute', 'O'), ('appropriate', 'O'), ('therapy', 'O'), ('.', 'O'))"
The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .,"(('The', 'O'), ('possibility', 'O'), ('of', 'O'), ('a', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('optic', 'B'), ('neuropathy', 'I'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('in', 'O'), ('the', 'O'), ('differential', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('visual', 'B'), ('loss', 'I'), ('in', 'O'), ('diabetics', 'B'), ('.', 'O'))"
Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .,"(('Plasma', 'O'), ('and', 'O'), ('urinary', 'O'), ('lipids', 'O'), ('and', 'O'), ('lipoproteins', 'O'), ('during', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('induced', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('by', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('.', 'O'))"
"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .","(('This', 'O'), ('study', 'O'), ('was', 'O'), ('undertaken', 'O'), ('to', 'O'), ('ascertain', 'O'), ('whether', 'O'), ('the', 'O'), ('alterations', 'O'), ('of', 'O'), ('plasma', 'O'), ('lipoproteins', 'O'), ('found', 'O'), ('in', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('induced', 'O'), ('by', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('were', 'O'), ('due', 'O'), ('to', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('per', 'O'), ('se', 'O'), (',', 'O'), ('or', 'O'), (',', 'O'), ('at', 'O'), ('least', 'O'), ('in', 'O'), ('part', 'O'), (',', 'O'), ('to', 'O'), ('the', 'O'), ('aminonucleoside', 'O'), ('.', 'O'))"
The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .,"(('The', 'O'), ('purpose', 'O'), ('of', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('plasma', 'O'), ('and', 'O'), ('urinary', 'O'), ('lipoproteins', 'O'), ('during', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('puromycin', 'O'), ('aminonucleoside', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('subsequent', 'O'), ('development', 'O'), ('of', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
"Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .","(('Since', 'O'), ('massive', 'O'), ('albuminuria', 'B'), ('occurred', 'O'), ('after', 'O'), ('6', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), (',', 'O'), ('the', 'O'), ('time', 'O'), ('-', 'O'), ('course', 'O'), ('study', 'O'), ('was', 'O'), ('divided', 'O'), ('into', 'O'), ('two', 'O'), ('stages', 'O'), (':', 'O'), ('pre', 'O'), ('-', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('(', 'O'), ('day', 'O'), ('1', 'O'), ('-', 'O'), ('5', 'O'), (')', 'O'), ('and', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('(', 'O'), ('day', 'O'), ('6', 'O'), ('-', 'O'), ('11', 'O'), (')', 'O'), ('.', 'O'))"
"In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .","(('In', 'O'), ('pre', 'O'), ('-', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('the', 'O'), ('plasma', 'O'), ('level', 'O'), ('of', 'O'), ('fatty', 'O'), ('acids', 'O'), (',', 'O'), ('triacylglycerol', 'O'), ('and', 'O'), ('VLDL', 'O'), ('decreased', 'O'), ('while', 'O'), ('that', 'O'), ('of', 'O'), ('phospholipid', 'O'), (',', 'O'), ('cholesteryl', 'O'), ('esters', 'O'), ('and', 'O'), ('HDL', 'O'), ('remained', 'O'), ('constant', 'O'), ('.', 'O'))"
"At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .","(('At', 'O'), ('the', 'O'), ('beginning', 'O'), ('of', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('(', 'O'), ('day', 'O'), ('6', 'O'), (')', 'O'), ('the', 'O'), ('concentration', 'O'), ('of', 'O'), ('plasma', 'O'), ('albumin', 'O'), ('dropped', 'O'), ('to', 'O'), ('a', 'O'), ('very', 'O'), ('low', 'O'), ('level', 'O'), (',', 'O'), ('while', 'O'), ('that', 'O'), ('of', 'O'), ('apolipoprotein', 'O'), ('A', 'O'), ('-', 'O'), ('I', 'O'), ('increased', 'O'), ('abruptly', 'O'), ('(', 'O'), ('4', 'O'), ('-', 'O'), ('fold', 'O'), ('increase', 'O'), (')', 'O'), ('and', 'O'), ('continued', 'O'), ('to', 'O'), ('rise', 'O'), (',', 'O'), ('although', 'O'), ('less', 'O'), ('steeply', 'O'), (',', 'O'), ('in', 'O'), ('the', 'O'), ('following', 'O'), ('days', 'O'), ('.', 'O'))"
"In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .","(('In', 'O'), ('the', 'O'), ('pre', 'O'), ('-', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('lipoproteinuria', 'O'), ('was', 'O'), ('negligible', 'O'), (',', 'O'), ('while', 'O'), ('in', 'O'), ('the', 'O'), ('early', 'O'), ('nephrotic', 'B'), ('stage', 'O'), ('the', 'O'), ('urinary', 'O'), ('loss', 'O'), ('of', 'O'), ('plasma', 'O'), ('lipoproteins', 'O'), ('consisted', 'O'), ('mainly', 'O'), ('of', 'O'), ('HDL', 'O'), ('.', 'O'))"
It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .,"(('It', 'O'), ('is', 'O'), ('likely', 'O'), ('that', 'O'), ('the', 'O'), ('early', 'O'), ('and', 'O'), ('striking', 'O'), ('increase', 'O'), ('of', 'O'), ('plasma', 'O'), ('HDL', 'O'), ('found', 'O'), ('in', 'O'), ('nephrotic', 'B'), ('rats', 'O'), ('is', 'O'), ('related', 'O'), ('to', 'O'), ('a', 'O'), ('direct', 'O'), ('effect', 'O'), ('of', 'O'), ('the', 'O'), ('drug', 'O'), ('on', 'O'), ('HDL', 'O'), ('metabolism', 'O'), ('.', 'O'))"
Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .,"(('Fatal', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('following', 'O'), ('topical', 'O'), ('administration', 'O'), ('of', 'O'), ('ophthalmic', 'O'), ('chloramphenicol', 'O'), ('.', 'O'))"
A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .,"(('A', 'O'), ('73', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('died', 'O'), ('of', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('less', 'O'), ('than', 'O'), ('two', 'O'), ('months', 'O'), ('after', 'O'), ('undergoing', 'O'), ('cataract', 'B'), ('extraction', 'O'), ('and', 'O'), ('beginning', 'O'), ('topical', 'O'), ('therapy', 'O'), ('with', 'O'), ('chloramphenicol', 'O'), ('.', 'O'))"
The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .,"(('The', 'O'), ('pattern', 'O'), ('of', 'O'), ('the', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('idiosyncratic', 'O'), ('response', 'O'), ('to', 'O'), ('chloramphenicol', 'O'), ('.', 'O'))"
"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .","(('This', 'O'), ('was', 'O'), ('the', 'O'), ('second', 'O'), ('report', 'O'), ('of', 'O'), ('fatal', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('after', 'O'), ('topical', 'O'), ('treatment', 'O'), ('with', 'O'), ('chloramphenicol', 'O'), ('for', 'O'), ('ocular', 'O'), ('conditions', 'O'), (',', 'O'), ('although', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('reversible', 'O'), ('bone', 'B'), ('marrow', 'I'), ('hypoplasia', 'I'), ('have', 'O'), ('also', 'O'), ('been', 'O'), ('reported', 'O'), ('.', 'O'))"
"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .","(('Any', 'O'), ('other', 'O'), ('suspected', 'O'), ('cases', 'O'), ('of', 'O'), ('ocular', 'B'), ('toxicity', 'I'), ('associated', 'O'), ('with', 'O'), ('topically', 'O'), ('applied', 'O'), ('chloramphenicol', 'O'), ('should', 'O'), ('be', 'O'), ('reported', 'O'), ('to', 'O'), ('the', 'O'), ('National', 'O'), ('Registry', 'O'), ('of', 'O'), ('Drug', 'O'), ('-', 'O'), ('Induced', 'O'), ('Ocular', 'O'), ('Side', 'O'), ('Effects', 'O'), (',', 'O'), ('Oregon', 'O'), ('Health', 'O'), ('Sciences', 'O'), ('University', 'O'), (',', 'O'), ('Portland', 'O'), (',', 'O'), ('OR', 'O'), ('97201', 'O'), ('.', 'O'))"
"In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v . Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .","(('In', 'O'), ('patients', 'O'), ('premedicated', 'O'), ('with', 'O'), ('scopolamine', 'O'), ('+', 'O'), ('morphine', 'O'), ('(', 'O'), ('+', 'O'), ('5', 'O'), ('mg', 'O'), ('nitrazepam', 'O'), ('the', 'O'), ('evening', 'O'), ('before', 'O'), ('surgery', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('sleep', 'O'), ('-', 'O'), ('inducing', 'O'), ('effect', 'O'), ('of', 'O'), ('midazolam', 'O'), ('0', 'O'), ('.', 'O'), ('15', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('was', 'O'), ('clearly', 'O'), ('slower', 'O'), ('in', 'O'), ('onset', 'O'), ('than', 'O'), ('that', 'O'), ('of', 'O'), ('thiopentone', 'O'), ('4', 'O'), ('.', 'O'), ('67', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('Somewhat', 'O'), ('fewer', 'O'), ('cardiovascular', 'O'), ('and', 'O'), ('local', 'O'), ('sequelae', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('midazolam', 'O'), ('group', 'O'), (',', 'O'), ('but', 'O'), (',', 'O'), ('although', 'O'), ('apnoea', 'B'), ('occurred', 'O'), ('less', 'O'), ('often', 'O'), ('in', 'O'), ('the', 'O'), ('midazolam', 'O'), ('group', 'O'), ('it', 'O'), ('lasted', 'O'), ('longer', 'O'), ('.', 'O'))"
The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('parkinsonism', 'B'), ('was', 'O'), ('higher', 'O'), ('at', 'O'), ('higher', 'O'), ('doses', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('and', 'O'), ('in', 'O'), ('younger', 'O'), ('patients', 'O'), ('.', 'O'))"
"However , these medications were more effective in both young and old patients when given after parkinsonism developed .","(('However', 'O'), (',', 'O'), ('these', 'O'), ('medications', 'O'), ('were', 'O'), ('more', 'O'), ('effective', 'O'), ('in', 'O'), ('both', 'O'), ('young', 'O'), ('and', 'O'), ('old', 'O'), ('patients', 'O'), ('when', 'O'), ('given', 'O'), ('after', 'O'), ('parkinsonism', 'B'), ('developed', 'O'), ('.', 'O'))"
"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .","(('Akathisia', 'B'), ('was', 'O'), ('controlled', 'O'), ('by', 'O'), ('the', 'O'), ('benzodiazepine', 'O'), ('lorazepam', 'O'), ('in', 'O'), ('14', 'O'), ('out', 'O'), ('of', 'O'), ('16', 'O'), ('patients', 'O'), (',', 'O'), ('while', 'O'), ('prophylactic', 'O'), ('antiparkinsonians', 'O'), ('were', 'O'), ('ineffective', 'O'), ('.', 'O'))"
Deaths from local anesthetic - induced convulsions in mice .,"(('Deaths', 'O'), ('from', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .,"(('Median', 'O'), ('convulsant', 'O'), ('(', 'O'), ('CD50', 'O'), (')', 'O'), ('and', 'O'), ('median', 'O'), ('lethal', 'O'), ('(', 'O'), ('LD50', 'O'), (')', 'O'), ('doses', 'O'), ('of', 'O'), ('three', 'O'), ('representative', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('were', 'O'), ('determined', 'O'), ('in', 'O'), ('adult', 'O'), ('mice', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('threat', 'O'), ('to', 'O'), ('life', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('-', 'O'), ('induced', 'O'), ('convulsions', 'B'), ('.', 'O'))"
"Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .","(('Convulsions', 'B'), ('always', 'O'), ('preceded', 'O'), ('death', 'O'), (',', 'O'), ('except', 'O'), ('after', 'O'), ('precipitous', 'O'), ('cardiopulmonary', 'B'), ('arrest', 'I'), ('from', 'O'), ('extreme', 'O'), ('doses', 'O'), ('.', 'O'))"
"A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .","(('A', 'O'), ('CD50', 'O'), ('dose', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetic', 'O'), ('(', 'O'), ('causing', 'O'), ('convulsions', 'B'), ('in', 'O'), ('50', 'O'), ('%', 'O'), ('of', 'O'), ('mice', 'O'), (')', 'O'), ('was', 'O'), ('fatal', 'O'), ('in', 'O'), ('90', 'O'), ('%', 'O'), ('of', 'O'), ('bupivacaine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), (',', 'O'), ('in', 'O'), ('57', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('chloroprocaine', 'O'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('in', 'O'), ('6', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('lidocaine', 'O'), ('group', 'O'), ('.', 'O'))"
The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .,"(('The', 'O'), ('narrow', 'O'), ('gap', 'O'), ('between', 'O'), ('convulsant', 'O'), ('and', 'O'), ('lethal', 'O'), ('doses', 'O'), ('of', 'O'), ('local', 'O'), ('anesthetics', 'O'), ('indicates', 'O'), ('that', 'O'), ('untreated', 'O'), ('convulsions', 'B'), ('present', 'O'), ('much', 'O'), ('more', 'O'), ('of', 'O'), ('a', 'O'), ('threat', 'O'), ('to', 'O'), ('life', 'O'), ('than', 'O'), ('heretofore', 'O'), ('appreciated', 'O'), ('.', 'O'))"
REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .,"(('REM', 'B'), ('sleep', 'I'), ('deprivation', 'I'), ('changes', 'O'), ('behavioral', 'O'), ('response', 'O'), ('to', 'O'), ('catecholaminergic', 'O'), ('and', 'O'), ('serotonergic', 'O'), ('receptor', 'O'), ('activation', 'O'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .,"(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('REM', 'B'), ('sleep', 'I'), ('deprivation', 'I'), ('(', 'O'), ('REMD', 'B'), (')', 'O'), ('on', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('aggressiveness', 'B'), ('and', 'O'), ('quipazine', 'O'), ('-', 'O'), ('induced', 'O'), ('head', 'B'), ('twitches', 'I'), ('in', 'O'), ('rats', 'O'), ('were', 'O'), ('determined', 'O'), ('.', 'O'))"
"Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .","(('Forty', 'O'), ('-', 'O'), ('eight', 'O'), ('hr', 'O'), ('of', 'O'), ('REMD', 'B'), ('increased', 'O'), ('apomorphine', 'O'), ('-', 'O'), ('induced', 'O'), ('aggressiveness', 'B'), (',', 'O'), ('and', 'O'), ('reduced', 'O'), ('(', 'O'), ('immediately', 'O'), ('after', 'O'), ('completing', 'O'), ('of', 'O'), ('REMD', 'B'), (')', 'O'), ('or', 'O'), ('increased', 'O'), ('(', 'O'), ('96', 'O'), ('hr', 'O'), ('after', 'O'), ('completing', 'O'), ('of', 'O'), ('REMD', 'B'), (')', 'O'), ('quipazine', 'O'), ('-', 'O'), ('induced', 'O'), ('head', 'B'), ('twitches', 'I'), ('.', 'O'))"
Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .,"(('Fatal', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('due', 'O'), ('to', 'O'), ('indomethacin', 'O'), ('-', 'O'), ('-', 'O'), ('lymphocyte', 'O'), ('transformation', 'O'), ('tests', 'O'), ('in', 'O'), ('vitro', 'O'), ('.', 'O'))"
"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .","(('Although', 'O'), ('indomethacin', 'O'), ('has', 'O'), ('been', 'O'), ('implicated', 'O'), ('as', 'O'), ('a', 'O'), ('possible', 'O'), ('cause', 'O'), ('of', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('on', 'O'), ('the', 'O'), ('basis', 'O'), ('of', 'O'), ('a', 'O'), ('few', 'O'), ('clinical', 'O'), ('observations', 'O'), (',', 'O'), ('its', 'O'), ('role', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('definitely', 'O'), ('established', 'O'), ('.', 'O'))"
A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('fatal', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('is', 'O'), ('described', 'O'), ('in', 'O'), ('which', 'O'), ('no', 'O'), ('drugs', 'O'), ('other', 'O'), ('than', 'O'), ('allopurinol', 'O'), ('and', 'O'), ('indomethacin', 'O'), ('were', 'O'), ('given', 'O'), ('.', 'O'))"
A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .,"(('A', 'O'), ('positive', 'O'), ('lymphocyte', 'O'), ('transformation', 'O'), ('test', 'O'), ('with', 'O'), ('indomethacin', 'O'), ('in', 'O'), ('vitro', 'O'), ('further', 'O'), ('substantiates', 'O'), ('the', 'O'), ('potential', 'O'), ('role', 'O'), ('of', 'O'), ('this', 'O'), ('drug', 'O'), ('in', 'O'), ('causing', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('in', 'O'), ('a', 'O'), ('susceptible', 'O'), ('patient', 'O'), ('.', 'O'))"
Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .,"(('Dose', 'O'), ('-', 'O'), ('effect', 'O'), ('and', 'O'), ('structure', 'O'), ('-', 'O'), ('function', 'O'), ('relationships', 'O'), ('in', 'O'), ('doxorubicin', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .,"(('The', 'O'), ('cardiomyopathy', 'B'), ('(', 'O'), ('CM', 'B'), (')', 'O'), ('produced', 'O'), ('by', 'O'), ('the', 'O'), ('anticancer', 'O'), ('drug', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('DXR', 'O'), (')', 'O'), ('(', 'O'), ('Adriamycin', 'O'), (')', 'O'), ('provides', 'O'), ('a', 'O'), ('unique', 'O'), ('opportunity', 'O'), ('to', 'O'), ('analyze', 'O'), ('dose', 'O'), ('-', 'O'), ('effect', 'O'), ('and', 'O'), ('structure', 'O'), ('-', 'O'), ('function', 'O'), ('relationships', 'O'), ('during', 'O'), ('development', 'O'), ('of', 'O'), ('myocardial', 'B'), ('disease', 'I'), ('.', 'O'))"
"In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .","(('In', 'O'), ('DXR', 'O'), ('-', 'O'), ('CM', 'B'), ('myocardial', 'B'), ('damage', 'I'), ('is', 'O'), ('proportional', 'O'), ('to', 'O'), ('the', 'O'), ('degree', 'O'), ('of', 'O'), ('cytotoxic', 'O'), ('insult', 'O'), ('(', 'O'), ('DXR', 'O'), ('dose', 'O'), (')', 'O'), ('while', 'O'), ('myocardial', 'O'), ('function', 'O'), ('is', 'O'), ('preserved', 'O'), ('until', 'O'), ('a', 'O'), ('critical', 'O'), ('dose', 'O'), ('or', 'O'), ('degree', 'O'), ('of', 'O'), ('damage', 'O'), ('is', 'O'), ('reached', 'O'), (',', 'O'), ('after', 'O'), ('which', 'O'), ('myocardial', 'O'), ('performance', 'O'), ('deteriorates', 'O'), ('rapidly', 'O'), ('.', 'O'))"
Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .,"(('Massive', 'O'), ('cerebral', 'B'), ('edema', 'I'), ('associated', 'O'), ('with', 'O'), ('fulminant', 'O'), ('hepatic', 'B'), ('failure', 'I'), ('in', 'O'), ('acetaminophen', 'O'), ('overdose', 'B'), (':', 'O'), ('possible', 'O'), ('role', 'O'), ('of', 'O'), ('cranial', 'O'), ('decompression', 'O'), ('.', 'O'))"
Cerebral edema may complicate the course of fulminant hepatic failure .,"(('Cerebral', 'B'), ('edema', 'I'), ('may', 'O'), ('complicate', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('fulminant', 'B'), ('hepatic', 'I'), ('failure', 'I'), ('.', 'O'))"
"We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .","(('We', 'O'), ('present', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('fatal', 'O'), ('acetaminophen', 'O'), ('-', 'O'), ('induced', 'O'), ('fulminant', 'B'), ('hepatic', 'I'), ('failure', 'I'), (',', 'O'), ('with', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('of', 'O'), ('cerebral', 'B'), ('edema', 'I'), (',', 'O'), ('unresponsive', 'O'), ('to', 'O'), ('conventional', 'O'), ('medical', 'O'), ('therapy', 'O'), ('.', 'O'))"
Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .,"(('Subjective', 'O'), ('assessment', 'O'), ('of', 'O'), ('sexual', 'B'), ('dysfunction', 'I'), ('of', 'O'), ('patients', 'O'), ('on', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('administration', 'O'), ('of', 'O'), ('digoxin', 'O'), ('.', 'O'))"
The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .,"(('The', 'O'), ('patients', 'O'), ('of', 'O'), ('the', 'O'), ('study', 'O'), ('and', 'O'), ('control', 'O'), ('group', 'O'), ('(', 'O'), ('without', 'O'), ('digoxin', 'O'), (')', 'O'), ('were', 'O'), ('of', 'O'), ('similar', 'O'), ('cardiac', 'O'), ('functional', 'O'), ('capacity', 'O'), ('and', 'O'), ('age', 'O'), ('(', 'O'), ('25', 'O'), ('-', 'O'), ('40', 'O'), ('years', 'O'), (')', 'O'), ('and', 'O'), ('were', 'O'), ('randomly', 'O'), ('selected', 'O'), ('from', 'O'), ('the', 'O'), ('rheumatic', 'B'), ('heart', 'I'), ('disease', 'I'), ('patients', 'O'), ('.', 'O'))"
"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .","(('Tests', 'O'), ('used', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('changes', 'O'), ('in', 'O'), ('sexual', 'O'), ('behavior', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('decrease', 'B'), ('in', 'I'), ('sexual', 'I'), ('desire', 'I'), (',', 'O'), ('sexual', 'O'), ('excitement', 'O'), ('phase', 'O'), ('(', 'O'), ('erection', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('frequency', 'O'), ('of', 'O'), ('sexual', 'O'), ('relations', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('group', 'O'), ('.', 'O'))"
Endometrial carcinoma after Hodgkin disease in childhood .,"(('Endometrial', 'B'), ('carcinoma', 'I'), ('after', 'O'), ('Hodgkin', 'B'), ('disease', 'I'), ('in', 'O'), ('childhood', 'O'), ('.', 'O'))"
A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .,"(('A', 'O'), ('34', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('patient', 'O'), ('developed', 'O'), ('metastic', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('after', 'O'), ('Hodgkin', 'B'), ('disease', 'I'), ('in', 'O'), ('childhood', 'O'), ('.', 'O'))"
"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .","(('She', 'O'), ('had', 'O'), ('ovarian', 'B'), ('failure', 'I'), ('after', 'O'), ('abdominal', 'O'), ('irradiation', 'O'), ('and', 'O'), ('chemotherapy', 'O'), ('for', 'O'), ('Hodgkin', 'B'), ('disease', 'I'), (',', 'O'), ('and', 'O'), ('received', 'O'), ('exogenous', 'O'), ('estrogens', 'O'), (',', 'O'), ('a', 'O'), ('treatment', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('in', 'O'), ('menopausal', 'O'), ('women', 'O'), ('.', 'O'))"
Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .,"(('Young', 'O'), ('women', 'O'), ('on', 'O'), ('replacement', 'O'), ('estrogens', 'O'), ('for', 'O'), ('ovarian', 'B'), ('failure', 'I'), ('after', 'O'), ('cancer', 'B'), ('therapy', 'O'), ('may', 'O'), ('also', 'O'), ('have', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('and', 'O'), ('should', 'O'), ('be', 'O'), ('examined', 'O'), ('periodically', 'O'), ('.', 'O'))"
Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .,"(('Nephrotoxicity', 'B'), ('of', 'O'), ('cyclosporin', 'O'), ('A', 'O'), ('and', 'O'), ('FK506', 'O'), (':', 'O'), ('inhibition', 'O'), ('of', 'O'), ('calcineurin', 'O'), ('phosphatase', 'O'), ('.', 'O'))"
"Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .","(('Cyclosporin', 'O'), ('A', 'O'), ('(', 'O'), ('CsA', 'O'), (';', 'O'), ('50', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('and', 'O'), ('Fujimycine', 'O'), ('(', 'O'), ('FK506', 'O'), (';', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('the', 'O'), ('related', 'O'), ('macrolide', 'O'), ('immunosuppressant', 'O'), ('rapamycin', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), (',', 'O'), ('caused', 'O'), ('a', 'O'), ('reduction', 'O'), ('of', 'O'), ('glomerular', 'O'), ('filtration', 'O'), ('rate', 'O'), (',', 'O'), ('degenerative', 'O'), ('changes', 'O'), ('of', 'O'), ('proximal', 'O'), ('tubular', 'O'), ('epithelium', 'O'), (',', 'O'), ('and', 'O'), ('hypertrophy', 'B'), ('of', 'O'), ('the', 'O'), ('juxtaglomerular', 'O'), ('apparatus', 'O'), ('in', 'O'), ('male', 'O'), ('Wistar', 'O'), ('rats', 'O'), ('when', 'O'), ('given', 'O'), ('for', 'O'), ('10', 'O'), ('days', 'O'), ('.', 'O'))"
The molecular mechanisms of CsA and FK506 toxicity were investigated .,"(('The', 'O'), ('molecular', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), ('toxicity', 'B'), ('were', 'O'), ('investigated', 'O'), ('.', 'O'))"
These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .,"(('These', 'O'), ('results', 'O'), ('suggest', 'O'), ('that', 'O'), ('the', 'O'), ('nephrotoxic', 'B'), ('effects', 'O'), ('of', 'O'), ('CsA', 'O'), ('and', 'O'), ('FK506', 'O'), ('is', 'O'), ('likely', 'O'), ('mediated', 'O'), ('through', 'O'), ('binding', 'O'), ('to', 'O'), ('renal', 'O'), ('immunophilin', 'O'), ('and', 'O'), ('inhibiting', 'O'), ('calcineurin', 'O'), ('phosphatase', 'O'), ('.', 'O'))"
Acute renal failure in high dose carboplatin chemotherapy .,"(('Acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('in', 'O'), ('high', 'O'), ('dose', 'O'), ('carboplatin', 'O'), ('chemotherapy', 'O'), ('.', 'O'))"
Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .,"(('Carboplatin', 'O'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('to', 'O'), ('cause', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('when', 'O'), ('administered', 'O'), ('in', 'O'), ('high', 'O'), ('doses', 'O'), ('to', 'O'), ('adult', 'O'), ('patients', 'O'), ('.', 'O'))"
Acute renal failure developed followed by a slow partial recovery of renal function .,"(('Acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('developed', 'O'), ('followed', 'O'), ('by', 'O'), ('a', 'O'), ('slow', 'O'), ('partial', 'O'), ('recovery', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('.', 'O'))"
"At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .","(('At', 'O'), ('various', 'O'), ('time', 'O'), ('intervals', 'O'), (',', 'O'), ('physical', 'O'), ('examination', 'O'), ('and', 'O'), ('blood', 'O'), ('collection', 'O'), ('for', 'O'), ('ex', 'O'), ('vivo', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('and', 'O'), ('determination', 'O'), ('of', 'O'), ('intraplatelet', 'O'), ('cAMP', 'O'), ('were', 'O'), ('performed', 'O'), ('.', 'O'))"
"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .","(('Seven', 'O'), ('out', 'O'), ('of', 'O'), ('12', 'O'), ('subjects', 'O'), ('experienced', 'O'), ('headache', 'B'), ('of', 'O'), ('a', 'O'), ('short', 'O'), ('duration', 'O'), ('accompanying', 'O'), ('facial', 'B'), ('flush', 'I'), ('in', 'O'), ('one', 'O'), ('and', 'O'), ('nausea', 'B'), ('in', 'O'), ('one', 'O'), (',', 'O'), ('especially', 'O'), ('after', 'O'), ('ingestion', 'O'), ('of', 'O'), ('CLZ', 'O'), ('.', 'O'))"
Pravastatin - associated myopathy .,"(('Pravastatin', 'O'), ('-', 'O'), ('associated', 'O'), ('myopathy', 'B'), ('.', 'O'))"
"A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .","(('A', 'O'), ('case', 'O'), ('of', 'O'), ('acute', 'O'), ('inflammatory', 'B'), ('myopathy', 'I'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('pravastatin', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('hydrophilic', 'O'), ('3', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('-', 'O'), ('3', 'O'), ('methylglutaril', 'O'), ('coenzyme', 'O'), ('A', 'O'), ('reductase', 'O'), ('inhibitor', 'O'), (',', 'O'), ('is', 'O'), ('reported', 'O'), ('.', 'O'))"
"The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .","(('The', 'O'), ('patient', 'O'), (',', 'O'), ('a', 'O'), ('69', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('was', 'O'), ('affected', 'O'), ('by', 'O'), ('non', 'B'), ('-', 'I'), ('insulin', 'I'), ('-', 'I'), ('dependent', 'I'), ('diabetes', 'I'), ('mellitus', 'I'), ('and', 'O'), ('hypertension', 'B'), ('.', 'O'))"
He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .,"(('He', 'O'), ('assumed', 'O'), ('pravastatin', 'O'), ('(', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('because', 'O'), ('of', 'O'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .,"(('He', 'O'), ('was', 'O'), ('admitted', 'O'), ('with', 'O'), ('acute', 'O'), ('myopathy', 'B'), ('of', 'O'), ('the', 'O'), ('lower', 'O'), ('limbs', 'O'), ('which', 'O'), ('resolved', 'O'), ('in', 'O'), ('a', 'O'), ('few', 'O'), ('days', 'O'), ('after', 'O'), ('pravastatin', 'O'), ('discontinuation', 'O'), ('.', 'O'))"
"A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .","(('A', 'O'), ('previously', 'O'), ('unknown', 'O'), ('hypothyroidism', 'B'), (',', 'O'), ('probably', 'O'), ('due', 'O'), ('to', 'O'), ('chronic', 'O'), ('autoimmune', 'B'), ('thyroiditis', 'I'), (',', 'O'), ('was', 'O'), ('evidenced', 'O'), ('.', 'O'))"
"While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .","(('While', 'O'), ('lovastatin', 'O'), ('and', 'O'), ('simvastatin', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('toxic', 'O'), ('myopathy', 'B'), (',', 'O'), ('pravastatin', 'O'), ('-', 'O'), ('associated', 'O'), ('myopathy', 'B'), ('could', 'O'), ('represent', 'O'), ('a', 'O'), ('distinct', 'O'), (',', 'O'), ('inflammatory', 'O'), ('entity', 'O'), ('.', 'O'))"
Reversal of ammonia coma in rats by L - dopa : a peripheral effect .,"(('Reversal', 'O'), ('of', 'O'), ('ammonia', 'O'), ('coma', 'B'), ('in', 'O'), ('rats', 'O'), ('by', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), (':', 'O'), ('a', 'O'), ('peripheral', 'O'), ('effect', 'O'), ('.', 'O'))"
Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .,"(('Ammonia', 'O'), ('coma', 'B'), ('was', 'O'), ('produced', 'O'), ('in', 'O'), ('rats', 'O'), ('within', 'O'), ('10', 'O'), ('to', 'O'), ('15', 'O'), ('minutes', 'O'), ('of', 'O'), ('an', 'O'), ('intraperitonealinjection', 'O'), ('of', 'O'), ('1', 'O'), ('.', 'O'), ('7', 'O'), ('mmol', 'O'), ('NH4CL', 'O'), ('.', 'O'))"
This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .,"(('This', 'O'), ('coma', 'B'), ('was', 'O'), ('prevented', 'O'), ('with', 'O'), ('1', 'O'), ('.', 'O'), ('68', 'O'), ('mmol', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('given', 'O'), ('by', 'O'), ('gastric', 'O'), ('intubation', 'O'), ('15', 'O'), ('minutes', 'O'), ('before', 'O'), ('the', 'O'), ('ammonium', 'O'), ('salt', 'O'), ('injection', 'O'), ('.', 'O'))"
Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .,"(('Intraventricular', 'O'), ('infusion', 'O'), ('of', 'O'), ('dopamine', 'O'), ('sufficient', 'O'), ('to', 'O'), ('raise', 'O'), ('the', 'O'), ('brain', 'O'), ('dopamine', 'O'), ('to', 'O'), ('the', 'O'), ('same', 'O'), ('extent', 'O'), ('did', 'O'), ('not', 'O'), ('prevent', 'O'), ('the', 'O'), ('ammonia', 'O'), ('coma', 'B'), ('nor', 'O'), ('affect', 'O'), ('the', 'O'), ('blood', 'O'), ('and', 'O'), ('brain', 'O'), ('ammonia', 'O'), ('concentrations', 'O'), ('.', 'O'))"
Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .,"(('Bilateral', 'O'), ('nephrectomy', 'O'), ('eliminated', 'O'), ('the', 'O'), ('beneficial', 'O'), ('effect', 'O'), ('of', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('on', 'O'), ('blood', 'O'), ('and', 'O'), ('brain', 'O'), ('ammonia', 'O'), ('and', 'O'), ('the', 'O'), ('ammonia', 'O'), ('coma', 'B'), ('was', 'O'), ('not', 'O'), ('prevented', 'O'), ('.', 'O'))"
"Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .","(('Thus', 'O'), (',', 'O'), ('the', 'O'), ('reduction', 'O'), ('in', 'O'), ('blood', 'O'), ('and', 'O'), ('brain', 'O'), ('ammonia', 'O'), ('and', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('ammonia', 'O'), ('coma', 'B'), ('after', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), (',', 'O'), ('can', 'O'), ('be', 'O'), ('accounted', 'O'), ('for', 'O'), ('by', 'O'), ('the', 'O'), ('peripheral', 'O'), ('effect', 'O'), ('of', 'O'), ('dopamine', 'O'), ('on', 'O'), ('renal', 'O'), ('function', 'O'), ('rather', 'O'), ('than', 'O'), ('its', 'O'), ('central', 'O'), ('action', 'O'), ('.', 'O'))"
Etoposide - related myocardial infarction .,"(('Etoposide', 'O'), ('-', 'O'), ('related', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('.', 'O'))"
"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .","(('The', 'O'), ('occurrence', 'O'), ('of', 'O'), ('a', 'O'), ('myocardial', 'B'), ('infarction', 'I'), ('is', 'O'), ('reported', 'O'), ('after', 'O'), ('chemotherapy', 'O'), ('containing', 'O'), ('etoposide', 'O'), (',', 'O'), ('in', 'O'), ('a', 'O'), ('man', 'O'), ('with', 'O'), ('no', 'O'), ('risk', 'O'), ('factors', 'O'), ('for', 'O'), ('coronary', 'B'), ('heart', 'I'), ('disease', 'I'), ('.', 'O'))"
"Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .","(('Two', 'O'), ('halogenated', 'O'), ('anesthetics', 'O'), (',', 'O'), ('enflurane', 'O'), ('and', 'O'), ('isoflurane', 'O'), (',', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('allergic', 'O'), ('-', 'O'), ('type', 'O'), ('hepatic', 'B'), ('injury', 'I'), ('both', 'O'), ('alone', 'O'), ('and', 'O'), ('following', 'O'), ('previous', 'O'), ('exposure', 'O'), ('to', 'O'), ('halothane', 'O'), ('.', 'O'))"
Halothane hepatitis appears to involve an aberrant immune response .,"(('Halothane', 'O'), ('hepatitis', 'B'), ('appears', 'O'), ('to', 'O'), ('involve', 'O'), ('an', 'O'), ('aberrant', 'O'), ('immune', 'O'), ('response', 'O'), ('.', 'O'))"
An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .,"(('An', 'O'), ('antibody', 'O'), ('response', 'O'), ('to', 'O'), ('a', 'O'), ('protein', 'O'), ('-', 'O'), ('bound', 'O'), ('biotransformation', 'O'), ('product', 'O'), ('(', 'O'), ('trifluoroacetyl', 'O'), ('adduct', 'O'), (')', 'O'), ('has', 'O'), ('been', 'O'), ('detected', 'O'), ('on', 'O'), ('halothane', 'O'), ('hepatitis', 'B'), ('patients', 'O'), ('.', 'O'))"
This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('performed', 'O'), ('to', 'O'), ('determine', 'O'), ('cross', 'O'), ('-', 'O'), ('reactivity', 'O'), ('between', 'O'), ('enflurane', 'O'), ('and', 'O'), ('isoflurane', 'O'), ('with', 'O'), ('the', 'O'), ('hypersensitivity', 'B'), ('induced', 'O'), ('by', 'O'), ('halothane', 'O'), ('.', 'O'))"
This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .,"(('This', 'O'), ('supports', 'O'), ('and', 'O'), ('extends', 'O'), ('previous', 'O'), ('evidence', 'O'), ('for', 'O'), ('a', 'O'), ('mechanism', 'O'), ('by', 'O'), ('which', 'O'), ('enflurane', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('isoflurane', 'O'), ('could', 'O'), ('produce', 'O'), ('a', 'O'), ('hypersensitivity', 'B'), ('condition', 'O'), ('similar', 'O'), ('to', 'O'), ('that', 'O'), ('of', 'O'), ('halothane', 'O'), ('hepatitis', 'B'), ('either', 'O'), ('alone', 'O'), ('or', 'O'), ('subsequent', 'O'), ('to', 'O'), ('halothane', 'O'), ('administration', 'O'), ('.', 'O'))"
Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .,"(('Cholinergic', 'O'), ('toxicity', 'B'), ('resulting', 'O'), ('from', 'O'), ('ocular', 'O'), ('instillation', 'O'), ('of', 'O'), ('echothiophate', 'O'), ('iodide', 'O'), ('eye', 'O'), ('drops', 'O'), ('.', 'O'))"
"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .","(('A', 'O'), ('patient', 'O'), ('developed', 'O'), ('a', 'O'), ('severe', 'O'), ('cholinergic', 'O'), ('syndrome', 'O'), ('from', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('echothiophate', 'O'), ('iodide', 'O'), ('ophthalmic', 'O'), ('drops', 'O'), (',', 'O'), ('presented', 'O'), ('with', 'O'), ('profound', 'O'), ('muscle', 'B'), ('weakness', 'I'), ('and', 'O'), ('was', 'O'), ('initially', 'O'), ('given', 'O'), ('the', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('myasthenia', 'B'), ('gravis', 'I'), ('.', 'O'))"
Seizure after flumazenil administration in a pediatric patient .,"(('Seizure', 'B'), ('after', 'O'), ('flumazenil', 'O'), ('administration', 'O'), ('in', 'O'), ('a', 'O'), ('pediatric', 'O'), ('patient', 'O'), ('.', 'O'))"
Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .,"(('Flumazenil', 'O'), ('is', 'O'), ('a', 'O'), ('benzodiazepine', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('used', 'O'), ('to', 'O'), ('reverse', 'O'), ('sedation', 'O'), ('and', 'O'), ('respiratory', 'B'), ('depression', 'I'), ('induced', 'O'), ('by', 'O'), ('benzodiazepines', 'O'), ('.', 'O'))"
Seizures and cardiac arrhythmias have complicated its use in adult patients .,"(('Seizures', 'B'), ('and', 'O'), ('cardiac', 'B'), ('arrhythmias', 'I'), ('have', 'O'), ('complicated', 'O'), ('its', 'O'), ('use', 'O'), ('in', 'O'), ('adult', 'O'), ('patients', 'O'), ('.', 'O'))"
We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('a', 'O'), ('generalized', 'O'), ('tonic', 'B'), ('-', 'I'), ('clonic', 'I'), ('seizure', 'I'), ('in', 'O'), ('a', 'O'), ('pediatric', 'O'), ('patient', 'O'), ('following', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('flumazenil', 'O'), ('.', 'O'))"
"This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .","(('This', 'O'), ('phase', 'O'), ('I', 'O'), ('trial', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('maximal', 'O'), ('-', 'O'), ('tolerated', 'O'), ('dosage', 'O'), ('(', 'O'), ('MTD', 'O'), (')', 'O'), (',', 'O'), ('toxicities', 'B'), (',', 'O'), ('and', 'O'), ('pharmacokinetics', 'O'), ('of', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('administered', 'O'), ('on', 'O'), ('an', 'O'), ('intermittent', 'O'), ('schedule', 'O'), ('in', 'O'), ('children', 'O'), ('with', 'O'), ('neuroblastoma', 'B'), ('following', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('(', 'O'), ('BMT', 'O'), (')', 'O'), ('.', 'O'))"
The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .,"(('The', 'O'), ('dose', 'O'), ('was', 'O'), ('escalated', 'O'), ('from', 'O'), ('100', 'O'), ('to', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('until', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('toxicity', 'B'), ('(', 'O'), ('DLT', 'O'), (')', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .","(('Dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('toxicities', 'B'), ('in', 'O'), ('six', 'O'), ('of', 'O'), ('nine', 'O'), ('patients', 'O'), ('at', 'O'), ('200', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('/', 'O'), ('d', 'O'), ('included', 'O'), ('hypercalcemia', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('3', 'O'), (')', 'O'), (',', 'O'), ('rash', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('2', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('anemia', 'B'), ('/', 'O'), ('thrombocytopenia', 'B'), ('/', 'O'), ('emesis', 'B'), ('/', 'O'), ('rash', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('1', 'O'), (')', 'O'), ('.', 'O'))"
All toxicities resolved after cis - RA was discontinued .,"(('All', 'O'), ('toxicities', 'B'), ('resolved', 'O'), ('after', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('was', 'O'), ('discontinued', 'O'), ('.', 'O'))"
"The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .","(('The', 'O'), ('DLT', 'O'), ('included', 'O'), ('hypercalcemia', 'B'), (',', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('predicted', 'O'), ('by', 'O'), ('serum', 'O'), ('cis', 'O'), ('-', 'O'), ('RA', 'O'), ('levels', 'O'), ('.', 'O'))"
"Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .","(('Time', 'O'), ('dependence', 'O'), ('of', 'O'), ('plasma', 'O'), ('malondialdehyde', 'O'), (',', 'O'), ('oxypurines', 'O'), (',', 'O'), ('and', 'O'), ('nucleosides', 'O'), ('during', 'O'), ('incomplete', 'O'), ('cerebral', 'B'), ('ischemia', 'I'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('.', 'O'))"
Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .,"(('Incomplete', 'O'), ('cerebral', 'B'), ('ischemia', 'I'), ('(', 'O'), ('30', 'O'), ('min', 'O'), (')', 'O'), ('was', 'O'), ('induced', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('by', 'O'), ('bilaterally', 'O'), ('clamping', 'O'), ('the', 'O'), ('common', 'O'), ('carotid', 'O'), ('arteries', 'O'), ('.', 'O'))"
"Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .","(('Peripheral', 'O'), ('venous', 'O'), ('blood', 'O'), ('samples', 'O'), ('were', 'O'), ('withdrawn', 'O'), ('from', 'O'), ('the', 'O'), ('femoral', 'O'), ('vein', 'O'), ('four', 'O'), ('times', 'O'), ('(', 'O'), ('once', 'O'), ('every', 'O'), ('5', 'O'), ('min', 'O'), (')', 'O'), ('before', 'O'), ('ischemia', 'B'), ('(', 'O'), ('0', 'O'), ('time', 'O'), (')', 'O'), ('and', 'O'), ('5', 'O'), (',', 'O'), ('15', 'O'), (',', 'O'), ('and', 'O'), ('30', 'O'), ('min', 'O'), ('after', 'O'), ('ischemia', 'B'), ('.', 'O'))"
"During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .","(('During', 'O'), ('ischemia', 'B'), (',', 'O'), ('a', 'O'), ('time', 'O'), ('-', 'O'), ('dependent', 'O'), ('increase', 'O'), ('of', 'O'), ('plasma', 'O'), ('oxypurines', 'O'), ('and', 'O'), ('nucleosides', 'O'), ('was', 'O'), ('observed', 'O'), ('.', 'O'))"
"Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .","(('Plasma', 'O'), ('malondialdehyde', 'O'), (',', 'O'), ('which', 'O'), ('was', 'O'), ('present', 'O'), ('in', 'O'), ('minimal', 'O'), ('amount', 'O'), ('at', 'O'), ('zero', 'O'), ('time', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('058', 'O'), ('mumol', 'O'), ('/', 'O'), ('liter', 'O'), ('plasma', 'O'), (';', 'O'), ('SD', 'O'), ('0', 'O'), ('.', 'O'), ('015', 'O'), (')', 'O'), (',', 'O'), ('increased', 'O'), ('after', 'O'), ('5', 'O'), ('min', 'O'), ('of', 'O'), ('ischemia', 'B'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('a', 'O'), ('fivefold', 'O'), ('increase', 'O'), ('after', 'O'), ('30', 'O'), ('min', 'O'), ('of', 'O'), ('carotid', 'O'), ('occlusion', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('298', 'O'), ('mumol', 'O'), ('/', 'O'), ('liter', 'O'), ('plasma', 'O'), (';', 'O'), ('SD', 'O'), ('0', 'O'), ('.', 'O'), ('078', 'O'), (')', 'O'), ('.', 'O'))"
"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w . of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w . of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .","(('Increased', 'O'), ('plasma', 'O'), ('malondialdehyde', 'O'), ('was', 'O'), ('also', 'O'), ('recorded', 'O'), ('in', 'O'), ('two', 'O'), ('other', 'O'), ('groups', 'O'), ('of', 'O'), ('animals', 'O'), ('subjected', 'O'), ('to', 'O'), ('the', 'O'), ('same', 'O'), ('experimental', 'O'), ('model', 'O'), (',', 'O'), ('one', 'O'), ('receiving', 'O'), ('20', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('b', 'O'), ('.', 'O'), ('w', 'O'), ('.', 'O'), ('of', 'O'), ('the', 'O'), ('cyclooxygenase', 'O'), ('inhibitor', 'O'), ('acetylsalicylate', 'O'), ('intravenously', 'O'), ('immediately', 'O'), ('before', 'O'), ('ischemia', 'B'), (',', 'O'), ('the', 'O'), ('other', 'O'), ('receiving', 'O'), ('650', 'O'), ('micrograms', 'O'), ('/', 'O'), ('kg', 'O'), ('b', 'O'), ('.', 'O'), ('w', 'O'), ('.', 'O'), ('of', 'O'), ('the', 'O'), ('hypotensive', 'B'), ('drug', 'O'), ('nitroprusside', 'O'), ('at', 'O'), ('a', 'O'), ('flow', 'O'), ('rate', 'O'), ('of', 'O'), ('103', 'O'), ('microliters', 'O'), ('/', 'O'), ('min', 'O'), ('intravenously', 'O'), ('during', 'O'), ('ischemia', 'B'), (',', 'O'), ('although', 'O'), ('in', 'O'), ('this', 'O'), ('latter', 'O'), ('group', 'O'), ('malondialdehyde', 'O'), ('was', 'O'), ('significantly', 'O'), ('higher', 'O'), ('.', 'O'))"
"The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('The', 'O'), ('present', 'O'), ('data', 'O'), ('indicate', 'O'), ('that', 'O'), ('the', 'O'), ('determination', 'O'), ('of', 'O'), ('malondialdehyde', 'O'), (',', 'O'), ('oxypurines', 'O'), (',', 'O'), ('and', 'O'), ('nucleosides', 'O'), ('in', 'O'), ('peripheral', 'O'), ('blood', 'O'), (',', 'O'), ('may', 'O'), ('be', 'O'), ('used', 'O'), ('to', 'O'), ('monitor', 'O'), ('the', 'O'), ('metabolic', 'O'), ('alterations', 'O'), ('of', 'O'), ('tissues', 'O'), ('occurring', 'O'), ('during', 'O'), ('ischemic', 'B'), ('phenomena', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .,"(('Acute', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('of', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('adriamycin', 'O'), (')', 'O'), ('-', 'O'), ('loaded', 'O'), ('cyanoacrylate', 'O'), ('nanoparticles', 'O'), ('.', 'O'))"
Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .,"(('Acute', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('loaded', 'O'), ('nanoparticle', 'O'), ('(', 'O'), ('DXNP', 'O'), (')', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('was', 'O'), ('explored', 'O'), ('in', 'O'), ('both', 'O'), ('normal', 'O'), ('rats', 'O'), ('and', 'O'), ('rats', 'O'), ('with', 'O'), ('experimental', 'O'), ('glomerulonephritis', 'B'), ('.', 'O'))"
A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .,"(('A', 'O'), ('3', 'O'), ('times', 'O'), ('higher', 'O'), ('proteinuria', 'B'), ('appeared', 'O'), ('in', 'O'), ('animals', 'O'), ('treated', 'O'), ('with', 'O'), ('DXNP', 'O'), ('than', 'O'), ('in', 'O'), ('those', 'O'), ('treated', 'O'), ('with', 'O'), ('DX', 'O'), ('.', 'O'))"
Free NP did not provoke any proteinuria .,"(('Free', 'O'), ('NP', 'O'), ('did', 'O'), ('not', 'O'), ('provoke', 'O'), ('any', 'O'), ('proteinuria', 'B'), ('.', 'O'))"
"In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .","(('In', 'O'), ('rats', 'O'), ('with', 'O'), ('immune', 'O'), ('experimental', 'O'), ('glomerulonephritis', 'B'), (',', 'O'), ('5', 'O'), ('/', 'O'), ('6', 'O'), ('rats', 'O'), ('given', 'O'), ('DX', 'O'), ('died', 'O'), ('within', 'O'), ('7', 'O'), ('days', 'O'), (',', 'O'), ('in', 'O'), ('contrast', 'O'), ('to', 'O'), ('animals', 'O'), ('treated', 'O'), ('by', 'O'), ('DXNP', 'O'), (',', 'O'), ('NP', 'O'), (',', 'O'), ('or', 'O'), ('untreated', 'O'), (',', 'O'), ('which', 'O'), ('all', 'O'), ('survived', 'O'), ('.', 'O'))"
"Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .","(('Proteinuria', 'B'), ('appeared', 'O'), ('in', 'O'), ('all', 'O'), ('series', 'O'), (',', 'O'), ('but', 'O'), ('was', 'O'), ('2', 'O'), ('-', 'O'), ('5', 'O'), ('times', 'O'), ('more', 'O'), ('intense', 'O'), ('(', 'O'), ('p', 'O'), ('>', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('and', 'O'), ('prolonged', 'O'), ('after', 'O'), ('doxorubicin', 'O'), ('treatment', 'O'), ('(', 'O'), ('400', 'O'), ('-', 'O'), ('700', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), (',', 'O'), ('without', 'O'), ('significant', 'O'), ('difference', 'O'), ('between', 'O'), ('DXNP', 'O'), ('and', 'O'), ('DX', 'O'), ('.', 'O'))"
"These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .","(('These', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('these', 'O'), ('experimental', 'O'), ('conditions', 'O'), (',', 'O'), ('DXNP', 'O'), ('killed', 'O'), ('less', 'O'), ('animals', 'O'), ('than', 'O'), ('free', 'O'), ('DX', 'O'), (',', 'O'), ('despite', 'O'), ('of', 'O'), ('an', 'O'), ('enhanced', 'O'), ('renal', 'B'), ('toxicity', 'I'), ('of', 'O'), ('the', 'O'), ('former', 'O'), ('.', 'O'))"
"Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .","(('Both', 'O'), ('effects', 'O'), ('(', 'O'), ('better', 'O'), ('survival', 'O'), ('and', 'O'), ('nephrosis', 'B'), (')', 'O'), ('are', 'O'), ('most', 'O'), ('probably', 'O'), ('related', 'O'), ('to', 'O'), ('an', 'O'), ('enhanced', 'O'), ('capture', 'O'), ('of', 'O'), ('DXNP', 'O'), ('by', 'O'), ('cells', 'O'), ('of', 'O'), ('the', 'O'), ('mononuclear', 'O'), ('phagocyte', 'O'), ('system', 'O'), (',', 'O'), ('including', 'O'), ('mesangial', 'O'), ('cells', 'O'), ('.', 'O'))"
"Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?","(('Prostaglandin', 'O'), ('E2', 'O'), ('-', 'O'), ('induced', 'O'), ('bladder', 'B'), ('hyperactivity', 'I'), ('in', 'O'), ('normal', 'O'), (',', 'O'), ('conscious', 'O'), ('rats', 'O'), (':', 'O'), ('involvement', 'O'), ('of', 'O'), ('tachykinins', 'O'), ('?', 'O'))"
"Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .","(('Prostanoids', 'O'), ('may', 'O'), (',', 'O'), ('via', 'O'), ('release', 'O'), ('of', 'O'), ('tachykinins', 'O'), (',', 'O'), ('contribute', 'O'), ('to', 'O'), ('both', 'O'), ('urge', 'O'), ('and', 'O'), ('bladder', 'B'), ('hyperactivity', 'I'), ('seen', 'O'), ('in', 'O'), ('inflammatory', 'O'), ('conditions', 'O'), ('of', 'O'), ('the', 'O'), ('lower', 'O'), ('urinary', 'O'), ('tract', 'O'), ('.', 'O'))"
Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .,"(('Refractory', 'O'), ('cardiogenic', 'B'), ('shock', 'I'), ('and', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('after', 'O'), ('verapamil', 'O'), ('SR', 'O'), ('and', 'O'), ('metoprolol', 'O'), ('treatment', 'O'), ('.', 'O'))"
A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .,"(('A', 'O'), ('seventy', 'O'), ('-', 'O'), ('eight', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('presented', 'O'), ('with', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('and', 'O'), ('refractory', 'O'), ('hypotension', 'B'), ('two', 'O'), ('days', 'O'), ('after', 'O'), ('a', 'O'), ('therapeutic', 'O'), ('dose', 'O'), ('of', 'O'), ('sustained', 'O'), ('-', 'O'), ('release', 'O'), ('verapamil', 'O'), ('with', 'O'), ('concomitant', 'O'), ('use', 'O'), ('of', 'O'), ('metoprolol', 'O'), ('.', 'O'))"
"The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .","(('The', 'O'), ('patient', 'O'), ('continued', 'O'), ('to', 'O'), ('remain', 'O'), ('hypotensive', 'B'), ('with', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), (',', 'O'), ('even', 'O'), ('with', 'O'), ('multiple', 'O'), ('uses', 'O'), ('of', 'O'), ('intravenous', 'O'), ('atropine', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('pressor', 'O'), ('agents', 'O'), ('such', 'O'), ('as', 'O'), ('dopamine', 'O'), ('and', 'O'), ('dobutamine', 'O'), ('.', 'O'))"
"However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .","(('However', 'O'), (',', 'O'), ('shortly', 'O'), ('after', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('intravenous', 'O'), ('calcium', 'O'), ('chloride', 'O'), (',', 'O'), ('the', 'O'), ('refractory', 'O'), ('hypotension', 'B'), ('and', 'O'), ('complete', 'O'), ('heart', 'B'), ('block', 'I'), ('resolved', 'O'), ('.', 'O'))"
Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .,"(('Protective', 'O'), ('effect', 'O'), ('of', 'O'), ('misoprostol', 'O'), ('on', 'O'), ('indomethacin', 'O'), ('induced', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('elderly', 'O'), ('patients', 'O'), ('.', 'O'))"
Response to treatment was estimated by the visual analog scale for severity of pain .,"(('Response', 'O'), ('to', 'O'), ('treatment', 'O'), ('was', 'O'), ('estimated', 'O'), ('by', 'O'), ('the', 'O'), ('visual', 'O'), ('analog', 'O'), ('scale', 'O'), ('for', 'O'), ('severity', 'O'), ('of', 'O'), ('pain', 'B'), ('.', 'O'))"
CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .,"(('CONCLUSION', 'O'), (':', 'O'), ('Hospitalized', 'O'), ('elderly', 'O'), ('patients', 'O'), ('are', 'O'), ('at', 'O'), ('risk', 'O'), ('for', 'O'), ('developing', 'O'), ('indomethacin', 'O'), ('related', 'O'), ('renal', 'B'), ('dysfunction', 'I'), ('.', 'O'))"
Addition of misoprostol can minimize this renal impairment without affecting pain control .,"(('Addition', 'O'), ('of', 'O'), ('misoprostol', 'O'), ('can', 'O'), ('minimize', 'O'), ('this', 'O'), ('renal', 'B'), ('impairment', 'I'), ('without', 'O'), ('affecting', 'O'), ('pain', 'B'), ('control', 'O'), ('.', 'O'))"
Cognitive deterioration from long - term abuse of dextromethorphan : a case report .,"(('Cognitive', 'B'), ('deterioration', 'I'), ('from', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('abuse', 'O'), ('of', 'O'), ('dextromethorphan', 'O'), (':', 'O'), ('a', 'O'), ('case', 'O'), ('report', 'O'), ('.', 'O'))"
"The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .","(('The', 'O'), ('drug', 'O'), ('is', 'O'), ('known', 'O'), ('to', 'O'), ('cause', 'O'), ('a', 'O'), ('variety', 'O'), ('of', 'O'), ('acute', 'O'), ('toxic', 'O'), ('effects', 'O'), (',', 'O'), ('ranging', 'O'), ('from', 'O'), ('nausea', 'B'), (',', 'O'), ('restlessness', 'B'), (',', 'O'), ('insomnia', 'B'), (',', 'O'), ('ataxia', 'B'), (',', 'O'), ('slurred', 'O'), ('speech', 'O'), ('and', 'O'), ('nystagmus', 'B'), ('to', 'O'), ('mood', 'O'), ('changes', 'O'), (',', 'O'), ('perceptual', 'O'), ('alterations', 'O'), (',', 'O'), ('inattention', 'O'), (',', 'O'), ('disorientation', 'O'), ('and', 'O'), ('aggressive', 'B'), ('behavior', 'I'), ('(', 'O'), ('Rammer', 'O'), ('et', 'O'), ('al', 'O'), ('1988', 'O'), (';', 'O'), ('Katona', 'O'), ('and', 'O'), ('Watson', 'O'), ('1986', 'O'), (';', 'O'), ('Isbell', 'O'), ('and', 'O'), ('Fraser', 'O'), ('1953', 'O'), (';', 'O'), ('Devlin', 'O'), ('et', 'O'), ('al', 'O'), ('1985', 'O'), (';', 'O'), ('McCarthy', 'O'), ('1971', 'O'), (';', 'O'), ('Dodds', 'O'), ('and', 'O'), ('Revai', 'O'), ('1967', 'O'), (';', 'O'), ('Degkwitz', 'O'), ('1964', 'O'), (';', 'O'), ('Hildebrand', 'O'), ('et', 'O'), ('al', 'O'), ('1989', 'O'), (')', 'O'), ('.', 'O'))"
This report describes a case of cognitive deterioration resulting from prolonged use of DM .,"(('This', 'O'), ('report', 'O'), ('describes', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('cognitive', 'B'), ('deterioration', 'I'), ('resulting', 'O'), ('from', 'O'), ('prolonged', 'O'), ('use', 'O'), ('of', 'O'), ('DM', 'O'), ('.', 'O'))"
Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .,"(('Effects', 'O'), ('of', 'O'), ('ouabain', 'O'), ('on', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('supply', 'O'), ('and', 'O'), ('demand', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('.', 'O'))"
"A hemodynamic , volumetric , and metabolic study in patients without heart failure .","(('A', 'O'), ('hemodynamic', 'O'), (',', 'O'), ('volumetric', 'O'), (',', 'O'), ('and', 'O'), ('metabolic', 'O'), ('study', 'O'), ('in', 'O'), ('patients', 'O'), ('without', 'O'), ('heart', 'B'), ('failure', 'I'), ('.', 'O'))"
"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('digitalis', 'O'), ('glycosides', 'O'), ('on', 'O'), ('myocardial', 'O'), ('oxygen', 'O'), ('supply', 'O'), ('and', 'O'), ('demand', 'O'), ('are', 'O'), ('of', 'O'), ('particular', 'O'), ('interest', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('obstructive', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), (',', 'O'), ('but', 'O'), ('have', 'O'), ('not', 'O'), ('been', 'O'), ('measured', 'O'), ('previously', 'O'), ('in', 'O'), ('man', 'O'), ('.', 'O'))"
"We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .","(('We', 'O'), ('assessed', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('ouabain', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('015', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), (')', 'O'), ('on', 'O'), ('hemodynamic', 'O'), (',', 'O'), ('volumetric', 'O'), (',', 'O'), ('and', 'O'), ('metabolic', 'O'), ('parameters', 'O'), ('in', 'O'), ('11', 'O'), ('patients', 'O'), ('with', 'O'), ('severe', 'O'), ('chronic', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('without', 'O'), ('clinical', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('.', 'O'))"
We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .,"(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('chronic', 'O'), ('coronary', 'B'), ('artery', 'I'), ('disease', 'I'), ('who', 'O'), ('are', 'O'), ('not', 'O'), ('in', 'O'), ('clinical', 'O'), ('congestive', 'B'), ('heart', 'I'), ('failure', 'I'), ('left', 'B'), ('ventricular', 'I'), ('end', 'I'), ('-', 'I'), ('diastolic', 'I'), ('volume', 'I'), ('falls', 'I'), ('after', 'O'), ('ouabain', 'O'), ('administration', 'O'), ('even', 'O'), ('when', 'O'), ('it', 'O'), ('is', 'O'), ('initially', 'O'), ('normal', 'O'), ('.', 'O'))"
Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .,"(('Dexamethasone', 'O'), ('-', 'O'), ('induced', 'O'), ('ocular', 'B'), ('hypertension', 'I'), ('in', 'O'), ('perfusion', 'O'), ('-', 'O'), ('cultured', 'O'), ('human', 'O'), ('eyes', 'O'), ('.', 'O'))"
PURPOSE : Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .,"(('PURPOSE', 'O'), (':', 'O'), ('Glucocorticoid', 'O'), ('administration', 'O'), ('can', 'O'), ('lead', 'O'), ('to', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('ocular', 'B'), ('hypertension', 'I'), ('and', 'O'), ('corticosteroid', 'B'), ('glaucoma', 'I'), ('in', 'O'), ('a', 'O'), ('subset', 'O'), ('of', 'O'), ('the', 'O'), ('population', 'O'), ('through', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('aqueous', 'O'), ('humor', 'O'), ('outflow', 'O'), ('facility', 'O'), ('.', 'O'))"
"In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .","(('In', 'O'), ('contrast', 'O'), (',', 'O'), ('the', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('treated', 'O'), ('hypertensive', 'B'), ('eyes', 'I'), ('had', 'O'), ('thickened', 'O'), ('trabecular', 'O'), ('beams', 'O'), (',', 'O'), ('decreased', 'O'), ('intertrabecular', 'O'), ('spaces', 'O'), (',', 'O'), ('thickened', 'O'), ('juxtacanalicular', 'O'), ('tissue', 'O'), (',', 'O'), ('activated', 'O'), ('trabecular', 'O'), ('meshwork', 'O'), ('cells', 'O'), (',', 'O'), ('and', 'O'), ('increased', 'O'), ('amounts', 'O'), ('of', 'O'), ('amorphogranular', 'O'), ('extracellular', 'O'), ('material', 'O'), (',', 'O'), ('especially', 'O'), ('in', 'O'), ('the', 'O'), ('juxtacanalicular', 'O'), ('tissue', 'O'), ('and', 'O'), ('beneath', 'O'), ('the', 'O'), ('endothelial', 'O'), ('lining', 'O'), ('of', 'O'), ('the', 'O'), ('canal', 'O'), ('of', 'O'), ('Schlemm', 'O'), ('.', 'O'))"
"CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .","(('CONCLUSION', 'O'), (':', 'O'), ('Dexamethasone', 'O'), ('treatment', 'O'), ('of', 'O'), ('isolated', 'O'), (',', 'O'), ('perfusion', 'O'), ('-', 'O'), ('cultured', 'O'), ('human', 'O'), ('eyes', 'O'), ('led', 'O'), ('to', 'O'), ('the', 'O'), ('generation', 'O'), ('of', 'O'), ('ocular', 'B'), ('hypertension', 'I'), ('in', 'O'), ('approximately', 'O'), ('30', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('dexamethasone', 'O'), ('-', 'O'), ('treated', 'O'), ('eyes', 'O'), ('.', 'O'))"
This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .,"(('This', 'O'), ('system', 'O'), ('may', 'O'), ('provide', 'O'), ('an', 'O'), ('acute', 'O'), ('model', 'O'), ('in', 'O'), ('which', 'O'), ('to', 'O'), ('study', 'O'), ('the', 'O'), ('pathogenic', 'O'), ('mechanisms', 'O'), ('involved', 'O'), ('in', 'O'), ('steroid', 'B'), ('glaucoma', 'I'), ('and', 'O'), ('primary', 'B'), ('open', 'I'), ('angle', 'I'), ('glaucoma', 'I'), ('.', 'O'))"
"In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .","(('In', 'O'), ('four', 'O'), ('patients', 'O'), ('hearing', 'B'), ('impairment', 'I'), ('on', 'O'), ('the', 'O'), ('side', 'O'), ('of', 'O'), ('the', 'O'), ('block', 'O'), ('was', 'O'), ('demonstrated', 'O'), ('after', 'O'), ('operation', 'O'), (',', 'O'), ('in', 'O'), ('three', 'O'), ('measurements', 'O'), ('on', 'O'), ('the', 'O'), ('day', 'O'), ('of', 'O'), ('surgery', 'O'), ('and', 'O'), ('in', 'O'), ('one', 'O'), ('on', 'O'), ('the', 'O'), ('following', 'O'), ('day', 'O'), ('.', 'O'))"
"IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .","(('IBPB', 'O'), ('may', 'O'), ('cause', 'O'), ('transient', 'O'), ('auditory', 'B'), ('dysfunction', 'I'), ('in', 'O'), ('the', 'O'), ('ipsilateral', 'O'), ('ear', 'O'), (',', 'O'), ('possibly', 'O'), ('via', 'O'), ('an', 'O'), ('effect', 'O'), ('on', 'O'), ('sympathetic', 'O'), ('innervation', 'O'), ('.', 'O'))"
The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .,"(('The', 'O'), ('safety', 'O'), ('and', 'O'), ('efficacy', 'O'), ('of', 'O'), ('combination', 'O'), ('N', 'O'), ('-', 'O'), ('butyl', 'O'), ('-', 'O'), ('deoxynojirimycin', 'O'), ('(', 'O'), ('SC', 'O'), ('-', 'O'), ('48334', 'O'), (')', 'O'), ('and', 'O'), ('zidovudine', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('HIV', 'B'), ('-', 'I'), ('1', 'I'), ('infection', 'I'), ('and', 'O'), ('200', 'O'), ('-', 'O'), ('500', 'O'), ('CD4', 'O'), ('cells', 'O'), ('/', 'O'), ('mm3', 'O'), ('.', 'O'))"
"Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )","(('Diarrhea', 'B'), (',', 'O'), ('flatulence', 'B'), (',', 'O'), ('abdominal', 'B'), ('pain', 'I'), (',', 'O'), ('and', 'O'), ('weight', 'B'), ('loss', 'I'), ('were', 'O'), ('common', 'O'), ('for', 'O'), ('combination', 'O'), ('recipients', 'O'), ('.', 'O'), ('(', 'O'), ('ABSTRACT', 'O'), ('TRUNCATED', 'O'), ('AT', 'O'), ('250', 'O'), ('WORDS', 'O'), (')', 'O'))"
Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .,"(('Prolonged', 'O'), ('paralysis', 'B'), ('due', 'O'), ('to', 'O'), ('nondepolarizing', 'O'), ('neuromuscular', 'O'), ('blocking', 'O'), ('agents', 'O'), ('and', 'O'), ('corticosteroids', 'O'), ('.', 'O'))"
"The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .","(('The', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('use', 'O'), ('of', 'O'), ('nondepolarizing', 'O'), ('neuromuscular', 'O'), ('blocking', 'O'), ('agents', 'O'), ('(', 'O'), ('ND', 'O'), ('-', 'O'), ('NMBA', 'O'), (')', 'O'), ('has', 'O'), ('recently', 'O'), ('been', 'O'), ('implicated', 'O'), ('as', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('prolonged', 'O'), ('muscle', 'B'), ('weakness', 'I'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('site', 'O'), ('of', 'O'), ('the', 'O'), ('lesion', 'O'), ('and', 'O'), ('the', 'O'), ('predisposing', 'O'), ('factors', 'O'), ('have', 'O'), ('been', 'O'), ('unclear', 'O'), ('.', 'O'))"
We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .,"(('We', 'O'), ('report', 'O'), ('3', 'O'), ('patients', 'O'), ('(', 'O'), ('age', 'O'), ('37', 'O'), ('-', 'O'), ('52', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('acute', 'O'), ('respiratory', 'B'), ('insufficiency', 'I'), ('who', 'O'), ('developed', 'O'), ('prolonged', 'O'), ('weakness', 'B'), ('following', 'O'), ('the', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('ND', 'O'), ('-', 'O'), ('NMBAs', 'O'), ('.', 'O'))"
"Renal function was normal but hepatic function was impaired in all patients , and all had acidosis .","(('Renal', 'O'), ('function', 'O'), ('was', 'O'), ('normal', 'O'), ('but', 'O'), ('hepatic', 'O'), ('function', 'O'), ('was', 'O'), ('impaired', 'O'), ('in', 'O'), ('all', 'O'), ('patients', 'O'), (',', 'O'), ('and', 'O'), ('all', 'O'), ('had', 'O'), ('acidosis', 'B'), ('.', 'O'))"
"A muscle biopsy in this patient showed loss of thick , myosin filaments .","(('A', 'O'), ('muscle', 'O'), ('biopsy', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('showed', 'O'), ('loss', 'B'), ('of', 'I'), ('thick', 'I'), (',', 'I'), ('myosin', 'I'), ('filaments', 'I'), ('.', 'O'))"
The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .,"(('The', 'O'), ('weakness', 'B'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('is', 'O'), ('due', 'O'), ('to', 'O'), ('pathology', 'B'), ('at', 'I'), ('both', 'I'), ('the', 'I'), ('neuromuscular', 'I'), ('junction', 'I'), ('(', 'O'), ('most', 'O'), ('likely', 'O'), ('due', 'O'), ('to', 'O'), ('ND', 'O'), ('-', 'O'), ('NMBA', 'O'), (')', 'O'), ('and', 'O'), ('muscle', 'O'), ('(', 'O'), ('most', 'O'), ('likely', 'O'), ('due', 'O'), ('to', 'O'), ('corticosteroids', 'O'), (')', 'O'), ('.', 'O'))"
Hepatic dysfunction and acidosis are contributing risk factors .,"(('Hepatic', 'B'), ('dysfunction', 'I'), ('and', 'O'), ('acidosis', 'B'), ('are', 'O'), ('contributing', 'O'), ('risk', 'O'), ('factors', 'O'), ('.', 'O'))"
Failure of ancrod in the treatment of heparin - induced arterial thrombosis .,"(('Failure', 'O'), ('of', 'O'), ('ancrod', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('arterial', 'O'), ('thrombosis', 'B'), ('.', 'O'))"
The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .,"(('The', 'O'), ('morbidity', 'O'), ('and', 'O'), ('mortality', 'O'), ('associated', 'O'), ('with', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombosis', 'B'), ('remain', 'O'), ('high', 'O'), ('despite', 'O'), ('numerous', 'O'), ('empirical', 'O'), ('therapies', 'O'), ('.', 'O'))"
"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .","(('Ancrod', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('successfully', 'O'), ('for', 'O'), ('prophylaxis', 'O'), ('against', 'O'), ('development', 'O'), ('of', 'O'), ('thrombosis', 'B'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('heparin', 'O'), ('induced', 'O'), ('platelet', 'B'), ('aggregation', 'I'), ('who', 'O'), ('require', 'O'), ('brief', 'O'), ('reexposure', 'O'), ('to', 'O'), ('heparin', 'O'), (',', 'O'), ('but', 'O'), ('its', 'O'), ('success', 'O'), ('in', 'O'), ('patients', 'O'), ('who', 'O'), ('have', 'O'), ('developed', 'O'), ('the', 'O'), ('thrombosis', 'B'), ('syndrome', 'O'), ('is', 'O'), ('not', 'O'), ('well', 'O'), ('defined', 'O'), ('.', 'O'))"
The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .,"(('The', 'O'), ('authors', 'O'), ('present', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('failure', 'O'), ('of', 'O'), ('ancrod', 'O'), ('treatment', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('heparin', 'O'), ('-', 'O'), ('induced', 'O'), ('thrombosis', 'B'), ('.', 'O'))"
Water intoxication associated with oxytocin administration during saline - induced abortion .,"(('Water', 'B'), ('intoxication', 'I'), ('associated', 'O'), ('with', 'O'), ('oxytocin', 'O'), ('administration', 'O'), ('during', 'O'), ('saline', 'O'), ('-', 'O'), ('induced', 'O'), ('abortion', 'B'), ('.', 'O'))"
Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .,"(('Four', 'O'), ('cases', 'O'), ('of', 'O'), ('water', 'B'), ('intoxication', 'I'), ('in', 'O'), ('connection', 'O'), ('with', 'O'), ('oxytocin', 'O'), ('administration', 'O'), ('during', 'O'), ('saline', 'O'), ('-', 'O'), ('induced', 'O'), ('abortions', 'B'), ('are', 'O'), ('described', 'O'), ('.', 'O'))"
The mechanism of water intoxication is discussed in regard to these cases .,"(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('water', 'B'), ('intoxication', 'I'), ('is', 'O'), ('discussed', 'O'), ('in', 'O'), ('regard', 'O'), ('to', 'O'), ('these', 'O'), ('cases', 'O'), ('.', 'O'))"
"Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .","(('Oxytocin', 'O'), ('administration', 'O'), ('during', 'O'), ('midtrimester', 'O'), ('-', 'O'), ('induced', 'O'), ('abortions', 'B'), ('is', 'O'), ('advocated', 'O'), ('only', 'O'), ('if', 'O'), ('it', 'O'), ('can', 'O'), ('be', 'O'), ('carried', 'O'), ('out', 'O'), ('under', 'O'), ('careful', 'O'), ('observations', 'O'), ('of', 'O'), ('an', 'O'), ('alert', 'O'), ('nursing', 'O'), ('staff', 'O'), (',', 'O'), ('aware', 'O'), ('of', 'O'), ('the', 'O'), ('symptoms', 'O'), ('of', 'O'), ('water', 'B'), ('intoxication', 'I'), ('and', 'O'), ('instructed', 'O'), ('to', 'O'), ('watch', 'O'), ('the', 'O'), ('diuresis', 'O'), ('and', 'O'), ('report', 'O'), ('such', 'O'), ('early', 'O'), ('signs', 'O'), ('of', 'O'), ('the', 'O'), ('syndrome', 'O'), ('as', 'O'), ('asthenia', 'B'), (',', 'O'), ('muscular', 'O'), ('irritability', 'B'), (',', 'O'), ('or', 'O'), ('headaches', 'B'), ('.', 'O'))"
Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .,"(('Light', 'O'), ('chain', 'O'), ('proteinuria', 'B'), ('and', 'O'), ('cellular', 'O'), ('mediated', 'O'), ('immunity', 'O'), ('in', 'O'), ('rifampin', 'O'), ('treated', 'O'), ('patients', 'O'), ('with', 'O'), ('tuberculosis', 'B'), ('.', 'O'))"
Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .,"(('Light', 'O'), ('chain', 'O'), ('proteinuria', 'B'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('9', 'O'), ('of', 'O'), ('17', 'O'), ('tuberculosis', 'B'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('rifampin', 'O'), ('.', 'O'))"
"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) . as well as of those of seven other tuberculous patients .","(('Response', 'O'), ('to', 'O'), ('Varidase', 'O'), ('skin', 'O'), ('test', 'O'), ('antigen', 'O'), ('was', 'O'), ('negative', 'O'), ('for', 'O'), ('all', 'O'), ('eight', 'O'), ('tuberculosis', 'B'), ('patients', 'O'), ('tested', 'O'), (',', 'O'), ('but', 'O'), ('there', 'O'), ('occurred', 'O'), ('a', 'O'), ('hyper', 'O'), ('-', 'O'), ('responsiveness', 'O'), ('of', 'O'), ('the', 'O'), ('lymphocytes', 'O'), ('of', 'O'), ('these', 'O'), ('eight', 'O'), ('patients', 'O'), ('to', 'O'), ('phytomitogen', 'O'), ('(', 'O'), ('PHA', 'O'), ('-', 'O'), ('P', 'O'), (')', 'O'), ('.', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('of', 'O'), ('those', 'O'), ('of', 'O'), ('seven', 'O'), ('other', 'O'), ('tuberculous', 'B'), ('patients', 'O'), ('.', 'O'))"
KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .,"(('KF17837', 'O'), ('also', 'O'), ('reduced', 'O'), ('the', 'O'), ('catalepsy', 'B'), ('induced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('and', 'O'), ('by', 'O'), ('reserpine', 'O'), ('(', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .","(('Furthermore', 'O'), (',', 'O'), ('KF17837', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('drug', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('parkinsonism', 'B'), ('.', 'O'))"
Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .,"(('Effect', 'O'), ('of', 'O'), ('nondopaminergic', 'O'), ('drugs', 'O'), ('on', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('in', 'O'), ('MPTP', 'O'), ('-', 'O'), ('treated', 'O'), ('monkeys', 'O'), ('.', 'O'))"
A group of four monkeys was rendered parkinsonian with the toxin MPTP .,"(('A', 'O'), ('group', 'O'), ('of', 'O'), ('four', 'O'), ('monkeys', 'O'), ('was', 'O'), ('rendered', 'O'), ('parkinsonian', 'B'), ('with', 'O'), ('the', 'O'), ('toxin', 'O'), ('MPTP', 'O'), ('.', 'O'))"
"This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .","(('This', 'O'), ('dose', 'O'), ('produced', 'O'), ('a', 'O'), ('striking', 'O'), ('antiparkinsonian', 'O'), ('effect', 'O'), (',', 'O'), ('but', 'O'), ('all', 'O'), ('animals', 'O'), ('manifested', 'O'), ('dyskinesia', 'B'), ('.', 'O'))"
A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .,"(('A', 'O'), ('series', 'O'), ('of', 'O'), ('agents', 'O'), ('acting', 'O'), ('primarily', 'O'), ('on', 'O'), ('neurotransmitters', 'O'), ('other', 'O'), ('than', 'O'), ('dopamine', 'O'), ('were', 'O'), ('then', 'O'), ('tested', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('L', 'O'), ('-', 'O'), ('DOPA', 'O'), ('to', 'O'), ('see', 'O'), ('if', 'O'), ('the', 'O'), ('dyskinetic', 'B'), ('movements', 'O'), ('would', 'O'), ('be', 'O'), ('modified', 'O'), ('.', 'O'))"
"Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .","(('Several', 'O'), ('drugs', 'O'), (',', 'O'), ('including', 'O'), ('clonidine', 'O'), (',', 'O'), ('physostigmine', 'O'), (',', 'O'), ('methysergide', 'O'), (',', 'O'), ('5', 'O'), ('-', 'O'), ('MDOT', 'O'), (',', 'O'), ('propranolol', 'O'), (',', 'O'), ('and', 'O'), ('MK', 'O'), ('-', 'O'), ('801', 'O'), (',', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('the', 'O'), ('dyskinetic', 'B'), ('movements', 'O'), ('but', 'O'), ('at', 'O'), ('the', 'O'), ('cost', 'O'), ('of', 'O'), ('a', 'O'), ('return', 'O'), ('of', 'O'), ('parkinsonian', 'B'), ('symptomatology', 'O'), ('.', 'O'))"
"However , yohimbine and meperidine reduced predominantly the dyskinetic movements .","(('However', 'O'), (',', 'O'), ('yohimbine', 'O'), ('and', 'O'), ('meperidine', 'O'), ('reduced', 'O'), ('predominantly', 'O'), ('the', 'O'), ('dyskinetic', 'B'), ('movements', 'O'), ('.', 'O'))"
Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .,"(('Baclofen', 'O'), ('was', 'O'), ('also', 'O'), ('useful', 'O'), ('in', 'O'), ('one', 'O'), ('monkey', 'O'), ('against', 'O'), ('a', 'O'), ('more', 'O'), ('dystonic', 'B'), ('form', 'O'), ('of', 'O'), ('dyskinesia', 'B'), ('.', 'O'))"
Hallucinations and ifosfamide - induced neurotoxicity .,"(('Hallucinations', 'B'), ('and', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
BACKGROUND : Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .,"(('BACKGROUND', 'O'), (':', 'O'), ('Hallucinations', 'B'), ('as', 'O'), ('a', 'O'), ('symptom', 'O'), ('of', 'O'), ('central', 'O'), ('neurotoxicity', 'B'), ('are', 'O'), ('a', 'O'), ('known', 'O'), ('but', 'O'), ('poorly', 'O'), ('described', 'O'), ('side', 'O'), ('effect', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('.', 'O'))"
Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .,"(('Most', 'O'), ('cases', 'O'), ('of', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('hallucinations', 'B'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('with', 'O'), ('other', 'O'), ('mental', 'O'), ('status', 'O'), ('changes', 'O'), ('.', 'O'))"
METHODS : The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .,"(('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('authors', 'O'), ('interviewed', 'O'), ('six', 'O'), ('persons', 'O'), ('with', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('hallucinations', 'B'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('a', 'O'), ('clear', 'O'), ('sensorium', 'O'), ('.', 'O'))"
"RESULTS : Hallucinations occurred only when the patient ' s eyes were closed and , in all but one case , were reported as disturbing or frightening .","(('RESULTS', 'O'), (':', 'O'), ('Hallucinations', 'B'), ('occurred', 'O'), ('only', 'O'), ('when', 'O'), ('the', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('eyes', 'O'), ('were', 'O'), ('closed', 'O'), ('and', 'O'), (',', 'O'), ('in', 'O'), ('all', 'O'), ('but', 'O'), ('one', 'O'), ('case', 'O'), (',', 'O'), ('were', 'O'), ('reported', 'O'), ('as', 'O'), ('disturbing', 'O'), ('or', 'O'), ('frightening', 'O'), ('.', 'O'))"
Underreporting of these hallucinations by patients is likely .,"(('Underreporting', 'O'), ('of', 'O'), ('these', 'O'), ('hallucinations', 'B'), ('by', 'O'), ('patients', 'O'), ('is', 'O'), ('likely', 'O'), ('.', 'O'))"
CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Hallucinations', 'B'), ('may', 'O'), ('be', 'O'), ('the', 'O'), ('sole', 'O'), ('or', 'O'), ('first', 'O'), ('manifestation', 'O'), ('of', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
"The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .","(('The', 'O'), ('clinician', 'O'), ('should', 'O'), ('be', 'O'), ('alerted', 'O'), ('for', 'O'), ('possible', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('hallucinations', 'B'), (',', 'O'), ('which', 'O'), ('may', 'O'), ('occur', 'O'), ('without', 'O'), ('other', 'O'), ('signs', 'O'), ('of', 'O'), ('neurotoxicity', 'B'), ('.', 'O'))"
"If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .","(('If', 'O'), ('agitation', 'B'), ('becomes', 'O'), ('marked', 'O'), (',', 'O'), ('high', 'O'), ('-', 'O'), ('potency', 'O'), ('neuroleptics', 'O'), ('(', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), (',', 'O'), ('haloperidol', 'O'), (')', 'O'), ('may', 'O'), ('be', 'O'), ('effective', 'O'), ('.', 'O'))"
Neither patient complained of photosensitivity or flushing .,"(('Neither', 'O'), ('patient', 'O'), ('complained', 'O'), ('of', 'O'), ('photosensitivity', 'O'), ('or', 'O'), ('flushing', 'B'), ('.', 'O'))"
Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .,"(('Penicillamine', 'O'), ('-', 'O'), ('induced', 'O'), ('rapidly', 'O'), ('progressive', 'O'), ('glomerulonephritis', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('.', 'O'))"
A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .,"(('A', 'O'), ('67', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('presented', 'O'), ('rapidly', 'O'), ('progressive', 'O'), ('glomerulonephritis', 'B'), ('(', 'O'), ('RPGN', 'B'), (')', 'O'), ('after', 'O'), ('5', 'O'), ('months', 'O'), ('of', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('(', 'O'), ('250', 'O'), ('mg', 'O'), ('/', 'O'), ('day', 'O'), (')', 'O'), ('treatment', 'O'), ('.', 'O'))"
Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .,"(('Light', 'O'), ('microscopy', 'O'), ('study', 'O'), ('showed', 'O'), ('severe', 'O'), ('glomerulonephritis', 'B'), ('with', 'O'), ('crescent', 'O'), ('formation', 'O'), ('in', 'O'), ('60', 'O'), ('%', 'O'), ('of', 'O'), ('the', 'O'), ('glomeruli', 'O'), ('and', 'O'), ('infiltration', 'O'), ('of', 'O'), ('inflammatory', 'O'), ('cells', 'O'), ('in', 'O'), ('the', 'O'), ('wall', 'O'), ('of', 'O'), ('an', 'O'), ('arteriole', 'O'), ('.', 'O'))"
This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .,"(('This', 'O'), ('new', 'O'), ('case', 'O'), ('of', 'O'), ('RPGN', 'B'), ('in', 'O'), ('the', 'O'), ('course', 'O'), ('of', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('treatment', 'O'), ('emphasizes', 'O'), ('the', 'O'), ('need', 'O'), ('for', 'O'), ('frequent', 'O'), ('monitoring', 'O'), ('of', 'O'), ('renal', 'O'), ('function', 'O'), ('and', 'O'), ('evaluation', 'O'), ('of', 'O'), ('urinary', 'O'), ('sediment', 'O'), ('and', 'O'), ('proteinuria', 'B'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('.', 'O'))"
A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .,"(('A', 'O'), ('case', 'O'), ('of', 'O'), ('polymyositis', 'B'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('primary', 'B'), ('biliary', 'I'), ('cirrhosis', 'I'), ('treated', 'O'), ('with', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('.', 'O'))"
"Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .","(('Although', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('has', 'O'), ('been', 'O'), ('used', 'O'), ('for', 'O'), ('many', 'O'), ('rheumatologic', 'B'), ('diseases', 'I'), (',', 'O'), ('toxicity', 'B'), ('limits', 'O'), ('its', 'O'), ('usefulness', 'O'), ('in', 'O'), ('many', 'O'), ('patients', 'O'), ('.', 'O'))"
"We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .","(('We', 'O'), ('report', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('primary', 'B'), ('biliary', 'I'), ('cirrhosis', 'I'), (',', 'O'), ('who', 'O'), ('developed', 'O'), ('polymyositis', 'B'), ('while', 'O'), ('receiving', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('therapy', 'O'), ('.', 'O'))"
Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .,"(('Hyperalgesia', 'B'), ('and', 'O'), ('myoclonus', 'B'), ('in', 'O'), ('terminal', 'O'), ('cancer', 'B'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('continuous', 'O'), ('intravenous', 'O'), ('morphine', 'O'), ('.', 'O'))"
Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .,"(('Eight', 'O'), ('cancer', 'B'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('terminal', 'O'), ('stages', 'O'), ('of', 'O'), ('the', 'O'), ('disease', 'O'), ('treated', 'O'), ('with', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('intravenous', 'O'), ('morphine', 'O'), ('developed', 'O'), ('hyperalgesia', 'B'), ('.', 'O'))"
Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .,"(('Five', 'O'), ('patients', 'O'), ('developed', 'O'), ('universal', 'O'), ('hyperalgesia', 'B'), ('and', 'O'), ('hyperesthesia', 'B'), ('which', 'O'), ('in', 'O'), ('2', 'O'), ('cases', 'O'), ('were', 'O'), ('accompanied', 'O'), ('by', 'O'), ('myoclonus', 'B'), ('.', 'O'))"
In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .,"(('In', 'O'), ('3', 'O'), ('patients', 'O'), ('a', 'O'), ('pre', 'O'), ('-', 'O'), ('existing', 'O'), ('neuralgia', 'B'), ('increased', 'O'), ('to', 'O'), ('excruciating', 'O'), ('intensity', 'O'), ('and', 'O'), ('in', 'O'), ('2', 'O'), ('of', 'O'), ('these', 'O'), ('cases', 'O'), ('myoclonus', 'B'), ('occurred', 'O'), ('simultaneously', 'O'), ('.', 'O'))"
"Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .","(('Although', 'O'), ('only', 'O'), ('few', 'O'), ('clinical', 'O'), ('descriptions', 'O'), ('of', 'O'), ('the', 'O'), ('relationship', 'O'), ('between', 'O'), ('hyperalgesia', 'B'), ('/', 'O'), ('myoclonus', 'B'), ('and', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('morphine', 'O'), ('are', 'O'), ('available', 'O'), (',', 'O'), ('experimental', 'O'), ('support', 'O'), ('from', 'O'), ('animal', 'O'), ('studies', 'O'), ('indicates', 'O'), ('that', 'O'), ('morphine', 'O'), (',', 'O'), ('or', 'O'), ('its', 'O'), ('metabolites', 'O'), (',', 'O'), ('plays', 'O'), ('a', 'O'), ('causative', 'O'), ('role', 'O'), ('for', 'O'), ('the', 'O'), ('observed', 'O'), ('behavioural', 'O'), ('syndrome', 'O'), ('.', 'O'))"
Liposomal daunorubicin in advanced Kaposi ' s sarcoma : a phase II study .,"(('Liposomal', 'O'), ('daunorubicin', 'O'), ('in', 'O'), ('advanced', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), (':', 'O'), ('a', 'O'), ('phase', 'O'), ('II', 'O'), ('study', 'O'), ('.', 'O'))"
We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi ' s sarcoma .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('non', 'O'), ('-', 'O'), ('randomized', 'O'), ('Phase', 'O'), ('II', 'O'), ('clinical', 'O'), ('trial', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('liposomal', 'O'), ('daunorubicin', 'O'), ('(', 'O'), ('DaunoXome', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('AIDS', 'B'), ('related', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('.', 'O'))"
Eleven homosexual men with advanced Kaposi ' s sarcoma were entered in the trial .,"(('Eleven', 'O'), ('homosexual', 'O'), ('men', 'O'), ('with', 'O'), ('advanced', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('were', 'O'), ('entered', 'O'), ('in', 'O'), ('the', 'O'), ('trial', 'O'), ('.', 'O'))"
"Clinical , biochemical and haematological toxicities were assessed .","(('Clinical', 'O'), (',', 'O'), ('biochemical', 'O'), ('and', 'O'), ('haematological', 'O'), ('toxicities', 'B'), ('were', 'O'), ('assessed', 'O'), ('.', 'O'))"
"Stabilization of Kaposi ' s sarcoma occurred in the remaining six , maintained until the end of the trial period in four .","(('Stabilization', 'O'), ('of', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('occurred', 'O'), ('in', 'O'), ('the', 'O'), ('remaining', 'O'), ('six', 'O'), (',', 'O'), ('maintained', 'O'), ('until', 'O'), ('the', 'O'), ('end', 'O'), ('of', 'O'), ('the', 'O'), ('trial', 'O'), ('period', 'O'), ('in', 'O'), ('four', 'O'), ('.', 'O'))"
"The drug was generally well tolerated , with few mild symptoms of toxicity .","(('The', 'O'), ('drug', 'O'), ('was', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), (',', 'O'), ('with', 'O'), ('few', 'O'), ('mild', 'O'), ('symptoms', 'O'), ('of', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .","(('The', 'O'), ('main', 'O'), ('problem', 'O'), ('encountered', 'O'), ('was', 'O'), ('haematological', 'O'), ('toxicity', 'B'), (',', 'O'), ('with', 'O'), ('three', 'O'), ('subjects', 'O'), ('experiencing', 'O'), ('severe', 'O'), ('neutropenia', 'B'), ('(', 'O'), ('neutrophil', 'O'), ('count', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('x', 'O'), ('10', 'O'), ('(', 'O'), ('9', 'O'), (')', 'O'), ('/', 'O'), ('l', 'O'), (')', 'O'), ('.', 'O'))"
There was no evidence of cardiotoxicity .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('evidence', 'O'), ('of', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
"In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi ' s sarcoma .","(('In', 'O'), ('this', 'O'), ('small', 'O'), ('patient', 'O'), ('sample', 'O'), (',', 'O'), ('liposomal', 'O'), ('daunorubicin', 'O'), ('was', 'O'), ('an', 'O'), ('effective', 'O'), ('and', 'O'), ('well', 'O'), ('tolerated', 'O'), ('agent', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Kaposi', 'B'), (""'"", 'I'), ('s', 'I'), ('sarcoma', 'I'), ('.', 'O'))"
Forty patients with Non - Hodgkin ' s Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .,"(('Forty', 'O'), ('patients', 'O'), ('with', 'O'), ('Non', 'B'), ('-', 'I'), ('Hodgkin', 'I'), (""'"", 'I'), ('s', 'I'), ('Lymphoma', 'I'), ('treated', 'O'), ('with', 'O'), ('vincristine', 'O'), ('between', 'O'), ('1984', 'O'), ('and', 'O'), ('1990', 'O'), ('(', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('12', 'O'), ('mg', 'O'), ('in', 'O'), ('18', 'O'), ('-', 'O'), ('24', 'O'), ('weeks', 'O'), (')', 'O'), ('were', 'O'), ('investigated', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('long', 'O'), ('term', 'O'), ('effects', 'O'), ('of', 'O'), ('vincristine', 'O'), ('on', 'O'), ('the', 'O'), ('peripheral', 'O'), ('nervous', 'O'), ('system', 'O'), ('.', 'O'))"
The patients were interviewed with emphasis on neuropathic symptoms .,"(('The', 'O'), ('patients', 'O'), ('were', 'O'), ('interviewed', 'O'), ('with', 'O'), ('emphasis', 'O'), ('on', 'O'), ('neuropathic', 'B'), ('symptoms', 'I'), ('.', 'O'))"
Twenty - seven patients reported neuropathic symptoms .,"(('Twenty', 'O'), ('-', 'O'), ('seven', 'O'), ('patients', 'O'), ('reported', 'O'), ('neuropathic', 'B'), ('symptoms', 'I'), ('.', 'O'))"
It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .,"(('It', 'O'), ('is', 'O'), ('concluded', 'O'), ('that', 'O'), ('with', 'O'), ('the', 'O'), ('above', 'O'), ('mentioned', 'O'), ('vincristine', 'O'), ('dose', 'O'), ('schedule', 'O'), ('signs', 'O'), ('and', 'O'), ('symptoms', 'O'), ('of', 'O'), ('vincristine', 'O'), ('neuropathy', 'B'), ('are', 'O'), ('reversible', 'O'), ('for', 'O'), ('a', 'O'), ('great', 'O'), ('deal', 'O'), ('and', 'O'), ('prognosis', 'O'), ('is', 'O'), ('fairly', 'O'), ('good', 'O'), ('.', 'O'))"
Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .,"(('Hepatic', 'O'), ('adenomas', 'B'), ('and', 'O'), ('focal', 'B'), ('nodular', 'I'), ('hyperplasia', 'I'), ('of', 'O'), ('the', 'O'), ('liver', 'O'), ('in', 'O'), ('young', 'O'), ('women', 'O'), ('on', 'O'), ('oral', 'O'), ('contraceptives', 'O'), (':', 'O'), ('case', 'O'), ('reports', 'O'), ('.', 'O'))"
"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .","(('Two', 'O'), ('cases', 'O'), ('of', 'O'), ('hepatic', 'O'), ('adenoma', 'B'), ('and', 'O'), ('one', 'O'), ('of', 'O'), ('focal', 'B'), ('nodular', 'I'), ('hyperplasia', 'I'), ('presumably', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('oral', 'O'), ('contraceptives', 'O'), (',', 'O'), ('are', 'O'), ('reported', 'O'), ('.', 'O'))"
Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .,"(('Histologic', 'O'), ('differences', 'O'), ('and', 'O'), ('clinical', 'O'), ('similarities', 'O'), ('between', 'O'), ('hepatic', 'O'), ('adenoma', 'B'), ('and', 'O'), ('focal', 'B'), ('nodular', 'I'), ('hyperplasia', 'I'), ('of', 'O'), ('the', 'O'), ('liver', 'O'), ('are', 'O'), ('discussed', 'O'), ('.', 'O'))"
Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .,"(('Loss', 'O'), ('of', 'O'), ('glutamate', 'O'), ('decarboxylase', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('following', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .,"(('In', 'O'), ('situ', 'O'), ('hybridization', 'O'), ('methods', 'O'), ('were', 'O'), ('used', 'O'), ('to', 'O'), ('determine', 'O'), ('if', 'O'), ('glutamic', 'O'), ('acid', 'O'), ('decarboxylase', 'O'), ('(', 'O'), ('GAD', 'O'), (')', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('within', 'O'), ('the', 'O'), ('hilus', 'O'), ('of', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('are', 'O'), ('vulnerable', 'O'), ('to', 'O'), ('seizure', 'B'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('in', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('chronic', 'O'), ('seizures', 'B'), ('.', 'O'))"
"Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .","(('Sprague', 'O'), ('-', 'O'), ('Dawley', 'O'), ('rats', 'O'), ('were', 'O'), ('injected', 'O'), ('intraperitoneally', 'O'), ('with', 'O'), ('pilocarpine', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('hippocampal', 'O'), ('formation', 'O'), ('was', 'O'), ('studied', 'O'), ('histologically', 'O'), ('at', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (',', 'O'), ('4', 'O'), (',', 'O'), ('and', 'O'), ('8', 'O'), ('week', 'O'), ('intervals', 'O'), ('after', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
"Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .","(('Additional', 'O'), ('neuronanatomical', 'O'), ('studies', 'O'), (',', 'O'), ('including', 'O'), ('cresyl', 'O'), ('violet', 'O'), ('staining', 'O'), (',', 'O'), ('neuronal', 'B'), ('degeneration', 'I'), ('methods', 'O'), (',', 'O'), ('and', 'O'), ('histochemical', 'O'), ('localization', 'O'), ('of', 'O'), ('glial', 'O'), ('fibrillary', 'O'), ('acidic', 'O'), ('protein', 'O'), (',', 'O'), ('suggested', 'O'), ('that', 'O'), ('the', 'O'), ('decrease', 'O'), ('in', 'O'), ('the', 'O'), ('number', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('was', 'O'), ('related', 'O'), ('to', 'O'), ('neuronal', 'B'), ('loss', 'I'), ('rather', 'O'), ('than', 'O'), ('to', 'O'), ('a', 'O'), ('decrease', 'O'), ('in', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('levels', 'O'), ('.', 'O'))"
"The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .","(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('this', 'O'), ('model', 'O'), (',', 'O'), ('a', 'O'), ('subpopulation', 'O'), ('of', 'O'), ('GAD', 'O'), ('mRNA', 'O'), ('-', 'O'), ('containing', 'O'), ('neurons', 'O'), ('within', 'O'), ('the', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('is', 'O'), ('selectively', 'O'), ('vulnerable', 'O'), ('to', 'O'), ('seizure', 'B'), ('-', 'O'), ('induced', 'O'), ('damage', 'O'), ('.', 'O'))"
Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .,"(('Effects', 'O'), ('of', 'O'), ('deliberate', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('by', 'O'), ('labetalol', 'O'), ('with', 'O'), ('isoflurane', 'O'), ('on', 'O'), ('neuropsychological', 'O'), ('function', 'O'), ('.', 'O'))"
The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .,"(('The', 'O'), ('effect', 'O'), ('of', 'O'), ('deliberate', 'O'), ('hypotension', 'B'), ('on', 'O'), ('brain', 'O'), ('function', 'O'), ('measured', 'O'), ('by', 'O'), ('neuropsychological', 'O'), ('tests', 'O'), ('was', 'O'), ('studied', 'O'), ('in', 'O'), ('41', 'O'), ('adult', 'O'), ('patients', 'O'), ('.', 'O'))"
Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .,"(('Twenty', 'O'), ('-', 'O'), ('four', 'O'), ('patients', 'O'), ('were', 'O'), ('anaesthetized', 'O'), ('for', 'O'), ('middle', 'O'), ('-', 'O'), ('ear', 'O'), ('surgery', 'O'), ('with', 'O'), ('deliberate', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('by', 'O'), ('labetalol', 'O'), ('with', 'O'), ('isoflurane', 'O'), ('(', 'O'), ('hypotensive', 'B'), ('group', 'O'), (')', 'O'), ('.', 'O'))"
Seventeen patients without hypotension served as a control group .,"(('Seventeen', 'O'), ('patients', 'O'), ('without', 'O'), ('hypotension', 'B'), ('served', 'O'), ('as', 'O'), ('a', 'O'), ('control', 'O'), ('group', 'O'), ('.', 'O'))"
"The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0 mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / - 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .","(('The', 'O'), ('mean', 'O'), ('arterial', 'O'), ('pressure', 'O'), ('was', 'O'), ('77', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('mmHg', 'O'), ('(', 'O'), ('10', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('kPa', 'O'), (')', 'O'), ('before', 'O'), ('hypotension', 'B'), ('and', 'O'), ('50', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('mmHg', 'O'), ('(', 'O'), ('6', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('0', 'O'), ('kPa', 'O'), (')', 'O'), ('during', 'O'), ('hypotension', 'B'), ('in', 'O'), ('the', 'O'), ('hypotensive', 'B'), ('group', 'O'), (',', 'O'), ('and', 'O'), ('86', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('mmHg', 'O'), ('(', 'O'), ('11', 'O'), ('.', 'O'), ('5', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('3', 'O'), ('kPa', 'O'), (')', 'O'), ('during', 'O'), ('anaesthesia', 'O'), ('in', 'O'), ('the', 'O'), ('control', 'O'), ('group', 'O'), ('.', 'O'))"
"The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .","(('The', 'O'), ('following', 'O'), ('psychological', 'O'), ('tests', 'O'), ('were', 'O'), ('performed', 'O'), (':', 'O'), ('four', 'O'), ('subtests', 'O'), ('of', 'O'), ('the', 'O'), ('Wechsler', 'O'), ('Adult', 'O'), ('Intelligence', 'O'), ('Scale', 'O'), ('(', 'O'), ('similarities', 'O'), (',', 'O'), ('digit', 'O'), ('span', 'O'), (',', 'O'), ('vocabulary', 'O'), ('and', 'O'), ('digit', 'O'), ('symbol', 'O'), (')', 'O'), (',', 'O'), ('Trail', 'O'), ('-', 'O'), ('Making', 'O'), ('tests', 'O'), ('A', 'O'), ('and', 'O'), ('B', 'O'), (',', 'O'), ('Zung', 'O'), ('tests', 'O'), ('(', 'O'), ('self', 'O'), ('-', 'O'), ('rating', 'O'), ('anxiety', 'B'), ('scale', 'O'), ('and', 'O'), ('self', 'O'), ('-', 'O'), ('rating', 'O'), ('depression', 'B'), ('scale', 'O'), (')', 'O'), ('and', 'O'), ('two', 'O'), ('-', 'O'), ('part', 'O'), ('memory', 'O'), ('test', 'O'), ('battery', 'O'), ('with', 'O'), ('immediate', 'O'), ('and', 'O'), ('delayed', 'O'), ('recall', 'O'), ('.', 'O'))"
The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .,"(('The', 'O'), ('results', 'O'), ('indicate', 'O'), ('that', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('by', 'O'), ('labetalol', 'O'), ('with', 'O'), ('isoflurane', 'O'), ('has', 'O'), ('no', 'O'), ('significant', 'O'), ('harmful', 'O'), ('effects', 'O'), ('on', 'O'), ('mental', 'O'), ('functions', 'O'), ('compared', 'O'), ('to', 'O'), ('normotensive', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
Apparent cure of rheumatoid arthritis by bone marrow transplantation .,"(('Apparent', 'O'), ('cure', 'O'), ('of', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('by', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('.', 'O'))"
We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .,"(('We', 'O'), ('describe', 'O'), ('the', 'O'), ('induction', 'O'), ('of', 'O'), ('sustained', 'O'), ('remissions', 'O'), ('and', 'O'), ('possible', 'O'), ('cure', 'O'), ('of', 'O'), ('severe', 'O'), ('erosive', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('(', 'O'), ('RA', 'B'), (')', 'O'), ('by', 'O'), ('bone', 'O'), ('marrow', 'O'), ('transplantation', 'O'), ('(', 'O'), ('BMT', 'O'), (')', 'O'), ('in', 'O'), ('2', 'O'), ('patients', 'O'), ('.', 'O'))"
BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .,"(('BMT', 'O'), ('was', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('severe', 'O'), ('aplastic', 'B'), ('anemia', 'I'), ('which', 'O'), ('was', 'O'), ('caused', 'O'), ('by', 'O'), ('gold', 'O'), ('in', 'O'), ('one', 'O'), ('case', 'O'), ('and', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('in', 'O'), ('the', 'O'), ('other', 'O'), ('.', 'O'))"
This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .,"(('This', 'O'), ('experience', 'O'), ('raises', 'O'), ('the', 'O'), ('question', 'O'), ('of', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('BMT', 'O'), ('itself', 'O'), ('as', 'O'), ('a', 'O'), ('therapeutic', 'O'), ('option', 'O'), ('for', 'O'), ('patients', 'O'), ('with', 'O'), ('uncontrolled', 'O'), ('destructive', 'O'), ('synovitis', 'B'), ('.', 'O'))"
Seizures induced by combined levomepromazine - fluvoxamine treatment .,"(('Seizures', 'B'), ('induced', 'O'), ('by', 'O'), ('combined', 'O'), ('levomepromazine', 'O'), ('-', 'O'), ('fluvoxamine', 'O'), ('treatment', 'O'), ('.', 'O'))"
We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('combined', 'O'), ('levomepromazine', 'O'), ('-', 'O'), ('fluvoxamine', 'O'), ('treatment', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('.', 'O'))"
Case report : pentamidine and polymorphic ventricular tachycardia revisited .,"(('Case', 'O'), ('report', 'O'), (':', 'O'), ('pentamidine', 'O'), ('and', 'O'), ('polymorphic', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('revisited', 'O'), ('.', 'O'))"
"Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .","(('Pentamidine', 'O'), ('isethionate', 'O'), ('has', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('ventricular', 'B'), ('tachyarrhythmias', 'I'), (',', 'O'), ('including', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('.', 'O'))"
Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .,"(('Pentamidine', 'O'), ('-', 'O'), ('induced', 'O'), ('torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('serum', 'O'), ('magnesium', 'O'), ('levels', 'O'), ('and', 'O'), ('hypomagnesemia', 'B'), ('may', 'O'), ('synergistically', 'O'), ('induce', 'O'), ('torsade', 'O'), ('.', 'O'))"
Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .,"(('Torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('occurred', 'O'), ('after', 'O'), ('an', 'O'), ('average', 'O'), ('of', 'O'), ('10', 'O'), ('days', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('pentamidine', 'O'), ('.', 'O'))"
"Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .","(('Torsade', 'B'), ('de', 'I'), ('pointes', 'I'), ('can', 'O'), ('be', 'O'), ('treated', 'O'), ('when', 'O'), ('recognized', 'O'), ('early', 'O'), (',', 'O'), ('possibly', 'O'), ('without', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('pentamidine', 'O'), ('.', 'O'))"
"When QTc interval prolongation is observed , early magnesium supplementation is advocated .","(('When', 'O'), ('QTc', 'B'), ('interval', 'I'), ('prolongation', 'I'), ('is', 'O'), ('observed', 'O'), (',', 'O'), ('early', 'O'), ('magnesium', 'O'), ('supplementation', 'O'), ('is', 'O'), ('advocated', 'O'), ('.', 'O'))"
Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .,"(('Efficacy', 'O'), ('and', 'O'), ('tolerability', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('in', 'O'), ('3390', 'O'), ('women', 'O'), ('with', 'O'), ('moderate', 'O'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('in', 'O'), ('women', 'O'), ('with', 'O'), ('moderate', 'O'), ('hypercholesterolemia', 'B'), ('.', 'O'))"
"Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .","(('Myopathy', 'B'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('muscle', 'O'), ('symptoms', 'O'), ('with', 'O'), ('creatine', 'O'), ('kinase', 'O'), ('elevations', 'O'), ('greater', 'O'), ('than', 'O'), ('10', 'O'), ('times', 'O'), ('the', 'O'), ('upper', 'O'), ('limit', 'O'), ('of', 'O'), ('normal', 'O'), (',', 'O'), ('was', 'O'), ('rare', 'O'), ('and', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('highest', 'O'), ('recommended', 'O'), ('daily', 'O'), ('dose', 'O'), ('of', 'O'), ('lovastatin', 'O'), ('(', 'O'), ('80', 'O'), ('mg', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .,"(('CONCLUSION', 'O'), (':', 'O'), ('Lovastatin', 'O'), ('is', 'O'), ('highly', 'O'), ('effective', 'O'), ('and', 'O'), ('generally', 'O'), ('well', 'O'), ('tolerated', 'O'), ('as', 'O'), ('therapy', 'O'), ('for', 'O'), ('primary', 'O'), ('hypercholesterolemia', 'B'), ('in', 'O'), ('women', 'O'), ('.', 'O'))"
Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .,"(('Tetany', 'B'), ('and', 'O'), ('rhabdomyolysis', 'B'), ('due', 'O'), ('to', 'O'), ('surreptitious', 'O'), ('furosemide', 'O'), ('-', 'O'), ('-', 'O'), ('importance', 'O'), ('of', 'O'), ('magnesium', 'O'), ('supplementation', 'O'), ('.', 'O'))"
"Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .","(('Diuretics', 'O'), ('may', 'O'), ('induce', 'O'), ('hypokalemia', 'B'), (',', 'O'), ('hypocalcemia', 'B'), ('and', 'O'), ('hypomagnesemia', 'B'), ('.', 'O'))"
"While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .","(('While', 'O'), ('severe', 'O'), ('hypokalemia', 'B'), ('may', 'O'), ('cause', 'O'), ('muscle', 'B'), ('weakness', 'I'), (',', 'O'), ('severe', 'O'), ('hypomagnesemia', 'B'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('muscle', 'B'), ('spasms', 'I'), ('and', 'O'), ('tetany', 'B'), ('which', 'O'), ('cannot', 'O'), ('be', 'O'), ('corrected', 'O'), ('by', 'O'), ('potassium', 'O'), ('and', 'O'), ('calcium', 'O'), ('supplementation', 'O'), ('alone', 'O'), ('(', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (')', 'O'), ('.', 'O'))"
"Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .","(('Symptomatic', 'O'), ('hypokalemia', 'B'), ('has', 'O'), ('been', 'O'), ('reported', 'O'), ('in', 'O'), ('such', 'O'), ('patients', 'O'), ('(', 'O'), ('3', 'O'), ('-', 'O'), ('7', 'O'), (')', 'O'), ('and', 'O'), ('in', 'O'), ('one', 'O'), ('case', 'O'), ('hypocalcemia', 'B'), ('was', 'O'), ('observed', 'O'), ('(', 'O'), ('8', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('magnesium', 'O'), ('depletion', 'O'), ('were', 'O'), ('not', 'O'), ('noted', 'O'), ('in', 'O'), ('these', 'O'), ('patients', 'O'), ('.', 'O'))"
Ciprofloxacin - induced nephrotoxicity in patients with cancer .,"(('Ciprofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrotoxicity', 'B'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('cancer', 'B'), ('.', 'O'))"
Nephrotoxicity associated with ciprofloxacin is uncommon .,"(('Nephrotoxicity', 'B'), ('associated', 'O'), ('with', 'O'), ('ciprofloxacin', 'O'), ('is', 'O'), ('uncommon', 'O'), ('.', 'O'))"
Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .,"(('Five', 'O'), ('patients', 'O'), ('with', 'O'), ('cancer', 'B'), ('who', 'O'), ('developed', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('that', 'O'), ('followed', 'O'), ('treatment', 'O'), ('with', 'O'), ('ciprofloxacin', 'O'), ('are', 'O'), ('described', 'O'), ('and', 'O'), ('an', 'O'), ('additional', 'O'), ('15', 'O'), ('cases', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('are', 'O'), ('reviewed', 'O'), ('.', 'O'))"
Allergic interstitial nephritis is believed to be the underlying pathological - process .,"(('Allergic', 'O'), ('interstitial', 'B'), ('nephritis', 'I'), ('is', 'O'), ('believed', 'O'), ('to', 'O'), ('be', 'O'), ('the', 'O'), ('underlying', 'O'), ('pathological', 'O'), ('-', 'O'), ('process', 'O'), ('.', 'O'))"
An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .,"(('An', 'O'), ('improvement', 'O'), ('in', 'O'), ('renal', 'O'), ('function', 'O'), ('that', 'O'), ('followed', 'O'), ('the', 'O'), ('discontinuation', 'O'), ('of', 'O'), ('the', 'O'), ('offending', 'O'), ('antibiotic', 'O'), ('supports', 'O'), ('the', 'O'), ('presumptive', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('ciprofloxacin', 'O'), ('-', 'O'), ('induced', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('.', 'O'))"
Venous complications of midazolam versus diazepam .,"(('Venous', 'B'), ('complications', 'I'), ('of', 'O'), ('midazolam', 'O'), ('versus', 'O'), ('diazepam', 'O'), ('.', 'O'))"
"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .","(('Although', 'O'), ('some', 'O'), ('studies', 'O'), ('have', 'O'), ('suggested', 'O'), ('fewer', 'O'), ('venous', 'B'), ('complications', 'I'), ('are', 'O'), ('associated', 'O'), ('with', 'O'), ('midazolam', 'O'), ('than', 'O'), ('with', 'O'), ('diazepam', 'O'), ('for', 'O'), ('endoscopic', 'O'), ('procedures', 'O'), (',', 'O'), ('this', 'O'), ('variable', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('well', 'O'), ('documented', 'O'), ('.', 'O'))"
We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .,"(('We', 'O'), ('prospectively', 'O'), ('evaluated', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('venous', 'B'), ('complications', 'I'), ('after', 'O'), ('intravenous', 'O'), ('injection', 'O'), ('of', 'O'), ('diazepam', 'O'), ('or', 'O'), ('midazolam', 'O'), ('in', 'O'), ('122', 'O'), ('consecutive', 'O'), ('patients', 'O'), ('undergoing', 'O'), ('colonoscopy', 'O'), ('and', 'O'), ('esophagogastroduodenoscopy', 'O'), ('.', 'O'))"
"Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .","(('Overall', 'O'), (',', 'O'), ('venous', 'B'), ('complications', 'I'), ('were', 'O'), ('more', 'O'), ('frequent', 'O'), ('with', 'O'), ('diazepam', 'O'), ('(', 'O'), ('22', 'O'), ('of', 'O'), ('62', 'O'), ('patients', 'O'), (')', 'O'), ('than', 'O'), ('with', 'O'), ('midazolam', 'O'), ('(', 'O'), ('4', 'O'), ('of', 'O'), ('60', 'O'), ('patients', 'O'), (')', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .,"(('Pain', 'B'), ('at', 'O'), ('the', 'O'), ('injection', 'O'), ('site', 'O'), ('occurred', 'O'), ('in', 'O'), ('35', 'O'), ('%', 'O'), ('(', 'O'), ('22', 'O'), ('of', 'O'), ('62', 'O'), (')', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('the', 'O'), ('diazepam', 'O'), ('group', 'O'), ('compared', 'O'), ('with', 'O'), ('7', 'O'), ('%', 'O'), ('(', 'O'), ('4', 'O'), ('of', 'O'), ('60', 'O'), ('patients', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('midazolam', 'O'), ('group', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), ('.', 'O'))"
"Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .","(('Smoking', 'O'), (',', 'O'), ('nonsteroidal', 'O'), ('anti', 'O'), ('-', 'O'), ('inflammatory', 'O'), ('drug', 'O'), ('use', 'O'), (',', 'O'), ('intravenous', 'O'), ('catheter', 'O'), ('site', 'O'), (',', 'O'), ('dwell', 'O'), ('time', 'O'), ('of', 'O'), ('the', 'O'), ('needle', 'O'), (',', 'O'), ('alcohol', 'O'), ('use', 'O'), (',', 'O'), ('and', 'O'), ('pain', 'B'), ('during', 'O'), ('the', 'O'), ('injection', 'O'), ('had', 'O'), ('no', 'O'), ('effect', 'O'), ('on', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('venous', 'B'), ('complications', 'I'), ('.', 'O'))"
Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .,"(('Clarithromycin', 'O'), ('-', 'O'), ('associated', 'O'), ('visual', 'B'), ('hallucinations', 'I'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('chronic', 'B'), ('renal', 'I'), ('failure', 'I'), ('on', 'O'), ('continuous', 'O'), ('ambulatory', 'O'), ('peritoneal', 'O'), ('dialysis', 'O'), ('.', 'O'))"
Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .,"(('Visual', 'B'), ('hallucinations', 'I'), ('are', 'O'), ('a', 'O'), ('rare', 'O'), ('event', 'O'), ('in', 'O'), ('chronic', 'B'), ('renal', 'I'), ('failure', 'I'), ('and', 'O'), ('not', 'O'), ('related', 'O'), ('to', 'O'), ('uremia', 'B'), ('per', 'O'), ('se', 'O'), ('.', 'O'))"
"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .","(('Unreported', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('is', 'O'), ('visual', 'B'), ('hallucinations', 'I'), ('occurring', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('the', 'O'), ('new', 'O'), ('macrolide', 'O'), ('antibiotic', 'O'), (',', 'O'), ('clarithromycin', 'O'), ('.', 'O'))"
We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .,"(('We', 'O'), ('describe', 'O'), ('such', 'O'), ('a', 'O'), ('case', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('with', 'O'), ('end', 'B'), ('-', 'I'), ('stage', 'I'), ('renal', 'I'), ('disease', 'I'), ('(', 'O'), ('ESRD', 'B'), (')', 'O'), ('maintained', 'O'), ('on', 'O'), ('continuous', 'O'), ('ambulatory', 'O'), ('peritoneal', 'O'), ('dialysis', 'O'), ('(', 'O'), ('CAPD', 'O'), (')', 'O'), ('.', 'O'))"
"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .","(('The', 'O'), ('combination', 'O'), ('of', 'O'), ('a', 'O'), ('relatively', 'O'), ('high', 'O'), ('dose', 'O'), ('of', 'O'), ('clarithromycin', 'O'), ('in', 'O'), ('face', 'O'), ('of', 'O'), ('chronic', 'B'), ('renal', 'I'), ('failure', 'I'), ('in', 'O'), ('a', 'O'), ('functionally', 'O'), ('anephric', 'O'), ('patient', 'O'), (',', 'O'), ('with', 'O'), ('underlying', 'O'), ('aluminum', 'O'), ('intoxication', 'O'), (',', 'O'), ('may', 'O'), ('have', 'O'), ('facilitated', 'O'), ('the', 'O'), ('appearance', 'O'), ('of', 'O'), ('this', 'O'), ('neurotoxic', 'B'), ('side', 'O'), ('effect', 'O'), ('.', 'O'))"
"It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .","(('It', 'O'), ('is', 'O'), ('important', 'O'), ('to', 'O'), ('understand', 'O'), ('the', 'O'), ('pharmacokinetics', 'O'), ('of', 'O'), ('medications', 'O'), ('in', 'O'), ('face', 'O'), ('of', 'O'), ('chronic', 'B'), ('renal', 'I'), ('failure', 'I'), (',', 'O'), ('the', 'O'), ('possibility', 'O'), ('of', 'O'), ('drug', 'O'), ('interactions', 'O'), (',', 'O'), ('and', 'O'), ('how', 'O'), ('these', 'O'), ('factors', 'O'), ('should', 'O'), ('help', 'O'), ('guide', 'O'), ('medication', 'O'), ('therapy', 'O'), ('in', 'O'), ('the', 'O'), ('ESRD', 'B'), ('patient', 'O'), ('.', 'O'))"
Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .,"(('Peroxisomes', 'O'), ('in', 'O'), ('hepatomas', 'B'), ('and', 'O'), ('hyperplastic', 'O'), ('preneoplastic', 'O'), ('liver', 'B'), ('lesions', 'I'), ('induced', 'O'), ('in', 'O'), ('mice', 'O'), ('by', 'O'), ('500', 'O'), ('ppm', 'O'), ('alpha', 'O'), ('-', 'O'), ('benzene', 'O'), ('hexachloride', 'O'), ('were', 'O'), ('examined', 'O'), ('histochemically', 'O'), ('and', 'O'), ('electron', 'O'), ('microscopically', 'O'), ('.', 'O'))"
"Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .","(('Although', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('hepatomas', 'B'), ('were', 'O'), ('well', 'O'), ('-', 'O'), ('differentiated', 'O'), ('tumors', 'B'), ('and', 'O'), ('contained', 'O'), ('a', 'O'), ('considerable', 'O'), ('number', 'O'), ('of', 'O'), ('peroxisomes', 'O'), (',', 'O'), ('the', 'O'), ('tumor', 'B'), ('cells', 'O'), ('did', 'O'), ('not', 'O'), ('respond', 'O'), ('to', 'O'), ('ethyl', 'O'), ('-', 'O'), ('alpha', 'O'), ('-', 'O'), ('p', 'O'), ('-', 'O'), ('chlorophenoxyisobutyrate', 'O'), ('with', 'O'), ('proliferation', 'O'), ('of', 'O'), ('peroxisomes', 'O'), ('.', 'O'))"
Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .,"(('Contribution', 'O'), ('of', 'O'), ('the', 'O'), ('sympathetic', 'O'), ('nervous', 'O'), ('system', 'O'), ('to', 'O'), ('salt', 'O'), ('-', 'O'), ('sensitivity', 'O'), ('in', 'O'), ('lifetime', 'O'), ('captopril', 'O'), ('-', 'O'), ('treated', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('.', 'O'))"
"OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .","(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('test', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), (',', 'O'), ('in', 'O'), ('lifetime', 'O'), ('captopril', 'O'), ('-', 'O'), ('treated', 'O'), ('spontaneously', 'O'), ('hypertensive', 'B'), ('rats', 'O'), ('(', 'O'), ('SHR', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('sympathetic', 'O'), ('nervous', 'O'), ('system', 'O'), ('contributes', 'O'), ('importantly', 'O'), ('to', 'O'), ('the', 'O'), ('hypertensive', 'B'), ('effect', 'O'), ('of', 'O'), ('dietary', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('supplementation', 'O'), ('.', 'O'))"
Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .,"(('Intravenous', 'O'), ('infusion', 'O'), ('of', 'O'), ('the', 'O'), ('ganglionic', 'O'), ('blocker', 'O'), ('hexamethonium', 'O'), ('resulted', 'O'), ('in', 'O'), ('a', 'O'), ('rapid', 'O'), ('decline', 'O'), ('in', 'O'), ('MAP', 'O'), ('that', 'O'), ('eliminated', 'O'), ('the', 'O'), ('dietary', 'O'), ('sodium', 'O'), ('chloride', 'O'), ('-', 'O'), ('induced', 'O'), ('increase', 'B'), ('in', 'I'), ('MAP', 'I'), ('in', 'O'), ('both', 'O'), ('groups', 'O'), ('.', 'O'))"
Angioedema associated with droperidol administration .,"(('Angioedema', 'B'), ('associated', 'O'), ('with', 'O'), ('droperidol', 'O'), ('administration', 'O'), ('.', 'O'))"
"Angioedema , also known as angioneurotic edema or Quincke ' s disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .","(('Angioedema', 'B'), (',', 'O'), ('also', 'O'), ('known', 'O'), ('as', 'O'), ('angioneurotic', 'B'), ('edema', 'I'), ('or', 'O'), ('Quincke', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('is', 'O'), ('a', 'O'), ('well', 'O'), ('-', 'O'), ('demarcated', 'O'), (',', 'O'), ('localized', 'O'), ('edema', 'B'), ('involving', 'O'), ('the', 'O'), ('subcutaneous', 'O'), ('tissues', 'O'), ('that', 'O'), ('may', 'O'), ('cause', 'O'), ('upper', 'B'), ('-', 'I'), ('airway', 'I'), ('obstruction', 'I'), ('.', 'O'))"
We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('previously', 'O'), ('healthy', 'O'), ('19', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('man', 'O'), ('with', 'O'), ('no', 'O'), ('known', 'O'), ('drug', 'B'), ('allergies', 'I'), ('in', 'O'), ('whom', 'O'), ('angioedema', 'B'), ('with', 'O'), ('significant', 'O'), ('tongue', 'B'), ('swelling', 'I'), ('and', 'O'), ('protrusion', 'O'), ('developed', 'O'), ('within', 'O'), ('10', 'O'), ('minutes', 'O'), ('of', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('a', 'O'), ('single', 'O'), ('IV', 'O'), ('dose', 'O'), ('of', 'O'), ('droperidol', 'O'), ('.', 'O'))"
Late cardiotoxicity after treatment for a malignant bone tumor .,"(('Late', 'O'), ('cardiotoxicity', 'B'), ('after', 'O'), ('treatment', 'O'), ('for', 'O'), ('a', 'O'), ('malignant', 'O'), ('bone', 'B'), ('tumor', 'I'), ('.', 'O'))"
"Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen ' s T5 or T10 protocol , both including doxorubicin .","(('Cardiac', 'O'), ('function', 'O'), ('was', 'O'), ('assessed', 'O'), ('in', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('survivors', 'O'), ('of', 'O'), ('malignant', 'O'), ('bone', 'B'), ('tumors', 'I'), ('who', 'O'), ('were', 'O'), ('treated', 'O'), ('according', 'O'), ('to', 'O'), ('Rosen', 'O'), (""'"", 'O'), ('s', 'O'), ('T5', 'O'), ('or', 'O'), ('T10', 'O'), ('protocol', 'O'), (',', 'O'), ('both', 'O'), ('including', 'O'), ('doxorubicin', 'O'), ('.', 'O'))"
"Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .","(('Eighteen', 'O'), ('of', 'O'), ('31', 'O'), ('(', 'O'), ('58', 'O'), ('%', 'O'), (')', 'O'), ('patients', 'O'), ('showed', 'O'), ('cardiac', 'B'), ('toxicity', 'I'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('having', 'O'), ('one', 'O'), ('or', 'O'), ('more', 'O'), ('of', 'O'), ('the', 'O'), ('following', 'O'), ('abnormalities', 'O'), (':', 'O'), ('late', 'O'), ('potentials', 'O'), (',', 'O'), ('complex', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), (',', 'O'), ('left', 'O'), ('ventricular', 'B'), ('dilation', 'I'), (',', 'O'), ('decreased', 'O'), ('shortening', 'O'), ('fraction', 'O'), (',', 'O'), ('or', 'O'), ('decreased', 'O'), ('ejection', 'O'), ('fraction', 'O'), ('.', 'O'))"
The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('cardiac', 'B'), ('abnormalities', 'I'), ('increased', 'O'), ('with', 'O'), ('length', 'O'), ('of', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('or', 'O'), ('=', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('.', 'O'))"
"The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('is', 'O'), ('high', 'O'), ('and', 'O'), ('increases', 'O'), ('with', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), (',', 'O'), ('irrespective', 'O'), ('of', 'O'), ('cumulative', 'O'), ('dose', 'O'), ('.', 'O'))"
The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .,"(('The', 'O'), ('results', 'O'), ('of', 'O'), ('our', 'O'), ('study', 'O'), ('suggest', 'O'), ('that', 'O'), ('heart', 'O'), ('rate', 'O'), ('variability', 'O'), ('and', 'O'), ('LVPW', 'O'), ('index', 'O'), ('could', 'O'), ('be', 'O'), ('sensitive', 'O'), ('indicators', 'O'), ('for', 'O'), ('cardiotoxicity', 'B'), ('.', 'O'))"
Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .,"(('Acute', 'O'), ('blood', 'O'), ('pressure', 'O'), ('elevations', 'O'), ('with', 'O'), ('caffeine', 'O'), ('in', 'O'), ('men', 'O'), ('with', 'O'), ('borderline', 'O'), ('systemic', 'O'), ('hypertension', 'B'), ('.', 'O'))"
Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .,"(('Whether', 'O'), ('the', 'O'), ('vasoconstrictive', 'O'), ('actions', 'O'), ('of', 'O'), ('caffeine', 'O'), ('are', 'O'), ('enhanced', 'O'), ('in', 'O'), ('hypertensive', 'B'), ('persons', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('demonstrated', 'O'), ('.', 'O'))"
Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm Hg .,"(('Borderline', 'O'), ('hypertensive', 'B'), ('men', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('24', 'O'), (')', 'O'), ('were', 'O'), ('selected', 'O'), ('with', 'O'), ('screening', 'O'), ('systolic', 'O'), ('blood', 'O'), ('pressure', 'O'), ('(', 'O'), ('BP', 'O'), (')', 'O'), ('of', 'O'), ('140', 'O'), ('to', 'O'), ('160', 'O'), ('mm', 'O'), ('Hg', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('diastolic', 'O'), ('BP', 'O'), ('90', 'O'), ('to', 'O'), ('99', 'O'), ('mm', 'O'), ('Hg', 'O'), ('.', 'O'))"
Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm Hg .,"(('Low', 'O'), ('-', 'O'), ('risk', 'O'), ('controls', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('24', 'O'), (')', 'O'), ('reported', 'O'), ('no', 'O'), ('parental', 'O'), ('history', 'O'), ('of', 'O'), ('hypertension', 'B'), ('and', 'O'), ('had', 'O'), ('screening', 'O'), ('BP', 'O'), ('<', 'O'), ('130', 'O'), ('/', 'O'), ('85', 'O'), ('mm', 'O'), ('Hg', 'O'), ('.', 'O'))"
"Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .","(('Consequently', 'O'), (',', 'O'), ('whereas', 'O'), ('all', 'O'), ('participants', 'O'), ('exhibited', 'O'), ('normotensive', 'O'), ('levels', 'O'), ('during', 'O'), ('the', 'O'), ('resting', 'O'), ('predrug', 'O'), ('baseline', 'O'), (',', 'O'), ('33', 'O'), ('%', 'O'), ('of', 'O'), ('borderline', 'O'), ('subjects', 'O'), ('achieved', 'O'), ('hypertensive', 'B'), ('BP', 'O'), ('levels', 'O'), ('after', 'O'), ('caffeine', 'O'), ('ingestion', 'O'), ('.', 'O'))"
"Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .","(('Thus', 'O'), (',', 'O'), ('in', 'O'), ('borderline', 'O'), ('hypertensive', 'B'), ('men', 'O'), (',', 'O'), ('exaggerated', 'O'), ('responses', 'O'), ('to', 'O'), ('caffeine', 'O'), ('were', 'O'), (':', 'O'), ('selective', 'O'), ('for', 'O'), ('diastolic', 'O'), ('BP', 'O'), (',', 'O'), ('consistent', 'O'), ('with', 'O'), ('greater', 'O'), ('vasoconstriction', 'O'), (',', 'O'), ('replicated', 'O'), ('in', 'O'), ('2', 'O'), ('protocols', 'O'), (',', 'O'), ('and', 'O'), ('representative', 'O'), ('of', 'O'), ('nearly', 'O'), ('all', 'O'), ('borderline', 'O'), ('hypertensives', 'B'), ('.', 'O'))"
Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .,"(('Absence', 'O'), ('of', 'O'), ('effect', 'O'), ('of', 'O'), ('sertraline', 'O'), ('on', 'O'), ('time', 'O'), ('-', 'O'), ('based', 'O'), ('sensitization', 'O'), ('of', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('with', 'O'), ('haloperidol', 'O'), ('.', 'O'))"
RESULTS : Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .,"(('RESULTS', 'O'), (':', 'O'), ('Impairment', 'B'), ('of', 'I'), ('cognitive', 'I'), ('function', 'I'), ('was', 'O'), ('observed', 'O'), ('6', 'O'), ('to', 'O'), ('8', 'O'), ('hours', 'O'), ('after', 'O'), ('administration', 'O'), ('of', 'O'), ('haloperidol', 'O'), ('on', 'O'), ('Day', 'O'), ('2', 'O'), ('but', 'O'), ('was', 'O'), ('not', 'O'), ('evident', 'O'), ('23', 'O'), ('hours', 'O'), ('after', 'O'), ('dosing', 'O'), ('.', 'O'))"
CONCLUSION : Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .,"(('CONCLUSION', 'O'), (':', 'O'), ('Haloperidol', 'O'), ('produced', 'O'), ('a', 'O'), ('clear', 'O'), ('profile', 'O'), ('of', 'O'), ('cognitive', 'B'), ('impairment', 'I'), ('that', 'O'), ('was', 'O'), ('not', 'O'), ('worsened', 'O'), ('by', 'O'), ('concomitant', 'O'), ('sertraline', 'O'), ('administration', 'O'), ('.', 'O'))"
Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .,"(('Coexistence', 'O'), ('of', 'O'), ('cerebral', 'B'), ('venous', 'I'), ('sinus', 'I'), ('and', 'I'), ('internal', 'I'), ('carotid', 'I'), ('artery', 'I'), ('thrombosis', 'I'), ('associated', 'O'), ('with', 'O'), ('exogenous', 'O'), ('sex', 'O'), ('hormones', 'O'), ('.', 'O'))"
"A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .","(('A', 'O'), ('forty', 'O'), ('-', 'O'), ('six', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('premenopausal', 'O'), ('woman', 'O'), ('developed', 'O'), ('headache', 'B'), (',', 'O'), ('nausea', 'B'), ('and', 'O'), ('vomiting', 'B'), (',', 'O'), ('left', 'O'), ('hemiparesis', 'B'), ('and', 'O'), ('seizure', 'B'), ('two', 'O'), ('days', 'O'), ('after', 'O'), ('parenteral', 'O'), ('use', 'O'), ('of', 'O'), ('progesterone', 'O'), ('and', 'O'), ('estradiol', 'O'), ('.', 'O'))"
Diabetes mellitus ( DM ) was found during admission .,"(('Diabetes', 'B'), ('mellitus', 'I'), ('(', 'O'), ('DM', 'B'), (')', 'O'), ('was', 'O'), ('found', 'O'), ('during', 'O'), ('admission', 'O'), ('.', 'O'))"
Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .,"(('Computed', 'O'), ('tomography', 'O'), ('showed', 'O'), ('a', 'O'), ('hemorrhagic', 'B'), ('infarct', 'I'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('frontal', 'O'), ('lobe', 'O'), ('and', 'O'), ('increased', 'O'), ('density', 'O'), ('in', 'O'), ('the', 'O'), ('superior', 'O'), ('sagittal', 'O'), ('sinus', 'O'), ('(', 'O'), ('SSS', 'O'), (')', 'O'), ('.', 'O'))"
Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .,"(('Left', 'O'), ('carotid', 'O'), ('angiography', 'O'), ('found', 'O'), ('occlusion', 'B'), ('of', 'I'), ('the', 'I'), ('left', 'I'), ('internal', 'I'), ('carotid', 'I'), ('artery', 'I'), ('(', 'O'), ('ICA', 'O'), (')', 'O'), ('.', 'O'))"
"Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .","(('Right', 'O'), ('carotid', 'O'), ('angiograms', 'O'), ('failed', 'O'), ('to', 'O'), ('show', 'O'), ('the', 'O'), ('SSS', 'O'), ('and', 'O'), ('inferior', 'O'), ('sagittal', 'O'), ('sinus', 'O'), (',', 'O'), ('suggestive', 'O'), ('of', 'O'), ('venous', 'B'), ('sinus', 'I'), ('thrombosis', 'I'), ('.', 'O'))"
Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .,"(('Coexistence', 'O'), ('of', 'O'), ('the', 'O'), ('cerebral', 'B'), ('artery', 'I'), ('and', 'I'), ('the', 'I'), ('venous', 'I'), ('sinus', 'I'), ('occlusion', 'I'), ('has', 'O'), ('been', 'O'), ('described', 'O'), ('infrequently', 'O'), ('.', 'O'))"
"In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .","(('In', 'O'), ('this', 'O'), ('case', 'O'), (',', 'O'), ('the', 'O'), ('authors', 'O'), ('postulate', 'O'), ('that', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('estradiol', 'O'), ('and', 'O'), ('progesterone', 'O'), ('and', 'O'), ('the', 'O'), ('underlying', 'O'), ('DM', 'B'), ('increased', 'O'), ('vascular', 'O'), ('thrombogenicity', 'O'), (',', 'O'), ('which', 'O'), ('provided', 'O'), ('a', 'O'), ('common', 'O'), ('denominator', 'O'), ('for', 'O'), ('thrombosis', 'B'), ('of', 'I'), ('both', 'I'), ('the', 'I'), ('ICA', 'I'), ('and', 'I'), ('the', 'I'), ('venous', 'I'), ('sinus', 'I'), ('.', 'O'))"
Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .,"(('Chemotherapy', 'O'), ('of', 'O'), ('advanced', 'O'), ('inoperable', 'O'), ('non', 'B'), ('-', 'I'), ('small', 'I'), ('cell', 'I'), ('lung', 'I'), ('cancer', 'I'), ('with', 'O'), ('paclitaxel', 'O'), (':', 'O'), ('a', 'O'), ('phase', 'O'), ('II', 'O'), ('trial', 'O'), ('.', 'O'))"
"Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .","(('Paclitaxel', 'O'), ('(', 'O'), ('Taxol', 'O'), (';', 'O'), ('Bristol', 'O'), ('-', 'O'), ('Myers', 'O'), ('Squibb', 'O'), ('Company', 'O'), (',', 'O'), ('Princeton', 'O'), (',', 'O'), ('NJ', 'O'), (')', 'O'), ('has', 'O'), ('demonstrated', 'O'), ('significant', 'O'), ('antineoplastic', 'O'), ('activity', 'O'), ('against', 'O'), ('different', 'O'), ('tumor', 'B'), ('types', 'O'), (',', 'O'), ('notably', 'O'), ('ovarian', 'B'), ('and', 'I'), ('breast', 'I'), ('carcinoma', 'I'), ('.', 'O'))"
Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .,"(('Two', 'O'), ('phase', 'O'), ('II', 'O'), ('trials', 'O'), ('of', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('paclitaxel', 'O'), ('infusions', 'O'), ('in', 'O'), ('chemotherapy', 'O'), ('-', 'O'), ('naive', 'O'), ('patients', 'O'), ('with', 'O'), ('stage', 'O'), ('IIIB', 'O'), ('or', 'O'), ('IV', 'O'), ('non', 'B'), ('-', 'I'), ('small', 'I'), ('cell', 'I'), ('lung', 'I'), ('cancer', 'I'), ('(', 'O'), ('NSCLC', 'B'), (')', 'O'), ('reported', 'O'), ('response', 'O'), ('rates', 'O'), ('of', 'O'), ('21', 'O'), ('%', 'O'), ('and', 'O'), ('24', 'O'), ('%', 'O'), ('.', 'O'))"
Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .,"(('Leukopenia', 'B'), ('was', 'O'), ('dose', 'O'), ('limiting', 'O'), (':', 'O'), ('as', 'O'), ('many', 'O'), ('as', 'O'), ('62', 'O'), ('.', 'O'), ('5', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('experienced', 'O'), ('grade', 'O'), ('4', 'O'), ('leukopenia', 'B'), ('.', 'O'))"
We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .,"(('We', 'O'), ('investigated', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('toxicity', 'B'), ('of', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('paclitaxel', 'O'), ('infusion', 'O'), ('in', 'O'), ('a', 'O'), ('phase', 'O'), ('II', 'O'), ('trial', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('inoperable', 'O'), ('stage', 'O'), ('IIIB', 'O'), ('or', 'O'), ('IV', 'O'), ('NSCLC', 'B'), ('.', 'O'))"
Most patients ( 72 . 4 % ) had stage IV NSCLC .,"(('Most', 'O'), ('patients', 'O'), ('(', 'O'), ('72', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), (')', 'O'), ('had', 'O'), ('stage', 'O'), ('IV', 'O'), ('NSCLC', 'B'), ('.', 'O'))"
"Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .","(('Hematologic', 'O'), ('toxicities', 'B'), ('were', 'O'), ('mild', 'O'), (':', 'O'), ('only', 'O'), ('one', 'O'), ('patient', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('developed', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('neutropenia', 'B'), (',', 'O'), ('while', 'O'), ('29', 'O'), ('%', 'O'), ('had', 'O'), ('grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('.', 'O'))"
Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .,"(('Grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('polyneuropathy', 'B'), ('affected', 'O'), ('56', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('while', 'O'), ('only', 'O'), ('one', 'O'), ('(', 'O'), ('2', 'O'), ('%', 'O'), (')', 'O'), ('experienced', 'O'), ('severe', 'O'), ('polyneuropathy', 'B'), ('.', 'O'))"
"Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .","(('Similarly', 'O'), (',', 'O'), ('grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('myalgia', 'B'), ('/', 'O'), ('arthralgia', 'B'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('63', 'O'), ('.', 'O'), ('2', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), (',', 'O'), ('but', 'O'), ('only', 'O'), ('14', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('experienced', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('.', 'O'))"
"Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .","(('Nausea', 'B'), ('and', 'O'), ('vomiting', 'B'), ('were', 'O'), ('infrequent', 'O'), (',', 'O'), ('with', 'O'), ('14', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('experiencing', 'O'), ('grade', 'O'), ('1', 'O'), ('or', 'O'), ('2', 'O'), ('and', 'O'), ('only', 'O'), ('2', 'O'), ('%', 'O'), ('experiencing', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('.', 'O'))"
"Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .","(('Paclitaxel', 'O'), ('is', 'O'), ('thus', 'O'), ('an', 'O'), ('active', 'O'), ('single', 'O'), ('agent', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('population', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('proving', 'O'), ('comparably', 'O'), ('effective', 'O'), ('to', 'O'), ('a', 'O'), ('24', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('and', 'O'), ('superior', 'O'), ('in', 'O'), ('terms', 'O'), ('of', 'O'), ('the', 'O'), ('incidence', 'O'), ('of', 'O'), ('hematologic', 'O'), ('and', 'O'), ('nonhematologic', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .","(('Further', 'O'), ('phase', 'O'), ('II', 'O'), ('studies', 'O'), ('with', 'O'), ('paclitaxel', 'O'), ('combined', 'O'), ('with', 'O'), ('other', 'O'), ('drugs', 'O'), ('active', 'O'), ('against', 'O'), ('NSCLC', 'B'), ('are', 'O'), ('indicated', 'O'), (',', 'O'), ('and', 'O'), ('phase', 'O'), ('III', 'O'), ('studies', 'O'), ('comparing', 'O'), ('paclitaxel', 'O'), ('with', 'O'), ('standard', 'O'), ('chemotherapy', 'O'), ('remain', 'O'), ('to', 'O'), ('be', 'O'), ('completed', 'O'), ('.', 'O'))"
Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .,"(('Paclitaxel', 'O'), ('combined', 'O'), ('with', 'O'), ('carboplatin', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('-', 'O'), ('line', 'O'), ('treatment', 'O'), ('of', 'O'), ('advanced', 'O'), ('ovarian', 'B'), ('cancer', 'I'), ('.', 'O'))"
"In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .","(('In', 'O'), ('a', 'O'), ('phase', 'O'), ('I', 'O'), ('study', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('maximum', 'O'), ('tolerated', 'O'), ('dose', 'O'), ('of', 'O'), ('paclitaxel', 'O'), ('(', 'O'), ('Taxol', 'O'), (';', 'O'), ('Bristol', 'O'), ('-', 'O'), ('Myers', 'O'), ('Squibb', 'O'), ('Company', 'O'), (',', 'O'), ('Princeton', 'O'), (',', 'O'), ('NJ', 'O'), (')', 'O'), ('given', 'O'), ('as', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('hour', 'O'), ('infusion', 'O'), ('in', 'O'), ('combination', 'O'), ('with', 'O'), ('carboplatin', 'O'), ('administered', 'O'), ('every', 'O'), ('21', 'O'), ('days', 'O'), ('to', 'O'), ('women', 'O'), ('with', 'O'), ('advanced', 'O'), ('ovarian', 'B'), ('cancer', 'I'), (',', 'O'), ('paclitaxel', 'O'), ('doses', 'O'), ('were', 'O'), ('escalated', 'O'), ('as', 'O'), ('follows', 'O'), (':', 'O'), ('level', 'O'), ('1', 'O'), (',', 'O'), ('135', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('level', 'O'), ('2', 'O'), (',', 'O'), ('160', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('level', 'O'), ('3', 'O'), (',', 'O'), ('185', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), (';', 'O'), ('and', 'O'), ('level', 'O'), ('4', 'O'), (',', 'O'), ('210', 'O'), ('mg', 'O'), ('/', 'O'), ('m2', 'O'), ('.', 'O'))"
"The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .","(('The', 'O'), ('dose', 'O'), ('-', 'O'), ('limiting', 'O'), ('toxicity', 'B'), ('of', 'O'), ('the', 'O'), ('combination', 'O'), ('was', 'O'), ('myelosuppression', 'B'), ('(', 'O'), ('leukopenia', 'B'), (',', 'O'), ('granulocytopenia', 'B'), (',', 'O'), ('and', 'O'), ('thrombocytopenia', 'B'), (')', 'O'), ('.', 'O'))"
Neurotoxicity was largely moderate .,"(('Neurotoxicity', 'B'), ('was', 'O'), ('largely', 'O'), ('moderate', 'O'), ('.', 'O'))"
Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .,"(('Occasional', 'O'), ('case', 'O'), ('reports', 'O'), ('have', 'O'), ('shown', 'O'), ('that', 'O'), ('acute', 'O'), ('myopathy', 'B'), ('may', 'O'), ('occur', 'O'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('massive', 'O'), ('doses', 'O'), ('of', 'O'), ('corticosteroids', 'O'), ('.', 'O'))"
The mechanism of this myopathy is poorly understood .,"(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('this', 'O'), ('myopathy', 'B'), ('is', 'O'), ('poorly', 'O'), ('understood', 'O'), ('.', 'O'))"
"Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .","(('Nutritional', 'O'), ('intake', 'O'), (',', 'O'), ('measured', 'O'), ('daily', 'O'), ('in', 'O'), ('15', 'O'), ('animals', 'O'), (',', 'O'), ('showed', 'O'), ('a', 'O'), ('significant', 'O'), ('reduction', 'B'), ('of', 'I'), ('food', 'I'), ('intake', 'I'), ('in', 'O'), ('the', 'O'), ('steroid', 'O'), ('-', 'O'), ('treated', 'O'), ('groups', 'O'), ('(', 'O'), ('-', 'O'), ('50', 'O'), ('and', 'O'), ('-', 'O'), ('79', 'O'), ('%', 'O'), ('in', 'O'), ('M', 'O'), ('and', 'O'), ('T', 'O'), (',', 'O'), ('respectively', 'O'), (')', 'O'), ('.', 'O'))"
This was associated with a similar loss in body weight .,"(('This', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('similar', 'O'), ('loss', 'B'), ('in', 'I'), ('body', 'I'), ('weight', 'I'), ('.', 'O'))"
"Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .","(('Half', 'O'), ('-', 'O'), ('relaxation', 'O'), ('time', 'O'), ('was', 'O'), ('prolonged', 'O'), ('in', 'O'), ('both', 'O'), ('steroid', 'O'), ('groups', 'O'), (',', 'O'), ('and', 'O'), ('time', 'O'), ('to', 'O'), ('peak', 'O'), ('tension', 'O'), ('was', 'O'), ('longer', 'O'), ('with', 'O'), ('M', 'O'), (',', 'O'), ('whereas', 'O'), ('tetanic', 'B'), ('tensions', 'O'), ('were', 'O'), ('similar', 'O'), ('.', 'O'))"
"ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .","(('ATPase', 'O'), ('staining', 'O'), ('of', 'O'), ('the', 'O'), ('diaphragm', 'O'), (',', 'O'), ('scalenus', 'O'), ('medius', 'O'), (',', 'O'), ('and', 'O'), ('gastrocnemius', 'O'), ('showed', 'O'), ('type', 'O'), ('IIb', 'O'), ('fiber', 'O'), ('atrophy', 'B'), ('in', 'O'), ('the', 'O'), ('steroid', 'O'), ('groups', 'O'), ('and', 'O'), ('also', 'O'), ('diaphragmatic', 'O'), ('type', 'O'), ('IIa', 'O'), ('atrophy', 'B'), ('with', 'O'), ('T', 'O'), (',', 'O'), ('whereas', 'O'), ('histologic', 'O'), ('examinations', 'O'), ('revealed', 'O'), ('a', 'O'), ('normal', 'O'), ('muscular', 'O'), ('pattern', 'O'), ('with', 'O'), ('absence', 'O'), ('of', 'O'), ('necrosis', 'B'), ('.', 'O'))"
"Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .","(('Finally', 'O'), (',', 'O'), ('a', 'O'), ('pair', 'O'), ('-', 'O'), ('fed', 'O'), ('(', 'O'), ('PF', 'O'), (')', 'O'), ('study', 'O'), (',', 'O'), ('performed', 'O'), ('in', 'O'), ('18', 'O'), ('rats', 'O'), ('(', 'O'), ('C', 'O'), (',', 'O'), ('T', 'O'), (',', 'O'), ('and', 'O'), ('PF', 'O'), (')', 'O'), (',', 'O'), ('showed', 'O'), ('that', 'O'), ('muscle', 'B'), ('atrophy', 'I'), ('was', 'O'), ('considerably', 'O'), ('less', 'O'), ('pronounced', 'O'), ('in', 'O'), ('PF', 'O'), ('animals', 'O'), ('than', 'O'), ('in', 'O'), ('T', 'O'), ('-', 'O'), ('treated', 'O'), ('animals', 'O'), ('.', 'O'))"
"We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .","(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('(', 'O'), ('1', 'O'), (')', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('treatment', 'O'), ('with', 'O'), ('massive', 'O'), ('doses', 'O'), ('of', 'O'), ('steroids', 'O'), ('induced', 'O'), ('severe', 'O'), ('respiratory', 'O'), ('and', 'O'), ('limb', 'O'), ('muscle', 'O'), ('wasting', 'O'), (';', 'O'), ('(', 'O'), ('2', 'O'), (')', 'O'), ('both', 'O'), ('types', 'O'), ('of', 'O'), ('steroids', 'O'), ('induced', 'O'), ('predominantly', 'O'), ('type', 'O'), ('IIb', 'O'), ('atrophy', 'B'), (',', 'O'), ('resulting', 'O'), ('in', 'O'), ('the', 'O'), ('expected', 'O'), ('alterations', 'O'), ('in', 'O'), ('diaphragm', 'O'), ('contractile', 'O'), ('properties', 'O'), (';', 'O'), ('(', 'O'), ('3', 'O'), (')', 'O'), ('neither', 'O'), ('steroid', 'O'), ('caused', 'O'), ('muscle', 'O'), ('necrosis', 'B'), (';', 'O'), ('(', 'O'), ('4', 'O'), (')', 'O'), ('type', 'O'), ('IIb', 'O'), ('atrophy', 'B'), ('was', 'O'), ('not', 'O'), ('caused', 'O'), ('by', 'O'), ('acute', 'O'), ('nutritional', 'O'), ('deprivation', 'O'), ('alone', 'O'), ('.', 'O'))"
Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .,"(('Continuous', 'O'), ('subcutaneous', 'O'), ('administration', 'O'), ('of', 'O'), ('mesna', 'O'), ('to', 'O'), ('prevent', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('hemorrhagic', 'B'), ('cystitis', 'I'), ('.', 'O'))"
Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .,"(('Hemorrhagic', 'B'), ('cystitis', 'I'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('potential', 'O'), ('toxicity', 'B'), ('of', 'O'), ('ifosfamide', 'O'), ('that', 'O'), ('can', 'O'), ('be', 'O'), ('prevented', 'O'), ('by', 'O'), ('administering', 'O'), ('mesna', 'O'), ('along', 'O'), ('with', 'O'), ('the', 'O'), ('cytotoxic', 'O'), ('agent', 'O'), ('.', 'O'))"
"In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .","(('In', 'O'), ('addition', 'O'), (',', 'O'), ('subcutaneous', 'O'), ('delivery', 'O'), ('of', 'O'), ('the', 'O'), ('neutralizing', 'O'), ('agent', 'O'), ('will', 'O'), ('not', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('risk', 'O'), ('of', 'O'), ('inadequate', 'O'), ('urinary', 'O'), ('mesna', 'O'), ('concentrations', 'O'), (',', 'O'), ('such', 'O'), ('as', 'O'), ('in', 'O'), ('a', 'O'), ('patient', 'O'), ('taking', 'O'), ('oral', 'O'), ('mesna', 'O'), ('who', 'O'), ('experiences', 'O'), ('severe', 'O'), ('ifosfamide', 'O'), ('-', 'O'), ('induced', 'O'), ('emesis', 'B'), ('and', 'O'), ('is', 'O'), ('unable', 'O'), ('to', 'O'), ('absorb', 'O'), ('the', 'O'), ('drug', 'O'), ('.', 'O'))"
Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .,"(('Leg', 'B'), ('and', 'I'), ('back', 'I'), ('pain', 'I'), ('after', 'O'), ('spinal', 'O'), ('anaesthesia', 'O'), ('involving', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), ('.', 'O'))"
Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .,"(('Thirteen', 'O'), ('of', 'O'), ('these', 'O'), ('patients', 'O'), ('experienced', 'O'), ('pain', 'B'), ('in', 'I'), ('the', 'I'), ('legs', 'I'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('back', 'I'), ('after', 'O'), ('recovery', 'O'), ('from', 'O'), ('anaesthesia', 'O'), ('.', 'O'))"
The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .,"(('The', 'O'), ('patients', 'O'), ('affected', 'O'), ('were', 'O'), ('younger', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('site', 'O'), ('of', 'O'), ('the', 'O'), ('dural', 'O'), ('puncture', 'O'), ('was', 'O'), ('higher', 'O'), ('(', 'O'), ('p', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('than', 'O'), ('those', 'O'), ('individuals', 'O'), ('without', 'O'), ('pain', 'B'), ('.', 'O'))"
"Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .","(('Five', 'O'), ('of', 'O'), ('the', 'O'), ('13', 'O'), ('patients', 'O'), ('(', 'O'), ('38', 'O'), ('%', 'O'), (')', 'O'), ('with', 'O'), ('pain', 'B'), ('and', 'O'), ('seven', 'O'), ('of', 'O'), ('the', 'O'), ('41', 'O'), ('patients', 'O'), ('(', 'O'), ('17', 'O'), ('%', 'O'), (')', 'O'), ('without', 'O'), ('pain', 'B'), ('admitted', 'O'), ('to', 'O'), ('a', 'O'), ('high', 'O'), ('alcohol', 'O'), ('intake', 'O'), (',', 'O'), ('which', 'O'), ('might', 'O'), ('be', 'O'), ('a', 'O'), ('contributing', 'O'), ('factor', 'O'), ('.', 'O'))"
Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .,"(('Leg', 'B'), ('and', 'I'), ('/', 'I'), ('or', 'I'), ('back', 'I'), ('pain', 'I'), ('is', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('intrathecal', 'O'), ('use', 'O'), ('of', 'O'), ('hyperbaric', 'O'), ('5', 'O'), ('%', 'O'), ('lignocaine', 'O'), ('.', 'O'))"
The use of serum cholinesterase in succinylcholine apnoea .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('in', 'O'), ('succinylcholine', 'O'), ('apnoea', 'B'), ('.', 'O'))"
Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .,"(('Fifteen', 'O'), ('patients', 'O'), ('demonstrating', 'O'), ('unexpected', 'O'), ('prolonged', 'O'), ('apnoea', 'B'), ('lasting', 'O'), ('several', 'O'), ('hours', 'O'), ('after', 'O'), ('succinylcholine', 'O'), ('have', 'O'), ('been', 'O'), ('treated', 'O'), ('by', 'O'), ('a', 'O'), ('new', 'O'), ('preparation', 'O'), ('of', 'O'), ('human', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('.', 'O'))"
The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('serum', 'O'), ('cholinesterase', 'O'), ('in', 'O'), ('succinylcholine', 'O'), ('apnoea', 'B'), ('provided', 'O'), ('considerable', 'O'), ('relief', 'O'), ('to', 'O'), ('both', 'O'), ('patient', 'O'), ('and', 'O'), ('anaesthetist', 'O'), ('.', 'O'))"
Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .,"(('Increased', 'O'), ('sulfation', 'O'), ('and', 'O'), ('decreased', 'O'), ('7alpha', 'O'), ('-', 'O'), ('hydroxylation', 'O'), ('of', 'O'), ('deoxycholic', 'O'), ('acid', 'O'), ('in', 'O'), ('ethinyl', 'O'), ('estradiol', 'O'), ('-', 'O'), ('induced', 'O'), ('cholestasis', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .,"(('Influence', 'O'), ('of', 'O'), ('diet', 'O'), ('free', 'O'), ('of', 'O'), ('NAD', 'O'), ('-', 'O'), ('precursors', 'O'), ('on', 'O'), ('acetaminophen', 'O'), ('hepatotoxicity', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .","(('Recently', 'O'), (',', 'O'), ('we', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('hepatoprotective', 'O'), ('effects', 'O'), ('of', 'O'), ('nicotinic', 'O'), ('acid', 'O'), ('amide', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('inhibitor', 'O'), ('of', 'O'), ('poly', 'O'), ('(', 'O'), ('ADP', 'O'), ('-', 'O'), ('ribose', 'O'), (')', 'O'), ('polymerase', 'O'), ('(', 'O'), ('PARP', 'O'), (';', 'O'), ('EC', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('.', 'O'), ('2', 'O'), ('.', 'O'), ('30', 'O'), (')', 'O'), ('on', 'O'), ('mice', 'O'), ('suffering', 'O'), ('from', 'O'), ('acetaminophen', 'O'), ('(', 'O'), ('AAP', 'O'), (')', 'O'), ('-', 'O'), ('hepatitis', 'B'), (',', 'O'), ('suggesting', 'O'), ('that', 'O'), ('the', 'O'), ('AAP', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('injury', 'I'), ('involves', 'O'), ('a', 'O'), ('step', 'O'), ('which', 'O'), ('depends', 'O'), ('on', 'O'), ('adenoribosylation', 'O'), ('.', 'O'))"
"The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .","(('The', 'O'), ('present', 'O'), ('study', 'O'), ('investigates', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('diet', 'O'), ('free', 'O'), ('of', 'O'), ('precursors', 'O'), ('of', 'O'), ('NAD', 'O'), (',', 'O'), ('the', 'O'), ('substrate', 'O'), ('on', 'O'), ('which', 'O'), ('PARP', 'O'), ('acts', 'O'), (',', 'O'), ('in', 'O'), ('female', 'O'), ('NMRI', 'O'), ('mice', 'O'), ('with', 'O'), ('AAP', 'O'), ('hepatitis', 'B'), ('and', 'O'), ('evaluates', 'O'), ('the', 'O'), ('influence', 'O'), ('of', 'O'), ('simultaneous', 'O'), ('ethanol', 'O'), ('consumption', 'O'), ('in', 'O'), ('these', 'O'), ('animals', 'O'), ('.', 'O'))"
Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .,"(('Liver', 'B'), ('injuries', 'I'), ('were', 'O'), ('quantified', 'O'), ('as', 'O'), ('serum', 'O'), ('activities', 'O'), ('of', 'O'), ('glutamate', 'O'), ('-', 'O'), ('oxaloacetate', 'O'), ('transaminase', 'O'), ('(', 'O'), ('GOT', 'O'), (')', 'O'), ('and', 'O'), ('glutamate', 'O'), ('-', 'O'), ('pyruvate', 'O'), ('transaminase', 'O'), ('(', 'O'), ('GPT', 'O'), (')', 'O'), ('.', 'O'))"
"In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .","(('In', 'O'), ('these', 'O'), ('animals', 'O'), (',', 'O'), ('only', 'O'), ('minor', 'O'), ('increases', 'O'), ('of', 'O'), ('serum', 'O'), ('transaminase', 'O'), ('activities', 'O'), ('were', 'O'), ('measured', 'O'), ('in', 'O'), ('the', 'O'), ('presence', 'O'), ('of', 'O'), ('AAP', 'O'), (',', 'O'), ('and', 'O'), ('unlike', 'O'), ('the', 'O'), ('exacerbation', 'O'), ('caused', 'O'), ('by', 'O'), ('ethanol', 'O'), ('in', 'O'), ('mice', 'O'), ('on', 'O'), ('a', 'O'), ('standard', 'O'), ('diet', 'O'), (',', 'O'), ('the', 'O'), ('liver', 'B'), ('damage', 'I'), ('was', 'O'), ('inhibited', 'O'), ('by', 'O'), ('50', 'O'), ('%', 'O'), ('by', 'O'), ('ethanol', 'O'), ('.', 'O'))"
"A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .","(('A', 'O'), ('further', 'O'), ('64', 'O'), ('%', 'O'), ('reduction', 'O'), ('of', 'O'), ('hepatitis', 'B'), ('was', 'O'), ('observed', 'O'), (',', 'O'), ('when', 'O'), ('NAA', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('ethanol', 'O'), ('/', 'O'), ('AAP', 'O'), ('-', 'O'), ('mice', 'O'), ('.', 'O'))"
Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .,"(('Our', 'O'), ('results', 'O'), ('provide', 'O'), ('evidence', 'O'), ('that', 'O'), ('the', 'O'), ('AAP', 'O'), ('-', 'O'), ('induced', 'O'), ('hepatitis', 'B'), ('and', 'O'), ('its', 'O'), ('exacerbation', 'O'), ('by', 'O'), ('ethanol', 'O'), ('can', 'O'), ('either', 'O'), ('be', 'O'), ('reduced', 'O'), ('by', 'O'), ('end', 'O'), ('-', 'O'), ('product', 'O'), ('inhibition', 'O'), ('of', 'O'), ('PARP', 'O'), ('by', 'O'), ('NAA', 'O'), ('or', 'O'), ('by', 'O'), ('dietary', 'O'), ('depletion', 'O'), ('of', 'O'), ('the', 'O'), ('enzyme', 'O'), (""'"", 'O'), ('s', 'O'), ('substrate', 'O'), ('NAD', 'O'), ('.', 'O'))"
We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .,"(('We', 'O'), ('see', 'O'), ('the', 'O'), ('main', 'O'), ('application', 'O'), ('of', 'O'), ('NAA', 'O'), ('as', 'O'), ('for', 'O'), ('the', 'O'), ('combinational', 'O'), ('use', 'O'), ('in', 'O'), ('pharmaceutical', 'O'), ('preparations', 'O'), ('of', 'O'), ('acetaminophen', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('avoid', 'O'), ('hepatic', 'B'), ('damage', 'I'), ('in', 'O'), ('patients', 'O'), ('treated', 'O'), ('with', 'O'), ('this', 'O'), ('widely', 'O'), ('used', 'O'), ('analgesic', 'O'), ('.', 'O'))"
Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .,"(('Nightmares', 'O'), ('and', 'O'), ('hallucinations', 'B'), ('after', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('intake', 'O'), ('of', 'O'), ('tramadol', 'O'), ('combined', 'O'), ('with', 'O'), ('antidepressants', 'O'), ('.', 'O'))"
Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .,"(('Tramadol', 'O'), ('is', 'O'), ('a', 'O'), ('weak', 'O'), ('opioid', 'O'), ('with', 'O'), ('effects', 'O'), ('on', 'O'), ('adrenergic', 'O'), ('and', 'O'), ('serotonergic', 'O'), ('neurotransmission', 'O'), ('that', 'O'), ('is', 'O'), ('used', 'O'), ('to', 'O'), ('treat', 'O'), ('cancer', 'B'), ('pain', 'B'), ('and', 'O'), ('chronic', 'O'), ('non', 'O'), ('malignant', 'O'), ('pain', 'B'), ('.', 'O'))"
This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .,"(('This', 'O'), ('drug', 'O'), ('was', 'O'), ('initiated', 'O'), ('in', 'O'), ('association', 'O'), ('with', 'O'), ('paroxetine', 'O'), ('and', 'O'), ('dosulepine', 'O'), ('hydrochloride', 'O'), ('in', 'O'), ('a', 'O'), ('tetraparetic', 'B'), ('patient', 'O'), ('with', 'O'), ('chronic', 'B'), ('pain', 'I'), ('.', 'O'))"
Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .,"(('Fifty', 'O'), ('-', 'O'), ('six', 'O'), ('days', 'O'), ('after', 'O'), ('initiation', 'O'), ('of', 'O'), ('the', 'O'), ('treatment', 'O'), ('the', 'O'), ('patient', 'O'), ('presented', 'O'), ('hallucinations', 'B'), ('that', 'O'), ('only', 'O'), ('stopped', 'O'), ('after', 'O'), ('the', 'O'), ('withdrawal', 'O'), ('of', 'O'), ('psycho', 'O'), ('-', 'O'), ('active', 'O'), ('drugs', 'O'), ('and', 'O'), ('tramadol', 'O'), ('.', 'O'))"
"The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .","(('The', 'O'), ('case', 'O'), ('report', 'O'), ('questions', 'O'), ('the', 'O'), ('long', 'O'), ('term', 'O'), ('use', 'O'), ('of', 'O'), ('pain', 'B'), ('killers', 'O'), ('combined', 'O'), ('with', 'O'), ('psycho', 'O'), ('-', 'O'), ('active', 'O'), ('drugs', 'O'), ('in', 'O'), ('chronic', 'O'), ('non', 'O'), ('malignant', 'O'), ('pain', 'B'), (',', 'O'), ('especially', 'O'), ('if', 'O'), ('pain', 'B'), ('is', 'O'), ('under', 'O'), ('control', 'O'), ('.', 'O'))"
Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .,"(('Effect', 'O'), ('of', 'O'), ('calcium', 'O'), ('chloride', 'O'), ('and', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('therapy', 'O'), ('on', 'O'), ('desipramine', 'O'), ('toxicity', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
BACKGROUND : Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .,"(('BACKGROUND', 'O'), (':', 'O'), ('Hypotension', 'B'), ('is', 'O'), ('a', 'O'), ('major', 'O'), ('contributor', 'O'), ('to', 'O'), ('mortality', 'O'), ('in', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('overdose', 'B'), ('.', 'O'))"
This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .,"(('This', 'O'), ('study', 'O'), ('addressed', 'O'), ('the', 'O'), ('potential', 'O'), ('role', 'O'), ('of', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blockade', 'O'), ('in', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .,"(('METHODS', 'O'), (':', 'O'), ('Two', 'O'), ('interventions', 'O'), ('were', 'O'), ('studied', 'O'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('shown', 'O'), ('previously', 'O'), ('to', 'O'), ('improve', 'O'), ('blood', 'O'), ('pressure', 'O'), ('with', 'O'), ('calcium', 'O'), ('channel', 'O'), ('blocker', 'O'), ('overdose', 'B'), ('.', 'O'))"
"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .","(('Anesthetized', 'O'), ('rats', 'O'), ('received', 'O'), ('the', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('desipramine', 'O'), ('IP', 'O'), ('to', 'O'), ('produce', 'O'), ('hypotension', 'B'), (',', 'O'), ('QRS', 'O'), ('prolongation', 'O'), (',', 'O'), ('and', 'O'), ('bradycardia', 'B'), ('.', 'O'))"
RESULTS : NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .,"(('RESULTS', 'O'), (':', 'O'), ('NaHCO3', 'O'), ('briefly', 'O'), ('(', 'O'), ('5', 'O'), ('min', 'O'), (')', 'O'), ('reversed', 'O'), ('hypotension', 'B'), ('and', 'O'), ('QRS', 'O'), ('prolongation', 'O'), ('.', 'O'))"
The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .,"(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('ventricular', 'B'), ('arrhythmias', 'I'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('004', 'O'), (')', 'O'), ('and', 'O'), ('seizures', 'B'), ('(', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), (')', 'O'), ('in', 'O'), ('the', 'O'), ('CaCl2', 'O'), ('group', 'O'), ('was', 'O'), ('higher', 'O'), ('than', 'O'), ('the', 'O'), ('other', 'O'), ('groups', 'O'), ('.', 'O'))"
CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .,"(('CONCLUSION', 'O'), (':', 'O'), ('The', 'O'), ('administration', 'O'), ('of', 'O'), ('CaCl2', 'O'), ('or', 'O'), ('4', 'O'), ('-', 'O'), ('aminopyridine', 'O'), ('did', 'O'), ('not', 'O'), ('reverse', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .,"(('CaCl2', 'O'), ('therapy', 'O'), ('may', 'O'), ('possibly', 'O'), ('worsen', 'O'), ('both', 'O'), ('cardiovascular', 'B'), ('and', 'I'), ('central', 'I'), ('nervous', 'I'), ('system', 'I'), ('toxicity', 'I'), ('.', 'O'))"
These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .,"(('These', 'O'), ('findings', 'O'), ('do', 'O'), ('not', 'O'), ('support', 'O'), ('a', 'O'), ('role', 'O'), ('for', 'O'), ('calcium', 'O'), ('channel', 'O'), ('inhibition', 'O'), ('in', 'O'), ('the', 'O'), ('pathogenesis', 'O'), ('of', 'O'), ('tricyclic', 'O'), ('antidepressant', 'O'), ('-', 'O'), ('induced', 'O'), ('hypotension', 'B'), ('.', 'O'))"
"Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .","(('Valsartan', 'O'), (',', 'O'), ('a', 'O'), ('new', 'O'), ('angiotensin', 'O'), ('II', 'O'), ('antagonist', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('essential', 'O'), ('hypertension', 'B'), (':', 'O'), ('a', 'O'), ('comparative', 'O'), ('study', 'O'), ('of', 'O'), ('the', 'O'), ('efficacy', 'O'), ('and', 'O'), ('safety', 'O'), ('against', 'O'), ('amlodipine', 'O'), ('.', 'O'))"
METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .,"(('METHODS', 'O'), (':', 'O'), ('One', 'O'), ('hundred', 'O'), ('sixty', 'O'), ('-', 'O'), ('eight', 'O'), ('adult', 'O'), ('outpatients', 'O'), ('with', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('hypertension', 'B'), ('were', 'O'), ('randomly', 'O'), ('allocated', 'O'), ('in', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('fashion', 'O'), ('and', 'O'), ('equal', 'O'), ('number', 'O'), ('to', 'O'), ('receive', 'O'), ('80', 'O'), ('mg', 'O'), ('valsartan', 'O'), ('or', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), ('for', 'O'), ('12', 'O'), ('weeks', 'O'), ('.', 'O'))"
"The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .","(('The', 'O'), ('incidence', 'O'), ('of', 'O'), ('drug', 'O'), ('-', 'O'), ('related', 'O'), ('dependent', 'O'), ('edema', 'B'), ('was', 'O'), ('somewhat', 'O'), ('higher', 'O'), ('in', 'O'), ('the', 'O'), ('amlodipine', 'O'), ('group', 'O'), (',', 'O'), ('particularly', 'O'), ('at', 'O'), ('a', 'O'), ('dose', 'O'), ('of', 'O'), ('10', 'O'), ('mg', 'O'), ('per', 'O'), ('day', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('4', 'O'), ('%', 'O'), ('for', 'O'), ('80', 'O'), ('mg', 'O'), ('valsartan', 'O'), (';', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('for', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (';', 'O'), ('0', 'O'), ('%', 'O'), ('for', 'O'), ('valsartan', 'O'), ('plus', 'O'), ('5', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (';', 'O'), ('14', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('for', 'O'), ('10', 'O'), ('mg', 'O'), ('amlodipine', 'O'), (')', 'O'), ('.', 'O'))"
CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('data', 'O'), ('show', 'O'), ('that', 'O'), ('valsartan', 'O'), ('is', 'O'), ('at', 'O'), ('least', 'O'), ('as', 'O'), ('effective', 'O'), ('as', 'O'), ('amlodipine', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('hypertension', 'B'), ('.', 'O'))"
Serotonin syndrome from venlafaxine - tranylcypromine interaction .,"(('Serotonin', 'B'), ('syndrome', 'I'), ('from', 'O'), ('venlafaxine', 'O'), ('-', 'O'), ('tranylcypromine', 'O'), ('interaction', 'O'), ('.', 'O'))"
"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .","(('Excessive', 'O'), ('stimulation', 'O'), ('of', 'O'), ('serotonin', 'O'), ('5HT1A', 'O'), ('receptors', 'O'), ('causes', 'O'), ('a', 'O'), ('syndrome', 'O'), ('of', 'O'), ('serotonin', 'O'), ('excess', 'O'), ('that', 'O'), ('consists', 'O'), ('of', 'O'), ('shivering', 'O'), (',', 'O'), ('muscle', 'B'), ('rigidity', 'I'), (',', 'O'), ('salivation', 'B'), (',', 'O'), ('confusion', 'B'), (',', 'O'), ('agitation', 'B'), ('and', 'O'), ('hyperthermia', 'B'), ('.', 'O'))"
We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('venlafaxine', 'O'), ('-', 'O'), ('MAOI', 'O'), ('interaction', 'O'), ('that', 'O'), ('resulted', 'O'), ('in', 'O'), ('the', 'O'), ('serotonin', 'B'), ('syndrome', 'I'), ('in', 'O'), ('a', 'O'), ('23', 'O'), ('-', 'O'), ('y', 'O'), ('-', 'O'), ('old', 'O'), ('male', 'O'), ('who', 'O'), ('was', 'O'), ('taking', 'O'), ('tranylcypromine', 'O'), ('for', 'O'), ('depression', 'B'), ('.', 'O'))"
"Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .","(('Within', 'O'), ('2', 'O'), ('h', 'O'), ('he', 'O'), ('became', 'O'), ('confused', 'O'), ('with', 'O'), ('jerking', 'O'), ('movements', 'O'), ('of', 'O'), ('his', 'O'), ('extremities', 'O'), (',', 'O'), ('tremors', 'B'), ('and', 'O'), ('rigidity', 'B'), ('.', 'O'))"
"He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .","(('He', 'O'), ('was', 'O'), ('brought', 'O'), ('directly', 'O'), ('to', 'O'), ('a', 'O'), ('hospital', 'O'), ('where', 'O'), ('he', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('be', 'O'), ('agitated', 'O'), ('and', 'O'), ('confused', 'O'), ('with', 'O'), ('shivering', 'O'), (',', 'O'), ('myoclonic', 'B'), ('jerks', 'I'), (',', 'O'), ('rigidity', 'B'), (',', 'O'), ('salivation', 'B'), ('and', 'O'), ('diaphoresis', 'O'), ('.', 'O'))"
After 180 mg of diazepam i . v . he remained tremulous with muscle rigidity and clenched jaws .,"(('After', 'O'), ('180', 'O'), ('mg', 'O'), ('of', 'O'), ('diazepam', 'O'), ('i', 'O'), ('.', 'O'), ('v', 'O'), ('.', 'O'), ('he', 'O'), ('remained', 'O'), ('tremulous', 'O'), ('with', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('and', 'O'), ('clenched', 'O'), ('jaws', 'O'), ('.', 'O'))"
"He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .","(('He', 'O'), ('was', 'O'), ('intubated', 'O'), ('for', 'O'), ('airway', 'O'), ('protection', 'O'), ('and', 'O'), ('because', 'O'), ('of', 'O'), ('hypoventilation', 'B'), (',', 'O'), ('and', 'O'), ('was', 'O'), ('paralyzed', 'B'), ('to', 'O'), ('control', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('.', 'O'))"
His subsequent course was remarkable for non - immune thrombocytopenia which resolved .,"(('His', 'O'), ('subsequent', 'O'), ('course', 'O'), ('was', 'O'), ('remarkable', 'O'), ('for', 'O'), ('non', 'O'), ('-', 'O'), ('immune', 'O'), ('thrombocytopenia', 'B'), ('which', 'O'), ('resolved', 'O'), ('.', 'O'))"
The patient ' s maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .,"(('The', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('maximal', 'O'), ('temperature', 'O'), ('was', 'O'), ('101', 'O'), ('.', 'O'), ('2', 'O'), ('F', 'O'), ('and', 'O'), ('his', 'O'), ('CPK', 'O'), ('remained', 'O'), ('<', 'O'), ('500', 'O'), ('units', 'O'), ('/', 'O'), ('L', 'O'), ('with', 'O'), ('no', 'O'), ('other', 'O'), ('evidence', 'O'), ('of', 'O'), ('rhabdomyolysis', 'B'), ('.', 'O'))"
This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .,"(('This', 'O'), ('patient', 'O'), ('survived', 'O'), ('without', 'O'), ('sequelae', 'O'), ('due', 'O'), ('to', 'O'), ('the', 'O'), ('aggressive', 'O'), ('sedation', 'O'), ('and', 'O'), ('neuromuscular', 'O'), ('paralysis', 'B'), ('.', 'O'))"
Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .,"(('Cyclophosphamide', 'O'), ('associated', 'O'), ('bladder', 'B'), ('cancer', 'I'), ('-', 'O'), ('-', 'O'), ('a', 'O'), ('highly', 'O'), ('aggressive', 'O'), ('disease', 'O'), (':', 'O'), ('analysis', 'O'), ('of', 'O'), ('12', 'O'), ('cases', 'O'), ('.', 'O'))"
"PURPOSE : We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .","(('PURPOSE', 'O'), (':', 'O'), ('We', 'O'), ('gained', 'O'), ('knowledge', 'O'), ('of', 'O'), ('the', 'O'), ('etiology', 'O'), (',', 'O'), ('treatment', 'O'), ('and', 'O'), ('prevention', 'O'), ('of', 'O'), ('cyclophosphamide', 'O'), ('associated', 'O'), ('urothelial', 'B'), ('cancer', 'I'), ('.', 'O'))"
MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .,"(('MATERIALS', 'O'), ('AND', 'O'), ('METHODS', 'O'), (':', 'O'), ('The', 'O'), ('medical', 'O'), ('records', 'O'), ('of', 'O'), ('6', 'O'), ('men', 'O'), ('and', 'O'), ('6', 'O'), ('women', 'O'), ('(', 'O'), ('mean', 'O'), ('age', 'O'), ('55', 'O'), ('years', 'O'), (')', 'O'), ('with', 'O'), ('cyclophosphamide', 'O'), ('associated', 'O'), ('bladder', 'B'), ('cancer', 'I'), ('were', 'O'), ('reviewed', 'O'), ('.', 'O'))"
RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .,"(('RESULTS', 'O'), (':', 'O'), ('All', 'O'), ('tumors', 'B'), ('were', 'O'), ('grade', 'O'), ('3', 'O'), ('or', 'O'), ('4', 'O'), ('transitional', 'O'), ('cell', 'O'), ('carcinoma', 'B'), ('.', 'O'))"
The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .,"(('The', 'O'), ('remaining', 'O'), ('patient', 'O'), ('with', 'O'), ('extensive', 'O'), ('cancer', 'B'), ('underwent', 'O'), ('partial', 'O'), ('cystectomy', 'O'), ('for', 'O'), ('palliation', 'O'), ('and', 'O'), ('died', 'O'), ('3', 'O'), ('months', 'O'), ('later', 'O'), ('.', 'O'))"
CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .,"(('CONCLUSIONS', 'O'), (':', 'O'), ('Cyclophosphamide', 'O'), ('associated', 'O'), ('bladder', 'B'), ('tumor', 'I'), ('is', 'O'), ('an', 'O'), ('aggressive', 'O'), ('disease', 'O'), ('.', 'O'))"
"However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .","(('However', 'O'), (',', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('survival', 'O'), ('is', 'O'), ('possible', 'O'), ('when', 'O'), ('radical', 'O'), ('cystectomy', 'O'), ('is', 'O'), ('performed', 'O'), ('for', 'O'), ('bladder', 'B'), ('tumors', 'I'), ('with', 'O'), ('any', 'O'), ('sign', 'O'), ('of', 'O'), ('invasion', 'O'), ('and', 'O'), ('for', 'O'), ('recurrent', 'O'), ('high', 'O'), ('grade', 'O'), ('disease', 'O'), (',', 'O'), ('even', 'O'), ('when', 'O'), ('noninvasive', 'O'), ('.', 'O'))"
"However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('initial', 'O'), ('clinical', 'O'), ('development', 'O'), ('of', 'O'), ('lometrexol', 'O'), ('was', 'O'), ('curtailed', 'O'), ('because', 'O'), ('of', 'O'), ('severe', 'O'), ('and', 'O'), ('cumulative', 'O'), ('antiproliferative', 'O'), ('toxicities', 'B'), ('.', 'O'))"
"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .","(('Preclinical', 'O'), ('murine', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('the', 'O'), ('toxicity', 'B'), ('of', 'O'), ('lometrexol', 'O'), ('can', 'O'), ('be', 'O'), ('prevented', 'O'), ('by', 'O'), ('low', 'O'), ('dose', 'O'), ('folic', 'O'), ('acid', 'O'), ('administration', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('e', 'O'), ('.', 'O'), ('for', 'O'), ('7', 'O'), ('days', 'O'), ('prior', 'O'), ('to', 'O'), ('and', 'O'), ('7', 'O'), ('days', 'O'), ('following', 'O'), ('a', 'O'), ('single', 'O'), ('bolus', 'O'), ('dose', 'O'), ('.', 'O'))"
This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .,"(('This', 'O'), ('observation', 'O'), ('prompted', 'O'), ('a', 'O'), ('Phase', 'O'), ('I', 'O'), ('clinical', 'O'), ('study', 'O'), ('of', 'O'), ('lometrexol', 'O'), ('given', 'O'), ('with', 'O'), ('folic', 'O'), ('acid', 'O'), ('supplementation', 'O'), ('which', 'O'), ('has', 'O'), ('confirmed', 'O'), ('that', 'O'), ('the', 'O'), ('toxicity', 'B'), ('of', 'O'), ('lometrexol', 'O'), ('can', 'O'), ('be', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('by', 'O'), ('folic', 'O'), ('acid', 'O'), ('supplementation', 'O'), ('.', 'O'))"
Thrombocytopenia and mucositis were the major toxicities .,"(('Thrombocytopenia', 'B'), ('and', 'O'), ('mucositis', 'B'), ('were', 'O'), ('the', 'O'), ('major', 'O'), ('toxicities', 'B'), ('.', 'O'))"
There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .,"(('There', 'O'), ('was', 'O'), ('no', 'O'), ('clear', 'O'), ('relationship', 'O'), ('between', 'O'), ('clinical', 'O'), ('toxicity', 'B'), ('and', 'O'), ('the', 'O'), ('extent', 'O'), ('of', 'O'), ('plasma', 'O'), ('folate', 'O'), ('elevation', 'O'), ('.', 'O'))"
Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .,"(('Associated', 'O'), ('studies', 'O'), ('demonstrated', 'O'), ('that', 'O'), ('lometrexol', 'O'), ('plasma', 'O'), ('pharmacokinetics', 'O'), ('were', 'O'), ('not', 'O'), ('altered', 'O'), ('by', 'O'), ('folic', 'O'), ('acid', 'O'), ('administration', 'O'), ('indicating', 'O'), ('that', 'O'), ('supplementation', 'O'), ('is', 'O'), ('unlikely', 'O'), ('to', 'O'), ('reduce', 'O'), ('toxicity', 'B'), ('by', 'O'), ('enhancing', 'O'), ('lometrexol', 'O'), ('plasma', 'O'), ('clearance', 'O'), ('.', 'O'))"
This information will facilitate the future evaluation of this class of compounds in cancer therapy .,"(('This', 'O'), ('information', 'O'), ('will', 'O'), ('facilitate', 'O'), ('the', 'O'), ('future', 'O'), ('evaluation', 'O'), ('of', 'O'), ('this', 'O'), ('class', 'O'), ('of', 'O'), ('compounds', 'O'), ('in', 'O'), ('cancer', 'B'), ('therapy', 'O'), ('.', 'O'))"
Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .,"(('Fatal', 'O'), ('excited', 'O'), ('delirium', 'B'), ('following', 'O'), ('cocaine', 'O'), ('use', 'O'), (':', 'O'), ('epidemiologic', 'O'), ('findings', 'O'), ('provide', 'O'), ('new', 'O'), ('evidence', 'O'), ('for', 'O'), ('mechanisms', 'O'), ('of', 'O'), ('cocaine', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .","(('We', 'O'), ('describe', 'O'), ('an', 'O'), ('outbreak', 'O'), ('of', 'O'), ('deaths', 'O'), ('from', 'O'), ('cocaine', 'O'), ('-', 'O'), ('induced', 'O'), ('excited', 'O'), ('delirium', 'B'), ('(', 'O'), ('EDDs', 'B'), (')', 'O'), ('in', 'O'), ('Dade', 'O'), ('County', 'O'), (',', 'O'), ('Florida', 'O'), ('between', 'O'), ('1979', 'O'), ('and', 'O'), ('1990', 'O'), ('.', 'O'))"
"From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .","(('From', 'O'), ('a', 'O'), ('registry', 'O'), ('of', 'O'), ('all', 'O'), ('cocaine', 'O'), ('-', 'O'), ('related', 'O'), ('deaths', 'O'), ('in', 'O'), ('Dade', 'O'), ('County', 'O'), (',', 'O'), ('Florida', 'O'), (',', 'O'), ('from', 'O'), ('1969', 'O'), ('-', 'O'), ('1990', 'O'), (',', 'O'), ('58', 'O'), ('EDDs', 'B'), ('were', 'O'), ('compared', 'O'), ('with', 'O'), ('125', 'O'), ('victims', 'O'), ('of', 'O'), ('accidental', 'O'), ('cocaine', 'O'), ('overdose', 'B'), ('without', 'O'), ('excited', 'O'), ('delirium', 'B'), ('.', 'O'))"
"They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .","(('They', 'O'), ('were', 'O'), ('less', 'O'), ('likely', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('low', 'O'), ('body', 'O'), ('mass', 'O'), ('index', 'O'), (',', 'O'), ('and', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('have', 'O'), ('died', 'O'), ('in', 'O'), ('police', 'O'), ('custody', 'O'), (',', 'O'), ('to', 'O'), ('have', 'O'), ('received', 'O'), ('medical', 'O'), ('treatment', 'O'), ('immediately', 'O'), ('before', 'O'), ('death', 'O'), (',', 'O'), ('to', 'O'), ('have', 'O'), ('survived', 'O'), ('for', 'O'), ('a', 'O'), ('longer', 'O'), ('period', 'O'), (',', 'O'), ('to', 'O'), ('have', 'O'), ('developed', 'O'), ('hyperthermia', 'B'), (',', 'O'), ('and', 'O'), ('to', 'O'), ('have', 'O'), ('died', 'O'), ('in', 'O'), ('summer', 'O'), ('months', 'O'), ('.', 'O'))"
"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .","(('The', 'O'), ('epidemiologic', 'O'), ('findings', 'O'), ('are', 'O'), ('most', 'O'), ('consistent', 'O'), ('with', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('chronic', 'O'), ('cocaine', 'O'), ('use', 'O'), ('disrupts', 'O'), ('dopaminergic', 'O'), ('function', 'O'), ('and', 'O'), (',', 'O'), ('when', 'O'), ('coupled', 'O'), ('with', 'O'), ('recent', 'O'), ('cocaine', 'O'), ('use', 'O'), (',', 'O'), ('may', 'O'), ('precipitate', 'O'), ('agitation', 'B'), (',', 'O'), ('delirium', 'B'), (',', 'O'), ('aberrant', 'O'), ('thermoregulation', 'O'), (',', 'O'), ('rhabdomyolysis', 'B'), (',', 'O'), ('and', 'O'), ('sudden', 'B'), ('death', 'I'), ('.', 'O'))"
BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .,"(('BACKGROUND', 'O'), (':', 'O'), ('Pemoline', 'O'), ('is', 'O'), ('an', 'O'), ('oxazolidine', 'O'), ('derivative', 'O'), ('that', 'O'), ('is', 'O'), ('structurally', 'O'), ('different', 'O'), ('from', 'O'), ('amphetamines', 'O'), ('and', 'O'), ('used', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('attention', 'B'), ('deficit', 'I'), ('disorder', 'I'), ('.', 'O'))"
Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .,"(('Pemoline', 'O'), ('has', 'O'), ('not', 'O'), ('been', 'O'), ('commonly', 'O'), ('associated', 'O'), ('in', 'O'), ('the', 'O'), ('literature', 'O'), ('as', 'O'), ('a', 'O'), ('cause', 'O'), ('of', 'O'), ('acute', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .,"(('The', 'O'), ('children', 'O'), ('had', 'O'), ('a', 'O'), ('medical', 'O'), ('history', 'O'), ('significant', 'O'), ('for', 'O'), ('attention', 'B'), ('deficit', 'I'), ('disorder', 'I'), ('previously', 'O'), ('treated', 'O'), ('with', 'O'), ('methylphenidate', 'O'), ('without', 'O'), ('success', 'O'), ('.', 'O'))"
The choreoathetoid movements began 45 min to 1 h after ingestion .,"(('The', 'O'), ('choreoathetoid', 'B'), ('movements', 'O'), ('began', 'O'), ('45', 'O'), ('min', 'O'), ('to', 'O'), ('1', 'O'), ('h', 'O'), ('after', 'O'), ('ingestion', 'O'), ('.', 'O'))"
The children gave no history of prior movement disorders and there was no family history of movement disorders .,"(('The', 'O'), ('children', 'O'), ('gave', 'O'), ('no', 'O'), ('history', 'O'), ('of', 'O'), ('prior', 'O'), ('movement', 'B'), ('disorders', 'I'), ('and', 'O'), ('there', 'O'), ('was', 'O'), ('no', 'O'), ('family', 'O'), ('history', 'O'), ('of', 'O'), ('movement', 'B'), ('disorders', 'I'), ('.', 'O'))"
The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .,"(('The', 'O'), ('children', 'O'), ('received', 'O'), ('gastrointestinal', 'O'), ('decontamination', 'O'), ('and', 'O'), ('high', 'O'), ('doses', 'O'), ('of', 'O'), ('intravenous', 'O'), ('benzodiazepines', 'O'), ('in', 'O'), ('an', 'O'), ('attempt', 'O'), ('to', 'O'), ('control', 'O'), ('the', 'O'), ('choreoathetoid', 'B'), ('movements', 'O'), ('.', 'O'))"
CONCLUSION : Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .,"(('CONCLUSION', 'O'), (':', 'O'), ('Pemoline', 'O'), ('associated', 'O'), ('movement', 'B'), ('disorder', 'I'), ('has', 'O'), ('been', 'O'), ('rarely', 'O'), ('reported', 'O'), ('in', 'O'), ('the', 'O'), ('acute', 'O'), ('toxicology', 'O'), ('literature', 'O'), ('.', 'O'))"
The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .,"(('The', 'O'), ('possibility', 'O'), ('of', 'O'), ('choreoathetoid', 'B'), ('movements', 'O'), ('should', 'O'), ('be', 'O'), ('considered', 'O'), ('in', 'O'), ('patients', 'O'), ('presenting', 'O'), ('after', 'O'), ('pemoline', 'O'), ('overdose', 'B'), ('.', 'O'))"
"During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .","(('During', 'O'), ('the', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), (',', 'O'), ('3', 'O'), ('patients', 'O'), ('(', 'O'), ('12', 'O'), ('%', 'O'), (')', 'O'), ('developed', 'O'), ('steroid', 'O'), ('-', 'O'), ('induced', 'O'), ('elevated', 'B'), ('intraocular', 'I'), ('pressure', 'I'), ('(', 'O'), ('IOP', 'O'), (')', 'O'), ('that', 'O'), ('resolved', 'O'), ('after', 'O'), ('corticosteroid', 'O'), ('therapy', 'O'), ('was', 'O'), ('discontinued', 'O'), ('.', 'O'))"
Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .,"(('Neutrophil', 'O'), ('superoxide', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('production', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('.', 'O'))"
Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .,"(('Defects', 'O'), ('in', 'O'), ('superoxide', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('production', 'O'), ('may', 'O'), ('be', 'O'), ('implicated', 'O'), ('in', 'O'), ('the', 'O'), ('high', 'O'), ('incidence', 'O'), ('of', 'O'), ('bacterial', 'B'), ('infections', 'I'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('acute', 'B'), ('liver', 'I'), ('failure', 'I'), ('(', 'O'), ('ALF', 'B'), (')', 'O'), ('.', 'O'))"
"In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('oxygen', 'O'), ('radical', 'O'), ('production', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('ALF', 'B'), ('due', 'O'), ('to', 'O'), ('paracetamol', 'O'), ('overdose', 'B'), ('was', 'O'), ('compared', 'O'), ('with', 'O'), ('that', 'O'), ('of', 'O'), ('healthy', 'O'), ('volunteers', 'O'), ('.', 'O'))"
Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .,"(('Neutrophils', 'O'), ('from', 'O'), ('14', 'O'), ('ALF', 'B'), ('patients', 'O'), ('were', 'O'), ('stimulated', 'O'), ('via', 'O'), ('the', 'O'), ('complement', 'O'), ('receptors', 'O'), ('using', 'O'), ('zymosan', 'O'), ('opsonized', 'O'), ('with', 'O'), ('ALF', 'B'), ('or', 'O'), ('control', 'O'), ('serum', 'O'), ('.', 'O'))"
Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .,"(('Superoxide', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('production', 'O'), ('by', 'O'), ('ALF', 'B'), ('neutrophils', 'O'), ('stimulated', 'O'), ('with', 'O'), ('zymosan', 'O'), ('opsonized', 'O'), ('with', 'O'), ('ALF', 'B'), ('serum', 'O'), ('was', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('compared', 'O'), ('with', 'O'), ('the', 'O'), ('control', 'O'), ('subjects', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('01', 'O'), (')', 'O'), ('.', 'O'))"
Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .,"(('Superoxide', 'O'), ('and', 'O'), ('hydrogen', 'O'), ('peroxide', 'O'), ('production', 'O'), ('in', 'O'), ('neutrophils', 'O'), ('stimulated', 'O'), ('with', 'O'), ('formyl', 'O'), ('-', 'O'), ('methionyl', 'O'), ('-', 'O'), ('leucyl', 'O'), ('-', 'O'), ('phenylalanine', 'O'), ('(', 'O'), ('fMLP', 'O'), (')', 'O'), ('from', 'O'), ('a', 'O'), ('further', 'O'), ('18', 'O'), ('ALF', 'B'), ('patients', 'O'), ('was', 'O'), ('unaffected', 'O'), ('compared', 'O'), ('with', 'O'), ('control', 'O'), ('neutrophils', 'O'), ('.', 'O'))"
Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .,"(('Serum', 'O'), ('C3', 'O'), ('complement', 'O'), ('levels', 'O'), ('were', 'O'), ('significantly', 'O'), ('reduced', 'O'), ('in', 'O'), ('ALF', 'B'), ('patients', 'O'), ('compared', 'O'), ('with', 'O'), ('control', 'O'), ('subjects', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('0005', 'O'), (')', 'O'), ('.', 'O'))"
"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .","(('These', 'O'), ('results', 'O'), ('demonstrate', 'O'), ('a', 'O'), ('neutrophil', 'O'), ('defect', 'O'), ('in', 'O'), ('ALF', 'B'), ('due', 'O'), ('to', 'O'), ('paracetamol', 'O'), ('overdose', 'B'), (',', 'O'), ('that', 'O'), ('is', 'O'), ('complement', 'O'), ('dependent', 'O'), ('but', 'O'), ('independent', 'O'), ('of', 'O'), ('serum', 'O'), ('complement', 'O'), (',', 'O'), ('possibly', 'O'), ('connected', 'O'), ('to', 'O'), ('the', 'O'), ('complement', 'O'), ('receptor', 'O'), ('.', 'O'))"
"In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .","(('In', 'O'), ('addition', 'O'), ('to', 'O'), ('its', 'O'), ('use', 'O'), ('as', 'O'), ('a', 'O'), ('stabilizer', 'O'), ('/', 'O'), ('rigidifier', 'O'), ('of', 'O'), ('membranes', 'O'), (',', 'O'), ('cholesteryl', 'O'), ('hemisuccinate', 'O'), (',', 'O'), ('tris', 'O'), ('salt', 'O'), ('(', 'O'), ('CS', 'O'), (')', 'O'), ('administration', 'O'), ('has', 'O'), ('also', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('protect', 'O'), ('rats', 'O'), ('from', 'O'), ('the', 'O'), ('hepatotoxic', 'B'), ('effects', 'O'), ('of', 'O'), ('carbon', 'O'), ('tetrachloride', 'O'), ('(', 'O'), ('CCl4', 'O'), (')', 'O'), ('.', 'O'))"
"To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .","(('To', 'O'), ('further', 'O'), ('our', 'O'), ('understanding', 'O'), ('of', 'O'), ('the', 'O'), ('mechanism', 'O'), ('of', 'O'), ('CS', 'O'), ('cytoprotection', 'O'), (',', 'O'), ('we', 'O'), ('examined', 'O'), ('in', 'O'), ('rats', 'O'), ('and', 'O'), ('mice', 'O'), ('the', 'O'), ('protective', 'O'), ('abilities', 'O'), ('of', 'O'), ('CS', 'O'), ('and', 'O'), ('the', 'O'), ('non', 'O'), ('-', 'O'), ('hydrolyzable', 'O'), ('ether', 'O'), ('form', 'O'), ('of', 'O'), ('CS', 'O'), (',', 'O'), ('gamma', 'O'), ('-', 'O'), ('cholesteryloxybutyric', 'O'), ('acid', 'O'), (',', 'O'), ('tris', 'O'), ('salt', 'O'), ('(', 'O'), ('CSE', 'O'), (')', 'O'), ('against', 'O'), ('acetaminophen', 'O'), ('-', 'O'), (',', 'O'), ('adriamycin', 'O'), ('-', 'O'), (',', 'O'), ('carbon', 'O'), ('tetrachloride', 'O'), ('-', 'O'), (',', 'O'), ('chloroform', 'O'), ('-', 'O'), ('and', 'O'), ('galactosamine', 'O'), ('-', 'O'), ('induced', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .","(('A', 'O'), ('24', 'O'), ('-', 'O'), ('h', 'O'), ('pretreatment', 'O'), ('of', 'O'), ('both', 'O'), ('rats', 'O'), ('and', 'O'), ('mice', 'O'), ('with', 'O'), ('a', 'O'), ('single', 'O'), ('dose', 'O'), ('of', 'O'), ('CS', 'O'), ('(', 'O'), ('100mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('resulted', 'O'), ('in', 'O'), ('significant', 'O'), ('protection', 'O'), ('against', 'O'), ('the', 'O'), ('hepatotoxic', 'B'), ('effects', 'O'), ('of', 'O'), ('CCl4', 'O'), (',', 'O'), ('CHCl3', 'O'), (',', 'O'), ('acetaminophen', 'O'), ('and', 'O'), ('galactosamine', 'O'), ('and', 'O'), ('against', 'O'), ('the', 'O'), ('lethal', 'O'), ('(', 'O'), ('and', 'O'), ('presumably', 'O'), ('cardiotoxic', 'B'), (')', 'O'), ('effect', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('administration', 'O'), ('.', 'O'))"
The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .,"(('The', 'O'), ('mechanism', 'O'), ('of', 'O'), ('CS', 'O'), ('protection', 'O'), ('does', 'O'), ('not', 'O'), ('appear', 'O'), ('to', 'O'), ('be', 'O'), ('dependent', 'O'), ('on', 'O'), ('the', 'O'), ('inhibition', 'O'), ('of', 'O'), ('chemical', 'O'), ('bioactivation', 'O'), ('to', 'O'), ('a', 'O'), ('toxic', 'O'), ('reactive', 'O'), ('intermediate', 'O'), ('(', 'O'), ('in', 'O'), ('light', 'O'), ('of', 'O'), ('the', 'O'), ('protection', 'O'), ('observed', 'O'), ('against', 'O'), ('galactosamine', 'O'), ('hepatotoxicity', 'B'), (')', 'O'), ('.', 'O'))"
"A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .","(('A', 'O'), ('murine', 'O'), ('model', 'O'), ('of', 'O'), ('adenomyosis', 'B'), (':', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('hyperprolactinemia', 'B'), ('induced', 'O'), ('by', 'O'), ('fluoxetine', 'O'), ('hydrochloride', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitor', 'O'), (',', 'O'), ('on', 'O'), ('adenomyosis', 'B'), ('induction', 'O'), ('in', 'O'), ('Wistar', 'O'), ('albino', 'O'), ('rats', 'O'), ('.', 'O'))"
OBJECTIVE : The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .,"(('OBJECTIVE', 'O'), (':', 'O'), ('The', 'O'), ('aim', 'O'), ('of', 'O'), ('this', 'O'), ('study', 'O'), ('was', 'O'), ('to', 'O'), ('investigate', 'O'), ('whether', 'O'), ('fluoxetine', 'O'), ('given', 'O'), ('to', 'O'), ('castrated', 'O'), ('and', 'O'), ('noncastrated', 'O'), ('rats', 'O'), ('caused', 'O'), ('hyperprolactinemia', 'B'), ('and', 'O'), ('its', 'O'), ('effects', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('adenomyosis', 'B'), ('.', 'O'))"
"DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .","(('DESIGN', 'O'), (':', 'O'), ('Fluoxetine', 'O'), (',', 'O'), ('a', 'O'), ('serotonin', 'O'), ('reuptake', 'O'), ('inhibitor', 'O'), (',', 'O'), ('was', 'O'), ('given', 'O'), ('to', 'O'), ('Wistar', 'O'), ('Albino', 'O'), ('rats', 'O'), ('for', 'O'), ('98', 'O'), ('days', 'O'), ('to', 'O'), ('produce', 'O'), ('hyperprolactinemia', 'B'), ('.', 'O'))"
Postinfarction ventricular septal defect associated with long - term steroid therapy .,"(('Postinfarction', 'O'), ('ventricular', 'B'), ('septal', 'I'), ('defect', 'I'), ('associated', 'O'), ('with', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('steroid', 'O'), ('therapy', 'O'), ('.', 'O'))"
Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .,"(('Two', 'O'), ('cases', 'O'), ('of', 'O'), ('postinfarction', 'O'), ('ventricular', 'B'), ('septal', 'I'), ('rupture', 'I'), ('in', 'O'), ('patients', 'O'), ('on', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('steroid', 'O'), ('therapy', 'O'), ('are', 'O'), ('presented', 'O'), ('and', 'O'), ('the', 'O'), ('favourable', 'O'), ('outcome', 'O'), ('in', 'O'), ('both', 'O'), ('cases', 'O'), ('described', 'O'), ('.', 'O'))"
A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .,"(('A', 'O'), ('possible', 'O'), ('association', 'O'), ('between', 'O'), ('steroid', 'O'), ('therapy', 'O'), ('and', 'O'), ('subsequent', 'O'), ('postinfarction', 'O'), ('septal', 'B'), ('rupture', 'I'), ('is', 'O'), ('discussed', 'O'), ('.', 'O'))"
Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .,"(('Neuroactive', 'O'), ('steroids', 'O'), ('protect', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('and', 'O'), ('kainic', 'O'), ('acid', 'O'), ('-', 'O'), ('induced', 'O'), ('limbic', 'O'), ('seizures', 'B'), ('and', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .","(('Several', 'O'), ('structurally', 'O'), ('related', 'O'), ('metabolites', 'O'), ('of', 'O'), ('progesterone', 'O'), ('(', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('pregnane', 'O'), ('-', 'O'), ('20', 'O'), ('-', 'O'), ('ones', 'O'), (')', 'O'), ('and', 'O'), ('deoxycorticosterone', 'O'), ('(', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('pregnane', 'O'), ('-', 'O'), ('21', 'O'), ('-', 'O'), ('diol', 'O'), ('-', 'O'), ('20', 'O'), ('-', 'O'), ('ones', 'O'), (')', 'O'), ('and', 'O'), ('their', 'O'), ('3', 'O'), ('beta', 'O'), ('-', 'O'), ('epimers', 'O'), ('were', 'O'), ('evaluated', 'O'), ('for', 'O'), ('protective', 'O'), ('activity', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('-', 'O'), (',', 'O'), ('kainic', 'O'), ('acid', 'O'), ('-', 'O'), ('and', 'O'), ('N', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('D', 'O'), ('-', 'O'), ('aspartate', 'O'), ('(', 'O'), ('NMDA', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('in', 'O'), ('mice', 'O'), ('.', 'O'))"
"Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .","(('Steroids', 'O'), ('with', 'O'), ('the', 'O'), ('3', 'O'), ('-', 'O'), ('hydroxy', 'O'), ('group', 'O'), ('in', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('position', 'O'), ('and', 'O'), ('5', 'O'), ('-', 'O'), ('H', 'O'), ('in', 'O'), ('the', 'O'), ('alpha', 'O'), ('-', 'O'), ('or', 'O'), ('beta', 'O'), ('-', 'O'), ('configurations', 'O'), ('were', 'O'), ('highly', 'O'), ('effective', 'O'), ('in', 'O'), ('protecting', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('(', 'O'), ('416', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('limbic', 'O'), ('motor', 'O'), ('seizures', 'B'), ('and', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('(', 'O'), ('ED50', 'O'), ('values', 'O'), (',', 'O'), ('7', 'O'), ('.', 'O'), ('0', 'O'), ('-', 'O'), ('18', 'O'), ('.', 'O'), ('7', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .","(('Although', 'O'), ('the', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('were', 'O'), ('considerably', 'O'), ('less', 'O'), ('potent', 'O'), ('than', 'O'), ('the', 'O'), ('benzodiazepine', 'O'), ('clonazepam', 'O'), ('in', 'O'), ('protecting', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('seizures', 'B'), (',', 'O'), ('steroids', 'O'), ('with', 'O'), ('the', 'O'), ('5', 'O'), ('alpha', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('configuration', 'O'), ('had', 'O'), ('comparable', 'O'), ('or', 'O'), ('higher', 'O'), ('protective', 'O'), ('index', 'O'), ('values', 'O'), ('(', 'O'), ('TD50', 'O'), ('for', 'O'), ('motor', 'O'), ('impairment', 'O'), ('divided', 'O'), ('by', 'O'), ('ED50', 'O'), ('for', 'O'), ('seizure', 'B'), ('protection', 'O'), (')', 'O'), ('than', 'O'), ('clonazepam', 'O'), (',', 'O'), ('indicating', 'O'), ('that', 'O'), ('some', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('may', 'O'), ('have', 'O'), ('lower', 'O'), ('relative', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .","(('Steroids', 'O'), ('with', 'O'), ('the', 'O'), ('5', 'O'), ('alpha', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('or', 'O'), ('5', 'O'), ('beta', 'O'), (',', 'O'), ('3', 'O'), ('alpha', 'O'), ('-', 'O'), ('configurations', 'O'), ('also', 'O'), ('produced', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('delay', 'O'), ('in', 'O'), ('the', 'O'), ('onset', 'O'), ('of', 'O'), ('limbic', 'O'), ('seizures', 'B'), ('induced', 'O'), ('by', 'O'), ('kainic', 'O'), ('acid', 'O'), ('(', 'O'), ('32', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('completely', 'O'), ('protect', 'O'), ('against', 'O'), ('the', 'O'), ('seizures', 'B'), ('.', 'O'))"
"However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .","(('However', 'O'), (',', 'O'), ('when', 'O'), ('a', 'O'), ('second', 'O'), ('dose', 'O'), ('of', 'O'), ('the', 'O'), ('steroid', 'O'), ('was', 'O'), ('administered', 'O'), ('1', 'O'), ('hr', 'O'), ('after', 'O'), ('the', 'O'), ('first', 'O'), ('dose', 'O'), (',', 'O'), ('complete', 'O'), ('protection', 'O'), ('from', 'O'), ('the', 'O'), ('kainic', 'O'), ('acid', 'O'), ('-', 'O'), ('induced', 'O'), ('limbic', 'O'), ('seizures', 'B'), ('and', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('was', 'O'), ('obtained', 'O'), ('.', 'O'))"
"The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .","(('The', 'O'), ('steroids', 'O'), ('also', 'O'), ('caused', 'O'), ('a', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('delay', 'O'), ('in', 'O'), ('NMDA', 'O'), ('(', 'O'), ('257', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (',', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('-', 'O'), ('induced', 'O'), ('lethality', 'O'), (',', 'O'), ('but', 'O'), ('did', 'O'), ('not', 'O'), ('completely', 'O'), ('protect', 'O'), ('against', 'O'), ('NMDA', 'O'), ('seizures', 'B'), ('or', 'O'), ('lethality', 'O'), ('.', 'O'))"
"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .","(('We', 'O'), ('conclude', 'O'), ('that', 'O'), ('neuroactive', 'O'), ('steroids', 'O'), ('are', 'O'), ('highly', 'O'), ('effective', 'O'), ('in', 'O'), ('protecting', 'O'), ('against', 'O'), ('pilocarpine', 'O'), ('-', 'O'), ('and', 'O'), ('kainic', 'O'), ('acid', 'O'), ('-', 'O'), ('induced', 'O'), ('seizures', 'B'), ('and', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('in', 'O'), ('mice', 'O'), (',', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('of', 'O'), ('utility', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('some', 'O'), ('forms', 'O'), ('of', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .,"(('Hepatic', 'O'), ('and', 'O'), ('extrahepatic', 'O'), ('angiotensinogen', 'O'), ('gene', 'O'), ('expression', 'O'), ('in', 'O'), ('rats', 'O'), ('with', 'O'), ('acute', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .,"(('Plasma', 'O'), ('concentration', 'O'), ('and', 'O'), ('urine', 'O'), ('excretion', 'O'), ('of', 'O'), ('the', 'O'), ('renin', 'O'), ('-', 'O'), ('angiotensin', 'O'), ('system', 'O'), ('proteins', 'O'), ('are', 'O'), ('altered', 'O'), ('in', 'O'), ('rats', 'O'), ('with', 'O'), ('nephrotic', 'B'), ('syndrome', 'I'), ('(', 'O'), ('NS', 'B'), (')', 'O'), ('.', 'O'))"
"In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .","(('In', 'O'), ('this', 'O'), ('work', 'O'), ('the', 'O'), ('messenger', 'O'), ('ribonucleic', 'O'), ('acid', 'O'), ('(', 'O'), ('mRNA', 'O'), (')', 'O'), ('levels', 'O'), ('of', 'O'), ('angiotensinogen', 'O'), ('(', 'O'), ('Ao', 'O'), (')', 'O'), ('were', 'O'), ('analyzed', 'O'), ('with', 'O'), ('the', 'O'), ('slot', 'O'), ('-', 'O'), ('blot', 'O'), ('hybridization', 'O'), ('technique', 'O'), ('in', 'O'), ('liver', 'O'), ('and', 'O'), ('other', 'O'), ('extrahepatic', 'O'), ('tissues', 'O'), (':', 'O'), ('kidney', 'O'), (',', 'O'), ('heart', 'O'), (',', 'O'), ('brain', 'O'), (',', 'O'), ('and', 'O'), ('adrenal', 'O'), ('gland', 'O'), ('from', 'O'), ('control', 'O'), (',', 'O'), ('nephrotic', 'B'), (',', 'O'), ('and', 'O'), ('pair', 'O'), ('-', 'O'), ('fed', 'O'), ('(', 'O'), ('PF', 'O'), (')', 'O'), ('rats', 'O'), ('.', 'O'))"
Neuroleptic malignant syndrome with risperidone .,"(('Neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('with', 'O'), ('risperidone', 'O'), ('.', 'O'))"
Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .,"(('Neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('is', 'O'), ('thought', 'O'), ('to', 'O'), ('be', 'O'), ('a', 'O'), ('result', 'O'), ('of', 'O'), ('dopamine', 'O'), ('D2', 'O'), ('receptor', 'O'), ('blockade', 'O'), ('in', 'O'), ('the', 'O'), ('striatum', 'O'), ('of', 'O'), ('the', 'O'), ('basal', 'O'), ('ganglia', 'O'), ('.', 'O'))"
The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .,"(('The', 'O'), ('high', 'O'), ('ratio', 'O'), ('is', 'O'), ('believed', 'O'), ('to', 'O'), ('impart', 'O'), ('the', 'O'), ('low', 'O'), ('frequency', 'O'), ('of', 'O'), ('extrapyramidal', 'B'), ('symptoms', 'I'), ('with', 'O'), ('risperidone', 'O'), ('at', 'O'), ('low', 'O'), ('dosages', 'O'), ('.', 'O'))"
"With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .","(('With', 'O'), ('this', 'O'), ('low', 'O'), ('frequency', 'O'), ('of', 'O'), ('extrapyramidal', 'B'), ('symptoms', 'I'), (',', 'O'), ('it', 'O'), ('was', 'O'), ('thought', 'O'), ('the', 'O'), ('frequency', 'O'), ('of', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('might', 'O'), ('also', 'O'), ('be', 'O'), ('lowered', 'O'), ('.', 'O'))"
A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .,"(('A', 'O'), ('73', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('developed', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('after', 'O'), ('monotherapy', 'O'), ('with', 'O'), ('risperidone', 'O'), ('.', 'O'))"
It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .,"(('It', 'O'), ('appears', 'O'), ('that', 'O'), ('the', 'O'), ('protection', 'O'), ('from', 'O'), ('extrapyramidal', 'O'), ('side', 'O'), ('effects', 'O'), ('observed', 'O'), ('with', 'O'), ('risperidone', 'O'), ('does', 'O'), ('not', 'O'), ('ensure', 'O'), ('protection', 'O'), ('from', 'O'), ('neuroleptic', 'B'), ('malignant', 'I'), ('syndrome', 'I'), ('.', 'O'))"
"The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .","(('The', 'O'), ('attenuating', 'O'), ('effect', 'O'), ('of', 'O'), ('carteolol', 'O'), ('hydrochloride', 'O'), (',', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonist', 'O'), (',', 'O'), ('on', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
"It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .","(('It', 'O'), ('is', 'O'), ('known', 'O'), ('that', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonists', 'O'), ('are', 'O'), ('effective', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('akathisia', 'B'), (',', 'O'), ('one', 'O'), ('of', 'O'), ('the', 'O'), ('extrapyramidal', 'O'), ('side', 'O'), ('effects', 'O'), ('that', 'O'), ('occur', 'O'), ('during', 'O'), ('neuroleptic', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .","(('Neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), (',', 'O'), ('a', 'O'), ('model', 'O'), ('of', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('extrapyramidal', 'O'), ('side', 'O'), ('effects', 'O'), (',', 'O'), ('was', 'O'), ('considered', 'O'), ('suitable', 'O'), ('as', 'O'), ('a', 'O'), ('model', 'O'), ('for', 'O'), ('predicting', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('akathisia', 'B'), ('in', 'O'), ('humans', 'O'), (',', 'O'), ('although', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('was', 'O'), ('not', 'O'), ('considered', 'O'), ('a', 'O'), ('specific', 'O'), ('test', 'O'), ('for', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('akathisia', 'B'), ('.', 'O'))"
"Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .","(('Therefore', 'O'), (',', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('carteolol', 'O'), (',', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonist', 'O'), (',', 'O'), ('on', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('in', 'O'), ('rats', 'O'), ('were', 'O'), ('behaviorally', 'O'), ('studied', 'O'), ('and', 'O'), ('compared', 'O'), ('with', 'O'), ('those', 'O'), ('of', 'O'), ('propranolol', 'O'), ('and', 'O'), ('biperiden', 'O'), (',', 'O'), ('a', 'O'), ('muscarinic', 'O'), ('receptor', 'O'), ('antagonist', 'O'), ('.', 'O'))"
"Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .","(('Carteolol', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('propranolol', 'O'), ('and', 'O'), ('biperiden', 'O'), (',', 'O'), ('inhibited', 'O'), ('the', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('.', 'O'))"
Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .,"(('Carteolol', 'O'), ('did', 'O'), ('not', 'O'), ('evoke', 'O'), ('postsynaptic', 'O'), ('dopamine', 'O'), ('receptor', 'O'), ('-', 'O'), ('stimulating', 'O'), ('behavioral', 'O'), ('signs', 'O'), ('such', 'O'), ('as', 'O'), ('stereotypy', 'O'), ('and', 'O'), ('hyperlocomotion', 'B'), ('in', 'O'), ('rats', 'O'), ('.', 'O'))"
These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .,"(('These', 'O'), ('results', 'O'), ('strongly', 'O'), ('suggest', 'O'), ('that', 'O'), ('carteolol', 'O'), ('improves', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('catalepsy', 'B'), ('via', 'O'), ('its', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonistic', 'O'), ('activity', 'O'), ('and', 'O'), ('is', 'O'), ('expected', 'O'), ('to', 'O'), ('be', 'O'), ('effective', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('akathisia', 'B'), ('without', 'O'), ('attenuating', 'O'), ('neuroleptic', 'O'), ('-', 'O'), ('induced', 'O'), ('antipsychotic', 'O'), ('effects', 'O'), ('due', 'O'), ('to', 'O'), ('its', 'O'), ('postsynaptic', 'O'), ('dopamine', 'O'), ('receptor', 'O'), ('antagonistic', 'O'), ('activity', 'O'), ('.', 'O'))"
Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .,"(('Granulosa', 'B'), ('cell', 'I'), ('tumor', 'I'), ('of', 'I'), ('the', 'I'), ('ovary', 'I'), ('associated', 'O'), ('with', 'O'), ('antecedent', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('.', 'O'))"
Review of the literature reveals an association between tamoxifen use and gynecologic tumors .,"(('Review', 'O'), ('of', 'O'), ('the', 'O'), ('literature', 'O'), ('reveals', 'O'), ('an', 'O'), ('association', 'O'), ('between', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('and', 'O'), ('gynecologic', 'O'), ('tumors', 'B'), ('.', 'O'))"
CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .,"(('CASE', 'O'), (':', 'O'), ('A', 'O'), ('52', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('postmenopausal', 'O'), ('woman', 'O'), ('was', 'O'), ('treated', 'O'), ('with', 'O'), ('tamoxifen', 'O'), ('for', 'O'), ('stage', 'O'), ('II', 'O'), ('estrogen', 'O'), ('receptor', 'O'), ('-', 'O'), ('positive', 'O'), ('breast', 'B'), ('carcinoma', 'I'), ('.', 'O'))"
"After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .","(('After', 'O'), ('an', 'O'), ('additional', 'O'), ('17', 'O'), ('months', 'O'), ('of', 'O'), ('elevated', 'O'), ('serum', 'O'), ('transaminases', 'O'), (',', 'O'), ('the', 'O'), ('patient', 'O'), ('was', 'O'), ('found', 'O'), ('to', 'O'), ('have', 'O'), ('a', 'O'), ('stage', 'O'), ('Ic', 'O'), ('granulosa', 'B'), ('cell', 'I'), ('tumor', 'I'), ('of', 'I'), ('the', 'I'), ('ovary', 'I'), ('.', 'O'))"
CONCLUSION : Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .,"(('CONCLUSION', 'O'), (':', 'O'), ('Patients', 'O'), ('with', 'O'), ('tamoxifen', 'O'), ('-', 'O'), ('induced', 'O'), ('liver', 'B'), ('dysfunction', 'I'), ('may', 'O'), ('be', 'O'), ('at', 'O'), ('increased', 'O'), ('risk', 'O'), ('for', 'O'), ('granulosa', 'B'), ('cell', 'I'), ('tumors', 'I'), ('because', 'O'), ('of', 'O'), ('alterations', 'O'), ('in', 'O'), ('tamoxifen', 'O'), ('metabolism', 'O'), ('.', 'O'))"
AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .,"(('AZT', 'O'), ('has', 'O'), ('induced', 'O'), ('a', 'O'), ('macrocytic', 'B'), ('anemia', 'I'), ('in', 'O'), ('AIDS', 'B'), ('patients', 'O'), ('on', 'O'), ('long', 'O'), ('term', 'O'), ('AZT', 'O'), ('therapy', 'O'), ('.', 'O'))"
Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .,"(('Histological', 'O'), ('examination', 'O'), ('on', 'O'), ('9', 'O'), ('of', 'O'), ('10', 'O'), ('mice', 'O'), ('with', 'O'), ('such', 'O'), ('thrombocytopenia', 'B'), ('showed', 'O'), ('changes', 'O'), ('compatible', 'O'), ('with', 'O'), ('myelodysplastic', 'B'), ('syndrome', 'I'), ('(', 'O'), ('MDS', 'B'), (')', 'O'), ('.', 'O'))"
"There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .","(('There', 'O'), ('were', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('hypocellular', 'O'), ('myelodysplasia', 'B'), (',', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('hypersegmented', 'O'), ('myelodysplastic', 'B'), ('granulocytosis', 'O'), (',', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('hypercellular', 'O'), ('marrow', 'O'), ('with', 'O'), ('abnormal', 'O'), ('megakaryocytes', 'O'), ('with', 'O'), ('bizarre', 'O'), ('nuclei', 'O'), (',', 'O'), ('one', 'O'), ('case', 'O'), ('of', 'O'), ('megakaryocytic', 'O'), ('myelosis', 'O'), ('associated', 'O'), ('with', 'O'), ('a', 'O'), ('hyperplastic', 'B'), ('marrow', 'I'), (',', 'O'), ('dysmyelopoiesis', 'B'), ('and', 'O'), ('a', 'O'), ('hypocellular', 'B'), ('marrow', 'I'), ('and', 'O'), ('two', 'O'), ('cases', 'O'), ('of', 'O'), ('myelodysplasia', 'B'), ('with', 'O'), ('dyserythropoiesis', 'B'), (',', 'O'), ('hemosiderosis', 'B'), ('and', 'O'), ('a', 'O'), ('hypocellular', 'B'), ('marrow', 'I'), ('.', 'O'))"
"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .","(('Above', 'O'), ('mentioned', 'O'), ('AZT', 'O'), ('incorporation', 'O'), ('may', 'O'), ('have', 'O'), ('induced', 'O'), ('an', 'O'), ('ineffective', 'O'), ('hemopoiesis', 'O'), ('in', 'O'), ('the', 'O'), ('primitive', 'O'), ('hemopoietic', 'O'), ('progenitor', 'O'), ('cells', 'O'), (',', 'O'), ('which', 'O'), ('is', 'O'), ('known', 'O'), ('to', 'O'), ('be', 'O'), ('seen', 'O'), ('commonly', 'O'), ('in', 'O'), ('the', 'O'), ('myelodysplastic', 'B'), ('syndrome', 'I'), ('.', 'O'))"
Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .,"(('Injections', 'O'), ('of', 'O'), ('ketamine', 'O'), ('in', 'O'), ('doses', 'O'), ('from', 'O'), ('100', 'O'), ('microgram', 'O'), ('to', 'O'), ('3', 'O'), ('mg', 'O'), ('into', 'O'), ('the', 'O'), ('artery', 'O'), ('produced', 'O'), ('a', 'O'), ('depression', 'B'), ('of', 'O'), ('the', 'O'), ('SA', 'O'), ('nodal', 'O'), ('activity', 'O'), ('by', 'O'), ('a', 'O'), ('direct', 'O'), ('action', 'O'), ('.', 'O'))"
This depression was followed by the sudden appearance of a stimulatory phase .,"(('This', 'O'), ('depression', 'B'), ('was', 'O'), ('followed', 'O'), ('by', 'O'), ('the', 'O'), ('sudden', 'O'), ('appearance', 'O'), ('of', 'O'), ('a', 'O'), ('stimulatory', 'O'), ('phase', 'O'), ('.', 'O'))"
"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .","(('Bilateral', 'O'), ('vagotomy', 'O'), ('and', 'O'), ('sympathectomy', 'O'), ('or', 'O'), ('prior', 'O'), ('administration', 'O'), ('of', 'O'), ('a', 'O'), ('ganglion', 'O'), ('blocker', 'O'), ('failed', 'O'), ('to', 'O'), ('inhibit', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('the', 'O'), ('ketamine', 'O'), ('-', 'O'), ('induced', 'O'), ('tachycardia', 'B'), (',', 'O'), ('while', 'O'), ('it', 'O'), ('was', 'O'), ('completely', 'O'), ('abolished', 'O'), ('in', 'O'), ('the', 'O'), ('reserpinized', 'O'), ('dogs', 'O'), ('or', 'O'), ('by', 'O'), ('a', 'O'), ('prior', 'O'), ('injection', 'O'), ('of', 'O'), ('a', 'O'), ('beta', 'O'), ('-', 'O'), ('blocking', 'O'), ('agent', 'O'), ('into', 'O'), ('the', 'O'), ('SA', 'O'), ('node', 'O'), ('artery', 'O'), ('.', 'O'))"
Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .,"(('Over', 'O'), ('expression', 'O'), ('of', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('and', 'O'), ('its', 'O'), ('receptor', 'O'), ('during', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('estrogen', 'O'), ('-', 'O'), ('induced', 'O'), ('rat', 'O'), ('pituitary', 'B'), ('tumors', 'I'), ('may', 'O'), ('mediate', 'O'), ('estrogen', 'O'), ('-', 'O'), ('initiated', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('.', 'O'))"
"Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .","(('Estrogens', 'O'), (',', 'O'), ('which', 'O'), ('have', 'O'), ('been', 'O'), ('associated', 'O'), ('with', 'O'), ('several', 'O'), ('types', 'O'), ('of', 'O'), ('human', 'O'), ('and', 'O'), ('animal', 'O'), ('cancers', 'B'), (',', 'O'), ('can', 'O'), ('induce', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('pituitary', 'O'), ('of', 'O'), ('Fischer', 'O'), ('344', 'O'), ('rats', 'O'), ('.', 'O'))"
"The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .","(('The', 'O'), ('mechanistic', 'O'), ('details', 'O'), ('of', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('induction', 'O'), (',', 'O'), ('during', 'O'), ('estrogen', 'O'), ('carcinogenesis', 'B'), (',', 'O'), ('are', 'O'), ('still', 'O'), ('unknown', 'O'), ('.', 'O'))"
"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .","(('To', 'O'), ('elucidate', 'O'), ('the', 'O'), ('role', 'O'), ('of', 'O'), ('estrogen', 'O'), ('in', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('pituitary', 'O'), ('of', 'O'), ('female', 'O'), ('rats', 'O'), (',', 'O'), ('the', 'O'), ('density', 'O'), ('of', 'O'), ('blood', 'O'), ('vessels', 'O'), ('was', 'O'), ('analysed', 'O'), ('using', 'O'), ('factor', 'O'), ('VIII', 'O'), ('related', 'O'), ('antigen', 'O'), ('(', 'O'), ('FVIIIRAg', 'O'), (')', 'O'), ('immunohistochemistry', 'O'), ('and', 'O'), ('the', 'O'), ('expression', 'O'), ('of', 'O'), ('vascular', 'O'), ('endothelial', 'O'), ('growth', 'O'), ('factor', 'O'), ('/', 'O'), ('vascular', 'O'), ('permeability', 'O'), ('factor', 'O'), ('(', 'O'), ('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), (')', 'O'), ('was', 'O'), ('examined', 'O'), ('by', 'O'), ('Western', 'O'), ('blot', 'O'), ('and', 'O'), ('immunohistochemical', 'O'), ('analysis', 'O'), ('.', 'O'))"
The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .,"(('The', 'O'), ('high', 'O'), ('tumor', 'B'), ('angiogenic', 'O'), ('potential', 'O'), ('was', 'O'), ('associated', 'O'), ('with', 'O'), ('an', 'O'), ('elevated', 'O'), ('VEGF', 'O'), ('/', 'O'), ('VPF', 'O'), ('protein', 'O'), ('expression', 'O'), ('in', 'O'), ('the', 'O'), ('E2', 'O'), ('exposed', 'O'), ('pituitary', 'O'), ('of', 'O'), ('ovariectomized', 'O'), ('(', 'O'), ('OVEX', 'O'), (')', 'O'), ('rats', 'O'), ('.', 'O'))"
These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('over', 'O'), ('expression', 'O'), ('of', 'O'), ('VEGF', 'O'), ('and', 'O'), ('its', 'O'), ('receptor', 'O'), ('(', 'O'), ('VEGFR', 'O'), ('-', 'O'), ('2', 'O'), (')', 'O'), ('may', 'O'), ('play', 'O'), ('an', 'O'), ('important', 'O'), ('role', 'O'), ('in', 'O'), ('the', 'O'), ('initial', 'O'), ('step', 'O'), ('of', 'O'), ('the', 'O'), ('regulation', 'O'), ('of', 'O'), ('estrogen', 'O'), ('induced', 'O'), ('tumor', 'B'), ('angiogenesis', 'O'), ('in', 'O'), ('the', 'O'), ('rat', 'O'), ('pituitary', 'O'), ('.', 'O'))"
Persistent nephrogenic diabetes insipidus following lithium therapy .,"(('Persistent', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), ('following', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('.', 'O'))"
We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .,"(('We', 'O'), ('report', 'O'), ('the', 'O'), ('case', 'O'), ('of', 'O'), ('a', 'O'), ('patient', 'O'), ('who', 'O'), ('developed', 'O'), ('severe', 'O'), ('hypernatraemic', 'O'), ('dehydration', 'B'), ('following', 'O'), ('a', 'O'), ('head', 'B'), ('injury', 'I'), ('.', 'O'))"
"Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .","(('Ten', 'O'), ('years', 'O'), ('previously', 'O'), ('he', 'O'), ('had', 'O'), ('been', 'O'), ('diagnosed', 'O'), ('to', 'O'), ('have', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), (',', 'O'), ('and', 'O'), ('lithium', 'O'), ('therapy', 'O'), ('had', 'O'), ('been', 'O'), ('discontinued', 'O'), ('.', 'O'))"
"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .","(('He', 'O'), ('remained', 'O'), ('thirsty', 'O'), ('and', 'O'), ('polyuric', 'B'), ('despite', 'O'), ('cessation', 'O'), ('of', 'O'), ('lithium', 'O'), ('and', 'O'), ('investigations', 'O'), ('on', 'O'), ('admission', 'O'), ('showed', 'O'), ('him', 'O'), ('to', 'O'), ('have', 'O'), ('normal', 'O'), ('osmoregulated', 'O'), ('thirst', 'O'), ('and', 'O'), ('vasopressin', 'O'), ('secretion', 'O'), (',', 'O'), ('with', 'O'), ('clear', 'O'), ('evidence', 'O'), ('of', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), ('.', 'O'))"
Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .,"(('Lithium', 'O'), ('induced', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), ('is', 'O'), ('considered', 'O'), ('to', 'O'), ('be', 'O'), ('reversible', 'O'), ('on', 'O'), ('cessation', 'O'), ('of', 'O'), ('therapy', 'O'), ('but', 'O'), ('polyuria', 'B'), ('persisted', 'O'), ('in', 'O'), ('this', 'O'), ('patient', 'O'), ('for', 'O'), ('ten', 'O'), ('years', 'O'), ('after', 'O'), ('lithium', 'O'), ('was', 'O'), ('stopped', 'O'), ('.', 'O'))"
We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .,"(('We', 'O'), ('discuss', 'O'), ('the', 'O'), ('possible', 'O'), ('renal', 'O'), ('mechanisms', 'O'), ('and', 'O'), ('the', 'O'), ('implications', 'O'), ('for', 'O'), ('management', 'O'), ('of', 'O'), ('patients', 'O'), ('with', 'O'), ('lithium', 'O'), ('-', 'O'), ('induced', 'O'), ('nephrogenic', 'B'), ('diabetes', 'I'), ('insipidus', 'I'), ('.', 'O'))"
Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .,"(('Effects', 'O'), ('of', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('on', 'O'), ('cholinesterase', 'O'), ('and', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('.', 'O'))"
"The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .","(('The', 'O'), ('effects', 'O'), ('of', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('on', 'O'), ('cholinesterase', 'O'), (',', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('and', 'O'), ('spontaneous', 'O'), ('movement', 'O'), ('were', 'O'), ('examined', 'O'), ('and', 'O'), ('compared', 'O'), ('with', 'O'), ('those', 'O'), ('of', 'O'), ('the', 'O'), ('well', 'O'), ('-', 'O'), ('known', 'O'), ('cholinesterase', 'O'), ('inhibitors', 'O'), ('tacrine', 'O'), ('and', 'O'), ('E', 'O'), ('-', 'O'), ('2020', 'O'), ('.', 'O'))"
All compounds at 0 . 1 - 1 mg / kg p . o . significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .,"(('All', 'O'), ('compounds', 'O'), ('at', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), ('significantly', 'O'), ('improved', 'O'), ('the', 'O'), ('amnesia', 'B'), ('induced', 'O'), ('by', 'O'), ('scopolamine', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('s', 'O'), ('.', 'O'), ('c', 'O'), ('.', 'O'), (')', 'O'), ('in', 'O'), ('rats', 'O'), ('performing', 'O'), ('a', 'O'), ('passive', 'O'), ('avoidance', 'O'), ('task', 'O'), ('.', 'O'))"
These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .,"(('These', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('at', 'O'), ('a', 'O'), ('low', 'O'), ('dose', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('1', 'O'), ('-', 'O'), ('1', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('p', 'O'), ('.', 'O'), ('o', 'O'), ('.', 'O'), (')', 'O'), ('improves', 'O'), ('scopolamine', 'O'), ('-', 'O'), ('induced', 'O'), ('amnesia', 'B'), ('but', 'O'), ('does', 'O'), ('not', 'O'), ('affect', 'O'), ('spontaneous', 'O'), ('movement', 'O'), ('.', 'O'))"
The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer ' s disease .,"(('The', 'O'), ('findings', 'O'), ('suggest', 'O'), ('that', 'O'), ('NIK', 'O'), ('-', 'O'), ('247', 'O'), ('may', 'O'), ('be', 'O'), ('a', 'O'), ('useful', 'O'), ('drug', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Alzheimer', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .","(('Potential', 'O'), ('therapeutic', 'O'), ('use', 'O'), ('of', 'O'), ('the', 'O'), ('selective', 'O'), ('dopamine', 'O'), ('D1', 'O'), ('receptor', 'O'), ('agonist', 'O'), (',', 'O'), ('A', 'O'), ('-', 'O'), ('86929', 'O'), (':', 'O'), ('an', 'O'), ('acute', 'O'), ('study', 'O'), ('in', 'O'), ('parkinsonian', 'B'), ('levodopa', 'O'), ('-', 'O'), ('primed', 'O'), ('monkeys', 'O'), ('.', 'O'))"
The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson ' s disease ( PD ) is still unclear .,"(('The', 'O'), ('clinical', 'O'), ('utility', 'O'), ('of', 'O'), ('dopamine', 'O'), ('(', 'O'), ('DA', 'O'), (')', 'O'), ('D1', 'O'), ('receptor', 'O'), ('agonists', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('(', 'O'), ('PD', 'B'), (')', 'O'), ('is', 'O'), ('still', 'O'), ('unclear', 'O'), ('.', 'O'))"
"We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 ,","(('We', 'O'), ('therefore', 'O'), ('conducted', 'O'), ('the', 'O'), ('present', 'O'), ('acute', 'O'), ('dose', 'O'), ('-', 'O'), ('response', 'O'), ('study', 'O'), ('in', 'O'), ('four', 'O'), ('1', 'O'), ('-', 'O'), ('methyl', 'O'), ('-', 'O'), ('4', 'O'), ('-', 'O'), ('phenyl', 'O'), ('-', 'O'), ('1', 'O'), (',', 'O'), ('2', 'O'), (',', 'O'), ('3', 'O'), (',', 'O'), ('6', 'O'), ('-', 'O'), ('tetrahydropyridine', 'O'), ('(', 'O'), ('MPTP', 'O'), (')', 'O'), ('-', 'O'), ('exposed', 'O'), ('cynomolgus', 'O'), ('monkeys', 'O'), ('primed', 'O'), ('to', 'O'), ('exhibit', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('to', 'O'), ('evaluate', 'O'), ('the', 'O'), ('locomotor', 'O'), ('and', 'O'), ('dyskinetic', 'B'), ('effects', 'O'), ('on', 'O'), ('challenge', 'O'), ('with', 'O'), ('four', 'O'), ('doses', 'O'), ('(', 'O'), ('from', 'O'), ('0', 'O'), ('.', 'O'), ('03', 'O'), ('to', 'O'), ('1', 'O'), ('.', 'O'), ('0', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('of', 'O'), ('A', 'O'), ('-', 'O'), ('86929', 'O'), ('(', 'O'), ('[', 'O'), ('-', 'O'), (']', 'O'), ('-', 'O'), ('[', 'O'), ('5aR', 'O'), (',', 'O'), ('11bS', 'O'), (']', 'O'), ('-', 'O'), ('4', 'O'), (',', 'O'), ('5', 'O'), (',', 'O'), ('5a', 'O'), (',', 'O'), ('6', 'O'), (',', 'O'))"
"Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .","(('Acute', 'O'), ('administration', 'O'), ('of', 'O'), ('A', 'O'), ('-', 'O'), ('86929', 'O'), ('was', 'O'), ('as', 'O'), ('efficacious', 'O'), ('in', 'O'), ('alleviating', 'O'), ('MPTP', 'O'), ('-', 'O'), ('induced', 'O'), ('parkinsonism', 'B'), ('as', 'O'), ('levodopa', 'O'), ('and', 'O'), ('LY', 'O'), ('-', 'O'), ('171555', 'O'), (',', 'O'), ('but', 'O'), ('was', 'O'), ('less', 'O'), ('likely', 'O'), ('to', 'O'), ('reproduce', 'O'), ('the', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('in', 'O'), ('these', 'O'), ('animals', 'O'), ('than', 'O'), ('with', 'O'), ('either', 'O'), ('LY', 'O'), ('-', 'O'), ('171555', 'O'), ('or', 'O'), ('subsequent', 'O'), ('challenge', 'O'), ('of', 'O'), ('levodopa', 'O'), ('.', 'O'))"
Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .,"(('Potent', 'O'), ('DA', 'O'), ('D1', 'O'), ('receptor', 'O'), ('agents', 'O'), ('with', 'O'), ('an', 'O'), ('intermediate', 'O'), ('duration', 'O'), ('of', 'O'), ('efficacy', 'O'), ('such', 'O'), ('as', 'O'), ('A', 'O'), ('-', 'O'), ('86929', 'O'), ('(', 'O'), ('approximately', 'O'), ('4', 'O'), ('hr', 'O'), ('at', 'O'), ('higher', 'O'), ('doses', 'O'), ('tested', 'O'), (')', 'O'), ('are', 'O'), ('potential', 'O'), ('therapeutic', 'O'), ('tools', 'O'), ('in', 'O'), ('PD', 'B'), ('and', 'O'), ('merit', 'O'), ('further', 'O'), ('attention', 'O'), ('.', 'O'))"
Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .,"(('Neuropeptide', 'O'), ('-', 'O'), ('Y', 'O'), ('immunoreactivity', 'O'), ('in', 'O'), ('the', 'O'), ('pilocarpine', 'O'), ('model', 'O'), ('of', 'O'), ('temporal', 'B'), ('lobe', 'I'), ('epilepsy', 'I'), ('.', 'O'))"
Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .,"(('Neuropeptide', 'O'), ('-', 'O'), ('Y', 'O'), ('(', 'O'), ('NPY', 'O'), (')', 'O'), ('is', 'O'), ('expressed', 'O'), ('by', 'O'), ('granule', 'O'), ('cells', 'O'), ('and', 'O'), ('mossy', 'O'), ('fibres', 'O'), ('of', 'O'), ('the', 'O'), ('hippocampal', 'O'), ('dentate', 'O'), ('gyrus', 'O'), ('during', 'O'), ('experimental', 'O'), ('temporal', 'B'), ('lobe', 'I'), ('epilepsy', 'I'), ('(', 'O'), ('TLE', 'B'), (')', 'O'), ('.', 'O'))"
This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .,"(('This', 'O'), ('expression', 'O'), ('may', 'O'), ('represent', 'O'), ('an', 'O'), ('endogenous', 'O'), ('damping', 'O'), ('mechanism', 'O'), ('since', 'O'), ('NPY', 'O'), ('has', 'O'), ('been', 'O'), ('shown', 'O'), ('to', 'O'), ('block', 'O'), ('seizure', 'B'), ('-', 'O'), ('like', 'O'), ('events', 'O'), ('following', 'O'), ('high', 'O'), ('-', 'O'), ('frequency', 'O'), ('stimulation', 'O'), ('in', 'O'), ('hippocampal', 'O'), ('slices', 'O'), ('.', 'O'))"
The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .,"(('The', 'O'), ('pilocarpine', 'O'), ('(', 'O'), ('PILO', 'O'), (')', 'O'), ('model', 'O'), ('of', 'O'), ('epilepsy', 'B'), ('is', 'O'), ('characterized', 'O'), ('by', 'O'), ('an', 'O'), ('acute', 'O'), ('period', 'O'), ('of', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('followed', 'O'), ('by', 'O'), ('spontaneous', 'O'), ('recurrent', 'O'), ('seizures', 'B'), ('and', 'O'), ('related', 'O'), ('brain', 'B'), ('damage', 'I'), ('.', 'O'))"
Posteroventral medial pallidotomy in advanced Parkinson ' s disease .,"(('Posteroventral', 'O'), ('medial', 'O'), ('pallidotomy', 'O'), ('in', 'O'), ('advanced', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('.', 'O'))"
"BACKGROUND : Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson ' s disease , but the studies to date have involved small numbers of patients and short - term follow - up .","(('BACKGROUND', 'O'), (':', 'O'), ('Posteroventral', 'O'), ('medial', 'O'), ('pallidotomy', 'O'), ('sometimes', 'O'), ('produces', 'O'), ('striking', 'O'), ('improvement', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('advanced', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('but', 'O'), ('the', 'O'), ('studies', 'O'), ('to', 'O'), ('date', 'O'), ('have', 'O'), ('involved', 'O'), ('small', 'O'), ('numbers', 'O'), ('of', 'O'), ('patients', 'O'), ('and', 'O'), ('short', 'O'), ('-', 'O'), ('term', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('.', 'O'))"
"METHODS : Forty patients with Parkinson ' s disease underwent serial , detailed assessments both after drug withdrawal ( "" off "" period ) and while taking their optimal medical regimens ( "" on "" period ) .","(('METHODS', 'O'), (':', 'O'), ('Forty', 'O'), ('patients', 'O'), ('with', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), ('underwent', 'O'), ('serial', 'O'), (',', 'O'), ('detailed', 'O'), ('assessments', 'O'), ('both', 'O'), ('after', 'O'), ('drug', 'O'), ('withdrawal', 'O'), ('(', 'O'), ('""', 'O'), ('off', 'O'), ('""', 'O'), ('period', 'O'), (')', 'O'), ('and', 'O'), ('while', 'O'), ('taking', 'O'), ('their', 'O'), ('optimal', 'O'), ('medical', 'O'), ('regimens', 'O'), ('(', 'O'), ('""', 'O'), ('on', 'O'), ('""', 'O'), ('period', 'O'), (')', 'O'), ('.', 'O'))"
"RESULTS : The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent","(('RESULTS', 'O'), (':', 'O'), ('The', 'O'), ('percent', 'O'), ('improvements', 'O'), ('at', 'O'), ('six', 'O'), ('months', 'O'), ('were', 'O'), ('as', 'O'), ('follows', 'O'), (':', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('score', 'O'), ('for', 'O'), ('overall', 'O'), ('motor', 'O'), ('function', 'O'), (',', 'O'), ('28', 'O'), ('percent', 'O'), ('(', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('19', 'O'), ('to', 'O'), ('38', 'O'), ('percent', 'O'), (')', 'O'), (',', 'O'), ('with', 'O'), ('most', 'O'), ('of', 'O'), ('the', 'O'), ('improvement', 'O'), ('in', 'O'), ('the', 'O'), ('contralateral', 'O'), ('limbs', 'O'), (';', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('score', 'O'), ('for', 'O'), ('activities', 'O'), ('of', 'O'), ('daily', 'O'), ('living', 'O'), (',', 'O'), ('29', 'O'), ('percent', 'O'), ('(', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('19', 'O'), ('to', 'O'), ('39', 'O'), ('percent', 'O'), (')', 'O'), (';', 'O'), ('on', 'O'), ('-', 'O'), ('period', 'O'), ('score', 'O'), ('for', 'O'), ('contralateral', 'O'), ('dyskinesias', 'B'), (',', 'O'), ('82', 'O'), ('percent', 'O'), ('(', 'O'), ('95', 'O'), ('percent', 'O'), ('confidence', 'O'), ('interval', 'O'), (',', 'O'), ('72', 'O'), ('to', 'O'), ('91', 'O'), ('percent', 'O'), (')', 'O'), (';', 'O'), ('and', 'O'), ('on', 'O'), ('-', 'O'), ('period', 'O'), ('score', 'O'), ('for', 'O'), ('ipsilateral', 'O'), ('dyskinesias', 'B'), (',', 'O'), ('44', 'O'), ('percent', 'O'), ('(', 'O'), ('95', 'O'), ('percent', 'O'))"
"The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .","(('The', 'O'), ('improvements', 'O'), ('in', 'O'), ('dyskinesias', 'B'), ('and', 'O'), ('the', 'O'), ('total', 'O'), ('scores', 'O'), ('for', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('parkinsonism', 'B'), (',', 'O'), ('contralateral', 'O'), ('bradykinesia', 'B'), (',', 'O'), ('and', 'O'), ('rigidity', 'B'), ('were', 'O'), ('sustained', 'O'), ('in', 'O'), ('the', 'O'), ('11', 'O'), ('patients', 'O'), ('examined', 'O'), ('at', 'O'), ('two', 'O'), ('years', 'O'), ('.', 'O'))"
"The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .","(('The', 'O'), ('improvement', 'O'), ('in', 'O'), ('ipsilateral', 'O'), ('dyskinesias', 'B'), ('was', 'O'), ('lost', 'O'), ('after', 'O'), ('one', 'O'), ('year', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('improvements', 'O'), ('in', 'O'), ('postural', 'O'), ('stability', 'O'), ('and', 'O'), ('gait', 'O'), ('lasted', 'O'), ('only', 'O'), ('three', 'O'), ('to', 'O'), ('six', 'O'), ('months', 'O'), ('.', 'O'))"
"CONCLUSIONS : In late - stage Parkinson ' s disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .","(('CONCLUSIONS', 'O'), (':', 'O'), ('In', 'O'), ('late', 'O'), ('-', 'O'), ('stage', 'O'), ('Parkinson', 'B'), (""'"", 'I'), ('s', 'I'), ('disease', 'I'), (',', 'O'), ('pallidotomy', 'O'), ('significantly', 'O'), ('reduces', 'O'), ('levodopa', 'O'), ('-', 'O'), ('induced', 'O'), ('dyskinesias', 'B'), ('and', 'O'), ('off', 'O'), ('-', 'O'), ('period', 'O'), ('disability', 'O'), ('.', 'O'))"
Clarithromycin - induced ventricular tachycardia .,"(('Clarithromycin', 'O'), ('-', 'O'), ('induced', 'O'), ('ventricular', 'B'), ('tachycardia', 'I'), ('.', 'O'))"
We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .,"(('We', 'O'), ('report', 'O'), ('a', 'O'), ('case', 'O'), ('of', 'O'), ('ventricular', 'B'), ('dysrhythmias', 'I'), ('that', 'O'), ('occurred', 'O'), ('after', 'O'), ('six', 'O'), ('therapeutic', 'O'), ('doses', 'O'), ('of', 'O'), ('clarithromycin', 'O'), ('.', 'O'))"
Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .,"(('Effect', 'O'), ('of', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('on', 'O'), ('the', 'O'), ('sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('spasm', 'I'), ('evoked', 'O'), ('by', 'O'), ('prostigmine', 'O'), ('-', 'O'), ('morphine', 'O'), ('administration', 'O'), ('.', 'O'))"
OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .,"(('OBJECTIVE', 'O'), (':', 'O'), ('In', 'O'), ('this', 'O'), ('study', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('on', 'O'), ('the', 'O'), ('prostigmine', 'O'), ('-', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('spasm', 'I'), ('was', 'O'), ('evaluated', 'O'), ('in', 'O'), ('nine', 'O'), ('female', 'O'), ('patients', 'O'), ('with', 'O'), ('sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('dyskinesia', 'I'), ('.', 'O'))"
METHOD : Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .,"(('METHOD', 'O'), (':', 'O'), ('Sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('spasm', 'I'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('prostigmine', 'O'), ('-', 'O'), ('morphine', 'O'), ('administration', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('prostigmine', 'O'), ('intramuscularly', 'O'), ('and', 'O'), ('10', 'O'), ('mg', 'O'), ('morphine', 'O'), ('subcutaneously', 'O'), (')', 'O'), ('and', 'O'), ('visualized', 'O'), ('by', 'O'), ('quantitative', 'O'), ('hepatobiliary', 'O'), ('scintigraphy', 'O'), ('.', 'O'))"
"01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .","(('01', 'O'), ('vs', 'O'), ('.', 'O'), ('27', 'O'), ('.', 'O'), ('37', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('19', 'O'), (')', 'O'), (',', 'O'), ('HH', 'O'), ('(', 'O'), ('117', 'O'), ('.', 'O'), ('61', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('14', 'O'), ('.', 'O'), ('71', 'O'), ('vs', 'O'), ('.', 'O'), ('31', 'O'), ('.', 'O'), ('85', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('99', 'O'), (')', 'O'), ('and', 'O'), ('CBD', 'O'), ('(', 'O'), ('158', 'O'), ('.', 'O'), ('11', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('9', 'O'), ('.', 'O'), ('18', 'O'), ('vs', 'O'), ('.', 'O'), ('40', 'O'), ('.', 'O'), ('1', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('24', 'O'), (')', 'O'), (',', 'O'), ('indicating', 'O'), ('a', 'O'), ('complete', 'O'), ('spasm', 'B'), ('at', 'O'), ('the', 'O'), ('level', 'O'), ('of', 'O'), ('the', 'O'), ('sphincter', 'O'), ('of', 'O'), ('Oddi', 'O'), ('.', 'O'))"
CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .,"(('CONCLUSION', 'O'), (':', 'O'), ('These', 'O'), ('results', 'O'), ('provide', 'O'), ('the', 'O'), ('first', 'O'), ('evidence', 'O'), ('of', 'O'), ('the', 'O'), ('effectiveness', 'O'), ('of', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('on', 'O'), ('the', 'O'), ('morphine', 'O'), ('-', 'O'), ('induced', 'O'), ('sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('spasm', 'I'), ('in', 'O'), ('humans', 'O'), ('.', 'O'))"
"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .","(('Since', 'O'), ('glyceryl', 'O'), ('trinitrate', 'O'), ('is', 'O'), ('able', 'O'), ('to', 'O'), ('overcome', 'O'), ('even', 'O'), ('the', 'O'), ('drastic', 'O'), ('effect', 'O'), ('of', 'O'), ('morphine', 'O'), (',', 'O'), ('it', 'O'), ('might', 'O'), ('be', 'O'), ('of', 'O'), ('relevance', 'O'), ('in', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('sphincter', 'B'), ('of', 'I'), ('Oddi', 'I'), ('dyskinesia', 'I'), ('.', 'O'))"
Immunopathology of penicillamine - induced glomerular disease .,"(('Immunopathology', 'O'), ('of', 'O'), ('penicillamine', 'O'), ('-', 'O'), ('induced', 'O'), ('glomerular', 'B'), ('disease', 'I'), ('.', 'O'))"
Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .,"(('Four', 'O'), ('patients', 'O'), ('with', 'O'), ('rheumatoid', 'B'), ('arthritis', 'I'), ('developed', 'O'), ('heavy', 'O'), ('proteinuria', 'B'), ('after', 'O'), ('five', 'O'), ('to', 'O'), ('12', 'O'), ('months', 'O'), ('of', 'O'), ('treatment', 'O'), ('with', 'O'), ('D', 'O'), ('-', 'O'), ('penicillamine', 'O'), ('.', 'O'))"
Experimental cranial pain elicited by capsaicin : a PET study .,"(('Experimental', 'O'), ('cranial', 'O'), ('pain', 'B'), ('elicited', 'O'), ('by', 'O'), ('capsaicin', 'O'), (':', 'O'), ('a', 'O'), ('PET', 'O'), ('study', 'O'), ('.', 'O'))"
"Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .","(('Using', 'O'), ('a', 'O'), ('positron', 'O'), ('emission', 'O'), ('tomography', 'O'), ('(', 'O'), ('PET', 'O'), (')', 'O'), ('study', 'O'), ('it', 'O'), ('was', 'O'), ('shown', 'O'), ('recently', 'O'), ('that', 'O'), ('in', 'O'), ('migraine', 'B'), ('without', 'O'), ('aura', 'O'), ('certain', 'O'), ('areas', 'O'), ('in', 'O'), ('the', 'O'), ('brain', 'O'), ('stem', 'O'), ('were', 'O'), ('activated', 'O'), ('during', 'O'), ('the', 'O'), ('headache', 'B'), ('state', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('in', 'O'), ('the', 'O'), ('headache', 'B'), ('free', 'O'), ('interval', 'O'), ('.', 'O'))"
It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .,"(('It', 'O'), ('was', 'O'), ('suggested', 'O'), ('that', 'O'), ('this', 'O'), ('brain', 'O'), ('stem', 'O'), ('activation', 'O'), ('is', 'O'), ('inherent', 'O'), ('to', 'O'), ('the', 'O'), ('migraine', 'B'), ('attack', 'O'), ('itself', 'O'), ('and', 'O'), ('represents', 'O'), ('the', 'O'), ('so', 'O'), ('called', 'O'), (""'"", 'O'), ('migraine', 'B'), ('generator', 'O'), (""'"", 'O'), ('.', 'O'))"
"To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .","(('To', 'O'), ('test', 'O'), ('this', 'O'), ('hypothesis', 'O'), ('we', 'O'), ('performed', 'O'), ('an', 'O'), ('experimental', 'O'), ('pain', 'B'), ('study', 'O'), ('in', 'O'), ('seven', 'O'), ('healthy', 'O'), ('volunteers', 'O'), (',', 'O'), ('using', 'O'), ('the', 'O'), ('same', 'O'), ('positioning', 'O'), ('in', 'O'), ('the', 'O'), ('PET', 'O'), ('scanner', 'O'), ('as', 'O'), ('in', 'O'), ('the', 'O'), ('migraine', 'B'), ('patients', 'O'), ('.', 'O'))"
A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .,"(('A', 'O'), ('small', 'O'), ('amount', 'O'), ('of', 'O'), ('capsaicin', 'O'), ('was', 'O'), ('administered', 'O'), ('subcutaneously', 'O'), ('in', 'O'), ('the', 'O'), ('right', 'O'), ('forehead', 'O'), ('to', 'O'), ('evoke', 'O'), ('a', 'O'), ('burning', 'O'), ('painful', 'B'), ('sensation', 'O'), ('in', 'O'), ('the', 'O'), ('first', 'O'), ('division', 'O'), ('of', 'O'), ('the', 'O'), ('trigeminal', 'O'), ('nerve', 'O'), ('.', 'O'))"
Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .,"(('Using', 'O'), ('the', 'O'), ('same', 'O'), ('stereotactic', 'O'), ('space', 'O'), ('limits', 'O'), ('as', 'O'), ('in', 'O'), ('the', 'O'), ('above', 'O'), ('mentioned', 'O'), ('migraine', 'B'), ('study', 'O'), ('no', 'O'), ('brain', 'O'), ('stem', 'O'), ('activation', 'O'), ('was', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('acute', 'O'), ('pain', 'B'), ('state', 'O'), ('compared', 'O'), ('to', 'O'), ('the', 'O'), ('pain', 'B'), ('free', 'O'), ('state', 'O'), ('.', 'O'))"
"The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .","(('The', 'O'), ('increase', 'O'), ('of', 'O'), ('activation', 'O'), ('in', 'O'), ('the', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('cavernous', 'O'), ('sinus', 'O'), ('however', 'O'), (',', 'O'), ('suggests', 'O'), ('that', 'O'), ('this', 'O'), ('structure', 'O'), ('is', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('be', 'O'), ('involved', 'O'), ('in', 'O'), ('trigeminal', 'O'), ('transmitted', 'O'), ('pain', 'B'), ('as', 'O'), ('such', 'O'), (',', 'O'), ('rather', 'O'), ('than', 'O'), ('in', 'O'), ('a', 'O'), ('specific', 'O'), ('type', 'O'), ('of', 'O'), ('headache', 'B'), ('as', 'O'), ('was', 'O'), ('suggested', 'O'), ('for', 'O'), ('cluster', 'B'), ('headache', 'I'), ('.', 'O'))"
Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .,"(('Value', 'O'), ('of', 'O'), ('methylprednisolone', 'O'), ('in', 'O'), ('prevention', 'O'), ('of', 'O'), ('the', 'O'), ('arthralgia', 'B'), ('-', 'O'), ('myalgia', 'B'), ('syndrome', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('total', 'O'), ('dose', 'O'), ('infusion', 'O'), ('of', 'O'), ('iron', 'O'), ('dextran', 'O'), (':', 'O'), ('a', 'O'), ('double', 'O'), ('blind', 'O'), ('randomized', 'O'), ('trial', 'O'), ('.', 'O'))"
"In 40 % of treated patients , an arthralgia - myalgia syndrome develops .","(('In', 'O'), ('40', 'O'), ('%', 'O'), ('of', 'O'), ('treated', 'O'), ('patients', 'O'), (',', 'O'), ('an', 'O'), ('arthralgia', 'B'), ('-', 'O'), ('myalgia', 'B'), ('syndrome', 'O'), ('develops', 'O'), ('.', 'O'))"
These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .,"(('These', 'O'), ('data', 'O'), ('demonstrate', 'O'), ('that', 'O'), ('administration', 'O'), ('of', 'O'), ('MP', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('TDI', 'O'), ('reduces', 'O'), ('the', 'O'), ('frequency', 'O'), ('and', 'O'), ('severity', 'O'), ('of', 'O'), ('the', 'O'), ('arthralgia', 'B'), ('-', 'O'), ('myalgia', 'B'), ('syndrome', 'O'), ('.', 'O'))"
Prolongation of the QT interval related to cisapride - diltiazem interaction .,"(('Prolongation', 'B'), ('of', 'I'), ('the', 'I'), ('QT', 'I'), ('interval', 'I'), ('related', 'O'), ('to', 'O'), ('cisapride', 'O'), ('-', 'O'), ('diltiazem', 'O'), ('interaction', 'O'), ('.', 'O'))"
"Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .","(('Cisapride', 'O'), (',', 'O'), ('a', 'O'), ('cytochrome', 'O'), ('P450', 'O'), ('3A4', 'O'), ('(', 'O'), ('CYP3A4', 'O'), (')', 'O'), ('substrate', 'O'), (',', 'O'), ('is', 'O'), ('widely', 'O'), ('prescribed', 'O'), ('for', 'O'), ('the', 'O'), ('treatment', 'O'), ('of', 'O'), ('gastrointestinal', 'B'), ('motility', 'I'), ('disorders', 'I'), ('.', 'O'))"
"Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .","(('Prolongation', 'B'), ('of', 'I'), ('QT', 'I'), ('interval', 'I'), (',', 'O'), ('torsades', 'B'), ('de', 'I'), ('pointes', 'I'), (',', 'O'), ('and', 'O'), ('sudden', 'B'), ('cardiac', 'I'), ('death', 'I'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('after', 'O'), ('concomitant', 'O'), ('administration', 'O'), ('with', 'O'), ('erythromycin', 'O'), ('or', 'O'), ('azole', 'O'), ('antifungal', 'O'), ('agents', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('with', 'O'), ('other', 'O'), ('CYP3A4', 'O'), ('inhibitors', 'O'), ('.', 'O'))"
"A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .","(('A', 'O'), ('possible', 'O'), ('drug', 'O'), ('interaction', 'O'), ('occurred', 'O'), ('in', 'O'), ('a', 'O'), ('45', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('woman', 'O'), ('who', 'O'), ('was', 'O'), ('taking', 'O'), ('cisapride', 'O'), ('for', 'O'), ('gastroesophageal', 'B'), ('reflux', 'I'), ('disorder', 'I'), ('and', 'O'), ('diltiazem', 'O'), (',', 'O'), ('an', 'O'), ('agent', 'O'), ('that', 'O'), ('has', 'O'), ('inhibitory', 'O'), ('effect', 'O'), ('on', 'O'), ('CYP3A4', 'O'), (',', 'O'), ('for', 'O'), ('hypertension', 'B'), ('.', 'O'))"
The patient was in near syncope and had QT - interval prolongation .,"(('The', 'O'), ('patient', 'O'), ('was', 'O'), ('in', 'O'), ('near', 'O'), ('syncope', 'B'), ('and', 'O'), ('had', 'O'), ('QT', 'B'), ('-', 'I'), ('interval', 'I'), ('prolongation', 'I'), ('.', 'O'))"
Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .,"(('Cortical', 'O'), ('motor', 'O'), ('overactivation', 'O'), ('in', 'O'), ('parkinsonian', 'B'), ('patients', 'O'), ('with', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('-', 'O'), ('induced', 'O'), ('peak', 'O'), ('-', 'O'), ('dose', 'O'), ('dyskinesia', 'B'), ('.', 'O'))"
"We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .","(('We', 'O'), ('have', 'O'), ('studied', 'O'), ('the', 'O'), ('regional', 'O'), ('cerebral', 'O'), ('blood', 'O'), ('flow', 'O'), ('(', 'O'), ('rCBF', 'O'), (')', 'O'), ('changes', 'O'), ('induced', 'O'), ('by', 'O'), ('the', 'O'), ('execution', 'O'), ('of', 'O'), ('a', 'O'), ('finger', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('thumb', 'O'), ('opposition', 'O'), ('motor', 'O'), ('task', 'O'), ('in', 'O'), ('the', 'O'), ('supplementary', 'O'), ('and', 'O'), ('primary', 'O'), ('motor', 'O'), ('cortex', 'O'), ('of', 'O'), ('two', 'O'), ('groups', 'O'), ('of', 'O'), ('parkinsonian', 'B'), ('patients', 'O'), ('on', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('medication', 'O'), (',', 'O'), ('the', 'O'), ('first', 'O'), ('one', 'O'), ('without', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('induced', 'O'), ('dyskinesia', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('23', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('other', 'O'), ('with', 'O'), ('moderate', 'O'), ('peak', 'O'), ('-', 'O'), ('dose', 'O'), ('dyskinesia', 'B'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('15', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('of', 'O'), ('a', 'O'), ('group', 'O'), ('of', 'O'), ('14', 'O'), ('normal', 'O'), ('subjects', 'O'), ('.', 'O'))"
"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .","(('The', 'O'), ('dyskinetic', 'B'), ('parkinsonian', 'B'), ('patients', 'O'), ('exhibited', 'O'), ('a', 'O'), ('pattern', 'O'), ('of', 'O'), ('response', 'O'), ('which', 'O'), ('was', 'O'), ('markedly', 'O'), ('different', 'O'), ('from', 'O'), ('those', 'O'), ('of', 'O'), ('the', 'O'), ('normal', 'O'), ('subjects', 'O'), ('and', 'O'), ('non', 'O'), ('-', 'O'), ('dyskinetic', 'B'), ('parkinsonian', 'B'), ('patients', 'O'), (',', 'O'), ('with', 'O'), ('a', 'O'), ('significant', 'O'), ('overactivation', 'O'), ('in', 'O'), ('the', 'O'), ('supplementary', 'O'), ('motor', 'O'), ('area', 'O'), ('and', 'O'), ('the', 'O'), ('ipsi', 'O'), ('-', 'O'), ('and', 'O'), ('contralateral', 'O'), ('primary', 'O'), ('motor', 'O'), ('areas', 'O'), ('.', 'O'))"
"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .","(('These', 'O'), ('results', 'O'), ('are', 'O'), ('compatible', 'O'), ('with', 'O'), ('the', 'O'), ('hypothesis', 'O'), ('that', 'O'), ('an', 'O'), ('hyperkinetic', 'B'), ('abnormal', 'B'), ('involuntary', 'I'), ('movement', 'I'), (',', 'O'), ('like', 'O'), ('L', 'O'), ('-', 'O'), ('dopa', 'O'), ('-', 'O'), ('induced', 'O'), ('peak', 'O'), ('dose', 'O'), ('dyskinesia', 'B'), (',', 'O'), ('is', 'O'), ('due', 'O'), ('to', 'O'), ('a', 'O'), ('disinhibition', 'O'), ('of', 'O'), ('the', 'O'), ('primary', 'O'), ('and', 'O'), ('associated', 'O'), ('motor', 'O'), ('cortex', 'O'), ('secondary', 'O'), ('to', 'O'), ('an', 'O'), ('excessive', 'O'), ('outflow', 'O'), ('of', 'O'), ('the', 'O'), ('pallidothalamocortical', 'O'), ('motor', 'O'), ('loop', 'O'), ('.', 'O'))"
"The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .","(('The', 'O'), ('most', 'O'), ('common', 'O'), ('drug', 'O'), ('-', 'O'), ('related', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('diarrhea', 'B'), (',', 'O'), ('flatulence', 'B'), (',', 'O'), ('and', 'O'), ('nausea', 'B'), (';', 'O'), ('most', 'O'), ('adverse', 'O'), ('events', 'O'), ('were', 'O'), ('mild', 'O'), ('to', 'O'), ('moderate', 'O'), ('in', 'O'), ('severity', 'O'), ('.', 'O'))"
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .,"(('Iatrogenic', 'O'), ('risks', 'O'), ('of', 'O'), ('endometrial', 'B'), ('carcinoma', 'I'), ('after', 'O'), ('treatment', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('a', 'O'), ('large', 'O'), ('French', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('.', 'O'))"
"Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .","(('Since', 'O'), ('tamoxifen', 'O'), ('is', 'O'), ('widely', 'O'), ('used', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), ('treatment', 'O'), ('and', 'O'), ('has', 'O'), ('been', 'O'), ('proposed', 'O'), ('for', 'O'), ('the', 'O'), ('prevention', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('its', 'O'), ('endometrial', 'O'), ('iatrogenic', 'O'), ('effects', 'O'), ('must', 'O'), ('be', 'O'), ('carefully', 'O'), ('examined', 'O'), ('.', 'O'))"
We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .,"(('We', 'O'), ('have', 'O'), ('investigated', 'O'), ('the', 'O'), ('association', 'O'), ('between', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('and', 'O'), ('tamoxifen', 'O'), ('use', 'O'), ('or', 'O'), ('other', 'O'), ('treatments', 'O'), ('in', 'O'), ('women', 'O'), ('treated', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('in', 'O'), ('a', 'O'), ('case', 'O'), ('-', 'O'), ('control', 'O'), ('study', 'O'), ('.', 'O'))"
"Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .","(('Cases', 'O'), ('of', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('diagnosed', 'O'), ('after', 'O'), ('breast', 'B'), ('cancer', 'I'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('135', 'O'), (')', 'O'), ('and', 'O'), ('467', 'O'), ('controls', 'O'), ('matched', 'O'), ('for', 'O'), ('age', 'O'), (',', 'O'), ('year', 'O'), ('of', 'O'), ('diagnosis', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('hospital', 'O'), ('and', 'O'), ('survival', 'O'), ('time', 'O'), ('with', 'O'), ('an', 'O'), ('intact', 'O'), ('uterus', 'O'), ('were', 'O'), ('included', 'O'), ('.', 'O'))"
"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .","(('Women', 'O'), ('who', 'O'), ('had', 'O'), ('received', 'O'), ('tamoxifen', 'O'), ('were', 'O'), ('significantly', 'O'), ('more', 'O'), ('likely', 'O'), ('to', 'O'), ('have', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('diagnosed', 'O'), ('than', 'O'), ('those', 'O'), ('who', 'O'), ('had', 'O'), ('not', 'O'), ('(', 'O'), ('crude', 'O'), ('relative', 'O'), ('risk', 'O'), ('=', 'O'), ('4', 'O'), ('.', 'O'), ('9', 'O'), (',', 'O'), ('p', 'O'), ('=', 'O'), ('0', 'O'), ('.', 'O'), ('0001', 'O'), (')', 'O'), ('.', 'O'))"
Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .,"(('Women', 'O'), ('who', 'O'), ('had', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('and', 'O'), ('had', 'O'), ('received', 'O'), ('tamoxifen', 'O'), ('had', 'O'), ('more', 'O'), ('advanced', 'B'), ('disease', 'I'), ('and', 'O'), ('poorer', 'O'), ('prognosis', 'O'), ('than', 'O'), ('those', 'O'), ('with', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('who', 'O'), ('had', 'O'), ('not', 'O'), ('received', 'O'), ('this', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .","(('Our', 'O'), ('results', 'O'), ('suggest', 'O'), ('a', 'O'), ('causal', 'O'), ('role', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('in', 'O'), ('endometrial', 'B'), ('cancer', 'I'), (',', 'O'), ('particularly', 'O'), ('when', 'O'), ('used', 'O'), ('as', 'O'), ('currently', 'O'), ('proposed', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('prevention', 'O'), ('.', 'O'))"
Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .,"(('Pelvic', 'O'), ('radiotherapy', 'O'), ('may', 'O'), ('be', 'O'), ('an', 'O'), ('additional', 'O'), ('iatrogenic', 'O'), ('factor', 'O'), ('for', 'O'), ('women', 'O'), ('with', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .,"(('Endometrial', 'B'), ('cancers', 'I'), ('diagnosed', 'O'), ('in', 'O'), ('women', 'O'), ('treated', 'O'), ('with', 'O'), ('tamoxifen', 'O'), ('have', 'O'), ('poorer', 'O'), ('prognosis', 'O'), ('.', 'O'))"
Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .,"(('Women', 'O'), ('who', 'O'), ('receive', 'O'), ('tamoxifen', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('should', 'O'), ('be', 'O'), ('offered', 'O'), ('gynaecological', 'O'), ('surveillance', 'O'), ('during', 'O'), ('and', 'O'), ('after', 'O'), ('treatment', 'O'), ('.', 'O'))"
A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .,"(('A', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('evaluation', 'O'), ('of', 'O'), ('the', 'O'), ('risk', 'O'), ('-', 'O'), ('benefit', 'O'), ('ratio', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('as', 'O'), ('a', 'O'), ('preventive', 'O'), ('treatment', 'O'), ('for', 'O'), ('breast', 'B'), ('cancer', 'I'), ('is', 'O'), ('clearly', 'O'), ('warranted', 'O'), ('.', 'O'))"
Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .,"(('Muscle', 'B'), ('rigidity', 'I'), ('was', 'O'), ('induced', 'O'), ('by', 'O'), ('haloperidol', 'O'), ('(', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('i', 'O'), ('.', 'O'), ('p', 'O'), ('.', 'O'), (')', 'O'), ('.', 'O'))"
"5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .","(('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('dichlorokynurenic', 'O'), ('acid', 'O'), ('(', 'O'), ('5', 'O'), (',', 'O'), ('7', 'O'), ('-', 'O'), ('DCKA', 'O'), (')', 'O'), (',', 'O'), ('a', 'O'), ('selective', 'O'), ('glycine', 'O'), ('site', 'O'), ('antagonist', 'O'), (',', 'O'), ('injected', 'O'), ('in', 'O'), ('doses', 'O'), ('of', 'O'), ('2', 'O'), ('.', 'O'), ('5', 'O'), ('and', 'O'), ('4', 'O'), ('.', 'O'), ('5', 'O'), ('microg', 'O'), ('/', 'O'), ('0', 'O'), ('.', 'O'), ('5', 'O'), ('microl', 'O'), ('bilaterally', 'O'), (',', 'O'), ('into', 'O'), ('the', 'O'), ('rostral', 'O'), ('region', 'O'), ('of', 'O'), ('the', 'O'), ('striatum', 'O'), (',', 'O'), ('decreased', 'O'), ('both', 'O'), ('the', 'O'), ('haloperidol', 'O'), ('-', 'O'), ('induced', 'O'), ('muscle', 'B'), ('rigidity', 'I'), ('(', 'O'), ('MMG', 'O'), (')', 'O'), ('and', 'O'), ('the', 'O'), ('enhanced', 'O'), ('electromyographic', 'O'), ('activity', 'O'), ('(', 'O'), ('EMG', 'O'), (')', 'O'), ('.', 'O'))"
BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .,"(('BACKGROUND', 'O'), (':', 'O'), ('The', 'O'), ('most', 'O'), ('striking', 'O'), ('of', 'O'), ('carboplatin', 'O'), (""'"", 'O'), ('s', 'O'), ('advantages', 'O'), ('(', 'O'), ('CBDCA', 'O'), (')', 'O'), ('over', 'O'), ('cisplatin', 'O'), ('(', 'O'), ('CDDP', 'O'), (')', 'O'), ('is', 'O'), ('its', 'O'), ('markedly', 'O'), ('reduced', 'O'), ('rate', 'O'), ('of', 'O'), ('neurotoxic', 'B'), ('effects', 'O'), ('.', 'O'))"
"However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .","(('However', 'O'), (',', 'O'), ('the', 'O'), ('use', 'O'), ('of', 'O'), ('CBDCA', 'O'), ('higher', 'O'), ('-', 'O'), ('intensity', 'O'), ('schedules', 'O'), ('and', 'O'), ('the', 'O'), ('association', 'O'), ('with', 'O'), ('other', 'O'), ('neurotoxic', 'B'), ('drugs', 'O'), ('in', 'O'), ('polychemotherapy', 'O'), ('may', 'O'), ('cause', 'O'), ('some', 'O'), ('concern', 'O'), ('about', 'O'), ('its', 'O'), ('safety', 'O'), ('with', 'O'), ('respect', 'O'), ('to', 'O'), ('peripheral', 'B'), ('nervous', 'I'), ('system', 'I'), ('damage', 'I'), ('.', 'O'))"
"Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .","(('Neurotoxicity', 'B'), ('was', 'O'), ('assessed', 'O'), ('for', 'O'), ('behavioral', 'O'), ('(', 'O'), ('tail', 'O'), ('-', 'O'), ('flick', 'O'), ('test', 'O'), (')', 'O'), (',', 'O'), ('neurophysiological', 'O'), ('(', 'O'), ('nerve', 'O'), ('conduction', 'O'), ('velocity', 'O'), ('in', 'O'), ('the', 'O'), ('tail', 'O'), ('nerve', 'O'), (')', 'O'), (',', 'O'), ('morphological', 'O'), (',', 'O'), ('morphometrical', 'O'), ('and', 'O'), ('analytical', 'O'), ('effects', 'O'), ('.', 'O'))"
RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .,"(('RESULTS', 'O'), (':', 'O'), ('CBDCA', 'O'), ('administration', 'O'), ('induced', 'O'), ('dose', 'O'), ('-', 'O'), ('dependent', 'O'), ('peripheral', 'B'), ('neurotoxicity', 'I'), ('.', 'O'))"
"Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .","(('Pain', 'B'), ('perception', 'O'), ('and', 'O'), ('nerve', 'O'), ('conduction', 'O'), ('velocity', 'O'), ('in', 'O'), ('the', 'O'), ('tail', 'O'), ('were', 'O'), ('significantly', 'O'), ('impaired', 'O'), (',', 'O'), ('particularly', 'O'), ('after', 'O'), ('the', 'O'), ('high', 'O'), ('-', 'O'), ('dose', 'O'), ('treatment', 'O'), ('.', 'O'))"
"CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .","(('CONCLUSIONS', 'O'), (':', 'O'), ('CBDCA', 'O'), ('is', 'O'), ('neurotoxic', 'B'), ('in', 'O'), ('our', 'O'), ('model', 'O'), (',', 'O'), ('and', 'O'), ('the', 'O'), ('type', 'O'), ('of', 'O'), ('pathological', 'O'), ('changes', 'O'), ('it', 'O'), ('induces', 'O'), ('are', 'O'), ('so', 'O'), ('closely', 'O'), ('similar', 'O'), ('to', 'O'), ('those', 'O'), ('caused', 'O'), ('by', 'O'), ('CDDP', 'O'), ('that', 'O'), ('it', 'O'), ('is', 'O'), ('probable', 'O'), ('that', 'O'), ('neurotoxicity', 'B'), ('is', 'O'), ('induced', 'O'), ('in', 'O'), ('the', 'O'), ('two', 'O'), ('drugs', 'O'), ('by', 'O'), ('the', 'O'), ('same', 'O'), ('mechanism', 'O'), ('.', 'O'))"
Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .,"(('Effects', 'O'), ('of', 'O'), ('cisapride', 'O'), ('on', 'O'), ('symptoms', 'O'), ('and', 'O'), ('postcibal', 'O'), ('small', 'O'), ('-', 'O'), ('bowel', 'O'), ('motor', 'O'), ('function', 'O'), ('in', 'O'), ('patients', 'O'), ('with', 'O'), ('irritable', 'B'), ('bowel', 'I'), ('syndrome', 'I'), ('.', 'O'))"
BACKGROUND : Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .,"(('BACKGROUND', 'O'), (':', 'O'), ('Irritable', 'B'), ('bowel', 'I'), ('syndrome', 'I'), ('is', 'O'), ('a', 'O'), ('common', 'O'), ('cause', 'O'), ('of', 'O'), ('abdominal', 'B'), ('pain', 'I'), ('and', 'O'), ('discomfort', 'O'), ('and', 'O'), ('may', 'O'), ('be', 'O'), ('related', 'O'), ('to', 'O'), ('disordered', 'B'), ('gastrointestinal', 'I'), ('motility', 'I'), ('.', 'O'))"
"Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .","(('Our', 'O'), ('aim', 'O'), ('was', 'O'), ('to', 'O'), ('assess', 'O'), ('the', 'O'), ('effects', 'O'), ('of', 'O'), ('long', 'O'), ('-', 'O'), ('term', 'O'), ('treatment', 'O'), ('with', 'O'), ('a', 'O'), ('prokinetic', 'O'), ('agent', 'O'), (',', 'O'), ('cisapride', 'O'), (',', 'O'), ('on', 'O'), ('postprandial', 'O'), ('jejunal', 'O'), ('motility', 'O'), ('and', 'O'), ('symptoms', 'O'), ('in', 'O'), ('the', 'O'), ('irritable', 'B'), ('bowel', 'I'), ('syndrome', 'I'), ('(', 'O'), ('IBS', 'B'), (')', 'O'), ('.', 'O'))"
"METHODS : Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .","(('METHODS', 'O'), (':', 'O'), ('Thirty', 'O'), ('-', 'O'), ('eight', 'O'), ('patients', 'O'), ('with', 'O'), ('IBS', 'B'), ('(', 'O'), ('constipation', 'B'), ('-', 'O'), ('predominant', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('17', 'O'), (';', 'O'), ('diarrhoea', 'B'), ('-', 'O'), ('predominant', 'O'), (',', 'O'), ('n', 'O'), ('=', 'O'), ('21', 'O'), (')', 'O'), ('underwent', 'O'), ('24', 'O'), ('-', 'O'), ('h', 'O'), ('ambulatory', 'O'), ('jejunal', 'O'), ('manometry', 'O'), ('before', 'O'), ('and', 'O'), ('after', 'O'), ('12', 'O'), ('week', 'O'), (""'"", 'O'), ('s', 'O'), ('treatment', 'O'), ('[', 'O'), ('cisapride', 'O'), (',', 'O'), ('5', 'O'), ('mg', 'O'), ('three', 'O'), ('times', 'O'), ('daily', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('19', 'O'), (')', 'O'), ('or', 'O'), ('placebo', 'O'), ('(', 'O'), ('n', 'O'), ('=', 'O'), ('19', 'O'), (')', 'O'), (']', 'O'), ('.', 'O'))"
RESULTS : In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .,"(('RESULTS', 'O'), (':', 'O'), ('In', 'O'), ('diarrhoea', 'B'), ('-', 'O'), ('predominant', 'O'), ('patients', 'O'), ('significant', 'O'), ('differences', 'O'), ('in', 'O'), ('contraction', 'O'), ('characteristics', 'O'), ('were', 'O'), ('observed', 'O'), ('between', 'O'), ('the', 'O'), ('cisapride', 'O'), ('and', 'O'), ('placebo', 'O'), ('groups', 'O'), ('.', 'O'))"
"In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ;","(('In', 'O'), ('cisapride', 'O'), ('-', 'O'), ('treated', 'O'), ('diarrhoea', 'B'), ('-', 'O'), ('predominant', 'O'), ('patients', 'O'), ('the', 'O'), ('mean', 'O'), ('contraction', 'O'), ('amplitude', 'O'), ('was', 'O'), ('higher', 'O'), ('(', 'O'), ('29', 'O'), ('.', 'O'), ('3', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('3', 'O'), ('.', 'O'), ('2', 'O'), ('versus', 'O'), ('24', 'O'), ('.', 'O'), ('9', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('2', 'O'), ('.', 'O'), ('6', 'O'), ('mm', 'O'), ('Hg', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'), ('pretreatment', 'O'), (',', 'O'), ('25', 'O'), ('.', 'O'), ('7', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('6', 'O'), ('.', 'O'), ('0', 'O'), ('mm', 'O'), ('Hg', 'O'), (')', 'O'), (',', 'O'), ('the', 'O'), ('mean', 'O'), ('contraction', 'O'), ('duration', 'O'), ('longer', 'O'), ('(', 'O'), ('3', 'O'), ('.', 'O'), ('4', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('versus', 'O'), ('3', 'O'), ('.', 'O'), ('0', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('0', 'O'), ('.', 'O'), ('2', 'O'), ('sec', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('001', 'O'), (')', 'O'), (';', 'O'))"
No significant differences in jejunal motility were found in the constipation - predominant IBS group .,"(('No', 'O'), ('significant', 'O'), ('differences', 'O'), ('in', 'O'), ('jejunal', 'O'), ('motility', 'O'), ('were', 'O'), ('found', 'O'), ('in', 'O'), ('the', 'O'), ('constipation', 'B'), ('-', 'O'), ('predominant', 'O'), ('IBS', 'B'), ('group', 'O'), ('.', 'O'))"
"Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .","(('Symptom', 'O'), ('scores', 'O'), ('relating', 'O'), ('to', 'O'), ('the', 'O'), ('severity', 'O'), ('of', 'O'), ('constipation', 'B'), ('were', 'O'), ('lower', 'O'), ('in', 'O'), ('cisapride', 'O'), ('-', 'O'), ('treated', 'O'), ('constipation', 'B'), ('-', 'O'), ('predominant', 'O'), ('IBS', 'B'), ('patients', 'O'), ('[', 'O'), ('score', 'O'), (',', 'O'), ('54', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('5', 'O'), ('versus', 'O'), ('67', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('14', 'O'), ('mm', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), (';', 'O'), ('pretreatment', 'O'), (',', 'O'), ('62', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('19', 'O'), ('mm', 'O'), (']', 'O'), ('.', 'O'))"
"Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .","(('Diarrhoea', 'B'), ('-', 'O'), ('predominant', 'O'), ('IBS', 'B'), ('patients', 'O'), ('had', 'O'), ('a', 'O'), ('higher', 'O'), ('pain', 'B'), ('score', 'O'), ('after', 'O'), ('cisapride', 'O'), ('therapy', 'O'), ('[', 'O'), ('score', 'O'), (',', 'O'), ('55', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('15', 'O'), ('versus', 'O'), ('34', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('12', 'O'), ('mm', 'O'), (',', 'O'), ('cisapride', 'O'), ('versus', 'O'), ('placebo', 'O'), ('(', 'O'), ('P', 'O'), ('<', 'O'), ('0', 'O'), ('.', 'O'), ('05', 'O'), (')', 'O'), (';', 'O'), ('pretreatment', 'O'), (',', 'O'), ('67', 'O'), ('+', 'O'), ('/', 'O'), ('-', 'O'), ('19', 'O'), ('mm', 'O'), (']', 'O'), ('.', 'O'))"
Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .,"(('Prevention', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('with', 'O'), ('tamoxifen', 'O'), (':', 'O'), ('preliminary', 'O'), ('findings', 'O'), ('from', 'O'), ('the', 'O'), ('Italian', 'O'), ('randomised', 'O'), ('trial', 'O'), ('among', 'O'), ('hysterectomised', 'O'), ('women', 'O'), ('.', 'O'))"
"BACKGROUND : Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .","(('BACKGROUND', 'O'), (':', 'O'), ('Tamoxifen', 'O'), ('is', 'O'), ('a', 'O'), ('candidate', 'O'), ('chemopreventive', 'O'), ('agent', 'O'), ('in', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('although', 'O'), ('the', 'O'), ('drug', 'O'), ('may', 'O'), ('be', 'O'), ('associated', 'O'), ('with', 'O'), ('the', 'O'), ('development', 'O'), ('of', 'O'), ('endometrial', 'B'), ('cancer', 'I'), ('.', 'O'))"
"METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .","(('METHODS', 'O'), (':', 'O'), ('In', 'O'), ('October', 'O'), (',', 'O'), ('1992', 'O'), (',', 'O'), ('we', 'O'), ('started', 'O'), ('a', 'O'), ('double', 'O'), ('-', 'O'), ('blind', 'O'), ('placebo', 'O'), ('-', 'O'), ('controlled', 'O'), (',', 'O'), ('randomised', 'O'), ('trial', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('in', 'O'), ('women', 'O'), ('(', 'O'), ('mainly', 'O'), ('in', 'O'), ('Italy', 'O'), (')', 'O'), ('who', 'O'), ('did', 'O'), ('not', 'O'), ('have', 'O'), ('breast', 'B'), ('cancer', 'I'), ('and', 'O'), ('who', 'O'), ('had', 'O'), ('had', 'O'), ('a', 'O'), ('hysterectomy', 'O'), ('.', 'O'))"
The primary endpoints are the occurrence of and deaths from breast cancer .,"(('The', 'O'), ('primary', 'O'), ('endpoints', 'O'), ('are', 'O'), ('the', 'O'), ('occurrence', 'O'), ('of', 'O'), ('and', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .,"(('41', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('occurred', 'O'), ('so', 'O'), ('far', 'O'), (';', 'O'), ('there', 'O'), ('have', 'O'), ('been', 'O'), ('no', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('.', 'O'))"
There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .,"(('There', 'O'), ('is', 'O'), ('no', 'O'), ('difference', 'O'), ('in', 'O'), ('breast', 'B'), ('-', 'I'), ('cancer', 'I'), ('frequency', 'O'), ('between', 'O'), ('the', 'O'), ('placebo', 'O'), ('(', 'O'), ('22', 'O'), ('cases', 'O'), (')', 'O'), ('and', 'O'), ('tamoxifen', 'O'), ('(', 'O'), ('19', 'O'), (')', 'O'), ('arms', 'O'), ('.', 'O'))"
"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .","(('There', 'O'), ('is', 'O'), ('a', 'O'), ('statistically', 'O'), ('significant', 'O'), ('reduction', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('among', 'O'), ('women', 'O'), ('receiving', 'O'), ('tamoxifen', 'O'), ('who', 'O'), ('also', 'O'), ('used', 'O'), ('hormone', 'O'), ('-', 'O'), ('replacement', 'O'), ('therapy', 'O'), ('during', 'O'), ('the', 'O'), ('trial', 'O'), (':', 'O'), ('among', 'O'), ('390', 'O'), ('women', 'O'), ('on', 'O'), ('such', 'O'), ('therapy', 'O'), ('and', 'O'), ('allocated', 'O'), ('to', 'O'), ('placebo', 'O'), (',', 'O'), ('we', 'O'), ('found', 'O'), ('eight', 'O'), ('cases', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), ('compared', 'O'), ('with', 'O'), ('one', 'O'), ('case', 'O'), ('among', 'O'), ('362', 'O'), ('women', 'O'), ('allocated', 'O'), ('to', 'O'), ('tamoxifen', 'O'), ('.', 'O'))"
"Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .","(('Compared', 'O'), ('with', 'O'), ('the', 'O'), ('placebo', 'O'), ('group', 'O'), (',', 'O'), ('there', 'O'), ('was', 'O'), ('a', 'O'), ('significantly', 'O'), ('increased', 'O'), ('risk', 'O'), ('of', 'O'), ('vascular', 'B'), ('events', 'I'), ('and', 'O'), ('hypertriglyceridaemia', 'B'), ('among', 'O'), ('women', 'O'), ('on', 'O'), ('tamoxifen', 'O'), ('.', 'O'))"
"INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .","(('INTERPRETATION', 'O'), (':', 'O'), ('Although', 'O'), ('this', 'O'), ('preliminary', 'O'), ('analysis', 'O'), ('has', 'O'), ('low', 'O'), ('power', 'O'), (',', 'O'), ('in', 'O'), ('this', 'O'), ('cohort', 'O'), ('of', 'O'), ('women', 'O'), ('at', 'O'), ('low', 'O'), ('-', 'O'), ('to', 'O'), ('-', 'O'), ('normal', 'O'), ('risk', 'O'), ('of', 'O'), ('breast', 'B'), ('cancer', 'I'), (',', 'O'), ('the', 'O'), ('postulated', 'O'), ('protective', 'O'), ('effects', 'O'), ('of', 'O'), ('tamoxifen', 'O'), ('are', 'O'), ('not', 'O'), ('yet', 'O'), ('apparent', 'O'), ('.', 'O'))"
There were no deaths from breast cancer recorded in women in the study .,"(('There', 'O'), ('were', 'O'), ('no', 'O'), ('deaths', 'O'), ('from', 'O'), ('breast', 'B'), ('cancer', 'I'), ('recorded', 'O'), ('in', 'O'), ('women', 'O'), ('in', 'O'), ('the', 'O'), ('study', 'O'), ('.', 'O'))"
Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy ),"(('Epileptogenic', 'O'), ('activity', 'O'), ('of', 'O'), ('folic', 'O'), ('acid', 'O'), ('after', 'O'), ('drug', 'O'), ('induces', 'O'), ('SLE', 'B'), ('(', 'O'), ('folic', 'O'), ('acid', 'O'), ('and', 'O'), ('epilepsy', 'B'), (')', 'O'))"
OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('study', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('folic', 'O'), ('acid', 'O'), ('-', 'O'), ('containing', 'O'), ('multivitamin', 'O'), ('supplementation', 'O'), ('in', 'O'), ('epileptic', 'B'), ('women', 'O'), ('before', 'O'), ('and', 'O'), ('during', 'O'), ('pregnancy', 'O'), ('in', 'O'), ('order', 'O'), ('to', 'O'), ('determine', 'O'), ('the', 'O'), ('rate', 'O'), ('of', 'O'), ('structural', 'O'), ('birth', 'B'), ('defects', 'I'), ('and', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('related', 'O'), ('side', 'O'), ('effects', 'O'), ('.', 'O'))"
"RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .","(('RESULTS', 'O'), (':', 'O'), ('Of', 'O'), ('60', 'O'), ('epileptic', 'B'), ('women', 'O'), ('with', 'O'), ('periconceptional', 'O'), ('folic', 'O'), ('acid', 'O'), ('(', 'O'), ('0', 'O'), ('.', 'O'), ('8', 'O'), ('mg', 'O'), (')', 'O'), ('-', 'O'), ('containing', 'O'), ('multivitamin', 'O'), ('supplementation', 'O'), (',', 'O'), ('no', 'O'), ('one', 'O'), ('developed', 'O'), ('epilepsy', 'B'), ('-', 'O'), ('related', 'O'), ('side', 'O'), ('effects', 'O'), ('during', 'O'), ('the', 'O'), ('periconception', 'O'), ('period', 'O'), ('.', 'O'))"
One epileptic woman delivered a newborn with cleft lip and palate .,"(('One', 'O'), ('epileptic', 'B'), ('woman', 'O'), ('delivered', 'O'), ('a', 'O'), ('newborn', 'O'), ('with', 'O'), ('cleft', 'B'), ('lip', 'I'), ('and', 'I'), ('palate', 'I'), ('.', 'O'))"
Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .,"(('Another', 'O'), ('patient', 'O'), ('exhibited', 'O'), ('with', 'O'), ('a', 'O'), ('cluster', 'O'), ('of', 'O'), ('seizures', 'B'), ('after', 'O'), ('the', 'O'), ('periconception', 'O'), ('period', 'O'), ('using', 'O'), ('another', 'O'), ('multivitamin', 'O'), ('.', 'O'))"
This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .,"(('This', 'O'), ('22', 'O'), ('-', 'O'), ('year', 'O'), ('-', 'O'), ('old', 'O'), ('epileptic', 'B'), ('woman', 'O'), ('was', 'O'), ('treated', 'O'), ('continuously', 'O'), ('by', 'O'), ('carbamazepine', 'O'), ('and', 'O'), ('a', 'O'), ('folic', 'O'), ('acid', 'O'), ('(', 'O'), ('1', 'O'), ('mg', 'O'), (')', 'O'), ('-', 'O'), ('containing', 'O'), ('multivitamin', 'O'), ('from', 'O'), ('the', 'O'), ('20th', 'O'), ('week', 'O'), ('of', 'O'), ('gestation', 'O'), ('.', 'O'))"
She developed status epilepticus and later symptoms of systemic lupus erythematodes .,"(('She', 'O'), ('developed', 'O'), ('status', 'B'), ('epilepticus', 'I'), ('and', 'O'), ('later', 'O'), ('symptoms', 'O'), ('of', 'O'), ('systemic', 'B'), ('lupus', 'I'), ('erythematodes', 'I'), ('.', 'O'))"
"CONCLUSIONS : The epileptic pregnant patient ' s autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .","(('CONCLUSIONS', 'O'), (':', 'O'), ('The', 'O'), ('epileptic', 'B'), ('pregnant', 'O'), ('patient', 'O'), (""'"", 'O'), ('s', 'O'), ('autoimmune', 'B'), ('disease', 'I'), ('(', 'O'), ('probably', 'O'), ('drug', 'O'), ('-', 'O'), ('induced', 'O'), ('lupus', 'B'), (')', 'O'), ('could', 'O'), ('damage', 'O'), ('the', 'O'), ('blood', 'O'), ('-', 'O'), ('brain', 'O'), ('barrier', 'O'), (',', 'O'), ('therefore', 'O'), ('the', 'O'), ('therapeutic', 'O'), ('dose', 'O'), ('(', 'O'), ('>', 'O'), ('or', 'O'), ('=', 'O'), ('1', 'O'), ('mg', 'O'), (')', 'O'), ('of', 'O'), ('folic', 'O'), ('acid', 'O'), ('triggered', 'O'), ('a', 'O'), ('cluster', 'O'), ('of', 'O'), ('seizures', 'B'), ('.', 'O'))"
"Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .","(('Physiological', 'O'), ('dose', 'O'), ('(', 'O'), ('<', 'O'), ('1', 'O'), ('mg', 'O'), (')', 'O'), ('of', 'O'), ('folic', 'O'), ('acid', 'O'), ('both', 'O'), ('in', 'O'), ('healthy', 'O'), ('and', 'O'), ('60', 'O'), ('epileptic', 'B'), ('women', 'O'), (',', 'O'), ('all', 'O'), ('without', 'O'), ('any', 'O'), ('autoimmune', 'B'), ('disease', 'I'), (',', 'O'), ('did', 'O'), ('not', 'O'), ('increase', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('epileptic', 'B'), ('seizures', 'I'), ('.', 'O'))"
Stroke and cocaine or amphetamine use .,"(('Stroke', 'B'), ('and', 'O'), ('cocaine', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('use', 'O'), ('.', 'O'))"
The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .,"(('The', 'O'), ('association', 'O'), ('of', 'O'), ('cocaine', 'O'), ('and', 'O'), ('amphetamine', 'O'), ('use', 'O'), ('with', 'O'), ('hemorrhagic', 'O'), ('and', 'O'), ('ischemic', 'B'), ('stroke', 'B'), ('is', 'O'), ('based', 'O'), ('almost', 'O'), ('solely', 'O'), ('on', 'O'), ('data', 'O'), ('from', 'O'), ('case', 'O'), ('series', 'O'), ('.', 'O'))"
The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .,"(('The', 'O'), ('limited', 'O'), ('number', 'O'), ('of', 'O'), ('epidemiologic', 'O'), ('studies', 'O'), ('of', 'O'), ('stroke', 'B'), ('and', 'O'), ('use', 'O'), ('of', 'O'), ('cocaine', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('have', 'O'), ('been', 'O'), ('done', 'O'), ('in', 'O'), ('settings', 'O'), ('that', 'O'), ('serve', 'O'), ('mostly', 'O'), ('the', 'O'), ('poor', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('minorities', 'O'), ('.', 'O'))"
"We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .","(('We', 'O'), ('attempted', 'O'), ('to', 'O'), ('identify', 'O'), ('all', 'O'), ('incident', 'O'), ('strokes', 'B'), ('in', 'O'), ('women', 'O'), ('ages', 'O'), ('15', 'O'), ('-', 'O'), ('44', 'O'), ('years', 'O'), ('during', 'O'), ('a', 'O'), ('3', 'O'), ('-', 'O'), ('year', 'O'), ('period', 'O'), ('using', 'O'), ('hospital', 'O'), ('admission', 'O'), ('and', 'O'), ('discharge', 'O'), ('records', 'O'), (',', 'O'), ('emergency', 'O'), ('department', 'O'), ('logs', 'O'), (',', 'O'), ('and', 'O'), ('payment', 'O'), ('requests', 'O'), ('for', 'O'), ('out', 'O'), ('-', 'O'), ('of', 'O'), ('-', 'O'), ('plan', 'O'), ('hospitalizations', 'O'), ('.', 'O'))"
"There were 347 confirmed stroke cases and 1 , 021 controls .","(('There', 'O'), ('were', 'O'), ('347', 'O'), ('confirmed', 'O'), ('stroke', 'B'), ('cases', 'O'), ('and', 'O'), ('1', 'O'), (',', 'O'), ('021', 'O'), ('controls', 'O'), ('.', 'O'))"
The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .,"(('The', 'O'), ('univariate', 'O'), ('matched', 'O'), ('odds', 'O'), ('ratio', 'O'), ('for', 'O'), ('stroke', 'B'), ('in', 'O'), ('women', 'O'), ('who', 'O'), ('admitted', 'O'), ('to', 'O'), ('using', 'O'), ('cocaine', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('was', 'O'), ('8', 'O'), ('.', 'O'), ('5', 'O'), ('(', 'O'), ('95', 'O'), ('%', 'O'), ('confidence', 'O'), ('interval', 'O'), ('=', 'O'), ('3', 'O'), ('.', 'O'), ('6', 'O'), ('-', 'O'), ('20', 'O'), ('.', 'O'), ('0', 'O'), (')', 'O'), ('.', 'O'))"
"The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .","(('The', 'O'), ('use', 'O'), ('of', 'O'), ('cocaine', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('amphetamine', 'O'), ('is', 'O'), ('a', 'O'), ('strong', 'O'), ('risk', 'O'), ('factor', 'O'), ('for', 'O'), ('stroke', 'B'), ('in', 'O'), ('this', 'O'), ('socioeconomically', 'O'), ('heterogeneous', 'O'), (',', 'O'), ('insured', 'O'), ('urban', 'O'), ('population', 'O'), ('.', 'O'))"
Acute renal failure subsequent to the administration of rifampicin .,"(('Acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('subsequent', 'O'), ('to', 'O'), ('the', 'O'), ('administration', 'O'), ('of', 'O'), ('rifampicin', 'O'), ('.', 'O'))"
A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .,"(('A', 'O'), ('clinical', 'O'), ('presentation', 'O'), ('is', 'O'), ('made', 'O'), ('of', 'O'), ('a', 'O'), ('2', 'O'), ('-', 'O'), ('3', 'O'), ('year', 'O'), ('follow', 'O'), ('-', 'O'), ('up', 'O'), ('of', 'O'), ('six', 'O'), ('cases', 'O'), ('of', 'O'), ('acute', 'B'), ('renal', 'I'), ('failure', 'I'), ('that', 'O'), ('have', 'O'), ('been', 'O'), ('reported', 'O'), ('earlier', 'O'), ('.', 'O'))"
The patients had developed transient renal failure after the intermittent administration of rifampicin .,"(('The', 'O'), ('patients', 'O'), ('had', 'O'), ('developed', 'O'), ('transient', 'O'), ('renal', 'B'), ('failure', 'I'), ('after', 'O'), ('the', 'O'), ('intermittent', 'O'), ('administration', 'O'), ('of', 'O'), ('rifampicin', 'O'), ('.', 'O'))"
"The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .","(('The', 'O'), ('stage', 'O'), ('of', 'O'), ('olig', 'O'), ('-', 'O'), ('anuria', 'B'), ('lasted', 'O'), ('for', 'O'), ('1', 'O'), ('-', 'O'), ('3', 'O'), ('weeks', 'O'), (',', 'O'), ('and', 'O'), ('five', 'O'), ('of', 'O'), ('the', 'O'), ('patients', 'O'), ('were', 'O'), ('treated', 'O'), ('by', 'O'), ('hemodialysis', 'O'), ('.', 'O'))"
"Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism cannot be excluded .","(('Although', 'O'), ('in', 'O'), ('the', 'O'), ('acute', 'O'), ('stage', 'O'), ('the', 'O'), ('renal', 'B'), ('lesions', 'I'), ('histologically', 'O'), ('appeared', 'O'), ('toxic', 'O'), (',', 'O'), ('evidence', 'O'), ('suggestive', 'O'), ('of', 'O'), ('an', 'O'), ('immunological', 'O'), ('mechanism', 'O'), ('cannot', 'O'), ('be', 'O'), ('excluded', 'O'), ('.', 'O'))"
Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .,"(('Chronic', 'O'), ('effects', 'O'), ('of', 'O'), ('a', 'O'), ('novel', 'O'), ('synthetic', 'O'), ('anthracycline', 'O'), ('derivative', 'O'), ('(', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), (')', 'O'), ('on', 'O'), ('normal', 'O'), ('heart', 'O'), ('and', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('beagle', 'O'), ('dogs', 'O'), ('.', 'O'))"
This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .,"(('This', 'O'), ('study', 'O'), ('was', 'O'), ('designed', 'O'), ('to', 'O'), ('investigate', 'O'), ('the', 'O'), ('chronic', 'O'), ('cardiotoxic', 'B'), ('potential', 'O'), ('of', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('and', 'O'), ('a', 'O'), ('possible', 'O'), ('deteriorating', 'O'), ('effect', 'O'), ('of', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('on', 'O'), ('low', 'O'), ('-', 'O'), ('grade', 'O'), ('cardiotoxicity', 'B'), ('pre', 'O'), ('-', 'O'), ('induced', 'O'), ('by', 'O'), ('doxorubicin', 'O'), ('in', 'O'), ('beagle', 'O'), ('dogs', 'O'), ('.', 'O'))"
"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .","(('Animals', 'O'), ('which', 'O'), ('received', 'O'), ('over', 'O'), ('six', 'O'), ('courses', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('demonstrated', 'O'), ('the', 'O'), ('electrocardiogram', 'O'), ('(', 'O'), ('ECG', 'O'), (')', 'O'), ('changes', 'O'), (',', 'O'), ('decrease', 'O'), ('of', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('high', 'O'), ('-', 'O'), ('grade', 'O'), ('histopathological', 'O'), ('cardiomyopathy', 'B'), (',', 'O'), ('while', 'O'), ('animals', 'O'), ('which', 'O'), ('were', 'O'), ('terminally', 'O'), ('sacrificed', 'O'), ('after', 'O'), ('the', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('administration', 'O'), ('did', 'O'), ('not', 'O'), ('show', 'O'), ('any', 'O'), ('changes', 'O'), ('in', 'O'), ('ECG', 'O'), (',', 'O'), ('blood', 'O'), ('pressure', 'O'), ('and', 'O'), ('histopathological', 'O'), ('examinations', 'O'), ('.', 'O'))"
"To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .","(('To', 'O'), ('examine', 'O'), ('a', 'O'), ('possibly', 'O'), ('deteriorating', 'O'), ('cardiotoxic', 'B'), ('effect', 'O'), ('of', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), (',', 'O'), ('low', 'O'), ('-', 'O'), ('grade', 'O'), ('cardiomyopathy', 'B'), ('was', 'O'), ('induced', 'O'), ('in', 'O'), ('dogs', 'O'), ('by', 'O'), ('four', 'O'), ('courses', 'O'), ('of', 'O'), ('doxorubicin', 'O'), ('(', 'O'), ('1', 'O'), ('.', 'O'), ('5', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), (')', 'O'), ('.', 'O'))"
The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .,"(('The', 'O'), ('low', 'O'), ('-', 'O'), ('grade', 'O'), ('cardiotoxic', 'B'), ('changes', 'O'), ('were', 'O'), ('enhanced', 'O'), ('by', 'O'), ('the', 'O'), ('additional', 'O'), ('doxorubicin', 'O'), ('treatment', 'O'), ('.', 'O'))"
"On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .","(('On', 'O'), ('the', 'O'), ('contrary', 'O'), (',', 'O'), ('the', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('treatment', 'O'), ('did', 'O'), ('not', 'O'), ('progress', 'O'), ('the', 'O'), ('grade', 'O'), ('of', 'O'), ('cardiomyopathy', 'B'), ('.', 'O'))"
"In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .","(('In', 'O'), ('conclusion', 'O'), (',', 'O'), ('SM', 'O'), ('-', 'O'), ('5887', 'O'), ('does', 'O'), ('not', 'O'), ('have', 'O'), ('any', 'O'), ('potential', 'O'), ('of', 'O'), ('chronic', 'O'), ('cardiotoxicity', 'B'), ('and', 'O'), ('deteriorating', 'O'), ('effect', 'O'), ('on', 'O'), ('doxorubicin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiotoxicity', 'B'), ('in', 'O'), ('dogs', 'O'), ('.', 'O'))"
Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .,"(('Risk', 'O'), ('for', 'O'), ('valvular', 'B'), ('heart', 'I'), ('disease', 'I'), ('among', 'O'), ('users', 'O'), ('of', 'O'), ('fenfluramine', 'O'), ('and', 'O'), ('dexfenfluramine', 'O'), ('who', 'O'), ('underwent', 'O'), ('echocardiography', 'O'), ('before', 'O'), ('use', 'O'), ('of', 'O'), ('medication', 'O'), ('.', 'O'))"
"BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .","(('BACKGROUND', 'O'), (':', 'O'), ('Because', 'O'), ('uncontrolled', 'O'), ('echocardiographic', 'O'), ('surveys', 'O'), ('suggested', 'O'), ('that', 'O'), ('up', 'O'), ('to', 'O'), ('30', 'O'), ('%', 'O'), ('to', 'O'), ('38', 'O'), ('%', 'O'), ('of', 'O'), ('users', 'O'), ('of', 'O'), ('fenfluramine', 'O'), ('and', 'O'), ('dexfenfluramine', 'O'), ('had', 'O'), ('valvular', 'B'), ('disease', 'I'), (',', 'O'), ('these', 'O'), ('drugs', 'O'), ('were', 'O'), ('withdrawn', 'O'), ('from', 'O'), ('the', 'O'), ('market', 'O'), ('.', 'O'))"
OBJECTIVE : To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('determine', 'O'), ('the', 'O'), ('risk', 'O'), ('for', 'O'), ('new', 'O'), ('or', 'O'), ('worsening', 'O'), ('valvular', 'B'), ('abnormalities', 'I'), ('among', 'O'), ('users', 'O'), ('of', 'O'), ('fenfluramine', 'O'), ('or', 'O'), ('dexfenfluramine', 'O'), ('who', 'O'), ('underwent', 'O'), ('echocardiography', 'O'), ('before', 'O'), ('they', 'O'), ('began', 'O'), ('to', 'O'), ('take', 'O'), ('these', 'O'), ('medications', 'O'), ('.', 'O'))"
"The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S .","(('The', 'O'), ('primary', 'O'), ('outcome', 'O'), ('was', 'O'), ('new', 'O'), ('or', 'O'), ('worsening', 'O'), ('valvulopathy', 'B'), (',', 'O'), ('defined', 'O'), ('as', 'O'), ('progression', 'O'), ('of', 'O'), ('either', 'O'), ('aortic', 'B'), ('or', 'I'), ('mitral', 'I'), ('regurgitation', 'I'), ('by', 'O'), ('at', 'O'), ('least', 'O'), ('one', 'O'), ('degree', 'O'), ('of', 'O'), ('severity', 'O'), ('and', 'O'), ('disease', 'O'), ('that', 'O'), ('met', 'O'), ('U', 'O'), ('.', 'O'), ('S', 'O'), ('.', 'O'))"
Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .,"(('Food', 'O'), ('and', 'O'), ('Drug', 'O'), ('Administration', 'O'), ('criteria', 'O'), ('(', 'O'), ('at', 'O'), ('least', 'O'), ('mild', 'O'), ('aortic', 'B'), ('regurgitation', 'I'), ('or', 'O'), ('moderate', 'O'), ('mitral', 'B'), ('regurgitation', 'I'), (')', 'O'), ('.', 'O'))"
"RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .","(('RESULTS', 'O'), (':', 'O'), ('Two', 'O'), ('patients', 'O'), ('(', 'O'), ('4', 'O'), ('.', 'O'), ('3', 'O'), ('%', 'O'), ('[', 'O'), ('95', 'O'), ('%', 'O'), ('CI', 'O'), (',', 'O'), ('0', 'O'), ('.', 'O'), ('6', 'O'), ('%', 'O'), ('to', 'O'), ('14', 'O'), ('.', 'O'), ('8', 'O'), ('%', 'O'), (']', 'O'), (')', 'O'), ('receiving', 'O'), ('fenfluramine', 'O'), ('-', 'O'), ('phentermine', 'O'), ('developed', 'O'), ('valvular', 'B'), ('heart', 'I'), ('disease', 'I'), ('.', 'O'))"
One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .,"(('One', 'O'), ('had', 'O'), ('baseline', 'O'), ('bicuspid', 'B'), ('aortic', 'I'), ('valve', 'I'), ('and', 'O'), ('mild', 'O'), ('aortic', 'B'), ('regurgitation', 'I'), ('that', 'O'), ('progressed', 'O'), ('to', 'O'), ('moderate', 'O'), ('regurgitation', 'O'), ('.', 'O'))"
The second patient developed new moderate aortic insufficiency .,"(('The', 'O'), ('second', 'O'), ('patient', 'O'), ('developed', 'O'), ('new', 'O'), ('moderate', 'O'), ('aortic', 'B'), ('insufficiency', 'I'), ('.', 'O'))"
CONCLUSION : Users of diet medications are at risk for valvular heart disease .,"(('CONCLUSION', 'O'), (':', 'O'), ('Users', 'O'), ('of', 'O'), ('diet', 'O'), ('medications', 'O'), ('are', 'O'), ('at', 'O'), ('risk', 'O'), ('for', 'O'), ('valvular', 'B'), ('heart', 'I'), ('disease', 'I'), ('.', 'O'))"
OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .,"(('OBJECTIVE', 'O'), (':', 'O'), ('To', 'O'), ('evaluate', 'O'), ('the', 'O'), ('effect', 'O'), ('of', 'O'), ('dosage', 'O'), ('regimen', 'O'), ('(', 'O'), ('once', 'O'), ('-', 'O'), ('daily', 'O'), ('vs', 'O'), ('.', 'O'), ('twice', 'O'), ('-', 'O'), ('daily', 'O'), (')', 'O'), ('of', 'O'), ('tobramicyn', 'O'), ('on', 'O'), ('steady', 'O'), ('-', 'O'), ('state', 'O'), ('serum', 'O'), ('concentrations', 'O'), ('and', 'O'), ('toxicity', 'B'), ('.', 'O'))"
"Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .","(('Increased', 'O'), ('serum', 'O'), ('creatinine', 'O'), ('was', 'O'), ('observed', 'O'), ('in', 'O'), ('73', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('OD', 'O'), ('versus', 'O'), ('57', 'O'), ('%', 'O'), ('of', 'O'), ('patients', 'O'), ('in', 'O'), ('TD', 'O'), (',', 'O'), ('without', 'O'), ('evidence', 'O'), ('of', 'O'), ('nephrotoxicity', 'B'), ('.', 'O'))"
"In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .","(('In', 'O'), ('TD', 'O'), ('group', 'O'), (',', 'O'), ('three', 'O'), ('patients', 'O'), ('developed', 'O'), ('decreased', 'B'), ('auditory', 'I'), ('function', 'I'), (',', 'O'), ('of', 'O'), ('which', 'O'), ('one', 'O'), ('presented', 'O'), ('with', 'O'), ('an', 'O'), ('auditory', 'B'), ('loss', 'I'), ('of', 'O'), ('-', 'O'), ('30', 'O'), ('dB', 'O'), (',', 'O'), ('whereas', 'O'), ('in', 'O'), ('the', 'O'), ('OD', 'O'), ('group', 'O'), ('only', 'O'), ('one', 'O'), ('patient', 'O'), ('presented', 'O'), ('decreased', 'B'), ('auditory', 'I'), ('function', 'I'), ('.', 'O'))"
Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .,"(('Enhanced', 'O'), ('bradycardia', 'B'), ('induced', 'O'), ('by', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonists', 'O'), ('in', 'O'), ('rats', 'O'), ('pretreated', 'O'), ('with', 'O'), ('isoniazid', 'O'), ('.', 'O'))"
"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .","(('High', 'O'), ('doses', 'O'), ('of', 'O'), ('isoniazid', 'O'), ('increase', 'O'), ('hypotension', 'B'), ('induced', 'O'), ('by', 'O'), ('vasodilators', 'O'), ('and', 'O'), ('change', 'O'), ('the', 'O'), ('accompanying', 'O'), ('reflex', 'O'), ('tachycardia', 'B'), ('to', 'O'), ('bradycardia', 'B'), (',', 'O'), ('an', 'O'), ('interaction', 'O'), ('attributed', 'O'), ('to', 'O'), ('decreased', 'O'), ('synthesis', 'O'), ('of', 'O'), ('brain', 'O'), ('gamma', 'O'), ('-', 'O'), ('aminobutyric', 'O'), ('acid', 'O'), ('(', 'O'), ('GABA', 'O'), (')', 'O'), ('.', 'O'))"
"In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .","(('In', 'O'), ('the', 'O'), ('present', 'O'), ('study', 'O'), (',', 'O'), ('the', 'O'), ('possible', 'O'), ('enhancement', 'O'), ('by', 'O'), ('isoniazid', 'O'), ('of', 'O'), ('bradycardia', 'B'), ('induced', 'O'), ('by', 'O'), ('beta', 'O'), ('-', 'O'), ('adrenoceptor', 'O'), ('antagonists', 'O'), ('was', 'O'), ('determined', 'O'), ('in', 'O'), ('rats', 'O'), ('anaesthetised', 'O'), ('with', 'O'), ('chloralose', 'O'), ('-', 'O'), ('urethane', 'O'), ('.', 'O'))"
"Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .","(('Isoniazid', 'O'), ('significantly', 'O'), ('increased', 'O'), ('bradycardia', 'B'), ('after', 'O'), ('propranolol', 'O'), (',', 'O'), ('pindolol', 'O'), (',', 'O'), ('labetalol', 'O'), ('and', 'O'), ('atenolol', 'O'), (',', 'O'), ('as', 'O'), ('well', 'O'), ('as', 'O'), ('after', 'O'), ('clonidine', 'O'), (',', 'O'), ('but', 'O'), ('not', 'O'), ('after', 'O'), ('hexamethonium', 'O'), ('or', 'O'), ('carbachol', 'O'), ('.', 'O'))"
Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome c oxidase II gene expression .,"(('Structural', 'B'), ('and', 'I'), ('functional', 'I'), ('impairment', 'I'), ('of', 'I'), ('mitochondria', 'I'), ('in', 'O'), ('adriamycin', 'O'), ('-', 'O'), ('induced', 'O'), ('cardiomyopathy', 'B'), ('in', 'O'), ('mice', 'O'), (':', 'O'), ('suppression', 'O'), ('of', 'O'), ('cytochrome', 'O'), ('c', 'O'), ('oxidase', 'O'), ('II', 'O'), ('gene', 'O'), ('expression', 'O'), ('.', 'O'))"
The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .,"(('The', 'O'), ('use', 'O'), ('of', 'O'), ('adriamycin', 'O'), ('(', 'O'), ('ADR', 'O'), (')', 'O'), ('in', 'O'), ('cancer', 'B'), ('chemotherapy', 'O'), ('has', 'O'), ('been', 'O'), ('limited', 'O'), ('due', 'O'), ('to', 'O'), ('its', 'O'), ('cumulative', 'O'), ('cardiovascular', 'B'), ('toxicity', 'I'), ('.', 'O'))"
"Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .","(('Our', 'O'), ('results', 'O'), ('indicated', 'O'), ('that', 'O'), ('1', 'O'), (')', 'O'), ('treatment', 'O'), ('of', 'O'), ('mice', 'O'), ('with', 'O'), ('ADR', 'O'), ('caused', 'O'), ('cardiovascular', 'B'), ('arrhythmias', 'I'), ('characterized', 'O'), ('by', 'O'), ('bradycardia', 'B'), (',', 'O'), ('extension', 'O'), ('of', 'O'), ('ventricular', 'O'), ('depolarization', 'O'), ('time', 'O'), ('(', 'O'), ('tQRS', 'O'), (')', 'O'), (',', 'O'), ('and', 'O'), ('failure', 'O'), ('of', 'O'), ('QRS', 'O'), ('at', 'O'), ('high', 'O'), ('concentrations', 'O'), ('(', 'O'), ('10', 'O'), ('-', 'O'), ('14', 'O'), ('mg', 'O'), ('/', 'O'), ('kg', 'O'), ('body', 'O'), ('weight', 'O'), ('cumulative', 'O'), ('dose', 'O'), (')', 'O'), (';', 'O'), ('2', 'O'), (')', 'O'), ('the', 'O'), ('heart', 'O'), ('mitochondria', 'O'), ('underwent', 'O'), ('swelling', 'B'), (',', 'O'), ('fusion', 'O'), (',', 'O'), ('dissolution', 'O'), (',', 'O'), ('and', 'O'), ('/', 'O'), ('or', 'O'), ('disruption', 'O'), ('of', 'O'), ('mitochondrial', 'O'), ('cristae', 'O'), ('after', 'O'), ('several', 'O'), ('weeks', 'O'), ('of', 'O'), ('treatment', 'O'), ('.', 'O'))"
"Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .","(('Knowing', 'O'), ('that', 'O'), ('heart', 'O'), ('mitochondria', 'O'), ('represent', 'O'), ('almost', 'O'), ('40', 'O'), ('%', 'O'), ('of', 'O'), ('heart', 'O'), ('muscle', 'O'), ('by', 'O'), ('weight', 'O'), (',', 'O'), ('we', 'O'), ('conclude', 'O'), ('that', 'O'), ('the', 'O'), ('deteriorating', 'O'), ('effects', 'O'), ('of', 'O'), ('ADR', 'O'), ('on', 'O'), ('cardiovascular', 'O'), ('function', 'O'), ('involve', 'O'), ('mitochondrial', 'B'), ('structural', 'I'), ('and', 'I'), ('functional', 'I'), ('impairment', 'I'), ('.', 'O'))"
